PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Villanueva, C; Balanzo, J; Novilla, MT; Soriano, G; Sainz, S; Torras, Z; Cusso, Z; Guarner, C; Vilardell, F				Villanueva, C; Balanzo, J; Novilla, MT; Soriano, G; Sainz, S; Torras, Z; Cusso, Z; Guarner, C; Vilardell, F			Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROSPECTIVE RANDOMIZED TRIAL; LONG-TERM MANAGEMENT; PORTAL-HYPERTENSION; ENDOSCOPIC SCLEROTHERAPY; CIRRHOTIC-PATIENTS; INJECTION SCLEROTHERAPY; ESOPHAGEAL-VARICES; ORAL PROPRANOLOL; HEMORRHAGE; ISOSORBIDE-5-MONONITRATE	Background. Patients who have bleeding from esophageal varices are at high risk for rebleeding and death. We compared the efficacy and safety of endoscopic sclerotherapy with the efficacy and safety of nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. Methods. Eighty-six hospitalized patients with cirrhosis and bleeding from esophageal varices diagnosed by endoscopy were randomly assigned to treatment with repeated sclerotherapy (43 patients) or nadolol plus isosorbide-5-mononitrate (43 patients). The primary outcomes were rebleeding, death, and complications. The hepatic venous pressure gradient was measured at base line and after three months. Results. Base-line data were similar in the two groups, and the median follow-up was 18 months in both. Eleven patients in the medication group and 23 in the sclerotherapy group had rebleeding. The actuarial probability of remaining free of rebleeding was higher in the medication group for all episodes related to portal hypertension (P = 0.001) and variceal rebleeding (P = 0.002). Four patients in the medication group and nine in the sclerotherapy group died (P = 0.07 for the difference in the actuarial probability of survival). Seven patients in the medication group and 16 in the sclerotherapy group had treatment-related complications (P = 0.03). Thirty-one patients in the medication group underwent two hemodynamic studies; 1 of the 13 patients with more than a 20 percent decrease in the hepatic venous pressure gradient had rebleeding, as compared with 8 of the 18 with smaller decreases in the pressure gradient (P = 0.04 for the actuarial probability of rebleeding at two years). Conclusions. As compared with sclerotherapy, nadolol plus isosorbide mononitrate significantly decreased the risk of rebleeding from esophageal varices.	HOSP SANTA CRUZ & SAN PABLO,SERV PATOL DIGEST,DEPT GASTROENTEROL,E-08025 BARCELONA,SPAIN					Soriano, German/0000-0002-9267-6811				ALEXANDRINO PT, 1988, J HEPATOL, V7, P175, DOI 10.1016/S0168-8278(88)80480-X; Armitage P., 1987, STAT METHODS MED RES; BALANZO J, 1990, SURG GYNECOL OBSTET, V171, P489; BALANZO J, 1989, ENDOSCOPY, V21, P251, DOI 10.1055/s-2007-1012963; BOSCH J, 1993, J HEPATOL, V17, pS41, DOI 10.1016/S0168-8278(05)80455-6; BURROUGHS AK, 1989, HEPATOLOGY, V9, P801, DOI 10.1002/hep.1840090602; BURROUGHS AK, 1992, GASTROENTEROL CLIN N, V21, P119; CHRISTENSEN E, 1987, HEPATOLOGY, V7, P1346, DOI 10.1002/hep.1840070628; DAMICO G, 1995, HEPATOLOGY, V22, P232; DAMICO G, 1990, GASTROENTEROLOGY, V99, P558; DASARATHY S, 1992, HEPATOLOGY, V16, P89, DOI 10.1002/hep.1840160116; DEFRANCHIS R, 1992, J HEPATOL, V15, P256, DOI 10.1016/0168-8278(92)90044-P; DOLLET JM, 1988, GASTROEN CLIN BIOL, V12, P234; FEU F, 1995, LANCET, V346, P1056, DOI 10.1016/S0140-6736(95)91740-3; FLEIG WE, 1987, HEPATOLOGY, V7, P355, DOI 10.1002/hep.1840070224; GARCIAPAGAN JC, 1990, HEPATOLOGY, V11, P230, DOI 10.1002/hep.1840110212; GARCIAPAGAN JC, 1991, ANN INTERN MED, V114, P869, DOI 10.7326/0003-4819-114-10-869; GARCIATSAO G, 1985, HEPATOLOGY, V5, P419, DOI 10.1002/hep.1840050313; GARDNER MJ, 1989, STAT CONFIDENCE CONF; GATTA A, 1984, AM HEART J, V108, P1167, DOI 10.1016/0002-8703(84)90602-1; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; GROSZMANN RJ, 1990, GASTROENTEROLOGY, V99, P1401, DOI 10.1016/0016-5085(90)91168-6; HENRIKSEN JH, 1993, HEPATOLOGY, V18, P688; IDEO G, 1988, HEPATOLOGY, V8, P6, DOI 10.1002/hep.1840080103; INFANTERIVARD C, 1989, GASTROENTEROLOGY, V96, P1087, DOI 10.1016/0016-5085(89)91627-2; MCCORMICK PA, 1994, HEPATOLOGY, V20, pA106; MERKEL C, 1995, HEPATOLOGY, V22, P808, DOI 10.1016/0270-9139(95)90301-1; MORILLAS RM, 1994, HEPATOLOGY, V20, P1502, DOI 10.1002/hep.1840200620; POLIO J, 1986, SEMIN LIVER DIS, V6, P318, DOI 10.1055/s-2008-1040614; READY JB, 1989, DRUGS, V37, P13, DOI 10.2165/00003495-198900372-00004; ROSSI V, 1991, J HEPATOL, V12, P283, DOI 10.1016/0168-8278(91)90828-Y; SALMERON JM, 1993, HEPATOLOGY, V17, P800, DOI 10.1016/0270-9139(93)90155-G; SCHUMAN BM, 1987, AM J GASTROENTEROL, V82, P823; TERES J, 1993, GASTROENTEROLOGY, V105, P1508, DOI 10.1016/0016-5085(93)90158-9; VOROBIOFF J, 1993, HEPATOLOGY, V18, P477, DOI 10.1016/0270-9139(93)90344-M; WESTABY D, 1990, HEPATOLOGY, V11, P353, DOI 10.1002/hep.1840110304	36	244	246	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1996	334	25					1624	1629		10.1056/NEJM199606203342502	http://dx.doi.org/10.1056/NEJM199606203342502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ706	8628357				2022-12-28	WOS:A1996UQ70600002
J	Csink, AK; Henikoff, S				Csink, AK; Henikoff, S			Genetic modification of heterochromatic association and nuclear organization in Drosophila	NATURE			English	Article							POSITION-EFFECT VARIEGATION; MELANOGASTER; EXPRESSION	HETEROCHROMATIN is the highly compact, usually pericentromeric, region of eukaryotic chromosomes. Unlike the more gene-rich euchromatin, heterochromatin remains condensed during interphase, when it is sequestered to the periphery of the nucleus(1-3). Here we show, by using fluorescent in situ hybridization to interphase diploid nuclei of Drosophila, that the insertion of heterochromatin into a euchromatic gene, which results in position-effect variegation (PEV), also causes the aberrant association of the gene and its homologous copy with heterochromatin. In correlation with the gene's mutant variegating phenotype, the cytological association of the heterochromatic region is affected by chromosomal distance from heterochromatin and by genic modifiers of PEV. Proteins that are thought to be involved in the formation of heterochromatin can therefore influence the interphase nuclear position of a chromosomal region. This suggests that heterochromatin and proteins involved in its formation provide a structural framework for the interphase nucleus.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute				Henikoff, Steven/0000-0002-7621-8685				Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; EBERL DF, 1993, GENETICS, V134, P277; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Heitz E., 1928, JAHRB WISS BOT, V69, P762; HENIKOFF S, 1989, P NATL ACAD SCI USA, V86, P6704, DOI 10.1073/pnas.86.17.6704; HENIKOFF S, 1995, GENETICS, V140, P1007; KELLUM R, 1995, J CELL SCI, V108, P1407; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOCKE J, 1988, GENETICS, V120, P181; LOHE AR, 1995, CURR OPIN GENET DEV, V5, P746, DOI 10.1016/0959-437X(95)80007-R; MAKUNIN IV, 1995, DOKL AKAD NAUK+, V344, P266; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Marshall WF, 1996, MOL BIOL CELL, V7, P825, DOI 10.1091/mbc.7.5.825; MAYFIELD JE, 1975, CHROMOSOMA, V52, P37, DOI 10.1007/BF00285787; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; Sokal R. R, 1981, BIOMETRY; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Swedlow JR, 1993, CURR OPIN CELL BIOL, V5, P412, DOI 10.1016/0955-0674(93)90005-B; TALBERT PB, 1994, GENETICS, V136, P559; VOURCH C, 1993, EXP CELL RES, V205, P142, DOI 10.1006/excr.1993.1068; WAKIMOTO BT, 1990, GENETICS, V125, P141; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3	23	269	279	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					529	531		10.1038/381529a0	http://dx.doi.org/10.1038/381529a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632827				2022-12-28	WOS:A1996UP43500062
J	Derrick, BE; Martinez, JL				Derrick, BE; Martinez, JL			Associative, bidirectional modifications at the hippocampal mossy fibre-CA3 synapse	NATURE			English	Article							LONG-TERM POTENTIATION; FIBER SYNAPSES; AREA CA1; DEPRESSION; INDUCTION; NEURONS; PLASTICITY; FORMS; CELLS	LONG-TERM potentiation (LTP) and long-term depression (LTD) are activity-dependent changes in synaptic strength that may serve as the cellular mechanisms of information storage in the vertebrate brain(1-4). The messy fibre-CA3 synapse displays NMDA (N-methyl-D-aspartate) receptor-independent forms of LTP(5-8) and LTD(9-11) that were thought to be non-associative(9-11). Here we report that the messy fibre-CA3 synapse displays each of the known types of LTD in vivo, including associative, heterosynaptic acid homosynaptic LTD. These types of LTD are induced when only two of the three conditions necessary for messy fibre LTP induction are provided. Because some of these conditions can be provided by convergent CA3 afferents, each type of LTD can be induced in an associative manner, which suggests that LTD is involved in associative information storage. Similar to the induction of NMDA receptor-dependent LTD and LTP at other cortical synapses, messy fibre LTD occurs when synaptic conditions are insufficient to induce LTP, and both LTP and LTD induction are influenced by previous synaptic activity, consistent with the view that common principles govern activity-dependent plasticity at cortical synapses(2,12,22).			Derrick, BE (corresponding author), UNIV TEXAS,DIV LIFE SCI,SAN ANTONIO,TX 78249, USA.							ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADLER JE, 1990, NEUROSCIENCE, V35, P265, DOI 10.1016/0306-4522(90)90080-N; CAUDLE RM, 1991, J PHARMACOL EXP THER, V258, P18; CHATTARJI S, 1989, BRAIN RES, V495, P145, DOI 10.1016/0006-8993(89)91228-6; DERRICK BE, 1994, P NATL ACAD SCI USA, V91, P10290, DOI 10.1073/pnas.91.22.10290; DERRICK BE, 1994, J NEUROSCI, V14, P4359; DERRICK BE, 1992, J PHARMACOL EXP THER, V263, P725; DRAKE CT, 1994, J NEUROSCI, V14, P3736; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; Intrator Nathan, 1993, P147; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; LAW CC, 1994, P NATL ACAD SCI USA, V91, P7797, DOI 10.1073/pnas.91.16.7797; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; MARTINEZ JL, 1995, A REV PSYCHOL, V47, P173; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MONTAGUE PR, 1994, LEARN MEMORY, V1, P1; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; WAGNER JJ, 1990, NEUROSCIENCE, V37, P45, DOI 10.1016/0306-4522(90)90190-F; WELSSKOPF M, 1993, NATURE, V362, P423; WHITE G, 1990, J NEUROPHYSIOL, V64, P1186, DOI 10.1152/jn.1990.64.4.1186; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; WILSHAW D, 1990, NEURAL COMPUT, V2, P85; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	29	34	35	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					429	434		10.1038/381429a0	http://dx.doi.org/10.1038/381429a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632800				2022-12-28	WOS:A1996UN47900053
J	Larsen, CP; Elwood, ET; Alexander, DZ; Ritchie, SC; Hendrix, R; TuckerBurden, C; Cho, HR; Aruffo, A; Hollenbaugh, D; Linsley, PS; Winn, KJ; Pearson, TC				Larsen, CP; Elwood, ET; Alexander, DZ; Ritchie, SC; Hendrix, R; TuckerBurden, C; Cho, HR; Aruffo, A; Hollenbaugh, D; Linsley, PS; Winn, KJ; Pearson, TC			Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways	NATURE			English	Article							TRANSPLANTATION TOLERANCE; MONOCLONAL-ANTIBODIES; CELL ACTIVATION; LYMPHOCYTES-T; RECEPTOR; ANTIGEN; INVIVO; COSTIMULATION; ALLOANTIGEN; EXPRESSION	THE receptor-ligand pairs CD28-B7 and CD40-gp39 are essential For the initiation and amplification of T-cell-dependent immune responses(1,2). CD28-B7 interactions provide 'second signals' necessary for optimal T-cell activation and IL-2 production(3-5), whereas CD40-gp39 signals co-stimulate B-cell, macrophage, endothelial cell and T-cell activation(6-12). Nonetheless, blockade of either of these pathways alone is not sufficient to permit engraftment of highly immunogenic allografts(13-15). Here we report that simultaneous but not independent blockade of the CD28 and CD40 pathways effectively aborts T-cell clonal expansion in vitro and in vivo, promotes long-term survival of fully allogeneic skin grafts, and inhibits the development of chronic vascular rejection of primarily vascularized cardiac allografts. The requirement for simultaneous blockade of these pathways for effective inhibition of alloimmunity indicates that, although they are interrelated, the CD28 and CD40 pathways are critical independent regulators of T-cell-dependent immune responses.	EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,CARLOS & MARGUERITE MASON TRANSPLANTAT RES CTR,ATLANTA,GA 30322; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Emory University; Emory University; Bristol-Myers Squibb	Larsen, CP (corresponding author), EMORY UNIV,SCH MED,DEPT SURG,1639 PIERCE DR,ATLANTA,GA 30322, USA.		Larsen, Christian P./B-6906-2012	Larsen, Christian P./0000-0001-6573-2649				ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; CAYABYAB M, 1994, J IMMUNOL, V152, P1523; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COBBOLD SP, 1986, NATURE, V323, P164, DOI 10.1038/323164a0; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; JENKINS MK, 1991, J IMMUNOL, V147, P2461; KAYE J, 1988, NATURE, V336, P580, DOI 10.1038/336580a0; Larsen CP, 1996, TRANSPLANTATION, V61, P4, DOI 10.1097/00007890-199601150-00002; LARSEN CP, 1994, J IMMUNOL, V152, P5208; LIDSTAD ST, 1984, NATURE, V307, P168; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MAYUMI H, 1989, J EXP MED, V169, P213, DOI 10.1084/jem.169.1.213; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PARKER DC, 1995, P NATL ACAD SCI USA, V92, P9560, DOI 10.1073/pnas.92.21.9560; Pearson TC, 1996, TRANSPLANTATION, V61, P997, DOI 10.1097/00007890-199604150-00002; PEARSON TC, 1993, TRANSPLANTATION, V55, P361, DOI 10.1097/00007890-199302000-00025; PEREIRA GMB, 1990, J IMMUNOL, V144, P2109; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0	29	1217	1283	2	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					434	438		10.1038/381434a0	http://dx.doi.org/10.1038/381434a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632801				2022-12-28	WOS:A1996UN47900054
J	Niederau, C; Heintges, T; Lange, S; Goldmann, G; Niederau, CM; Mohr, L; Haussinger, D				Niederau, C; Heintges, T; Lange, S; Goldmann, G; Niederau, CM; Mohr, L; Haussinger, D			Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; VIRUS-INFECTION; E-ANTIGEN; LYMPHOBLASTOID INTERFERON; ALPHA-INTERFERON; SEROCONVERSION; THERAPY	Background, In patients with chronic hepatitis B, treatment with interferon alfa and the consequent loss of hepatitis B e antigen (HBeAg) from the blood leads to a reduction in inflammatory activity, but the clinical benefits of this treatment have not been established, We evaluated whether HBeAg seroconversion induced by interferon alfa improves clinical outcome. Methods. We studied prospectively a cohort of 103 patients treated with interferon alfa for chronic hepatitis B; the mean (+/-SD) follow-up was 50.0+/-19.8 months, Fifty-three untreated patients served as controls. Results. After treatment with interferon alfa, 53 of 103 patients no longer had detectable HBeAg or hepatitis B virus DNA, although only 10 patients became seronegative for hepatitis B surface antigen (HBsAg) (Kaplan-Meier estimates of cumulative clearance rates at five years, 56.0 percent for HBeAg and 11.6 percent for HBsAg), Of the 53 untreated patients, only 7 spontaneously eliminated HBeAg (28.1 percent at five years), and all remained positive for HBsAg (P<0.001 for the comparison with the treated patients, by the proportional-hazards model). During follow-up, 6 of the 103 treated patients died of liver failure, and 2 needed liver transplantation; all 8 were persistently positive for HBeAg, In another eight treated patients, complications of cirrhosis developed; all but one of these patients remained positive for HBeAg, Overall survival and survival without clinical complications were significantly longer in patients who were seronegative for HBeAg after therapy with interferon alfa than in those who remained seropositive (P=0.004 and P=0.018, respectively), In a regression analysis, clearance of HBeAg was the strongest predictor of survival, Of the 53 untreated patients, 13 had severe complications (including 4 deaths and 1 need for liver transplantation); all 13 continued to be HBeAg-positive. Conclusions. In patients with chronic hepatitis B infection, the clearance of HBeAg after treatment with interferon alfa is associated with improved clinical outcomes. (C) 1996, Massachusetts Medical Society.	RUHR UNIV BOCHUM,DEPT MED INFORMAT BIOMETR & EPIDEMIOL,W-4630 BOCHUM,GERMANY	Ruhr University Bochum	Niederau, C (corresponding author), UNIV DUSSELDORF,DEPT MED,DIV GASTROENTEROL HEPATOL & INFECT DIS,MOORENSTR 5,D-40225 DUSSELDORF,GERMANY.							ALEXANDER GJM, 1987, LANCET, V2, P66; BROOK MG, 1989, BRIT MED J, V299, P652, DOI 10.1136/bmj.299.6700.652; BROOK MG, 1989, GUT, V30, P1116, DOI 10.1136/gut.30.8.1116; CARRENO V, 1992, J HEPATOL, V15, P102, DOI 10.1016/0168-8278(92)90019-L; FATTOVICH G, 1986, HEPATOLOGY, V6, P167, DOI 10.1002/hep.1840060203; FATTOVICH G, 1990, J HEPATOL, V11, P29, DOI 10.1016/0168-8278(90)90267-U; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; HOOFNAGLE JH, 1981, ANN INTERN MED, V94, P744, DOI 10.7326/0003-4819-94-6-744; KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629; LOK ASF, 1993, GASTROENTEROLOGY, V105, P1833, DOI 10.1016/0016-5085(93)91082-S; Niederau C, 1992, Eur J Med, V1, P396; NIEDERAU C, 1991, CHRONISCHE VIRUSHEPA, P35; PERRILLO PP, 1993, J HEPATOL         S3, V17, pS56; PERRILLO RP, 1991, ANN INTERN MED, V115, P113, DOI 10.7326/0003-4819-115-2-113; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; REALDI G, 1980, GASTROENTEROLOGY, V79, P195; RYFF JC, 1993, J HEPATOL, V17, pS42, DOI 10.1016/S0168-8278(05)80422-2; SARACCO G, 1989, HEPATOLOGY, V10, P336, DOI 10.1002/hep.1840100315; SCOTTO J, 1983, HEPATOLOGY, V3, P279; TINE F, 1993, J HEPATOL, V18, P154, DOI 10.1016/S0168-8278(05)80241-7	20	669	702	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1996	334	22					1422	1427		10.1056/NEJM199605303342202	http://dx.doi.org/10.1056/NEJM199605303342202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM493	8618580				2022-12-28	WOS:A1996UM49300002
J	Kannel, WB				Kannel, WB			Blood pressure as a cardiovascular risk factor - Prevention and treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; HYPERTENSION	Objective.-To examine the prevalence, incidence, predisposing factors for hypertension, its hazards as an ingredient of the cardiovascular risk profile, and the implications of this information for prevention and treatment. Methods.-Prospective longitudinal analysis of 36-year follow-up data from the Framingham Study of the relation of antecedent blood pressure to occurrence of subsequent cardiovascular morbidity and mortality depending on the metabolically linked burden of associated risk factors. Results.-Hypertension is one of the most prevalent and powerful contributors to cardiovascular diseases, the leading cause of death in the United States. There is, on average, a 20 mm Hg systolic and 10 mm Hg diastolic increment increase in blood pressure from age 30 to 65 years. Isolated systolic hypertension is the dominant variety. There is no evidence of a decline in the prevalence of hypertension over 4 decades despite improvements in its detection and treatment. Hypertension contributes to all of the major atherosclerotic cardiovascular disease outcomes increasing risk, on average, 2- to 3-fold. Coronary disease, the most lethal and common sequela, deserves highest priority. Hypertension clusters with dyslipidemia, insulin resistance, glucose intolerance, and obesity, occurring in isolation in less than 20%. The hazard depends on the number of these associated metabolically linked risk factors present. Coexistent overt cardiovascular disease also influences the hazard and choice of therapy. Conclusion.-The absence of a decline in the prevalence of hypertension indicates an urgent need for primary prevention by weight control, exercise, and reduced salt and alcohol intake. The urgency and choice of therapy of existing hypertension should be based on the multivariate cardiovascular risk profile that more appropriately targets hypertensive persons for treatment and prevention of cardiovascular sequelae.			Kannel, WB (corresponding author), BOSTON UNIV,SCH MED,FRAMINGHAM HEART STUDY,EVANS MEM RES FDN,DEPT MED,BOSTON,MA 02118, USA.				NHLBI NIH HHS [N01-HV-52971, N01-HV-92922] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; Anderson K. M., 1991, CIRCULATION, V83, P357; BELANGER A, 1988, 802970 US DEP HHS PH; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CUPPLES LA, 1987, SOME RISK FACTORS RE, P87; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DANNENBERG AL, 1988, AM J PUBLIC HEALTH, V7, P676; GARRISON RJ, 1987, PREV MED, V16, P234; Hypertension Prevention Trial Research Group, 1990, ARCH INTERN MED, V150, P153, DOI [10.1001/archinte.1990.00390130131021, DOI 10.1001/ARCHINTE.1990.00390130131021]; KANNEL WB, 1993, AM HEART J, V125, P1154, DOI 10.1016/0002-8703(93)90129-W; KANNEL WB, 1985, AM HEART J, V109, P581, DOI 10.1016/0002-8703(85)90566-6; KANNEL WB, 1987, AM J CARDIOL, V60, P851; KANNEL WB, 1991, P R COLL PHYS EDINB, V21, P273; Kannel William B., 1994, Am J Geriatr Cardiol, V3, P33; KRUMHOLZ HM, 1995, J AM COLL CARDIOL, V25, P879, DOI 10.1016/0735-1097(94)00473-4; LEAVERTON PE, 1987, J CHRON DIS, V40, P775, DOI 10.1016/0021-9681(87)90129-9; LEVY D, 1994, CIRCULATION, V90, P1786, DOI 10.1161/01.CIR.90.4.1786; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; *NIH, 1993, 932669 NIH NAT HEART; REAVEN GM, 1991, AM HEART J, V121, P1283, DOI 10.1016/0002-8703(91)90434-J; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; WILSON PWF, 1995, HYPERTENSION PATHOPH, V1, P99; WOLF PA, 1991, STROKE, V22, P312, DOI 10.1161/01.STR.22.3.312; 1993, ARCH INTERN MED, V153, P154; 1992, JAMA-J AM MED ASSOC, V267, P1213; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1988, ARCH INTERN MED, V148, P1023	29	921	962	0	76	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1571	1576		10.1001/jama.275.20.1571	http://dx.doi.org/10.1001/jama.275.20.1571			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622248				2022-12-28	WOS:A1996UL02900029
J	Altman, LK				Altman, LK			The Ingelfinger rule, embargoes, and journal peer review .1.	LANCET			English	Article							JFK DEATH; MDS	It is 27 years since Dr Franz Ingelfinger announced that a manuscript would be rejected by his journal, the New England Journal of Medicine, if it had been published elsewhere. Many other medical journals have since adopted this so-called Ingelfinger rule. The restrictions resulting from the rule have generated enormous controversy in medical journalism, as shown by the first of the two-part article The Ingelfinger rule, embargoes, and journal peer review. Critics say that the rule restricts the free flow of information, whereas proponents claim that information from a paper released early may be Inaccurate because the paper has not been subjected to peer review. Yet peer review itself has also come under scrutiny, with its many limitations rarely being openly discussed.			Altman, LK (corresponding author), NEW YORK TIMES CO, 229 W 23RD ST, NEW YORK, NY 10024 USA.							ALTMAN LE, 1994, NEW ENGL J MED, V331, P810; [Anonymous], 1969, N Engl J Med, V281, P676; BLOOM M, 1979, NASW NEWSLETTER  NOV, P10; BREO DL, 1992, JAMA-J AM MED ASSOC, V267, P2804, DOI 10.1001/jama.267.20.2804; BREO DL, 1992, JAMA-J AM MED ASSOC, V267, P2794, DOI 10.1001/jama.267.20.2794; CULLITON OB, 1972, SCIENCE, V176, P1403, DOI 10.1126/science.176.4042.1403; ELLIOTT J, 1979, NASW NEWSLETTER  AUG, P5; FLETCHER RH, 1992, J INTERN MED, V232, P215, DOI 10.1111/j.1365-2796.1992.tb00575.x; HARRIS J, 1995, CATIGNY C SERIES, P37; HINES W, 1989, CHICAGO SUN TIM 0517; HUTH EJ, 1980, NASW NEWSLETTER  JAN, P9; INGELFINGER FJ, 1977, NEW ENGL J MED, V296, P1258, DOI 10.1056/NEJM197706022962204; INGELFINGER FJ, 1970, SCIENCE, V169, P831, DOI 10.1126/science.169.3948.831; INGELFINGER FJ, 1969, NEW ENGL J MED, V281, P386, DOI 10.1056/NEJM196908142810712; INGELFINGER FJ, 1969, NEW ENGL J MED, V281, P526, DOI 10.1056/NEJM196909042811005; JUDSON G, 1995, NY TIMES        0422; KASSIRER JP, 1995, NEW ENGL J MED, V332, P1709, DOI 10.1056/NEJM199506223322509; Pini P, 1995, LANCET, V346, P1681, DOI 10.1016/S0140-6736(95)92845-6; RELMAN AS, 1979, NEW ENGL J MED, V300, P554, DOI 10.1056/NEJM197903083001009; RELMAN AS, 1983, NEW ENGL J MED, V308, P1219, DOI 10.1056/NEJM198305193082009; RELMAN AS, 1983, NEW ENGL J MED, V308, P1415, DOI 10.1056/NEJM198306093082311; RELMAN AS, 1988, NEW ENGL J MED, V318, P918, DOI 10.1056/NEJM198804073181409; RELMAN AS, 1990, WESTERN J MED, V153, P520; RELMAN AS, 1988, NEW ENGL J MED, V318, P1125, DOI 10.1056/NEJM198804283181709; RELMAN AS, 1981, NEW ENGL J MED, V305, P824, DOI 10.1056/NEJM198110013051408; RELMAN AS, 1988, NEW ENGL J MED, V318, P1680, DOI 10.1056/NEJM198806233182508; RELMAN AS, 1979, NASW NEWSLETTER  NOV, P9; RELMAN AS, 1989, J SOC RES ADM, V21; Rosenberg SA, 1996, NEW ENGL J MED, V334, P392, DOI 10.1056/NEJM199602083340610; SMITH R, 1994, BRIT MED J, V309, P143, DOI 10.1136/bmj.309.6948.143; WILKES MS, 1992, JAMA-J AM MED ASSOC, V268, P999, DOI 10.1001/jama.268.8.999; 1990, JAMA-J AM MED ASSOC, V263, P1309	32	56	56	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	1996	347	9012					1382	1386		10.1016/S0140-6736(96)91016-8	http://dx.doi.org/10.1016/S0140-6736(96)91016-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637347	Bronze			2022-12-28	WOS:A1996UL90400015
J	Franceschi, S; Favero, A; Decarli, A; Negri, E; LaVecchia, C; Ferraroni, M; Russo, A; Salvini, S; Amadori, D; Conti, E; Montella, M; Giacosa, A				Franceschi, S; Favero, A; Decarli, A; Negri, E; LaVecchia, C; Ferraroni, M; Russo, A; Salvini, S; Amadori, D; Conti, E; Montella, M; Giacosa, A			Intake of macronutrients and risk of breast cancer	LANCET			English	Article							DIETARY-FAT	Background The association between risk of breast cancer and dietary fat and intakes of other energy sources remains controversial. The Italian population offers special opportunities to assess the influence of high intakes of unsaturated fat and starch and, because the population has low awareness of diet and cancer issues, there is less scope for recall bias. We have assessed the relations of various macronutrient intakes with risk of breast cancer. Methods In this case-control study, 2569 women with incident breast cancer (median age 55 years) and 2588 control women (median age 56 years) in hospital with acute, non-neoplastic diseases, were interviewed in six different areas of Italy between 1991 and 1994. A validated food-frequency questionnaire was used. It included questions on 78 foods and recipes grouped into six sections, as well as specific questions on individual fat-intake pattern. Findings The risk of breast cancer decreased with increasing total fat intake (trend p 0.01) whereas the risk increased with increasing intake of available carbohydrates (trend p=0.002). The odds ratios for women in the highest compared with the lowest quintile of energy-adjusted intake were 0.81 for total fat and 1.30 for available carbohydrates. Starch was the chief contributor to the positive association with available carbohydrates. High intakes of polyunsaturated and unsaturated fatty acids tie, polyunsaturated fatty acids plus oleic acid) were associated with a decreased risk of breast cancer (odds ratios for highest vs lowest quintile 0.70 and 0.74, respectively). Conversely, the intakes of saturated fatty acids, protein, and fibre were not significantly associated with breast-cancer risk. Interpretation This case-control study shows that unsaturated fatty acids protect against breast cancer, possibly because intake of these nutrients is closely correlated with a high intake of raw vegetables. The findings also suggest a possible risk, in southern European populations, of reliance on a diet largely based on starch.	UNIV MILAN,IST STAT MED & BIOMETRIA,I-20122 MILAN,ITALY; IST NAZL TUMORI,I-20133 MILAN,ITALY; IST RIC FARMACOL MARIO NEGRI,MILAN,ITALY; IST EUROPEO ONCOL,DIV EPIDEMIOL & BIOSTAT,MILAN,ITALY; OSPED L PIERANTONI,FORLI,ITALY; IST REGINA ELENA STUDIO & CURA TUMORI,ROME,ITALY; IST STUDIO & CURA TUMORI SENATORE PASCALE,NAPLES,ITALY; IST NAZL RIC CANC,I-16132 GENOA,ITALY	University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS European Institute of Oncology (IEO); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Genoa; IRCCS AOU San Martino IST	Franceschi, S (corresponding author), CTR RIFERIMENTO ONCOL,SERV EPIDEMIOL,VIA PEDEMONTANA,I-33081 AVIANO,ITALY.		Ferraroni, Monica/D-6548-2017; Decarli, Adriano/C-3129-2017; Russo, Antonio Giampiero/O-2244-2019; Russo, Antonio Giampiero/K-2230-2018; Negri, Eva/B-7244-2013; franceschi, silvia/M-2452-2014; Negri, Eva Vanna Lorenza/AAC-5698-2019; Decarli, Adriano/AAF-3314-2021	Ferraroni, Monica/0000-0002-4542-4996; Decarli, Adriano/0000-0003-1451-8292; Russo, Antonio Giampiero/0000-0002-5681-5861; Negri, Eva/0000-0001-9712-8526; franceschi, silvia/0000-0003-4181-8071; Negri, Eva Vanna Lorenza/0000-0001-9712-8526; Decarli, Adriano/0000-0003-1451-8292; La Vecchia, Carlo/0000-0003-1441-897X				BAGHURST PA, 1994, INT J CANCER, V56, P173, DOI 10.1002/ijc.2910560204; BIDOLI E, 1992, INT J CANCER, V50, P223, DOI 10.1002/ijc.2910500211; BINGHAM SA, 1994, BRIT J NUTR, V72, P619, DOI 10.1079/BJN19940064; BOYD NF, 1990, BRIT J CANCER, V62, P878, DOI 10.1038/bjc.1990.400; BOYD NF, 1993, BRIT J CANCER, V68, P627, DOI 10.1038/bjc.1993.398; DAVANZO B, 1991, EUR J CANCER, V27, P420, DOI 10.1016/0277-5379(91)90376-O; Decarli A, 1996, ANN EPIDEMIOL, V6, P110, DOI 10.1016/1047-2797(95)00129-8; DOLL R, 1994, NUTR REV, V52, P233, DOI 10.1111/j.1753-4887.1994.tb01428.x; FRANCESCHI S, 1993, EUR J CANCER, V29A, P2298, DOI 10.1016/0959-8049(93)90225-5; Franceschi S, 1995, INT J CANCER, V63, P785, DOI 10.1002/ijc.2910630606; Franceschi Silvia, 1995, Annals of Epidemiology, V5, P69, DOI 10.1016/1047-2797(95)92893-D; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; Hunter DJ, 1996, NEW ENGL J MED, V334, P356, DOI 10.1056/NEJM199602083340603; IP C, 1993, PREV MED, V22, P728, DOI 10.1006/pmed.1993.1067; KATSOUYANNI K, 1994, BRIT J CANCER, V70, P537, DOI 10.1038/bjc.1994.341; KATSOUYANNI K, 1986, INT J CANCER, V38, P815, DOI 10.1002/ijc.2910380606; KUSHI LH, 1992, J NATL CANCER I, V84, P1092, DOI 10.1093/jnci/84.14.1092; Landa M C, 1994, Eur J Cancer Prev, V3, P313, DOI 10.1097/00008469-199407000-00003; LAVECCHIA C, 1987, INT J CANCER, V40, P484, DOI 10.1002/ijc.2910400409; LONDON SJ, 1993, JNCI-J NATL CANCER I, V85, P785, DOI 10.1093/jnci/85.10.785; MARTINMORENO JM, 1994, INT J CANCER, V58, P774, DOI 10.1002/ijc.2910580604; Negri E, 1996, INT J CANCER, V65, P140, DOI 10.1002/(SICI)1097-0215(19960117)65:2&lt;140::AID-IJC3&gt;3.0.CO;2-Z; Salvini Simonetta, 1996, Journal of Food Composition and Analysis, V9, P57, DOI 10.1006/jfca.1996.0007; TONIOLO P, 1989, J NATL CANCER I, V81, P278, DOI 10.1093/jnci/81.4.278; TRICHOPOULOU A, 1995, JNCI-J NATL CANCER I, V87, P110, DOI 10.1093/jnci/87.2.110; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P848, DOI 10.1093/oxfordjournals.aje.a117333; Willett W, 1990, MONOGRAPHS EPIDEMIOL, V15; WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037	29	119	123	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1351	1356		10.1016/S0140-6736(96)91008-9	http://dx.doi.org/10.1016/S0140-6736(96)91008-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637339				2022-12-28	WOS:A1996UL90400007
J	Paunio, M; Virtamo, J; Gref, CG; Heinonen, OP				Paunio, M; Virtamo, J; Gref, CG; Heinonen, OP			Serum high density lipoprotein cholesterol, alcohol, and coronary mortality in male smokers	BRITISH MEDICAL JOURNAL			English	Article							RESEARCH CLINICS PREVALENCE; ACUTE MYOCARDIAL-INFARCTION; HEART-DISEASE; CARDIOVASCULAR-DISEASE; ETHANOL INTOXICATION; BRAIN INFARCTION; MEN; RISK; CONSUMPTION; SUBFRACTIONS	Objective-To determine whether the increase in mortality from coronary heart disease with high concentrations (>1.75 mmol/1) of high density Lipoprotein cholesterol could be due to alcohol intake. Design-Cohort study. Setting-Placebo group of the alpha tocopherol, beta carotene cancer prevention (ATBC) study of south western population in Finland. Participants-7052 male smokers aged 50-69 years enrolled to the ATBC study in the 1980s. Main outcome measures-The relative and absolute rates for clinically or pathologically verified deaths from coronary heart disease for different concentrations of high density lipoprotein cholesterol with and without stratification for alcohol intake. Similar rates were also calculated for different alcohol consumption groups. Results-During the average follow up period of 6.7 years 258 men died from verified coronary heart disease. Coronary death rate steadily decreased with increasing concentration of high density Lipoprotein cholesterol until a high concentration. An increase in the rate was observed above 1.75 mol/1. This increase occurred among those who reported alcohol intake. Mortality was associated with alcohol intake in a J shaped dose response, and those who reported consuming more than five drinks a day (heavy drinkers) had the highest death rate. Mortality was higher in heavy drinkers than in non-drinkers or light or moderate drinkers in all high density lipoprotein categories from 0.91 mmol/1 upward. Conclusions-Mortality from coronary heart disease increases at concentrations of high density lipoprotein cholesterol over 1.75 mmol/1. The mortality was highest among heavy drinkers, but an increase was found among light drinkers also.	HELSINKI NATL PUBL HLTH INST,HELSINKI,FINLAND		Paunio, M (corresponding author), HELSINKI UNIV,DEPT PUBL HLTH,POB 21,SF-00014 HELSINKI,FINLAND.				DIVISION OF CANCER PREVENTION AND CONTROL [N01CN045165] Funding Source: NIH RePORTER; NCI NIH HHS [N0I-CN-45165] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, Ann Epidemiol, V4, P1, DOI 10.1016/1047-2797(94)90036-1; Barrett-Connor E, 1992, Ann Epidemiol, V2, P77, DOI 10.1016/1047-2797(92)90040-W; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; FRIEDMAN GD, 1993, NEW ENGL J MED, V329, P1882, DOI 10.1056/NEJM199312163292510; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GOLDBOURT U, 1990, ARTERIOSCLEROSIS, V10, P512, DOI 10.1161/01.ATV.10.4.512; GOLDBOURT U, 1979, AM J EPIDEMIOL, V109, P296, DOI 10.1093/oxfordjournals.aje.a112683; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON DJ, 1986, CIRCULATION, V74, P1217, DOI 10.1161/01.CIR.74.6.1217; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HILLBOM M, 1983, NEUROLOGY, V33, P381, DOI 10.1212/WNL.33.3.381; HILLBOM M, 1985, STROKE, V16, P19, DOI 10.1161/01.STR.16.1.19; HILLBOM M, 1990, ANN MED, V22, P347, DOI 10.3109/07853899009147918; HILLBOM ME, 1983, EUR J CLIN INVEST, V13, P45, DOI 10.1111/j.1365-2362.1983.tb00063.x; JACKSON R, 1992, AM J EPIDEMIOL, V136, P819, DOI 10.1093/aje/136.7.819; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; KAPRIO J, 1982, INT J EPIDEMIOL, V11, P378, DOI 10.1093/ije/11.4.378; KATTERMANN R, 1984, J CLIN CHEM CLIN BIO, V22, P245; KUSTNER GM, 1976, CLIN CHEM, V22, P695; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LEE ET, 1980, STATISTICAL METHODS; MCGARRY GW, 1994, BRIT MED J, V309, P640, DOI 10.1136/bmj.309.6955.640; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; MOREYRA AE, 1982, CLIN CARDIOL, V5, P425, DOI 10.1002/clc.4960050707; PAUNIO M, 1994, CIRCULATION, V90, P2909, DOI 10.1161/01.CIR.90.6.2909; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PIETINEN P, 1988, AM J EPIDEMIOL, V128, P655, DOI 10.1093/oxfordjournals.aje.a115013; REED D, 1986, AM J MED, V80, P871, DOI 10.1016/0002-9343(86)90631-5; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Romanov K, 1987, Alcohol Alcohol Suppl, V1, P619; ROSSII KZ, 1994, GOSUDARSTVENNY NAUCH; *SAS STAT SOFTW, 1991, PHREG PROC PREL DOC; SHESTOV DB, 1993, CIRCULATION, V88, P846, DOI 10.1161/01.CIR.88.3.846; SHESTOV DB, 1982, NIH831966 US DEP HLT, P391; SIMPURA J, 1995, ADDICTION, V90, P673, DOI 10.1111/j.1360-0443.1995.tb02205.x; STENSVOLD I, 1992, EUR HEART J, V13, P1155, DOI 10.1093/oxfordjournals.eurheartj.a060331; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; TASKINEN MR, 1982, METABOLISM, V31, P1168, DOI 10.1016/0026-0495(82)90169-X; WANNAMETHEE G, 1988, J ROY COLL GEN PRACT, V38, P440; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; 1986, PREV MED, V15, P254; 1994, NEW ENGL J MED, V330, P1029	43	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1200	1203						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634563				2022-12-28	WOS:A1996UL05800019
J	Olson, KE; Higgs, S; Gaines, PJ; Powers, AM; Davis, BS; Kamrud, KI; Carlson, JO; Blair, CD; Beaty, BJ				Olson, KE; Higgs, S; Gaines, PJ; Powers, AM; Davis, BS; Kamrud, KI; Carlson, JO; Blair, CD; Beaty, BJ			Genetically engineered resistance to dengue-2 virus transmission in mosquitoes	SCIENCE			English	Article							AMINO-ACID SEQUENCE; YELLOW-FEVER VIRUS; NUCLEOTIDE-SEQUENCE; MONOCLONAL-ANTIBODIES; JAMAICA GENOTYPE; TYPE-2 VIRUS; PROTEINS; EXPRESSION; GENOME; RNA	The control of arthropod-borne virus diseases such as dengue may ultimately require the genetic manipulation of mosquito vectors to disrupt virus transmission to human populations. To reduce the ability of mosquitoes to transmit dengue viruses, a recombinant Sindbis virus was used to transduce female Aedes aegypti with a 567-base antisense RNA targeted to the premembrane coding region of dengue type 2 (DEN-2) virus. The transduced mosquitoes were unable to support replication of DEN-P virus in their salivary glands and therefore were not able to transmit the virus.			Olson, KE (corresponding author), COLORADO STATE UNIV,DEPT MICROBIOL,ARTHROPAD BARNE & INFECT DIS LAB,FT COLLINS,CO 80523, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034014] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34014, AI07352] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHBURNER M, 1995, SCIENCE, V270, P1941, DOI 10.1126/science.270.5244.1941; BEATY BJ, 1979, MOSQ NEWS, V39, P232; BESANSKY NJ, 1995, PARASITOL TODAY, V270, P1941; CARLSON J, 1995, ANNU REV ENTOMOL, V40, P359, DOI 10.1146/annurev.en.40.010195.002043; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHANAS AC, 1982, J GEN VIROL, V58, P37, DOI 10.1099/0022-1317-58-1-37; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAMPTON J, 1990, PARASITOL TODAY, V6, P31, DOI 10.1016/0169-4758(90)90057-B; DEUBEL V, 1986, VIROLOGY, V155, P365, DOI 10.1016/0042-6822(86)90200-X; DEUBEL V, 1988, VIROLOGY, V165, P234, DOI 10.1016/0042-6822(88)90677-0; FALLON AM, 1991, NATURE, V352, P828, DOI 10.1038/352828a0; Gaines PJ, 1996, J VIROL, V70, P2132, DOI 10.1128/JVI.70.4.2132-2137.1996; GOULD EA, 1985, J GEN VIROL, V66, P1369, DOI 10.1099/0022-1317-66-7-1369; GUBLER DJ, 1994, INFECT AGENT DIS, V2, P383; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; HAHN YS, 1988, VIROLOGY, V162, P167, DOI 10.1016/0042-6822(88)90406-0; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HIGGS S, 1993, PARASITOL TODAY, V9, P444, DOI 10.1016/0169-4758(93)90098-Z; Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914; MARCHUK D, 1990, NUCLEIC ACIDS RES, V19, P1154; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; MURRAY JM, 1993, J GEN VIROL, V74, P175, DOI 10.1099/0022-1317-74-2-175; OLSON KE, 1994, INSECT BIOCHEM MOLEC, V24, P39, DOI 10.1016/0965-1748(94)90121-X; POWERS AM, 1994, VIRUS RES, V32, P57, DOI 10.1016/0168-1702(94)90061-2; POWERS AM, UNPUB; POWERS AM, IN PRESS P NATL ACAD; RaymsKeller A, 1995, INSECT MOL BIOL, V4, P245, DOI 10.1111/j.1365-2583.1995.tb00030.x; RICE CM, 1987, J VIROL, V61, P3809, DOI 10.1128/JVI.61.12.3809-3819.1987; ROSEN L, 1974, AM J TROP MED HYG, V23, P1153, DOI 10.4269/ajtmh.1974.23.1153; Sambrook J., 2002, MOL CLONING LAB MANU; SANFORD JC, 1985, J THEOR BIOL, V113, P395, DOI 10.1016/S0022-5193(85)80234-4; WHITEHEAD RH, 1971, T ROY SOC TROP MED H, V65, P661, DOI 10.1016/0035-9203(71)90051-4	32	157	162	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					884	886		10.1126/science.272.5263.884	http://dx.doi.org/10.1126/science.272.5263.884			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629025				2022-12-28	WOS:A1996UK75700062
J	Xanthoudakis, S; Viola, JPB; Shaw, KTY; Luo, C; Wallace, JD; Bozza, PT; Curran, T; Rao, A				Xanthoudakis, S; Viola, JPB; Shaw, KTY; Luo, C; Wallace, JD; Bozza, PT; Curran, T; Rao, A			An enhanced immune response in mice lacking the transcription factor NFAT1	SCIENCE			English	Article							ACTIVATED T-CELLS; CYCLOSPORINE-A; NUCLEAR FACTOR; GENE; IDENTIFICATION; LYMPHOCYTE; COMPLEX; DISEASE	Transcription factors of the NFAT family are thought to play a major role in regulating the expression of cytokine genes and other inducible genes during the immune response. The role of NFAT1 was investigated by targeted disruption of the NFAT1 gene. Unexpectedly, cells from NFAT1(-/-) mice showed increased primary responses to Leishmania major and mounted increased secondary responses to ovalbumin in vitro. In an in vivo model of allergic inflammation, the accumulation of eosinophils and levels of serum immunoglobulin E were increased in NFAT1(-/-) mice. These results suggest that NFAT1 exerts a negative regulatory influence on the immune response.	ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38105 USA; HOFFMANN LA ROCHE INC, DEPT CNS RES, NEUROGENET PROGRAM, NUTLEY, NJ 07110 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, HARVARD THORNDIKE LAB, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,CHARLES A DANA RES INST, SCH MED, BOSTON, MA 02115 USA	St Jude Children's Research Hospital; Roche Holding; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Curran, Tom/C-1164-2008; Bozza, Patricia T./AAE-2933-2021; Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019; Viola, Joao P.B./AAP-4125-2020; Curran, Tom/F-5234-2018; Bozza, Patricia T./AAM-4537-2021	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Viola, Joao P.B./0000-0002-0698-3146; Curran, Tom/0000-0003-1444-7551; Bozza, Patricia T./0000-0001-8349-9529	NATIONAL CANCER INSTITUTE [P30CA021765, R37CA042471, R01CA042471] Funding Source: NIH RePORTER; NCI NIH HHS [CA42471, P30 CA21765] Funding Source: Medline; NIGMS NIH HHS [GM46227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; BACHMANN MF, 1995, J VIROL, V69, P4842, DOI 10.1128/JVI.69.8.4842-4846.1995; BOZZA PT, 1994, IMMUNOPHARMACOLOGY, V27, P131, DOI 10.1016/0162-3109(94)90047-7; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRADLEY LM, 1995, J IMMUNOL, V155, P1713; BROMBERG JS, 1995, CURR OPIN IMMUNOL, V7, P639, DOI 10.1016/0952-7915(95)80070-0; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Daser A, 1995, CURR OPIN IMMUNOL, V7, P762, DOI 10.1016/0952-7915(95)80045-X; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1993, J IMMUNOL, V151, P837; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LUO C, UNPUB; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SADLACK B, 1994, EUR J IMMUNOL, V24, P281, DOI 10.1002/eji.1830240144; SADLACK B, 1995, EUR J IMMUNOL, V25, P3053, DOI 10.1002/eji.1830251111; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHUBERT LA, 1995, J BIOL CHEM, V270, P29624; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SHANKAR AH, 1993, J EXP MED, V178, P101, DOI 10.1084/jem.178.1.101; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; STROBER W, 1993, CELL, V75, P203, DOI 10.1016/0092-8674(93)80062-J; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tsytsykova AV, 1996, J BIOL CHEM, V271, P3763; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wang DZ, 1995, ANN NY ACAD SCI, V766, P182, DOI 10.1111/j.1749-6632.1995.tb26661.x; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; YASEEN NR, 1993, J BIOL CHEM, V268, P14285; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845	54	310	317	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					892	895		10.1126/science.272.5263.892	http://dx.doi.org/10.1126/science.272.5263.892			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629027				2022-12-28	WOS:A1996UK75700065
J	Muller, T; Feichtinger, H; Berger, H; Muller, W				Muller, T; Feichtinger, H; Berger, H; Muller, W			Endemic Tyrolean infantile cirrhosis: An ecogenetic disorder	LANCET			English	Article							INDIAN CHILDHOOD CIRRHOSIS; COPPER STORAGE DISEASE; LIVER	Background 138 infants and young children died from an endemic infantile liver cirrhosis in a circumscribed rural area of western Austria between 1900 and 1974. Frequency of the disease peaked between 1930 and 1960. It has disappeared from this area since 1974. Methods Clinical and genetic data on the patients was gathered; pedigrees analysed and ethnographic studies and interviews were undertaken. Findings The disease, which was clinically and pathologically indistinguishable from Indian childhood cirrhosis and hepatic copper toxicosis, was transmitted by autosomal recessive inheritance. Cow's milk, contaminated with copper from untinned copper or brass vessels, may have contributed to the development of copper toxicosis. Replacement of untinned copper cooking utensils by modern industrial vessels has eradicated the disease. Interpretation Our findings strongly suggest that the endemic Tyrolean childhood cirrhosis-and by analogy non-Wilsonian hepatic copper toxicosis occurring elsewhere-is an ecogenetic disorder requiring the involvement of both genetic and environmental factors for the disease to become manifest.	COMMUNITY HOSP, DEPT PAEDIAT, A-6600 REUTTE, AUSTRIA; UNIV INNSBRUCK, DEPT PAEDIAT, REUTTE, AUSTRIA; UNIV INNSBRUCK, DEPT PATHOL, REUTTE, AUSTRIA	University of Innsbruck; University of Innsbruck								ADAMSON M, 1992, GASTROENTEROLOGY, V102, P1771, DOI 10.1016/0016-5085(92)91742-M; ALJAJEH IA, 1994, VIRCHOWS ARCH, V424, P225; BAKER A, 1995, J HEPATOL, V23, P538, DOI 10.1016/0168-8278(95)80059-X; BHAVE SA, 1992, ANN TROP PAEDIATR, V12, P23, DOI 10.1080/02724936.1992.11747542; BHAVE SA, 1982, ARCH DIS CHILD, V57, P922, DOI 10.1136/adc.57.12.922; Finney DJ., 1947, ANN EUGEN, V14, P319, DOI [10.1111/j.1469-1809.1947.tb02410.x, DOI 10.1111/J.1469-1809.1947.TB02410.X]; Fodisch H J, 1968, Verh Dtsch Ges Pathol, V52, P557; GOGL H, 1947, WIENER BEIRAGE KINDE, V1; HORSLEN SP, 1994, GUT, V35, P1497, DOI 10.1136/gut.35.10.1497; KAELIN A., 1955, ARCH JULIUS KLAUS STIFT, V30, P263; LEFKOWITCH JH, 1982, NEW ENGL J MED, V307, P271, DOI 10.1056/NEJM198207293070502; Lim C T, 1979, J Singapore Paediatr Soc, V21, P99; MULLERHOCKER J, 1987, VIRCHOWS ARCH A, V411, P379, DOI 10.1007/BF00713384; MULLERHOCKER J, 1988, PATHOL RES PRACT, V183, P39, DOI 10.1016/S0344-0338(88)80157-2; SCHEINBERG IH, 1994, LANCET, V344, P1002, DOI 10.1016/S0140-6736(94)91649-7; SCHULER F., 1942, Arch. Kinderheilk., V126, P5; TANNER MS, 1979, LANCET, V1, P1203; TANNER MS, 1983, LANCET, V2, P992; TANNER MS, 1986, RECENT ADV PAEDIATRI, V8, P103; VOGEL F, 1979, HUMAN GENETICS PROBL, P105; WALKERSMITH J, 1973, ARCH DIS CHILD, V48, P476, DOI 10.1136/adc.48.6.476; WEISS M, 1989, ACTA PAEDIATR SCAND, V79, P152	22	120	123	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					877	880		10.1016/S0140-6736(96)91351-3	http://dx.doi.org/10.1016/S0140-6736(96)91351-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622397				2022-12-28	WOS:A1996UC45000015
J	Qu, DQ; Ludwig, DS; Gammeltoft, S; Piper, M; Pelleymounter, MA; Cullen, MJ; Mathes, WF; Przypek, J; Kanarek, R; MaratosFlier, E				Qu, DQ; Ludwig, DS; Gammeltoft, S; Piper, M; Pelleymounter, MA; Cullen, MJ; Mathes, WF; Przypek, J; Kanarek, R; MaratosFlier, E			A role for melanin-concentrating hormone in the central regulation of feeding behaviour	NATURE			English	Article							MESSENGER-RIBONUCLEIC-ACID; RAT-BRAIN; PUTATIVE NEUROPEPTIDES; HYPOTHALAMUS; PEPTIDE; GENE; LOCALIZATION; STIMULATION; SYSTEM; RNA	THE hypothalamus plays a central role in the integrated regulation of energy homeostasis and body weight, and a number of hypothalamic neuropeptides, such as neuropeptide Y (ref. 1), galanin(2), CRH (ref. 3), and GLP-1 (ref. 4), have been implicated in the mediation of these effects. To discover new hypothalamic peptides involved in the regulation of body weight, we used differential display polymerase chain reaction(5) to identify messenger RNAs that are differentially expressed in the hypothalamus of ob/+ compared with ob/ob C57Bl/6J mice. We show here that one mRNA that is overexpressed in the hypothalamus of ob/ob mice encodes the neuropeptide melanin-concentrating hormone (MCH). Fasting further increased expression of MCH mRNA in both normal and obese animals. Neurons containing MCH are located in the zona incerta and in the lateral hypothalamus. These areas are involved in regulation of ingestive behaviour, but the role of MCH in mammalian physiology is unknown. To determine whether MCH is involved in the regulation of feeding, we injected MCH into the lateral ventricles of rats and found that their food consumption increased. These findings suggest that MCH participates in the hypothalamic regulation of body weight.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,JOSLIN DIABET CTR,ELLIOT P JOSLIN RES LAB,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02215; AMGEN INC,DEPT NEUROBIOL,THOUSAND OAKS,CA 91320; TUFTS UNIV,DEPT PSYCHOL,MEDFORD,MA 02155	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Amgen; Tufts University				Ludwig, David/0000-0003-3307-8544				ARASE K, 1988, AM J PHYSIOL, V255, pE255, DOI 10.1152/ajpendo.1988.255.3.E255; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRETON C, 1993, MOL CELL NEUROSCI, V4, P271, DOI 10.1006/mcne.1993.1035; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CECHETTO DF, 1988, J COMP NEUROL, V272, P579, DOI 10.1002/cne.902720410; CONE RD, 1993, ANN NY ACAD SCI, V680, P342, DOI 10.1111/j.1749-6632.1993.tb19694.x; JAKUBOWSKI M, 1991, J NEUROENDOCRIN; KAWAUCHI H, 1993, ANN NY ACAD SCI, V680, P64, DOI 10.1111/j.1749-6632.1993.tb19675.x; KAWAUCHI H, 1983, NATURE, V305, P423; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; KYRKOULI SE, 1986, EUR J PHARMACOL, V122, P159, DOI 10.1016/0014-2999(86)90175-5; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MATSUNAGA TO, 1989, PEPTIDES, V10, P773, DOI 10.1016/0196-9781(89)90112-5; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; NAHON JL, 1993, ANN NY ACAD SCI, V680, P111, DOI 10.1111/j.1749-6632.1993.tb19678.x; NAITO N, 1988, CELL TISSUE RES, V253, P291; OOMURA Y, 1987, NEWS PHYSIOL SCI, V2, P199; PARKES D, 1992, ENDOCRINOLOGY, V131, P1826, DOI 10.1210/en.131.4.1826; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RANCE T, 1979, GEN COMP ENDOCR, V37, P64, DOI 10.1016/0016-6480(79)90047-9; RISOLD PY, 1992, NEUROSCI LETT, V136, P145, DOI 10.1016/0304-3940(92)90035-6; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; SKOFITSCH G, 1985, BRAIN RES BULL, V15, P635, DOI 10.1016/0361-9230(85)90213-8; STANLEY BG, 1989, PHYSIOL BEHAV, V46, P173, DOI 10.1016/0031-9384(89)90251-5; TEMPEL DL, 1990, BRAIN RES BULL, V25, P821, DOI 10.1016/0361-9230(90)90177-2; THOMPSON RC, 1990, DNA CELL BIOL, V9, P637, DOI 10.1089/dna.1990.9.637; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; ZAMIR N, 1986, P NATL ACAD SCI USA, V83, P1528, DOI 10.1073/pnas.83.5.1528; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	1099	1153	0	58	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					243	247		10.1038/380243a0	http://dx.doi.org/10.1038/380243a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637571				2022-12-28	WOS:A1996UB11700050
J	Cleveland, DW				Cleveland, DW			Neuronal growth and death: Order and disorder in the axoplasm	CELL			English	Review							AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MICE; NF-L; NEUROFILAMENT; EXPRESSION; CALIBER; CELLS; GENE		UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	Cleveland, DW (corresponding author), UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,9500 GILMAN DR,LA JOLLA,CA 92093, USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BROWN RH, 1995, CELL, V80, P687, DOI 10.1016/0092-8674(95)90346-1; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DALCANTO MC, 1994, AM J PATHOL, V145, P1271; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1757, DOI 10.1093/hmg/3.10.1757; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P471, DOI 10.1097/00005072-198409000-00002; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; WIEDAUPAZOS M, 1996, IN PRESS SCIENCE; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; WONG PC, 1995, J CELL BIOL, V130, P1413, DOI 10.1083/jcb.130.6.1413; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L	17	38	39	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					663	666		10.1016/S0092-8674(00)81044-2	http://dx.doi.org/10.1016/S0092-8674(00)81044-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625404	Bronze			2022-12-28	WOS:A1996TZ99000004
J	Dikstein, R; Ruppert, S; Tjian, R				Dikstein, R; Ruppert, S; Tjian, R			TAF(11)250 is a bipartite protein kinase that phosphorylates the basal transcription factor RAP74	CELL			English	Article							RNA POLYMERASE-II; MOLECULAR-CLONING; INITIATION-FACTOR; BINDING PROTEIN; TERMINAL DOMAIN; COACTIVATORS; GENE; ACTIVATION; PROMOTER; HELICASE	Some TAF subunits of transcription factor TFIID play a pivotal role in transcriptional activation by mediating protein-protein interactions, whereas other TAFs direct promoter selectivity via protein-DNA recognition. Here, we report that purified recombinant TAF(II)250 is a protein serine kinase that selectively phosphorylates RAP74 but not other basal transcription factors or common phosphoacceptor proteins. The phosphorylation of RAP74 also occurs in the context of the complete TFIID complex. Deletion analysis revealed that TAF(II)250 contains two distinct kinase domains each capable of autophosphorylation. However, both the N- and C-terminal kinase domains of TAF(II)250 are required for efficient transphosphorylation of RAP74 on serine residues. These findings suggest that the targeted phosphorylation of RAP74 by TAF(II)250 may provide a mechanism for signaling between components within the initiation complex to regulate transcription.			Dikstein, R (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,401 BARKER HALL,BERKELEY,CA 94720, USA.							BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; NOGUCHI E, 1994, SOMAT CELL MOLEC GEN, V20, P505, DOI 10.1007/BF02255841; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OREILLEY DR, 1994, BACULOVIRUS EXPRESSI; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SOPTA M, 1985, J BIOL CHEM, V260, P353; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER P, 1995, CELL, V81, P1115; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351	40	179	185	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					781	790		10.1016/S0092-8674(00)81055-7	http://dx.doi.org/10.1016/S0092-8674(00)81055-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625415	Bronze			2022-12-28	WOS:A1996TZ99000015
J	Wang, G; Seidman, MM; Glazer, PM				Wang, G; Seidman, MM; Glazer, PM			Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair	SCIENCE			English	Article							C-MYC GENE; FORMING OLIGONUCLEOTIDES; SACCHAROMYCES-CEREVISIAE; TARGETED MUTAGENESIS; TELOMERIC DNA; FREE-EXTRACTS; BINDING; INHIBITION; MUTATIONS; CLEAVAGE	When mammalian cells were treated with tripler-forming oligonucleotides of sufficient binding affinity, mutations were specifically induced in a simian virus 40 vector contained within the cells. Tripler-induced mutagenesis was not detected in xeroderma pigmentosum group A cells nor in Cockayne's syndrome group B cells, indicating a requirement for excision repair and for transcription-coupled repair, respectively, in the process. Tripler formation was also found to stimulate DNA repair synthesis in human cell extracts, in a pattern correlating with the inhibition of transcription in such extracts. These findings may have implications for therapeutic applications of tripler DNA and raise the possibility that naturally occurring triple helices are a source of genetic instability.	YALE UNIV, SCH MED, DEPT THERAPEUT RADIOL, NEW HAVEN, CT 06520 USA; ONCORPHARM, GAITHERSBURG, MD 20877 USA	Yale University			Glazer, Peter/S-7651-2019	Glazer, Peter/0000-0003-4525-5560	NATIONAL CANCER INSTITUTE [R01CA064186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005775, R01ES005775] Funding Source: NIH RePORTER; NCI NIH HHS [CA64186] Funding Source: Medline; NIEHS NIH HHS [ES05775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DATTA A, 1995, SCIENCE, V268, P1616, DOI 10.1126/science.7777859; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GLAZER PM, 1987, MOL CELL BIOL, V7, P218, DOI 10.1128/MCB.7.1.218; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HAVRE PA, 1993, P NATL ACAD SCI USA, V90, P7879, DOI 10.1073/pnas.90.16.7879; HAVRE PA, 1993, J VIROL, V67, P7324, DOI 10.1128/JVI.67.12.7324-7331.1993; Helene Claude, 1993, Current Opinion in Biotechnology, V4, P29, DOI 10.1016/0958-1669(93)90028-U; ING NH, 1993, NUCLEIC ACIDS RES, V21, P2789, DOI 10.1093/nar/21.12.2789; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LAWRENCE CW, 1984, MOL GEN GENET, V195, P487, DOI 10.1007/BF00341451; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; LEVY DD, 1995, CARCINOGENESIS, V16, P1557, DOI 10.1093/carcin/16.7.1557; LIU ZP, 1993, P NATL ACAD SCI USA, V90, P3157, DOI 10.1073/pnas.90.8.3157; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PRAKASH L, 1976, GENETICS, V83, P285; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; QUAH SK, 1980, GENETICS, V96, P819; READ GS, 1982, P NATL ACAD SCI-BIOL, V79, P5215, DOI 10.1073/pnas.79.17.5215; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; WANG G, 1995, MOL CELL BIOL, V15, P1759; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	45	291	309	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					802	805		10.1126/science.271.5250.802	http://dx.doi.org/10.1126/science.271.5250.802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628995				2022-12-28	WOS:A1996TU69400044
J	Keteyian, SJ; Levine, AB; Brawner, CA; Kataoka, T; Rogers, FJ; Schairer, JR; Stein, PD; Levine, TB; Goldstein, S				Keteyian, SJ; Levine, AB; Brawner, CA; Kataoka, T; Rogers, FJ; Schairer, JR; Stein, PD; Levine, TB; Goldstein, S			Exercise training in patients with heart failure - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							V-SLOPE METHOD; ANAEROBIC THRESHOLD; GAS-EXCHANGE; VENTRICULAR-FUNCTION; MUSCLE METABOLISM; PERFORMANCE; CAPACITY; DISEASE	Objective: To assess the benefit of exercise training in patients with heart failure caused by left ventricular systolic dysfunction and to further describe the physiologic changes associated with exercise training in these patients. Design: Randomized, controlled trial. Setting: Urban outpatient clinic. Patients: 40 men with compensated heart failure who were receiving standard medical therapy were randomly assigned to an exercise-training group or to a control group that did not exercise. Fifteen of the 21 patients assigned to exercise training and 14 of the 19 patients assigned to the control group completed the study. Intervention: Patients assigned to exercise training participated in a program of three exercise sessions per week for 24 weeks. Measurements: Symptom-limited exercise tests with gas exchange analysis done just before randomization, at week 12, and at week 24. Results: At week 24, the following changes (mean +/- SE) were seen in patients in the exercise group and patients in the control group, respectively: exercise duration, 2.8 +/- 0.6 minutes and 0.5 +/- 0.5 minutes; peak oxygen consumption (VO2), 231 +/- 54 L/min and 58 +/- 38 L/min; peak ventilation, 12 +/- 3 L/min and -4 +/- 3 L/min; peak heart rate, 10 +/- 4 beats/min and -2 +/- 4 beats/min; and peak power output, 20 +/- 6 W and 2 +/- 5 W. Differences between the increases occurring in the exercise group and the changes occurring in the control group were significant (P < 0.05). Among patients in the exercise group, 85% of the increase in peak VO2 occurred by week 12, and 46% of the increase in peak VO2 was caused by the increase in peak heart rate. Conclusions: Exercise training does not appear to be contraindicated in patients with compensated heart failure. Exercise training improved exercise tolerance, as measured by increases in peak VO2, exercise duration, and power output. This improved exercise tolerance was caused in part by an increase in peak heart rate.			Keteyian, SJ (corresponding author), HENRY FORD HOSP, HENRY FORD HEART & VASC INST, SUITE 1107, 2921 W GRAND BLVD, DETROIT, MI 48202 USA.		Brawner, Clinton A./K-6859-2019	Brawner, Clinton A./0000-0002-1705-6620				ADAMOPOULOS S, 1993, J AM COLL CARDIOL, V21, P1101, DOI 10.1016/0735-1097(93)90231-O; *AM COLL SPORTS ME, 1991, GUID EX TEST PRESCR, P148; ARVAN S, 1988, AM J CARDIOL, V62, P197, DOI 10.1016/0002-9149(88)90211-1; BEAVER WL, 1986, J APPL PHYSIOL, V60, P2020, DOI 10.1152/jappl.1986.60.6.2020; BULLER NP, 1990, BRIT HEART J, V63, P281; Chandrashekhar Y, 1993, Indian Heart J, V45, P493; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; COHENSOLAL A, 1994, HEART FAILURE    APR, P46; DICKSTEIN K, 1990, AM J CARDIOL, V66, P1363, DOI 10.1016/0002-9149(90)91169-7; GELSSER S, 1958, ANN MATH STAT, V29, P885; GOLDSTEIN S, 1988, JAMA-J AM MED ASSOC, V259, P539; HAMBRECHT R, 1995, J AM COLL CARDIOL, V25, P1239, DOI 10.1016/0735-1097(94)00568-B; JETTE M, 1991, CIRCULATION, V84, P1561, DOI 10.1161/01.CIR.84.4.1561; KETEYIAN S, 1991, J APPL PHYSIOL, V70, P2627, DOI 10.1152/jappl.1991.70.6.2627; KIILAVUORI K, 1995, EUR HEART J, V16, P490; KOCH M, 1992, CHEST, V101, pS231, DOI 10.1378/chest.101.5_Supplement.231S; KOSTIS JB, 1994, CHEST, V106, P996, DOI 10.1378/chest.106.4.996; LEE AP, 1979, CIRCULATION, V60, P1519, DOI 10.1161/01.CIR.60.7.1519; MANCINI DM, 1992, CIRCULATION, V85, P1364, DOI 10.1161/01.CIR.85.4.1364; MEYER TE, 1991, J INTERN MED, V230, P407, DOI 10.1111/j.1365-2796.1991.tb00465.x; MINOTTI JR, 1990, J CLIN INVEST, V86, P751, DOI 10.1172/JCI114771; MYERS J, 1991, ANN INTERN MED, V115, P377, DOI 10.7326/0003-4819-115-5-377; SCHNEIDER DA, 1993, MED SCI SPORT EXER, V25, P1180; SMITH RF, 1993, CIRCULATION, V87, P88; STRATTON JR, 1994, J APPL PHYSIOL, V76, P1575, DOI 10.1152/jappl.1994.76.4.1575; SUE DY, 1988, CHEST, V94, P931, DOI 10.1378/chest.94.5.931; SULLIVAN MJ, 1990, CIRCULATION, V81, P518, DOI 10.1161/01.CIR.81.2.518; SULLIVAN MJ, 1988, CIRCULATION, V78, P506, DOI 10.1161/01.CIR.78.3.506	28	150	152	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1051	1057		10.7326/0003-4819-124-12-199606150-00004	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633818				2022-12-28	WOS:A1996UQ65800004
J	Schapiro, JM; Winters, MA; Stewart, F; Efron, B; Norris, J; Kozal, MJ; Merigan, TC				Schapiro, JM; Winters, MA; Stewart, F; Efron, B; Norris, J; Kozal, MJ; Merigan, TC			The effect of high-dose saquinavir on viral load and CD4(+) T-cell counts in HIV-infected patients	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; REVERSE-TRANSCRIPTASE; PROTEASE; LYMPHOCYTES; INHIBITORS; PROTEINASE; MUTATIONS; SAFETY	Objective: To evaluate the efficacy and safety of high-dose therapy with the human immunodeficiency virus (HIV) protease inhibitor saquinavir and to establish the duration of the effect of this therapy. Design: Open-label study. Setting: Clinical research referral center. Patients: 40 adults with human immunodeficiency virus type 1 (HIV-1) infection and CD4(+) T-cell counts of 200 to 500 cells/mm(3). Intervention: Monotherapy with 3600 mg or 7200 mg of saquinavir per day, in six divided doses, for 24 weeks. Measurements: Patients were monitored for adverse events and were evaluated monthly for CD4(+) T-cell count, HIV-1 viral load (as measured by reverse transcriptase polymerase chain reaction [PCR] for plasma HIV RNA levels), immune-complex-disassociated p24 antigen levels, peripheral blood mononuclear cell viral DNA levels (as measured by PCR), and resistance mutations to saquinavir. Quantitative peripheral blood mononuclear cell cultures were also done every 2 months. Results: The low-dose saquinavir regimen (3600 mg/d) resulted in a maximal mean decrease in plasma HIV RNA levels of 1.06 log RNA copies/mL of plasma and a mean maximal increase in CD4 counts of 72 cells/mm(3). At week 24, the plasma HIV RNA level remained 0.48 log RNA copies/mL of plasma lower than baseline (P < 0.001) and the CD4 count remained 31 cells/mm(3) higher than baseline (P = 0.165). The high-dose saquinavir regimen (7200 mg/d) produced a mean maximal decrease in the plasma HIV RNA level of 1.34 log RNA copies/mL of plasma and a mean maximal increase in CD4 count of 121 cells/mm(3). At week 24, the plasma HIV RNA level remained 0.85 log RNA copies/mL of plasma lower than baseline (P < 0.001) and the CD4 count remained 82 cells/mm(3) higher than baseline (P = 0.002). The high-dose regimen produced a greater reduction in plasma HIV RNA level (P = 0.08), a greater reduction in peripheral blood mononuclear cell cultures (P = 0.008), and a greater increase in CD4 count (P = 0.002) than did the low-dose regimen. Higher plasma drug concentrations in individual patients correlated with greater reductions in plasma HIV RNA levels over the two doses. Nine patients receiving the low-dose regimen and four patients receiving the high-dose regimen developed key saquinavir resistance mutations. Adverse reactions, most commonly gastrointestinal problems and elevated serum aminotransferase levels, were more common in patients receiving the high-dose regimen, but most adverse events were mild and all were reversible. Conclusion: Saquinavir is a potent antiviral agent that has a favorable toxicity profile at high doses. Higher doses produce a greater and more durable suppression of viral load and elevation in CD4(+) T-cell counts and may delay the development of resistance mutations. Therapy with high-dose saquinavir alone or in combination with other antiretroviral agents should be investigated further.	ROCHE PROD LTD, WELWYN GARDEN CITY AL7 3AY, HERTS, ENGLAND; STANFORD UNIV, CTR AIDS RES, SCH MED, DIV INFECT DIS, STANFORD, CA 94305 USA; UNIV IOWA, COLL MED, DIV INFECT DIS, IOWA CITY, IA 52242 USA	Roche Holding; Stanford University; University of Iowa			Merigan, Thomas/AGQ-7464-2022	, Michael/0000-0002-7719-7396; Kozal, Michael/0000-0002-3100-8254	NCRR NIH HHS [RR00070] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; COLLIER AC, 1995, 35 INT C ANT AG CHEM; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; EBERLE J, 1995, AIDS RES HUM RETROV, V11, P671, DOI 10.1089/aid.1995.11.671; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992; JACOBSEN H, 1995, VIROLOGY, V206, P527, DOI 10.1016/S0042-6822(95)80069-7; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597; KING RW, 1995, ANTIVIR CHEM CHEMOTH, V6, P80, DOI 10.1177/095632029500600202; KITCHEN VS, 1995, LANCET, V345, P952, DOI 10.1016/S0140-6736(95)90699-1; KOZAL MJ, 1993, J INFECT DIS, V167, P526, DOI 10.1093/infdis/167.3.526; KOZAL MJ, 1994, ANN INTERN MED, V121, P263, DOI 10.7326/0003-4819-121-4-199408150-00005; LAMBERT DM, 1992, ANTIMICROB AGENTS CH, V36, P982, DOI 10.1128/AAC.36.5.982; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MARTIN JA, 1991, BIOCHEM BIOPH RES CO, V176, P180, DOI 10.1016/0006-291X(91)90906-N; MASCHERA B, 1995, J VIROL, V69, P5431, DOI 10.1128/JVI.69.9.5431-5436.1995; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MELLORS JW, 1995, 4 INT WORKSH HIV DRU; MERIGAN TC, 1990, AM J MED, V88, pS11, DOI 10.1016/0002-9343(90)90415-A; MOLLA A, 1995, 4 INT WORKSH HIV DRU; PATICK AK, 1995, J VIROL, V69, P2148, DOI 10.1128/JVI.69.4.2148-2152.1995; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROBERTS NA, 1995, 35 INT C ANT AG CHEM; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704; TURRIZIANI O, 1994, ACTA VIROL, V38, P297; WILLIAMS PE, 1992, W141, P786; WINTERS MA, 1993, J CLIN MICROBIOL, V31, P2960, DOI 10.1128/JCM.31.11.2960-2966.1993; WOOD R, 1993, J ACQ IMMUN DEF SYND, V6, P237; YARCHOAN R, 1990, LANCET, V336, P526, DOI 10.1016/0140-6736(90)92085-V	40	253	255	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1039	1050		10.7326/0003-4819-124-12-199606150-00003	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00003			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633817				2022-12-28	WOS:A1996UQ65800003
J	Keeler, EB; Malkin, JD; Goldman, DP; Buchanan, JL				Keeler, EB; Malkin, JD; Goldman, DP; Buchanan, JL			Can medical savings accounts for the nonelderly reduce health care costs?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSURANCE	Objective.-To understand how medical savings account (MSA) legislation for the nonelderly would affect health care costs. Design.-Economic policy evaluation based on the RAND Health Expenditures Simulation Model. Setting.-National probability sample of nonelderly noninstitutionalized households, Participants.-Persons in 23157 sampled households from the 1993 Current Population Survey. Interventions.-Medical savings account legislation would allow all Americans who are covered only by a catastrophic health care plan to set up a tax-exempt act count that they can use to pay medical bills not covered by their health insurance. The interventions we evaluate differ in the deductibles of the catastrophic plan and in whether the employee or employer funds the MSA. Main Outcome Measures.-Changes in national health expenditures and net societal benefits of health care. Results.-If all insured nonelderly Americans switched to MSAs, their health care expenditures would decline by between 0% and 13%, depending on how the MSAs are designed. However, not all nonelderly Americans would choose MSAs; taking into account selection patterns, health spending would change by +1% to -2%. Conclusions.-Medical savings account legislation would have little impact on health care costs of Americans with employer-provided insurance. However, depending on the size of the catastrophic limit, waste from the excessive use of generously insured care could be reduced, and MSAs would be attractive to both sick and healthy people.	RAND CORP, RAND GRAD SCH, SANTA MONICA, CA USA	RAND Corporation; Pardee RAND Graduate School	Keeler, EB (corresponding author), RAND CORP, HLTH SCI PROGRAM, 1700 MAIN ST, SANTA MONICA, CA 90407 USA.		Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396				*AM AC ACT, 1995, MED SAV ACC COST IMP; BUCHANAN JL, 1991, MANAGE SCI, V37, P1067, DOI 10.1287/mnsc.37.9.1067; *BUR LAB STAT, 1994, EMPL BEN MED LARG PR; Chakraborty G, 1994, J Health Care Mark, V14, P21; Ellis R P, 1985, Adv Health Econ Health Serv Res, V6, P149; ELLWOOD PM, 1995, HEALTH AFFAIR, V14, P24, DOI 10.1377/hlthaff.14.2.24; FELDSTEIN M, 1977, J PUBLIC ECON, V7, P155, DOI 10.1016/0047-2727(77)90044-5; FREUDENHEIM M, 1995, NY TIMES        0414, pA1; Goodman JC, 1994, PATIENT POWER FREE E; GRAMM P, 1994, NEW ENGL J MED, V330, P1752, DOI 10.1056/NEJM199406163302411; GRUBER J, 1995, 5147 NBER; *JOINT COMM TAX ST, 1995, DESCR WAYS MEANS CHA, V3, P1470; KEELER EB, 1988, R3454HHS RAND; MARQUIS MS, 1992, SUBSIDIES NATL HLTH; Newhouse JP, 1993, FREE ALL LESSONS RAN; NICHOLS LM, 1995, HEALTH AFFAIR, V14, P275, DOI 10.1377/hlthaff.14.2.275; PAULY MARK V., 1994, ANAL MED SAVINGS ACC; PAULY MV, 1986, J ECON LIT, V24, P629; PAULY MV, 1995, HEALTH AFFAIR, V14, P125, DOI 10.1377/hlthaff.14.1.125; SHORT PF, 1989, J HEALTH ECON, V8, P293, DOI 10.1016/0167-6296(89)90023-4; SINE JJ, 1994, RGSD110 RAND GRAD SC; *US BUR CENS, 1994, HLTH INS COV 1993; WARDEN C, 1993, INVESTORS BUSIN 0520, P1; WILDAVSKY R, 1993, READERS DIGEST   OCT, V143, P77; 1994, NY TIMES        0816, pA27	25	44	44	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1666	1671		10.1001/jama.275.21.1666	http://dx.doi.org/10.1001/jama.275.21.1666			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UN252	8637141				2022-12-28	WOS:A1996UN25200030
J	Krause, PJ; Telford, SR; Spielman, A; Sikand, V; Ryan, R; Christianson, D; Burke, G; Brassard, P; Pollack, R; Peck, J; Persing, DH				Krause, PJ; Telford, SR; Spielman, A; Sikand, V; Ryan, R; Christianson, D; Burke, G; Brassard, P; Pollack, R; Peck, J; Persing, DH			Concurrent lyme disease and babesiosis - Evidence for increased severity and duration of illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BORRELIA-BURGDORFERI; MICROTI	Objective.-To determine whether patients coinfected with Lyme disease and babesiosis in sites where both diseases are zoonotic experience a greater number of symptoms for a longer period of time than those with either infection alone. Design.-Community-based, yearly serosurvey and clinic-based cohort study. Setting.-Island community in Rhode Island and 2 Connecticut medical clinics from 1990 to 1994. Study Participants.-Long-term residents of the island community and patients seeking treatment at the clinics. Main Outcome Measures.-Seroreactivity to the agents of Lyme disease and babesiosis and number and duration of symptoms. Results.-Of 1156 serosurvey subjects, 97 (8.4%) were seroreactive against Lyme disease spirochete antigen, of whom 14 (14%) also were seroreactive against babesial antigen. Of 240 patients diagnosed with Lyme disease, 26 (11%) were coinfected with babesiosis. Coinfected patients experienced fatigue (P=.002), headache (P<.001), sweats (P<.001), chills (P=.03), anorexia (P=.04), emotional lability (P=.02), nausea (P=.004), conjunctivitis (P=.04), and splenomegaly (P=.01) more frequently than those with Lyme disease alone. Thirteen (50%) of 26 coinfected patients were symptomatic for 3 months or longer compared with 7 (4%) of the 184 patients with Lyme disease alone from whom follow-up data were available (P<.001), Patients coinfected with Lyme disease experienced more symptoms and a more persistent episode of illness than did those (n=10) experiencing babesial infection alone. Circulating spirochetal DNA was detected more than 3 times as often in coinfected patients as in those with Lyme disease alone (P=.06). Conclusions.-Approximately 10% of patients with Lyme disease in southern New England are coinfected with babesiosis in sites where both diseases are zoonotic. The number of symptoms and duration of illness in patients with concurrent Lyme disease and babesiosis are greater than in patients with either infection alone. In areas where both Lyme disease and babesiosis have been reported, the possibility of concomitant babesial infection should be considered when moderate to severe Lyme disease has been diagnosed.	UNIV CONNECTICUT,SCH MED,DEPT LAB MED,FARMINGTON,CT 06030; HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115; MAYO CLIN,DEPT MED,ROCHESTER,MN; MAYO CLIN,DEPT PATHOL,ROCHESTER,MN	University of Connecticut; Harvard University; Harvard T.H. Chan School of Public Health; Mayo Clinic; Mayo Clinic	Krause, PJ (corresponding author), UNIV CONNECTICUT,SCH MED,DEPT PEDIAT,FARMINGTON,CT 06030, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019693, R01AI032403, P01AI030548, R01AI019693] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19693, AI 30548, AI 32403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG AL, 1992, AM J TROP MED HYG, V47, P249, DOI 10.4269/ajtmh.1992.47.249; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BENACH JL, 1981, J INFECT DIS, V144, P473; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; GOLIGHTLY LM, 1989, REV INFECT DIS, V11, P629; GRUNWALDT E, 1983, NEW ENGL J MED, V308, P1166; KIMSEY PB, 1990, CLIN RES, V38, P596; KRAUSE PJ, 1994, J INFECT DIS, V169, P923, DOI 10.1093/infdis/169.4.923; KRAUSE PJ, 1991, J CLIN MICROBIOL, V29, P1; KRAUSE PJ, 1992, PEDIATRICS, V89, P1045; MALAWISTA SE, 1994, J INFECT DIS, V170, P1312, DOI 10.1093/infdis/170.5.1312; MARCUS LC, 1985, ANN INTERN MED, V103, P374, DOI 10.7326/0003-4819-103-3-374; MELDRUM SC, 1992, CLIN INFECT DIS, V15, P1019, DOI 10.1093/clind/15.6.1019; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992; PERSING DH, 1994, J INFECT DIS, V169, P668, DOI 10.1093/infdis/169.3.668; PURVIS AC, 1977, PARASITOLOGY, V75, P197, DOI 10.1017/S003118200006234X; RUEBUSH TK, 1977, ANN INTERN MED, V86, P6, DOI 10.7326/0003-4819-86-1-6; SPIELMAN A, 1985, ANNU REV ENTOMOL, V30, P439, DOI 10.1146/annurev.en.30.010185.002255; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; TELFORD SR, 1995, ANN INTERN MED, V123, P277, DOI 10.7326/0003-4819-123-4-199508150-00006; TELFORD SR, IN PRESS TOPLEY WILS; Vos A. J. de, 1987, Immune responses in parasitic infections: immunology, immunopathology, and immunoprophylaxis. Volume III: Protozoa, P183; 1991, LYME DIS SURVEILL SU, V2, P1	24	326	340	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1657	1660		10.1001/jama.275.21.1657	http://dx.doi.org/10.1001/jama.275.21.1657			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637139				2022-12-28	WOS:A1996UN25200028
J	Kaplan, NM; Gifford, RW				Kaplan, NM; Gifford, RW			Choice of initial therapy for hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHARMACOLOGICAL TREATMENT; ANTIHYPERTENSIVE AGENTS; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; GUIDELINES; MANAGEMENT; SOCIETY; TRIAL	Hypertension is one of the most common conditions treated by the clinician, yet accurate diagnosis and selection of the appropriate treatment can be challenging and recommendations regarding antihypertensive medications continue to evolve. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure recommends diet and exercise for the initial treatment of mild hypertension, followed by a diuretic or P-blocker if necessary, unless contraindicated. This recommendation is based on outcome studies using these drugs that demonstrate reductions in major diseases that treatment of hypertension is intended to prevent: stroke and cardiovascular morbidity and mortality. Other antihypertensive drugs, while not tested in large trials evaluating outcomes, have unique advantages for certain patients. Consideration of the patient's medical conditions and needs, including the cost of medication, is essential to ensuring optimal treatment of hypertension.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; CLEVELAND CLIN FDN,DEPT NEPHROL INTERNAL MED & HYPERTENS,CLEVELAND,OH 44195	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation	Kaplan, NM (corresponding author), UNIV TEXAS,SW MED CTR,DIV HYPERTENS,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ACKER CG, 1995, NEW ENGL J MED, V333, P1572, DOI 10.1056/NEJM199512073332316; [Anonymous], 1993, BMJ, V307, P1541; APPLEGATE WB, 1991, ARCH INTERN MED, V151, P1817, DOI 10.1001/archinte.151.9.1817; BURNIER M, 1992, J INTERN MED, V232, P381, DOI 10.1111/j.1365-2796.1992.tb00603.x; CARTER BL, 1989, J FAM PRACTICE, V29, P257; FRISHMAN WH, 1994, ARCH INTERN MED, V154, P1461, DOI 10.1001/archinte.154.13.1461; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GIFFORD RW, 1989, HYPERTENSION S, V2, P65; GILLENWATER JY, 1995, J UROLOGY, V154, P110, DOI 10.1016/S0022-5347(01)67243-4; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; Kaplan NM, 1994, CLIN HYPERTENSION, P191; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MAHEUX P, 1994, AM J HYPERTENS, V7, P416, DOI 10.1093/ajh/7.5.416; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; OGILVIE RI, 1993, CAN MED ASSOC J, V149, P575; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PIERDOMENICO SD, 1995, EUR HEART J, V16, P692, DOI 10.1093/oxfordjournals.eurheartj.a060975; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; REEVES RA, 1995, JAMA-J AM MED ASSOC, V273, P1211, DOI 10.1001/jama.1995.03520390071036; RIBACKE M, 1995, J INTERN MED, V237, P473, DOI 10.1111/j.1365-2796.1995.tb00872.x; *ROYAL AUSTR COLL, 1991, HYP DIAGN TREATM MAI; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SILAGY CA, 1992, AM J CARDIOL, V70, P1299, DOI 10.1016/0002-9149(92)90765-Q; SWALES JD, 1993, J HYPERTENS, V11, P899, DOI 10.1097/00004872-199309000-00003; TOBIAN L, 1994, AM J HYPERTENS, V7, P859, DOI 10.1093/ajh/7.10.859; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793; WRIGHT JT, 1995, AM J HYPERTENS, V8, pA27; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1993, ARCH INTERN MED, V153, P154	30	59	59	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1577	1580		10.1001/jama.275.20.1577	http://dx.doi.org/10.1001/jama.275.20.1577			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622249				2022-12-28	WOS:A1996UL02900030
J	Bacher, G; Lutcke, H; Jungnickel, B; Rapoport, TA; Dobberstein, B				Bacher, G; Lutcke, H; Jungnickel, B; Rapoport, TA; Dobberstein, B			Regulation by the ribosome of the GTPase of the signal-recognition particle during protein targeting	NATURE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; TRANSLOCATION; RECEPTOR; HYDROLYSIS; SEQUENCE; BINDING; POLYPEPTIDE; REQUIRES; SRP	THE signal-recognition particle (SRP) is important for the targeting of many secretory and membrane proteins to the endoplasmic reticulum (ER). Targeting is regulated by three GTPases, the 54K subunit of SRP (SRP54), and the alpha- and beta-subunits of the SRP receptor(1). When a signal sequence emerges from the ribosome, SRP interacts with it and targets the resulting complex to the ER membrane by binding to the SRP receptor. Subsequently, SRP releases the signal sequence into the translocation channel(2,3). Here we use a complex of a ribosome with a nascent peptide chain, the SRP and its receptor, to investigate GTP binding to SRP54, and GTP hydrolysis. Our findings indicate that a ribosomal component promotes GTP binding to the SRP54 subunit of SRP, GTP-bound SRP54 is essential for high-affinity interaction between SRP and its receptor in the ER membrane. This interaction induces the release of the signal sequence from SRP, the insertion of the nascent polypeptide chain into the translocation channel, and GTP hydrolysis. The contribution of the ribosome had previously escaped detection because only synthetic signal peptides were used in the analysis(4).	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	Bacher, G (corresponding author), UNIV HEIDELBERG,ZMBH,ZENTRUM MOLEK BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HAUSER S, 1995, EMBO J, V14, P5485, DOI 10.1002/j.1460-2075.1995.tb00235.x; HIGH S, 1991, J CELL BIOL, V113, P54; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; RAPIEJKO PJ, 1994, MOL BIOL CELL, V5, P887, DOI 10.1091/mbc.5.8.887; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201	26	121	122	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					248	251		10.1038/381248a0	http://dx.doi.org/10.1038/381248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622769				2022-12-28	WOS:A1996UL24900058
J	Reijo, R; Alagappan, RK; Patrizio, P; Page, DC				Reijo, R; Alagappan, RK; Patrizio, P; Page, DC			Severe oligozoospermia resulting from deletions of azoospermia factor gene on Y chromosome	LANCET			English	Article							INFERTILITY; REGION	Background About 13% of cases of non-obstructive azoospermia are caused by deletion of the azoospermia factor (AZF), a gene or gene complex normally located on the long arm of the Y chromosome. Oligozoospermia is far more common than azoospermia, but little is known about genetic causes. We investigated whether severe oligozoospermia is caused by AZF deletions and, if so, whether those deletions are present in mature spermatozoa, Methods By PCR, we tested leucocyte DNA, from 35 men who presented at infertility clinics and who had severe oligozoospermia, for the presence of 118 DNA landmarks scattered across the Y chromosome. In the two men in whom Y-chromosome deletions in leucocyte DNA were detected, we also tested leucocyte DNA from the individuals' fathers, and in one man we tested sperm DNA. Findings In two men with ejaculate sperm counts of 40 000-100 000 per mL, we detected Y-chromosome leucocyte DNA similar in location to those reported in azoospermic individuals. No Y-chromosome deletions were detected in the fathers of the two men, For one of the two men, sperm DNA was tested, and it showed the same Y-chromosome deletion seen in leucocytes. Interpretation The Y-chromosome deletions in these two men are de-novo mutations, and are therefore the cause of their severe oligozoospermia. Not only is the absence of AZF compatible with spermatogenesis, albeit at reduced rate, but also the resultant sperm bear the mutant Y chromosome. Because intracytoplasmic sperm injection is increasingly used as a means of circumventing oligozoospermia, AZF deletions could be transmitted by this practice, and would probably result in infertile sons. In cases of severe oligozoospermia, it may be appropriate to offer Y-DNA testing and genetic counselling before starting assisted reproductive procedures.	WHITEHEAD INST,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA; FERTIL CTR SAN ANTONIO,MALE INFERTIL SERV,SAN ANTONIO,TX	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Patrizio, Pasquale/AGO-0674-2022	Reijo Pera, Renee/0000-0002-6487-1329				ANDERSSON M, 1988, HUM GENET, V79, P2, DOI 10.1007/BF00291700; BHASIN S, 1994, J CLIN ENDOCR METAB, V79, P1525, DOI 10.1210/jc.79.6.1525; BORGAONKAR DS, 1971, NATURE, V230, P52, DOI 10.1038/230052a0; CHANDLEY AC, 1994, HUM MOL GENET, V3, P1449, DOI 10.1093/hmg/3.suppl_1.1449; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GYLLENSTEN U, 1990, PCR PROTOCOLS, V1, P300; HULL MGR, 1985, BRIT MED J, V291, P1693, DOI 10.1136/bmj.291.6510.1693; KOBAYASHI K, 1994, HUM MOL GENET, V3, P1965, DOI 10.1093/hmg/3.11.1965; NAKAHORI Y, 1994, HUM MOL GENET, V3, P1709, DOI 10.1093/hmg/3.9.1709; ORD T, 1990, HUM REPROD, V5, P987, DOI 10.1093/oxfordjournals.humrep.a137233; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; SILBER SJ, 1995, HUM REPROD, V10, P148, DOI 10.1093/humrep/10.1.148; TESARIK JN, 1995, NEW ENGL J MED, V333, P525, DOI 10.1056/NEJM199508243330819; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; VANZYL JA, 1975, INT J FERTIL, V20, P129; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769	18	437	459	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1290	1293		10.1016/S0140-6736(96)90938-1	http://dx.doi.org/10.1016/S0140-6736(96)90938-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622504				2022-12-28	WOS:A1996UK75800009
J	Reneman, RS; Klaassen, ABM; Visser, HKA				Reneman, RS; Klaassen, ABM; Visser, HKA			Discipline-planning: Blessing or curse?	LANCET			English	Article									ERASMUS UNIV ROTTERDAM,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	Reneman, RS (corresponding author), INST CARDIOVASC RES,MAASTRICHT,NETHERLANDS.							DEJONG JW, IN PRESS EUR HEART J; RIGTER H, 1986, RES POLICY, V15, P33, DOI 10.1016/0048-7333(86)90021-1; 1993, ENDOKRINOLOGIE INFOR, V17, P36	3	0	0	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1231	1233		10.1016/S0140-6736(96)90741-2	http://dx.doi.org/10.1016/S0140-6736(96)90741-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622455				2022-12-28	WOS:A1996UJ59700015
J	Watson, MA; Chaconas, G				Watson, MA; Chaconas, G			Three-site synapsis during Mu DNA transposition: A critical intermediate preceding engagement of the active site	CELL			English	Article							INTEGRATION HOST FACTOR; STRAND-TRANSFER-REACTION; BACTERIOPHAGE-MU; INVITRO TRANSPOSITION; PHAGE-MU; B-PROTEIN; HIN INVERTASOME; A-PROTEIN; ENHANCER; ENDS	The chemical steps of bacteriophage Mu DNA transposition take place within a higher order nucleoprotein structure. We describe a novel intermediate that precedes the previously characterized transpososomes and directly demonstrates the interaction of a distant enhancer element with recombination regions. The transpositional enhancer interacts with the Mu left and right ends to form a three-site synaptic (LER) complex. Under normal reaction conditions, the LER complex is rapidly converted into the more stable Mu transpososomes. However, mutation of the Mu terminal nucleotides results in accumulation of the LER and a failure to form the type 0 transpososome. During the transition from LER to type 0, the Mu DNA termini and the active site of the transposase engage in a catalytically competent conformation.			Watson, MA (corresponding author), UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON, ON N6A 5C1, CANADA.			Watson, Mark/0000-0002-3557-101X				ALLISON RG, 1992, J BIOL CHEM, V267, P19963; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; CRISONA NJ, 1994, J MOL BIOL, V243, P437, DOI 10.1006/jmbi.1994.1671; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kleinschmidt A.K.=, 1968, METHODS ENZYMOL, V12, P361; KLIPPEL A, 1993, EMBO J, V12, P1047, DOI 10.1002/j.1460-2075.1993.tb05746.x; KRAUSE HM, 1986, J BIOL CHEM, V261, P3744; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LAVOIE BD, 1995, CURR TOP MICROBIOL I, V204, P83; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; Sherratt D. J., 1987, DNA REPLICATION RECO, P703; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; VANPUTTE P, 1992, TRENDS GENET, V8, P457; WANG ZG, 1994, P NATL ACAD SCI USA, V91, P699, DOI 10.1073/pnas.91.2.699; WESTMORELAND BC, 1969, SCIENCE, V163, P1343, DOI 10.1126/science.163.3873.1343; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, GENE DEV, V9, P2545, DOI 10.1101/gad.9.20.2545; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; ZOU A, 1991, J BIOL CHEM, V266, P20476	51	66	66	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					435	445		10.1016/S0092-8674(00)81121-6	http://dx.doi.org/10.1016/S0092-8674(00)81121-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616898	Bronze			2022-12-28	WOS:A1996UK14000016
J	Yoto, Y; Kudoh, T; Haseyama, K; Suzuki, N; Chiba, S				Yoto, Y; Kudoh, T; Haseyama, K; Suzuki, N; Chiba, S			Human parvovirus B19 infection associated with acute hepatitis	LANCET			English	Article							DISEASE	Background Human parvovirus (HPV) B19 infection produces a range manifestations including erythema infectiosum in children. Here we describe seven children who had acute hepatitis with HPV B19 infection. Methods Hepatic dysfunction was noted in three children referred to our hospital during the course of erythema infectiosum caused by HPV B19 infection diagnosed by ELISA and PCR. The role of HPV B19 in the pathogenesis of hepatic involvement was investigated retrospectively by PCR assay of stored serum samples from 773 patients admitted to our hospital. Findings 15 patients admitted to our hospital from January, 1991, to June, 1992, were HPV B19 DNA positive, of whom four had acute hepatitis of unknown origin. These four patients were aged between 7 months and 5 years. Of the seven patients, infection with hepatitis A, B, or C viruses or Epstein-Barr virus was ruled out in six by virological examinations. Interpretation Epidemiological evidence suggests that HPV B19 can be the cause of acute hepatitis.			Yoto, Y (corresponding author), SAPPORO MED UNIV,SCH MED,DEPT PEDIAT,CHUO KU,S-1,W-16,SAPPORO,HOKKAIDO 060,JAPAN.							BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; HAAS L, 1990, J VET MED B, V37, P106, DOI 10.1111/j.1439-0450.1990.tb01033.x; JELINEK F, 1987, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V31, P69; METZMAN R, 1989, J PEDIATR GASTR NUTR, V9, P112; MUIR K, 1992, LANCET, V339, P1139, DOI 10.1016/0140-6736(92)90735-L; OHGA S, 1993, AM J PEDIAT HEMATOL, V15, P291; SALIMANS MMM, 1989, J CLIN PATHOL, V42, P525, DOI 10.1136/jcp.42.5.525; TSUDA H, 1993, AM J GASTROENTEROL, V88, P1463; YOTO Y, 1994, LANCET, V344, P624, DOI 10.1016/S0140-6736(94)92014-1; YOTO Y, 1993, ACTA HAEMATOL-BASEL, V90, P8	10	115	120	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					868	869		10.1016/S0140-6736(96)91348-3	http://dx.doi.org/10.1016/S0140-6736(96)91348-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622394				2022-12-28	WOS:A1996UC45000012
J	Sonneborn, K; Collier, J				Sonneborn, K; Collier, J			Ethics committees	LANCET			English	Letter											Sonneborn, K (corresponding author), ST GEORGE HOSP,WANDSWORTH DIST RES ETH COMM,LONDON SW17 0QT,ENGLAND.							Kellett JM, 1996, LANCET, V347, P331, DOI 10.1016/S0140-6736(96)90508-5; *WANDSW DISTR LOC, 1995, TERMS REF CONST ETH	2	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					833	834		10.1016/S0140-6736(96)90912-5	http://dx.doi.org/10.1016/S0140-6736(96)90912-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622366				2022-12-28	WOS:A1996UB15300057
J	Jia, L; Bonaventura, C; Bonaventura, J; Stamler, JS				Jia, L; Bonaventura, C; Bonaventura, J; Stamler, JS			S-nitrosohaemoglobin: A dynamic activity of blood involved in vascular control	NATURE			English	Article							HUMAN-HEMOGLOBIN; NITRIC-OXIDE; BINDING	A dynamic cycle exists in which haemoglobin is S-nitrosylated in the lung when red blood cells are oxygenated, and the NO group is released during arterial-venous transit. The vasoactivity of S-nitrosohaemoglobin is promoted by the erythrocytic export of S-nitrosothiols. These findings highlight newly discovered allosteric and electronic properties of haemoglobin that appear to be involved in the control of blood pressure and which may facilitate efficient delivery of oxygen to tissues. The role of S-nitrosohaemoglobin in the transduction of NO-related activities may have therapeutic applications.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE MARINE BIOMED CTR,NICHOLAS SCH ENVIRONM,PIVERS ISL,NC 28516	Duke University; Duke University	Jia, L (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV RESP & CARDIOVASC MED,MSRB BLDG,ROOM 321,BOX 2612,DURHAM,NC 27710, USA.			JIA, LEE/0000-0001-6839-5545; Stamler, Jonathan/0000-0002-6866-1572				AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P29; BECKMAN JS, 1996, METHODS NITRIC OXIDE; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; CRAESCU CT, 1986, J BIOL CHEM, V261, P4710; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; GAREL MC, 1982, EUR J BIOCHEM, V123, P513; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; JOCELYN PC, 1972, BIOCH SH GROUP, P243; KILBOURN RG, 1994, BIOCHEM BIOPH RES CO, V199, P155, DOI 10.1006/bbrc.1994.1208; KONDO T, 1995, METHOD ENZYMOL, V252, P72; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; MANSOURI A, 1979, BIOCHEM BIOPH RES CO, V89, P441, DOI 10.1016/0006-291X(79)90649-1; OLSEN SB, 1996, CIRCULATION, V93, P329; Olson J S, 1981, Methods Enzymol, V76, P631; SALHANY JM, 1981, TRENDS BIOCH SCI JAN, P1; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; SHEN WQ, 1995, CIRCULATION, V92, P3505, DOI 10.1161/01.CIR.92.12.3505; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TOOTHILL C, 1967, BRIT J ANAESTH, V39, P405, DOI 10.1093/bja/39.5.405; VOGEL WM, 1986, AM J PHYSIOL, V251, pH413, DOI 10.1152/ajpheart.1986.251.2.H413; WENNMALM A, 1992, BRIT J PHARMACOL, V106, P6507; WOOD J, 1994, NEUROPHARMACOLOGY, V33, P1235, DOI 10.1016/0028-3908(94)90022-1	26	1384	1442	1	40	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					221	226		10.1038/380221a0	http://dx.doi.org/10.1038/380221a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637569				2022-12-28	WOS:A1996UB11700043
J	Kost, RG; Straus, SE				Kost, RG; Straus, SE			Postherpetic neuralgia pathogenesis, treatment, and prevention	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POST-HERPETIC NEURALGIA; VARICELLA-ZOSTER VIRUS; ORAL ACYCLOVIR; TOPICAL CAPSAICIN; NEUROPATHIC PAIN; PSYCHOTROPIC-DRUGS; IMMUNE-RESPONSES; DOUBLE-BLIND; AMITRIPTYLINE; PLACEBO				Kost, RG (corresponding author), NIAID, CLIN INVEST LAB,NIH,MED VIROL SECT,BLDG 10, RM 11N228, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							[Anonymous], 1985, CLIN J PAIN; BALFOUR HH, 1988, AM J MED, V85, P68; BENNETT GJ, 1994, ANN NEUROL, V35, pS38, DOI 10.1002/ana.410350712; BERNSTEIN JE, 1987, J AM ACAD DERMATOL, V17, P93, DOI 10.1016/S0190-9622(87)70178-9; BEUTNER KR, 1995, ANTIMICROB AGENTS CH, V39, P1546, DOI 10.1128/AAC.39.7.1546; BONICA JJ, 1990, MANAGEMENT PAIN, V2, P1883; BROWN GR, 1976, SOUTHERN MED J, V69, P576, DOI 10.1097/00007611-197605000-00028; BURGOON CF, 1957, JAMA-J AM MED ASSOC, V164, P265, DOI 10.1001/jama.1957.02980030041010; BURKE BL, 1982, ARCH INTERN MED, V142, P291, DOI 10.1001/archinte.142.2.291; CLEMMENSEN OJ, 1984, CLIN EXP DERMATOL, V9, P557, DOI 10.1111/j.1365-2230.1984.tb00859.x; COBO LM, 1986, OPHTHALMOLOGY, V93, P763; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; COLDING A, 1969, ACTA ANAESTH SCAND, V13, P133, DOI 10.1111/j.1399-6576.1969.tb00440.x; CROOKS RJ, 1991, SCAND J INFECT DIS, P62; CRUE BL, 1994, HDB PAIN MANAGEMENT, P377; DAN K, 1985, ADV PAIN RES THER, V9, P831; DEBENEDITTIS G, 1992, PAIN, V48, P383, DOI 10.1016/0304-3959(92)90088-S; DEGREEF H, 1994, INT J ANTIMICROB AG, V4, P241, DOI 10.1016/0924-8579(94)90024-8; DEMORAGAS JM, 1957, ARCH DERMATOL, V75, P193, DOI 10.1001/archderm.1957.01550140037006; Denny-Brown D., 1944, ARCH NEUROL AND PSYCHIAT, V51, P216; Devor M, 1988, 5TH P WORLD C PAIN A, P114; DUBNER R, 1983, ANNU REV NEUROSCI, V6, P381, DOI 10.1146/annurev.ne.06.030183.002121; DWORKIN RH, 1992, J ABNORM PSYCHOL, V101, P200, DOI 10.1037/0021-843X.101.1.200; EAGLSTEIN WH, 1970, J AMER MED ASSOC, V211, P1681, DOI 10.1001/jama.211.10.1681; EBERT MH, 1949, ARCH DERMATOL SYPH, V60, P641, DOI 10.1001/archderm.1949.01530050003001; EIDE PK, 1994, PAIN, V58, P347, DOI 10.1016/0304-3959(94)90129-5; Epstein E, 1976, Int J Dermatol, V15, P762, DOI 10.1111/j.1365-4362.1976.tb00177.x; ESMANN V, 1987, LANCET, V2, P126; Fields HL, 1994, HARRISONS PRINCIPLES, P49; FINE PG, 1993, HERPES ZOSTER POSTHE, V8, P173; FRIEDMANKIEN AE, 1986, J AM ACAD DERMATOL, V14, P1023, DOI 10.1016/S0190-9622(86)70127-8; GARLAND J., 1943, New England Journal of Medicine, V228, P336, DOI 10.1056/NEJM194303182281103; GERSHON AA, 1979, INFECT IMMUN, V25, P170, DOI 10.1128/IAI.25.1.170-174.1979; GERSON GR, 1977, POSTGRAD MED J, V53, P104; GILDEN DH, 1991, NEUROLOGY, V41, P1215, DOI 10.1212/WNL.41.8.1215; GILDEN DH, 1992, J INFECT DIS, V166, pS30, DOI 10.1093/infdis/166.Supplement_1.S30; GLYNN C, 1990, J ROY SOC MED, V83, P617, DOI 10.1177/014107689008301007; GUESS HA, 1985, PEDIATRICS, V76, P512; HARDING SP, 1987, BRIT J OPHTHALMOL, V71, P353, DOI 10.1136/bjo.71.5.353; HARDING SP, 1991, CURR EYE RES, V10, P177, DOI 10.3109/02713689109020376; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; Hatangdi VS, 1976, ADV PAIN RES THER, V1, P583; HAYWARD A, 1992, J INFECT DIS, V166, P260, DOI 10.1093/infdis/166.2.260; Head H, 1900, BRAIN, V23, P353, DOI 10.1093/brain/23.3.353; Hope-Simpson R E, 1975, J R Coll Gen Pract, V25, P571; HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106; HUFF JC, 1988, AM J MED, V85, P84; HUFF JC, 1987, RES CLIN FORUMS, V9, P37; JESSELL TM, 1978, BRAIN RES, V152, P183, DOI 10.1016/0006-8993(78)90146-4; KECZKES K, 1980, BRIT J DERMATOL, V102, P551, DOI 10.1111/j.1365-2133.1980.tb07654.x; KILLIAN JM, 1968, ARCH NEUROL-CHICAGO, V19, P129, DOI 10.1001/archneur.1968.00480020015001; KISHOREKUMAR R, 1990, CLIN PHARMACOL THER, V47, P305, DOI 10.1038/clpt.1990.33; KISHOREKUMAR R, 1989, PAIN, V37, P223, DOI 10.1016/0304-3959(89)90134-6; LEVIN MJ, 1992, J INFECT DIS, V166, P253, DOI 10.1093/infdis/166.2.253; LEWITH GT, 1983, PAIN, V17, P361, DOI 10.1016/0304-3959(83)90167-7; LOESER JD, 1986, PAIN, V25, P149, DOI 10.1016/0304-3959(86)90089-8; MAX MB, 1988, CLIN PHARMACOL THER, V43, P363, DOI 10.1038/clpt.1988.44; MAX MB, 1988, NEUROLOGY, V38, P1427, DOI 10.1212/WNL.38.9.1427; Mazars G, 1979, ADV PAIN RES THER, V3, P541; MCKENDRICK MW, 1986, BRIT MED J, V293, P1529, DOI 10.1136/bmj.293.6561.1529; MCKENDRICK MW, 1989, BRIT MED J, V298, P431, DOI 10.1136/bmj.298.6671.431; MEIER JL, 1992, J INFECT DIS, V166, pS13, DOI 10.1093/infdis/166.Supplement_1.S13; MERSELIS JG, 1964, ARCH INTERN MED, V113, P679, DOI 10.1001/archinte.1964.00280110059012; MERSKEY H, 1972, POSTGRAD MED J, V48, P594, DOI 10.1136/pgmj.48.564.594; MILLIGAN KA, 1989, BRIT MED J, V298, P253, DOI 10.1136/bmj.298.6668.253-b; MOLIN L, 1969, ACTA DERM-VENEREOL, V49, P569; MORTON P, 1989, NEW ZEAL MED J, V102, P93; MULLER SA, 1969, J INVEST DERMATOL, V52, P71, DOI 10.1038/jid.1969.10; NATHAN PW, 1974, BRIT MED J, V3, P645, DOI 10.1136/bmj.3.5932.645; NATHAN PW, 1978, PAIN, V5, P367, DOI 10.1016/0304-3959(78)90005-2; NORTH RB, 1994, NEUROSURGERY, V34, P756, DOI 10.1227/00006123-199404000-00031; NURMIKKO T, 1991, ACTA NEUROL SCAND, V84, P146, DOI 10.1111/j.1600-0404.1991.tb04923.x; NURMIKKO T, 1990, J NEUROL NEUROSUR PS, V53, P135, DOI 10.1136/jnnp.53.2.135; PORTENOY RK, 1986, ANN NEUROL, V20, P651, DOI 10.1002/ana.410200602; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; RAGOZZINO MW, 1982, MEDICINE, V61, P310, DOI 10.1097/00005792-198209000-00003; RIOPELLE JM, 1984, ARCH DERMATOL, V120, P747, DOI 10.1001/archderm.120.6.747; ROGERS RS, 1971, J AM GERIATR SOC, V19, P495, DOI 10.1111/j.1532-5415.1971.tb01208.x; ROWBOTHAM MC, 1989, PAIN, V38, P297, DOI 10.1016/0304-3959(89)90216-9; ROWBOTHAM MC, 1989, PAIN, V39, P129, DOI 10.1016/0304-3959(89)90001-8; ROWBOTHAM MC, 1995, ANN NEUROL, V37, P246, DOI 10.1002/ana.410370216; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; RUSTHOVEN JJ, 1988, ARCH INTERN MED, V148, P1561, DOI 10.1001/archinte.148.7.1561; STOW PJ, 1989, PAIN, V39, P301, DOI 10.1016/0304-3959(89)90044-4; STRAUS SE, 1984, NEW ENGL J MED, V311, P1362, DOI 10.1056/NEJM198411223112107; SWERDLOW M, 1980, POSTGRAD MED J, V56, P159, DOI 10.1136/pgmj.56.653.159; SWERDLOW M, 1984, CLIN NEUROPHARMACOL, V7, P51, DOI 10.1097/00002826-198403000-00003; TAUB A, 1973, J NEUROSURG, V39, P235, DOI 10.3171/jns.1973.39.2.0235; TAUB A, 1974, ADV NEUROL, V4, P309; TAVERNER D, 1960, LANCET, V2, P671; TYRING S, 1995, ANN INTERN MED, V123, P89, DOI 10.7326/0003-4819-123-2-199507150-00002; WALL PD, 1991, BRIT MED BULL, V47, P631, DOI 10.1093/oxfordjournals.bmb.a072497; WATSON CP, 1982, NEUROLOGY, V32, P671, DOI 10.1212/WNL.32.6.671; WATSON CPN, 1988, PAIN, V35, P289, DOI 10.1016/0304-3959(88)90139-X; WATSON CPN, 1988, PAIN, V34, P129, DOI 10.1016/0304-3959(88)90158-3; WATSON CPN, 1993, CLIN THER, V15, P510; WATSON CPN, 1988, PAIN, V33, P333, DOI 10.1016/0304-3959(88)90292-8; WATSON CPN, 1991, PAIN, V46, P195, DOI 10.1016/0304-3959(91)90076-A; WATSON CPN, 1991, PAIN, V44, P105, DOI 10.1016/0304-3959(91)90124-G; WATSON CPN, 1985, PAIN, V23, P387, DOI 10.1016/0304-3959(85)90009-0; WATSON CPN, 1992, PAIN, V48, P29, DOI 10.1016/0304-3959(92)90128-X; WATSON CPN, 1989, NEUROL CLIN, V7, P231, DOI 10.1016/S0733-8619(18)30811-9; WELLER TH, 1992, J INFECT DIS, V166, pS1; WHITE JC, 1969, PAIN NEUROSURGEON 40, P435; Whitley R. J., 1995, Journal of Investigative Medicine, V43, p252A; WINNIE AP, 1993, REGION ANESTH, V18, P277; WOOD M, 1993, HOW CAN BURDEN ZOSTE, P3; WOOD MJ, 1988, AM J MED, V85, P79; WOOD MJ, 1994, NEW ENGL J MED, V330, P896, DOI 10.1056/NEJM199403313301304; ZACKS SI, 1964, NEUROLOGY, V14, P744, DOI 10.1212/WNL.14.8_Part_1.744	110	433	461	1	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					32	42		10.1056/NEJM199607043350107	http://dx.doi.org/10.1056/NEJM199607043350107			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637540				2022-12-28	WOS:A1996UU47900007
J	Petitti, DB; Sidney, S; Bernstein, A; Wolf, S; Quesenberry, C; Ziel, HK				Petitti, DB; Sidney, S; Bernstein, A; Wolf, S; Quesenberry, C; Ziel, HK			Stroke in users of low-dose oral contraceptives	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THROMBOEMBOLIC DISEASE; RISK; PROGESTOGENS; SAFETY	Background Previous studies have linked the use of oral contraceptive agents to an increased risk of stroke, but those studies have been limited to oral contraceptives containing more estrogen than is now generally used. Methods In a population-based, case-control study, we identified fatal and nonfatal strokes in female members of the California Kaiser Permanente Medical Care Program who were 15 through 44 years of age. Matched controls were randomly selected from female members who had not had strokes. Information about the use of oral contraceptives (essentially limited to low-estrogen preparations) was obtained in interviews. Results-A total of 408 confirmed strokes occurred in a total of 1.1 million women during 3.6 million woman-years of observation. The incidence of stroke was thus 11.3 per 100,000 woman-years. On the basis of data from 295 women with stroke who were interviewed and their controls, the odds ratio for ischemic stroke among current users of oral contraceptives, as compared with former users and women who had never used such drugs, was 1.18 (95 percent confidence interval, 0.54 to 2.59) after adjustment for other risk factors for stroke. The adjusted odds ratio for hemorrhagic stroke was 1.14 (95 percent confidence interval, 0.60 to 2.16). With respect to the risk of hemorrhagic stroke, there was a positive interaction between the current use of oral contraceptives and smoking (odds ratio for women with both these factors, 3.64; 95 percent confidence interval, 0.95 to 13.87). Conclusions Stroke is rare among women of childbearing age. Low-estrogen oral-contraceptive preparations do not appear to increase the risk of stroke. (C)1996, Massachusetts Medical Society.	KAISER PERMANENTE MED CARE PROGRAM,PASADENA,CA; KAISER PERMANENTE MED CARE PROGRAM,OAKLAND,CA	Kaiser Permanente; Kaiser Permanente					NICHD NIH HHS [N01-HD-3108] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1995, LANCET, V346, P1575; DYKEN ML, 1984, STROKE, V15, P1105; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JORDAN WM, 1961, LANCET, V2, P1146, DOI DOI 10.1016/S0140-6736(61)91061-3; KAY CR, 1982, AM J OBSTET GYNECOL, V142, P762; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; Lorentz IT, 1962, BRIT MED J, V2, P1191; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; ORY HW, 1983, MAKING CHOICES; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; STOLLEY PD, 1975, AM J EPIDEMIOL, V102, P197, DOI 10.1093/oxfordjournals.aje.a112148; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VESSEY MP, 1984, BRIT MED J, V289, P530, DOI 10.1136/bmj.289.6444.530-a; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; 1975, JAMA-J AM MED ASSOC, V231, P718	19	268	274	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					8	15		10.1056/NEJM199607043350102	http://dx.doi.org/10.1056/NEJM199607043350102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637557				2022-12-28	WOS:A1996UU47900002
J	delaMaza, LM; Pezzlo, M				delaMaza, LM; Pezzlo, M			Purpura fulminans in Neisseria meningitidis Sepsis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											delaMaza, LM (corresponding author), UNIV CALIF IRVINE,ORANGE,CA 92668, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1709	1709		10.1056/NEJM199606273342605	http://dx.doi.org/10.1056/NEJM199606273342605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT400	8637516				2022-12-28	WOS:A1996UT40000005
J	Dichter, MA; Brodie, MJ				Dichter, MA; Brodie, MJ			Drug therapy - New antiepileptic drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PLACEBO-CONTROLLED CROSSOVER; RESISTANT PARTIAL SEIZURES; PARTIAL-ONSET SEIZURES; GABA UPTAKE INHIBITOR; GAMMA-VINYL-GABA; ADD-ON TREATMENT; DOUBLE-BLIND; CONTROLLED TRIAL; REFRACTORY EPILEPSY; FELBAMATE MONOTHERAPY		UNIV PENN, DEPT NEUROL, PHILADELPHIA, PA 19104 USA; UNIV GLASGOW, WESTERN INFIRM, DEPT MED & THERAPEUT, EPILEPSY RES UNIT, GLASGOW G11 6NT, LANARK, SCOTLAND	University of Pennsylvania; University of Glasgow								AGOSTI R, 1990, EPILEPSY RES, V6, P166, DOI 10.1016/0920-1211(90)90092-A; ALLEN JW, 1983, BRIT MED J, V286, P1246, DOI 10.1136/bmj.286.6373.1246; ANDERSEN KE, 1993, J MED CHEM, V36, P1716, DOI 10.1021/jm00064a005; ANHUT H, 1994, EPILEPSIA, V35, P795, DOI 10.1111/j.1528-1157.1994.tb02513.x; [Anonymous], 1989, LANCET, V2, P196; [Anonymous], 1990, Lancet, V335, P1114; ASCONAPE JJ, 1994, EPILEPSIA S8, V35; BARDY AH, 1991, BRAIN DEV-JPN, V13, P174, DOI 10.1016/S0387-7604(12)80025-8; BINNIE CD, 1989, EPILEPSY RES, V4, P222, DOI 10.1016/0920-1211(89)90007-7; BOURGEOIS B, 1993, NEUROLOGY, V43, P693, DOI 10.1212/WNL.43.4.693; BRODIE M, 1994, LAMOTRIGINE NEW ADV, P83; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Brodie MJ, 1996, NEW ENGL J MED, V334, P168, DOI 10.1056/NEJM199601183340308; BRODIE MJ, 1992, LANCET, V339, P1397, DOI 10.1016/0140-6736(92)91207-O; BUCHANAN N, 1993, J ROY SOC MED, V86, P378; BUTLER WH, 1989, EPILEPSIA, V30, pS15, DOI 10.1111/j.1528-1157.1989.tb05827.x; CALLAGHAN N, 1988, EPILEPSIA, V29, pS29, DOI 10.1111/j.1528-1157.1988.tb05789.x; CHEUNG H, 1992, EPILEPSY RES, V13, P107; CHIRON C, 1991, J CHILD NEUROL, V6, pS52; Cocito L, 1992, Seizure, V1, P163, DOI 10.1016/1059-1311(92)90019-W; COSI V, 1988, EUR NEUROL, V28, P42, DOI 10.1159/000116227; COSI V, 1989, BRIT J CLIN PHARMACO, V27, pS61, DOI 10.1111/j.1365-2125.1989.tb03463.x; CRITCHLEY EMR, 1981, CLOBAZAM, V43, P159; DAM M, 1989, EPILEPSY RES, V3, P70; DICHTER MA, 1995, CURR OPIN NEUROL, V8, P95, DOI 10.1097/00019052-199504000-00001; DULAC O, 1991, J CHILD NEUROL, V6, pS30, DOI 10.1177/0883073891006002071; DULAC O, 1983, PRESSE MED, V12, P1067; FAUGHT E, 1993, NEUROLOGY, V43, P688, DOI 10.1212/WNL.43.4.688; FAUGHT E, IN PRESS NEUROLOGY; FEELY M, 1982, LANCET, V2, P71; FEELY M, 1984, J NEUROL NEUROSUR PS, V47, P1279, DOI 10.1136/jnnp.47.12.1279; French JA, 1996, NEUROLOGY, V46, P54, DOI 10.1212/WNL.46.1.54; FRIIS ML, 1993, ACTA NEUROL SCAND, V87, P224; GOA KL, 1993, DRUGS, V46, P152, DOI 10.2165/00003495-199346010-00009; GRAHAM D, 1989, BRIT J CLIN PHARMACO, V27, pS43, DOI 10.1111/j.1365-2125.1989.tb03460.x; GRANT SM, 1992, DRUGS, V43, P873, DOI 10.2165/00003495-199243060-00007; GREENBLATT DJ, 1981, BRIT J CLIN PHARMACO, V12, P631, DOI 10.1111/j.1365-2125.1981.tb01281.x; Haefely W, 1975, Adv Biochem Psychopharmacol, P131; HAIGH JRM, 1987, BRIT J CLIN PHARMACO, V23, P213, DOI 10.1111/j.1365-2125.1987.tb03032.x; HAMMOND EJ, 1992, EPILEPSY RES, V12, P261, DOI 10.1016/0920-1211(92)90080-D; HELLER AJ, 1988, EPILEPSY RES, V2, P276, DOI 10.1016/0920-1211(88)90020-4; HILL DR, 1993, EUR J PHARM-MOLEC PH, V244, P303, DOI 10.1016/0922-4106(93)90156-4; HINDMARCH I, 1991, NEUROPSYCHOBIOLOGY, V24, P84, DOI 10.1159/000119466; JAWAD S, 1989, EPILEPSIA, V30, P356, DOI 10.1111/j.1528-1157.1989.tb05309.x; KALVIAINEN R, 1991, J CHILD NEUROL S, V2; KILPATRICK E, IN PRESS EPILEPSIA; KOCSIS JD, 1994, NEUROSCI LETT, V169, P181, DOI 10.1016/0304-3940(94)90386-7; KOEPPEN D, 1987, EPILEPSIA, V28, P495, DOI 10.1111/j.1528-1157.1987.tb03678.x; LARKIN JG, 1991, BRIT J CLIN PHARMACO, V31, P65, DOI 10.1111/j.1365-2125.1991.tb03858.x; Leach John P., 1995, P889; LEPPIK IE, 1993, EPILEPSY RES, V14, P165, DOI 10.1016/0920-1211(93)90021-X; LEPPIK IE, 1991, NEUROLOGY, V41, P1785, DOI 10.1212/WNL.41.11.1785; LIEGEOISCHAUVEL C, 1989, BRIT J CLIN PHARMACO, V27, pS69, DOI 10.1111/j.1365-2125.1989.tb03464.x; LIEGEOISCHAUVEL C, 1989, EPILEPSIA, V30, pS23, DOI 10.1111/j.1528-1157.1989.tb05829.x; LIPORACE J, 1994, EPILEPSIA S8, V35; LOISEAU P, 1990, EPILEPSY RES, V7, P136, DOI 10.1016/0920-1211(90)90099-H; MATSUO F, 1993, NEUROLOGY, V43, P2284, DOI 10.1212/WNL.43.11.2284; MCKEE PJW, 1993, EPILEPSIA, V34, P937, DOI 10.1111/j.1528-1157.1993.tb02115.x; MESSENHEIMER J, 1994, EPILEPSIA, V35, P113, DOI 10.1111/j.1528-1157.1994.tb02920.x; MILLER AA, 1986, EPILEPSIA, V27, P483, DOI 10.1111/j.1528-1157.1986.tb03572.x; MUMFORD JP, 1989, BRIT J CLIN PHARMACO, V27, pS101, DOI 10.1111/j.1365-2125.1989.tb03469.x; MUNN R, 1988, CAN J NEUROL SCI, V15, P406, DOI 10.1017/S0317167100028146; NIELSEN EB, 1991, EUR J PHARMACOL, V196, P257, DOI 10.1016/0014-2999(91)90438-V; OH DJ, 1994, EPILEPSIA, V35, P426, DOI 10.1111/j.1528-1157.1994.tb02455.x; OOMMEN K, 1993, NEUROLOGY, V43, P2292; PEDERSEN B, 1987, EPILEPSY RES, V1, P74, DOI 10.1016/0920-1211(87)90054-4; PETROFF OAC, 1995, EPILEPSIA, V36, P457, DOI 10.1111/j.1528-1157.1995.tb00486.x; PISANI F, 1991, J NEUROL NEUROSUR PS, V54, P845, DOI 10.1136/jnnp.54.9.845-a; PULLAR T, 1987, BRIT J CLIN PHARMACO, V24, P793, DOI 10.1111/j.1365-2125.1987.tb03247.x; RHO JM, 1994, ANN NEUROL, V35, P229, DOI 10.1002/ana.410350216; RICHENS A, 1995, EPILEPSY RES, V21, P37, DOI 10.1016/0920-1211(95)00006-V; RISNER M, 1994, EPILEPSIA, V31, P619; RITTER FJ, 1993, NEW ENGL J MED, V328, P29; ROBERTSON MM, 1986, EPILEPSIA, V27, pS27, DOI 10.1111/j.1528-1157.1986.tb05730.x; ROCK DM, 1989, EPILEPSY RES, V3, P138, DOI 10.1016/0920-1211(89)90041-7; SACHDEO R, 1992, ANN NEUROL, V32, P386, DOI 10.1002/ana.410320313; SANDER JWAS, 1990, EPILEPSY RES, V6, P221, DOI 10.1016/0920-1211(90)90077-9; SANDER JWAS, 1991, J NEUROL NEUROSUR PS, V54, P435, DOI 10.1136/jnnp.54.5.435; SCHAPEL GJ, 1993, J NEUROL NEUROSUR PS, V56, P448, DOI 10.1136/jnnp.56.5.448; SCHAUF CL, 1987, BRAIN RES, V413, P185, DOI 10.1016/0006-8993(87)90168-5; SCHMIDT D, 1993, EPILEPSY RES, V15, P67, DOI 10.1016/0920-1211(93)90011-U; SCHMIDT D, 1986, ARCH NEUROL-CHICAGO, V43, P824, DOI 10.1001/archneur.1986.00520080064023; SCOTT DF, 1988, ACTA NEUROL SCAND, V77, P498, DOI 10.1111/j.1600-0404.1988.tb05947.x; SEINO M, 1991, EPILEPSY RES, P169; SHANK RP, 1994, EPILEPSIA, V35, P450, DOI 10.1111/j.1528-1157.1994.tb02459.x; SIVENIUS J, 1993, EPILEPSIA, V34, P193, DOI 10.1111/j.1528-1157.1993.tb02398.x; SMITH D, 1993, EPILEPSIA, V34, P312, DOI 10.1111/j.1528-1157.1993.tb02417.x; STEINHOFF BJ, 1992, EPILEPSY RES, V11, P67, DOI 10.1016/0920-1211(92)90023-M; STEWART JA, 1991, EPILEPSIA, V32, P407; SUZUKI S, 1992, EPILEPSY RES, V12, P21, DOI 10.1016/0920-1211(92)90087-A; THEODORE WH, 1991, EPILEPSIA, V32, P392, DOI 10.1111/j.1528-1157.1991.tb04668.x; THOMPSON SM, 1992, J NEUROPHYSIOL, V67, P1698, DOI 10.1152/jn.1992.67.6.1698; VANAMELSVOORT T, 1994, EPILEPSIA, V35, P181; WAGNER JG, 1984, THER DRUG MONIT, V6, P277, DOI 10.1097/00007691-198409000-00004; WAMIL AW, 1994, EPILEPSY RES, V17, P1, DOI 10.1016/0920-1211(94)90074-4; WANG JJ, 1993, J EPILEPSY, V6, P180, DOI 10.1016/S0896-6974(05)80087-8; White H. Steve, 1994, Epilepsia, V35, P67; WHITE HS, 1992, EPILEPSIA, V33, P564, DOI 10.1111/j.1528-1157.1992.tb01711.x; WILDIN JD, 1990, BRIT J CLIN PHARMACO, V29, P169, DOI 10.1111/j.1365-2125.1990.tb03616.x; WOLFF DL, 1994, EPILEPSIA S8, V35; YAGI K, 1987, CLIN PSYCHIATR, V29, P111	101	229	238	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1583	1590		10.1056/NEJM199606133342407	http://dx.doi.org/10.1056/NEJM199606133342407			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP663	8628341				2022-12-28	WOS:A1996UP66300007
J	Hartl, FU				Hartl, FU			Molecular chaperones in cellular protein folding	NATURE			English	Review							HEAT-SHOCK PROTEINS; RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI GROEL; ATP HYDROLYSIS; THERMOPHILIC ARCHAEBACTERIUM; BINDING-SPECIFICITY; CENTRAL CAVITY; TRANSLOCATION; COMPLEX; DNAK	The folding of many newly synthesized proteins in the cell depends on a set of conserved proteins known as molecular chaperones. These prevent the formation of misfolded protein structures, both under normal conditions and when cells are exposed to stresses such as high temperature. Significant progress has been made in the understanding of the ATP-dependent mechanisms used by the Hsp70 and chaperonin families of molecular chaperones, which can cooperate to assist in folding new polypeptide chains.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Hartl, FU (corresponding author), MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, 1275 YORK AVE, NEW YORK, NY 10021 USA.		Hartl, F. Ulrich/Y-8206-2019					AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CANNON S, 1986, J CELL BIOL, V103, P1327, DOI 10.1083/jcb.103.4.1327; CHATTOPADHYAY S, 1994, BIOCHEM J, V300, P717, DOI 10.1042/bj3000717; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; COPPO A, 1973, J MOL BIOL, V76, P61, DOI 10.1016/0022-2836(73)90081-8; Creighton T. E., 1993, PROTEINS STRUCTURES; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DOBSON C M, 1992, Current Biology, V2, P343, DOI 10.1016/0960-9822(92)90047-E; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; Ellis RJ, 1996, FOLD DES, V1, pR9, DOI 10.1016/S1359-0278(96)00004-1; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1994, CURR BIOL, V4, P633; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FEDOROV AN, 1995, P NATL ACAD SCI USA, V92, P1227, DOI 10.1073/pnas.92.4.1227; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAITANARIS GA, 1994, MOL MICROBIOL, V14, P861, DOI 10.1111/j.1365-2958.1994.tb01322.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGELLIS D, 1995, MOL MICROBIOL, V16, P1259, DOI 10.1111/j.1365-2958.1995.tb02347.x; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HOHFELD J, 1994, J CELL BIOL, V126, P305, DOI 10.1083/jcb.126.2.305; HOHFELD J, 1995, CELL, V83, P589; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; Koonin EV, 1996, CURR BIOL, V6, P404, DOI 10.1016/S0960-9822(02)00508-0; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; KUDLICKI W, 1994, J MOL BIOL, V244, P319, DOI 10.1006/jmbi.1994.1732; KUDLICKI W, 1995, J BIOL CHEM, V270, P10650, DOI 10.1074/jbc.270.18.10650; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NILSSON B, 1991, ANNU REV MICROBIOL, V45, P607; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; Rospert S, 1996, EMBO J, V15, P764, DOI 10.1002/j.1460-2075.1996.tb00412.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; SAIBIL HR, 1994, NAT STRUCT BIOL, V1, P838, DOI 10.1038/nsb1294-838; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHMID FXA, 1993, REV BIOPHYS BIOMOL S, V22, P123; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; TETHING MJ, 1992, NATUR, V355, P33; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VYSOKANOV AV, 1995, FEBS LETT, V375, P211, DOI 10.1016/0014-5793(95)01213-X; WALDMANN T, 1995, BIOL CHEM H-S, V376, P119, DOI 10.1515/bchm3.1995.376.2.119; WALL D, 1994, J BIOL CHEM, V269, P5446; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WANG TF, 1993, J BIOL CHEM, V268, P26049; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; XZABO A, 1994, P NATL ACAD SCI USA, V91, P10345; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x; [No title captured]	154	2972	3138	7	468	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					571	580		10.1038/381571a0	http://dx.doi.org/10.1038/381571a0			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637592				2022-12-28	WOS:A1996UQ65700041
J	Nelson, DE; GrantWorley, JA; Powell, K; Mercy, J; Holtzman, D				Nelson, DE; GrantWorley, JA; Powell, K; Mercy, J; Holtzman, D			Population estimates of household firearm storage practices and firearm carrying in Oregon	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUN OWNERSHIP; UNITED-STATES; ALCOHOL-USE; HOME; HOMICIDE; HANDGUNS; SUICIDE; PREVENTION; CHILDREN; VIOLENCE	Objectives.-To examine statewide data on exposure of adults and children to loaded and unlocked household firearms, and to estimate the prevalence of firearm carrying among adults in Oregon. Design.-Analyses of 1992 and 1993 telephone survey data from 6202 adults aged 18 years and older using the Oregon Behavioral Risk Factor Surveillance System. Main Outcome Measures.-Number of adults and children exposed to household firearms always or sometimes stored loaded and unlocked. Adjusted odds ratios (ORs) for exposure to loaded and unlocked firearms and firearm carrying among adults by demographic and alcohol use patterns. Results.-Ten percent of adults (197 400 persons) lived in households with firearms that were always or sometimes stored loaded and unlocked. An estimated 6.2% of households with children had firearms that were loaded and unlocked, and about 40 000 children lived in these households. Overall, 4.4% of adults carried loaded firearms in the past month, Rural residence, male sex, and less than a college education were associated with living in a household with loaded and unlocked firearms and with firearm carrying. Drinking 5 or more alcoholic beverages on 1 or more occasions in the past month (OR, 1.7, 95% confidence interval, 1.3-2.3) or drinking 60 or more alcoholic beverages in the past month (OR, 1.8; 95% confidence interval, 1.2-2.7) were independently associated with living in households with loaded and unlocked firearms. Conclusions.-Many adults and children are exposed to unsafely stored firearms in Oregon, and many adults early loaded firearms. Improved public health surveillance of firearm storage and firearm carrying using standardized questions and definitions is needed at the national, state, and local levels.	CTR DIS CONTROL & PREVENT, NATL CTR INJURY PREVENT & CONTROL, ATLANTA, GA 30341 USA; OREGON HLTH DIV, PORTLAND, OR USA	Centers for Disease Control & Prevention - USA; Oregon Health & Science University	Nelson, DE (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, DIV ADULT & COMMUNITY HLTH, ATLANTA, GA 30341 USA.							*AM AC PED CTR PRE, 1994, STOP FIR INJ; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BRENT DA, 1991, JAMA-J AM MED ASSOC, V266, P2989, DOI 10.1001/jama.266.21.2989; BRYANT CD, 1988, PSYCHOL REP, V62, P61, DOI 10.2466/pr0.1988.62.1.61; CALLAHAN CM, 1992, JAMA-J AM MED ASSOC, V267, P3038, DOI 10.1001/jama.267.22.3038; Centers for Disease Control and Prevention, 1992, USING CHRONIC DIS DA; CENTERWALL BS, 1991, AM J EPIDEMIOL, V134, P1245, DOI 10.1093/oxfordjournals.aje.a116027; *CTR POP RES CENS, 1994, POP EST OR JUL 1 199; DAVIS JA, 1991, GENERAL SOCIAL SURVE; DAVIS R, 1995, US TODAY        0627, pA9; DIENER E, 1979, J SOC PSYCHOL, V107, P227, DOI 10.1080/00224545.1979.9922703; *FED BUR INV, 1986, UN CRIM REP US 1985; FINGERHUT LA, 1993, ADV DATA VITAL HLTH, V231; FLANAGAN TJ, 1988, SOURCEBOOK CRIMINAL; GOODMAN RA, 1986, AM J PUBLIC HEALTH, V76, P144, DOI 10.2105/AJPH.76.2.144; HEMENWAY D, 1995, JAMA-J AM MED ASSOC, V273, P46, DOI 10.1001/jama.273.1.46; KELLERMANN AL, 1990, AM J EPIDEMIOL, V131, P1080, DOI 10.1093/oxfordjournals.aje.a115600; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KELLERMANN AL, 1995, JAMA-J AM MED ASSOC, V273, P1759, DOI 10.1001/jama.273.22.1759; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; KILLIAS M, 1993, CAN MED ASSOC J, V148, P1721; Kleck G., 1991, POINT BLANK GUNS VIO; KOCHANEK KD, 1994, MONTHLY VITAL STAT S, V43; LEE RK, 1990, JAMA-J AM MED ASSOC, V264, P2210, DOI 10.1001/jama.1990.03450170058010; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LEPKOWSKI JM, 1988, TELEPHONE SURVEY MET, P92; LIZOTTE AJ, 1980, J POLIT MIL SOCIOL, V8, P243; LIZOTTE AJ, 1980, AM SOCIOL REV, V45, P229, DOI 10.2307/2095123; MARKS A, 1976, SOC PROBL, V23, P622; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P1743, DOI 10.1001/jama.273.22.1743; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; McDowall, 1993, J QUANTITATIVE CRIMI, V9, P289, DOI DOI 10.1007/BF01064463; MCDOWALL D, 1994, AM J PUBLIC HEALTH, V84, P1982, DOI 10.2105/AJPH.84.12.1982; MCDOWALL D, 1995, 15 DEP CRIM CRIM JUS; MERCY JA, 1986, NEW ENGL J MED, V319, P1283; OCONNOR JF, 1978, SOC PROBL, V25, P420, DOI 10.1525/sp.1978.25.4.03a00070; PATTERSON PJ, 1987, AM J DIS CHILD, V141, P221, DOI 10.1001/archpedi.1987.04460020111042; RAFFERTY AP, 1995, PUBLIC HEALTH REP, V110, P282; *SAS I INC, 1990, SAS US GUID STAT VER; SEIDEN RH, 1977, OMEGA-J DEATH DYING, V8, P267, DOI 10.2190/KXY8-J7QB-7BR7-J8YW; SENTURIA YD, 1994, PEDIATRICS, V93, P469; SHAH BV, 1993, SOFTWARE SURVEY DATA; SIEGAL PZ, 1993, CDC SURVEILL SUMM, V42, P1; SIENKO DG, 1991, FIREARM INJURY CONTR; SMITH PF, 1990, AM J PUBLIC HEALTH, V80, P309, DOI 10.2105/AJPH.80.3.309; THORNBERRY OT, 1988, WILEY S PRO, P25; Toch H, 1992, PSYCHOL SOCIAL POLIC, P223; *US BUR CENS, 1992, 1990 CENS POP; *US BUR CENS, 1994, 1994 STAT ABSTR US; *US DEP HHS, 1993, NIH PUBL; *US DEP JUST, 1993, SOURC CRIM JUST STAT; VOGEL RE, 1986, J POLICE SCI ADMIN, V14, P242; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WALL JL, 1994, LOUISIANAS BEHAV RIS; WEIL DS, 1992, JAMA-J AM MED ASSOC, V267, P3033, DOI 10.1001/jama.267.22.3033; WHITE AA, 1983, P AM STAT ASS SECT S, P277; WIKTOR SZ, 1994, WESTERN J MED, V161, P137; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; WRIGHT JD, 1992, SOCIETY, V30, P84, DOI 10.1007/BF02719110; WRIGHT JD, 1975, SOC PROBL, V23, P93, DOI 10.1525/sp.1975.23.1.03a00090; WRIGHT JD, 1981, WEAPONS CRIME VIOLEN; 1992, J SCH HLTH, V62, P439; 1991, MMWR-MORBID MORTAL W, V40, P681; 1989, US TODAY        0428, pA6; 1991, LOS ANGELES TIM 0529, pB5	67	45	46	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1744	1748		10.1001/jama.275.22.1744	http://dx.doi.org/10.1001/jama.275.22.1744			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP307	8637172				2022-12-28	WOS:A1996UP30700028
J	Michelson, AM				Michelson, AM			A new turn (or two) for twist	SCIENCE			English	Editorial Material							DROSOPHILA EMBRYOS; CELLS; EXPRESSION; GENE; PROTEIN; PATTERN; MUSCLE; MYOD		BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Michelson, AM (corresponding author), BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA.							BATE M, 1991, DEVELOPMENT, V113, P79; BAYLIES MK, 1995, DEVELOPMENT, V121, P3829; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Borkowski OMD, 1995, DEVELOPMENT, V121, P4183; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; CAUDY M, 1988, CELL, V55, P2061; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CURRIE DA, 1991, DEVELOPMENT, V113, P113; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FUCHTBAUER EM, 1995, DEV DYNAM, V204, P316; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Lawrence PA, 1995, DEVELOPMENT, V121, P4303; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; ROHWEDEL J, 1995, EXP CELL RES, V220, P92, DOI 10.1006/excr.1995.1295; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SIMPSON P, 1983, GENETICS, V105, P615; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; STOETZEL C, 1995, MECH DEVELOP, V51, P251, DOI 10.1016/0925-4773(95)00369-X; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; WU XS, 1995, DEV BIOL, V169, P619, DOI 10.1006/dbio.1995.1174	31	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1449	1450		10.1126/science.272.5267.1449	http://dx.doi.org/10.1126/science.272.5267.1449			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633234				2022-12-28	WOS:A1996UP89900036
J	Fukugita, M; Hogan, CJ; Peebles, PJE				Fukugita, M; Hogan, CJ; Peebles, PJE			The history of the galaxies	NATURE			English	Review							REDSHIFT RADIO GALAXIES; LYMAN-ALPHA SYSTEMS; ABSORPTION SYSTEMS; EVOLUTION; CLUSTERS; SPECTRA; QUASAR; LINE; QSOS	Astronomical observations now reach far enough back in time, in enough depth and detail, to reveal the history of galaxies since their formation. The early Universe contained a network of gas clouds that filled much of the space between the young galaxies, where stars were forming at a high rate. Since then, intergalactic space has been swept clean, and galaxies have continued to convert the dwindling supply of gas slow into stars.	KYOTO UNIV, YUKAWA INST, KYOTO 606, JAPAN; PRINCETON UNIV, PRINCETON, NJ 08544 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA	Kyoto University; Princeton University; University of Washington; University of Washington Seattle	Fukugita, M (corresponding author), INST ADV STUDY, PRINCETON, NJ 08540 USA.		Fukugita, Masataka/A-4438-2011					ALCOCK C, 1995, PHYS REV LETT, V74, P2867, DOI 10.1103/PhysRevLett.74.2867; BECHTOLD J, 1994, ASTROPHYS J, V437, pL83, DOI 10.1086/187688; BERGERON J, 1991, ASTRON ASTROPHYS, V243, P344; BROADHURST TJ, 1988, MON NOT R ASTRON SOC, V235, P827, DOI 10.1093/mnras/235.3.827; BUTCHER H, 1984, ASTROPHYS J, V285, P426, DOI 10.1086/162519; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1, DOI 10.1093/mnras/268.1.L1; CEN RY, 1994, ASTROPHYS J, V431, P451, DOI 10.1086/174499; CEN RY, 1994, ASTROPHYS J, V437, pL9, DOI 10.1086/187670; CHARLTON JC, 1994, ASTROPHYS J, V430, pL29, DOI 10.1086/187430; COPI CJ, 1995, SCIENCE, V267, P192, DOI 10.1126/science.7809624; COWIE LL, 1995, ASTRON J, V109, P1522, DOI 10.1086/117381; COWLE LL, 1995, NATURE, V377, P603; CRAMPTON D, 1995, ASTROPHYS J, V455, P96, DOI 10.1086/176559; CROTTS APS, 1994, ASTROPHYS J, V437, pL79, DOI 10.1086/187687; DALY RA, 1992, ASTROPHYS J, V399, P426, DOI 10.1086/171938; Davidsen AF, 1996, NATURE, V380, P47, DOI 10.1038/380047a0; DINSHAW N, 1995, NATURE, V373, P223, DOI 10.1038/373223a0; DINSHAW N, 1994, ASTROPHYS J, V437, pL87, DOI 10.1086/187689; DINSHAW N, UNPUB ASTR J; DJORGOVSKI S, 1995, ASTROPHYS J, V438, pL13, DOI 10.1086/187703; DRESSLER A, 1980, ASTROPHYS J, V236, P351, DOI 10.1086/157753; DRIVER SP, 1995, ASTROPHYS J, V449, pL23, DOI 10.1086/309637; DUNLOP J, IN PRESS NATURE; Elston R, 1996, ASTROPHYS J, V456, pL13, DOI 10.1086/309853; FALL SM, 1993, ASTROPHYS J, V402, P479, DOI 10.1086/172151; FALL SM, IN PRESS ASTROPHYS J; FOLTZ CB, 1993, ASTRON J, V105, P22, DOI 10.1086/116405; FRANCIS PJ, 1993, ASTRON J, V105, P1633, DOI 10.1086/116542; GARDNER JP, 1993, ASTROPHYS J, V415, pL9, DOI 10.1086/187020; GILMORE G, 1989, ANNU REV ASTRON ASTR, V27, P555; GLAZEBROOK K, 1995, MON NOT R ASTRON SOC, V273, P157, DOI 10.1093/mnras/273.1.157; GLAZEBROOK K, 1995, MON NOT R ASTRON SOC, V275, P169, DOI 10.1093/mnras/275.1.169; GLAZEBROOK K, 1995, MON NOT R ASTRON SOC, V275, pL19, DOI 10.1093/mnras/275.1.L19; GRIFFITHS RE, 1994, ASTROPHYS J, V435, pL19, DOI 10.1086/187584; GRONWALL C, 1995, ASTROPHYS J, V440, pL1, DOI 10.1086/187746; HEMQUIST L, 1996, J ASTROPHYS J, V457, pL51; HEMQUIST L, 1995, ASTROPHYS J, V448, P41; HEWETT PC, 1994, PUBL ASTRON SOC PAC, V106, P113, DOI 10.1086/133355; HOGAN CJ, 1995, PHYS REV LETT, V74, P3105, DOI 10.1103/PhysRevLett.74.3105; JAKOBSEN P, 1994, NATURE, V370, P35, DOI 10.1038/370035a0; KAISER N, 1984, ASTROPHYS J, V284, pL9, DOI 10.1086/184341; Katz N, 1996, ASTROPHYS J, V457, pL57, DOI 10.1086/309900; KENNICUTT RC, 1992, ASTROPHYS J, V388, P310, DOI 10.1086/171154; KLYPIN A, 1995, ASTROPHYS J, V444, P1, DOI 10.1086/175578; KOO DC, 1992, ANNU REV ASTRON ASTR, V30, P613; LACY M, 1994, MON NOT R ASTRON SOC, V271, P504, DOI 10.1093/mnras/271.2.504; LANZETTA KM, 1995, ASTROPHYS J, V442, P538, DOI 10.1086/175459; LANZETTA KM, 1995, ASTROPHYS J, V440, P435, DOI 10.1086/175286; LEFEVRE O, 1995, 9510090; LEITHERER C, 1995, ASTROPHYS J SUPPL S, V96, P9, DOI 10.1086/192112; LILLY SJ, 1995, ASTROPHYS J, V455, P108, DOI 10.1086/176560; Lu LM, 1996, ASTROPHYS J, V457, pL1; MA CP, 1994, ASTROPHYS J, V434, pL5, DOI 10.1086/187559; MADAU P, 1994, ASTROPHYS J, V433, pL53, DOI 10.1086/187546; MAJEWSKI SR, 1993, ANNU REV ASTRON ASTR, V31, P575; MCCARTHY PJ, 1993, ANNU REV ASTRON ASTR, V31, P639; MIRALDAESCUDE J, 1994, MON NOT R ASTRON SOC, V266, P343, DOI 10.1093/mnras/266.2.343; MO HJ, 1993, MON NOT R ASTRON SOC, V264, P705, DOI 10.1093/mnras/264.3.705; MORRIS SL, 1993, ASTROPHYS J, V419, P524, DOI 10.1086/173505; Mulchaey JS, 1996, ASTROPHYS J, V456, P80, DOI 10.1086/176629; OSTRIKER JP, 1975, ASTROPHYS J, V202, P353, DOI 10.1086/153983; PEEBLES PJE, 1991, NATURE, V352, P769, DOI 10.1038/352769a0; PEEBLES PJE, 1994, ASTROPHYS J, V432, pL1, DOI 10.1086/187497; PEEBLES PJE, 1993, PRINCIPLES PHYSICAL; PEI YCC, 1995, ASTROPHYS J, V454, P69, DOI 10.1086/176466; PETTINI M, 1995, ASTROPHYS J, V451, P100, DOI 10.1086/176203; PETTINI M, 1994, ASTROPHYS J, V426, P79, DOI 10.1086/174041; PILDIS RA, 1995, ASTROPHYS J, V443, P514, DOI 10.1086/175544; RAO S, 1993, ASTROPHYS J, V419, P515, DOI 10.1086/173504; Rugers M, 1996, ASTROPHYS J, V459, pL1, DOI 10.1086/309931; SALPETER EE, 1995, ASTROPHYS J, V441, P51, DOI 10.1086/175334; SALUCCI P, IN PRESS MON NOT R A; SARGENT WLW, 1980, ASTROPHYS J SUPPL S, V42, P41, DOI 10.1086/190644; SMETTE A, 1992, ASTROPHYS J, V389, P39, DOI 10.1086/171187; SONGAILA A, 1994, NATURE, V368, P599, DOI 10.1038/368599a0; SONGAILA A, UNPUB ASTR J; SPINRAD H, 1995, ASTROPHYS J, V438, pL51, DOI 10.1086/187713; STEIDEL CC, 1993, ASTROPHYS SPACE SC L, V188, P263; Steidel CC, 1995, ASTRON J, V110, P2519, DOI 10.1086/117709; Steidel CC, 1996, ASTROPHYS J, V462, pL17, DOI 10.1088/1538-4357/462/1/L17; STEIDEL CC, 1994, ASTROPHYS J, V437, pL75, DOI 10.1086/187686; STOCKE JT, 1995, ASTROPHYS J, V451, P24, DOI 10.1086/176197; Unavane M, 1996, MON NOT R ASTRON SOC, V278, P727, DOI 10.1093/mnras/278.3.727; WARREN SJ, 1994, ASTROPHYS J, V421, P412, DOI 10.1086/173660; WHITE DA, 1995, MON NOT R ASTRON SOC, V273, P72, DOI 10.1093/mnras/273.1.72; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0; WOLFE AM, 1993, ANN NY ACAD SCI, V688, P281, DOI 10.1111/j.1749-6632.1993.tb43904.x; WOLFE AM, 1995, ASTROPHYS J, V454, P698, DOI 10.1086/176523; WOLFE AM, 1993, ASTROPHYS J, V402, P411, DOI 10.1086/172145; WOLFE AM, 1994, ASTROPHYS J, V435, pL101, DOI 10.1086/187604; YUN MS, 1994, NATURE, V372, P530, DOI 10.1038/372530a0	92	39	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					489	495		10.1038/381489a0	http://dx.doi.org/10.1038/381489a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632822				2022-12-28	WOS:A1996UP43500049
J	Kirkwood, A; Rioult, MG; Bear, MF				Kirkwood, A; Rioult, MG; Bear, MF			Experience-dependent modification of synaptic plasticity in visual cortex	NATURE			English	Article							LONG-TERM DEPRESSION; AREA CA1; HIPPOCAMPUS; NEURONS; RAT	IN many regions of the cerebral cortex, Ca2+ influx through NMDA (N-methyl-D-aspartate) sensitive glutamate receptors (NMDA receptors) can trigger two forms of synaptic plasticity: long-term depression (LTD) and long-term potentiation (LTP)(1). LTD is induced by low levels of postsynaptic NMDA-receptor activation, for instance in response to low-frequency stimulation, whereas LTP is induced by the stronger activation that occurs following high-frequency stimulation(2-4). Theoretical studies have shown that the properties of synaptic LTD and LTP can account for many aspects of experience-dependent plasticity in the developing visual cortex, provided that the LTD-LTP crossover point (the modification threshold, theta(m)) varies as a function of the history of cortical activity(5-7). Here we provide direct experimental evidence that the value of theta(m) depends on sensory experience. We find in visual cortex of light-deprived rats that LTP is enhanced and LTD diminished over a range of stimulation frequencies, and that these effects can be reversed by as little as two days of light exposure. Our findings support the idea that a variable synaptic-modification threshold allows synaptic weights in neural networks to achieve a stable equilibrium.	BROWN UNIV,DEPT NEUROSCI,PROVIDENCE,RI 02912; BROWN UNIV,HOWARD HUGHES MED INST,PROVIDENCE,RI 02912	Brown University; Brown University; Howard Hughes Medical Institute				Bear, Mark/0000-0002-9903-2541; Rioult, Marika G/0000-0002-7473-2664				Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BUISSERET P, 1976, J PHYSIOL-LONDON, V255, P511, DOI 10.1113/jphysiol.1976.sp011293; BUISSERET P, 1978, NATURE, V272, P816, DOI 10.1038/272816a0; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CLOTHIAUX EE, 1991, J NEUROPHYSIOL, V66, P1785, DOI 10.1152/jn.1991.66.5.1785; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; FREGNAC Y, 1994, J NEUROPHYSIOL, V71, P1403, DOI 10.1152/jn.1994.71.4.1403; GABBOTT PLA, 1986, EXP BRAIN RES, V64, P225; KERR DS, 1996, P NATL ACAD SCI USA, V62, P11637; Kimura F, 1990, Neuroreport, V1, P65, DOI 10.1097/00001756-199009000-00018; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; MAYFORD M, 1905, CELL, V81, P1; Mulkey R. M., 1992, Society for Neuroscience Abstracts, V18, P1498; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; SEJNOWSKI IJ, 1977, J THEOR BIOL, V69, P385, DOI 10.1016/0022-5193(77)90146-1; SELIG DK, 1995, NEURON, V15, P417, DOI 10.1016/0896-6273(95)90045-4; SHOUVAL H, IN PRESS NEURAL COMP; Steele P. M., 1994, Society for Neuroscience Abstracts, V20, P1514; WAGNER JJ, 1995, J NEUROSCI, V15, P1577; WEXLER EM, 1993, NEUROREPORT, V4, P591, DOI 10.1097/00001756-199305000-00034	30	445	454	1	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					526	528		10.1038/381526a0	http://dx.doi.org/10.1038/381526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632826				2022-12-28	WOS:A1996UP43500061
J	Delbanco, TL; Obstbaum, SA				Delbanco, TL; Obstbaum, SA			An 82-year-old woman with cataracts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RISK; SURGERY; INDIA; EYE; 2ND		LENOX HILL HOSP, DEPT OPHTHALMOL, NEW YORK, NY 10021 USA; NYU, SCH MED, NEW YORK, NY USA	Northwell Health; New York University	Delbanco, TL (corresponding author), BETH ISRAEL HOSP, DIV GEN MED & PRIMARY CARE, 330 BROOKLINE AVE, LY339, BOSTON, MA 02215 USA.							*AM AC OPHTH QUAL, 1989, PREF PRACT PATT CAT; BASS EB, 1995, ARCH OPHTHALMOL-CHIC, V113, P1248, DOI 10.1001/archopht.1995.01100100036025; BHATNAGAR R, 1991, ARCH OPHTHALMOL-CHIC, V109, P696, DOI 10.1001/archopht.1991.01080050110040; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; Cataract Management Guideline Panel, 1993, AHCPR PUBL; JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P686, DOI 10.1001/archopht.1993.01090050120041; KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; LAIDLAW A, 1993, EYE, V7, P680, DOI 10.1038/eye.1993.155; LESKE MC, 1983, AM J EPIDEMIOL, V118, P152, DOI 10.1093/oxfordjournals.aje.a113625; MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004; MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017; MELE L, 1990, Investigative Ophthalmology and Visual Science, V31, P236; MINASSIAN DC, 1984, LANCET, V1, P751; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; OBSTBAUM SA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1241, DOI 10.1001/archopht.1995.01100100029021; OSHIKA T, 1995, OPHTHALMIC SURG LAS, V26, P309; SCHEIN OD, 1994, OPHTHALMOLOGY, V101, P1142; SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9; SLOANE ME, 1992, NONINVASIVE ASSESSME, V1, P26; STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026; STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131; STEINBERG EP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1041, DOI 10.1001/archopht.1993.01090080037016; TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201; WILHELMUS KR, 1980, OPHTHALMIC SURG LAS, V11, P264	25	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1675	1680						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637143				2022-12-28	WOS:A1996UN25200032
J	Clouthier, DE; Avarbock, MR; Maika, SD; Hammer, RE; Brinster, RL				Clouthier, DE; Avarbock, MR; Maika, SD; Hammer, RE; Brinster, RL			Rat spermatogenesis in mouse testis	NATURE			English	Article								RECENTLY, transplantation of mouse donor spermatogonial stem cells from a fertile testis to an infertile recipient mouse testis was described(1,2). The donor tells established spermatogenesis in the seminiferous tubules of the host, and normal spermatozoa were produced. In the most successful transplants, the recipient mice were fertile and sired up to 80 per cent of progeny from donor cells(2). Here we examine the feasibility of transplanting spermatogonial stem cells from other species to the mouse seminiferous tubule to generate spermatogenesis. Marked testis cells from transgenic rats sere transplanted to the testes of immunodeficient mice, and in all of 10 recipient mice (in 19 of 20 testes), rat spermatogenesis occurred. Epididymides of eight mice were examined, and the three from mice with the longest transplants (greater than or equal to 110 days) contained rat spermatozoa with normal morphology. The generation of rat spermatogenesis in mouse testes suggests that spermatogonial stem cells of many species could be transplanted, and opens the possibility of xenogeneic spermatogenesis for other species.	UNIV PENN, SCH VET MED, REPROD PHYSIOL LAB, PHILADELPHIA, PA 19104 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Clouthier, David/A-7062-2009	Hammer, Robert E./0000-0001-5487-7551; Brinster, Ralph/0000-0003-1408-7656	NICHD NIH HHS [R01 HD036504] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036504] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AVARBOCK MR, IN PRESS NATURE MED; Baker TG., 1972, REPROD BIOL, P398; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303; BUCCI LR, 1987, MUTAT RES, V176, P259, DOI 10.1016/0027-5107(87)90057-1; CAMPER SA, 1995, BIOL REPROD, V52, P246, DOI 10.1095/biolreprod52.2.246; CATZEFLIS FM, 1993, MAMMAL PHYLOGENY : PLACENTALS, P159; DEKRETSER DM, 1988, PHYSL REPROD, P932; ENDERS GC, 1993, SERTOLI CELL, P447; FISHEL S, 1995, LANCET, V345, P1641, DOI 10.1016/S0140-6736(95)90149-3; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Hogan B, 1994, MANIPULATING MOUSE E; Jiang FX, 1995, INT J ANDROL, V18, P326, DOI 10.1111/j.1365-2605.1995.tb00570.x; KIMURA Y, 1995, DEVELOPMENT, V121, P2397; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; RHIM JA, 1994, SCIENCE, V263, P1149, DOI 10.1126/science.8108734; Russell LD, 1993, SERTOLI CELL, P365; Russell LD, 1990, HISTOLOGICAL HISTOPA, P1; TESARIK JN, 1995, NEW ENGL J MED, V333, P525, DOI 10.1056/NEJM199508243330819	22	285	320	2	20	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 30	1996	381	6581					418	421		10.1038/381418a0	http://dx.doi.org/10.1038/381418a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632797	Green Accepted			2022-12-28	WOS:A1996UN47900050
J	Lalvani, A; Shastri, JS				Lalvani, A; Shastri, JS			HIV epidemic in India: Opportunity to learn from the past	LANCET			English	Editorial Material									RN COOPER HOSP,AIDS SURVEILLANCE & ZONAL BLOOD TESTING CTR,BOMBAY,MAHARASHTRA,INDIA		Lalvani, A (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND.			Lalvani, Ajit/0000-0002-2396-246X				BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; ESSEX M, 1996, 8 ANN M NAT COOP VAC; GREZ M, 1994, J VIROL, V68, P2161, DOI 10.1128/JVI.68.4.2161-2168.1994; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; JACOB KS, 1989, BRIT MED J, V299, P721, DOI 10.1136/bmj.299.6701.721; JAIN MK, 1994, J ACQ IMMUN DEF SYND, V7, P1185; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; 1995, WKLY EPIDEMIOL REC, V70, P353	10	28	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1349	1350		10.1016/S0140-6736(96)91007-7	http://dx.doi.org/10.1016/S0140-6736(96)91007-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637338				2022-12-28	WOS:A1996UL90400006
J	Minakami, H; Sato, I				Minakami, H; Sato, I			Reestimating date of delivery in multifetal pregnancies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRIPLETS; STILLBIRTH; BIRTHS; RISK	Objective.-To clarify the optimal estimated date of delivery for multifetal pregnancies. Design, Subjects, and Setting.-A retrospective study of all 88 936 infants born of multifetal pregnancies and all 6 020 542 infants born of singleton pregnancies that occurred at 26 weeks or more of gestation between 1989 and 1993 in Japan. Main Outcome Measure.-Incidence of stillbirth and early neonatal death according to gestational age at delivery. Results.-The mean+/-SD duration of pregnancy was 37.0+/-2.7 weeks for multifetal pregnancies and 39.6+/-1.6 weeks for singleton pregnancies. In multifetal pregnancies, the incidence of stillbirth and of early neonatal death gradually declined until 37 to 38 weeks' gestation and then increased. These parameters in singleton pregnancies declined until 39 weeks' gestation before increasing. The lowest incidence of perinatal death (stillbirth plus early neonatal death) seen at 38 weeks' gestation in multifetal pregnancies corresponded to that seen at 43 weeks' gestation in singleton pregnancies (10.5 vs 9.7 per 1000 infants). The risk of perinatal death was more than 6 times as high for fetuses of multifetal pregnancies born at 37 weeks or later than for singleton fetuses born at 40 weeks or later (relative risk, 6.6; 95% confidence interval, 6.1-7.1). Conclusion.-Fetuses of multifetal pregnancies are at an increased risk of death after reaching the normative gestational age for singleton pregnancies. Limiting the estimated date of delivery to 37 to 38 weeks may be appropriate in multifetal pregnancies.			Minakami, H (corresponding author), JICHI MED SCH,DEPT OBSTET & GYNECOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.		MINAKAMI, HISANORI/D-6477-2012					AHLENIUS I, 1995, ACTA OBSTET GYN SCAN, V74, P109, DOI 10.3109/00016349509008917; CHISWICK M, 1995, BRIT MED J, V310, P141, DOI 10.1136/bmj.310.6973.141; COLLINS MS, 1990, AM J OBSTET GYNECOL, V162, P1384, DOI 10.1016/0002-9378(90)90896-F; Crowley P., 1989, EFFECTIVE CARE PREGN, P776; ELSTER AD, 1991, OBSTET GYNECOL, V77, P387; FELDMAN GB, 1992, OBSTET GYNECOL, V79, P547; HANNAH ME, 1992, NEW ENGL J MED, V326, P1587, DOI 10.1056/NEJM199206113262402; Imaizumi Y., 1994, J EPIDEMIOL, V4, P103; KIELY JL, 1992, AM J DIS CHILD, V146, P862, DOI 10.1001/archpedi.1992.02160190094029; LAMMER EJ, 1989, JAMA-J AM MED ASSOC, V261, P1757, DOI 10.1001/jama.261.12.1757; MCCLUREBROWNE JC, 1963, AM J OBSTET GYNECOL, V85, P573, DOI 10.1016/0002-9378(63)90304-1; MCLENNAN A, 1990, LANCET, V335, P267; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; *MIN HLTH WELF CHI, 1994, TAB INF; MINAKAMI H, 1993, LANCET, V341, P1603, DOI 10.1016/0140-6736(93)90746-4; MORRISON I, 1985, AM J OBSTET GYNECOL, V152, P975, DOI 10.1016/0002-9378(85)90542-3; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239	17	106	112	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1432	1434		10.1001/jama.275.18.1432	http://dx.doi.org/10.1001/jama.275.18.1432			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618370				2022-12-28	WOS:A1996UJ30300030
J	Zeni, AI; Hoffman, MD; Clifford, PS				Zeni, AI; Hoffman, MD; Clifford, PS			Energy expenditure with indoor exercise machines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERCEIVED EXERTION; PHYSIOLOGICAL-RESPONSES; LACTATE THRESHOLD; RATINGS; ERGOMETER	Objective.-To compare the rates of energy expenditure at given rating of perceived exertion (RPE) levels among 6 different indoor exercise machines. Design.-Repeated measures design. Participants.-Healthy young-adult volunteers, including 8 men and 5 women. Interventions.-Subjects underwent a 4-week habituation period to become familiar with the RPE scale and exercise on an Airdyne, a cross-country skiing simulator, a cycle ergometer, a rowing ergometer, a stair stepper, and a treadmill. Following habituation, each subject completed an exercise test with each exercise machine. The exercise test comprised 3 stages of 5 minutes at self-selected work rates corresponding to RPE values of 11 (fairly light), 13 (somewhat hard), and 15 (hard). Oxygen consumption, from which the rate of energy expenditure was calculated, was measured during the last minute of each 5-minute exercise stage. Heart rate was measured during the last minute of each stage of the exercise test, and blood lactate levels were obtained immediately after each exercise stage. Main Outcome Measure.-Rate of energy expenditure at specified RPE values. Results.-Rates of energy expenditure at a given RPE varied by 1093 kJ/h (261 kcal/h) for the exercise machines. The treadmill induced higher (P<.05) rates of energy expenditure for fixed RPE values than all other exercise machines. The cross-country skiing simulator, rowing ergometer, and stair stepper induced higher (P<.05) rates of energy expenditure than the Airdyne and cycle ergometer. Heart rate varied significantly (P<.001) among exercise machines, with highest values associated with the treadmill and the stair stepper. Lactate concentration varied significantly (P=.004), with highest values associated with use of the stair stepper and the rowing ergometer. Conclusions.-Under the conditions of the study, the treadmill is the optimal indoor exercise machine for enhancing energy expenditure when perceived exertion is used to establish exercise intensity.	MED COLL WISCONSIN,SPORTS PERFORMANCE & TECHNOL LAB,MILWAUKEE,WI 53295; MED COLL WISCONSIN,DEPT PHYS MED & REHABIL,MILWAUKEE,WI 53295; MED COLL WISCONSIN,DEPT ANESTHESIOL,MILWAUKEE,WI 53295; MED COLL WISCONSIN,DEPT PHYSIOL,MILWAUKEE,WI 53295; VET AFFAIRS MED CTR,MILWAUKEE,WI	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Clifford, Philip/0000-0003-1849-3969				*AM COLL SPORTS ME, 1995, ACSMS GUID EX TEST P; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; BOUCKAERT J, 1983, EUR J APPL PHYSIOL O, V51, P51, DOI 10.1007/BF00952537; BOUTCHER SH, 1989, EUR J APPL PHYSIOL O, V59, P365, DOI 10.1007/BF02389812; BUTTS NK, 1995, MED SCI SPORT EXER, V27, P121; BUTTS NK, 1993, MED SCI SPORT EXER, V25, P378; DEMELLO JJ, 1987, MED SCI SPORT EXER, V19, P354; DISHMAN RK, 1994, MED SCI SPORT EXER, V26, P1087; EKBLOM B, 1971, ACTA PHYSIOL SCAND, V83, P399, DOI 10.1111/j.1748-1716.1971.tb05093.x; FARIA IE, 1979, MED SCI SPORT EXER, V11, P79; HAGBERG JM, 1981, J APPL PHYSIOL, V51, P447, DOI 10.1152/jappl.1981.51.2.447; HAGERMAN FC, 1988, MED SCI SPORT EXER, V20, P479; HASKVITZ EM, 1992, INT J SPORTS MED, V13, P377, DOI 10.1055/s-2007-1021284; HETZLER RK, 1991, MED SCI SPORT EXER, V23, P88; Higgs S L, 1981, Can J Appl Sport Sci, V6, P191; HOFFMAN MD, 1994, MED SCI SPORT EXER, V26, P1284; HOFFMAN MD, 1990, MED SCI SPORT EXER, V22, P391; HOFFMAN MD, 1992, INT J SPORTS MED, V13, P137, DOI 10.1055/s-2007-1021245; HORSTMAN DH, 1977, MED SCI SPORT EXER, V9, P52, DOI 10.1249/00005768-197721000-00034; HOWLEY ET, 1992, MED SCI SPORT EXER, V24, P1055; JACKSON AS, 1985, PHYSICIAN SPORTSMED, V13, P76, DOI 10.1080/00913847.1985.11708790; Lusk G, 1924, J BIOL CHEM, V59, P41; Pollock ML, 1990, EXERCISE HLTH DIS EV; RAGG KE, 1980, AM HEART J, V100, P581, DOI 10.1016/0002-8703(80)90676-6; SARGEANT A J, 1973, Journal of Human Ergology, V2, P3; THOMAS TR, 1989, J SPORT MED PHYS FIT, V29, P77; Zeni AI, 1996, ARCH PHYS MED REHAB, V77, P237, DOI 10.1016/S0003-9993(96)90104-5	27	65	67	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1424	1427		10.1001/jama.275.18.1424	http://dx.doi.org/10.1001/jama.275.18.1424			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618368				2022-12-28	WOS:A1996UJ30300028
J	Do, H; Falcone, D; Lin, JL; Andrews, DW; Johnson, AE				Do, H; Falcone, D; Lin, JL; Andrews, DW; Johnson, AE			The cotranslational integration of membrane proteins into the phospholipid bilayer is a multistep process	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL SEQUENCE; POLYPEPTIDE TRANSLOCATION; PHOTOCROSS-LINKING; ER; SEC61P; INSERTION; ADJACENT; IDENTIFICATION; PREPROLACTIN	During the cotranslational integration of a nascent protein into the endoplasmic reticulum membrane, the transmembrane (TM) sequence moves out of an aqueous pore formed by Sec61 alpha, TRAM, and other proteins and into the nonpolar lipid bilayer. Photocross-linking reveals that this movement involves the sequential passage of the TM domain through three different proteinaceous environments: one adjacent to Sec61 alpha and TRAM and two adjacent to TRAM that place different restrictions on TM domain movement. In addition, the TM sequence is not allowed to diffuse into the bilayer from the final TRAM-proximal site until translation terminates. Cotranslational integration is therefore linked to translation and occurs via an ordered multistep pathway at an endoplasmic reticulum site that is multilayered both structurally and functionally.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	McMaster University	Do, H (corresponding author), TEXAS A&M UNIV,HLTH SCI CTR,DEPT MED BIOCHEM & GENET,COLLEGE STN,TX 77843, USA.		Johnson, Arthur E/G-3457-2012	Andrews, David/0000-0002-9266-7157	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HIGH S, 1995, PROG BIOPHYS MOL BIO, V63, P233, DOI 10.1016/0079-6107(95)00005-8; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1993, J BIOL CHEM, V268, P26745; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; JANIAK F, 1994, J BIOL CHEM, V269, P9842; JANIAK F, 1994, BIOCHEM J, V300, P191, DOI 10.1042/bj3000191; JOHNSON AE, 1996, IN PRESS COLD SPRING, V60; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	35	213	214	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					369	378		10.1016/S0092-8674(00)81115-0	http://dx.doi.org/10.1016/S0092-8674(00)81115-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616892	Bronze			2022-12-28	WOS:A1996UK14000010
J	Avramopoulos, D; Mikkelsen, M; Vassilopoulos, D; Grigoriadou, M; Petersen, MB				Avramopoulos, D; Mikkelsen, M; Vassilopoulos, D; Grigoriadou, M; Petersen, MB			Apolipoprotein E allele distribution in parents of Down's syndrome children	LANCET			English	Article							FAMILIAL ALZHEIMER-DISEASE; DNA POLYMORPHISMS; TYPE-4 ALLELE; TRISOMY-21; NONDISJUNCTION; BINDING; PROTEIN; STAGE; GENE; AGE	Background An increased risk of Alzheimer's disease (AD) has been reported in young mothers of Down's syndrome (DS) probands. Allele epsilon 4 of the apolipoprotein E (apoE) gene is a genetic susceptibility factor for AD. We examined the distribution of apoE alleles in people with DS and their parents. Methods We studied 188 Danish people with non-mosaic, free trisomy 21 of known parental origin (determined by DNA polymorphism analysis), and their parents, chosen from a population-based study of DS, and compared the frequency of apoE alleles with a previously published Danish control sample. Findings In people with DS, there was no significant difference in apoE allele distribution compared with controls. The frequency of allele epsilon 4 in the fathers (11.8%) was significantly lower than in controls (17.4%, p=0.02). The frequency of allele epsilon 4 in the mothers (19.4%) was not significantly different from that of controls. Nevertheless, in young mothers with a meiosis II error, epsilon 4 frequency was 30.0%, significantly higher than in older mothers with a meiosis II error (13 0%, p=0.03). Interpretation We suggest that apoE allele epsilon 4 is a risk factor for meiosis II non-disjunction in young mothers, but the biological role of apoE in oocytes remains to be investigated.	INST CHILD HLTH,DEPT GENET,ATHENS,GREECE; JOHN F KENNEDY INST,DEPT MED GENET,DK-2600 GLOSTRUP,DENMARK; UNIV ATHENS,DEPT NEUROL,ATHENS,GREECE	National & Kapodistrian University of Athens			Petersen, Michael Bjørn B/D-1483-2017; Avramopoulos, Dimitrios/J-4392-2012	Petersen, Michael Bjørn B/0000-0003-0316-8207; 	NICHD NIH HHS [N01 HD92707] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMOUYEL P, 1994, LANCET, V344, P1315, DOI 10.1016/S0140-6736(94)90691-2; ANTONARAKIS SE, 1991, NEW ENGL J MED, V324, P872, DOI 10.1056/NEJM199103283241302; ANTONARAKIS SE, 1992, AM J HUM GENET, V50, P544; BROOK JD, 1984, HUM GENET, V66, P41, DOI 10.1007/BF00275184; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; EMANUEL I, 1972, LANCET, V2, P361; FISHER JM, 1995, AM J HUM GENET, V56, P669; GAULDEN ME, 1992, MUTAT RES, V296, P69, DOI 10.1016/0165-1110(92)90033-6; GERDES LU, 1992, GENET EPIDEMIOL, V9, P155, DOI 10.1002/gepi.1370090302; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HARDY J, 1994, LANCET, V343, P979, DOI 10.1016/S0140-6736(94)90106-6; Hook EB, 1981, TRISOMY 21 DOWN SYND, P3; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MIKKELSEN M, 1995, DEV BRAIN DYSFUNCT, V8, P4; NAKAGAWA Y, 1995, LANCET, V345, P68, DOI 10.1016/S0140-6736(95)91196-0; Penrose LS, 1933, J GENET, V27, P219, DOI 10.1007/BF02984413; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PETERSEN MB, 1993, HUM MOL GENET, V2, P1691; PICKERINGBROWN SM, 1994, LANCET, V343, P1155, DOI 10.1016/S0140-6736(94)90257-7; ROYSTON MC, 1994, NEUROREPORT, V5, P2583, DOI 10.1097/00001756-199412000-00044; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SCHUPF N, 1994, LANCET, V344, P353, DOI 10.1016/S0140-6736(94)91398-6; SHERMAN SL, 1994, HUM MOL GENET, V3, P1529, DOI 10.1093/hmg/3.9.1529; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; WARREN AC, 1987, SCIENCE, V237, P652, DOI 10.1126/science.2955519; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	37	51	53	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					862	865		10.1016/S0140-6736(96)91346-X	http://dx.doi.org/10.1016/S0140-6736(96)91346-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622392				2022-12-28	WOS:A1996UC45000010
J	Lee, GH; Proenca, R; Montez, JM; Carroll, KM; Darvishzadeh, JG; Lee, JI; Friedman, JM				Lee, GH; Proenca, R; Montez, JM; Carroll, KM; Darvishzadeh, JG; Lee, JI; Friedman, JM			Abnormal splicing of the leptin receptor in diabetic mice	NATURE			English	Article							YEAST; FRAGMENTS; MUTATION; CLONING; GENES; DNA	MUTATIONS in the mouse diabetes (db) gene result in obesity and diabetes in a syndrome resembling morbid human obesity(1), Previous data suggest that the db gene encodes the receptor for the obese (ob) gene product, leptin(2-7). A leptin receptor was recently cloned from choroid plexus and shown to map to the same 6-cM interval on mouse chromosome 4 as db(8). This receptor maps to the same 300-kilobase interval as db, and has at least six alternatively spliced forms. One of these splice variants is expressed at a high level in the hypothalamus, and is abnormally spliced in C57BL/Ks db/db mice, The mutant protein is missing the cytoplasmic region, and is likely to be defective in signal transduction. This suggests that the weight-reducing effects of leptin may be mediated by signal transduction through a leptin receptor in the hypothalamus.	ROCKEFELLER UNIV, DEPT MOLEC GENET, NEW YORK, NY 10021 USA	Rockefeller University	Lee, GH (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Friedman, Jeffrey M/E-5784-2011					BAHARY N, 1990, P NATL ACAD SCI USA, V87, P8642, DOI 10.1073/pnas.87.21.8642; BAHARY N, 1993, MAMM GENOME, V4, P511, DOI 10.1007/BF00364786; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; Lodish H, 1986, MOL CELL BIOL; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MILATOVICH A, 1994, SOMAT CELL MOLEC GEN, V20, P75, DOI 10.1007/BF02290677; MODI WS, 1995, CYTOGENET CELL GENET, V69, P232, DOI 10.1159/000133971; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NURMINSKY DI, 1993, BIOTECHNIQUES, V15, P201; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TARTON MD, 1996, NATURE, V379, P69; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	27	1988	2082	0	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					632	635		10.1038/379632a0	http://dx.doi.org/10.1038/379632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628397				2022-12-28	WOS:A1996TV68800050
J	Rubin, DM; Coux, O; Wefes, I; Hengartner, C; Young, RA; Goldberg, AL; Finley, D				Rubin, DM; Coux, O; Wefes, I; Hengartner, C; Young, RA; Goldberg, AL; Finley, D			Identification of the gal4 suppressor Sug1 as a subunit of the yeast 26S proteasome	NATURE			English	Article							TAT-MEDIATED TRANSACTIVATION; BINDING-PROTEIN; 26-S PROTEASE; MODULATOR; FAMILY; GENES	THE SUG1 gene of Saccharomyces cerevisiae encodes a putative ATPase. Mutations in SUG1 were isolated(1) as suppressors of a mutation in the transcriptional activation domain of GAL4. Sug1 was recently proposed to be a subunit of the RNA polymerase II holoenzyme and to mediate the association of transcriptional activators with holoenzyme(2). We show here that Sug1 is not a subunit of the holoenzyme, at least in its purified form, but of the 26S proteasome(3,4), a large complex of relative molecular-mass 2,000K that catalyses the ATP-dependent degradation of ubiquitin-protein conjugates. Sug1 co-purifies with the proteasome in both conventional and nickel-chelate affinity chromatography. Our observations account for the reduced ubiquitin-dependent proteolysis in sug1 mutants(5) and suggest that the effects of sug1 mutations on transcription are indirect results of defective proteolysis.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Coux, Olivier/P-6847-2019; Hengartner, Christoph/AAF-5132-2021; Young, Richard A/F-6495-2012; Coux, Olivier/B-3406-2010	Coux, Olivier/0000-0001-8455-3849; Young, Richard A/0000-0001-8855-8647; Coux, Olivier/0000-0001-8455-3849				AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; Crowe J, 1994, Methods Mol Biol, V31, P371; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PETERS JM, 1994, J BIOL CHEM, V269, P7709; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; XU QL, 1995, MOL CELL BIOL, V15, P6025; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050	28	146	147	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					655	657		10.1038/379655a0	http://dx.doi.org/10.1038/379655a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628401				2022-12-28	WOS:A1996TV68800057
J	Smith, SB; Cui, YJ; Bustamante, C				Smith, SB; Cui, YJ; Bustamante, C			Overstretching B-DNA: The elastic response of individual double-stranded and single-stranded DNA molecules	SCIENCE			English	Article								Single molecules of double-stranded DNA (dsDNA) were stretched with force-measuring laser tweezers. Under a longitudinal stress of similar to 65 piconewtons (pN), dsDNA molecules in aqueous buffer undergo a highly cooperative transition into a stable form with 5.8 angstroms rise per base pair, that is, 70% longer than B-form dsDNA. When the stress was relaxed below 65 pN, the molecules rapidly and reversibly contracted to their normal contour lengths. This transition was affected by changes in the ionic strength of the medium and the water activity or by cross-linking of the two strands of dsDNA. Individual molecules of single-stranded DNA were also stretched giving a persistence length of 7.5 angstroms and a stretch modulus of 800 pN. The overstretched form may play a significant role in the energetics of DNA recombination.	UNIV OREGON,INST MOLEC BIOL,DEPT CHEM,EUGENE,OR 97403; UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403	University of Oregon; Howard Hughes Medical Institute; University of Oregon; University of Oregon				Bustamante, Carlos/0000-0002-2970-0073	NIGMS NIH HHS [GM-32543] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032543, R01GM032543] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHTER EK, 1971, BIOPOLYMERS, V10, P1625, DOI 10.1002/bip.360100916; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; BERMAN HM, 1994, CURR OPIN STRUC BIOL, V4, P345, DOI 10.1016/S0959-440X(94)90102-3; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CALLADINE CR, 1992, UNDERSTANDING DNA MO; Callen H.B., 1985, THERMODYNAMICS INTRO; DAVIDSON N, 1971, BACTERIOPHAGE LAMBDA, P56; GHISLAIN LP, 1994, REV SCI INSTRUM, V65, P2762, DOI 10.1063/1.1144613; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1503, DOI 10.1002/bip.1981.360200710; HEARST JE, 1984, Q REV BIOPHYS, V17, P1, DOI 10.1017/S0033583500005242; KLUG A, 1975, NATURE, V255, P530; LANDAU LD, 1986, THEORY ELASTICITY, P67; LANDAU LD, 1980, STATISTICAL PHYSIC 1; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; REES WA, 1993, BIOCHEMISTRY-US, V32, P137, DOI 10.1021/bi00052a019; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHELLMAN JA, 1995, BIOPHYS CHEM, V55, P95, DOI 10.1016/0301-4622(94)00144-9; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Smith Steven B., 1995, Biophysical Journal, V68, pA250; SOBEL ES, 1991, BIOPOLYMERS, V31, P1559, DOI 10.1002/bip.360311311; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; THUNDAT T, 1994, NUCLEIC ACIDS RES, V22, P4224, DOI 10.1093/nar/22.20.4224; Trifonov E.N., 1987, STRUCTURE EXPRESSION, P243; USSERY DW, 1992, METHOD ENZYMOL, V212, P242; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	29	2227	2328	13	384	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					795	799		10.1126/science.271.5250.795	http://dx.doi.org/10.1126/science.271.5250.795			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628994				2022-12-28	WOS:A1996TU69400042
J	Bone, LI				Bone, LI			As I was dying - An examination of classic literature and dying	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Bone, LI (corresponding author), MED COLL OHIO, 3000 ARLINGTON AVE, TOLEDO, OH 43699 USA.								0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1091	1093		10.7326/0003-4819-124-12-199606150-00013	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633826				2022-12-28	WOS:A1996UQ65800012
J	Iezzoni, LI				Iezzoni, LI			100 apples divided by 15 red herrings: A cautionary tale from the mid-19th century on comparing hospital mortality rates	ANNALS OF INTERNAL MEDICINE			English	Article								In 1863, Florence Nightingale argued that London hospitals were dangerous, especially compared with provincial facilities. She bolstered this contention with statistics published in William Farr's Registrar-General report, which claimed that 24 London hospitals had mortality rates exceeding 90%, whereas rural hospitals had an average mortality rate of 13%. Farr had calculated mortality rates by dividing the total number of patients who died throughout the year by the number of inpatients on a single day. When calculated as the annual number of deaths divided by the total number of inpatients during the year, the mortality rate of London hospitals was 10%. A raucous debate erupted in the London medical press over how best to calculate hospital mortality rates. Critics claimed that Farr had not adjusted for differences in severity of illness between urban and rural hospitals and that his figures would mislead the public. Farr and Nightingale, in turn, criticized the poor quality of hospital data. This story reinforces the need to understand the methodologic derivation of statistics intended to compare provider quality.			Iezzoni, LI (corresponding author), BETH ISRAEL HOSP, DEPT MED, DIV GEN MED & PRIMARY CARE, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							[Anonymous], 1908, BIOMETRIKA, V6, P1; BRISTOWE JS, 1864, 1863 MED OFF PRIV CO; BRISTOWE JS, 1864, MED TIMES GAZET 0130, P491; BUCKLE F, 1865, EC STAT HOSP INFIRMA; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; COHEN IB, 1984, SCI AM, V250, P128, DOI 10.1038/scientificamerican0384-128; DIAMOND M, 1981, J R STAT SOC A STAT, V144, P66, DOI 10.2307/2982160; Eyler John M., 1979, VICTORIAN SOCIAL MED; FARR W, 1864, LANCET           APR, P420; FARR W, 1839, LANCET          0713, P572; FARR W, 1864, TIMED TIMES GAZ 0213, P187; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HOLMES T, 1864, LANCET, P451; HOLMES T, 1864, LANCET          0626, P365; Iezzoni LI, 1996, MED CARE, V34, P11, DOI 10.1097/00005650-199601000-00002; IEZZONI LI, 1991, JAMA-J AM MED ASSOC, V265, P3006, DOI 10.1001/jama.265.22.3006; IEZZONI LI, 1996, IN PRESS AM J PUBLIC, V86; IPSTEIN A, 1995, NEW ENGL J MED, V333, P57; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; Keith J M, 1988, Int Nurs Rev, V35, P147; KONG D, 1994, BOSTON GLOBE    1003, P6; KONG D, 1994, BOSTON GLOBE    1003, P7; KONG D, 1994, BOSTON GLOBE    1003, P1; LOCALIO AR, 1995, ANN INTERN MED, V123, P802, DOI 10.7326/0003-4819-123-10-199511150-00010; Nightingale F., 1863, NOTES ON HOSP; Nightingale Florence, 1859, NOTES HOSP; Omoigui NA, 1996, CIRCULATION, V93, P27, DOI 10.1161/01.CIR.93.1.27; Pearson K, 1900, PHILOS MAG, V50, P157, DOI 10.1080/14786440009463897; Pennsylvania Health Care Cost Containment Council, 1995, CONS GUID COR ART BY, V4; SIMPSN JY, 1869, HOSP ITS EFFECTS RES; Simpson James Y., 1869, HOSP ITS EFFECTS RES; SIMPSON JY, 1869, HOSP ITS EFFECTS R 1; Tait L, 1877, ESSAY HOSP MORTALITY; *US HLTH CAR FIN A, 1991, MED HOSP MORT INF 19; Walker H. M., 1929, STUDIES HIST STAT ME; Woodward John, 1974, DO SICK NO HARM STUD; WU AW, 1995, ANN INTERN MED, V122, P149, DOI 10.7326/0003-4819-122-2-199501150-00013; 1964, MED TIMES GAZET 0130, P129; 1865, J STAT SOC LONDON, V28, P527	42	31	31	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1079	1085		10.7326/0003-4819-124-12-199606150-00009	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633823				2022-12-28	WOS:A1996UQ65800009
J	Risold, PY; Swanson, LW				Risold, PY; Swanson, LW			Structural evidence for functional domains in the rat hippocampus	SCIENCE			English	Article							INSITU HYBRIDIZATION; MESSENGER-RNA; AMMONS HORN; NEURONS; NUCLEUS; BRAIN; LOCALIZATION; ORGANIZATION; CONNECTIONS; PROJECTIONS	The hippocampus has two major outputs: multisynaptic pathways to the cerebral cortex and a massive descending projection directly to the lateral septal part of the basal ganglia. Here it is shown that the descending output is organized in such a way that different hippocampal regions map in an orderly way onto hypothalamic systems mediating the expression of different classes of goal-oriented behavior. This mapping is characterized by a unidirectional hippocampo-lateral septal projection and then by bidirectional lateral septo-hypothalamic projections, all topographically organized. The connectional evidence predicts that information processing in different regions of the hippocampus selectively influences the expression of different classes of behavior.	UNIV SO CALIF,PROGRAM NEURAL INFORMAT & BEHAV SCI,LOS ANGELES,CA 90089; UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089	University of Southern California; University of Southern California			Risold, Pierre-Yves/M-7730-2018; Risold, Pierre-Yves/AAJ-9535-2021	Risold, Pierre-Yves/0000-0001-6801-591X; 				CANTERAS NS, 1994, J COMP NEUROL, V348, P41, DOI 10.1002/cne.903480103; CANTERAS NS, UNPUB; COHEN RS, 1992, PROG NEUROBIOL, V38, P423, DOI 10.1016/0301-0082(92)90045-G; ESCLAPEZ M, 1993, J COMP NEUROL, V331, P339, DOI 10.1002/cne.903310305; HAGLUND L, 1984, J COMP NEUROL, V229, P171, DOI 10.1002/cne.902290204; HANSEN S, 1982, BRAIN RES, V239, P213, DOI 10.1016/0006-8993(82)90843-5; HARLAN RE, 1987, J COMP NEUROL, V258, P159, DOI 10.1002/cne.902580202; KOHLER C, 1984, ANAT EMBRYOL, V170, P1, DOI 10.1007/BF00319452; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Ramon y Cajal S, 1995, HISTOLOGY NERVOUS SY; RISOLD PY, 1995, P NATL ACAD SCI USA, V92, P3898, DOI 10.1073/pnas.92.9.3898; RISOLD PY, 1994, J COMP NEUROL, V348, P1, DOI 10.1002/cne.903480102; RISOLD PY, UNPUB; SIEGEL A, 1988, PROG NEUROBIOL, V31, P261, DOI 10.1016/0301-0082(88)90015-9; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; SIMERLY RB, 1988, J COMP NEUROL, V270, P209, DOI 10.1002/cne.902700205; Squire L. R., 1987, MEMORY BRAIN; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; SWANSON LW, 1989, J COMP NEUROL, V285, P413, DOI 10.1002/cne.902850402; SWANSON LW, 1981, J NEUROSCI, V1, P548; SWANSON LW, 1975, SCIENCE, V189, P303, DOI 10.1126/science.49928; SWANSON LW, 1978, J COMP NEUROL, V181, P681, DOI 10.1002/cne.901810402; SWANSON LW, 1977, J COMP NEUROL, V172, P49, DOI 10.1002/cne.901720104; Swanson LW, 1987, HDB CHEM NEUROANATOM, P125; TAUBE JS, 1995, J NEUROSCI, V15, P70; [No title captured]	26	282	283	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1484	1486		10.1126/science.272.5267.1484	http://dx.doi.org/10.1126/science.272.5267.1484			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633241				2022-12-28	WOS:A1996UP89900048
J	Attenburrow, MEJ; Dowling, BA; Sharpley, AL; Cowen, PJ				Attenburrow, MEJ; Dowling, BA; Sharpley, AL; Cowen, PJ			Case-control study of evening melatonin concentration in primary insomnia	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,LITTLEMORE HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND	University of Oxford				Sharpley, Ann L/0000-0002-0623-1067; Cowen, Philip/0000-0001-5518-6138				DEMENT WC, 1982, J AM GERIATR SOC, V30, P25, DOI 10.1111/j.1532-5415.1982.tb03700.x; GARFINKEL D, 1995, LANCET, V346, P541, DOI 10.1016/S0140-6736(95)91382-3; HAIMOV I, 1994, BRIT MED J, V309, P167, DOI 10.1136/bmj.309.6948.167; IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem-55-1-27; ZHDANOVA IV, 1995, CLIN PHARMACOL THER, V57, P552, DOI 10.1016/0009-9236(95)90040-3	5	18	18	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1263	1264		10.1136/bmj.312.7041.1263	http://dx.doi.org/10.1136/bmj.312.7041.1263			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UM404	8634615	Green Published			2022-12-28	WOS:A1996UM40400020
J	Goadsby, PJ; Olesen, J				Goadsby, PJ; Olesen, J			Fortnightly review - Diagnosis and management of migraine	BRITISH MEDICAL JOURNAL			English	Article							SUMATRIPTAN		GLOSTRUP CTY HOSP, DEPT NEUROL, GLOSTRUP, DENMARK	University of Copenhagen	Goadsby, PJ (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, INST NEUROL, LONDON WC1N 3BG, ENGLAND.		Goadsby, Peter J/B-2267-2009; Goadsby, Peter J/Z-1970-2019	Goadsby, Peter J/0000-0003-3260-5904; Olesen, Jes/0000-0002-6712-2702				ALTER M, 1994, NEUROLOGY, V44, P1353; Cull RE, 1992, BRIT J EC, V2, P103; EDWARDS C, 1991, EUR NEUROL, V31, P300; FERRARI MD, 1991, NEW ENGL J MED, V325, P316; GOADSBY PJ, 1993, ANN NEUROL, V33, P48, DOI 10.1002/ana.410330109; GOADSBY PJ, 1991, LANCET, V338, P782, DOI 10.1016/0140-6736(91)90666-D; GOADSBY PJ, 1991, HEADACHE, V31, P365, DOI 10.1111/j.1526-4610.1991.hed3106365.x; Headache Classification Committee of the International Headache Society, 1988, CEPHALALGIA S7, V8, P1; HERING R, 1992, CEPHALALGIA, V12, P81, DOI 10.1046/j.1468-2982.1992.1202081.x; HUMPHREY PPA, 1994, CEPHALALGIA, V14, P401, DOI 10.1046/j.1468-2982.1994.1406401.x; JENSEN R, 1994, NEUROLOGY, V44, P647, DOI 10.1212/WNL.44.4.647; LANGEMARK M, 1984, PAIN, V19, P81, DOI 10.1016/0304-3959(84)90067-8; MOSKOWITZ MA, 1993, ANNU REV MED, V44, P145, DOI 10.1146/annurev.med.44.1.145; OLESEN J, 1991, CEREBROVAS BRAIN MET, V3, P1; OLESEN J, 1995, BRIT MED J, V310, P479, DOI 10.1136/bmj.310.6978.479; RASSMUSSEN BK, 1995, CEPHALALGIA, V15, P45; RUSSELL MB, 1994, CEPHALALGIA, V14, P107, DOI 10.1046/j.1468-2982.1994.1402107.x; RUSSELL MB, 1992, CEPHALALGIA, V12, P369, DOI 10.1111/j.1468-2982.1992.00369.x; SCHARFF L, 1995, HEADACHE, V35, P397, DOI 10.1111/j.1526-4610.1995.hed3507397.x; TFELTHANSEN P, 1995, LANCET, V346, P923, DOI 10.1016/S0140-6736(95)91554-0	20	48	49	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1279	1283		10.1136/bmj.312.7041.1279	http://dx.doi.org/10.1136/bmj.312.7041.1279			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634619	Green Published			2022-12-28	WOS:A1996UM40400025
J	Zhang, JA; HagopianDonaldson, S; Serbedzija, G; Elsemore, J; PlehnDujowich, D; McMahon, AP; Flavell, RA; Williams, T				Zhang, JA; HagopianDonaldson, S; Serbedzija, G; Elsemore, J; PlehnDujowich, D; McMahon, AP; Flavell, RA; Williams, T			Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2	NATURE			English	Article							RETINOIC ACID; DNA-BINDING	THE retinoic acid-inducible transcription factor AP-2 is expressed in epithelial and neural crest cell lineages during murine development(1-5). AP-2 can regulate neural and epithelial gene transcription, and is associated with overexpression of c-erbB-2 in human breast-cancer cell lines(4-6). To ascertain the importance of AP-2 for normal development, we have derived mice containing a homozygous disruption of the AP-2 gene. These AP-2-null mice have multiple congenital defects and die at birth, In particular, the AP-2 knockout mice exhibit anencephaly, craniofacial defects and thoraco-abdominoschisis. Skeletal defects occur in the head and trunk region, where many bones are deformed or absent. Analysis of these mice earlier in embryogenesis indicates a failure of cranial neural-tube closure and defects in cranial ganglia development. We have shown that AP-2 is a fundamental regulator of mammalian craniofacial development.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA; HARVARD UNIV, BIOL LABS, DEPT CELLULAR & DEV BIOL, CAMBRIDGE, MA 02138 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA	Yale University; Harvard University; Howard Hughes Medical Institute; Yale University; Yale University			McMahon, Andrew P/ABE-7520-2020					BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CHEN JM, 1952, J ANAT, V86, P373; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; COPP AJ, 1994, CIBA F SYMP, V181, P118; DAVIES AF, 1995, HUM MOL GENET, V4, P121; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; GUNTHER T, 1994, DEVELOPMENT, V120, P3119; Hall B. K., 1988, NEURAL CREST; HALL BK, 1986, J EMBRYOL EXP MORPH, V93, P133; KOTCH LE, 1992, AM J MED GENET, V44, P168, DOI 10.1002/ajmg.1320440210; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MARK M, 1993, DEVELOPMENT, V119, P319; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; MORRISSKAY G, 1994, NEURAL TUBE DEFECTS, P55; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Warren G, 1996, GENOMICS, V31, P234, DOI 10.1006/geno.1996.0037; WEI X, 1993, AM J MED GENET, V47, P862, DOI 10.1002/ajmg.1320470613; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	30	497	515	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	1996	381	6579					238	241		10.1038/381238a0	http://dx.doi.org/10.1038/381238a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622766				2022-12-28	WOS:A1996UL24900055
J	Stasiak, A				Stasiak, A			Getting down to the core of homologous recombination	SCIENCE			English	Editorial Material							SINGLE-STRANDED FRAGMENTS; COLI RECA PROTEIN; SUPERHELICAL DNA; EXCHANGE; FILAMENT				Stasiak, A (corresponding author), UNIV LAUSANNE,LAB ANAL ULTRASTRUCT,BATIMENT BIOL,CH-1015 LAUSANNE,SWITZERLAND.		Stasiak, Andrzej/E-5551-2010	Stasiak, Andrzej/0000-0002-0398-1989				BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Cluzel P, 1996, SCIENCE, V271, P792, DOI 10.1126/science.271.5250.792; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; KOWALCZYKOWSKI SC, 1987, TRENDS BIOCHEM SCI, V12, P141, DOI 10.1016/0968-0004(87)90070-3; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; RADDING CM, 1977, J MOL BIOL, V116, P825, DOI 10.1016/0022-2836(77)90273-X; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; STASIAK A, 1981, J MOL BIOL, V151, P557, DOI 10.1016/0022-2836(81)90010-3; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; YU X, 1993, J MOL BIOL, V231, P29, DOI 10.1006/jmbi.1993.1254	14	8	10	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					828	829		10.1126/science.272.5263.828	http://dx.doi.org/10.1126/science.272.5263.828			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629012				2022-12-28	WOS:A1996UK75700041
J	Lynn, JT				Lynn, JT			Friday afternoon	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1382	1382						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618348				2022-12-28	WOS:A1996UJ30300001
J	AbouElela, S; Igel, H; Ares, M				AbouElela, S; Igel, H; Ares, M			RNase III cleaves eukaryotic preribosomal RNA at a U3 snoRNP-dependent site	CELL			English	Article							EXTERNAL TRANSCRIBED SPACER; PRECURSOR RIBOSOMAL-RNA; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RIBONUCLEASE-III; PROCESSING EVENT; POLYMERASE-I; S-POMBE; YEAST	A yeast gene homologous to bacterial RNase III (RNT1) encodes a double-strand-specific endoribonuclease essential for ribosome synthesis. Two rRNA processing events are blocked in cells temperature sensitive for RNT1: cleavage at the snoRNA-dependent A0 site in the 5' ETS and cleavage in the 3' ETS. Recombinant RNT1 protein accurately cleaves a synthetic 5' ETS RNA at the AO site in vitro, in the absence of snoRNA or other factors. A synthetic 3' ETS substrate is specifically cleaved at a site 21 nt downstream of the 3' end of 28S rRNA. These observations show that a protein endonuclease collaborates with snoRNAs in eukaryotic rRNA processing and exclude a catalytic role for snoRNAs at certain pre-rRNA cleavage sites.			AbouElela, S (corresponding author), UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, DEPT BIOL, CTR MOL BIOL RNA, SANTA CRUZ, CA 95064 USA.			Ares, Manny/0000-0002-2552-9168	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APIRION D, 1993, BIOESSAYS, V15, P113, DOI 10.1002/bies.950150207; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BAYEV AA, 1980, NUCLEIC ACIDS RES, V8, P4919, DOI 10.1093/nar/8.21.4919; BELTRAME M, 1994, NUCLEIC ACIDS RES, V22, P4057, DOI 10.1093/nar/22.20.4057; BELTRAME M, 1995, EMBO J, V14, P4350, DOI 10.1002/j.1460-2075.1995.tb00109.x; BRAM RJ, 1980, CELL, V19, P393, DOI 10.1016/0092-8674(80)90513-9; COURT D, 1993, CONTROL MRNA STABILI, P70; CRAIG N, 1991, MOL CELL BIOL, V11, P458, DOI 10.1128/MCB.11.1.458; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GEGENHEIMER P, 1977, J BIOL CHEM, V252, P3064; GONZALEZ IL, 1990, J MOL BIOL, V212, P27, DOI 10.1016/0022-2836(90)90302-3; GOOD L, 1994, J BIOL CHEM, V269, P22169; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; IINO Y, 1991, EMBO J, V10, P221, DOI 10.1002/j.1460-2075.1991.tb07939.x; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KLEMENZ R, 1980, NUCLEIC ACIDS RES, V8, P2679, DOI 10.1093/nar/8.12.2679; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIANG WQ, 1995, GENE DEV, V9, P2433, DOI 10.1101/gad.9.19.2433; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MARCH PE, 1985, NUCLEIC ACIDS RES, V13, P4677, DOI 10.1093/nar/13.13.4677; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MELEKHOVETS YF, 1994, J MOL BIOL, V239, P170, DOI 10.1006/jmbi.1994.1361; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; NICHOLSON AW, 1988, NUCLEIC ACIDS RES, V16, P1577, DOI 10.1093/nar/16.4.1577; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; Perbal B., 1988, PRACTICAL GUIDE MOL; POTTER S, 1995, SCIENCE, V268, P1056, DOI 10.1126/science.7538698; ROBERTSON HD, 1968, J BIOL CHEM, V243, P82; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROTONDO G, 1995, MOL GEN GENET, V247, P698, DOI 10.1007/BF00290401; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SHUMARD CM, 1988, J BIOL CHEM, V263, P19346; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEITZ JA, 1995, SCIENCE, V270, P1626, DOI 10.1126/science.270.5242.1626; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON LD, 1988, J BIOL CHEM, V263, P17951; THOMPSON LD, 1989, CAN J MICROBIOL, V35, P36, DOI 10.1139/m89-006; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; VANDERSANDE CAFM, 1989, NUCLEIC ACIDS RES, V17, P9127, DOI 10.1093/nar/17.22.9127; VELDMAN GM, 1980, NUCLEIC ACIDS RES, V8, P5179, DOI 10.1093/nar/8.22.5179; VENEMA J, 1995, EMBO J, V14, P4883, DOI 10.1002/j.1460-2075.1995.tb00169.x; Wells SE, 1996, GENE DEV, V10, P220, DOI 10.1101/gad.10.2.220; XU HP, 1990, NUCLEIC ACIDS RES, V18, P5304, DOI 10.1093/nar/18.17.5304; YEH LCC, 1992, J MOL BIOL, V228, P827, DOI 10.1016/0022-2836(92)90867-J; YIP MT, 1989, J BIOL CHEM, V264, P4045	61	203	215	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					115	124		10.1016/S0092-8674(00)81087-9	http://dx.doi.org/10.1016/S0092-8674(00)81087-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620530	Bronze, Green Submitted			2022-12-28	WOS:A1996UE55900014
J	Pisetsky, DS				Pisetsky, DS			Moments of love	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					433	434						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627953				2022-12-28	WOS:A1996TU63800012
J	Eliasson, L; Renstrom, E; Ammala, C; Berggren, PO; Bertorello, AM; Bokvist, K; Chibalin, A; Deeney, JT; Flatt, PR; Gabel, J; Gromada, J; Larsson, O; Lindstrom, P; Rhodes, CJ; Rorsman, P				Eliasson, L; Renstrom, E; Ammala, C; Berggren, PO; Bertorello, AM; Bokvist, K; Chibalin, A; Deeney, JT; Flatt, PR; Gabel, J; Gromada, J; Larsson, O; Lindstrom, P; Rhodes, CJ; Rorsman, P			PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells	SCIENCE			English	Article							DIAZOXIDE; GLIBENCLAMIDE; TOLBUTAMIDE; ACTIVATION; CHANNELS; CURRENTS; RELEASE	Hypoglycemic sulfonylureas represent a group of clinically useful antidiabetic compounds that stimulate insulin secretion from pancreatic beta cells. The molecular mechanisms involved are not fully understood but are believed to involve inhibition of potassium channels sensitive to adenosine triphosphate (K-ATP channels) in the beta cell membrane, causing membrane depolarization, calcium influx, and activation of the secretory machinery. In addition to these effects, sulfonylureas also promoted exocytosis by direct interaction with the secretory machinery not involving closure of the plasma membrane K-ATP channels. This effect was dependent on protein kinase C (PKC) and was observed at therapeutic concentrations of sulfonylureas, which suggests that it contributes to their hypoglycemic action in diabetics.	NOVO NORDISK AS,DEPT ISLET CELL PHYSIOL,DK-2100 COPENHAGEN,DENMARK; GOTHENBURG UNIV,DEPT PHYSIOL & PHARMACOL,DIV BIOPHYS,S-41390 GOTHENBURG,SWEDEN; KAROLINSKA INST,ROLF LUFT CTR DIABET RES,DEPT MOLEC MED,S-17176 STOCKHOLM,SWEDEN; BOSTON UNIV,SCH MED,EVANS DEPT MED,DIABET & METAB UNIT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV ULSTER,DEPT BIOL & BIOMED SCI,COLERAINE BT52 1SA,LONDONDERRY,NORTH IRELAND; UMEA UNIV,DEPT HISTOL & CELL BIOL,S-90187 UMEA,SWEDEN; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215	Novo Nordisk; University of Gothenburg; Karolinska Institutet; Boston University; Boston University; Ulster University; Umea University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.			Rorsman, Patrik/A-4331-2016; Eliasson, Lena/E-9294-2012; Tuluc, Petronel/C-2527-2011	Rorsman, Patrik/0000-0001-7578-0767; Eliasson, Lena/0000-0002-6467-5029; Deeney, Jude/0000-0003-0988-9419; Berggren, Per-Olof/0000-0001-8991-413X; Flatt, Peter/0000-0001-8548-7943; Chibalin, Alexander/0000-0002-6339-6271				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8214; AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BERNARDI H, 1993, P NATL ACAD SCI USA, V90, P1340, DOI 10.1073/pnas.90.4.1340; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; CARPENTIER JL, 1986, DIABETOLOGIA, V29, P259, DOI 10.1007/BF00454887; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; LINDAU M, 1986, NATURE, V319, P150, DOI 10.1038/319150a0; MEISSNER HP, 1976, FEBS LETT, V67, P37; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OZANNE SE, 1995, DIABETOLOGIA, V38, P277; PANTEN U, 1992, HORM METAB RES, V24, P549, DOI 10.1055/s-2007-1003387; PHILIPSON LH, 1995, SCIENCE, V270, P1159, DOI 10.1126/science.270.5239.1159; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RENSTROM E, UNPUB; THEVENOD F, 1992, J MEMBRANE BIOL, V129, P253; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; ZUNKLER BJ, 1988, N-S ARCH PHARMACOL, V337, P225	28	172	174	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					813	815		10.1126/science.271.5250.813	http://dx.doi.org/10.1126/science.271.5250.813			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628999				2022-12-28	WOS:A1996TU69400048
J	Pronk, GJ; Ramer, K; Amiri, P; Williams, LT				Pronk, GJ; Ramer, K; Amiri, P; Williams, LT			Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER	SCIENCE			English	Article							DEATH GENE CED-3; INHIBITION; ENZYME; ENCODES	Genetic studies indicated that the Drosophila melanogaster protein REAPER (RPR) controls apoptosis during embryo development. Induction of RPR expression in Drosophila Schneider cells rapidly stimulated apoptosis. RPR-mediated apoptosis was blocked by N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk) which suggests that an interleukin-1 beta converting enzyme (ICE)-like protease is required for RPR function. RPR-induced apoptosis was associated with increased ceramide production that was also blocked by Z-VAD-fmk, which suggests that ceramide generation requires an ICE-like protease as well. Thus, the intracellular RPR protein uses cell death signaling pathways similar to those used by the vertebrate transmembrane receptors Fas (CD95) and tumor necrosis factor receptor type 1.	UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Pronk, GJ (corresponding author), CHIRON CORP,ROOM M348,4560 HORTON ST,EMERYVILLE,CA 94608, USA.							ASHBURNER M, 1989, DROSOPHILA LABORATOR, P142; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; INOUE S, 1991, J BIOL CHEM, V266, P13311; JACOBSON MD, 1994, CURR BIOL, V4, P337, DOI 10.1016/S0960-9822(00)00073-7; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LOS M, 1995, NATURE, V376, P37; MARTIN JM, 1995, CELL, V82, P349; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICHOLSON DW, 1995, NATURE, V376, P379; NITATORI T, 1995, J NEUROSCI, V15, P1001; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PRONK GJ, UNPUB; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SCHLEGEL J, 1995, FEBS LETT, V364, P139, DOI 10.1016/0014-5793(95)00374-I; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WNAG L, 1994, CELL, V78, P739; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	45	253	259	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					808	810		10.1126/science.271.5250.808	http://dx.doi.org/10.1126/science.271.5250.808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628997				2022-12-28	WOS:A1996TU69400046
J	Miller, FG; Fins, JJ				Miller, FG; Fins, JJ			A proposal to restructure hospital care for dying patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									CORNELL UNIV,COLL MED,NEW YORK,NY 10021; UNIV VIRGINIA,CHARLOTTESVILLE,VA 22908; NEW YORK HOSP,CORNELL MED CTR,NEW YORK,NY 10021	Cornell University; University of Virginia; Cornell University; NewYork-Presbyterian Hospital			Ram, Prem/K-4511-2012	Fins, Joseph/0000-0002-7221-0053				COLBURN D, 1995, WASHINGTON POST 1122, pA1; COLBURN D, 1995, WASHINGTON POST 1205, P7; COWLEY G, 1995, NEWSWEEK        1204, P74; Gilbert Susan, 1995, N Y Times Web, pC7; GOMEZ CF, 1996, CARING DYING IDENTIF, P27; GOODMAN E, 1995, JAMA-J AM MED ASSOC, V273, P1039; HORSBURGH CR, 1995, NEW ENGL J MED, V333, P735, DOI 10.1056/NEJM199509143331117; JAMES N, 1992, SOC SCI MED, V34, P1363, DOI 10.1016/0277-9536(92)90145-G; JECKER NS, 1991, J MED PHILOS, V16, P285, DOI 10.1093/jmp/16.3.285; Konner M., 1987, BECOMING DOCTOR JOUR; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; MATHEWS JJ, 1991, WOMEN HEALTH, V17, P39, DOI 10.1300/J013v17n01_03; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; NULAND SB, 1994, HOW WE DIE RELFECTIO; Quill TE, 1993, DEATH DIGNITY MAKING; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SCOTT JR, 1976, NEW ENGL J MED, V294, P1205, DOI 10.1056/NEJM197605272942203; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Solomon MZ, 1995, HASTINGS CENT REP, V25, pS28, DOI 10.2307/3527856; STODDARD S, 1992, HOSPICE MOVEMENT; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WINSLOW R, 1995, WALL STREET J   0721, pB1; 1995, JAMA-J AM MED ASSOC, V274, P1591	24	57	57	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1740	1742		10.1056/NEJM199606273342612	http://dx.doi.org/10.1056/NEJM199606273342612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UT400	8637523				2022-12-28	WOS:A1996UT40000012
J	Sinauer, N; Annest, JL; Mercy, JA				Sinauer, N; Annest, JL; Mercy, JA			Unintentional, nonfatal firearm-related injuries - A preventable public health burden	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUNSHOT WOUNDS; NORTH-CAROLINA; FATALITIES; CHILDREN; CALIFORNIA; DEATHS	Objective.-To describe the magnitude and characteristics of unintentional, nonfatal firearm-related injuries treated in US hospital emergency departments. Design.-Data were obtained from medical records for all firearm-related injury cases identified using the National Electronic Injury Surveillance System (NEISS) from June 1, 1992, through May 31, 1994. We report on cases classified as unintentional gunshot wounds. Setting.-NEISS comprises 91 hospitals that are a stratified probability sample of all hospitals in the United States and its territories that have at least 6 beds and provide 24-hour emergency service. Main Outcome Measures.-Number of and population rates for unintentional, nonfatal firearm-related injuries. Results.-An estimated 34 485 (95% confidence interval [CI], 25 225-43 745) persons (6.7 per 100 000 population; 95% CI, 4.9-8.5) were treated for unintentional, nonfatal firearm-related injuries in US emergency departments during the 2-year study period. The majority of patients were male (87%) and aged 15 to 34 years (61%); 38% required hospitalization. Injuries were most often to an extremity (73%), were self-inflicted (70%), involved a handgun (57%), and resulted during common gun-related activities. Conclusions.-Further development of effective interventions are needed to reduce the risk of injury from unintentional discharge of a firearm during routine gun-handling practices by those who own and use firearms. These injuries often occur during common gun-related activities such as gun cleaning, loading/unloading, hunting, target shooting, and showing, handling, or carrying. Studies are needed to evaluate the efficacy of existing gun safety training courses and assess the potential role of various gun safety devices (eg, trigger locks and loading indicators) in future prevention strategies.	NATL CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,OFF STAT & PROGRAMMING,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA								American Academy of Pediatrics, 1994, STOP FIR INJ; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BAKER SP, 1992, INJURY FACT BOOK, P149; CARTER GL, 1989, ANN EMERG MED, V18, P406, DOI 10.1016/S0196-0644(89)80581-5; CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; COLE TB, 1988, AM J PUBLIC HEALTH, V78, P1585, DOI 10.2105/AJPH.78.12.1585; Davis Y, 1996, J SAFETY RES, V27, P83, DOI 10.1016/0022-4375(96)00002-3; DOWD MD, 1994, PEDIATRICS, V94, P867; Go Bette K., 1995, P21; *HANDG CONTR INC, 1995, STAT WHICH REQ SAF T; HEMENWAY D, 1995, JAMA-J AM MED ASSOC, V273, P46, DOI 10.1001/jama.273.1.46; HEMENWAY D, 1990, J POLICY ANAL MANAG, V9, P94, DOI 10.2307/3325116; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; LEE RK, 1993, AM J PREV MED, V9, P16, DOI 10.1016/S0749-3797(18)30673-1; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MARTIN JR, 1991, ANN EMERG MED, V20, P58, DOI 10.1016/S0196-0644(05)81120-5; MORROW PL, 1986, AM J PUBLIC HEALTH, V76, P1120, DOI 10.2105/AJPH.76.9.1120; *NATL CTR INJ, 1995, INJ MORT NAT SUMM IN; *OUTD EMP PUBL, 1993, 1993 HUNT ED PROGR P; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Senturia YD, 1996, ARCH PEDIAT ADOL MED, V150, P265, DOI 10.1001/archpedi.1996.02170280035006; STUCKY W, 1991, J PEDIATR ORTHOPED, V11, P64, DOI 10.1097/01241398-199101000-00013; *US BUR CENS, 1993, CURR POP REP P25, V1104, P12; *US CONS PROD SAF, 1994, NAT EL INJ SURV SYST; *US DEP JUST, 1993, CRIM VICT US; WALLER J A, 1973, Accident Analysis and Prevention, V5, P351, DOI 10.1016/0001-4575(73)90033-X; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; WINTEMUTE GJ, 1989, J TRAUMA, V29, P457, DOI 10.1097/00005373-198904000-00007; Zawitz MW, 1996, NCJ160093 US DEP JUS; Zimring F. E., 1987, CITIZENS GUIDE GUN C; 1992, MMWR-MORBID MORTAL W, V41, P442	31	53	54	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1740	1743						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP307	8637171				2022-12-28	WOS:A1996UP30700027
J	Connolly, AJ; Ishihara, H; Kahn, ML; Farese, RV; Coughlin, SR				Connolly, AJ; Ishihara, H; Kahn, ML; Farese, RV; Coughlin, SR			Role of the thrombin receptor In development and evidence for a second receptor	NATURE			English	Article							ACTIVATION; DOMAIN; MICE	THROMBIN, a coagulation protease generated at sites of vascular injury, activates platelets, endothelial cells, leukocytes and mesenchymal cells(1,2). A G-protein-coupled receptor that is proteolytically activated by thrombin(3) is a target for drug development aimed at blocking thrombosis, inflammation and proliferation. Here we show that although disruption of the thrombin-receptor (tr) gene in mice causes about half the tr(-/-) embryos to die at embryonic day 9-10, half survive to become grossly normal adult mice with no bleeding diathesis. Strikingly, tr(-/-) platelets respond strongly to thrombin, whereas tr(-/-) fibroblasts lose their ability to respond to thrombin. We conclude that the thrombin receptor plays an unexpected role in embryonic development, suggesting a possible new function for the 'coagulation' proteases themselves. Moreover, a second platelet thrombin receptor exists, and different thrombin receptors have tissue-specific roles. This may allow development of therapeutics that will selectively block thrombin's different cellular actions.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes								BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BEVIGLIA L, 1993, THROMB RES, V71, P3001; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; CONNOLLY TM, 1994, THROMB HAEMOSTASIS, V72, P627; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; DERIAN CK, 1995, THROMB RES, V78, P505, DOI 10.1016/0049-3848(95)00084-5; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FENTON JZ, 1983, HEMAT ONVOL CLIN N A, V7, P1107; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GOODWIN CA, 1994, BIOCHEM BIOPH RES CO, V202, P321, DOI 10.1006/bbrc.1994.1930; HOGAN B, 1994, MANIPULATING MOUSE E, P1; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1994, J BIOL CHEM, V269, P1125; Kahn M, 1996, MOL MED, V2, P349, DOI 10.1007/BF03401632; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KINLOUGHRATHBONE RL, 1993, THROMB HAEMOSTASIS, V70, P1019; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LAGES B, 1994, BLOOD, V83, P2549, DOI 10.1182/blood.V83.9.2549.bloodjournal8392549; LAU LF, 1994, BIOCHEM J, V303, P391, DOI 10.1042/bj3030391; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; RYDEL TJ, 1994, J BIOL CHEM, V269, P22000; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; SOIFER SJ, 1994, AM J PATHOL, V144, P60; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	30	433	446	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					516	519		10.1038/381516a0	http://dx.doi.org/10.1038/381516a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632823				2022-12-28	WOS:A1996UP43500058
J	Kanopka, A; Muhlemann, O; Akusjarvi, G				Kanopka, A; Muhlemann, O; Akusjarvi, G			Inhibition by SR proteins of splicing of a regulated adenovirus pre-mRNA	NATURE			English	Article							RNA; BINDING; INVITRO; SITE; TERMINATION; EXPRESSION; SELECTION; ENHANCER; SF2	THE adenovirus L1 unit(1) represents an example of an alternatively spliced precursor messenger (pre-mRNA) where one 5' splice can be joined to one of two alternative 3' splice sites, producing the 52,55K or the IIIa mRNAs (Fig, 1a). Efficient usage of the distal IIIa 3' splice site requires late viral protein synthesis and is therefore confined to the late phase of virus infection(2-4). Here we show that, in extracts from uninfected cells, the classical SR proteins(5), which are essential splicing factors(5-7), inhibit IIIa pre-mRNA splicing by binding to an intronic repressor element and preventing recruitment of the U2 small nuclear ribonucleoprotein particle to the spliceosome. We further show that the viral repressor element has splicing-enhancer activity when appropriately placed in the pre-mRNA. Together, our results demonstrate that SR proteins function as activators or repressors of splicing depending on where on the pre-mRNA they bind.	UNIV UPPSALA,DEPT IMMUNOL & MED MICROBIOL,BMC,S-75123 UPPSALA,SWEDEN	Uppsala University				Muhlemann, Oliver/0000-0003-0657-1368				AKUSJARVI G, 1981, NATURE, V292, P420, DOI 10.1038/292420a0; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; FU XD, 1995, RNA, V1, P663; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; HIMMELSPACH M, 1995, RNA, V1, P794; HORNIG H, 1986, NATURE, V324, P589, DOI 10.1038/324589a0; IMPERIALE M, 1995, CURR TOP MICROBIOL, P139; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P2379, DOI 10.1093/nar/19.9.2379; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P6956, DOI 10.1093/nar/19.24.6956; KREIVI JP, 1994, NUCLEIC ACIDS RES, V22, P332, DOI 10.1093/nar/22.3.332; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Moore DD, 1995, GLOB MOB SURV; Moore M., 1993, RNA WORLD, P303; NEVINS JR, 1981, NATURE, V290, P113, DOI 10.1038/290113a0; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; SVENSSON C, 1986, P NATL ACAD SCI USA, V83, P4690, DOI 10.1073/pnas.83.13.4690; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363	30	208	211	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					535	538		10.1038/381535a0	http://dx.doi.org/10.1038/381535a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632829				2022-12-28	WOS:A1996UP43500064
J	Mechanic, D; Schlesinger, M				Mechanic, D; Schlesinger, M			The impact of managed care on patients' trust in medical care and their physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; VIEWS	Social trust in health care organizations and interpersonal trust in physicians may be mutually supportive, but they also diverge in important ways. The success of medical care depends most importantly on patients' trust that their physicians are competent, take appropriate responsibility and control, and give their patients' welfare the highest priority, Utilization review and structural arrangements in managed care potentially challenge trust in physicians by restricting choice, contradicting medical decisions and control, and restricting open communication with patients, Gatekeeping and incentives to limit care also raise serious trust issues, We argue that managed care plans rather than physicians should be required to disclose financial arrangements, that limits be placed on incentives that put physicians at financial risk, and that professional norms and public policies should encourage clear separation of interests of physicians from health plan organization and finance.	YALE UNIV,SCH PUBL HLTH,NEW HAVEN,CT	Yale University	Mechanic, D (corresponding author), RUTGERS STATE UNIV,INST HLTH HLTH CARE POLICY & AGING RES,30 COLL AVE,NEW BRUNSWICK,NJ 08903, USA.							BLENDON RJ, 1989, HEALTH AFFAIR, V8, P149, DOI 10.1377/hlthaff.8.1.149; BLENDON RJ, 1993, JAMA-J AM MED ASSOC, V269, P2573, DOI 10.1001/jama.269.19.2573; DAVIS K, 1995, HEALTH AFFAIR, V14, P99, DOI 10.1377/hlthaff.14.2.99; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; EMMONS D, 1991, SOCIOECONOMIC CHARAC; Gillis CR, 1996, BRIT MED J, V312, P145, DOI 10.1136/bmj.312.7024.145; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; HAYS RD, 1995, ARCH GEN PSYCHIAT, V52, P11; HIBBARD JH, 1987, MED CARE, V25, P1019, DOI 10.1097/00005650-198711000-00001; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; Luhmann N, 1989, TRUST POWER; LUPTON D, 1991, SOC SCI MED, V33, P559, DOI 10.1016/0277-9536(91)90213-V; MACKLIN R, 1993, ENEMIES PATIENTS; MCGRAW KM, 1989, BR J POLIT SCI, V20, P119; Mechanic D, 1996, MILBANK Q, V74, P171, DOI 10.2307/3350245; MECHANIC D, 1990, INQUIRY-J HEALTH CAR, V27, P14; PEAR R, 1995, NY TIMES        1221, V21, pA1; Rodwin M. A., 1993, MED MONEY MORALS PHY; ROSENTHAL E, 1996, NY TIMES        0115, P1; RYAN KJ, 1994, J ROY SOC MED, V87, P17; SCHLESINGER M, IN PRESS HLTH AFF MI; Shaver K. G., 1985, ATTRIBUTION BLAME CA; SHEILS JF, 1992, HEALTH AFFAIR, V11, P7, DOI 10.1377/hlthaff.11.1.7; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P3298, DOI 10.1001/jama.262.23.3298	26	341	342	2	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1693	1697		10.1001/jama.275.21.1693	http://dx.doi.org/10.1001/jama.275.21.1693			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UN252	8637148				2022-12-28	WOS:A1996UN25200037
J	Nennig, ME; Shinefield, HR; Edwards, KM; Black, SB; Fireman, BH				Nennig, ME; Shinefield, HR; Edwards, KM; Black, SB; Fireman, BH			Prevalence and incidence of adult pertussis in an urban population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTION; OUTBREAK	Objectives.-To determine the prevalence of Bordetella pertussis infection among adults who have prolonged cough for 2 weeks or longer and to estimate the incidence of B pertussis infection in adults in a defined urban population. Design.-A prospective clinical study. Setting.-Kaiser Permanente, San Francisco (Calif) Medical Center. Participants.-One hundred fifty-three referred and participating health plan members 18 years old or older with the complaint of cough:persisting for 2 weeks or longer and 154 health plan members 18 years old or older with no cough for the past 3 months (controls) were enrolled. Medical records for an additional 100 patients randomly sampled from 676 patients 18 years old or older with an ambulatory diagnosis of cough (60 with prolonged cough) were also reviewed. Main Outcome Measures.-Prevalence of adult pertussis as determined by enzyme-linked immunosorbent assay IgG antibody levers to pertussis toxin in individuals with prolonged cough for 2 weeks or longer and the incidence of adult pertussis in San Francisco Kaiser health plan members. Results.-The prevalence of adult pertussis was 12.4% of the participating referrals. The incidence of adult pertussis was estimated to be 176 cases per 100 000 person-years (95% confidence interval, 97 to 255 cases). Conclusions.-Adult pertussis is a significantly greater public health threat than previously suspected, Booster doses of acellular pertussis vaccine after 7 years of age may bean effective approach to minimize transmission and infection.	KAISER PERMANENTE MED GRP,KAISER PERMANENTE PEDIAT VACCINE STUDY CTR,OAKLAND,CA; KAISER PERMANENTE MED GRP,DIV RES,OAKLAND,CA; VANDERBILT UNIV,MED CTR,DEPT PEDIAT,DIV INFECT DIS,NASHVILLE,TN 37232	Kaiser Permanente; Permanente Medical Groups; Kaiser Permanente; Permanente Medical Groups; Vanderbilt University								ADDISS DG, 1991, J INFECT DIS, V164, P704, DOI 10.1093/infdis/164.4.704; AOYAMA T, 1992, AM J DIS CHILD, V146, P163, DOI 10.1001/archpedi.1992.02160140029015; BASS JW, 1987, PEDIATR INFECT DIS J, V6, P141, DOI 10.1097/00006454-198702000-00001; Cherry J D, 1984, Curr Probl Pediatr, V14, P1; CHERRY JD, 1995, CLIN INFECT DIS, V20, P1271, DOI 10.1093/clinids/20.5.1271; CROMER BA, 1993, AM J DIS CHILD, V147, P575, DOI 10.1001/archpedi.1993.02160290081031; EDWARDS KM, 1993, JAMA-J AM MED ASSOC, V269, P53, DOI 10.1001/jama.269.1.53; FARIZO KM, 1992, CLIN INFECT DIS, V14, P708, DOI 10.1093/clinids/14.3.708; HERWALDT LA, 1991, ARCH INTERN MED, V151, P1510, DOI 10.1001/archinte.151.8.1510; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; MORTIMER EA, 1990, J INFECT DIS, V161, P473, DOI 10.1093/infdis/161.3.473; MORTIMER EA, 1994, VACCINES, P91; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; PATRIARCA PA, 1988, AM J PUBLIC HEALTH, V78, P833, DOI 10.2105/AJPH.78.7.833; ROBERTSON PW, 1987, MED J AUSTRALIA, V147, P522; SCHMITTGROHE S, 1995, CLIN INFECT DIS, V21, P860, DOI 10.1093/clinids/21.4.860; STEKETEE RW, 1988, J INFECT DIS, V157, P441, DOI 10.1093/infdis/157.3.441; WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044; 1993, MMWR-MORBID MORTAL W, V42, P959; 1993, MMWR-MORBID MORTAL W, V42, P952; 1982, MMWR-MORBID MORTAL W, V30, P1; 1995, MMWR-MORBID MORTAL W, V44, P525	25	183	188	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1672	1674		10.1001/jama.275.21.1672	http://dx.doi.org/10.1001/jama.275.21.1672			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637142				2022-12-28	WOS:A1996UN25200031
J	Casey, KL				Casey, KL			Match and mismatch: Identifying the neuronal determinants of pain	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							VENTROBASAL THALAMUS; AFFERENT INHIBITION; STIMULATION; INTENSITY; SENSATION; SKIN; RAT	Despite the increased intensity and sophistication of research on pain mechanisms in the past three decades, serious uncertainties remain about the neuronal origin of pain, especially in painful clinical conditions. Although a positive correlation between nociceptive afferent activity and the subjective perception of pain has been seen under controlled experimental conditions, important mismatches point to the critical importance of central nervous system processes as determinants of pain. Multiple peripheral, segmental, and supraspinal neuronal activities control nociceptive processing at all levels of the neuraxis. Three studies in this issue highlight the problem of identifying the neuronal determinants of pain by addressing contrasting mismatches: angina-like chest pain without an obvious cause and a potential source of angina (myocardial ischemia) without pain. The results of these studies suggest that selective visceral hyperalgesia and hypoalgesia of peripheral or central origin may be present without other clinical evidence for neurologic abnormality. Complex mechanisms interacting at several levels of the nervous system appear to be involved.			Casey, KL (corresponding author), VET AFFAIRS MED CTR, NEUROL SERV, 2215 FULLER RD, ANN ARBOR, MI 48105 USA.							ADRIAENSEN H, 1984, HUM NEUROBIOL, V3, P53; BESSOU P, 1969, J NEUROPHYSIOL, V32, P1025, DOI 10.1152/jn.1969.32.6.1025; BINI G, 1984, PAIN, V18, P239, DOI 10.1016/0304-3959(84)90819-4; BRUGGEMANN J, 1994, J NEUROSCI, V14, P6796; BURGESS PR, 1967, J PHYSIOL-LONDON, V190, P541, DOI 10.1113/jphysiol.1967.sp008227; CASEY KL, 1993, SOMATOSENS MOT RES, V10, P327, DOI 10.3109/08990229309028841; CASEY KL, 1991, SYMP PAIN R, P1; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; CERVERO F, 1994, PHYSIOL REV, V74, P95, DOI 10.1152/physrev.1994.74.1.95; COGHILL RC, 1994, J NEUROSCI, V14, P4095; FIELDS HL, 1978, ANNU REV PHYSIOL, V40, P217, DOI 10.1146/annurev.ph.40.030178.001245; Frobert O, 1996, ANN INTERN MED, V124, P959, DOI 10.7326/0003-4819-124-11-199606010-00003; Gebhart GF, 1986, SPINAL AFFERENT PROC, P391, DOI DOI 10.1007/978-1-4684-4994-5; HAMMOND DL, 1986, SPINAL AFFERENT PROC, P363; HSIEH JC, 1995, PAIN, V63, P225, DOI 10.1016/0304-3959(95)00048-W; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; JONES EG, 1985, THALAMUS, P5; LAMOTTE RH, 1984, J NEUROPHYSIOL, V51, P1434, DOI 10.1152/jn.1984.51.6.1434; LENZ FA, 1994, NEUROSCI LETT, V180, P46, DOI 10.1016/0304-3940(94)90910-5; MELZACK R, 1968, P423; MENSE S, 1993, PAIN, V54, P241, DOI 10.1016/0304-3959(93)90027-M; NESS TJ, 1990, PAIN, V41, P167, DOI 10.1016/0304-3959(90)90021-5; PRICE DD, 1989, J NEUROPHYSIOL, V62, P1270, DOI 10.1152/jn.1989.62.6.1270; Rao SSC, 1996, ANN INTERN MED, V124, P950, DOI 10.7326/0003-4819-124-11-199606010-00002; REES H, 1993, PAIN, V53, P121, DOI 10.1016/0304-3959(93)90072-W; ROBERTS WA, 1992, EXP BRAIN RES, V89, P363; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; Rosen SD, 1996, ANN INTERN MED, V124, P939, DOI 10.7326/0003-4819-124-11-199606010-00001; SALT TE, 1989, NEUROSCIENCE, V28, P17, DOI 10.1016/0306-4522(89)90228-5; SIMONE DA, 1994, J NEUROPHYSIOL, V72, P883, DOI 10.1152/jn.1994.72.2.883; SWEET WH, 1982, NEW PERSPECTIVES CER, P205; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; TOREBJOR.HE, 1974, ACTA PHYSIOL SCAND, V92, P374, DOI 10.1111/j.1748-1716.1974.tb05755.x; WAHREN LK, 1989, PAIN, V38, P313, DOI 10.1016/0304-3959(89)90218-2; WILLIS WD, 1985, PAIN SYSTEM NEURAL B, P346	35	18	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1996	124	11					995	998		10.7326/0003-4819-124-11-199606010-00007	http://dx.doi.org/10.7326/0003-4819-124-11-199606010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL905	8624067				2022-12-28	WOS:A1996UL90500007
J	Giffin, W; Torrance, H; Rodda, DJ; Prefontaine, GG; Pope, L; Hache, RJG				Giffin, W; Torrance, H; Rodda, DJ; Prefontaine, GG; Pope, L; Hache, RJG			Sequence-specific DNA binding by Ku autoantigen and its effects on transcription	NATURE			English	Article							MAMMARY-TUMOR VIRUS; ACTIVATED PROTEIN-KINASE; GLUCOCORTICOID RECEPTOR; REGULATORY ELEMENT; REGION; ANTIGEN; DOMAIN	DNA-DEPENDENT protein kinase (DNA-PK) has been implicated in several nuclear processes including transcription(1-3), DNA replication(4,5), double-stranded DNA break repair, and V(D)J recom bination(6-10). Linkage of kinase and substrate on DNA in cis is required for efficient phosphorylation(11). Recruitment of DNA-PK to DNA is by Ku autoantigen, a DNA-end-binding protein required for DNA-PK catalytic activity(11). Although Ku is known to translocate along naked DNA(12), how DNA-end binding by Ku might lead to DNA-PK-mediated phosphorylation of sequence-specific DNA-binding proteins in vivo has not been obvious. Here we report the identification of Ku as a transcription factor that recruits DNA-PK directly to specific DNA sequences. NRE1 (negative regulatory element 1) is a DNA sequence element (-394/ - 381) in the long terminal repeat of mouse mammary tumour virus (MMTV) that is important for repressing inappropriate viral expression(13-16). We show that direct binding of Ku/DNA-PK to NRE1 represses glucocorticoid-induced MMTV transcription.	UNIV OTTAWA,OTTAWA CIVIC HOSP,LOEB INST MED RES,DEPT MED,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,OTTAWA CIVIC HOSP,LOEB INST MED RES,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute								Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; FALZON M, 1993, J BIOL CHEM, V268, P10546; FINNIE N, 1993, BIOCHEM SOC T, V21, P930, DOI 10.1042/bst0210930; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GIFFIN W, 1994, J BIOL CHEM, V269, P1449; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEE JW, 1991, J BIOL CHEM, V266, P24101; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; MAY G, 1991, J BIOL CHEM, V266, P3052; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; YANAGAWA SI, 1993, J VIROL, V67, P112, DOI 10.1128/JVI.67.1.112-118.1993; YANEVA M, 1989, J BIOL CHEM, V264, P13407	28	187	188	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					265	268		10.1038/380265a0	http://dx.doi.org/10.1038/380265a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637578				2022-12-28	WOS:A1996UB11700057
J	HunterEnsor, M; Ousley, A; Sehgal, A				HunterEnsor, M; Ousley, A; Sehgal, A			Regulation of the Drosophila protein timeless suggests a mechanism for resetting the circadian clock by light	CELL			English	Article							PERIOD GENE-PRODUCT; VISUAL-SYSTEM; MELANOGASTER; EXPRESSION	Circadian behavioral rhythms in Drosophila depend on the appropriate regulation of at least two genes, period (per) and timeless (tim). Previous studies demonstrated that levels of PER and TIM RNA cycle with the same phase and that the PER and TIM proteins interact directly. Here we show the cyclic expression of TIM protein in adult heads and report that it lags behind peak levels of TIM RNA by several hours. We also show that nuclear expression of TIM depends upon the expression of PER protein. Finally, we report that the expression of TIM, but not PER, is rapidly reduced by light, suggesting that TIM mediates light-induced resetting of the circadian clock. Since both PER and TIM RNA are unaffected by light treatment, the effects of light on TIM appear to be posttranscriptional.	UNIV PENN,SCH MED,CTR SLEEP & RESP NEUROBIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine	HunterEnsor, M (corresponding author), UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104, USA.							ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; EDERY I, 1994, SCIENCE, V263, P237, DOI 10.1126/science.8284676; ESKIN A, 1979, FED PROC, V38, P2570; EWER J, 1992, J NEUROSCI, V12, P3321; FELDMAN J F, 1973, Genetics, V75, P605; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1994, MOL CELL BIOL, V14, P7211, DOI 10.1128/MCB.14.11.7211; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LEVINE JD, 1994, NEURON, V13, P967, DOI 10.1016/0896-6273(94)90262-3; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; MILLAR AJ, 1995, SCIENCE, V267, P1161, DOI 10.1126/science.7855595; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; NASSEL DR, 1993, J COMP NEUROL, V331, P183, DOI 10.1002/cne.903310204; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; PITTENDRIGH CS, 1976, MOL BASIS CIRCADIAN, P11; PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; REPPERT SM, 1994, NEURON, V13, P1167, DOI 10.1016/0896-6273(94)90054-X; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1995, NEURON, V15, P345, DOI 10.1016/0896-6273(95)90039-X; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Worden, 1974, NEUROSCIENCES 3RD ST, P437; ZATZ M, 1992, DISCUSS NEUROSCI, V8, P67; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x; ZERR DM, 1990, J NEUROSCI, V10, P2749	40	324	333	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					677	685		10.1016/S0092-8674(00)81046-6	http://dx.doi.org/10.1016/S0092-8674(00)81046-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625406	hybrid			2022-12-28	WOS:A1996TZ99000006
J	Brauer, M; Kennedy, SM				Brauer, M; Kennedy, SM			Gas stoves and respiratory health	LANCET			English	Editorial Material							NITROGEN-DIOXIDE		UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 1M9,CANADA	University of British Columbia	Brauer, M (corresponding author), UNIV BRITISH COLUMBIA,OCCUPAT HYG PROGRAM,VANCOUVER,BC V5Z 1M9,CANADA.		Brauer, Michael/Y-2810-2019	Brauer, Michael/0000-0002-9103-9343				HARLOS DP, 1988, THESIS HARVARD SCH P; HASSELBLAD V, 1992, J AIR WASTE MANAGE, V42, P662, DOI 10.1080/10473289.1992.10467018; KOONTZ MD, 1992, GRI930013 GAS RES I; LAMBERT WE, 1993, 58 HLTH EFF I REP; RYAN PB, 1988, JAPCA J AIR WASTE MA, V38, P22, DOI 10.1080/08940630.1988.10466348; SAMET JM, 1990, TOXICOL IND HEALTH, V6, P247, DOI 10.1177/074823379000600204; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X	7	5	5	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					412	412		10.1016/S0140-6736(96)90002-1	http://dx.doi.org/10.1016/S0140-6736(96)90002-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618476				2022-12-28	WOS:A1996TV72200002
J	Martin, A; Wiggs, CL; Ungerleider, LG; Haxby, JV				Martin, A; Wiggs, CL; Ungerleider, LG; Haxby, JV			Neural correlates of category-specific knowledge	NATURE			English	Article							MENTAL-IMAGERY; VISUAL-CORTEX; RECOGNITION; IMPAIRMENT; PICTURES	AN intriguing and puzzling consequence of damage to the human brain is selective loss of knowledge about a specific category of objects, One patient may be unable to identify or name living things(1-3), whereas another may have selective difficulty identifying man-made objects(4-6). To investigate the neural correlates of this remarkable dissociation, we used positron emission tomography to map regions of the normal brain that are associated with naming animals and tools. We found that naming pictures of animals and tools was associated with bilateral activation of the ventral temporal lobes and Broca's area, In addition, naming animals selectively activated the left medial occipital lobe-a region involved in the earliest stages of visual processing. In contrast, naming tools selectively activated a left premotor area also activated by imagined hand movements(7), and an area in the left middle temporal gyrus also activated by the generation of action words(8-10). Thus the brain regions active during object identification are dependent, in part, on the intrinsic properties of the object presented.			Martin, A (corresponding author), NIMH, PSYCHOL & PSYCHOPATHOL LAB, BLDG 10, ROOM 3D-41, BETHESDA, MD 20892 USA.		martin, alex/B-6176-2009					CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DECETY J, 1994, NATURE, V371, P600, DOI 10.1038/371600a0; FARAH MJ, 1989, TRENDS NEUROSCI, V12, P395, DOI 10.1016/0166-2236(89)90079-9; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1991, J COMPUT ASSIST TOMO, V15, P634, DOI 10.1097/00004728-199107000-00020; GLASER WR, 1992, COGNITION, V42, P61, DOI 10.1016/0010-0277(92)90040-O; HUMPHREYS GW, 1988, COGNITIVE NEUROPSYCH, V5, P67, DOI 10.1080/02643298808252927; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; KROLL JF, 1984, J VERB LEARN VERB BE, V23, P39, DOI 10.1016/S0022-5371(84)90499-7; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SACCHETT C, 1992, COGNITIVE NEUROPSYCH, V9, P73, DOI 10.1080/02643299208252053; SAFFRAN EM, 1994, ATTENTION PERFORM, V15, P507; SHERIDAN J, 1993, COGNITIVE NEUROPSYCH, V10, P143, DOI 10.1080/02643299308253459; SILVERI MC, 1988, COGNITIVE NEUROPSYCH, V5, P677, DOI 10.1080/02643298808253278; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Talairach J., 1988, COPLANAR STEREOTAXIC; TULVING E, 1994, NEUROREPORT, V5, P2525, DOI 10.1097/00001756-199412000-00030; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WARRINGTON EK, 1987, BRAIN, V110, P1273, DOI 10.1093/brain/110.5.1273; WARRINGTON EK, 1983, BRAIN, V106, P859, DOI 10.1093/brain/106.4.859; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; ZEKI S, 1991, J NEUROSCI, V11, P641	26	1192	1213	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					649	652		10.1038/379649a0	http://dx.doi.org/10.1038/379649a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TV688	8628399	Green Submitted			2022-12-28	WOS:A1996TV68800055
J	Goodwin, F; Delbanco, TL				Goodwin, F; Delbanco, TL			A 47-year-old man with chronic depression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							ATYPICAL DEPRESSION; PRIMARY CARE; DISORDERS; ANXIETY		GEORGE WASHINGTON UNIV,CTR NEUROSCI BEHAV & SOC,WASHINGTON,DC	George Washington University								BARRETT JE, 1988, ARCH GEN PSYCHIAT, V45, P1100; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOLDENWATSON C, 1993, LIFE SCI, V52, P1023, DOI 10.1016/0024-3205(93)90194-8; CLARE AW, 1986, MENTAL ILLNESS PRIMA, P22; COULEHAN JL, 1989, J GEN INTERN MED, V4, P542; EHLERS CL, 1988, ARCH GEN PSYCHIAT, V45, P948; FAWCETT J, 1987, AM J PSYCHIAT, V144, P35; GOODE DJ, 1973, ARCH GEN PSYCHIAT, V29, P391; GOODNICK PJ, 1992, AM J PSYCHIAT, V149, P399; Goodwin F, 1990, MANIC DEPRESSIVE ILL; GOODWIN FK, 1993, PHI KAPPA PHI J, V73, P25; KLERMAN GL, 1978, HARVARD GUIDE MODERN, P252; LIEBOWITZ MR, 1988, ARCH GEN PSYCHIAT, V45, P129; LUSTMAN PJ, 1986, J NERV MENT DIS, V174, P736, DOI 10.1097/00005053-198612000-00005; MEREDITH CH, 1983, J CLIN PSYCHIAT, V44, P85; MUMFORD E, 1984, AM J PSYCHIAT, V141, P1145; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P949; NELSON JC, 1991, ARCH GEN PSYCHIAT, V48, P303; POST RM, 1992, AM J PSYCHIAT, V149, P99; QUITKIN FM, 1991, ARCH GEN PSYCHIAT, V48, P319; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; REGIER DA, 1985, PSYCHOL MED, V15, P265, DOI 10.1017/S0033291700023540; ROBINSON N, 1988, DIABETIC MED, V5, P268, DOI 10.1111/j.1464-5491.1988.tb00983.x; SIMON G, 1995, AM J PSYCHIAT, V152, P352; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Thase Michael E., 1995, P1081; VONEULER OS, 1971, SCIENCE, V172, P202; VONKORFF M, 1987, ARCH GEN PSYCHIAT, V44, P152; Wehr T.A., 1983, CIRCADIAN RHYTHMS PS, P129; WEISSMAN MM, 1981, ARCH GEN PSYCHIAT, V38, P51; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WELLS KB, 1989, GEN HOSP PSYCHIAT, V11, P320, DOI 10.1016/0163-8343(89)90119-9; WING RR, 1990, DIABETES CARE, V13, P170, DOI 10.2337/diacare.13.2.170; WOGGON B, 1993, INT CLIN PSYCHOPHARM, V7, P137, DOI 10.1097/00004850-199300730-00003; WORTHINGTON JJ, IN PRESS PSYCHOSOMAT; ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P3; 1994, INT J CLIN PSYCHOPHA, V9, P139; 1993, AM J PSYCHIAT, V150, P1447	38	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					479	485						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TU638	8627971				2022-12-28	WOS:A1996TU63800038
J	Walker, DH; Barbour, AG; Oliver, JH; Lane, RS; Dumler, JS; Dennis, DT; Persing, DH; Azad, AF; McSweegan, E				Walker, DH; Barbour, AG; Oliver, JH; Lane, RS; Dumler, JS; Dennis, DT; Persing, DH; Azad, AF; McSweegan, E			Emerging bacterial zoonotic and vector-borne diseases - Ecological and epidemiological factors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAT-SCRATCH DISEASE; FEVER GROUP RICKETTSIOSIS; SPOTTED-FEVER; HUMAN EHRLICHIOSIS; LYME-DISEASE; BORRELIA-BURGDORFERI; TRANSOVARIAL TRANSMISSION; SEROLOGIC SURVEY; ETIOLOGIC AGENT; INNER-MONGOLIA	Among the etiologic agents of emerging infectious diseases are several bacterial organisms that naturally reside in animal and arthropod hosts. The most compelling emerging bacterial zoonotic and vector-borne diseases in the United States are Lyme disease; a Southern erythema migrans-like illness; human monocytic ehrlichiosis; human granulocytic ehrlichiosis; a novel cat flea-associated typhus group rickettsiosis; bartonelloses of immunocompetent and immunocompromised persons, particularly with AIDS; and sylvatic plague. Some of these antimicrobial-treatable infections are life threatening. During the acute stage of illness when antimicrobial agents are most effective, the flulike clinical signs and symptoms and available laboratory tests frequently do not point to a particular diagnosis. Epidemiological factors determined by the ecology of the bacteria are often the most useful diagnostic clues. The recognition of these evolving problems emphasizes the need for development of better laboratory diagnostic methods, for surveillance for and tracking of disease, and for continued research into factors contributing to transmission of the organisms. The continual appearance of previously unidentified bacterial infections requires prospective national strategies for timely recognition of the syndrome, identification of the agent, establishment of criteria and methods for diagnosis, optimization of the treatment regimen, and determination of successful approaches to prevention and control.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA; UNIV TEXAS, HLTH SCI CTR, DEPT MED, SAN ANTONIO, TX 78284 USA; GEORGIA SO UNIV, DEPT BIOL, STATESBORO, GA 30460 USA; UNIV CALIF BERKELEY, DEPT ENVIRONM SCI POLICY & MANAGEMENT, BERKELEY, CA USA; UNIV MARYLAND, SCH MED, DEPT PATHOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; CTR DIS CONTROL & PREVENT, DIV VECTOR BORNE INFECT DIS, FT COLLINS, CO USA; MAYO CLIN & MAYO FDN, DEPT LAB MED & PATHOL, ROCHESTER, MN USA; NIAID, BETHESDA, MD 20892 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University System of Georgia; Georgia Southern University; University of California System; University of California Berkeley; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Centers for Disease Control & Prevention - USA; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Walker, DH (corresponding author), UNIV TEXAS, MED BRANCH, DEPT PATHOL, 301 UNIV BLVD, GALVESTON, TX 77555 USA.		Barbour, Alan/B-3160-2009	Barbour, Alan/0000-0002-0719-5248	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021242, R01AI031431, R21AI031431] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31431, AI21242] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAL KA, 1994, NEW ENGL J MED, V330, P1509, DOI 10.1056/NEJM199405263302108; ANDERSON BE, 1993, AM J TROP MED HYG, V49, P239, DOI 10.4269/ajtmh.1993.49.239; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; ANDERSON JF, 1993, CLIN DERMATOL, V11, P339, DOI 10.1016/0738-081X(93)90088-T; AZAD AF, 1992, P NATL ACAD SCI USA, V89, P43, DOI 10.1073/pnas.89.1.43; BAIRD RW, 1992, J CLIN MICROBIOL, V30, P2896, DOI 10.1128/JCM.30.11.2896-2902.1992; Bakken JS, 1996, JAMA-J AM MED ASSOC, V275, P199, DOI 10.1001/jama.275.3.199; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; BARBOUR AG, 1993, SCIENCE, V260, P1610, DOI 10.1126/science.8503006; BARBOUR AG, IN PRESS LYME DISEAS; BARLOUGH JE, 1995, J CLIN MICROBIOL, V33, P3333, DOI 10.1128/JCM.33.12.3333-3334.1995; BARTON LL, 1990, ANN NY ACAD SCI, V590, P68, DOI 10.1111/j.1749-6632.1990.tb42208.x; BREITSCHWERDT EB, 1995, J CLIN MICROBIOL, V33, P154, DOI 10.1128/JCM.33.1.154-160.1995; BROUQUI P, 1995, LANCET, V346, P782, DOI 10.1016/S0140-6736(95)91544-3; BROWN RN, 1992, SCIENCE, V256, P1439, DOI 10.1126/science.1604318; CAMPBELL GL, 1995, J INFECT DIS, V172, P470, DOI 10.1093/infdis/172.2.470; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; DALY JS, 1993, J CLIN MICROBIOL, V31, P872, DOI 10.1128/JCM.31.4.872-881.1993; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DAWSON JE, 1994, J CLIN MICROBIOL, V32, P2725, DOI 10.1128/JCM.32.11.2725-2728.1994; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; DOLL JM, 1994, AM J TROP MED HYG, V51, P109, DOI 10.4269/ajtmh.1994.51.109; DRANCOURT M, 1995, NEW ENGL J MED, V332, P419, DOI 10.1056/NEJM199502163320702; DUMLER JS, 1993, HUM PATHOL, V24, P391; EIDSON M, 1988, AM J PUBLIC HEALTH, V78, P1333, DOI 10.2105/AJPH.78.10.1333; EVERETT ED, 1994, ANN INTERN MED, V120, P730, DOI 10.7326/0003-4819-120-9-199405010-00002; EWING SA, 1995, J MED ENTOMOL, V32, P368, DOI 10.1093/jmedent/32.3.368; FAN MY, 1987, J CLIN MICROBIOL, V25, P628, DOI 10.1128/JCM.25.4.628-632.1987; FAN MY, 1987, AM J TROP MED HYG, V36, P615; FENG HM, 1991, MICROBIOL IMMUNOL, V35, P687, DOI 10.1111/j.1348-0421.1991.tb01602.x; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; FISHBEIN DB, 1989, J INFECT DIS, V160, P803, DOI 10.1093/infdis/160.5.803; Greig B, 1996, J CLIN MICROBIOL, V34, P44, DOI 10.1128/JCM.34.1.44-48.1996; HARDALO CJ, 1995, CLIN INFECT DIS, V21, P910, DOI 10.1093/clinids/21.4.910; HARKESS JR, 1989, J INFECT DIS, V159, P576, DOI 10.1093/infdis/159.3.576; HUTCHESON HJ, 1995, J MED ENTOMOL, V32, P827, DOI 10.1093/jmedent/32.6.827; JOHANSSON KE, 1995, RES VET SCI, V58, P109, DOI 10.1016/0034-5288(95)90061-6; KASS EM, 1994, NEW ENGL J MED, V331, P1612, DOI 10.1056/NEJM199412153312403; KELLY PJ, 1994, J TROP MED HYG, V97, P129; KELLY PJ, 1991, J TROP MED HYG, V94, P304; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KORDICK DL, 1995, J CLIN MICROBIOL, V33, P1655, DOI 10.1128/JCM.33.6.1655-1656.1995; LANE RS, 1994, J MED ENTOMOL, V31, P417, DOI 10.1093/jmedent/31.3.417; LANE RS, 1991, ANNU REV ENTOMOL, V36, P587, DOI 10.1146/annurev.en.36.010191.003103; LIU QH, 1990, ANN NY ACAD SCI, V590, P237, DOI 10.1111/j.1749-6632.1990.tb42225.x; MADIGAN JE, 1995, J INFECT DIS, V172, P1141, DOI 10.1093/infdis/172.4.1141; MAGNARELLI LA, 1995, J CLIN MICROBIOL, V33, P2710, DOI 10.1128/JCM.33.10.2710-2714.1995; MAHARA F, 1991, RICKETTSIAE RICKETTS, P526; MARGILETH AM, 1992, PEDIATR INFECT DIS J, V11, P474, DOI 10.1097/00006454-199206000-00010; Masters E J, 1995, Mo Med, V92, P346; MAUPIN GO, 1994, J INFECT DIS, V170, P636, DOI 10.1093/infdis/170.3.636; MORAIS JD, 1991, LANCET, V338, P633, DOI 10.1016/0140-6736(91)90644-5; NORRIS DE, IN PRESS J MED ENTOM; Oliver JH, 1996, ANN MO BOT GARD, V83, P37, DOI 10.2307/2399966; OLIVER JH, 1993, P NATL ACAD SCI USA, V90, P7371, DOI 10.1073/pnas.90.15.7371; OLIVER JH, 1995, J PARASITOL, V81, P30, DOI 10.2307/3284001; OLIVER JH, 1995, J AGROMEDICINE, V2, P79; PANCHOLI P, 1995, J INFECT DIS, V172, P1007, DOI 10.1093/infdis/172.4.1007; PANCHOLI P, 1995, CLIN INFECT DIS, V21, P723; Paparone P W, 1994, J Am Osteopath Assoc, V94, P568; PERINE PL, 1992, CLIN INFECT DIS, V14, P1149, DOI 10.1093/clinids/14.5.1149; RADULOVIC S, IN PRESS CLIN INFECT; REED KD, 1995, JAMA-J AM MED ASSOC, V273, P23, DOI 10.1001/jama.273.1.23b; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; RICHTER PJ, IN PRESS J MED ENTOM; ROBERTSON RG, 1973, AM J EPIDEMIOL, V97, P55, DOI 10.1093/oxfordjournals.aje.a121485; RUIZBELTRAN R, 1990, EUR J EPIDEMIOL, V6, P293, DOI 10.1007/BF00150435; SANDERS FH, 1995, J MED ENTOMOL, V32, P402, DOI 10.1093/jmedent/32.4.402; SCHOELER GB, 1993, J MED ENTOMOL, V30, P80, DOI 10.1093/jmedent/30.1.80; SCHRIEFER ME, 1994, J CLIN MICROBIOL, V32, P949, DOI 10.1128/JCM.32.4.949-954.1994; SIRISANTHANA T, 1994, AM J TROP MED HYG, V50, P682, DOI 10.4269/ajtmh.1994.50.682; SPACH DH, 1995, NEW ENGL J MED, V332, P424, DOI 10.1056/NEJM199502163320703; STANDAERT SM, 1995, NEW ENGL J MED, V333, P420, DOI 10.1056/NEJM199508173330704; STEWART RS, 1991, MED J AUSTRALIA, V154, P94, DOI 10.5694/j.1326-5377.1991.tb120993.x; Takada Nobuhiro, 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P354; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; TARASEVICH IV, 1991, EUR J EPIDEMIOL, V7, P294, DOI 10.1007/BF00145681; TELFORD SR, 1995, ANN INTERN MED, V123, P277, DOI 10.7326/0003-4819-123-4-199508150-00006; UCHIDA T, 1992, INT J SYST BACTERIOL, V42, P303, DOI 10.1099/00207713-42-2-303; UCHIDA T, 1993, MICROBIOL IMMUNOL, V37, P91, DOI 10.1111/j.1348-0421.1993.tb03185.x; UHAA IJ, 1992, AM J TROP MED HYG, V46, P161, DOI 10.4269/ajtmh.1992.46.161; VANDAM AP, 1993, CLIN INFECT DIS, V17, P708, DOI 10.1093/clinids/17.4.708; WALKER DH, 1995, AM J TROP MED HYG, V52, P569, DOI 10.4269/ajtmh.1995.52.569; WILLIAMS SG, 1992, J CLIN MICROBIOL, V30, P1758, DOI 10.1128/JCM.30.7.1758-1762.1992; YU XJ, 1993, J CLIN MICROBIOL, V31, P83, DOI 10.1128/JCM.31.1.83-88.1993; YU XJ, 1993, J CLIN MICROBIOL, V31, P3284, DOI 10.1128/JCM.31.12.3284-3288.1993; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102; 1995, WKLY EPIDEMIOL REC, V70, P45; 1995, MMWR MORBID MORTAL W, V44, P593; 1994, MMWR MORBID MORTAL W, V43, P242; 1994, MMWR MORBID MORTAL W, V43, P689; 1994, MMWR MORBID MORTAL W, V43, P805	92	88	95	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					463	469		10.1001/jama.275.6.463	http://dx.doi.org/10.1001/jama.275.6.463			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627968				2022-12-28	WOS:A1996TU63800035
J	Fricker, EJ; McDonald, TJ				Fricker, EJ; McDonald, TJ			Tropheryma whippelii	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									ROBERT PACKER HOSP,SAYRE,PA 18840		Fricker, EJ (corresponding author), SO GEORGIA MED CTR,VALDOSTA,GA 31602, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					26	26		10.1056/NEJM199607043350105	http://dx.doi.org/10.1056/NEJM199607043350105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637538				2022-12-28	WOS:A1996UU47900005
J	Rodgers, GB				Rodgers, GB			The safety effects of child-resistant packaging for oral prescription drugs - Two decades of experience	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACT	Objective.-To evaluate the effectiveness of child-resistant packaging in reducing the mortality rate for children younger than 5 years from the unintentional ingestion of oral prescription drugs. Design.-Annual mortality rates for children younger than 5 years associated with the unintentional ingestion of oral prescription drugs are constructed for 1964 through 1992. The effect of child-resistant packaging on the child mortality rate during the postintervention period (1974 through 1992) is evaluated with a multivariate time series regression model. The analysis controls for changes in the consumption of oral prescription drugs over time and for long-term safety trends. Setting.-United States. Subjects.-Children younger than 5 years. Main Outcome Measure.-Estimated reductions in the child mortality rate associated with the use of child-resistant packaging. Results.-After controlling for covariates, the use of child-resistant packaging was associated with an annual reduction in the oral prescription drug-related mortality rate of 1.40 (95% confidence interval, 0.85-1.95) deaths per million children younger than 5 years. This suggests a reduction of about 460 child deaths from 1974, the year oral prescription drugs became subject to child-resistant packaging requirements, through 1992-a mortality rate reduction of about 45% from levels projected without the child-resistant requirements. Conclusion.-Child-resistant packaging reduces child mortality from the unintentional ingestion of oral prescription drugs.			Rodgers, GB (corresponding author), US CONSUMER PROD SAFETY COMMISS,DIRECTORATE ECON ANAL,WASHINGTON,DC 20207, USA.							BREAULT HJ, 1974, CLIN TOXICOL, V7, P91, DOI 10.3109/15563657408987980; CLARKE A, 1979, PEDIATRICS, V63, P687; DEPPA S, 1990, HUMAN FACTORS ISSUE; DOLE EJ, 1986, AM J PUBLIC HEALTH, V76, P1335, DOI 10.2105/AJPH.76.11.1335; DRAPER NR, 1981, APPLIED REGRESSION A; JACOBSON BJ, 1989, AM J PUBLIC HEALTH, V79, P853, DOI 10.2105/AJPH.79.7.853; KESSLER E, 1996, NEISS SAMPLE DESIGN; KHANDERIA M, 1980, VET HUM TOXICOL, V22, P239; KNAPP JF, 1995, PEDIATRICS, V96, P173; LITOVITZ T, 1992, PEDIATRICS, V89, P999; Maddala G.S., 2001, INTRO ECONOMETRICS, V3rd ed.; MCINTIRE MS, 1977, AM J PUBLIC HEALTH, V67, P169, DOI 10.2105/AJPH.67.2.169; MYERS CE, 1977, AM J HOSP PHARM, V34, P255, DOI 10.1093/ajhp/34.3.255; *NAT CTR HLTH STAT, 1995, INSTR MAN 2A; *NAT CTR HLTH STAT, 1994, PUBL US DAT TAP DOC; *NAT SAF COUNC, 1994, ACC FACTS, P29; National Center for Health Statistics, 1980, VIT STAT US, VII; *QUANT MICR SOFTW, 1990, MICR TIM SER AN REGR; SCHACHTER L, 1989, UNINTENTIONAL INGEST; SCHERZ RG, 1969, PEDIATRICS, V43, P84; SCHERZ RG, 1979, VET HUM TOXICOL, V21, P127; SHERMAN FT, 1979, JAMA-J AM MED ASSOC, V241, P1001, DOI 10.1001/jama.241.10.1001; SIMONSEN L, 1991, PHARM TIMES      APR, P57; SIMONSEN LL, 1993, PHARM TIMES, P29; SIMONSEN LLP, 1988, PHARM TIMES      APR, P38; SIMONSEN LLP, 1990, PHARM TIMES      APR, P56; TAINTER ML, 1969, ASPIRIN MODERN THERA; THIEN WMA, 1984, ACCIDENT ANAL PREV, V16, P185, DOI 10.1016/0001-4575(84)90012-5; *US BUR CENS, 1975, CURR POP REP 196 P25, V519; *US BUR CENS, 1993, CURR POP REP 196 P25, V1095; *US BUR CENS, 1982, CURR POP REP 196 P25, V917; VISCUSI WK, 1985, J LAW ECON, V28, P527, DOI 10.1086/467100; WALTON WW, 1982, PEDIATRICS, V69, P363; *WHO, 1967, MAN INT STAT CLASS D; WILBER CJ, 1988, SPECIAL PACKAGING RE; WILLIAMS D, 1986, VET HUM TOXICOL, V28, P427; World Health Organization, 1977, INT CLASS DIS; World Health Organization, 1957, MAN INT STAT CLASS D; 1983, FED REG         0119, V48, P2389; 1995, FED REG         0721, V60, P37710	40	110	116	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1661	1665		10.1001/jama.275.21.1661	http://dx.doi.org/10.1001/jama.275.21.1661			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UN252	8637140	Green Published			2022-12-28	WOS:A1996UN25200029
J	Langham, S; Thorogood, M; Normand, C; Muir, J; Jones, L; Fowler, G				Langham, S; Thorogood, M; Normand, C; Muir, J; Jones, L; Fowler, G			Costs and cost effectiveness of health checks conducted by nurses in primary care: The Oxcheck study	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure the costs and cost effectiveness of the Oxcheck cardiovascular risk factor screening and intervention programme. Design-Cost effectiveness analysis of a randomised controlled trial using clinical and economc data taken from the trial. Setting-Five general practices in Luton and Dunstable, England. Subjects-2205 patients who attended a health check in 1989-90 and were scheduled for reexamination in 1992-3 (intervention group); 1916 patients who attended their initial health check in 1992-3 (control group). Participants were men and women aged 35-64years. Intervention-Health check conducted by nurse, with health education and follow up according to degree of risk. Main outcome measures-Cost of health check programme; cost per 1 % reduction in coronary risk. Results-Health check and follow up cost pound 29.27 per patient. Estimated programme cost per 1% reduction in coronary risk per participant was between pound 1.46 and pound 2.25; it was nearly twice as much for men as women. Conclusions-The cost to the practice of implementing Oxcheck-style health checks in an average sized practice of 7500 patients would be pound 47 000, a proportion of which could be paid for through staff pay reimbursements and Band Three health promotion target payments. This study highlights the considerable difficulties faced when calculating the costs and benefits of a health promotion programme. Economic evaluations should be integrated into the protocols of randomised controlled trials to enable judgments to be made on the relative cost effectiveness of different prevention strategies.	LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC2E 7HT,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,GEN PRACTICE RES GRP,OXFORD OX2 6HE,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; Radcliffe Infirmary; University of Oxford				Normand, Charles/0000-0002-0885-5754				FIELD K, 1995, BRIT MED J, V310, P1109, DOI 10.1136/bmj.310.6987.1109; HAVELOCK C, 1994, 1994 NCN NAT COORD N; *OFF HLTH EC, 1995, COMP STAT; *OFF POP CENS SURV, 1994, OPCS MON 1994; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; Wonderling D, 1996, BRIT MED J, V312, P1274, DOI 10.1136/bmj.312.7041.1274; Wonderling D, 1996, BRIT MED J, V312, P1269, DOI 10.1136/bmj.312.7041.1269; 1994, BRIT MED J, V308, P3008; 1994, BRIT MED J, V308, P313; 1995, BRIT MED J, V310, P1099; 1991, BRIT MED J, V302, P1057; 1994, BR J GEN PRACT, V44, P62	12	45	45	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1265	1268		10.1136/bmj.312.7041.1265	http://dx.doi.org/10.1136/bmj.312.7041.1265			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634616	Green Published			2022-12-28	WOS:A1996UM40400021
J	Aiton, NR; Fox, GF; Hannam, S; Stern, CMM; Milner, AD				Aiton, NR; Fox, GF; Hannam, S; Stern, CMM; Milner, AD			Lesson of the week - Pulmonary hypoplasia presenting as persistent tachypnoea in the first few months of life	BRITISH MEDICAL JOURNAL			English	Article							POLYHYDRAMNIOS		UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PAEDIAT,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London				Aiton, Neil/0000-0001-9762-1169				AGAPITOS M, 1988, Pediatric Pathology, V8, P409; BOYLAN P, 1977, IRISH J MED SCI, V146, P179, DOI 10.1007/BF03030956; DELLEPOULE F, 1991, ARCH FR PEDIATR, V48, P703; FREYSCHUSS U, 1984, ACTA PAEDIATR SCAND, V73, P589, DOI 10.1111/j.1651-2227.1984.tb09979.x; ILAGAN NB, 1992, AM J PERINAT, V9, P9, DOI 10.1055/s-2007-994660; MENDELSOHN G, 1977, AM J DIS CHILD, V131, P1220, DOI 10.1001/archpedi.1977.02120240038008; PAGE DV, 1982, AM REV RESPIR DIS, V125, P216; Polgar G, 1971, PULMONARY FUNCTION T; STOCKS J, 1995, EUR RESPIR J, V8, P492, DOI 10.1183/09031936.95.08030492; SWISCHUK LE, 1979, J PEDIATR-US, V95, P573; THOMPSON PJ, 1990, ARCH DIS CHILD, V65, P878, DOI 10.1136/adc.65.8.878; WRIGGLESWORTH JS, 1982, LANCET, V1, P264	12	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1149	1150						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620135				2022-12-28	WOS:A1996UK06900030
J	Cleland, JGF; Swedberg, K				Cleland, JGF; Swedberg, K			Carvedilol for heart failure, with care	LANCET			English	Editorial Material							SURVIVAL		GOTHENBURG UNIV,OSTRA HOSP,DEPT MED,S-41685 GOTHENBURG,SWEDEN; UNIV GLASGOW,CLIN RES INITIAT HEART FAILURE,GLASGOW G61 1BD,LANARK,SCOTLAND	Sahlgrenska University Hospital; University of Gothenburg; University of Glasgow			Cleland, John G./AAZ-4185-2020; Swedberg, Karl/B-2475-2008	Cleland, John G./0000-0002-1471-7016; 				Bristow MR, 1995, CIRCULATION S1, V92, P142; Cohn Jay N., 1996, Journal of the American College of Cardiology, V27, p169A; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COLUCCI WS, 1995, CIRCULATION, V92, P394; CUBEDDU LX, 1987, CLIN PHARMACOL THER, V41, P31, DOI 10.1038/clpt.1987.6; Fowler Michael B., 1996, Journal of the American College of Cardiology, V27, p169A; HELD P, 1993, AM J CARDIOL, V71, pC39, DOI 10.1016/0002-9149(93)90085-Q; PACKER M, 1995, CIRCULATION S1, V92, P143; PACKER M, 1995, CIRCULATION S1, V92, P142; SACKNERBERNSTEI.J, 1995, CIRCULATION S1, V92, P395; SUNG CP, 1993, J CARDIOVASC PHARM, V21, P221, DOI 10.1097/00005344-199302000-00006; SWEDBERG K, 1979, LANCET, V1, P1374; YUE TL, 1992, J PHARMACOL EXP THER, V263, P92; 1995, CIRCULATION, V92, P394; 1995, CIRCULATION, V92, P212	15	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1199	1201		10.1016/S0140-6736(96)90729-1	http://dx.doi.org/10.1016/S0140-6736(96)90729-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622445				2022-12-28	WOS:A1996UJ59700004
J	Dawson, C; Whitfield, H				Dawson, C; Whitfield, H			ABC of urology - Urological malignancy .3. Renal and testicular carcinoma	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON NW10 7NS,ENGLAND; INST UROL & NEPHROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	Dawson, C (corresponding author), EDITH CAVELL HOSP,PETERBOROUGH,ENGLAND.							DEKERNION JB, 1992, CAMPBELLS UROLOGY; GORE ME, 1993, ADV UROLOGY ANDROLOG, V6; JENKINS BJ, 1995, CANC TOPICS, V10, P10; RICHIE JP, 1992, CMAPBELLS UROLOGY	4	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1146	1148						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620134				2022-12-28	WOS:A1996UK06900029
J	Giles, GG; Armstrong, BK; Burton, RC; Staples, MP; Thursfield, VJ				Giles, GG; Armstrong, BK; Burton, RC; Staples, MP; Thursfield, VJ			Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; SKIN; QUEENSLAND; EDUCATION; CAMPAIGN	Objective-To describe recent trends in mortality from melanoma in Australia. Design-An analysis of trends in age standardised and age and sex specific mortalities by year of death and median year of birth (cohort). Setting-Australia. Subjects-All deaths from melanoma registered in Australia between 1931 and 1994. Results-Melanoma mortality rose steadily from 1931 to 1985. From 1959 the annual rate of increase was 6.3% in men and 2.9% in women, resulting in mortalities of 4.82 and 2.51 per 100 000 person years in 1985 and 1989, respectively. Mortalities for both sexes seem to have plateaued from June 1985 onwards. In 1990-4 the rate rose by 3.7% in men to 5.00 per 100 000 and in women it fell by 5.2% to 2.38 per 100 000. The non-significant increase after 1985 in mortality in men was restricted to those aged over 70 years of age, whereas the fall in rates in women was mostly in those aged under 55 years. This pattern was generally reflected in the state trends, though with some variation: rates for women in Queensland had peaked in the late 1970s; while rates for men in New South Wales continued to rise in 1990-4, placing them above those for Queensland. Examination of mortalities specific for age, period, and cohort for Australia as a whole showed several salient features. Rates in men rose steeply in cohorts born before about 1930; were stable in cohorts born between 1930 and 1950; and fell in more recent cohorts. Rates in women showed similar changes but about five years earlier. Conclusion-Melanoma mortality in Australia peaked in about 1985 and has now plateaued. On the basis of trends in cohorts it can be expected to fall in coming years.	AUSTRALIAN INST HLTH & WELF, ACTON, ACT 2061, AUSTRALIA; UNIV NEWCASTLE, FAC MED & HLTH SCI, CALLAGHAN, NSW 2308, AUSTRALIA	University of Newcastle	Giles, GG (corresponding author), ANTICANC COUNCIL VICTORIA, CANC EPIDEMIOL CTR, CARLTON, VIC 3053, AUSTRALIA.			Giles, Graham/0000-0003-4946-9099				ARMSTRONG BK, 1994, CANCER SURV, V20, P219; ARMSTRONG BK, 1987, MED J AUSTRALIA, V147, P150; Beardmore G. L., 1972, MELANOMA SKIN CANCER, P39; BONETT A, 1989, MED J AUSTRALIA, V151, P502, DOI 10.5694/j.1326-5377.1989.tb128496.x; BURTON RC, 1994, MELANOMA RES, V4, P107, DOI 10.1097/00008390-199404000-00005; BURTON RC, 1993, INT J CANCER, V55, P765, DOI 10.1002/ijc.2910550512; COATES M, 1994, CANC NEW S WALES INC; COOKE K, 1992, NEW ZEAL MED J, V105, P303; CRISTOFOLINI M, 1993, J DERMATOL SURG ONC, V19, P117, DOI 10.1111/j.1524-4725.1993.tb03439.x; Davis N C, 1966, Med J Aust, V1, P643; ELWOOD JM, 1989, T MENZIES F, V15, P131; GILES GG, 1994, CANC FORUM, V18, P12; GILES GG, 1994, CANSTAT SKIN CANC; Green A, 1982, Australas J Dermatol, V23, P105, DOI 10.1111/j.1440-0960.1982.tb00739.x; Hill D, 1993, Eur J Cancer Prev, V2, P447; HOLMAN CDJ, 1980, INT J CANCER, V26, P703, DOI 10.1002/ijc.2910260602; HOLMAN CDJ, 1984, JNCI-J NATL CANCER I, V72, P257; JELFS PL, 1994, MED J AUSTRALIA, V161, P182, DOI 10.5694/j.1326-5377.1994.tb127379.x; JONES ME, 1992, MED J AUSTRALIA, V157, P373, DOI 10.5694/j.1326-5377.1992.tb137243.x; KHLAT M, 1992, AM J EPIDEMIOL, V135, P1103, DOI 10.1093/oxfordjournals.aje.a116210; KRICKER A, 1993, 13 IARC INT AG RES C; LANCASTER H. O., 1956, MED JOUR AUSTRALIA I, V43, P1082; MACKIE RM, 1992, BRIT MED J, V304, P1012, DOI 10.1136/bmj.304.6833.1012; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MCCARTHY WH, 1980, MED J AUSTRALIA, V2, P137, DOI 10.5694/j.1326-5377.1980.tb76944.x; ROUSH GC, 1992, CANCER-AM CANCER SOC, V69, P1714, DOI 10.1002/1097-0142(19920401)69:7&lt;1714::AID-CNCR2820690712&gt;3.0.CO;2-Z; SCOTTO J, 1991, INT J CANCER, V49, P490, DOI 10.1002/ijc.2910490403; SMITH T, 1979, BRIT MED J, V1, P253, DOI 10.1136/bmj.1.6158.253; STREETLY A, 1995, INT J EPIDEMIOL, V24, P897, DOI 10.1093/ije/24.5.897; SWERDLOW AJ, 1990, ANN NY ACAD SCI, V609, P235, DOI 10.1111/j.1749-6632.1990.tb32071.x; THORN M, 1992, BRIT J CANCER, V66, P563, DOI 10.1038/bjc.1992.315; VENZON DJ, 1984, AM J EPIDEMIOL, V119, P62, DOI 10.1093/oxfordjournals.aje.a113726; [No title captured]	33	157	160	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 4	1996	312	7039					1121	1125						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620126				2022-12-28	WOS:A1996UK06900019
J	Torcia, M; BracciLaudiero, L; Lucibello, M; Nencioni, L; Labardi, D; Rubartelli, A; Cozzolino, F; Aloe, L; Garaci, E				Torcia, M; BracciLaudiero, L; Lucibello, M; Nencioni, L; Labardi, D; Rubartelli, A; Cozzolino, F; Aloe, L; Garaci, E			Nerve growth factor is an autocrine survival factor for memory B lymphocytes	CELL			English	Article							MESSENGER-RNA; REGIONAL DISTRIBUTION; TRK PROTOONCOGENE; FACTOR RECEPTORS; FACTOR FAMILY; CELL MEMORY; FACTOR NGF; BCL-2; EXPRESSION; AFFINITY	Production of nerve growth factor (NGF) was assessed in cultures of human T and B lymphocytes and macrophages. NGF was constitutively produced by B cells only, which also expressed surface p140(trk-A) and p75(NGFR) molecules and hence efficiently bound and internalized the cytokine. Neutralization of endogenous NGF caused disappearance of Bcl-2 protein and apoptotic death of resting lymphocytes bearing surface IgG or IgA, a population comprising memory cells, while surface IgM/IgD ''virgin'' B lymphocytes were not affected. In vivo administration of neutralizing anti-NGF antibodies caused strong reduction in the titer of specific lgG in mice immunized with tetanus toroid, nitrophenol, or arsonate and reduced numbers of surface IgG or IgA B lymphocytes. Thus, NGF is an autocrine survival factor for memory B lymphocytes.	UNIV ROMA TOR VERGATA,DEPT EXPTL MED,I-00133 ROME,ITALY; UNIV FLORENCE,DEPT CLIN PHYSIOPATHOL,I-50139 FLORENCE,ITALY; CNR,INST NEUROBIOL,I-00185 ROME,ITALY; NATL INST CANC RES,SERV CLIN PATHOL,I-16132 GENOA,ITALY	University of Rome Tor Vergata; University of Florence; Consiglio Nazionale delle Ricerche (CNR); University of Genoa; IRCCS AOU San Martino IST			Rubartelli, Anna/AAA-1259-2021; Nencioni, Lucia/K-5988-2016; lucibello, maria/AAI-1417-2020; Torcia, Maria Gabriella G/K-1840-2018; Bracci-Laudiero, Luisa/H-1541-2013; Bracci Laudiero, Luisa/AAC-3521-2022	Nencioni, Lucia/0000-0003-4427-4823; Torcia, Maria Gabriella G/0000-0003-4740-4646; Bracci-Laudiero, Luisa/0000-0002-1682-6371; Cozzolino, Federico/0000-0002-2800-640X				ALOE L, 1994, AUTOIMMUNITY, V19, P141, DOI 10.3109/08916939409009542; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BARBACID M, 1994, J NEUROBIOL, V25, P386; BARDE Y-A, 1990, Progress in Growth Factor Research, V2, P237, DOI 10.1016/0955-2235(90)90021-B; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BRACCILAUDIERO L, 1993, NEUROREPORT, V4, P563, DOI 10.1097/00001756-199305000-00025; BRODIE C, 1992, J IMMUNOL, V148, P3492; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DICOU E, 1993, NEUROREPORT, V5, P321, DOI 10.1097/00001756-199312000-00036; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; EAGER KB, 1991, ONCOGENE, V6, P819; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10981; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FANSLOW WC, 1992, J IMMUNOL, V149, P655; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HAWKINS CJ, 1994, IMMUNOL REV, V142, P127, DOI 10.1111/j.1600-065X.1994.tb00886.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; ISHII Y, 1992, J CLIN INVEST, V89, P794, DOI 10.1172/JCI115658; JANET T, 1995, J NEUROSCI RES, V40, P707, DOI 10.1002/jnr.490400602; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON EM, 1986, TRENDS NEUROSCI, V9, P33, DOI 10.1016/0166-2236(86)90012-3; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KATAYAMA N, 1993, BLOOD, V81, P610; KIMATA H, 1991, EUR J IMMUNOL, V21, P137, DOI 10.1002/eji.1830210121; KISHIMOTO T, 1989, FUNDAMENTAL IMMUNOLO, P385; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; LEVIMONT.R, 1966, PHARMACOL REV, V18, P619; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MCCONKEY DJ, 1989, FASEB J, V3, P1844; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NISONOFF A, 1967, METHODS IMMUNOLOGY I, P1; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; ROMAGNANI S, 1982, J IMMUNOL, V129, P596; SANTAMBROGIO L, 1994, J IMMUNOL, V153, P4488; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; SHELTON DL, 1986, P NATL ACAD SCI USA, V83, P2714, DOI 10.1073/pnas.83.8.2714; SIEKEVITZ M, 1987, CELL, V48, P757, DOI 10.1016/0092-8674(87)90073-0; SODERSTROM S, 1990, J NEUROSCI RES, V27, P665, DOI 10.1002/jnr.490270427; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; UEYAMA T, 1993, J HYPERTENS, V11, P1061, DOI 10.1097/00004872-199310000-00009; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2840; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	62	357	374	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					345	356		10.1016/S0092-8674(00)81113-7	http://dx.doi.org/10.1016/S0092-8674(00)81113-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616890	Green Published, Bronze			2022-12-28	WOS:A1996UK14000008
J	Wellinger, RJ; Ethier, K; Labrecque, P; Zakian, VA				Wellinger, RJ; Ethier, K; Labrecque, P; Zakian, VA			Evidence for a new step in telomere maintenance	CELL			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; QUADRUPLEX STRUCTURE; MACRONUCLEAR DNA; BINDING PROTEIN; YEAST TELOMERE; 3' TERMINUS; S-PHASE; REPLICATION; RECOMBINATION	The strand of telomeric DNA that runs 5'3' toward a chromosome end is typically G rich. Telomerase-generated G tails are expected at one end of individual DNA molecules. Saccharomyces telomeres acquire TG(1-3) tails late in S phase. Moreover, the telomeres of linear plasmids can interact when the TG(1-3) tails are present. Molecules that mimic the structures predicted for telomere replication intermediates were generated in vitro. These in vitro generated molecules formed telomere-telomere interactions similar to those on molecules isolated from yeast, but only if both ends that interacted had a TG(1-3) tail. Moreover, TG(1-3), tails were generated in vivo in cells lacking telomerase. These data suggest a new step in telomere maintenance, cell cycle-regulated degradation of the C(1-3)A strand, which can generate a potential substrate for telomerase and telomere-binding proteins at every telomere.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University	Wellinger, RJ (corresponding author), UNIV SHERBROOKE, FAC MED, DEPT MICROBIOL, SHERBROOKE, PQ J1H 5N4, CANADA.		Wellinger, Raymund/K-3207-2019	Wellinger, Raymund/0000-0001-6670-2759	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM026938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BEELER T, 1994, J BIOL CHEM, V269, P7279; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHENG AJ, 1993, NUCLEIC ACIDS RES, V21, P5630, DOI 10.1093/nar/21.24.5630; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GILSON E, 1994, NUCLEIC ACIDS RES, V22, P5310, DOI 10.1093/nar/22.24.5310; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GREIDER XCW, 1995, TELOMERES, V29, P35; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HENIKOFF S, 1987, GENETICS, V117, P711; HOBZA P, 1987, J AM CHEM SOC, V109, P1302, DOI 10.1021/ja00239a003; HUANG KN, 1993, MOL CELL BIOL, V13, P3125, DOI 10.1128/MCB.13.6.3125; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KERR C, 1972, J BIOL CHEM, V247, P311; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; McClintock B, 1941, GENETICS, V26, P234; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PLUTA AF, 1982, NUCLEIC ACIDS RES, V10, P8145, DOI 10.1093/nar/10.24.8145; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; PRICE CM, 1990, MOL CELL BIOL, V10, P3421, DOI 10.1128/MCB.10.7.3421; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; SADOWSKI PD, 1985, NUCLEASES, P23; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCARIA PV, 1992, P NATL ACAD SCI USA, V89, P10336, DOI 10.1073/pnas.89.21.10336; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SOMMERVILLE FW, 1987, ELECT MICROSCOPY MOL; STINCHCOMB DT, 1980, P NATL ACAD SCI-BIOL, V77, P4559, DOI 10.1073/pnas.77.8.4559; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNDQUIST WI, 1993, CURR BIOL, V3, P893, DOI 10.1016/0960-9822(93)90229-H; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SUNDQUIST WI, 1990, NUCL ACIDS MOL BIOL, V5, P1; SUTCLIFFE JG, 1978, NUCLEIC ACIDS RES, V5, P2721, DOI 10.1093/nar/5.8.2721; VOLOSHIN ON, 1992, J BIOMOL STRUCT DYN, V9, P643, DOI 10.1080/07391102.1992.10507945; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WELLINGER RJ, 1989, P NATL ACAD SCI USA, V86, P973, DOI 10.1073/pnas.86.3.973; WELLINGER RJ, 1992, CHROMOSOMA, V102, pS150, DOI 10.1007/BF02451800; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WELLINGER RJ, 1993, CHROMOSOME SEGRATI H, V72, P133; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WILEY EA, 1995, GENETICS, V139, P67; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	73	258	264	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					423	433		10.1016/S0092-8674(00)81120-4	http://dx.doi.org/10.1016/S0092-8674(00)81120-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616897	Bronze			2022-12-28	WOS:A1996UK14000015
J	Faux, MC; Scott, JD				Faux, MC; Scott, JD			Molecular glue: Kinase anchoring and scaffold proteins	CELL			English	Review											Faux, MC (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST, MAIL CODE L474, PORTLAND, OR 97201 USA.							AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KLAUCK TM, 1995, CELL SIGNAL, V7, P747, DOI 10.1016/0898-6568(95)02003-9; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YASHAR B, 1995, MOL CELL BIOL, V15, P6545	19	231	239	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					9	12		10.1016/S0092-8674(00)81075-2	http://dx.doi.org/10.1016/S0092-8674(00)81075-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620541	Bronze			2022-12-28	WOS:A1996UE55900003
J	Landi, G				Landi, G			No to DNR orders in acute stroke	LANCET			English	Editorial Material											Landi, G (corresponding author), OSPED MAGGIORE POLICLIN,MILAN,ITALY.							Alexandrov AV, 1996, STROKE, V27, P232, DOI 10.1161/01.STR.27.2.232; BURTIN P, 1994, INTENS CARE MED, V20, P32, DOI 10.1007/BF02425052; COTE R, 1989, NEUROLOGY, V39, P638, DOI 10.1212/WNL.39.5.638; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; GROTTA J, 1995, NEUROLOGY, V45, P640, DOI 10.1212/WNL.45.4.640; Multicentre Acute Stroke Trial-Italy Group, 1995, LANCET, V346, P1509; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					848	848		10.1016/S0140-6736(96)91342-2	http://dx.doi.org/10.1016/S0140-6736(96)91342-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622388				2022-12-28	WOS:A1996UC45000006
J	Levy, A				Levy, A			Perioperative steroid cover	LANCET			English	Editorial Material											Levy, A (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.							BROMBERG JS, 1991, TRANSPLANTATION, V51, P385, DOI 10.1097/00007890-199102000-00023; FRASER CG, 1952, JAMA-J AM MED ASSOC, V149, P1542, DOI 10.1001/jama.1952.72930340001009; Friedman RJ, 1995, J BONE JOINT SURG AM, V77A, P1801, DOI 10.2106/00004623-199512000-00002; KEHLET H, 1973, BRIT J ANAESTH, V45, P1043, DOI 10.1093/bja/45.10.1043; LEWIS L, 1953, ANN INTERN MED, V39, P116, DOI 10.7326/0003-4819-39-1-116	5	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					846	847		10.1016/S0140-6736(96)91340-9	http://dx.doi.org/10.1016/S0140-6736(96)91340-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622386				2022-12-28	WOS:A1996UC45000004
J	Bishai, WR; Graham, NMH; Harrington, S; Page, C; MooreRice, K; Hooper, N; Chaisson, RE				Bishai, WR; Graham, NMH; Harrington, S; Page, C; MooreRice, K; Hooper, N; Chaisson, RE			Rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; INFECTION; MUTATIONS; COMPLEX		JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOLEC MICROBIOL & IMMUNOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; MARYLAND DEPT HLTH & MENTAL HYG,BALTIMORE,MD 21202; BALTIMORE CITY DEPT HLTH,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene					NIAID NIH HHS [AI36973] Funding Source: Medline; NIDA NIH HHS [DA07061] Funding Source: Medline; PHS HHS [U300466-10] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036973, R01AI036973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BODMER T, 1995, J ANTIMICROB CHEMOTH, V35, P345, DOI 10.1093/jac/35.2.345; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; CHAISSON RE, IN PRESS AM J RESPIR; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; Cole Stewart T., 1994, Trends in Microbiology, V2, P411, DOI 10.1016/0966-842X(94)90621-1; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1993, NEW ENGL J MED, V329, P148; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GRAHAM NMH, 1995, AM J RESPIR CRIT C S, V151, pA145; HAVLIR DV, 1996, 3 C RETR OPP INF WAS; HONORE N, 1993, ANTIMICROB AGENTS CH, V37, P414, DOI 10.1128/AAC.37.3.414; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; JABES D, 1994, ANTIMICROB AGENTS CH, V38, P2346, DOI 10.1128/AAC.38.10.2346; JI BH, 1993, AM REV RESPIR DIS, V148, P1541, DOI 10.1164/ajrccm/148.6_Pt_1.1541; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292; Kent PT, 1985, GUIDE LEVEL 3 LAB; MILLER LP, 1994, ANTIMICROB AGENTS CH, V38, P805, DOI 10.1128/AAC.38.4.805; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; NOLAN CM, 1995, AM J RESP CRIT CARE, V152, P1067, DOI 10.1164/ajrccm.152.3.7663785; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; PIERCE M, 1995, 35 INT C ANT AG CHEM; POULET S, 1995, ARCH MICROBIOL, V163, P87, DOI 10.1007/s002030050176; REICHMAN LB, 1994, NEW ENGL J MED, V330, P437; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SALOMON N, 1995, CLIN INFECT DIS, V21, P1245, DOI 10.1093/clinids/21.5.1245; SIDDIQI SH, 1992, CLIN MICROBIOLOGY PR, V1; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; WELTMAN AC, 1995, LANCET, V345, P1513, DOI 10.1016/S0140-6736(95)91074-3; 1995, MMWR-MORBID MORTAL W, V44, P1; 1991, MMWR-MORBID MORTAL W, V40, P585; 1993, MMWR-MORBID MORTAL W, V42, P14; 1992, AM REV RESPIR DIS, V145, P36; 1989, MMWR-MORBID MORTAL W, V38, P236	43	38	38	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1573	1576		10.1056/NEJM199606133342404	http://dx.doi.org/10.1056/NEJM199606133342404			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP663	8628338	Bronze			2022-12-28	WOS:A1996UP66300004
J	deCharms, RC; Merzenich, MM				deCharms, RC; Merzenich, MM			Primary cortical representation of sounds by the coordination of action-potential timing	NATURE			English	Article							AUDITORY-CORTEX; STRIATE CORTEX; MACAQUE MONKEY; NEURONS; RESPONSES; CAT; SYNCHRONIZATION	CORTICAL population coding could in principle rely on either the mean rate of neuronal action potentials, or the relative timing of action potentials, or both, When a single sensory stimulus drives many neurons to fire at elevated rates, the spikes of these neurons become tightly synchronized(1,2), which could be involved in 'binding' together individual firing-rate feature representations into a unified object percept(3), Here we demonstrate that the relative timing of cortical action potentials can signal stimulus features themselves, a function even more basic than feature grouping, Populations of neurons in the primary auditory cortex can coordinate the relative timing of their action potentials such that spikes occur closer together in time during continuous stimuli. In this way cortical neurons can signal stimuli even when their firing rates do not change, Population coding based on relative spike timing can systematically signal stimulus features, it is topographically mapped, and it follows the stimulus time course even where mean firing rate does not.	UNIV CALIF SAN FRANCISCO, KECK CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco								ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Abeles M., 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; ADRIAN ED, 1950, ELECTROEN CLIN NEURO, V2, P377, DOI 10.1016/0013-4694(50)90075-7; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHISSAR M, 1992, J NEUROPHYSIOL, V67, P203, DOI 10.1152/jn.1992.67.1.203; BEMANDER O, 1994, NEURAL COMPUT, V6, P622; BRUGGE JF, 1973, J NEUROPHYSIOL, V36, P1138, DOI 10.1152/jn.1973.36.6.1138; CREUTZFELDT O, 1980, EXP BRAIN RES, V39, P87; DICKSON JW, 1974, J NEUROPHYSIOL, V37, P1239, DOI 10.1152/jn.1974.37.6.1239; Efron B, 1982, JACKKNIFE BOOTSTRAP, P75, DOI [10.1137/1.9781611970319.ch10, DOI 10.1137/1.9781611970319.CH10]; EGGERMONT JJ, 1994, J NEUROPHYSIOL, V71, P246, DOI 10.1152/jn.1994.71.1.246; GABBOTT PLA, 1987, NEUROSCIENCE, V21, P833, DOI 10.1016/0306-4522(87)90040-6; GRANNAN ER, 1993, NEURAL COMPUT, V5, P550, DOI 10.1162/neco.1993.5.4.550; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; LEHMANN EL, 1975, NONPARAMETRICS; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P374, DOI 10.1152/jn.1957.20.4.374; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; MOUNTCASTLE VB, 1969, J NEUROPHYSIOL, V32, P452, DOI 10.1152/jn.1969.32.3.452; MURTHY VN, 1994, NEURAL COMPUT, V6, P1111, DOI 10.1162/neco.1994.6.6.1111; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; PERKEL DH, 1967, BIOPHYS J, V7, P391, DOI 10.1016/S0006-3495(67)86596-2; PFINGST BE, 1981, J NEUROPHYSIOL, V45, P16, DOI 10.1152/jn.1981.45.1.16; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; TSO DY, 1986, J NEUROSCI, V6, P1160; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; VONDERMALSBURG C, 1981, INTERNAL REPORT M PL	30	393	397	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					610	613		10.1038/381610a0	http://dx.doi.org/10.1038/381610a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637597				2022-12-28	WOS:A1996UQ65700052
J	Yuan, JM; Ross, RK; Wang, XL; Gao, YT; Henderson, BE; Yu, MC				Yuan, JM; Ross, RK; Wang, XL; Gao, YT; Henderson, BE; Yu, MC			Morbidity and mortality in relation to cigarette smoking in Shanghai, China - A prospective male cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MAJOR RISK-FACTORS; MIDDLE-AGED MEN; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; FOLLOW-UP; STROKE; CANCER; SMOKERS; WOMEN	Objective.-To evaluate prospectively the health risk of cigarette smoking in middle-aged men in Shanghai, China. Design.-Prospective cohort study with annual follow-up. Participants.-A total of 18244 male residents of Shanghai, China. enrolled in the study during January 1, 1986, through September 30, 1989, and actively followed via annual visits. Results.-By September 30, 1993, 852 deaths and 554 incident cancer cases were identified during the follow-up period, which averaged 5.4 years per subject. The overall incidence rate for cancer was 568 per 100 000 man-years, with the 3 leading sites being lung (146/100000), stomach (116/100000), and liver (81/100000). Forty-one percent of all deaths were from cancer. Stroke was the most frequent cause of death unrelated to cancer, with an age-adjusted rate 4.2 times higher than that of US white men (201/100000 vs 48/100000), followed by ischemic heart disease, with an age-adjusted rate one-fifth that of US white men (69/100000 vs 366/100000). Compared with lifelong nonsmokers, the relative risks in heavy smokers (20 or more cigarettes per day) after adjustment for alcohol consumption were 2.2 fdr any incident cancer, 9.4 for incident lung cancer, 6.7 for head and neck cancer, and 1.8 for liver cancer. In terms of mortality, heavy smokers were at a 60% greater risk of death relative to lifelong nonsmokers; there was a 2.3-fold excess risk of death gram cancer and 2-fold to 3-fold excess risk of death from heart disease. Conclusions.-Cigarette smoking is an important predictor of risk of cancer and mortality in men in Shanghai. Among the study subjects, 36% of all cases of cancer and 21% of all deaths could be attributed to cigarette smoking.	SHANGHAI CANC INST,SHANGHAI,PEOPLES R CHINA	Shanghai Jiao Tong University	Yuan, JM (corresponding author), UNIV SO CALIF,NORRIS COMPREHENS CANC CTR,1441 EASTLAKE AVE,LOS ANGELES,CA 90033, USA.		Gao, Yu/HGE-1937-2022	Yuan, Jian-Min/0000-0002-4620-3108	NCI NIH HHS [R35 CA53890, R01 CA043092, R01 CA43092, R01 CA043092-20] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA053890, R01CA043092] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BARON AE, 1993, CANCER EPIDEM BIOMAR, V2, P519; BRESLOW NE, 1987, INT AGENCY RES CANC, V82; CARSTENSEN JM, 1987, J EPIDEMIOL COMMUN H, V41, P166, DOI 10.1136/jech.41.2.166; *CDC, 1989, 898411 CDC US DEP HL; CHEN DY, 1992, NEUROEPIDEMIOLOGY, V11, P15, DOI 10.1159/000110902; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P59; DAGENAIS GR, 1990, CAN J CARDIOL, V6, P274; DENG J, 1985, CHIN J PREV MED, V5, P271; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; Freund K M, 1993, Ann Epidemiol, V3, P417, DOI 10.1016/1047-2797(93)90070-K; HAHEIM LL, 1993, STROKE, V24, P1484, DOI 10.1161/01.STR.24.10.1484; HAMMOND EC, 1961, J NATL CANCER I, V27, P419; HAMMOND EC, 1980, PREV MED, V9, P169, DOI 10.1016/0091-7435(80)90071-7; HARMSEN P, 1990, STROKE, V21, P223, DOI 10.1161/01.STR.21.2.223; Kodama K, 1993, Ann Epidemiol, V3, P524; LAM KC, 1982, CANCER RES, V42, P5246; LEUNG HM, 1981, BIOMETRICS, V37, P293, DOI 10.2307/2530418; MENOTTI A, 1990, PREV MED, V19, P270, DOI 10.1016/0091-7435(90)90027-H; *NAT CTR HLTH STAT, 1993, US DEP HLTH HUM SERV; NOVOTNY TE, 1988, PUBLIC HLTH REPORTS, V103, P552; PAGANINIHILL A, 1994, AM J PUBLIC HEALTH, V84, P992, DOI 10.2105/AJPH.84.6.992; PARKIN DM, 1992, INT AGENCY RES CANC, V120; PETO R, 1986, LANCET, V2, P1038; RAGLAND DR, 1988, AM J EPIDEMIOL, V127, P462, DOI 10.1093/oxfordjournals.aje.a114823; ROBBINS AS, 1994, ANN INTERN MED, V120, P458, DOI 10.7326/0003-4819-120-6-199403150-00002; ROGOT E, 1980, PUBLIC HLTH REP, V95, P218; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; ROSS RK, IN PRESS AM J EPIDEM; SEMENCIW RM, 1988, INT J EPIDEMIOL, V17, P317, DOI 10.1093/ije/17.2.317; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; Thom T J, 1993, Ann Epidemiol, V3, P509; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YU JJ, 1990, JAMA-J AM MED ASSOC, V264, P1575, DOI 10.1001/jama.264.12.1575; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; 1993, MMWR-MORBID MORTAL W, V42, P645; 1987, CHIN MED J, V67, P229	39	147	155	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1646	1650						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637137				2022-12-28	WOS:A1996UN25200026
J	Tytler, D; Fan, XM; Burles, S				Tytler, D; Fan, XM; Burles, S			Cosmological baryon density derived from the deuterium abundance at redshift z=3.57	NATURE			English	Article								THE primordial ratio of deuterium to hydrogen nuclei (D/H), created as a result of the Big Bang, provides the most sensitive measure of the cosmological density of baryons(1-5). Measurements of the D/H ratio in the interstellar medium of our Galaxy place a strict lower limit on the primordial ratio(6), because processing of gas by stars reduces the abundance of deuterium relative to hydrogen. Absorption of radiation from distant quasars by intervening clouds of gas offers a means of probing D/H ratios at large redshifts, where the effects of stellar processing should be negligible. Measurements(7,8) on one absorption system have indicated an extremely high primordial abundance ratio of 24 x 10(-5). Here we report a measurement of the D/H ratio in another high-redshift absorption system, and obtain a value that is an order of magnitude lower than that reported previously(7,8). The measured ratio of 2.3 x 10(-5) is consistent with that in the interstellar medium (after allowing for Galactic chemical evolution(9,10)), and indicates that the absorption spectra on which the earlier estimates are based may have been subject to strong contamination. We calculate a baryon density that is 5% of the critical density required to close the Universe.	UNIV CALIF SAN DIEGO, CTR ASTROPHYS & SPACE SCI, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	Tytler, D (corresponding author), UNIV CALIF SAN DIEGO, DEPT PHYS, C0111, LA JOLLA, CA 92093 USA.							Carswell RF, 1996, MON NOT R ASTRON SOC, V278, P506, DOI 10.1093/mnras/278.2.506; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1; CHARBONNEL C, 1995, ASTROPHYS J, V453, pL41; COPI CJ, 1995, SCIENCE, V267, P192, DOI 10.1126/science.7809624; DONAHUE M, 1991, ASTROPHYS J, V383, P511, DOI 10.1086/170809; EDMUNDS MG, 1994, MON NOT R ASTRON SOC, V270, pL37; GAIL HP, 1974, ASTRON ASTROPHYS, V32, P65; GALLI D, 1995, ASTROPHYS J, V443, P536, DOI 10.1086/175546; GEISS J, 1994, ORIGIN EVOLUTION ELE, V89; HU EM, 1995, ASTRON J, V110, P1526, DOI 10.1086/117625; JAKOBSEN P, 1994, NATURE, V370, P35, DOI 10.1038/370035a0; KRAUSS LM, 1995, PHYS LETT B, V347, P347, DOI 10.1016/0370-2693(95)00082-V; Levshakov SA, 1996, MON NOT R ASTRON SOC, V278, P497, DOI 10.1093/mnras/278.2.497; LINSKY JL, 1995, ASTROPHYS J, V451, P335, DOI 10.1086/176223; MATHEWS WG, 1987, ASTROPHYS J, V323, P456, DOI 10.1086/165843; MCCULLOUGH PR, 1992, ASTROPHYS J, V390, P213, DOI 10.1086/171271; MORTON DC, 1991, ASTROPHYS J SUPPL S, V77, P119, DOI 10.1086/191601; PAGEL BEJ, 1992, MON NOT R ASTRON SOC, V255, P325, DOI 10.1093/mnras/255.2.325; PAGEL BEJ, 1994, ESO EIPC WORKSH LIGH, P155; PERSIC M, 1992, MON NOT R ASTRON SOC, V258, pP14, DOI 10.1093/mnras/258.1.14P; PETITJEAN P, 1990, ASTRON ASTROPHYS, V231, P309; PRATT M, 1996, WORKSHOP DARK MATTER; Ryan SG, 1996, ASTROPHYS J, V458, P543, DOI 10.1086/176838; SARKAR S, UNPUB REP PROG PHYS; SASSELOV D, 1995, ASTROPHYS J, V444, pL5; SMITH MS, 1993, ASTROPHYS J SUPPL S, V85, P219, DOI 10.1086/191763; SONGAILA A, 1994, NATURE, V368, P599, DOI 10.1038/368599a0; STEIGMAN G, 1992, ASTROPHYS J, V401, P150, DOI 10.1086/172048; STEIGMAN G, 1995, ASTROPHYS J, V453, P173, DOI 10.1086/176378; THUAN TX, 1996, INTERPLAY MASSIVE ST; VAUCLAIR S, 1995, ASTRON ASTROPHYS, V295, P715; VOGT S, 1994, P SOC PHOTO-OPT INS, V2198, P362, DOI 10.1117/12.176725; WALKER TP, 1991, ASTROPHYS J, V376, P51, DOI 10.1086/170255; WAMPLER EJ, UNPUB	34	287	289	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					207	209		10.1038/381207a0	http://dx.doi.org/10.1038/381207a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622761	Green Submitted			2022-12-28	WOS:A1996UL24900044
J	Levy, EM; Viscoli, CM; Horwitz, RI				Levy, EM; Viscoli, CM; Horwitz, RI			The effect of acute renal failure on mortality - A cohort analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE UNIT; RISK-FACTORS; APACHE-II; PREDICTION; SURVIVAL; INSUFFICIENCY; HEMODIALYSIS; PROGNOSIS; VARIABLES; PATTERNS	Objective.-To determine if the high mortality in acute renal failure is explained by underlying illnesses (comorbidity). Design.-Cohort analytic study. Setting.-An 826-bed general hospital providing primary, secondary, and tertiary care. Patients.-From 16248 inpatients undergoing radiocontrast procedures between 1987 and 1989, we identified 183 index subjects who developed contrast media-associated renal failure (defined as an increase in serum creatinine level of at least 25%, to at least 177 mu mol/L [2 mg/dL], within 2 days of receiving contrast material) and 174 paired subjects, matched for age and baseline serum creatinine level, who underwent similar contrast procedures without developing renal failure. Main Outcome Measure.-Death during hospitalization. Results.-The mortality rate in subjects without renal failure was 7%, compared with 34% in the corresponding index subjects with renal failure (odds ratio, 6.5; P<.001). After adjusting for differences in comorbidity, renal failure was associated with an odds ratio of dying of 5.5. Subjects who died after developing renal failure had complicated clinical courses characterized by sepsis, bleeding, delirium, and respiratory failure; most of these complications developed after the onset of renal failure. Deaths from renal causes were rare. Conclusions.-The high mortality rate in acute renal failure is not explained by the underlying conditions alone, Renal failure appears to increase the risk of developing severe nonrenal complications that lead to death and should not be regarded as a treatable complication of serious illness.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510	Yale University	Levy, EM (corresponding author), BRIGHAM & WOMENS HOSP,DIV RENAL,75 FRANCIS ST,BOSTON,MA 02115, USA.							ABREO K, 1986, ARCH INTERN MED, V146, P1338, DOI 10.1001/archinte.146.7.1338; ANDERSON RJ, 1977, NEW ENGL J MED, V296, P1134, DOI 10.1056/NEJM197705192962002; BOULTONJONES M, 1994, LANCET, V344, P559, DOI 10.1016/S0140-6736(94)91958-5; BULLOCK ML, 1985, AM J KIDNEY DIS, V5, P97, DOI 10.1016/S0272-6386(85)80003-2; CAMERON JS, 1986, Q J MED, V59, P337; CENTOR RM, 1984, NEW ENGL J MED, V310, P577, DOI 10.1056/NEJM198403013100907; CIOFFI WG, 1984, ANN SURG, V200, P205, DOI 10.1097/00000658-198408000-00015; CORWIN HL, 1987, AM J NEPHROL, V7, P8, DOI 10.1159/000167421; DOUMA CE, 1994, J AM SOC NEPHROL, V5, P391; FLEISS JL, 1981, STATISTICAL METHODS, P143; FROST L, 1993, SCAND J UROL NEPHROL, V27, P453, DOI 10.3109/00365599309182277; GROENEVELD ABJ, 1991, NEPHRON, V59, P602, DOI 10.1159/000186651; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; Halstenberg W., 1993, Journal of the American Society of Nephrology, V4, P317; HOSMER DW, 1989, APPL LOGISTIC REGRES, V1, P10; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEVY EM, 1994, J AM SOC NEPHROL, V4, P319; LIEN J, 1985, ARCH INTERN MED, V145, P2067, DOI 10.1001/archinte.145.11.2067; MAHER ER, 1989, Q J MED, V72, P857; MCMURRAY SD, 1978, ARCH INTERN MED, V138, P950, DOI 10.1001/archinte.138.6.950; PARFREY PS, 1989, NEW ENGL J MED, V320, P143, DOI 10.1056/NEJM198901193200303; RASMUSSEN HH, 1985, ARCH INTERN MED, V145, P2015, DOI 10.1001/archinte.145.11.2015; RASMUSSEN HH, 1982, AM J MED, V73, P211, DOI 10.1016/0002-9343(82)90181-4; ROSE CC, 1984, NEW ENGL J MED, V310, P573, DOI 10.1056/NEJM198403013100906; ROUTH GS, 1980, POSTGRAD MED J, V56, P244, DOI 10.1136/pgmj.56.654.244; SCHAEFER JH, 1991, INTENS CARE MED, V17, P19, DOI 10.1007/BF01708404; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; SHUSTERMAN N, 1987, AM J MED, V83, P65, DOI 10.1016/0002-9343(87)90498-0; SPIEGEL DM, 1991, AM J NEPHROL, V11, P44, DOI 10.1159/000168271; WERB R, 1979, RESUSCITATION, V7, P95, DOI 10.1016/0300-9572(79)90003-0; WHEELER DC, 1986, Q J MED, V61, P977; WILKINS RG, 1983, ANAESTHESIA, V38, P628, DOI 10.1111/j.1365-2044.1983.tb12153.x	35	1063	1127	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1489	1494		10.1001/jama.275.19.1489	http://dx.doi.org/10.1001/jama.275.19.1489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622223				2022-12-28	WOS:A1996UJ93700032
J	Dowling, S; Martin, R; Skidmore, P; Doyal, L; Cameron, A; Lloyd, S				Dowling, S; Martin, R; Skidmore, P; Doyal, L; Cameron, A; Lloyd, S			Nurses taking on junior doctors' work: A confusion of accountability	BRITISH MEDICAL JOURNAL			English	Article								The number of hospital based posts in which nurses take over clinical work previously done by junior doctors is growing. Accountability for the scope of such new roles and the standards of practice which apply to them are still unclear. When analysed together and compared, the regulations arising from the professional bodies (GMC and UKCC), civil law concerning certain wrongs to patients, and employment law are sometimes contradictory and hard to interpret. The resulting uncertainties about appropriate management for clinical roles evolving between the professions, coupled with an increasingly litigious public, put the nurses and consultants involved at risk of complaints and of disciplinary and legal action. Drawing on our current research into changing clinical roles at the medical-nursing interface, we suggest strategies to reduce risk. Doctors and nurses should be equal partners in planning and managing these new posts, patients should be informed adequately about the nature of the postholder's role and training, significant changes in the work of such postholders should be formally acknowledged by the employer and relevant insurers, individuals taking up new roles should have access to legal advice and support to cover legal risk, and national regulatory bodies need to work together to harmonise their codes of practice in relation to changing clinical roles between the professions.	UNIV BRISTOL,DEPT LAW,BRISTOL BS8 2PR,AVON,ENGLAND; UNIV BRISTOL,SCH POLICY STUDIES,BRISTOL BS8 4AE,AVON,ENGLAND; OPUS CONSULTING,BRISTOL BS8 1AT,AVON,ENGLAND	University of Bristol; University of Bristol	Dowling, S (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND.							Davies C., 1995, GENDER PROFESSIONAL; *DEP HLTH, 1995, PAT CHART; *DEP HLTH SOC SEC, 1989, HCFP8922 DHSS; DIMAOND B, 1995, LEGAL ASPECTS NURSIN; DIMOND B, 1994, EXPANDING ROLE NURSE; DOWLING S, 1995, BRIT MED J, V311, P309, DOI 10.1136/bmj.311.7000.309; DOYAL L, IN PRESS EVALUATION; Dyer C, 1996, BRIT MED J, V312, P330; *GEN MED COUNC, 1995, DUT DOCT GUID GEN ME; Harrison A, 1996, ACUTE FUTURES; *HLTH SERV COMM, 1995, 3 REP SESS 1994 5 AN; HOYTE P, 1994, MED LAW INT, V1, P261; KORGAONKAR G, 1995, LAW NURSES; MASON JK, 1994, LAW MED ETHICS; *MED WORKSF STAND, 1995, PLANN MED WORKF 2 RE; MONTGOMERY J, 1992, LAW HLTH MED REGULAT; *NHS MAN EX, 1993, RISK MAN NHS; *NHS MAN EX, 1991, JUN DOCT NEW DEAL; READ S, 1994, REDUCTION JUNIOR DOC; READ S, 1995, CATCHING TIDE NEW VO; SALVAGE J, 1995, BRIT MED J, V311, P274, DOI 10.1136/bmj.311.7000.274; *UK CENTR COUNC NU, 1992, SCOP PROF PRACT; *UK CENTR COUNC NU, 1989, EX ACC UKCC ADV DOC; Walby Sylvia, 1994, MED NURSING PROFESSI; *WORK GROUP SPEC M, 1993, HOSP DOCT TRAIN FUT; 1996, J ROY COLL PHYS LOND, V30, P57	26	37	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1211	1214						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634568				2022-12-28	WOS:A1996UL05800025
J	Poinar, HN; Hoss, M; Bada, JL; Paabo, S				Poinar, HN; Hoss, M; Bada, JL; Paabo, S			Amino acid racemization and the preservation of ancient DNA	SCIENCE			English	Article							DEOXYRIBONUCLEIC ACID; CHAIN-REACTION; FOSSIL BONES; SEQUENCE; KINETICS	The extent of racemization of aspartic acid, alanine, and leucine provides criteria for assessing whether ancient tissue samples contain endogenous DNA, In samples in which the D/L ratio of aspartic acid exceeds 0.08, ancient DNA sequences could not be retrieved. Paleontological finds from which DNA sequences purportedly millions of years old have been reported show extensive racemization, and the amino acids present are mainly contaminates, An exception is the amino acids in some insects preserved in amber.	UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093	University of California System; University of California San Diego; Scripps Institution of Oceanography	Poinar, HN (corresponding author), UNIV MUNICH,INST ZOOL,LUISENSTR 14,POB 202136,D-80021 MUNICH,GERMANY.							Bada J.L, 1985, CHEM BIOCH AMINO ACI, P399; BADA JL, 1980, EARTH-SCI REV, V16, P21, DOI 10.1016/0012-8252(80)90003-3; BADA JL, 1994, GEOCHIM COSMOCHIM AC, V58, P3131, DOI 10.1016/0016-7037(94)90185-6; BADA JL, 1985, ANNU REV EARTH PL SC, V13, P241; BADA JL, 1972, J AM CHEM SOC, V94, P1371, DOI 10.1021/ja00759a064; BADA JL, 1972, EARTH PLANET SC LETT, V15, P223, DOI 10.1016/0012-821X(72)90167-7; BADA JL, UNPUB; BADA JL, 1973, NATURE, V245, P208; BARRETT GC, 1991, PHILOS T R SOC LON B, V333, P349; CANO RJ, 1993, NATURE, V363, P536, DOI 10.1038/363536a0; COLLURA RV, 1995, NATURE, V378, P485, DOI 10.1038/378485a0; COOPER A, IN PRESS AVIAN MOL E; DESALLE R, 1992, SCIENCE, V257, P1933, DOI 10.1126/science.1411508; ELSTER H, 1991, J ARCHAEOL SCI, V18, P605, DOI 10.1016/0305-4403(91)90055-T; GOLENBERG EM, 1990, NATURE, V344, P656, DOI 10.1038/344656a0; HANDT O, 1994, EXPERIENTIA, V50, P524, DOI 10.1007/BF01921720; HOSS M, 1993, NUCLEIC ACIDS RES, V21, P3913, DOI 10.1093/nar/21.16.3913; Hoss M, 1996, NUCLEIC ACIDS RES, V24, P1304, DOI 10.1093/nar/24.7.1304; Hoss M, 1996, P NATL ACAD SCI USA, V93, P181, DOI 10.1073/pnas.93.1.181; HOSS M, 1994, NATURE, V370, P333, DOI 10.1038/370333a0; LINDAHL T, 1993, NATURE, V365, P700, DOI 10.1038/365700a0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; LOGAN GA, 1994, ORG GEOCHEM, V21, P857, DOI 10.1016/0146-6380(94)90045-0; LOGAN GA, 1993, P NATL ACAD SCI USA, V90, P2246, DOI 10.1073/pnas.90.6.2246; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PAABO S, 1989, J BIOL CHEM, V264, P9709; PAABO S, 1993, SCI AM, V269, P86; PAABO S, 1991, Current Biology, V1, P45, DOI 10.1016/0960-9822(91)90125-G; POINAR HN, 1993, NATURE, V363, P677, DOI 10.1038/363677a0; POINAR HN, UNPUB; RICHARDSON S, 1994, DISVOERY         JAN, P55; SIDOW A, 1991, PHILOS T ROY SOC B, V333, P429, DOI 10.1098/rstb.1991.0093; SOLTIS PS, 1992, P NATL ACAD SCI USA, V89, P449, DOI 10.1073/pnas.89.1.449; WANG XS, 1995, AMBER RESINITE FOSSI, P255; WOODWARD SR, 1994, NATURE, V266, P1299; ZAHO M, 1995, J CHROMATOGR A, V690, P55; ZISCHLER H, 1995, SCIENCE, V268, P1192, DOI 10.1126/science.7605504	39	292	313	0	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					864	866		10.1126/science.272.5263.864	http://dx.doi.org/10.1126/science.272.5263.864			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629020				2022-12-28	WOS:A1996UK75700056
J	Anderson, IB; Mullen, WH; Meeker, JE; KhojastehBakht, SC; Oishi, S; Nelson, SD; Blanc, PD				Anderson, IB; Mullen, WH; Meeker, JE; KhojastehBakht, SC; Oishi, S; Nelson, SD; Blanc, PD			Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature	ANNALS OF INTERNAL MEDICINE			English	Article						abortifacient agents; pennyroyal; medicine, herbal; acetylcysteine; poisoning	ACETAMINOPHEN OVERDOSE; HEPATOTOXICITY; MENTHOFURAN; PULEGONE; OIL; (R)-(+)-PULEGONE; R-(+)-PULEGONE; GLUTATHIONE; MOUSE	Background: Pennyroyal is a widely available herb that has long been used as an abortifacient despite its potentially lethal hepatotoxic effects. However, quantitative data for pennyroyal constituents and their metabolites in humans have not been previously reported. Objectives: To quantify pennyroyal metabolites in human overdose, to correlate these findings with clinical variables, and to place these findings in the context of previously reported cases of pennyroyal toxicity. Design: Clinical case series of pennyroyal ingestions; quantification of pennyroyal metabolites by gas chromatography and mass spectrometry; qualitative detection of protein-bound adducts of the metabolites of pennyroyal constituents in human liver by Western blot assay; and review of the literature based on a search of MEDLINE, Index Medicus, and the reference citations of all available publications. Results: We report four cases of pennyroyal ingestion. One patient died, one received N-acetylcysteine, and two ingested minimally toxic amounts of pennyroyal and were not treated with N-acetylcysteine. In the fatal case, postmortem examination of a serum sample, which had been obtained 72 hours after the acute ingestion, identified 18 ng of pulegone per mL and 1 ng of menthofuran per mL. In a serum sample from the patient treated with N-acetylcysteine, which had been obtained 10 hours after ingestion, the menthofuran level was 40 ng/mL. Review of 18 previous case reports of pennyroyal ingestion documented moderate to severe toxicity in patients who had been exposed to at least 10 mL of pennyroyal oil. Conclusion: Pennyroyal continues to be an herbal toxin of public health importance. Data on human metabolites may provide new insights into the toxic mechanisms and treatment of pennyroyal poisoning, including the potential role of N-acetylcysteine, Better understanding of the toxicity of pennyroyal may also lead to stricter control of and more restricted access to the herb.	UNIV CALIF SAN FRANCISCO, DIV ENVIRONM & OCCUPAT MED, SAN FRANCISCO, CA 94143 USA; INST FORENS SCI, TOXICOL LAB, OAKLAND, CA USA; UNIV WASHINGTON, SCH PHARM, DEPT MED CHEM, SEATTLE, WA 98195 USA	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle	Anderson, IB (corresponding author), SAN FRANCISCO GEN HOSP, SAN FRANCISCO BAY AREA REG POISON CONTROL CTR, ROOM 1E86, 1001 POTRERO AVE, SAN FRANCISCO, CA 94110 USA.				NIGMS NIH HHS [GM32165, GM25418] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025418, P01GM032165] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN WT, 1897, LANCET, P1022; Braithwaite PF, 1906, BRIT MED J, V2, P865; BUECHEL DW, 1983, J AM OSTEOPATH ASSOC, V82, P793; DERMARDEROSIAN A, 1988, NATURAL PRODUCT MED; EARLY DF, 1961, LANCET, V2, P580; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Flynn EF, 1893, BRIT MED J, V2, P1270; Girling J, 1887, BRIT MED J, V1, P1214, DOI [10.1136/bmj.1.1379.1214, DOI 10.1136/BMJ.1.1379.1214]; GORDON WP, 1987, DRUG METAB DISPOS, V15, P589; GORDON WP, 1982, TOXICOL APPL PHARM, V65, P413, DOI 10.1016/0041-008X(82)90387-8; GRIEVE M, 1981, MODERN HERBAL, V2, P624; Gunby P, 1979, JAMA, V241, P2246, DOI 10.1001/jama.241.21.2246; HOLLAND GW, 1902, VIRGINIA MED SEMIMON, V7, P319; HUXTABLE RJ, 1992, ANN INTERN MED, V117, P165, DOI 10.7326/0003-4819-117-2-165; JONES CO, 1913, BRIT MED J, P745; KIMBALLHW, 1898, ATLANTIC MED WEEKLY, P307; LIEHLAI MW, 1984, J PEDIATR-US, V105, P125, DOI 10.1016/S0022-3476(84)80376-5; LUST J, 1974, HERB BOOK; MADYASTHA KM, 1993, XENOBIOTICA, V23, P509, DOI 10.3109/00498259309059391; MADYASTHA KM, 1990, BIOCHEM BIOPH RES CO, V173, P1086, DOI 10.1016/S0006-291X(05)80897-6; MCCLANAHAN RH, 1989, CHEM RES TOXICOL, V2, P349, DOI 10.1021/tx00011a013; MCCLANAHAN RH, 1988, J AM CHEM SOC, V110, P1979, DOI 10.1021/ja00214a060; MCENVOY GK, 1995, AM HOSP FORMULARY SE; MOORTHY B, 1989, TOXICOLOGY, V55, P327, DOI 10.1016/0300-483X(89)90022-X; NELSON SD, 1983, J NAT PROD, V46, P71, DOI 10.1021/np50025a005; NELSON SD, 1992, ENVIR SCI R, V44, P287; OSOL A, 1955, DISPENSATORY US AM; ROSE J, 1972, HERBS THINGS; RUMACK BH, 1984, AM J DIS CHILD, V138, P428, DOI 10.1001/archpedi.1984.02140430006003; RUNNALLS HB, 1904, MED SENTINEL, V12, P325; *SAN FRANC BAY AR, 1993 1994 SAN FRANC; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; SPOERKE DG, 1980, HERBAL MEDICATIONS; STEPHEN WH, 1994, PROVINCIAL MED J, V1, P466; SUDEKUM M, 1992, J AM VET MED ASSOC, V200, P817; SULLIVAN JB, 1979, JAMA-J AM MED ASSOC, V242, P2873; THOMASSEN D, 1991, DRUG METAB DISPOS, V19, P997; THOMASSEN D, 1988, J PHARMACOL EXP THER, V244, P825; THOMASSEN D, 1990, J PHARMACOL EXP THER, V253, P567; THOMASSEN D, 1992, CHEM RES TOXICOL, V5, P123, DOI 10.1021/tx00025a021; VALLANCE WB, 1955, ALNCET, V850; WILCOX WA, 1869, BOSTON MED SURGICAL, V79, P394; Wingate UOB, 1889, BOSTON MED SURG J, V120, P536, DOI 10.1056/NEJM188905301202206; 1992, LAWRENCE REV NATURAL; 1883, SO MED CLIN, V6, P323; 1978, MMWR-MORBID MORTAL W, V27, P511	46	178	183	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					726	+		10.7326/0003-4819-124-8-199604150-00004	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633832				2022-12-28	WOS:A1996UD93600004
J	Phillips, MJ; Ackerley, CA; Superina, RA; Roberts, EA; Filler, RM; Levy, GA				Phillips, MJ; Ackerley, CA; Superina, RA; Roberts, EA; Filler, RM; Levy, GA			Excess zinc associated with severe progressive cholestasis in Cree and Ojibwa-Cree children	LANCET			English	Article								Background High hepatic copper concentrations have been reported in several liver disorders. We report six Native Canadian children with severe chronic cholestatic liver disease, who had excess hepatic copper and zinc. Methods The children, aged 22 months to 8 years, dame from northern Ontario, Canada. All were referred for possible liver transplantation because of end-stage liver disease. We examined explanted liver samples (or liver biopsy material in one case) by scanning transmission electronmicroscopic (STEM) X-ray elemental microanalysis and atomic absorption spectrophotometry. Samples from four controls (two with no liver pathology, one with biliary atresia, and one with Wilson's disease) were also analysed by atomic absorption spectrophotometry. Findings The explanted livers showed similar distinctive signs of advanced biliary cirrhosis, and on electronmicroscopy there were dense deposits in enlarged lyosomes and in cytoplasm. Hepatic copper concentrations were many times higher in the five patients with measurements (47.6-56.9 mu g/g dry weight) than in two samples of normal control liver tissue (2.3 and 2.9 mu g/g). Similarly, hepatic zinc concentrations were many times higher in the patients than in controls (104-128 vs 1.9-3.2 mu g/g dry weight). Interpretation The excess copper may be due to chronic cholestasis but the excess zinc is unexplained. Since three of the patients are related (shared grandparents), a genetic disorder of metal metabolism is possible, but we cannot exclude environmental factors.	HOSP SICK CHILDREN,DEPT PATHOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT SURG,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT PAEDIAT,TORONTO,ON M5G 1X8,CANADA; TORONTO HOSP,DEPT MED,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PAEDIAT,TORONTO,ON,CANADA; UNIV TORONTO,DEPT SURG,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto								ADAMS PC, 1994, HEPATOLOGY, V19, P101, DOI 10.1016/0270-9139(94)90059-0; HORSLEN SP, 1994, GUT, V35, P1497, DOI 10.1136/gut.35.10.1497; SCHEINBERG IH, 1994, LANCET, V344, P1002, DOI 10.1016/S0140-6736(94)91649-7; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; VONMUHLENDAHL KE, 1994, LANCET, V344, P1515; WEBER AM, 1981, GASTROENTEROLOGY, V81, P653	6	23	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					866	868		10.1016/S0140-6736(96)91347-1	http://dx.doi.org/10.1016/S0140-6736(96)91347-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622393				2022-12-28	WOS:A1996UC45000011
J	Raffle, AE				Raffle, AE			Trust me, I'm a scientist: Will urologists set a lead for geneticists to follow?	LANCET			English	Editorial Material											Raffle, AE (corresponding author), AVON HLTH AUTHOR,KING SQ HOUSE,KING SQ,BRISTOL BS2 8EE,AVON,ENGLAND.							Harper PS, 1995, LANCET, V346, P1645, DOI 10.1016/S0140-6736(95)92835-9; KNOX EG, 1982, CANC UTERINE CERVIX; KNOX G, 1991, PUBLIC HEALTH, V105, P55, DOI 10.1016/S0033-3506(05)80317-8; MANT D, 1994, LANCET, V344, P1343, DOI 10.1016/S0140-6736(94)90698-X; MILLER AB, 1986, IARC SCI PUBLICATION, V76; MURPHY SB, 1991, LANCET, V337, P344, DOI 10.1016/0140-6736(91)90957-Q; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1993, LANCET, V341, P100; STROUD E, 1990, BLOOD CHOLESTEROL TE; Wilson JM, 1968, PUBLIC HLTH PAPERS W, V34; 1994, BRIT MED J, V308, P313; 1994, BRIT MED J, V308, P308; 1995, NATURE, V337, P273	13	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					883	884		10.1016/S0140-6736(96)91353-7	http://dx.doi.org/10.1016/S0140-6736(96)91353-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622399				2022-12-28	WOS:A1996UC45000017
J	Coupland, RM				Coupland, RM			The effect of weapons on health	LANCET			English	Editorial Material							RED-CROSS				Coupland, RM (corresponding author), RED CROSS,INT COMM,DIV MED,19 AVE PAIX,CH-1202 GENEVA,SWITZERLAND.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; BECK LD, 1993, BLINDING WEAPONS; COUPLAND RM, 1992, WORLD J SURG, V16, P910, DOI 10.1007/BF02066991; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; GILLOW JT, 1995, J ROY SOC MED, V88, pP347; 1994, LANCET, V344, P1649	7	17	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					450	451		10.1016/S0140-6736(96)90017-3	http://dx.doi.org/10.1016/S0140-6736(96)90017-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618490				2022-12-28	WOS:A1996TV72200016
J	Pei, X; Moss, F				Pei, X; Moss, F			Characterization of low-dimensional dynamics in the crayfish caudal photoreceptor	NATURE			English	Article							STRANGE SETS; TIME-SERIES; CHAOS; ORBITS; SYSTEM	ATTEMPTS to detect and characterize chaos in biological systems are of considerable interest, especially in medical science, where successful demonstrations may lead to new diagnostic tools and therapies(1). Unfortunately, conventional methods for identifying chaos often yield equivocal results when applied to biological data(2-8), which are usually heavily contaminated with noise. For such applications, a new technique(1) based on the detection of unstable periodic orbits holds promise, Infinite sets of unstable periodic orbits underlie chaos in dissipative systems(4,9); accordingly, the new method searches a time series only for rare events(8) characteristic of these unstable orbits(10), rather than analysing the structure of the series as a whole. Here we demonstrate the efficacy of the method when applied to the dynamics of the crayfish caudal photoreceptor (subject to stimuli representative of the animal's natural habitat). Our findings confirm the existence of low-dimensional dynamics in the system, and strongly suggest the existence of deterministic chaos. More importantly, these results demonstrate the power of methods based on the detection of unstable periodic orbits for identifying low-dimensional dynamics-and, in particular, chaos-in biological systems.			Pei, X (corresponding author), UNIV MISSOURI, DEPT PHYS & ASTRON, LAB NEURODYNAM, ST LOUIS, MO 63121 USA.							Abraham NB, 1993, INT J BIFURCAT CHAOS, V3, P485, DOI 10.1142/S0218127493000398; ARTUSO R, 1990, NONLINEARITY, V3, P325, DOI 10.1088/0951-7715/3/2/005; ARTUSO R, 1990, NONLINEARITY, V3, P361, DOI 10.1088/0951-7715/3/2/006; BEVINGTON PR, 1969, DATA REDUCTION ERROR, P48; CHANG T, 1994, BIOPHYS J, V67, P671, DOI 10.1016/S0006-3495(94)80526-0; CHRISTINI DJ, 1995, PHYS REV LETT, V75, P2782, DOI 10.1103/PhysRevLett.75.2782; CVITANOVIC P, 1988, PHYS REV LETT, V61, P2729, DOI 10.1103/PhysRevLett.61.2729; CVITANOVIC P, 1991, PHYSICA D, V51, P138, DOI 10.1016/0167-2789(91)90227-Z; DITTO WL, 1990, PHYS REV LETT, V65, P3211, DOI 10.1103/PhysRevLett.65.3211; GARFINKEL A, 1992, SCIENCE, V257, P1230, DOI 10.1126/science.1519060; GRASSBERGER P, 1983, PHYSICA D, V9, P189, DOI 10.1016/0167-2789(83)90298-1; HAYASHI H, 1992, J THEOR BIOL, V156, P269, DOI 10.1016/S0022-5193(05)80676-9; HERMANN HT, 1968, J GEN PHYSIOL, V51, P534, DOI 10.1085/jgp.51.4.534; HUNT ER, 1991, PHYS REV LETT, V67, P1953, DOI 10.1103/PhysRevLett.67.1953; KAPLAN DT, 1994, PHYSICA D, V73, P38, DOI 10.1016/0167-2789(94)90224-0; KENNEDY DONALD, 1963, JOUR GEN PHYSIOL, V46, P551, DOI 10.1085/jgp.46.3.551; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MAY RM, 1979, ANN NY ACAD SCI, V316, P517; Moon F.C., 1987, CHAOTIC VIBRATIONS; PETROV V, 1993, NATURE, V361, P240, DOI 10.1038/361240a0; PIERSON D, 1995, PHYS REV LETT, V75, P2124, DOI 10.1103/PhysRevLett.75.2124; ROLLINS RW, 1993, PHYS REV E, V47, pR780, DOI 10.1103/PhysRevE.47.R780; ROY R, 1992, PHYS REV LETT, V68, P1259, DOI 10.1103/PhysRevLett.68.1259; RUELLE D, 1971, COMMUN MATH PHYS, V20, P167, DOI 10.1007/BF01646553; RUELLE D, 1990, P ROY SOC LOND A MAT, V427, P241, DOI 10.1098/rspa.1990.0010; RUELLE D, 1994, PHYS TODAY, V47, P24, DOI 10.1063/1.881395; RUELLE D, 1980, RECHERCHE, V11, P132; RUELLE D, 1987, 8TH INT C MATH PHYS, P273; SCHIFF SJ, 1994, NATURE, V370, P615, DOI 10.1038/370615a0; Scott DA, 1995, BIOPHYS J, V69, P1748, DOI 10.1016/S0006-3495(95)80044-5; SHINBROT T, 1993, NATURE, V363, P411, DOI 10.1038/363411a0; STROGATZ SH, 1994, NONLINEAR DYNAMICS C, pCH12; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; WILKENS LA, 1994, J EXP BIOL, V189, P263; WILKENS LA, 1988, COMP BIOCHEM PHYS C, V91, P61, DOI 10.1016/0742-8413(88)90169-7; WOLF A, 1985, PHYSICA D, V16, P285, DOI 10.1016/0167-2789(85)90011-9	37	104	106	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					618	621		10.1038/379618a0	http://dx.doi.org/10.1038/379618a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628396				2022-12-28	WOS:A1996TV68800045
J	Angell, M				Angell, M			Shattuck lecture - Evaluating the health risks of breast implants: The interplay of medical science, the law, and public opinion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE DISEASE; COSMETIC SURGERY											ANGELL M, 1994, NEW ENGL J MED, V330, P1748, DOI 10.1056/NEJM199406163302409; BURTON TM, 1994, WALL STREET J   0902, pB2; CARLSEN W, 1991, SAN FRANCISCO C 1214, pA13; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; ENGLERT HJ, 1994, AUST NZ J MED, V24, P74, DOI 10.1111/j.1445-5994.1994.tb04439.x; *FOOD DRUG ADM, 1994, BREAST IMPL INF UPD; FOSTER KR, 1993, PHANTOM RISK SCI INF; FRANKEL A, 1992, AM LAWYER        JUN, P82; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; Glendon M. A., 1994, NATION LAWYERS CRISI; GORDON M, 1994, FDA SAID HAVE REVERS; GOTT DM, 1994, MED DEVICES AGEN DEC; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; HOCHBERG MC, 1995, J CLIN EPIDEMIOL, V48, P565, DOI 10.1016/0895-4356(94)00214-B; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; KOLATA G, 1995, NY TIMES        0516, pD6; KOLATA G, 1995, NY TIMES        0228, P3; KOLATA G, 1995, NY TIMES        0313, pD1; Kolata Gina, 1995, N Y Times Web, P29; Kolata Gina, 1994, N Y Times Web, pA16; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; KUMAGAI Y, 1979, ARTHRITIS RHEUM, V22, P532, DOI 10.1002/art.1780220514; MATTHEWS J, 1995, WASHINGTON POST 0516, pA1; MEIER B, 1995, NY TIMES        1003, pA14; MEIER B, 1995, NY TIMES        0929, pA16; MESCE D, 1990, BREAST IMPLANT CONTR; MIYOSHI K, 1964, JPN MED J, V9, P2122; ROSENFELD S, 1994, SAN FRANCISCO E 0521, pA1; Sagan Carl., 1995, DEMON HAUNTED WORLD; SANCHEZGUERRERO J, 1994, ARTHRITIS RHEUM-US, V37, P158; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SINGER A, 1993, AM LAW           MAR, P86; STOMBLER RE, 1993, ACS B, V78, P11; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; THOMAS U, 1992, IDAHO STATESMAN 0314; VANNUNEN SA, 1982, ARTHRITIS RHEUM, V25, P694, DOI 10.1002/art.1780250613; ZANDER M, 1977, AM JURY SYSTEM FINAL; 1994, DAILY REPORT EX 0523, pA2; 1994, CHEM MARK REP, V245, P20; 1995, TJFR HLTH NEWS  0604, P9; 1995, MED LEGAL ASPECTS BR, V3, P1; 1996, PBS FRONTLINE   0227	42	87	88	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1513	1518		10.1056/NEJM199606063342306	http://dx.doi.org/10.1056/NEJM199606063342306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618607				2022-12-28	WOS:A1996UN79900006
J	Funabiki, H; Yamano, H; Kumada, K; Nagao, K; Hunt, T; Yanagida, M				Funabiki, H; Yamano, H; Kumada, K; Nagao, K; Hunt, T; Yanagida, M			Cut2 proteolysis required for sister-chromatid separation in fission yeast	NATURE			English	Article							MATURATION-PROMOTING FACTOR; CELL-DIVISION CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; MUTANTS; MITOSIS; KINASE; GENE; DEGRADATION	ALTHOUGH mitotic cyclins are well-known substrates for ubiquitin-mediated proteolysis at the metaphase-anaphase transition(1-4), their degradation is not essential for separation of sister chromatids(5-8); several lines of evidence suggest that proteolysis of other protein(s) is required, however(4,6,9-11). Here we report the anaphase-specific proteolysis of the Schizosaccharomyces pombe Cut2 protein, which is essential for sister-chromatid separation(12,13). Cut2 is located in the nucleus, where it is concentrated along the short metaphase spindle. The rapid degradation of Cut2 at anaphase requires its amino-terminal region and the activity of Cut9 (ref. 14), a component of the 20S cyclosome/anaphase-promoting complex (APC), which is necessary for cyclin destruction(3,4,11). Expression of non-degradable Cut2 blocks sister-chromatid separation but not cell-cycle progression. This defect can be overcome by grafting the N terminus of cyclin B onto the truncated Cut2, demonstrating that the regulated proteolysis of Cut2 is essential for sister-chromatid separation.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND	Kyoto University			Nagao, Koji/F-5281-2011	Nagao, Koji/0000-0003-1418-6988; Funabiki, Hironori/0000-0003-4831-4087				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; CREANOR J, 1990, J CELL SCI, V96, P435; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HAGAN IM, 1988, J CELL SCI, V89, P343; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IMIGER S, 1995, CELL, V81, P269; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; RIMMINGTON G, 1994, J CELL SCI, V107, P2729; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H	27	407	414	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					438	441		10.1038/381438a0	http://dx.doi.org/10.1038/381438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632802				2022-12-28	WOS:A1996UN47900055
J	deLecea, L; Criado, JR; ProsperoGarcia, O; Gautvik, KM; Schweitzer, P; Danielson, PE; Dunlop, CLM; Siggins, GR; Henriksen, SJ; Sutcliffe, JG				deLecea, L; Criado, JR; ProsperoGarcia, O; Gautvik, KM; Schweitzer, P; Danielson, PE; Dunlop, CLM; Siggins, GR; Henriksen, SJ; Sutcliffe, JG			A cortical neuropeptide with neuronal depressant and sleep-modulating properties	NATURE			English	Article							HIPPOCAMPAL-NEURONS; ARACHIDONIC-ACID; SOMATOSTATIN; METABOLITES; INHIBITION; BRAIN; CA1	ACETYLCHOLINE (ACh) plays a key role in the transitions between the different phases of sleep(1): Slow-wave sleep requires low ACh concentrations in the brain, whereas rapid-eye-movement (REM) sleep is associated with high levels of ACh, Also, these phases of sleep are differentially sensitive to a number of endogenous neuropeptides and cytokines, including somatostatin, which has been shown to increase REM sleep without significantly affecting other phases(2). Here we report the cloning and initial characterization of cortistatin, a neuropeptide that exhibits strong structural similarity to somatostatin, although it is the product of a different gene. Administration of cortistatin depresses neuronal electrical activity but, unlike somatostatin, induces low-frequency waves in the cerebral cortex and antagonizes the effects of acetylcholine on hippocampal and cortical measures of excitability. This suggests a mechanism for cortical synchronization related to sleep.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			de Lecea, Luis/ABE-4005-2021; de Lecea, Luis/B-3171-2009	de Lecea, Luis/0000-0002-8921-5942; de Lecea, Luis/0000-0002-8921-5942	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058543] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH058543] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN P, 1971, EXP BRAIN RES, V13, P208; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P607; BORBELY AA, 1989, PHYSIOL REV, V69, P605, DOI 10.1152/physrev.1989.69.2.605; DANGUIR J, 1986, BRAIN RES, V367, P26, DOI 10.1016/0006-8993(86)91574-X; DELECEA L, 1994, MOL BRAIN RES, V25, P286, DOI 10.1016/0169-328X(94)90164-3; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GLUSCHANKOF P, 1984, P NATL ACAD SCI-BIOL, V81, P6662, DOI 10.1073/pnas.81.21.6662; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P243, DOI 10.1152/jn.1961.24.3.243; MAURER R, 1982, P NATL ACAD SCI-BIOL, V79, P4815, DOI 10.1073/pnas.79.15.4815; MOORE SD, 1988, SCIENCE, V239, P278, DOI 10.1126/science.2892268; PROSPEROGARCIA O, 1994, PHARMACOL BIOCHEM BE, V49, P413, DOI 10.1016/0091-3057(94)90442-1; SCHARFMAN HE, 1989, BRAIN RES, V493, P205, DOI 10.1016/0006-8993(89)91155-4; SCHONBRUNN AH, 1978, J BIOL CHEM, V235, P6473; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SHIROMANI PJ, 1987, ANNU REV PHARMACOL, V27, P137; STEFFENSEN SC, 1991, BRAIN RES, V538, P46, DOI 10.1016/0006-8993(91)90374-5; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; VEBER DF, 1979, NATURE, V280, P512, DOI 10.1038/280512a0	21	309	318	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					242	245		10.1038/381242a0	http://dx.doi.org/10.1038/381242a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622767				2022-12-28	WOS:A1996UL24900056
J	Triolo, T; Sternglanz, R				Triolo, T; Sternglanz, R			Role of interactions between the origin recognition complex and SIR1 in transcriptional silencing	NATURE			English	Article							DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; YEAST; PROTEIN; STATES; LOCI	TRANSCRIPTIONAL silencing of the HM mating-type loci in the yeast Saccharomyces cerevisiae is caused by the localized formation of an altered chromatin structure, analogous to heterochromatin in higher eukaryotes. Silencing depends on cis-acting sequences, termed silencers, as well as several trans-acting factors, including histones H4 and H3, proteins RAP1 and ABF1, and the four SIR proteins (SIR1-4)(1). Each of the four HM silencers contains an autonomously replicating sequence (ARS) to which the origin replication complex (ORC)(2) binds. This six-protein complex is required for initiation of DNA replication, as well as for silencing(3-7). Efficient establishment of the silenced state requires both passage through the S phase of the cell cycle(8) and SIR1 protein(9,10). Previous experiments suggested that SIR1 might be localized to the silencers by binding to ORC and/or RAP1 (ref. 11). Here we report that SIR1 can bind directly to ORC1, the largest of the ORC subunits, and that targeting of SIR1 to ORC1 at a silencer is sufficient to establish a silenced state.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; STUDIER W, 1990, METHOD ENZYMOL, V185, P5	18	234	240	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					251	253		10.1038/381251a0	http://dx.doi.org/10.1038/381251a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622770				2022-12-28	WOS:A1996UL24900059
J	Mayer, A; Wickner, W; Haas, A				Mayer, A; Wickner, W; Haas, A			Sec18p (NSF)-driven release of sec17p (alpha-SNAP) can precede docking and fusion of yeast vacuoles	CELL			English	Article							VESICULAR TRANSPORT; SACCHAROMYCES-CEREVISIAE; VESICLE FUSION; GOLGI STACK; MEMBRANE-PROTEINS; SEGREGATION; ATTACHMENT; PATHWAY; PURIFICATION; INHERITANCE	S. cerevisiae inherits its vacuole by projecting vacuole-derived membrane vesicles and tubules into the bud, where they fuse to establish the daughter vacuole. This homotypic fusion event can be assayed in vitro. It requires Sec17p and Sec18p, the homologs of the mammalian alpha-SNAP and NSF, which cooperate in multiple steps of membrane trafficking. We now report that Sec17p, Sec18p, and ATP are only needed for an early stage of the reaction that results in Sec17p release. Sec17p and Sec18p actions precede, and are needed for, the step employing the Ras-like GTPase Ypt7p. Sec18p-driven release of Sec17p can even precede vacuole docking, as it can occur prior to mixing of vacuoles and is insensitive to vacuole concentration. Sec17p and Sec18p thus may function in a predocking stage of the reaction, rather than in bilayer fusion per se.			Mayer, A (corresponding author), DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755, USA.		Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DEMESQUITA DSG, 1991, J GEN MICROBIOL, V137, P2447, DOI 10.1099/00221287-137-10-2447; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HAAS A, IN PRESS EMBO J; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HIEBSCH RR, 1992, BIOCHEMISTRY-US, V31, P6111, DOI 10.1021/bi00141a022; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; NICOLSON TA, 1995, J CELL BIOL, V130, P835, DOI 10.1083/jcb.130.4.835; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; OTTO H, 1995, BIOCHEM BIOPH RES CO, V212, P945, DOI 10.1006/bbrc.1995.2061; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RAYMOND CK, 1992, INT REV CYTOL, V139, P59, DOI 10.1016/S0074-7696(08)61410-2; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTH D, 1994, FEBS LETT, V351, P207, DOI 10.1016/0014-5793(94)00833-7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SHAW JM, 1991, EMBO J, V10, P1741, DOI 10.1002/j.1460-2075.1991.tb07698.x; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; WEISMAN LS, 1990, P NATL ACAD SCI USA, V87, P1076, DOI 10.1073/pnas.87.3.1076; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; XU Z, 1996, IN PRESS J CELL BIOL	63	496	501	1	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					83	94		10.1016/S0092-8674(00)81084-3	http://dx.doi.org/10.1016/S0092-8674(00)81084-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620540	hybrid			2022-12-28	WOS:A1996UE55900011
J	Nishiyama, KI; Suzuki, T; Tokuda, H				Nishiyama, KI; Suzuki, T; Tokuda, H			Inversion of the membrane topology of SecG coupled with SecA-dependent preprotein translocation	CELL			English	Article							PROTON MOTIVE FORCE; COLI PLASMA-MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; CYTOPLASMIC MEMBRANE; INNER MEMBRANE; INVITRO TRANSLOCATION; ALKALINE-PHOSPHATASE; SECRETORY PROTEINS; RECONSTITUTION	E. coli preprotein translocase comprises SecA and a SecY/E/G complex. SecA delivers the preprotein to the putative protein-conducting channel formed by SecY/E by undergoing ATP-driven cycles of membrane insertion and deinsertion. SecG renders the translocase highly efficient. An antibody raised against the C-terminal region of SecG inhibits preprotein translocation into everted membrane vesicles despite the exposure of this region to the inside of membrane vesicles in the absence of preprotein translocation. When preprotein translocation was started with ATP and then blocked by the inhibition of ATP hydrolysis, the C-terminal region was exposed to the outside of membrane vesicles. Another region of SecG showed a change in membrane sidedness upon preprotein translocation, indicating that SecG undergoes topology inversion. This topology inversion was tightly coupled to the SecG function and linked with the insertion-deinsertion cycle of SecA.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; BOST S, 1995, EMBO J, V14, P4412, DOI 10.1002/j.1460-2075.1995.tb00120.x; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KIM YJ, 1994, CELL, V78, P845; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; NISHIYAMA K, 1992, J BIOL CHEM, V267, P7170; NISHIYAMA K, 1991, BIOCHIM BIOPHYS ACTA, V1065, P89, DOI 10.1016/0005-2736(91)90015-Z; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOKUDA H, 1991, FEBS LETT, V279, P233, DOI 10.1016/0014-5793(91)80156-W; TOKUDA H, 1994, FEBS LETT, V346, P65, DOI 10.1016/0014-5793(94)00317-3; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358	44	187	189	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					71	81		10.1016/S0092-8674(00)81083-1	http://dx.doi.org/10.1016/S0092-8674(00)81083-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620539	Bronze			2022-12-28	WOS:A1996UE55900010
J	Gomperts, SN				Gomperts, SN			Clustering membrane proteins: It's all coming together with the PSD-95/SAP90 protein family	CELL			English	Review							TUMOR-SUPPRESSOR PROTEIN; SEPTATE JUNCTIONS; DROSOPHILA; HOMOLOG; BRAIN; GENE				Gomperts, SN (corresponding author), UNIV CALIF SAN FRANCISCO,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143, USA.		Gomperts, Stephen/AAC-6949-2020					APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Apel Elizabeth D., 1995, Current Opinion in Neurobiology, V5, P62, DOI 10.1016/0959-4388(95)80088-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1995, FEBS LETT, V359, P159, DOI 10.1016/0014-5793(95)00030-D; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; NIETHAMMER M, 1996, IN PRESS J NEUROSCI; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	19	221	224	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					659	662		10.1016/S0092-8674(00)81043-0	http://dx.doi.org/10.1016/S0092-8674(00)81043-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625403	Bronze			2022-12-28	WOS:A1996TZ99000003
J	Hareven, D; Gutfinger, T; Parnis, A; Eshed, Y; Lifschitz, E				Hareven, D; Gutfinger, T; Parnis, A; Eshed, Y; Lifschitz, E			The making of a compound leaf: Genetic manipulation of leaf architecture in tomato	CELL			English	Article							PLANT DEVELOPMENT; CLONAL ANALYSIS; HOMEOBOX GENE; MAIZE; EXPRESSION; LEAVES; KNOTTED-1; MERISTEM; FATES	The most distinctive morphogenetic feature of leaves is their being either simple or compound. To study the basis for this dichotomy, we have exploited the maize homeobox-containing Knotted-1 (Kn1) gene in conjunction with mutations that alter the tomato compound leaf. We show that misexpression of Kn1 confers different phenotypes on simple and compound leaves. Up to 2000 leaflets, organized in compound reiterated units, are formed in tomato leaves expressing Kn1. In contrast, Kn1 induces leaf malformations but fails to elicit leaf ramification in plants with inherent simple leaves such as Arabidopsis or in tomato mutant plants with simple leaves. Moreover, the tomato Kn1 ortholog, unlike that of Arabidopsis, is expressed in the leaf primordia. Presumably, the two alternative leaf forms are conditioned by different developmental programs in the primary appendage that is common to all types of leaves.	HEBREW UNIV JERUSALEM, FAC AGR, DEPT GENET & FIELD CROPS, IL-70700 REHOVOT, ISRAEL	Hebrew University of Jerusalem	Hareven, D (corresponding author), TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL.			Eshed, Yuval/0000-0001-8290-0018				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BECRAFT PW, 1994, GENETICS, V136, P295; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; CARUSO JL, 1968, AM J BOT, V55, P1169, DOI 10.2307/2440737; CUTTER EG, 1971, PLANT ANATOMY EXPT I, P117; DENGLER NG, 1984, BOT GAZ, V145, P66, DOI 10.1086/337428; DOLAN L, 1991, DEVELOPMENT, P39; FREELING M, 1992, DEV BIOL, V153, P44, DOI 10.1016/0012-1606(92)90090-4; FREELING M, 1985, GENETICS, V111, P617; HAKE S, 1992, TRENDS GENET, V8, P109, DOI 10.1016/0168-9525(92)90065-C; HAKE S, 1989, EMBO J, V8, P15, DOI 10.1002/j.1460-2075.1989.tb03343.x; HAREVEN D, 1994, EUPHYTICA, V79, P235, DOI 10.1007/BF00022524; HELM J., 1951, Zuchter, V21, P89, DOI 10.1007/BF00710588; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jackson D.P., 1991, MOL PLANT PATHOLOGY; KAPLAN D R, 1973, Cellule, V69, P251; KAPLAN DR, 1983, SCI AM, V249, P98, DOI 10.1038/scientificamerican0783-98; KERSTETTER R, 1994, PLANT CELL, V6, P1877, DOI 10.1105/tpc.6.12.1877; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; MA HC, 1994, PLANT MOL BIOL, V24, P465, DOI 10.1007/BF00024114; MARKS GA, 1987, PLANT MOL BIOL REP, V5, P311; MATHAN DS, 1962, AM J BOT, V49, P504, DOI 10.2307/2439421; MATSUOKA M, 1993, PLANT CELL, V5, P1039, DOI 10.1105/tpc.5.9.1039; MCCORMICK S, 1991, PLANT TISSUE CULTU B, V6, P1; PNUELI L, 1994, PLANT CELL, V6, P175, DOI 10.1105/tpc.6.2.175; POETHIG RS, 1985, PLANTA, V165, P170, DOI 10.1007/BF00395039; POETHIG RS, 1987, AM J BOT, V74, P581, DOI 10.2307/2443838; PRIHADASH A, 1992, PLANT CELL, V4, P149, DOI 10.1105/tpc.4.2.149; SIHA N, 1994, DEV GENET, V15, P401; SINHA N, 1993, CURR TOP DEV BIOL, V28, P47, DOI 10.1016/S0070-2153(08)60209-4; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; SMITH LG, 1992, PLANT CELL, V4, P1017, DOI 10.1105/tpc.4.9.1017; SMITH LG, 1992, DEVELOPMENT, V116, P21; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STETTLER RF, 1964, AM J BOT, V51, P253, DOI 10.2307/2440294; STEVENS AM, 1986, TOMATO CROP; SUSSEX IM, 1989, CELL, V56, P225, DOI 10.1016/0092-8674(89)90895-7; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0	41	328	356	3	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					735	744		10.1016/S0092-8674(00)81051-X	http://dx.doi.org/10.1016/S0092-8674(00)81051-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625411	Bronze			2022-12-28	WOS:A1996TZ99000011
J	Callanan, V; OConnor, AF				Callanan, V; OConnor, AF			Cochlear implantation for children and adults	LANCET			English	Editorial Material											Callanan, V (corresponding author), ST THOMAS HOSP,COCHLEAR IMPLANT CTR,LONDON,ENGLAND.							COHEN NL, 1993, NEW ENGL J MED, V328, P233, DOI 10.1056/NEJM199301283280403; DAVIS AR, 1993, PAEDIATRIC AUDIOLOGY, P13; DJOURNO A, 1957, PRESSE MED, V35, P1417; GIBBIN PK, 1993, ARCH DIS CHILD, V67, P669; HOUSE WF, 1991, WESTERN J MED, V154, P717; PARISIER SC, 1991, MED CLIN N AM, V75, P1267, DOI 10.1016/S0025-7125(16)30387-X; Volta Alessandro, 1800, PHILOS T ROYAL SOC L, V90, P403, DOI DOI 10.1098/RSTL.1800.0018; WEBB RL, 1991, ANN OTO RHINOL LARYN, V100, P131, DOI 10.1177/000348949110000208; WESTON SC, 1995, ANN OTO RHINOL LARYN, V104, P19; WILSON BS, 1991, NATURE, V352, P236, DOI 10.1038/352236a0; NUCLEUS COCHLEAR IMP; CLARION COCHLEAR IMP; MED EL COMBI 40 COCH	13	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					412	414		10.1016/S0140-6736(96)90003-3	http://dx.doi.org/10.1016/S0140-6736(96)90003-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618477				2022-12-28	WOS:A1996TV72200003
J	Kachur, SP; Stennies, GM; Powell, KE; Modzeleski, W; Stephens, R; Murphy, R; Kresnow, MJ; Sleet, D; Lowry, R				Kachur, SP; Stennies, GM; Powell, KE; Modzeleski, W; Stephens, R; Murphy, R; Kresnow, MJ; Sleet, D; Lowry, R			School-associated violent deaths in the United States, 1992 to 1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To conduct the first nationwide investigation of violent deaths associated with schools in the United States, to quantify the risk of school-associated violent death, and to identify epidemiologic features of these deaths. Design.-Descriptive case series. Setting.-United States, July 1, 1992, through June 30, 1994. Methods.-School-associated violent deaths were identified by study collaborators and through 2 online news databases. Police reports, medical examiners' records, and interviews with police and school officials provided detailed information about each case. Results.-In a 2-year period, 105 school-associated violent deaths were identified. The estimated incidence of school-associated violent death was 0.09 per 100 000 student-years. Students in secondary schools, students of minority racial and ethnic backgrounds, and students in urban school districts had higher levels of risk. The deaths occurred in communities of all sizes in 25 different states. Homicide was the predominant cause of death (n=85 [80.9%]), and firearms were responsible for a majority (n=81 [77.1%]) of the deaths. Most victims were students (n=76 [72.4%]). Both victims and offenders tended to be young (median ages, 16 and 17 years, respectively) and male (82.9% and 95.6%, respectively). Approximately equal numbers of deaths occurred inside school buildings (n=31 [29.5%]), outdoors but on school property (n=37 [35.2%]), and at off-campus locations while the victim was in transit to or from school (n=37 [35.2%]). Equal numbers of deaths occurred during classes or other school activities (n=46 [43.8%]) and before or after official school activities (n=46 [43.8%]). Conclusions.-School-associated violent deaths were more common than previously estimated. The epidemiologic features of these deaths were similar to those of homicides and suicides that occur elsewhere. A comprehensive approach that addresses violent injury and death among young people at school and elsewhere in the community is suggested.	CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30341; US DEPT EDUC,SAFE & DRUG FREE SCH PROGRAM,WASHINGTON,DC; NATL SCH SAFETY CTR,WESTLAKE VILLAGE,CA; US DEPT JUSTICE,NATL INST JUSTICE,WASHINGTON,DC 20530	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; US Department of Education			Kachur, Patrick/ABE-7220-2021					[Anonymous], PRINCIPLES PRACTICE; BASTIAN LD, 1991, NCJ131645 US DEP JUS; *CTR PREV HANDG VI, 1990, CAUGHT CROSSF REP GU; Dean A.G., 1994, EPI INFO VERSION 6 W; Kachur, 1995, Adolesc Med, V6, P171; Kann L, 1995, MMWR CDC Surveill Summ, V44, P1; KOCHANEK KD, 1994, MONTHLY VITAL STAT S, V43, P56; *L HARR ASS INC, 1993, VIOL AM PUBL SCH SUR; LOWRY R, 1995, EDUC PSYCHOL REV, V7, P7, DOI 10.1007/BF02214205; Mausner J, 1985, EPIDEMIOLOGY INTRO T; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; *NATL CTR HLTH STA, 1994, VIT STAT MORT DAT; *NATL CTR INJ PRE, 1993, PREV YOUTH VIOL FRAM; *NATL LEAG CIT, 1994, SCH VIOL AM CIT NLC; *NATL SCH BOARDS A, 1993, VIOL SCH AM SCH BOAR; RUTSTEIN DD, 1983, AM J PUBLIC HEALTH, V73, P1054, DOI 10.2105/AJPH.73.9.1054; SHELEY JF, 1992, AM J DIS CHILD, V146, P677, DOI 10.1001/archpedi.1992.02160180035012; *US DEP ED, 1994, COMM COR DAT; *US DEP ED, 1993, REACH GOALS GOAL 6 S; *US GEN ACC OFF, 1995, GAOHEHS95106 US GEN; *VA ASS SCH SUP, 1992, VIOL SCH REC ACT ED; [No title captured]; 1995, MMWR-MORBID MORTAL W, V44, P289; 1994, MMWR-MORBID MORTAL W, V43, P725	25	80	81	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1729	1733		10.1001/jama.275.22.1729	http://dx.doi.org/10.1001/jama.275.22.1729			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP307	8637169				2022-12-28	WOS:A1996UP30700025
J	Spicer, DB; Rhee, J; Cheung, WL; Lassar, AB				Spicer, DB; Rhee, J; Cheung, WL; Lassar, AB			Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein twist	SCIENCE			English	Article							MUSCLE-SPECIFIC ENHANCER; CREATINE-KINASE GENE; REGULATORY ELEMENTS; DROSOPHILA-TWIST; BINDING-FACTOR; HLH PROTEINS; CELLS; EXPRESSION; MYF-5; INACTIVATION	The myogenic basic helix-loop-helix (bHLH) and MEF2 transcription factors are expressed in the myotome of developing somites and cooperatively activate skeletal muscle gene expression. The bHLH protein Twist is expressed throughout the epithelial somite and is subsequently excluded from the myotome. Ectopically expressed mouse Twist (Mtwist) was shown to inhibit myogenesis by blocking DNA binding by MyoD, by titrating E proteins, and by inhibiting trans-activation by MEF2. For inhibition of MEF2, Mtwist required heterodimerization with E proteins and an intact basic domain and carboxyl-terminus. Thus, Mtwist inhibits both families of myogenic regulators and may regulate myotome formation temporally or spatially.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Rhee, James/V-9973-2019		NIAMS NIH HHS [5-F32-AR08214-02] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008214] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BATE M, 1991, DEVELOPMENT, V113, P79; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1994, J BIOL CHEM, V269, P16740; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FUCHTBAUER EM, 1995, DEV DYNAM, V204, P316; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; IP YT, 1992, GENE DEV, V6, P1516; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JANES J, 1988, MOL CELL BIOL, V8, P62; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; Lassar AB, 1996, CURR OPIN NEUROBIOL, V6, P57, DOI 10.1016/S0959-4388(96)80009-2; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LILY B, 1994, P NATL ACAD SCI USA, V91, P5662; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NAIDU PS, 1995, MOL CELL BIOL, V15, P3703; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SIMPSON P, 1983, GENETICS, V105, P605; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; SPICER DB, UNPUB; STOETZEL C, 1995, MECH DEVELOP, V51, P251, DOI 10.1016/0925-4773(95)00369-X; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; TAYLOR MV, 1995, CURR BIOL, V5, P740, DOI 10.1016/S0960-9822(95)00149-7; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHANG W, 1995, GENE DEV, V9, P1386	62	268	272	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1476	1480		10.1126/science.272.5267.1476	http://dx.doi.org/10.1126/science.272.5267.1476			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633239				2022-12-28	WOS:A1996UP89900046
J	Tang, XJ; Halleck, MS; Schlegel, RA; Williamson, P				Tang, XJ; Halleck, MS; Schlegel, RA; Williamson, P			A subfamily of P-type ATPases with aminophospholipid transporting activity	SCIENCE			English	Article							TRANSBILAYER MOVEMENT; SENSITIVE ATPASE; PLASMA-MEMBRANE; PHOSPHATIDYLSERINE; PROTEIN; PURIFICATION; RECOGNITION; MACROPHAGES; ASYMMETRY; SURFACE	The appearance of phosphatidylserine on the surface of animal cells triggers phagocytosis and blood coagulation. Normally, phosphatidylserine is confined to the inner leaflet of the plasma membrane by an aminophospholipid translocase, which has now been cloned and sequenced. The bovine enzyme is a member of a previously unrecognized subfamily of P-type adenosine triphosphatases (ATPases) that may have diverged from the primordial enzyme before the separation of the known families of ion-translocating ATPases. Studies in Saccharomyces cerevisiae suggest that aminophospholipid translocation is a general function of members of this family.	AMHERST COLL,DEPT BIOL,AMHERST,MA 01002; PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Amherst College; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park								ALLEN TM, 1988, P NATL ACAD SCI USA, V85, P8067, DOI 10.1073/pnas.85.21.8067; AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; BOGDANOV A, 1993, BIOCHEM SOC T, V21, P271, DOI 10.1042/bst0210271; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAGAN MJ, 1994, J MOL EVOL, V38, P57; HICKS BW, 1992, J NEUROCHEM, V58, P1211, DOI 10.1111/j.1471-4159.1992.tb11331.x; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; KRISHNA S, 1994, EXP PARASITOL, V78, P113, DOI 10.1006/expr.1994.1011; LI HH, 1990, P NATL ACAD SCI USA, V87, P4580, DOI 10.1073/pnas.87.12.4580; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; MORIYAMA Y, 1988, J BIOL CHEM, V263, P8521; MORROT G, 1990, FEBS LETT, V266, P29, DOI 10.1016/0014-5793(90)81498-D; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PRADHAN D, 1994, MOL MEMBR BIOL, V11, P181, DOI 10.3109/09687689409162237; RIPMASTER TL, 1993, MOL CELL BIOL, V13, P7901, DOI 10.1128/MCB.13.12.7901; SCHLEGEL RA, IN PRESS P 6 INT C L; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; TROTTEIN F, 1995, EUR J BIOCHEM, V227, P214, DOI 10.1111/j.1432-1033.1995.tb20379.x; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; XIE XS, 1989, J BIOL CHEM, V264, P1710; ZACHOWSKI A, 1989, NATURE, V340, P75, DOI 10.1038/340075a0; ZACHOWSKI A, 1987, BIOCHIM BIOPHYS ACTA, V897, P197, DOI 10.1016/0005-2736(87)90328-2; ZACHOWSKI A, 1990, J NEUROCHEM, V55, P1352, DOI 10.1111/j.1471-4159.1990.tb03146.x	30	405	412	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1495	1497		10.1126/science.272.5267.1495	http://dx.doi.org/10.1126/science.272.5267.1495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633245				2022-12-28	WOS:A1996UP89900052
J	Soloway, S; Weissgold, D				Soloway, S; Weissgold, D			Hypopyon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									VET AFFAIRS MED CTR,PHILADELPHIA,PA 19104	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center									0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1512	1512		10.1056/NEJM199606063342305	http://dx.doi.org/10.1056/NEJM199606063342305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618606				2022-12-28	WOS:A1996UN79900005
J	Midgley, JP; Matthew, AG; Greenwood, CMT; Logan, AG				Midgley, JP; Matthew, AG; Greenwood, CMT; Logan, AG			Effect of reduced dietary sodium on blood pressure - A meta-analysis of randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBESE HYPERTENSIVE MEN; SALT RESTRICTION; MODERATE HYPERTENSION; NORMOTENSIVE SUBJECTS; DOUBLE-BLIND; MILD HYPERTENSION; GENERAL-PRACTICE; POTASSIUM SUPPLEMENTATION; PILOT INTERVENTION; WEIGHT-REDUCTION	Objective.-To ascertain whether restriction of dietary sodium lowers blood pressure in hypertensive and normotensive individuals. Data Sources.-An English-language computerized literature search, restricted to human studies with Medical Subject Heading terms, ''hypertension,'' ''blood pressure,'' ''vascular resistance,'' ''sodium and dietary,'' ''diet and sodium restricted, ''sodium chloride,'' ''clinical trial,'' ''randomized controlled trial,'' and ''prospective studies,'' was conducted. Bibliographies of review articles and personal files were also searched. Trial Selection.-Trials that had randomized allocation to control and dietary sodium intervention groups, monitored by timed sodium excretion, with outcome measures of both systolic and diastolic blood pressure were selected by blinded review of the methods section. Data Extraction.-Two observers extracted data independently, using purpose-designed forms, and discrepancies were resolved by discussion. Data Synthesis.-The 56 trials that met our inclusion criteria showed significant heterogeneity. Publication bias was also evident. The mean reduction (95% confidence interval) in daily urinary sodium excretion, a proxy measure of dietary sodium intake, was 95 mmol/d (71-119 mmol/d) in 28 trials with 1131 hypertensive subjects and 125 mmol/d (95-156 mmol/d) in 28 trials with 2374 normotensive subjects. After adjustment for measurement error of urinary sodium excretion, the decrease in blood pressure for a 100-mmol/d reduction in daily sodium excretion was 3.7 mm Hg (2.35-5.05 mm Hg) for systolic (P<.001) and 0.9 mm Hg (-0.13 to 1.85 mm Hg) for diastolic (P=.09) in the hypertensive trials, and 1.0 mm Hg (0.51-1.56 mm Hg) for systolic (P<.001) and 0.1 mm Hg (-0.32 to 0.51 mm Hg) for diastolic (P=.64) in the normotensive trials. Decreases in blood pressure were larger in trials of older hypertensive individuals and small and nonsignificant in trials of normotensive individuals whose meals were prepared and who lived outside the institution setting. Conclusion.-Dietary sodium restriction for older hypertensive individuals might be considered, but the evidence in the normotensive population does not support current recommendations for universal dietary sodium restriction.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, HENRY S ROSENBERG DIV CLIN EPIDEMIOL, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MED, DIV NEPHROL, TORONTO, ON, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Logan, Alexander G/E-4626-2013	Greenwood, Celia/0000-0002-2427-5696				ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; Andersson O K, 1983, J Hypertens Suppl, V1, P35; ANDERSSON OK, 1984, HYPERTENSION, V6, P814, DOI 10.1161/01.HYP.6.6.814; [Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; APPLEGATE WB, 1992, ARCH INTERN MED, V152, P1162, DOI 10.1001/archinte.152.6.1162; BENETOS A, 1992, J HYPERTENS, V10, P355, DOI 10.1097/00004872-199204000-00006; BOMPIANI GD, 1988, INT J CLIN PHARM TH, V26, P129; BRUUN NE, 1990, J HYPERTENS, V8, P219; BURNIER M, 1993, HYPERTENSION, V22, P339, DOI 10.1161/01.HYP.22.3.339; CHALMERS J, 1986, J HYPERTENS, V4, pS629; CHALMERS JP, 1989, LANCET, V1, P399; Cooper R, 1984, J Hypertens, V2, P361; CUTLER JA, 1991, HYPERTENSION, V17, pI27, DOI 10.1161/01.HYP.17.1_Suppl.I27; DELRIO A, 1993, J INTERN MED, V233, P409; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DONOVAN DS, 1993, AM J PHYSIOL, V264, pE730, DOI 10.1152/ajpendo.1993.264.5.E730; DYER AR, 1994, AM J EPIDEMIOL, V139, P927, DOI 10.1093/oxfordjournals.aje.a117099; EGAN BM, 1991, AM J HYPERTENS, V4, P416, DOI 10.1093/ajh/4.5.416; ELASHRY A, 1987, J HUM HYPERTENS, V1, P105; ERWTEMAN TM, 1984, BMJ-BRIT MED J, V289, P406, DOI 10.1136/bmj.289.6442.406; FAGERBERG B, 1985, HYPERTENSION, V7, P586, DOI 10.1161/01.HYP.7.4.586; FAGERBERG B, 1985, ACTA MED SCAND, V218, P157; FAGERBERG B, 1984, BRIT MED J, V288, P11, DOI 10.1136/bmj.288.6410.11; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; FOTHERBY MD, 1993, J HYPERTENS, V11, P657, DOI 10.1097/00004872-199306000-00010; FRIBERG P, 1990, HYPERTENSION, V16, P121, DOI 10.1161/01.HYP.16.2.121; FUCHS FD, 1987, BRAZ J MED BIOL RES, V20, P25; GILL JS, 1985, LANCET, V1, P567; GILLUM RF, 1981, HYPERTENSION, V3, P698, DOI 10.1161/01.HYP.3.6.698; GOW IF, 1992, EUR J CLIN PHARMACOL, V43, P635, DOI 10.1007/BF02284963; GROBBEE DE, 1987, J HYPERTENS, V5, P115, DOI 10.1097/00004872-198702000-00016; HARGREAVES M, 1989, CLIN SCI, V76, P553, DOI 10.1042/cs0760553; HOWE PRC, 1991, J HYPERTENS, V9, P181, DOI 10.1097/00004872-199102000-00014; JULA A, 1990, J INTERN MED, V227, P413, DOI 10.1111/j.1365-2796.1990.tb00180.x; JULA AM, 1992, SCAND J CLIN LAB INV, V52, P159, DOI 10.3109/00365519209088780; Koolen M I, 1983, J Hypertens Suppl, V1, P21; Koolen M I, 1984, J Hypertens, V2, P55, DOI 10.1097/00004872-198402000-00010; KOOLEN MI, 1984, HYPERTENSION, V6, P820, DOI 10.1161/01.HYP.6.6.820; KOOPMAN H, 1990, J HUM HYPERTENS, V4, P372; KOOPMAN H, 1990, J HUM HYPERTENS, V4, P368; KUMANYIKA SK, 1993, HYPERTENSION, V22, P502, DOI 10.1161/01.HYP.22.4.502; KURTZ TW, 1987, NEW ENGL J MED, V317, P1043, DOI 10.1056/NEJM198710223171702; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LAWTON WJ, 1988, HYPERTENSION, V11, P529, DOI 10.1161/01.HYP.11.6.529; LOGAN AG, 1986, CAN J PHYSIOL PHARM, V64, P793, DOI 10.1139/y86-136; LUFT FC, 1991, HYPERTENSION, V17, pI102, DOI 10.1161/01.HYP.17.1_Suppl.I102; LUFT FC, 1987, KLIN WOCHENSCHR, V65, P101, DOI 10.1007/BF01728599; MACGREGOR GA, 1982, LANCET, V1, P351, DOI 10.1016/S0140-6736(82)91389-7; MACGREGOR GA, 1985, SCAND J CLIN LAB INV, V45, P25; MACGREGOR GA, 1989, LANCET, V2, P1244, DOI 10.1016/S0140-6736(89)91852-7; MACGREGOR GA, 1982, CLIN SCI, V63, pS399, DOI 10.1042/cs063399s; MARK AL, 1975, CIRC RES, V36, P194, DOI 10.1161/01.RES.36.6.194; MASCIOLI S, 1991, HYPERTENSION, V17, pI21, DOI 10.1161/01.HYP.17.1_Suppl.I21; MILLER JZ, 1988, AM J CLIN NUTR, V47, P113, DOI 10.1093/ajcn/47.1.113; MORGAN T, 1988, J HUM HYPERTENS, V1, P311; MORGAN T, 1978, LANCET, V1, P227; MUNTZEL M, 1992, AM J HYPERTENS, V5, pS1, DOI 10.1093/ajh/5.4S.1S; MYERS J, 1983, CLIN EXP HYPERTENS A, V5, P99, DOI 10.3109/10641968309048813; MYERS J, 1992, CLIN EXP PHARM PHY S, V9, P287; MYERS JB, 1989, J HUM HYPERTENS, V3, P97; MYERS JB, 1984, J CARDIOVASC PHARM, V6, pS204, DOI 10.1097/00005344-198400061-00032; NESTEL PJ, 1993, J HYPERTENS, V11, P1387, DOI 10.1097/00004872-199312000-00011; NOWSON CA, 1988, CLIN EXP PHARMACOL P, V15, P225, DOI 10.1111/j.1440-1681.1988.tb01065.x; OVERLACK A, 1993, HYPERTENSION, V22, P331, DOI 10.1161/01.HYP.22.3.331; PUSKA P, 1983, LANCET, V1, P1; RICHARDS AM, 1986, J HYPERTENS, V4, pS559; RICHARDS AM, 1984, LANCET, V1, P757, DOI 10.1016/S0140-6736(84)91276-5; RICHARDS AM, 1985, HYPERTENSION, V7, P681, DOI 10.1161/01.HYP.7.5.681; RUPPERT M, 1993, J HYPERTENS, V11, P743, DOI 10.1097/00004872-199307000-00010; RUPPERT M, 1991, KLIN WOCHENSCHR, V69, P51; RUPPERT M, 1994, AM J MED SCI, V307, pS87; *SAS I INC, 1989, SS STAT US GUID VERS; SCHMID M, 1990, J HYPERTENS, V8, P277; SEBER GAI, 1977, LINEAR REGRESSION AN, P155; SHARMA AM, 1991, J HYPERTENS, V9, P329, DOI 10.1097/00004872-199104000-00004; SHARMA AM, 1993, HYPERTENSION, V21, P273, DOI 10.1161/01.HYP.21.3.273; SHARMA AM, 1990, KLIN WOCHENSCHR, V68, P664, DOI 10.1007/BF01667013; SILMAN AJ, 1983, LANCET, V1, P1179; SKRABAL F, 1981, LANCET, V2, P895; SKRABAL F, 1984, HYPERTENSION, V6, P152, DOI 10.1161/01.HYP.6.2_Pt_1.152; STAMLER J, 1993, ANN NY ACAD SCI, V676, P122; TEOW BH, 1985, CLIN EXP HYPERTENS A, V7, P1681, DOI 10.3109/10641968509073618; TONASCIA J, 1989, 703 J HOPK U DEP BIO; Watt G, 1983, J Hypertens Suppl, V1, P18; WATT G C M, 1986, Journal of Clinical Hypertension, V2, P141; WATT GCM, 1983, BMJ-BRIT MED J, V286, P432, DOI 10.1136/bmj.286.6363.432; WATT GCM, 1985, BMJ-BRIT MED J, V291, P1525, DOI 10.1136/bmj.291.6508.1525; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; ZOCCALI C, 1993, J HYPERTENS, V11, pS326; 1989, CLIN EXP HYPERTENS, V11, P1011; 1991, FED REGISTER, V56, P60825; [No title captured]	93	419	430	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1590	1597		10.1001/jama.275.20.1590	http://dx.doi.org/10.1001/jama.275.20.1590			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622251				2022-12-28	WOS:A1996UL02900032
J	Schorle, H; Meier, P; Buchert, M; Jaenisch, R; Mitchell, PJ				Schorle, H; Meier, P; Buchert, M; Jaenisch, R; Mitchell, PJ			Transcription factor AP-2 essential for cranial closure and craniofacial development	NATURE			English	Article							NEURAL CREST; VERTEBRATES; DISRUPTION; BINDING; ORIGIN; CELLS; TUBE	DURING closure of the neural tube in the mouse, transcription factor AP-2 (refs 1-4) is expressed in ectoderm and in neural-crest cells migrating from the cranial neural folds(5). Cranial neural crest cells provide patterning information for craniofacial morphogenesis, generate most of the skull bones, and, together with placodal ectoderm, form the cranial ganglia(6-8). To study the role of AP-2 during embryogenesis, we undertook a targeted mutagenesis of the AP-2 gene in the mouse. Here we report that AP-2(-/-) mice died perinatally with cranio-abdominoschisis and severe dismorphogenesis of the face, skull, sensory organs and cranial ganglia. Failure of cranial closure between 9 and 9.5 days postcoitum coincided with increased apoptosis in the midbrain, anterior hindbrain and proximal mesenchyme of the first branchial arch, but did not involve loss of expression of twist or Pax-3, two other regulatory genes known to be required for cranial closure.	MIT, DEPT BIOL, CAMBRIDGE, MA 02138 USA; UNIV ZURICH, INST MOLEC BIOL, CH-8057 ZURICH, SWITZERLAND; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); University of Zurich; Massachusetts Institute of Technology (MIT); Whitehead Institute			Schorle, Hubert/M-5001-2016; Schorle, Hubert/S-1713-2019; Buchert, Michael/Z-1777-2019	Schorle, Hubert/0000-0001-8272-0076; Buchert, Michael/0000-0003-2672-0148; Meier, Pascal/0000-0003-2760-6523				CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Copp Andrew J., 1994, Current Opinion in Pediatrics, V6, P624, DOI 10.1097/00008480-199412000-00002; COULY GF, 1993, DEVELOPMENT, V117, P409; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; EMFORS P, 1995, NATURE, V368, P147; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON R, 1985, J EMBRYOL EXP MORPH, V89, P229; Hogan B, 1994, MANIPULATING MOUSE E; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kaufman M.H., 1992, ATLAS MOUSE DEV; Le Douarin N.M., 1982, NEURAL CREST; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; QIU MS, 1995, GENE DEV, V9, P2523, DOI 10.1101/gad.9.20.2523; Richman J, 1996, CURR BIOL, V6, P364, DOI 10.1016/S0960-9822(02)00496-7; RIVERAPEREZ JA, 1995, DEVELOPMENT, V121, P3005; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; WILKINSON DG, 1992, IN SITU HYDRIDIZATIO; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YAMADA G, 1995, DEVELOPMENT, V121, P2917	30	492	501	0	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 16	1996	381	6579					235	238		10.1038/381235a0	http://dx.doi.org/10.1038/381235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622765				2022-12-28	WOS:A1996UL24900054
J	Dale, J; Shipman, C; Lacock, L; Davies, M				Dale, J; Shipman, C; Lacock, L; Davies, M			Creating a shared vision of out of hours care: Using rapid appraisal methods to create an interagency, community oriented, approach to service development	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To undertake a district wide review of out of hours primary health care services and identify the views of users and providers about current arrangements and options for development. Design-A range of qualitative and quantitative survey methods based on rapid appraisal methods, modified to apply to an inner city district. Setting-Socially deprived, multiethnic district in south east London with a population of over 700 000. Main outcome measures-Strengths and weaknesses of current out of hours services and suggestions for developments. Results-Widespread dissatisfaction with current arrangements was identified, with specific problems relating to access, availability, demand for services, and interagency communication. Several areas for development were identified, including the establishment of an out of hours cooperative, multiagency primary care emergency centres, and telephone advice-triage. Many of these are now being planned or piloted. Conclusions-Rapid appraisal provided a helpful method, enabling partnerships to be established between local agencies and users in relation to service development. The shared understanding and commitment to improving services that resulted is now having a major impact on out of hours care in the district.	UNIV LONDON KINGS COLL,DEPT GEN PRACTICE,LONDON SE5 9PJ,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SE5 9PJ,ENGLAND	University of London; King's College London; University of London; King's College London	Dale, J (corresponding author), UNIV LONDON KINGS COLL,DEPT ACCID & EMERGENCY MED,LONDON SE5 9PJ,ENGLAND.			Dale, Jeremy/0000-0001-9256-3553				ANNETT H, 1988, IMPROVING URBAN HLTH; DALE J, 1995, LAMBETH SOUTHWORK LE; *GEN MED SERV COMM, 1992, YOUR CHOIC FUT SURV; Glaser B.G., 1965, AWARENESS DYING; GREEN J, 1992, SOC SCI MED, V35, P987, DOI 10.1016/0277-9536(92)90238-L; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; HURWITZ B, 1994, BRIT MED J, V309, P1593, DOI 10.1136/bmj.309.6969.1593; HURWITZ B, 1995, BRIT MED J, V311, P824, DOI 10.1136/bmj.311.7009.824; MURRAY SA, 1994, BRIT MED J, V308, P698, DOI 10.1136/bmj.308.6930.698; MURRAY SA, 1995, BRIT MED J, V310, P1443, DOI 10.1136/bmj.310.6992.1443; NHS Management Executive, 1992, LOC VOIC VIEWS LOC P; ONG B, 1994, PRACTICE HLTH SERVIC; ONG BN, 1991, SOC SCI MED, V32, P909, DOI 10.1016/0277-9536(91)90246-9; Silverman D., 2015, INTERPRETING QUALITA; Winkler F, 1994, Health Serv J, V104, P31; World Health Organisation, 1985, TARG HLTH ALL 2000	16	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1206	1210						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634567				2022-12-28	WOS:A1996UL05800024
J	Bentham, G				Bentham, G			Association between incidence of non-Hodgkin's lymphoma and solar ultraviolet radiation in England and Wales	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA; TIME TRENDS; EXPOSURE; EPIDEMIOLOGY; CANCER; RISK	Objectives-To examine whether the incidence of non-Hodgkin's lymphoma in different areas of England and Wales is associated with levels of solar ultraviolet radiation. Design-Geographically based study examining the association between incidence of non-Hodgkin's lymphoma and estimated levels of solar ultraviolet radiation, controlling for social class and employment in agriculture. Setting-59 counties in England and Wales. Subjects-All registered cases of non-Hodgkin's lymphoma during the period 1968-85. Main outcome measure-Age and sex adjusted odds ratio for non-Hodgkin's lymphoma in each county. Results-Incidence of non-Hodgkin's lymphoma was significantly associated with solar ultraviolet radiation levels (P<0.001), even after social class and employment in agriculture were controlled for (P=0.004). In a comparison of counties in the highest and lowest quarters of solar ultraviolet radiation, the relative risk of non-Hodgkin's lymphoma was 1.27 (95% confidence interval 1.24 to 1.29), rising to 1.34 (1.32 to 1.37) after adjustment for social class and employment in agriculture. Conclusions-The incidence of non-Hodgkin's lymphoma in different areas of England and Wales is positively associated with levels of solar ultraviolet radiation. These results are consistent with the hypothesis that exposure to solar ultraviolet radiation increases the risk of non-Hodgkin's lymphoma.			Bentham, G (corresponding author), UNIV E ANGLIA,SCH ENVIRONM SCI,CTR SOCIAL & ECON RES GLOBAL ENVIRONM,NORWICH NR4 7TJ,NORFOLK,ENGLAND.							ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; ADAMI J, 1995, BMJ-BRIT MED J, V311, P750, DOI 10.1136/bmj.311.7007.750b; BARROW EM, 1993, 1961 90 BASELINE CLI; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; DEVESA SS, 1992, CANCER RES, V52, pS5432; DOLL R, 1991, AM J EPIDEMIOL, V134, P675, DOI 10.1093/oxfordjournals.aje.a116143; ELWOOD JM, 1990, INT J EPIDEMIOL, V19, P801, DOI 10.1093/ije/19.4.801; ELWOOD JM, 1985, INT J CANCER, V35, P427, DOI 10.1002/ijc.2910350403; FILIPOVICH AH, 1992, CANCER RES, V52, pS5465; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOETTSCH W, 1993, THYMUS, V21, P93; GREINER TC, 1994, DIAGN ONCOL, V4, P26; Hartge P., 1992, CANC RES S, V52, p5466s; HOLFORD TR, 1992, CANCER RES, V52, pS5443; KINLEN L, 1992, CANCER RES, V52, pS5474; KIRKPATRICK CS, 1990, INT J CANCER, V46, P1; LEVINE AM, 1992, CANCER RES, V52, pS5482; MADRONICH S, 1995, AMBIO, V24, P143; MCKINNEY PA, 1991, LEUKEMIA LYMPHOMA, V4, P123, DOI 10.3109/10428199109068055; MO T, 1974, PHOTOCHEM PHOTOBIOL, V20, P483, DOI 10.1111/j.1751-1097.1974.tb06607.x; MUELLER NE, 1992, CANCER RES, V52, pS5479; NEWTON R, 1995, BRIT MED J, V311, P750, DOI 10.1136/bmj.311.7007.750a; *OFF POP CENS SURV, 1975, CENS 1971 ENGL WAL E; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; PEARCE N, 1992, CANCER RES, V52, pS5496; SASIENI P, 1995, BRIT MED J, V311, P749, DOI 10.1136/bmj.311.7007.749a; SCHERR PA, 1992, CANCER RES, V52, pS5503; SWERDLOW A, 1993, ATLAS CANC INCIDENCE; VICKERS M, 1995, BRIT MED J, V311, P750, DOI 10.1136/bmj.311.7007.750; WEISENBURGER DD, 1994, ANN ONCOL, V5, pS19, DOI 10.1093/annonc/5.suppl_1.S19; WHO World Health Organization, 1994, ENV HLTH CRIT, V160; ZAHM SH, 1992, CANCER RES, V52, pS5485; 1990, ARCH INTERN MED, V150, P2473	34	78	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1128	1131						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620128				2022-12-28	WOS:A1996UK06900021
J	Rietschel, RL				Rietschel, RL			Reproducibility of patch-test results	LANCET			English	Editorial Material							ANGRY BACK				Rietschel, RL (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN,DEPT DERMATOL,NEW ORLEANS,LA 70121, USA.							BANDMANN HJ, 1981, CONTACT DERMATITIS, V7, P23, DOI 10.1111/j.1600-0536.1981.tb03954.x; BRUYNZEEL DP, 1983, J AM ACAD DERMATOL, V8, P392, DOI 10.1016/S0190-9622(83)70044-7; GOLLHAUSEN R, 1989, J AM ACAD DERMATOL, V21, P1196, DOI 10.1016/S0190-9622(89)70329-7; GOLLHAUSEN R, 1989, J AM ACAD DERMATOL, V21, P843, DOI 10.1016/S0190-9622(89)70263-2; LACHAPELLE JM, 1989, J AM ACAD DERMATOL, V21, P850, DOI 10.1016/S0190-9622(89)70265-6; Memon AA, 1996, BRIT J DERMATOL, V134, P208; Mitchell J C, 1975, Contact Dermatitis, V1, P193, DOI 10.1111/j.1600-0536.1975.tb05380.x; NETHERCOTT JR, 1989, IMMUNOL ALLERGY CLIN, V9, P549	8	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1202	1202		10.1016/S0140-6736(96)90731-X	http://dx.doi.org/10.1016/S0140-6736(96)90731-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622447				2022-12-28	WOS:A1996UJ59700006
J	Turow, J				Turow, J			Television entertainment and the US health-care debate	LANCET			English	Editorial Material								Some experts on the media say that entertainment can be more successful than news at providing insights into certain institutions, medicine being a good example. US television series that feature physicians as the central-characters have been Immensely popular. In the early series, dating back to the 1952 debut of City Hospital, the physician was an all-powerful hero working in a sparkling centre of healing, with medicine portrayed as a resource freely available to all. The programmes began to change in the 1970s. Plots centred more around the physicians' personal problems than on the patients, but economic and health-policy issues were still rarely discussed adequately. In the end, what viewers come away with may lead them towards false expectations, and they may increasingly blame doctors for decisions that others make and enforce.			Turow, J (corresponding author), UNIV PENN,ANNENBERG SCH COMMUN,3620 WALNUT ST,PHILADELPHIA,PA 19104, USA.							ALLEY R, 1985, TV GENRES HDB REFERE, P73; ATKIN C, 1990, MASS COMMUNICATION P, P13; GERBNER G, 1981, NEW ENGL J MED, V305, P901, DOI 10.1056/NEJM198110083051530; GERBNER G, 1980, J COMMUN, V30, P10, DOI 10.1111/j.1460-2466.1980.tb01987.x; GERBNER G, 1974, MEDIA SYMBOLS 1; Giddens A., 1991, MODERNITY SELF IDENT; HAMBERG B, 1982, TELEVISION BEHAV, V2; JAMIESON K, 1995, MEDIA MIDDLE FAIRNES; KALISCH PA, 1983, IMAGES NURSES TELEVI; Kreps G., 1992, HLTH COMMUNICATION T, V2nd; Meyrowitz Joshua, 1986, NO SENSE PLACE IMPAC; Morgan M., 1990, CULTIVATION ANAL NEW; PFAU M, 1995, J BROADCAST ELECTRON, V39, P441, DOI 10.1080/08838159509364318; SOLOMON D, 1982, TELEVISION BEHAV, V2; STARR P, 1983, SOCIAL TRANSFORMATIO, P347; STARR P, 1983, SOCIAL TRANSFORMATIO, P336; Stevens Rosemary, 1971, AM MED PUBLIC INTERE; TUROW J, 1985, J COMMUN, P36; TUROW J, 1996, REVOLUTION WASNT TEL; Turow Joseph, 1989, PLAYING DOCTOR TELEV; 1989, PLAYING DOCTOR TELEV	21	35	39	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1240	1243		10.1016/S0140-6736(96)90747-3	http://dx.doi.org/10.1016/S0140-6736(96)90747-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622461	Green Submitted			2022-12-28	WOS:A1996UJ59700021
J	Borel, AC; Simon, SM				Borel, AC; Simon, SM			Biogenesis of polytopic membrane proteins: Membrane segments assemble within translocation channels prior to membrane integration	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; BACTERIAL TRANSPORT PROTEINS; P-GLYCOPROTEIN; SECRETORY PROTEINS; TRANSMEMBRANE GLYCOPROTEIN; MULTIDRUG RESISTANCE; TRANSLATION PRODUCTS; ESCHERICHIA-COLI; SIGNAL SEQUENCE; INSERTION	The initial steps in the biogenesis of membrane proteins parallel that of secretory proteins. The translocation of membrane proteins, however, must be interrupted prior to the complete traversal of the membrane. This is followed by their folding and integrating into the lipid bilayer. We have previously shown that as each latent transmembrane segment (TMS) in a polytopic membrane protein emerges from the ribosome, it sequentially translocates across the membrane. Here we demonstrate that these translocated TMSs can be extracted from the membrane with urea. This suggests that nascent TMSs do not integrate into the bilayer as they achieve a transmembrane topography. The integration is delayed until after the protein is synthesized and released from the ribosome. Prior to insertion into the bilayer, these TMSs appear to be stabilized by salt-sensitive electrostatic bonds within an aqueous-accessible compartment.	ROCKEFELLER UNIV,LAB CELLULAR BIOPHYS,NEW YORK,NY 10021	Rockefeller University				Simon, Sanford/0000-0002-8615-4224				ANDERSON DJ, 1982, J CELL BIOL, V93, P501, DOI 10.1083/jcb.93.2.501; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1967, J MOL BIOL, V26, P293, DOI 10.1016/0022-2836(67)90298-7; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KAWAHARA K, 1965, BIOCHEMISTRY-US, V4, P1203, DOI 10.1021/bi00883a001; LINGAPPA VR, 1978, J BIOL CHEM, V253, P8667; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOO TW, 1994, J BIOL CHEM, V269, P28683; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCCUNE JM, 1981, P NATL ACAD SCI-BIOL, V78, P5127, DOI 10.1073/pnas.78.8.5127; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; MONRO RE, 1967, J MOL BIOL, V25, P347, DOI 10.1016/0022-2836(67)90146-5; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; REDMAN CM, 1966, P NATL ACAD SCI USA, V56, P608, DOI 10.1073/pnas.56.2.608; REDMAN CM, 1966, J BIOL CHEM, V241, P1150; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SKOGERSON L, 1968, ARCH BIOCHEM BIOPHYS, V125, P497, DOI 10.1016/0003-9861(68)90607-3; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1983, METHOD ENZYMOL, V96, P84; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	53	115	115	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					379	389		10.1016/S0092-8674(00)81116-2	http://dx.doi.org/10.1016/S0092-8674(00)81116-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616893	Bronze			2022-12-28	WOS:A1996UK14000011
J	Feldmann, M; Brennan, FM; Maini, RN				Feldmann, M; Brennan, FM; Maini, RN			Rheumatoid arthritis	CELL			English	Review							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; FACTOR-ALPHA; ANTIBODIES; MICE				Feldmann, M (corresponding author), HAMMERSMITH HOSP,KENNEDY INST RHEUMATOL,LONDON W6 8LW,ENGLAND.							AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; BRENNAN FM, 1989, LANCET, V2, P244; COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0; CUSH JJ, 1988, ARTHRITIS RHEUM-US, V31, P1230, DOI 10.1002/art.1780311003; DIGIOVINE FS, 1988, ANN RHEUM DIS, V47, P768, DOI 10.1136/ard.47.9.768; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; FAVA R, 1989, J EXP MED, V169, P291, DOI 10.1084/jem.169.1.291; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; FONG YM, 1989, J EXP MED, V170, P1627, DOI 10.1084/jem.170.5.1627; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847; JANOSSY G, 1981, LANCET, V2, P839; KATSIKIS PD, 1994, J EXP MED, V179, P1517, DOI 10.1084/jem.179.5.1517; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KIRKHAM BW, 1992, J RHEUMATOL, V19, P1348; MAINI RN, 1995, IMMUNOL REV, V144, P195, DOI 10.1111/j.1600-065X.1995.tb00070.x; MORELAND LW, 1995, ARTHRITIS RHEUM, V38, P1177, DOI 10.1002/art.1780380902; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OLEE TW, 1992, J EXP MED, V175, P831, DOI 10.1084/jem.175.3.831; Olsen N. J., 1994, Arthritis and Rheumatism, V37, pS295; PINCUS T, 1993, RHEUM DIS CLIN N AM, V19, P123; PLATERZYBERK C, 1985, ARTHRITIS RHEUM, V28, P971, DOI 10.1002/art.1780280903; RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334; RONNELID J, 1994, ARTHRITIS RHEUM-US, V37, P1023, DOI 10.1002/art.1780370707; SEBBAG M, 1995, J CLIN INVEST, V95, P2572; STASTNY P, 1978, NEW ENGL J MED, V298, P869, DOI 10.1056/NEJM197804202981602; THORBECKE GJ, 1992, P NATL ACAD SCI USA, V89, P7375, DOI 10.1073/pnas.89.16.7375; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; VANDERLUBBE PA, 1995, ARTHRITIS RHEUM, V38, P1097, DOI 10.1002/art.1780380812; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; WILLIAMS RO, 1994, P NATL ACAD SCI USA, V91, P2762, DOI 10.1073/pnas.91.7.2762; Woulfe SL, 1995, ARTHRITIS RHEUM, V38, P1744, DOI 10.1002/art.1780381207; ZIFF M, 1990, J RHEUMATOL, V17, P127	35	966	1026	3	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					307	310		10.1016/S0092-8674(00)81109-5	http://dx.doi.org/10.1016/S0092-8674(00)81109-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616886	Bronze			2022-12-28	WOS:A1996UK14000004
J	Mal, A; Poon, RYC; Howe, PH; Toyoshima, H; Hunter, T; Harter, ML				Mal, A; Poon, RYC; Howe, PH; Toyoshima, H; Hunter, T; Harter, ML			Inactivation of p27(Kip1) by the viral E1A oncoprotein in TGF beta-treated cells	NATURE			English	Article							GROWTH ARREST; INHIBITION; KINASE; PHOSPHORYLATION; PROTEINS; P34CDC2; CYCLE	THE adenovirus oncoprotein E1A and the simian virus SV40 large T antigen can both reverse the strong growth-inhibitory effect of transforming growth factor(TGF)-beta on mink lung epithelial cells(1,2): exposure of TGF-beta causes these cells to arrest late in the G1 phase of the cell cycle (ref. 3). This arrest correlates with an increase in expression of the protein p15(Ink4B) (ref. 4), inactivation of the cyclin E/A-cdk2 complex by the inhibitory protein p27(Kip1) (refs 5-7), and with the accumulation of unphosphorylated retinoblastoma protein(8). The rescue by E1A of cells from TGF-beta arrest is partly independent of its binding to retinoblastoma protein(1). Here we show that E1A directly affects the cyclin-dependent kinase inhibitor p27(Kip1) in TGF-beta-treated cells by binding to it and blocking its inhibitory effect, thereby restoring the activity of the cyclin-cdk2 kinase complex. In this way, E1A can overcome the effect of TGF-beta and modulate the cell cycle. To our knowledge, E1A provides the first example of a viral oncoprotein that can disable a cellular protein whose function is to inhibit the activity of cyclin-dependent kinases.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,RES INST,DEPT CELL BIOL,CLEVELAND,OH 44195; SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Salk Institute				Poon, Randy/0000-0001-5571-6231				ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; BANERJEE AC, 1994, ONCOGENE, V9, P1733; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOWE PH, 1993, J BIOL CHEM, V268, P21448; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; NEVINS JR, 1993, BIOCHEM SOC T, V21, P935, DOI 10.1042/bst0210935; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; REYNISDOTTIR I, 1995, J GENES DEV, V9, P1831; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; STACEY DW, 1994, EMBO J, V13, P6107, DOI 10.1002/j.1460-2075.1994.tb06957.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7	26	136	139	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					262	265		10.1038/380262a0	http://dx.doi.org/10.1038/380262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637577				2022-12-28	WOS:A1996UB11700056
J	Lesperance, F; FrasureSmith, N				Lesperance, F; FrasureSmith, N			Negative emotions and coronary heart disease: Getting to the heart of the matter	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; ARTERY DISEASE; A BEHAVIOR; IMPACT		MCGILL UNIV,MONTREAL,PQ,CANADA	McGill University	Lesperance, F (corresponding author), UNIV MONTREAL,MONTREAL HEART INST,MONTREAL,PQ,CANADA.		Lesperance, Francois/C-4716-2015	Lesperance, Francois/0000-0003-4604-2823				APPELS A, 1988, EUR HEART J, V9, P758, DOI 10.1093/eurheartj/9.7.758; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; DERNBROSKI TM, 1985, PSYCHOSOM MED, V47, P219; DIMSDALE JE, 1988, NEW ENGL J MED, V318, P110, DOI 10.1056/NEJM198801143180209; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; FRASURESMITH N, 1989, PSYCHOSOM MED, V51, P485, DOI 10.1097/00006842-198909000-00002; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; FRIEDMAN M, 1986, AM HEART J, V112, P653, DOI 10.1016/0002-8703(86)90458-8; LADWIG KH, 1994, LANCET, V343, P20, DOI 10.1016/S0140-6736(94)90877-X; LESPERANCE F, IN PRESS PSYCHOSOM M; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520	12	45	45	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					414	415		10.1016/S0140-6736(96)90004-5	http://dx.doi.org/10.1016/S0140-6736(96)90004-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618478				2022-12-28	WOS:A1996TV72200004
J	Michels, KB; Willett, WC; Rosner, BA; Manson, JE; Hunter, DJ; Colditz, GA; Hankinson, SE; Speizer, FE				Michels, KB; Willett, WC; Rosner, BA; Manson, JE; Hunter, DJ; Colditz, GA; Hankinson, SE; Speizer, FE			Prospective assessment of breastfeeding and breast cancer incidence among 89887 women	LANCET			English	Article							RISK-FACTORS; LACTATION; POPULATION; AGE; ASSOCIATION; PREGNANCY; DURATION; 1ST	Background The relation between breastfeeding and breast-cancer risk has been examined in many studies; some have reported no association, and others a reduced risk, particularly among premenopausal women. In the only prospective cohort study, no association was found. We have assessed prospectively the association between breastfeeding and incidence of breast cancer among 89 887 women in the US Nurses' Health Study. Methods In 1986, participants were asked about the number of months they breastfed for all their children combined. Parous women with no history of cancer were included in this analysis. During 6 years of follow-up (513 015 person-years), 1459 invasive breast cancer cases were diagnosed. Findings Relative to women who had never breastfed, no significant overall association was found-after adjusting for established risk factors for breast cancer-between a history of having breastfed and subsequent development of breast cancer (relative risk [RR] 0.93, 95% CI 0.83-1.03). No inverse trend was observed with duration of breastfeeding; women who breastfed for 2 years or longer had a RR of 1.11 (0.90-1.38). Among women who had given birth only once, women who had breastfed their child experienced a lower incidence of breast cancer (RR 0.68, 0.46-1.00). Among premenopausal women, who tended to be near menopause due to the age structure of the cohort, the RR of breast cancer for those who had lactated was 1.16 (0.89-1.50). Premenopausal women who had lactated for 1 year or more had a RR of 1.10 (0.78-1.57). Interpretation These data suggest that there is no important overall association between breast-feeding and the occurrence of breast cancer.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Michels, KB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; BRIGNONE G, 1987, INT J EPIDEMIOL, V16, P356, DOI 10.1093/ije/16.3.356; BRINTON LA, 1983, BRIT J CANCER, V47, P757, DOI 10.1038/bjc.1983.128; BYERS T, 1985, AM J EPIDEMIOL, V121, P664, DOI 10.1093/aje/121.5.664; CHILVERS CED, 1993, BRIT MED J, V307, P17, DOI 10.1136/bmj.307.6895.17; DEWAILLY E, 1994, J NATL CANCER I, V86, P803, DOI 10.1093/jnci/86.10.803-a; Haring M H, 1992, Ned Tijdschr Geneeskd, V136, P743; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HENDERSHOT GE, 1984, PEDIATRICS, V74, P591; HENDERSON BE, 1985, CANCER, V56, P1206, DOI 10.1002/1097-0142(19850901)56:5<1206::AID-CNCR2820560541>3.0.CO;2-9; ING R, 1977, LANCET, V2, P124; Jensen A.A., 1991, CHEM CONTAMINANTS HU; KALACHE A, 1980, BRIT MED J, V280, P223, DOI 10.1136/bmj.280.6209.223-a; KELSEY JL, 1994, NEW ENGL J MED, V330, P136, DOI 10.1056/NEJM199401133300210; KURINIJ N, 1989, AM J PUBLIC HEALTH, V79, P1247, DOI 10.2105/AJPH.79.9.1247; KVALE G, 1988, J EPIDEMIOL COMMUN H, V42, P30, DOI 10.1136/jech.42.1.30; LAING AE, 1993, J NATL MED ASSOC, V85, P931; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P157, DOI 10.1007/BF01830262; LANECLAYPON JE, 1926, 32 HM STAT OFF REP; LAWRENCE RA, 1994, BREASTFEEDING GUIDE; LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3; LONDON SJ, 1994, NEW ENGL J MED, V330, P1682, DOI 10.1056/NEJM199406093302311; LONDON SJ, 1990, AM J EPIDEMIOL, V132, P17, DOI 10.1093/oxfordjournals.aje.a115629; LUBIN JH, 1982, J NATL CANCER I, V68, P211; MACMAHON B, 1982, JNCI-J NATL CANCER I, V69, P1035; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V42, P185; MACMAHON B, 1993, JNCI-J NATL CANCER I, V71, P3183; MCTIERNAN A, 1986, AM J EPIDEMIOL, V124, P353, DOI 10.1093/oxfordjournals.aje.a114405; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; Romieu I., 1994, American Journal of Epidemiology, V139, pS68; ROSEROBIXBY L, 1987, INT J CANCER, V40, P747, DOI 10.1002/ijc.2910400606; Rosner B., 2011, FUNDAMENTALS BIOSTAT, V7th; RUSSO J, 1980, AM J PATHOL, V100, P497; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Segi M, 1957, GANN               S, V48, P1; SIMOPOULOS AP, 1984, PEDIATRICS, V74, P603; SISKIND V, 1989, AM J EPIDEMIOL, V130, P229; TAO SC, 1988, INT J CANCER, V42, P495, DOI 10.1002/ijc.2910420404; THOMAS DB, 1993, INT J EPIDEMIOL, V22, P619, DOI 10.1093/ije/22.4.619; Wainwright JM, 1931, AM J CANCER, V15, P10; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; YOO KY, 1992, AM J EPIDEMIOL, V135, P726, DOI 10.1093/oxfordjournals.aje.a116359	42	75	78	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 17	1996	347	8999					431	436		10.1016/S0140-6736(96)90010-0	http://dx.doi.org/10.1016/S0140-6736(96)90010-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618484				2022-12-28	WOS:A1996TV72200010
J	Giros, B; Jaber, M; Jones, SR; Wightman, RM; Caron, MG				Giros, B; Jaber, M; Jones, SR; Wightman, RM; Caron, MG			Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter	NATURE			English	Article							NUCLEUS-ACCUMBENS; MESSENGER-RNA; RECEPTOR GENE; RAT STRIATUM; NEURONS; MECHANISMS; EXPRESSION; NEUROTRANSMISSION; INHIBITOR; RELEASE	Disruption of the mouse dopamine transporter gene results in spontaneous hyperlocomotion despite major adaptive changes, such as decreases in neurotransmitter and receptor levels. In homozygote mice, dopamine persists at least 100 times longer in the extracellular space, explaining the biochemical basis of the hyperdopaminergic phenotype and demonstrating the critical role of the transporter in regulating neurotransmission. The dopamine transporter is an obligatory target of cocaine and amphetamine, as these psychostimulants have no effect on locomotor activity or dopamine release and uptake in mice lacking the transporter.	DUKE UNIV, MED CTR, DEPT CELL BIOL, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; UNIV N CAROLINA, CURRICULUM NEUROBIOL, CHAPEL HILL, NC 27514 USA; UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27514 USA	Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			GIROS, Bruno/ABD-5790-2021; Jones, Sara R/K-4816-2014; Jansen, Heiko T./A-5770-2008	GIROS, Bruno/0000-0001-5876-9822; Jones, Sara R/0000-0002-3424-7576; Jansen, Heiko T./0000-0003-0178-396X; Jaber, Mohamed/0000-0003-2536-1913				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BALK JH, 1995, NATURE, V377, P424; BARKER EL, 1994, MOL PHARMACOL, V46, P799; BAUMANN MH, 1993, BRAIN RES, V608, P175, DOI 10.1016/0006-8993(93)90792-L; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Byck R, 1977, NIDA Res Monogr, VSeries 13, P97; CERRUTI C, 1993, MOL BRAIN RES, V18, P181, DOI 10.1016/0169-328X(93)90187-T; CHIODO LA, 1992, NEUROCHEM INT, V20, pS81; CILIAX BJ, 1995, J NEUROSCI, V15, P1714, DOI 10.1523/JNEUROSCI.15-03-01714.1995; CROW TJ, 1980, BRIT J PSYCHIAT, V137, P383, DOI 10.1192/S0007125000071919; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; EHRINGER H, 1960, KLIN WOCHENSCHR, V38, P1236, DOI 10.1007/BF01485901; ESHLEMAN AJ, 1994, MOL PHARMACOL, V45, P312; FISCHER JF, 1979, J PHARMACOL EXP THER, V208, P203; FULLER RW, 1991, MED RES REV, V11, P17, DOI 10.1002/med.2610110103; GERFEN CR, 1992, TRENDS NEUROSCI, V15, P133, DOI 10.1016/0166-2236(92)90355-C; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GRAHAM JH, 1995, J PHARMACOL EXP THER, V274, P707; HITRI A, 1994, CLIN NEUROPHARMACOL, V17, P1, DOI 10.1097/00002826-199402000-00001; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JABER M, 1995, NEUROSCIENCE, V65, P1041, DOI 10.1016/0306-4522(94)00537-F; JACOCKS HM, 1992, J PHARMACOL EXP THER, V262, P356; JONES SR, 1995, J NEUROCHEM, V64, P2581; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4; KENNEDY RT, 1992, J NEUROCHEM, V59, P449, DOI 10.1111/j.1471-4159.1992.tb09391.x; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LEMOINE C, 1990, P NATL ACAD SCI USA, V87, P230, DOI 10.1073/pnas.87.1.230; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; MEISTER B, 1993, NEUROENDOCRINOLOGY, V58, P388, DOI 10.1159/000126568; PARKER EM, 1986, J PHARMACOL EXP THER, V237, P179; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; RAITERI M, 1979, J PHARMACOL EXP THER, V208, P195; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SULZER D, 1995, J NEUROSCI, V15, P4102; TISON F, 1994, NEUROSCI LETT, V166, P48, DOI 10.1016/0304-3940(94)90837-0; WALL SC, 1995, MOL PHARMACOL, V47, P544; WIGHTMAN RM, 1990, BRAIN RES REV, V15, P135, DOI 10.1016/0165-0173(90)90015-G; Wise R A, 1985, Psychiatr Med, V3, P445; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0; ZIMMERBERG B, 1992, PHYSIOL BEHAV, V52, P379, DOI 10.1016/0031-9384(92)90287-C	48	1948	1989	2	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					606	612		10.1038/379606a0	http://dx.doi.org/10.1038/379606a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628395				2022-12-28	WOS:A1996TV68800042
J	Tiku, PE; Gracey, AY; Macartney, AI; Beynon, RJ; Cossins, AR				Tiku, PE; Gracey, AY; Macartney, AI; Beynon, RJ; Cossins, AR			Cold-induced expression of Delta(9)-desaturase in carp by transcriptional and posttranslational mechanisms	SCIENCE			English	Article							STEARYL-COA DESATURASE; LIVER; MEMBRANES	Poikilothermic animals respond to chronic cold by increasing phosphoglyceride unsaturation to restore the fluidity of cold-rigidified membranes. Despite the importance of this compensatory response,the enzymes involved have not-been clearly identified, and the mechanisms that control their activity are unknown. In carp liver, cold induces an 8- to 10-fold increase in specific activity of the microsomal stearoyl coenzyme A desaturase. Cold-induced up-regulation of gene transcription resulted in a 10-fold increase in desaturase transcript amounts after 48 to 60 hours. However, this increase was preceded by the activation of latent desaturase, probably by a posttranslational mechanism. These two mechanisms may act sequentially to match desaturase expression to the demands imposed by a progressive decrease in temperature.	UNIV LIVERPOOL,DEPT ENVIRONM & EVOLUTIONARY BIOL,ENVIRONM PHYSIOL RES GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV MANCHESTER,INST SCI & TECHNOL,DEPT BIOCHEM & APPL MOLEC BIOL,MANCHESTER M60 1QD,LANCS,ENGLAND	University of Liverpool; University of Manchester			Gracey, Andrew Y/A-3060-2008; Beynon, Robert J/K-1408-2014	Beynon, Robert J/0000-0003-0857-495X; Cossins, Andrew/0000-0002-0813-5212				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSSINS AR, 1982, BIOCHIM BIOPHYS ACTA, V687, P303, DOI 10.1016/0005-2736(82)90559-4; Cossins AR, 1994, TEMPERATURE ADAPTATI; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; HAZEL JR, 1995, ANNU REV PHYSIOL, V57, P19, DOI 10.1146/annurev.ph.57.030195.000315; LEIFKOWITH JB, 1990, BIOCHIM BIOPHYS ACTA, V1044, P13; Liu Z J, 1990, DNA Seq, V1, P125, DOI 10.3109/10425179009016040; Macartney A., 1994, TEMPERATURE ADAPTATI, P129; MACARTNEY AI, UNPUB; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SCHUNKE M, 1983, BIOCHIM BIOPHYS ACTA, V734, P70, DOI 10.1016/0005-2736(83)90076-7; STRITTMATTER P, 1988, J BIOL CHEM, V263, P2532; TAKAMURA H, 1986, LIPIDS, V21, P356, DOI 10.1007/BF02535701; WODTKE E, 1991, BIOCHIM BIOPHYS ACTA, V1064, P343, DOI 10.1016/0005-2736(91)90321-X	15	228	244	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					815	818		10.1126/science.271.5250.815	http://dx.doi.org/10.1126/science.271.5250.815			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8629000				2022-12-28	WOS:A1996TU69400049
J	Waytes, AT; Rosen, FS; Frank, MM				Waytes, AT; Rosen, FS; Frank, MM			Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANGIONEUROTIC-EDEMA; ESTERASE INHIBITOR; ACID THERAPY; C1-INHIBITOR; MANAGEMENT	Background. Hereditary angioedema results from a congenital deficiency of functional C1 inhibitor and is characterized by episodic bouts of edema, which may be life-threatening when they involve the larynx. We evaluated the effectiveness of a C1 inhibitor concentrate in the prevention and treatment of attacks of hereditary angioedema. The concentrate was vapor-heated to inactivate hepatitis and hunan immunodeficiency viruses. Methods. We conducted two double-blind, placebo-controlled studies. The first was a crossover study consisting of two 17-day trials in which prophylactic infusions of either C1 inhibitor (25 plasma units per kilogram of body weight) or placebo were given intravenously every third day to six patients with hereditary angioedema. The second study was conducted in patients with acute attacks of hereditary angioedema and assessed the length of time to a clinical response after infusions of either 25 plasma units of C1 inhibitor per kilogram (55 infusions in 11 patients). Results. The infusions of C1 inhibitor concentrate resulted in close to normal functional levels of C1 inhibitor and C4. As compared with placebo, prophylactic infusions of C1 inhibitor resulted in significantly lower daily symptom scores for the severity of edema of the extremities (P < 0.01), larynx (P < 0.05), abdomen (P < 0.05), and genitourinary tract (P < 0.05). Likewise, during the treatment study the time from the start of an infusion to the beginning of improvement in symptoms was shorter for the C1 inhibitor infusions than the placebo infusions (55 vs. 563 minutes, P < 0.001). There was no evidence of toxicity. Conclusions. Infusions of a vapor-heated C1 inhibitor concentrate are safe and effective means of both preventing attacks of hereditary angioedema and treating acute attacks. (C) 1996, Massachusetts Medical Society.	CHILDRENS HOSP,CTR BLOOD RES,DIV IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; NIAID,CLIN INVEST LAB,NIH,BETHESDA,MD 20892	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NCRR NIH HHS [GCRC RR-02172] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGOSTONI A, 1980, ANN ALLERGY, V44, P299; AGOSTONI A, 1989, COMPLEMENT INFLAMMAT, V6, P112, DOI 10.1159/000463083; Agresti A., 1990, CATEGORICAL DATA ANA, pXV; AUSTEN KF, 1965, NEW ENGL J MED, V272, P649, DOI 10.1056/NEJM196504012721301; BRACKERTZ D, 1973, KLIN WOCHENSCHR, V51, P620, DOI 10.1007/BF01468576; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1966, PEDIATRICS, V37, P1017; DONALDSON VH, 1964, J CLIN INVEST, V43, P2204, DOI 10.1172/JCI105094; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; GAITHER TA, 1974, J IMMUNOL, V113, P574; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; JAFFE CJ, 1975, J ALLERGY CLIN IMMUN, V55, P386, DOI 10.1016/0091-6749(75)90077-9; KLEINDEL M, 1983, THROMB HAEMOSTASIS, V50, P244; LANDERMAN NS, 1962, J ALLERGY, V33, P316, DOI 10.1016/0021-8707(62)90031-X; MANNUCCI PM, 1992, TRANSFUSION, V32, P134, DOI 10.1046/j.1537-2995.1992.32292180141.x; Osler W, 1888, AM J MED SCI, V95, P362; Quincke H, 1882, MONATSH PRAKT DERMAT, V1, P129; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; SHEFFER AL, 1987, J ALLERGY CLIN IMMUN, V80, P855, DOI 10.1016/S0091-6749(87)80277-4; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; SHEFFER AL, 1988, J ALLERGY CLIN IMMUN, V81, P1208; SHIRLEY EAC, 1987, J R STAT SOC C-APPL, V36, P205, DOI 10.2307/2347552; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	27	259	266	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1996	334	25					1630	1634		10.1056/NEJM199606203342503	http://dx.doi.org/10.1056/NEJM199606203342503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ706	8628358	Bronze			2022-12-28	WOS:A1996UQ70600003
J	Baylies, MK; Bate, M				Baylies, MK; Bate, M			twist: A myogenic switch in Drosophila	SCIENCE			English	Article							GENE FAMILY; DORSOVENTRAL PATTERN; ZYGOTIC GENE; MYOD FAMILY; EXPRESSION; MEMBER; SPECIFICATION; MESODERM; CELLS; INACTIVATION	Somatic muscle is derived from a subset of embryonic mesoderm. In Drosophila, Twist (Twi), a basic helix-loop-helix transcription factor, is a candidate regulator of mesodermal differentiation and myogenesis. Altering amounts of Twist after gastrulation revealed that high levels of Twist are required for somatic myogenesis and block the formation of other mesodermal derivatives. Expression of twist in the ectoderm drives these cells into myogenesis. Thus, after an initial role in gastrulation, twist regulates mesodermal differentiation and propels a specific subset of mesodermal cells into somatic myogenesis. Vertebrate homologs of twist may also participate in the subdivision of mesoderm.			Baylies, MK (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.							AZPLAZU N, 1993, GENE DEV, V7, P1325; BATE M, 1991, DEVELOPMENT, V113, P79; BATE M, 1993, CR ACAD SCI III-VIE, V316, P1055; BATE M, IN PRESS SEM DEV BIO; BATE M, UNPUB; Bate Michael, 1993, P1013; BAYLIES MK, 1995, DEVELOPMENT, V121, P3829; BAYLIES MK, 1992, NEURON, V9, P575, DOI 10.1016/0896-6273(92)90194-I; BAYLIES MK, UNPUB; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870, DOI 10.1073/pnas.92.13.5870; BODMER R, 1993, DEVELOPMENT, V118, P719; Borkowski OMD, 1995, DEVELOPMENT, V121, P4183; BRAND A, 1994, PRACTICAL USES CELL, P643; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUCKINGHAM M, 1994, CELL, V78, P15, DOI 10.1016/0092-8674(94)90568-1; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; IP YT, 1994, EMBO J, V13, P5826, DOI 10.1002/j.1460-2075.1994.tb06926.x; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; KLERMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; MICHELSON AM, 1994, DEVELOPMENT, V120, P755; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROHWEDEL J, 1995, EXP CELL RES, V220, P92, DOI 10.1006/excr.1995.1295; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SIMPSON P, 1983, GENETICS, V105, P615; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	52	272	279	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1481	1484		10.1126/science.272.5267.1481	http://dx.doi.org/10.1126/science.272.5267.1481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633240				2022-12-28	WOS:A1996UP89900047
J	Zuckerman, JD				Zuckerman, JD			Current concepts - Hip fracture	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FEMORAL-NECK FRACTURES; PROSPECTIVE PAYMENT SYSTEM; ELDERLY PATIENTS; OSTEOPOROTIC FRACTURES; FUNCTIONAL RECOVERY; MORTALITY; RISK; THROMBOEMBOLISM; PROPHYLAXIS; ANESTHESIA				Zuckerman, JD (corresponding author), HOSP JOINT DIS & MED CTR, DEPT ORTHOPAED SURG, 301 E 17TH ST, NEW YORK, NY 10003 USA.							ALFFRAM PER-AXEL, 1964, ACTA ORTHOPAED SCAND SUPPL, V65, P1; ALHO A, 1984, ANN CHIR GYNAECOL FE, V73, P225; Baker S P, 1985, Clin Geriatr Med, V1, P501; BARNES B, 1984, PHYS THER, V64, P317, DOI 10.1093/ptj/64.3.317; BARNES R, 1976, J BONE JOINT SURG BR, V58, P2, DOI 10.1302/0301-620X.58B1.1270491; BERGQVIST D, 1979, ACTA CHIR SCAND, V145, P213; BONAR SK, 1990, J AM GERIATR SOC, V38, P1139, DOI 10.1111/j.1532-5415.1990.tb01378.x; BROOS PLO, 1988, INT SURG, V73, P148; CEDER L, 1980, CLIN ORTHOP RELAT R, P173; CRAXFORD AD, 1979, INJURY, V11, P19, DOI 10.1016/S0020-1383(79)80118-7; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1990, CLIN ORTHOP RELAT R, P163; DAHL E, 1980, ACTA ORTHOP SCAND, V51, P163, DOI 10.3109/17453678008990781; DAVIS FM, 1987, BRIT J ANAESTH, V59, P1080, DOI 10.1093/bja/59.9.1080; ELMERSON S, 1988, GERONTOLOGY, V34, P186, DOI 10.1159/000212951; EVENTOV I, 1983, J TRAUMA, V23, P98, DOI 10.1097/00005373-198302000-00004; FARMER ME, 1989, J AM GERIATR SOC, V37, P9, DOI 10.1111/j.1532-5415.1989.tb01562.x; Feldman D S, 1993, J Orthop Trauma, V7, P1, DOI 10.1097/00005131-199302000-00001; FINSEN V, 1986, ACTA ORTHOP SCAND, V57, P431, DOI 10.3109/17453678609014764; FITZGERALD J F, 1987, Journal of the American Medical Association, V258, P218, DOI 10.1001/jama.258.2.218; FITZGERALD JF, 1988, NEW ENGL J MED, V319, P1392, DOI 10.1056/NEJM198811243192106; GALLAGHER JC, 1980, CLIN ORTHOP RELAT R, P163; GATES B, 1986, INJURY, V17, P383, DOI 10.1016/0020-1383(86)90076-8; GERHART TN, 1991, J BONE JOINT SURG AM, V73A, P494, DOI 10.2106/00004623-199173040-00003; GRUNDY M, 1970, Journal of Bone and Joint Surgery British Volume, V52, P252; HAYES WC, 1993, CALCIFIED TISSUE INT, V52, P192, DOI 10.1007/BF00298717; HEDLUND R, 1987, J ORTHOPAED RES, V5, P242, DOI 10.1002/jor.1100050210; HEDSTROM SA, 1987, ACTA ORTHOP SCAND, V58, P361, DOI 10.3109/17453678709146355; HERNANDEZAVILA M, 1991, AM J CLIN NUTR, V54, P157, DOI 10.1093/ajcn/54.1.157; HOLMBERG S, 1986, ACTA ORTHOP SCAND, V57, P8, DOI 10.3109/17453678608993205; IONS GK, 1987, J BONE JOINT SURG BR, V69, P384, DOI 10.1302/0301-620X.69B3.3584189; JENSEN JS, 1979, ACTA ORTHOP SCAND, V50, P161, DOI 10.3109/17453677908989751; JETTE AM, 1987, ARCH PHYS MED REHAB, V68, P735; KENZORA JE, 1984, CLIN ORTHOP RELAT R, P45; Koval, 1994, J Am Acad Orthop Surg, V2, P141; KOVAL KJ, 1995, CLIN ORTHOP RELAT R, P150; KOVAL KJ, 1994, J BONE JOINT SURG AM, V76A, P751, DOI 10.2106/00004623-199405000-00018; KYLE RF, 1979, J BONE JOINT SURG AM, V61, P216, DOI 10.2106/00004623-197961020-00009; MAGAZINER J, 1990, J GERONTOL, V45, pM101, DOI 10.1093/geronj/45.3.M101; MAGAZINER J, 1989, AM J PUBLIC HEALTH, V79, P274, DOI 10.2105/AJPH.79.3.274; MYRVOLD HE, 1973, ACTA CHIR SCAND, V139, P609; NEVITT MC, 1993, J AM GERIATR SOC, V41, P1226, DOI 10.1111/j.1532-5415.1993.tb07307.x; NIEMANN KMW, 1968, J BONE JOINT SURG AM, VA 50, P1327, DOI 10.2106/00004623-196850070-00003; OGILVIEHARRIS DJ, 1993, J ORTHOP TRAUMA, V7, P428, DOI 10.1097/00005131-199310000-00005; Paganini-Hill A, 1991, Epidemiology, V2, P16; PRYOR GA, 1988, LANCET, V1, P401; RAO JP, 1983, CLIN ORTHOP RELAT R, P65; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RIIS J, 1983, ACTA ANAESTH SCAND, V27, P44, DOI 10.1111/j.1399-6576.1983.tb01903.x; RIZZO PF, 1993, J BONE JOINT SURG AM, V75A, P395, DOI 10.2106/00004623-199303000-00011; Sexson S B, 1987, J Orthop Trauma, V1, P298, DOI 10.1097/00005131-198701040-00005; STAPPAERTS KH, 1985, ARCH ORTHOP TRAUM SU, V104, P314, DOI 10.1007/BF00435949; STROMQVIST B, 1988, CLIN ORTHOP RELAT R, P75; TARHAN S, 1972, J AMER MED ASSOC, V220, P1451, DOI 10.1001/jama.220.11.1451; TENGVE B, 1978, J BONE JOINT SURG AM, V60, P97, DOI 10.2106/00004623-197860010-00014; VALENTIN N, 1986, BRIT J ANAESTH, V58, P284, DOI 10.1093/bja/58.3.284; WATHNE RA, 1995, J ORTHOP TRAUMA, V9, P298, DOI 10.1097/00005131-199509040-00005; WHITE BL, 1987, J BONE JOINT SURG AM, V69A, P1335; ZUCKERMAN JD, 1995, J BONE JOINT SURG AM, V77, P1551, DOI 10.2106/00004623-199510000-00010; ZUCKERMAN JD, 1992, CLIN ORTHOP RELAT R, P213; ZUCKERMAN JD, 1990, COMPREHENSIVE CARE O, V23, P112	62	502	535	1	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1519	1525		10.1056/NEJM199606063342307	http://dx.doi.org/10.1056/NEJM199606063342307			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618608				2022-12-28	WOS:A1996UN79900007
J	Engholm, G; Palmgren, F; Lynge, E				Engholm, G; Palmgren, F; Lynge, E			Lung cancer, smoking, and environment: A cohort study of the Danish population	BRITISH MEDICAL JOURNAL			English	Article							AIR-POLLUTION	Objective-The almost twofold difference in lung cancer incidence between people living in Copenhagen and in the rural areas of Denmark in the 1980s led to public concern; this study was undertaken to assess the effects of air pollution and occupation on lung cancer in Denmark, with control for smoking habits. Design-Cohort study of national population. Subjects-People aged 30-64 and economically active in 1970 (927 470 men and 486 130 women). Main outcome measures-Relative risks for lung cancer estimated with multiplicative Poisson modelling of incidence rates. Results-Differences in smoking habit explained about 60% of the excess lung cancer risk in Copenhagen for men and 90% for women. After control for smoking, workers had double the lung cancer risk of teachers and academics. There was only a small independent effect of region. Conclusion-Smoking is the main factor behind the regional differences in lung cancer incidence in Denmark, and occupational risk factors also seem to have an important role. The outdoor air in Copenhagen around 1970 contained on average 50-80 mu g/m(3) of sulphur dioxide, 80-100 mu g/m(3) total suspended particulate matter, and up to 10 ng/m(3) benzo(a)pyrene and had peak values of daily smoke of 120 mu g/m(3). Region had only a small effect on incidence of lung cancer in the present study, which suggests that an influence of outdoor air pollution on lung cancer is identifiable only above this pollution level.	NATL ENVIRONM RES INST,DK-4000 ROSKILDE,DENMARK	Aarhus University	Engholm, G (corresponding author), DANISH CANC SOC,DIV CANC EPIDEMIOL,BOX 839,DK-2100 COPENHAGEN O,DENMARK.			Lynge, Elsebeth/0000-0003-4785-5236				CARSTENSEN JM, 1988, INT J EPIDEMIOL, V17, P753, DOI 10.1093/ije/17.4.753; *DANM STAT, 1975, 1970 POP HOUS CENS, P72; FRIIS S, 1993, EUR J CANCER, V29A, P538, DOI 10.1016/S0959-8049(05)80147-9; HEMMINKI K, 1994, ENVIRON HEALTH PERSP, V102, P187, DOI 10.2307/3431951; *INT AG RES CANC, 1985, MON EV CARC RISK CHE, V38, P203; JEDRYCHOWSKI W, 1990, J EPIDEMIOL COMMUN H, V44, P114, DOI 10.1136/jech.44.2.114; JENSEN FP, 1994, ENVIRON HEALTH PERSP, V102, P55, DOI 10.2307/3431931; KATSOUYANNI K, 1991, PREV MED, V20, P271, DOI 10.1016/0091-7435(91)90026-Z; LYNGE E, 1990, Scandinavian Journal of Work Environment and Health, V16, P1; LYNGE E, 1979, 37 DENM STAT, P27; LYNGE E, IN PRESS SOCIOECONOM; NIELSEN P E, 1988, Ugeskrift for Laeger, V150, P2229; Nielsen T., 1995, TRAFFIC PAH OTHER MU; NOY D, 1990, ATMOS ENVIRON A-GEN, V24, P2903, DOI 10.1016/0960-1686(90)90470-8; PERSHAGEN G, 1994, NEW ENGL J MED, V330, P159, DOI 10.1056/NEJM199401203300302; Speizer FE, 1994, EPIDEMIOLOGY LUNG CA, P131; *STAT I STRAL, 1987, NAT RAD DAN DWELL, P94; VANLOON AJM, 1995, J EPIDEMIOL COMMUN H, V49, P65, DOI 10.1136/jech.49.1.65; XU ZY, 1989, J NATL CANCER I, V81, P1800, DOI 10.1093/jnci/81.23.1800	19	32	33	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1259	1263		10.1136/bmj.312.7041.1259	http://dx.doi.org/10.1136/bmj.312.7041.1259			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634614	Green Published			2022-12-28	WOS:A1996UM40400019
J	Dawson, C; Whitfield, H				Dawson, C; Whitfield, H			ABC of urology - Urinary stone disease	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON,ENGLAND; INST UROL & NEPHROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	Dawson, C (corresponding author), EDITH CAVELL HOSP,PETERBOROUGH,ENGLAND.							DRACH GW, URINARY LITHIASIS ET; PREMINGER GM, 1992, SEMIN NEPHROL, V12, P200; WALSH PC, 1992, CAMPBELLS UROLOGY	3	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1219	1221						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634570				2022-12-28	WOS:A1996UL05800027
J	Williams, J; Spurlock, G; McGuffin, P; Mallet, J; Nothen, MM; Gill, M; Aschauer, H; Nylander, PO; Macciardi, F; Owen, MJ				Williams, J; Spurlock, G; McGuffin, P; Mallet, J; Nothen, MM; Gill, M; Aschauer, H; Nylander, PO; Macciardi, F; Owen, MJ			Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene	LANCET			English	Article							LINKAGE	Background An association between schizophrenia and the T102C polymorphism of the gene for 5-hydroxytryptamine type 2a (5-HT2a) receptor has been reported; the proportion of allele 2 of this polymorphism is higher than expected among schizophrenic patients. We looked for an association between schizophrenia and this variant of the 5-HT2a-receptor gene in a large multicentre study. Methods Seven countries recruited 1210 participants: 571 white schizophrenic patients and 639 ethnically matched controls. All patients had a diagnosis of schizophrenia or schizoaffective disorder. High-molecular-weight DNA was isolated from lymphocytes. PCR amplification and restriction enzyme digestion was used to examine sequence variation of the 5-HT2a-receptor gene. Genotypes 1/1, 1/2, and 2/2 were assigned. Woolf's method was used to look for an association between schizophrenia and allele 2 and the 2/2 genotype. Findings We found a significant overall association between schizophrenia and allele 2 with an odds ratio of 1.3 (95% CI 1.1-1.53, p=0.003). No evidence for heterogeneity was observed between samples. We found a highly significant excess of the 1-2/2-2 genotypes in schizophrenia (p=0.008) with a relative risk of 1.7 (1.22-2.36) and an attributable fraction of 0.35. Interpretation Our findings suggest that the gene for 5-HT2a-receptor, or a locus in linkage disequilibrium with it, confers susceptibility to schizophrenia. Allele 2 is common in the population and it is, therefore, likely that this variant, or a nearby polymorphism, may affect a significant proportion of schizophrenic patients.	UNIV WALES COLL MED,DEPT MED GENET,CARDIFF CF4 4XN,S GLAM,WALES; HOP LA PITIE SALPETRIERE,PARIS,FRANCE; UNIV BONN,INST HUMAN GENET,BONN,GERMANY; ST JAMES HOSP,DEPT PSYCHIAT,TRINITY CTR HLTH SCI,DUBLIN 8,IRELAND; UNIV HOSP PSYCHIAT,DEPT GEN PSYCHIAT,VIENNA,AUSTRIA; UMEA UNIV,DEPT PSYCHIAT,UMEA,SWEDEN; UNIV MILAN,SCH MED,IST SCI H SAN RAFFAELE,DEPT NEUROSCI,MILAN,ITALY	Cardiff University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Bonn; Trinity College Dublin; Umea University; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Williams, J (corresponding author), UNIV WALES COLL MED,DEPT PSYCHOL MED,CARDIFF CF4 4XN,S GLAM,WALES.		Aschauer, Harald/G-8850-2016; McGuffin, Peter/A-1565-2012; Macciardi, Fabio/N-3768-2014; Nöthen, Markus/B-2027-2009	Aschauer, Harald/0000-0002-4449-372X; McGuffin, Peter/0000-0002-9888-2907; Macciardi, Fabio/0000-0003-0537-4266; Nöthen, Markus/0000-0002-8770-2464; Gill, Michael/0000-0003-0206-5337; Williams, Julie/0000-0002-4069-0259				ARRANZ M, 1995, LANCET, V346, P281, DOI 10.1016/S0140-6736(95)92168-0; BURNET PWJ, 1995, LANCET, V346, P909; Erdmann J, 1996, HUM GENET, V97, P614, DOI 10.1007/s004390050104; Gaddum John H., 1954, CIBA F S HYPERTENSIO, P75; INAYAMA Y, 1994, NEUROPSYCHOPHARMACOL, V10, pS56; LEYSEN JE, 1994, J CLIN PSYCHIAT, V55, P5; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; MCGUFFIN P, 1995, LANCET, V346, P678, DOI 10.1016/S0140-6736(95)92285-7; NOTHEN MM, 1993, J MED GENET, V30, P634, DOI 10.1136/jmg.30.8.634; NOTHEN MM, 1995, LANCET, V346, P908, DOI 10.1016/S0140-6736(95)92756-5; OWEN MJ, 1993, J MED GENET, V30, P638, DOI 10.1136/jmg.30.8.638; PLOMIN R, 1990, SCIENCE, V248, P183, DOI 10.1126/science.2183351; SMITH CAD, 1994, EUR J CANCER, V30A, P1921, DOI 10.1016/0959-8049(94)00382-F; WARREN JT, 1993, HUM MOL GENET, V2, P338, DOI 10.1093/hmg/2.3.338; Williams J., 1995, NEW TRENDS EXP CLIN, V11, P7; WILLIAMS J, 1996, IN PRESS PSYCHOL MED; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	17	229	236	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1294	1296		10.1016/S0140-6736(96)90939-3	http://dx.doi.org/10.1016/S0140-6736(96)90939-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622505				2022-12-28	WOS:A1996UK75800010
J	Ast, G; Weiner, AM				Ast, G; Weiner, AM			A U1/U4/U5 snRNP complex induced by a 2'-O-methyl-oligoribonucleotide complementary to U5 snRNA	SCIENCE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; PRE-MESSENGER-RNA; 3' SPLICE SITE; PREMESSENGER RNA; U6 SNRNA; U2; PROTEIN; ASSOCIATION; RECOGNIZES; DEPLETION	Nuclear messenger RNA splicing involves multiple interactions between the five spliceosomal small nuclear ribonucleoprotein particles (snRNPs) U1, U2, U4, U5, and U6 and numerous spliceosomal proteins. Here it is shown that binding of a 2'-O-methyl-oligoribonucleotide complementary to U5 small nuclear RNA (snRNA) nucleotides 68 to 88 (BU5Ae) disrupts the initial U4/U5/U6 tri-snRNP complex, enhances the U2/U6 interaction, and induces a U1/U4/U5 snRNP complex. The U1/U4/U5 snRNP complex interacts specifically with an RNA oligonucleotide containing the 5' splice site sequence and may therefore represent a transitional stage in the displacement of U1 from the 5' splice site by U5 snRNP.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031073] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AST G, UNPUB; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CHABOT B, 1985, SCIENCE, V230, P1344, DOI 10.1126/science.2933810; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; KONFORTI BB, 1994, GENE DEV, V8, P1962, DOI 10.1101/gad.8.16.1962; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1991, NUCLEIC ACIDS RES, V19, P3857, DOI 10.1093/nar/19.14.3857; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WILL CL, 1993, MOL BIOL REP, V18, P121, DOI 10.1007/BF00986766; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542	34	17	17	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					881	884		10.1126/science.272.5263.881	http://dx.doi.org/10.1126/science.272.5263.881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629024				2022-12-28	WOS:A1996UK75700061
J	Naylor, CD; Guyatt, GH				Naylor, CD; Guyatt, GH			Users' guides to the medical literature .11. How to use an article about a clinical utilization review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; NEW-YORK-STATE; IMMEDIATE ANGIOPLASTY; CORONARY ANGIOPLASTY; APPROPRIATENESS; THERAPY; DISEASE; CARE; QUALITY		MCMASTER UNIV,HLTH SCI CTR,HAMILTON,ON L8N 3Z5,CANADA; UNIV TORONTO,INST CLIN EVALUAT SCI ONTARIO,CLIN EPIDEMIOL & HLTH CARE RES PROGRAM,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,DEPT SURG,TORONTO,ON,CANADA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; University of Toronto; University of Toronto								BASINSKI ASH, 1992, CAN MED ASSOC J, V146, P2153; BASINSKI ASH, 1992, CAN MED ASSOC J, V147, P163; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; BROOK RH, 1988, LANCET, V1, P750; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; FINK A, 1987, WESTERN J MED, V147, P609; Fraser G M, 1993, Qual Assur Health Care, V5, P75; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; HILBORNE LH, 1991, JRA01 RAND; KAHN KL, 1988, MED CARE, V26, P415, DOI 10.1097/00005650-198804000-00010; KAHN KL, 1988, J CLIN EPIDEMIOL, V41, P115, DOI 10.1016/0895-4356(88)90085-6; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; KRAVITZ RL, 1995, JAMA-J AM MED ASSOC, V274, P632, DOI 10.1001/jama.274.8.632; Leape L L, 1992, Qual Assur Health Care, V4, P151; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P554, DOI 10.1001/jama.275.7.554; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1292, DOI 10.1001/jama.273.16.1292; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; STRUMWASSER I, 1990, MED CARE, V28, P95, DOI 10.1097/00005650-199002000-00001; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1993, LANCET, V341, P573	34	63	68	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1435	1439		10.1001/jama.275.18.1435	http://dx.doi.org/10.1001/jama.275.18.1435			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618371				2022-12-28	WOS:A1996UJ30300031
J	Aoufouchi, S; Yelamos, J; Milstein, C				Aoufouchi, S; Yelamos, J; Milstein, C			Nonsense mutations inhibit RNA splicing in a cell-free system: Recognition of mutant codon is independent of protein synthesis	CELL			English	Article							MESSENGER-RNA; SITE SELECTION; GENE; MATURATION; EXON; TRANSLATION; STABILITY; SEQUENCES; PRODUCT; OCCURS	Mutations resulting in premature termination codons reduce the corresponding mRNA levels. We describe a cell-free system in which depletion of the mutant immunoglobulin kappa mRNA pool correlates with inefficient splicing and not with RNA decay. Splicing deficiency does not depend on the sequence surrounding the in-frame nonsense codon and can be partially corrected by mutating the methionine initiation codon. Despite the apparent link between translation and low mutant mRNA levels, inefficient splicing is not dependent on protein synthesis. Abnormal splicing of mutant immunoglobulin RNA is observed with B-cell but not with HeLa or T-cell extracts. A nonsense mutant beta-globin RNA is normally spliced by B-cell extract. We propose that the phenomenon exhibits tissue and gene specificity.			Aoufouchi, S (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Yelamos, Jose/N-2842-2016; Aoufouchi, Said/I-2985-2016; AOUFOUCHI, Said/P-9926-2019	AOUFOUCHI, Said/0000-0001-6547-2664; Yelamos, Jose/0000-0003-1195-1496				BARKER GF, 1991, MOL CELL BIOL, V11, P2760, DOI 10.1128/MCB.11.5.2760; BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; BELGRADER P, 1994, MOL CELL BIOL, V14, P6326, DOI 10.1128/MCB.14.9.6326; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; COOK GP, 1995, INT IMMUNOL, V7, P89, DOI 10.1093/intimm/7.1.89; DIETZ HC, 1994, NAT GENET, V8, P183, DOI 10.1038/ng1094-183; Goldfarb D, 1991, Trends Cell Biol, V1, P20, DOI 10.1016/0962-8924(91)90065-H; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; MAQUAT LE, 1995, RNA, V1, P453; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MURALIDHAR S, 1994, J VIROL, V68, P170, DOI 10.1128/JVI.68.1.170-176.1994; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; PEABODY DS, 1987, J BIOL CHEM, V262, P11847; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; QIAN L, 1993, J IMMUNOL, V151, P6801; QIAN LA, 1993, MOL CELL BIOL, V13, P1686, DOI 10.1128/MCB.13.3.1686; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RITTNER K, 1995, J MOL BIOL, V248, P562, DOI 10.1006/jmbi.1995.0243; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHARPE MJ, 1991, EMBO J, V10, P2139, DOI 10.1002/j.1460-2075.1991.tb07748.x; SIMPSON SB, 1994, MOL CELL BIOL, V14, P1835, DOI 10.1128/MCB.14.3.1835; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868	33	127	130	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					415	422		10.1016/S0092-8674(00)81119-8	http://dx.doi.org/10.1016/S0092-8674(00)81119-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616896	Bronze			2022-12-28	WOS:A1996UK14000014
J	Vyse, TJ; Todd, JA				Vyse, TJ; Todd, JA			Genetic analysis of autoimmune disease	CELL			English	Review							DIABETES-MELLITUS IDDM; INSULIN GENE; NOD MOUSE; SUSCEPTIBILITY; MICE; MAPS		UNIV OXFORD,NUFFIELD DEPT SURG,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND	University of Oxford; Wellcome Centre for Human Genetics	Vyse, TJ (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.		Todd, John A/A-3542-2010; Vyse, Tim J/G-3887-2011	Todd, John A/0000-0003-2740-8148; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER D, 1995, J IMMUNOL, V155, P4046; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BENNETT ST, 1996, IN PRESS J AUTOIMMUN; BLAKEMORE AIF, 1995, J CLIN ENDOCR METAB, V80, P111, DOI 10.1210/jc.80.1.111; BROWN MA, 1996, INFLAMMATORY ARHTR P; Charlton B, 1995, CURR OPIN IMMUNOL, V7, P793, DOI 10.1016/0952-7915(95)80050-6; CHESNUT K, 1993, MAMM GENOME, V4, P549, DOI 10.1007/BF00361383; COPEMAN JB, 1995, NAT GENET, V9, P80, DOI 10.1038/ng0195-80; CORDELL HJ, 1995, AM J HUM GENET, V57, P920; CUCCA F, 1996, IN PRESS HLA MHC GEN; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DEGOUYON B, 1993, P NATL ACAD SCI USA, V90, P1877, DOI 10.1073/pnas.90.5.1877; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DRAKE CG, 1994, P NATL ACAD SCI USA, V91, P4082; EBERS GC, 1995, NATURE, V377, P160; ELDER JT, 1994, ARCH DERMATOL, V130, P216, DOI 10.1001/archderm.130.2.216; FIELD LL, 1994, NAT GENET, V8, P189, DOI 10.1038/ng1094-189; FRANKEL WN, 1995, TRENDS GENET, V11, P471, DOI 10.1016/S0168-9525(00)89155-6; GARCHON HJ, 1994, EUR J IMMUNOL, V24, P380, DOI 10.1002/eji.1830240217; GHOSH S, 1993, NAT GENET, V4, P404, DOI 10.1038/ng0893-404; Ghosh S, 1996, DIABETES, V45, P1, DOI 10.2337/diabetes.45.1.1; GILL BM, 1995, DIABETES, V44, P614, DOI 10.2337/diabetes.44.6.614; GREGORY WL, 1994, J HEPATOL, V20, P689, DOI 10.1016/S0168-8278(05)80135-7; GUILLEMINAULT C, 1989, LANCET, V2, P1376; Guler ML, 1996, SCIENCE, V271, P984, DOI 10.1126/science.271.5251.984; GYAPAY G, 1994, NAT GENET, V7, P248; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HOCHBERG MC, 1987, J RHEUMATOL, V14, P867; IKEGAMI H, 1995, J CLIN INVEST, V96, P1936, DOI 10.1172/JCI118239; JORDE LB, 1995, AM J HUM GENET, V56, P11; KONO DH, 1994, P NATL ACAD SCI USA, V91, P10168, DOI 10.1073/pnas.91.21.10168; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LORD CJ, 1995, MAMM GENOME, V6, P563, DOI 10.1007/BF00352359; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; LUO DF, 1995, AM J HUM GENET, V57, P911; MCALEER MA, 1995, DIABETES, V44, P1186, DOI 10.2337/diabetes.44.10.1186; MEEKER ND, 1995, P NATL ACAD SCI USA, V92, P5684, DOI 10.1073/pnas.92.12.5684; MORAHAN G, 1994, P NATL ACAD SCI USA, V91, P5898, DOI 10.1073/pnas.91.13.5898; MOREL L, 1994, IMMUNITY, V1, P219, DOI 10.1016/1074-7613(94)90100-7; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; OWERBACH D, 1995, DIABETES, V44, P132, DOI 10.2337/diabetes.44.1.132; PATERSON AH, 1995, GENOME RES, V5, P321, DOI 10.1101/gr.5.4.321; PENHAGONCALVES C, 1995, GENOMICS, V28, P398, DOI 10.1006/geno.1995.1167; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; RISCH N, 1990, AM J HUM GENET, V46, P222; RISCH N, 1993, AM J HUM GENET, V53, P702; RISCH N, 1987, AM J HUM GENET, V40, P1; RISCH N, 1991, AM J HUM GENET, V48, P1058; SATSANGI J, IN PRESS LANCET; SERREZE DV, 1994, J EXP MED, V180, P1553, DOI 10.1084/jem.180.4.1553; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; SUDWEEKS JD, 1993, P NATL ACAD SCI USA, V90, P3700, DOI 10.1073/pnas.90.8.3700; SUNDVALL M, 1995, NAT GENET, V10, P313, DOI 10.1038/ng0795-313; TEUSCHER C, 1996, J EXP MED, V183, P831; THEOFILOPOULOS AN, 1995, IMMUNOL TODAY, V16, P150, DOI 10.1016/0167-5699(95)80133-2; THOMSON G, 1995, CRIT REV CL LAB SCI, V32, P183, DOI 10.3109/10408369509084684; THORSBY E, 1995, IMMUNOLOGIST, V3, P51; TODD JA, 1995, P NATL ACAD SCI USA, V92, P8560, DOI 10.1073/pnas.92.19.8560; VIDAL S, 1995, J EXP MED, V182, P855; WARDELL BB, 1995, P NATL ACAD SCI USA, V92, P4758, DOI 10.1073/pnas.92.11.4758; WATSON ML, 1992, J EXP MED, V176, P1645, DOI 10.1084/jem.176.6.1645; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEEKS DE, 1995, TRENDS GENET, V11, P513, DOI 10.1016/S0168-9525(00)89163-5; WICKER LS, 1994, J EXP MED, V180, P1705, DOI 10.1084/jem.180.5.1705; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; WORDSWORTH P, 1995, BRIT MED BULL, V51, P249, DOI 10.1093/oxfordjournals.bmb.a072959	70	596	612	2	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					311	318		10.1016/S0092-8674(00)81110-1	http://dx.doi.org/10.1016/S0092-8674(00)81110-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616887	Bronze			2022-12-28	WOS:A1996UK14000005
J	Dawson, C; Whitfield, H				Dawson, C; Whitfield, H			Urological malignancy .2. Urothelial tumours	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON NW10 7NS,ENGLAND; INST UROL & NEPHROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	Dawson, C (corresponding author), EDITH CAVELL HOSP,PETERBOROUGH,ENGLAND.							CATALONA WJ, 1995, CAMPBELLS UROLOGY; GARDINER RA, 1995, AUST NZ J SURG, V65, P350, DOI 10.1111/j.1445-2197.1995.tb00654.x; HUDSON MA, 1995, J UROLOGY, V153, P564, DOI 10.1016/S0022-5347(01)67650-X; THRASHER JB, 1993, J UROLOGY, V149, P957, DOI 10.1016/S0022-5347(17)36270-5	4	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1090	1094						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616422				2022-12-28	WOS:A1996UH81600035
J	Hahnemann, JM; Vejerslev, LO				Hahnemann, JM; Vejerslev, LO			Prenatal and postnatal prevalence of Turner's syndrome - No reason to doubt standard of prenatal diagnosis	BRITISH MEDICAL JOURNAL			English	Letter											Hahnemann, JM (corresponding author), JOHN F KENNEDY INST,DEPT MED GENET,EUROPEAN COLLABORAT RES MOSAICISM CVS,DK-2600 GLOSTRUP,DENMARK.							Gravholt CH, 1996, BMJ-BRIT MED J, V312, P16, DOI 10.1136/bmj.312.7022.16	1	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1100	1100						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616438				2022-12-28	WOS:A1996UH81600059
J	Bobola, N; Jansen, RP; Shin, TH; Nasmyth, K				Bobola, N; Jansen, RP; Shin, TH; Nasmyth, K			Asymmetric accumulation of ASH1p in postanaphase nuclei depends on a myosin and restricts yeast mating-type switching to mother cells	CELL			English	Article							HO GENE; SACCHAROMYCES-CEREVISIAE; CYCLE REGULATION; PROTEIN-KINASE; TRANSCRIPTION; EXPRESSION; FINGER; SW15; REPRESSION; ACTIVATION	Cell division in haploid yeast gives rise to a ''mother'' cell capable of mating-type switching and a ''daughter'' cell that is not. Switching is initiated by the HO endonuclease, whose gene is only transcribed in cells that have previously given birth to a bud (mother cells). HO expression depends on a minimyosin, She1p/Myo4p, which accumulates preferentially in growing buds. We describe a gene, ASH1, that is necessary to repress HO in daughters. ASH1 encodes a zinc finger protein whose preferential accumulation in daughter cell nuclei at the end of anaphase depends on She1p/Myo4p. The greater abundance of Ash1p in daughter cells is responsible for restricting HO expression to mother cells.			Bobola, N (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; HAARER BK, 1994, J CELL SCI, V107, P1055; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOCH C, 1993, SCIENCE, V261, P1550; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517	38	285	287	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					699	709		10.1016/S0092-8674(00)81048-X	http://dx.doi.org/10.1016/S0092-8674(00)81048-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625408	Bronze			2022-12-28	WOS:A1996TZ99000008
J	Frenette, PS; Wagner, DD				Frenette, PS; Wagner, DD			Adhesion molecules .2. Blood vessels and blood cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School			Frenette, Paul S/J-8272-2012	Frenette, Paul S/0000-0003-0862-9922				Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; COLLER BS, 1995, THROMB HAEMOSTASIS, V74, P302; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143	5	253	259	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					43	45		10.1056/NEJM199607043350108	http://dx.doi.org/10.1056/NEJM199607043350108			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637541				2022-12-28	WOS:A1996UU47900008
J	Goodfriend, TL; Elliott, ME; Catt, KJ				Goodfriend, TL; Elliott, ME; Catt, KJ			Drug therapy - Angiotensin receptors and their antagonists	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SMOOTH-MUSCLE CELLS; II RECEPTOR; GLOMERULOSA CELLS; NORMAL VOLUNTEERS; HEALTHY-SUBJECTS; CALCIUM SIGNAL; HYPERTROPHY; INHIBITION; RESPONSES; HYPERPLASIA		UNIV WISCONSIN, SCH MED, DEPT MED, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, DEPT PHARMACOL, MADISON, WI 53706 USA; NICHHD, ENDOCRINOL & REPROD RES BRANCH, BETHESDA, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Goodfriend, TL (corresponding author), WILLIAM S MIDDLETON MEM VET ADM MED CTR, 2500 OVERLOOK TERRACE, MADISON, WI 53705 USA.							AGUILERA G, 1989, AM J HYPERTENS, V2, P395, DOI 10.1093/ajh/2.5.395; AGUILERA G, 1994, KIDNEY INT, V46, P973, DOI 10.1038/ki.1994.356; BALLA T, 1991, MOL PHARMACOL, V40, P401; BERK BC, 1993, J CELL PHYSIOL, V154, P368, DOI 10.1002/jcp.1041540221; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BOHR DF, 1974, HDB EXPT PHARMACOLOG, V37, P424; BONNARDEAUX A, 1994, HYPERTENSION, V24, P63, DOI 10.1161/01.HYP.24.1.63; BROWN CEL, 1990, AM J OBSTET GYNECOL, V163, P1853, DOI 10.1016/0002-9378(90)90764-X; BRUNNER HR, 1994, J HYPERTENS, V12, pS29; BURNIER M, 1993, HYPERTENSION, V22, P339, DOI 10.1161/01.HYP.22.3.339; CARINI DJ, 1991, J MED CHEM, V34, P2525, DOI 10.1021/jm00112a031; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; CHEN LH, 1995, HYPERTENSION, V26, P83, DOI 10.1161/01.HYP.26.1.83; CRANDALL DL, 1994, J LIPID RES, V35, P1378; CROZIER I, 1995, CIRCULATION, V91, P691, DOI 10.1161/01.CIR.91.3.691; DEGASPARO M, 1995, HYPERTENSION, V25, P924, DOI 10.1161/01.HYP.25.5.924; DZAU VJ, 1991, HYPERTENSION, V18, P100, DOI 10.1161/01.HYP.18.4_Suppl.II100; FOUAD FM, 1980, CIRCULATION, V61, P163, DOI 10.1161/01.CIR.61.1.163; FOUCART S, 1991, CAN J PHYSIOL PHARM, V69, P1, DOI 10.1139/y91-001; GANSEVOORT RT, 1994, KIDNEY INT, V45, P861, DOI 10.1038/ki.1994.113; GAVRAS I, 1993, RENIN ANGIOTENSIN SY, V1; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GOLDBERG MR, 1995, HYPERTENSION, V25, P37, DOI 10.1161/01.HYP.25.1.37; GOODFRIEND T, 1971, CLIN PHARMACOL THER, V12, P292; GOODFRIEND TL, 1991, ENDOCRINOLOGY, V128, P2511, DOI 10.1210/endo-128-5-2511; GORBEAOPPLIGER VJ, 1994, J PHARMACOL EXP THER, V271, P804; GRADMAN AH, 1995, HYPERTENSION, V25, P1345, DOI 10.1161/01.HYP.25.6.1345; GRIFFIN SA, 1991, HYPERTENSION, V17, P626, DOI 10.1161/01.HYP.17.5.626; HALL JE, 1983, AM J PHYSIOL, V245, pR166, DOI 10.1152/ajpregu.1983.245.2.R166; HANSSENS M, 1991, OBSTET GYNECOL, V78, P128; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; JAISWAL N, 1993, J PHARMACOL EXP THER, V265, P664; JI H, 1994, J BIOL CHEM, V269, P16533; JOHNSTON CI, 1992, J HYPERTENS, V10, pS13; KABOUR A, 1994, J CARDIOVASC PHARM, V23, P547, DOI 10.1097/00005344-199404000-00005; KAI H, 1994, HYPERTENSION, V24, P523, DOI 10.1161/01.HYP.24.4.523; KALENGA MK, 1995, J CLIN ENDOCR METAB, V80, P1233, DOI 10.1210/jc.80.4.1233; KENT KM, 1972, CIRC RES, V30, P196, DOI 10.1161/01.RES.30.2.196; KOIKE G, 1994, BIOCHEM BIOPH RES CO, V203, P1842, DOI 10.1006/bbrc.1994.2402; KON V, 1993, KIDNEY INT, V44, P545, DOI 10.1038/ki.1993.279; KUNERTRADEK J, 1994, BIOCHEM BIOPH RES CO, V198, P1034, DOI 10.1006/bbrc.1994.1147; LACOURCIERE Y, 1994, J HYPERTENS, V12, P1387; LARAGH JH, 1960, JAMA-J AM MED ASSOC, V174, P234, DOI 10.1001/jama.1960.03030030014003; LIAO YB, 1995, CAN J CARDIOL, V11, pF13; LIN L, 1991, HYPERTENSION, V18, P158, DOI 10.1161/01.HYP.18.2.158; LIN SY, 1970, AM J PHYSIOL, V218, P1319, DOI 10.1152/ajplegacy.1970.218.5.1319; LINZ W, 1995, PHARMACOL REV, V47, P25; MCGIFF JC, 1970, CIRC RES, V27, pI121; MENARD J, 1991, HYPERTENSION, V18, P257, DOI 10.1161/01.HYP.18.3.257; MITCHELL KD, 1992, HYPERTENSION, V19, pI18, DOI 10.1161/01.HYP.19.1_Suppl.I18; MOHABIR R, 1994, J CARDIOVASC PHARM, V23, P291, DOI 10.1097/00005344-199402000-00017; MORAVEC CS, 1990, CIRCULATION, V82, P1973, DOI 10.1161/01.CIR.82.6.1973; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MUNAFO A, 1992, CLIN PHARMACOL THER, V51, P513, DOI 10.1038/clpt.1992.56; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAHMIAS C, 1995, TRENDS PHARMACOL SCI, V16, P223, DOI 10.1016/S0165-6147(00)89030-6; NAKASHIMA M, 1992, EUR J CLIN PHARMACOL, V42, P333; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; REID IA, 1992, AM J PHYSIOL, V262, pE763, DOI 10.1152/ajpendo.1992.262.6.E763; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHINKE M, 1991, EUR J PHARMACOL, V204, P165, DOI 10.1016/0014-2999(91)90701-Q; SEYEDI N, 1995, HYPERTENSION, V26, P164, DOI 10.1161/01.HYP.26.1.164; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; STERN N, 1993, ENDOCRINOLOGY, V133, P843, DOI 10.1210/en.133.2.843; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; STREETEN DHP, 1979, KIDNEY INT, V15, pS44; SWARTZ SL, 1990, THROMB HAEMOSTASIS, V63, P87; SZPIRER C, 1993, J HYPERTENS, V11, P919, DOI 10.1097/00004872-199309000-00005; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUDA T, 1993, J VASC RES, V30, P241, DOI 10.1159/000159002; TUFROMCREDDIE A, 1994, AM J PHYSIOL, V266, pF911, DOI 10.1152/ajprenal.1994.266.6.F911; VANDEKERCKHOVE A, 1989, J ENDOCRINOL, V123, P131, DOI 10.1677/joe.0.1230131; VINSON GP, 1995, J ENDOCRINOL, V144, P369, DOI 10.1677/joe.0.1440369; WALSH DA, 1994, BRIT J PHARMACOL, V112, P435, DOI 10.1111/j.1476-5381.1994.tb13091.x; WEBER KT, 1995, CARDIOL REV, V3, P53; WEBER MA, 1995, ARCH INTERN MED, V155, P405, DOI 10.1001/archinte.155.4.405; WEBER MA, 1995, ARCH INTERN MED, V155, P876; WILLIAMS GH, 1994, ENDOCRIN METAB CLIN, V23, P429, DOI 10.1016/S0889-8529(18)30106-3; WRIGHT JW, 1995, FRONT NEUROENDOCRIN, V16, P23, DOI 10.1006/frne.1995.1002	82	466	502	2	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1996	334	25					1649	1654		10.1056/NEJM199606203342507	http://dx.doi.org/10.1056/NEJM199606203342507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ706	8628362				2022-12-28	WOS:A1996UQ70600007
J	Erkman, L; McEvilly, RJ; Luo, L; Ryan, AK; Hooshmand, F; OConnell, SM; Keithley, EM; Rapaport, DH; Ryan, AF; Rosenfeld, MG				Erkman, L; McEvilly, RJ; Luo, L; Ryan, AK; Hooshmand, F; OConnell, SM; Keithley, EM; Rapaport, DH; Ryan, AF; Rosenfeld, MG			Role of transcription factors Brn-3.1 and Brn-3.2 in auditory and visual system development	NATURE			English	Article							CELL LINEAGE; CAT RETINA; C-ELEGANS; GENE; MOUSE; DIFFERENTIATION; HOMEODOMAIN; EXPRESSION; DISTINCT; IDENTITY	THE neurally expressed genes Brn-3.1 and Brn-3.2 (refs 1-6) are mammalian orthologues of the Caenorhabditis elegans unc-86 gene(7) that constitute, with Brn-3.0 (refs 1-3,8,9), the class IV POU-domain transcription factors(10), Brn-3.1 and Brn-3.2 provide a means of exploring the potentially distinct biological functions of expanded gene families in neural development, The highly related members of the Brn-3 family have similar DNA-binding preferences(1,2) and overlapping expression patterns in the sensory nervous system, midbrain and hindbrain(1-6,8,9), suggesting functional redundancy, Here we report that Brn-3.1 and Brn-3.2 critically modulate the terminal differentiation of distinct sensorineural cells in which they exhibit selective spatial and temporal expression patterns, Deletion of the Brn-3.2 gene causes the loss of most retinal ganglion cells, defining distinct ganglion cell populations, Mutation of Brn-3.1 results in complete deafness, owing to a failure of hair cells to appear in the inner ear, with subsequent loss of cochlear and vestibular ganglia.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT SURG, DIV ANAT, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, VET ADM MED CTR, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT SURG OTOLARYNGOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University of California System; University of California San Diego					Veterans Affairs [I01BX001205] Funding Source: NIH RePORTER; BLRD VA [I01 BX001205] Funding Source: Medline	Veterans Affairs(US Department of Veterans Affairs); BLRD VA		COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; CRENSHAW EB, 1991, J NEUROSCI, V11, P1524; DRAGER UC, 1981, INVEST OPHTH VIS SCI, V20, P285; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1995, NEURON, V14, P1153, DOI 10.1016/0896-6273(95)90263-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; KELLEY MW, 1993, DEVELOPMENT, V119, P1041; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; LUO L, 1993, HEARING RES, V69, P182; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; RAPAPORT DH, 1991, J COMP NEUROL, V312, P341, DOI 10.1002/cne.903120303; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; Sidman R.L., 1961, STRUCTURE EYE; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Stone J., 1981, WHOLEMOUNT HDB; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; WASSLE H, 1987, J COMP NEUROL, V265, P391, DOI 10.1002/cne.902650308; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WONG ROL, 1987, J COMP NEUROL, V255, P159, DOI 10.1002/cne.902550202; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIA YR, 1993, GENOMICS, V18, P126, DOI 10.1006/geno.1993.1435; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; XIANG MQ, 1995, J NEUROSCI, V15, P4762; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	30	419	435	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					603	606		10.1038/381603a0	http://dx.doi.org/10.1038/381603a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637595				2022-12-28	WOS:A1996UQ65700050
J	Frydman, J; Hartl, FU				Frydman, J; Hartl, FU			Principles of chaperone-assisted protein folding: Differences between in vitro and in vivo mechanisms	SCIENCE			English	Article							T-COMPLEX POLYPEPTIDE-1; MOLECULAR CHAPERONES; MESSENGER-RNA; IN-VIVO; ACTIN; DEGRADATION	Molecular chaperones in the eukaryotic cytosol were shown to interact differently with chemically denatured proteins and their newly translated counterparts. During refolding from denaturant, actin partitioned freely between 70-kilodalton heat shock protein, the bulk cytosol, and the chaperonin TCP1-ring complex. In contrast, during cell-free translation, the chaperones were recruited to the elongating polypeptide and protected it from exposure to the bulk cytosol during folding. Posttranslational cycling between chaperone-bound and free states was observed with subunits of oligomeric proteins and with aberrant polypeptides; this cycling allowed the subunits to assemble and the aberrant polypeptides to be degraded. Thus, folding, oligomerization, and degradation are linked hierarchically to ensure the correct fate of newly synthesized polypeptides.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019	, judith/0000-0003-2302-6943				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS J, 1994, CURR OPIN STRUC BIOL, V4, P117; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; Freedman Robert B., 1992, P455; FREEMAN BC, 1996, EMBO J, V12, P2969; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; SOLOMON JM, 1991, NEW BIOL, V3, P1106; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; URSIC D, 1994, MOL BIOL CELL, V5, P1065, DOI 10.1091/mbc.5.10.1065; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WALDMANN T, 1995, BIOL CHEM H-S, V376, P119, DOI 10.1515/bchm3.1995.376.2.119; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; ZECHEL K, 1980, EUR J BIOCHEM, V110, P343, DOI 10.1111/j.1432-1033.1980.tb04873.x	43	210	224	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1497	1502		10.1126/science.272.5267.1497	http://dx.doi.org/10.1126/science.272.5267.1497			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633246				2022-12-28	WOS:A1996UP89900053
J	Gilmore, AP; Burridge, K				Gilmore, AP; Burridge, K			Regulation of vinculin binding to talin and actin by phosphatidyl-inositol-4-5-bisphosphate	NATURE			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; PURIFICATION; PROTEINS	VINCULIN, a prominent cytoskeletal protein at cell-substrate adhesions (focal adhesions) and cell-cell adhesions (adherens junctions)(1), interacts with other cytoskeletal proteins, including talin and actin(2,3). An intramolecular interaction between the head and tail domains of vinculin masks the binding sites for both proteins(4,5). The exposure of cryptic binding sites may be important for promoting focal adhesion assembly. Several agents that induce the formation of focal adhesions act through the GTP-binding protein Rho(6-9), which elevates phosphatidylinositol-4,5-bisphosphate (PtdInsP(2)) levels by activating phosphatidylinositol-4-phosphate-5-OH kinase (PtdIns-5-OH kinase)(10). PtdInsP(2) regulates several actin-binding proteins, including profilin(11), gelsolin(12) and alpha-actinin(13), and interacts with vinculin(14,15). Here we report that PtdInsP(2) dissociates vinculin's head-tail interaction, unmasking its talin- and actin-binding sites. Microinjection of antibodies against PtdInsP(2) inhibit assembly of stress fibres and focal adhesions.			Gilmore, AP (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599, USA.							BARRY ST, 1994, J CELL SCI, V107, P2033; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHRZANOWSKAWODN.M, 1994, J CELL SCI, V107, P3543; EVANS RR, 1984, J BIOL CHEM, V259, P3916; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; WOOD CK, 1994, J CELL SCI, V107, P709	30	442	450	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					531	535		10.1038/381531a0	http://dx.doi.org/10.1038/381531a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632828				2022-12-28	WOS:A1996UP43500063
J	Havlir, DV; Richman, DD				Havlir, DV; Richman, DD			Viral dynamics of HIV: Implications for drug development and therapeutic strategies	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED LYMPHADENOPATHY; FOLLICULAR DENDRITIC CELLS; POLYMERASE CHAIN-REACTION; HIGH-LEVEL RESISTANCE; REVERSE-TRANSCRIPTASE; LYMPH-NODES; COMBINATION THERAPY; MONONUCLEAR-CELLS; INFECTED PERSONS	The ability to quantitate human immunodeficiency virus (HIV) in blood and tissues from patients at all stages of disease has provided new insights into the pathogenesis of HIV disease. There is a dynamic equilibrium between HIV production and clearance even during the period of clinical latency, which may permit resistant virus to emerge with the imposition of drug pressure. Disruption of the equilibrium with effective drugs reduces circulating levels of HIV within 1 week, thus allowing the rapid assessment of new candidate drugs. To maximize the magnitude and durability of HIV RNA suppression, therapeutic strategies must be implemented that are effective against high levels of rapidly replicating virus that consist of many genetic variants.	UNIV CALIF SAN DIEGO, DEPT PATHOL, SAN DIEGO, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Havlir, DV (corresponding author), UNIV CALIF SAN DIEGO, SAN DIEGO TREATMENT CTR, 2760 5TH AVE, SUITE 300, SAN DIEGO, CA 92103 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027670, R01AI029164, R37AI029164, P30AI036214] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 29164, AI 27670, AI 36214] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT J, 1987, J MED VIROL, V23, P67, DOI 10.1002/jmv.1890230108; ARMSTRONG JA, 1984, LANCET, V2, P370; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BARONI CD, 1986, HISTOPATHOLOGY, V10, P5, DOI 10.1111/j.1365-2559.1986.tb02456.x; BIBERFELD P, 1986, AM J PATHOL, V125, P436; BRICHACEK B, 1995, 2 NAT C HUM RETR REL; BURCHETT SK, 1996, 3 C RETR OPP INF WAS; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CHEESEMAN SH, 1995, J ACQ IMMUN DEF SYND, V8, P141; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COHEN OJ, 1995, P NATL ACAD SCI USA, V92, P6017, DOI 10.1073/pnas.92.13.6017; COLLIER AC, 1993, ANN INTERN MED, V119, P786, DOI 10.7326/0003-4819-119-8-199310150-00003; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DEGRUTTOLA V, 1994, J INFECT DIS, V169, P713, DOI 10.1093/infdis/169.4.713; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; DICKOVER K, 1995, J CELL BIOCH S B, V21, P233; DICKOVER RE, 1994, J INFECT DIS, V170, P1279, DOI 10.1093/infdis/170.5.1279; EHRNST A, 1988, J MED VIROL, V26, P23, DOI 10.1002/jmv.1890260105; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EPSTEIN L G, 1984, AIDS Research, V1, P447; ERICKSON JW, 1995, NAT STRUCT BIOL, V2, P523, DOI 10.1038/nsb0795-523; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FALK LA, 1987, NEW ENGL J MED, V316, P1547; FISCHL MA, 1995, 2 NAT C HUM RETR REL; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; FRENKEL LM, 1995, CLIN INFECT DIS, V20, P1321, DOI 10.1093/clinids/20.5.1321; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; GAO WY, 1993, J CLIN INVEST, V91, P2326, DOI 10.1172/JCI116463; GULICK R, 1996, 3 NAT C HUM RETR REL; HAMILTON B, 1995, 2 NAT C HUM RETR REL; HAMMER S, 1995, 35 INT C ANT AG CHEM; HAVLIR D, 1995, J INFECT DIS, V172, P1379, DOI 10.1093/infdis/172.5.1379; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; HAVLIR D, 1995, 1 NAT C HUM RETR REL; HENRARD DR, 1995, J ACQ IMMUN DEF SYND, V9, P305; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; HOLLANDER H, 1987, ANN INTERN MED, V106, P692, DOI 10.7326/0003-4819-106-5-692; HOOPER C, 1994, HIV DRUG RES 3 INT W; JACKSON JB, 1990, J CLIN MICROBIOL, V28, P16, DOI 10.1128/JCM.28.1.16-19.1990; JACOBSEN H, 1995, 4 INT HIV DRUG RES W; JURRIAANS S, 1995, AIDS RES HUM RETROV, V11, P473, DOI 10.1089/aid.1995.11.473; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KATLAMA C, 1995, 2 NAT C HUM RETR REL; KATZENSTEIN D, 1995, 35 INT C ANT AG CHEM; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOUP RA, 1994, J EXP MED, V180, P779, DOI 10.1084/jem.180.3.779; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, 1996, 3 C RETR OPP INF WAS; KOZAL MJ, IN PRESS NATURE MED; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LETOURNEAU A, 1986, HUM PATHOL, V17, P1047, DOI 10.1016/S0046-8177(86)80089-2; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MASQUELIER B, 1993, NEW ENGL J MED, V329, P1123; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MOLE L, 1995, 2 NAT C HUM RETR REL; MOUTOUH L, IN PRESS P NATL ACAD; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; NAJERA I, 1994, AIDS RES HUM RETROV, V10, P1479, DOI 10.1089/aid.1994.10.1479; NAJERA I, 1995, J VIROL, V69, P23; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; RICHMAN DD, 1995, AIDS SA, P549; Rouzioux C, 1995, Drugs, V49 Suppl 1, P17, DOI 10.2165/00003495-199500491-00006; SAAG MS, 1991, J INFECT DIS, V164, P72, DOI 10.1093/infdis/164.1.72; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; SEI S, 1994, J INFECT DIS, V170, P325, DOI 10.1093/infdis/170.2.325; SONNERBORG AB, 1988, AIDS, V2, P89, DOI 10.1097/00002030-198804000-00003; SPRUANCE SL, 1994, ANN INTERN MED, V120, P360, DOI 10.7326/0003-4819-120-5-199403010-00002; TENNERRACZ K, 1986, AM J PATHOL, V123, P9; TENNERRACZ K, 1985, LANCET, V1, P105; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; URDEA MS, 1994, AIDS S2, V7; VANGEMEN B, 1994, J VIROL METHODS, V49, P157, DOI 10.1016/0166-0934(94)90040-X; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARNER TFCS, 1984, LANCET, V1, P860; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEISER B, 1994, P NATL ACAD SCI USA, V91, P8037, DOI 10.1073/pnas.91.17.8037; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WINTERS MA, 1993, J CLIN MICROBIOL, V31, P2960, DOI 10.1128/JCM.31.11.2960-2966.1993; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006	112	177	180	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1996	124	11					984	994		10.7326/0003-4819-124-11-199606010-00006	http://dx.doi.org/10.7326/0003-4819-124-11-199606010-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL905	8624066				2022-12-28	WOS:A1996UL90500006
J	deCelis, JF; Barrio, R; Kafatos, FC				deCelis, JF; Barrio, R; Kafatos, FC			A gene complex acting downstream of dpp in Drosophila wing morphogenesis	NATURE			English	Article							EXPRESSION; DISK	LOCALIZED expression of the transforming growth factor-beta (TGF-beta) homologue decapentaplegic (dpp) is crucial for Drosophila wing development(1-4). Here we show that spalt and spalt-related (sal and salr), two closely related genes that encode transcription factors, are expressed in response to dpp in a central territory of the wing imaginal disc, where they are required for the patterning of the wing. They are among the first identified elements that act downstream of dpp in wing development. The phenotypic consequences of misexpression of sal and salr suggest that an important outcome of dpp activity is the subdivision of the wing disc into territories smaller than lineage compartments, through the regulation of transcription-factor-encoding genes such as sal and salr.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 4TH,ENGLAND; INST MOLEC BIOL & BIOTECHNOL,GR-71110 IRAKLION,CRETE,GREECE	European Molecular Biology Laboratory (EMBL); University of Cambridge			de+Celis, Jose/AAE-8142-2019; Barrio, Rosa/F-8712-2011	Barrio, Rosa/0000-0002-9663-0669; de Celis, Jose F./0000-0003-4808-9844				BAKER NE, 1988, DEVELOPMENT, V102, P489; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DECELIS JF, 1995, DEVELOPMENT, V121, P3467; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GOMEZSKARMETA JL, 1995, GENE DEV, V9, P1869, DOI 10.1101/gad.9.15.1869; HOCH M, 1993, CURR OPIN GENET DEV, V3, P566, DOI 10.1016/0959-437X(93)90092-4; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; Reuter D, 1996, CHROMOSOMA, V104, P445, DOI 10.1007/BF00352268; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SWEENEY ST, 1985, NEURON, V14, P342; TABATA T, 1995, DEVELOPMENT, V121, P3359	21	197	199	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					421	424		10.1038/381421a0	http://dx.doi.org/10.1038/381421a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632798				2022-12-28	WOS:A1996UN47900051
J	Erickson, JC; Clegg, KE; Palmiter, RD				Erickson, JC; Clegg, KE; Palmiter, RD			Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y	NATURE			English	Article							RAT HIPPOCAMPAL SLICE; PRESYNAPTIC INHIBITION; FOOD-DEPRIVATION; FEEDING-BEHAVIOR; RECEPTOR; NEURONS; MECHANISM; INVITRO; BRAIN	NEUROPEPTIDE Y (NPY), a 36-amino-acid transmitter distributed throughout the nervous system(1,2), is thought to function as a central stimulator of feeding behaviour(1-4). NPY has also been implicated in the modulation of mood(5), cerebrocortical excitability(6), hypothalamic-pituitary signalling(7), cardiovascular physiology(1,8) and sympathetic function(9,10). However, the biological significance of NPY has been difficult to establish owing to a lack of pharmacological antagonists, We report here that mice deficient for NPY have normal food intake and body weight, and become hyperphagic following food deprivation. Mutant mice decrease their food intake and lose weight, initially to a greater extent than controls, when treated with recombinant leptin. Occasional, mild seizures occur in NPY-deficient mice and mutants are more susceptible to seizures induced by a GABA (gamma-aminobutyric acid) antagonist, These results indicate that NPY is not essential for certain feeding responses or leptin actions but is an important modulator of excitability in the central nervous system.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								BECK B, 1990, BRAIN RES, V528, P245, DOI 10.1016/0006-8993(90)91664-3; BLEAKMAN D, 1992, BRIT J PHARMACOL, V107, P334, DOI 10.1111/j.1476-5381.1992.tb12747.x; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; COLMERS WF, 1987, J PHYSIOL-LONDON, V383, P285; COLMERS WF, 1991, BRIT J PHARMACOL, V102, P41, DOI 10.1111/j.1476-5381.1991.tb12129.x; COLMERS WF, 1994, TRENDS NEUROSCI, V17, P373, DOI 10.1016/0166-2236(94)90046-9; COLMERS WF, 1988, J NEUROSCI, V8, P3827; COLMERS WF, 1993, BIOL NEUROPEPTIDE Y; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; HAAS HL, 1987, J COMP NEUROL, V257, P208, DOI 10.1002/cne.902570207; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; KLAPSTEIN GJ, 1993, HIPPOCAMPUS, V3, P103, DOI 10.1002/hipo.450030111; LEIBOWITZ SF, 1991, BRAIN RES BULL, V27, P333, DOI 10.1016/0361-9230(91)90121-Y; MCDERMOTT BJ, 1993, CARDIOVASC RES, V27, P893, DOI 10.1093/cvr/27.6.893; MCDONALD JK, 1993, BIOL NEUROPEPTIDE Y, P457; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; ORLOFF MJ, 1949, P SOC EXP BIOL MED, V70, P254; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; SCHWARTZ MW, IN PRESS DIABETES; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STJARNE L, 1986, NEUROSCIENCE, V18, P151, DOI 10.1016/0306-4522(86)90184-3; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; TOTH PT, 1993, NATURE, V364, P635, DOI 10.1038/364635a0; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	894	911	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					415	418		10.1038/381415a0	http://dx.doi.org/10.1038/381415a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632796				2022-12-28	WOS:A1996UN47900049
J	Hedges, SB; Parker, PH; Sibley, CG; Kumar, S				Hedges, SB; Parker, PH; Sibley, CG; Kumar, S			Continental breakup and the ordinal diversification of birds and mammals	NATURE			English	Article							EVOLUTION; PHYLOGENY	THE classical hypothesis for the diversification of birds and mammals proposes that most of the orders diverged rapidly in adaptive radiations after the Cretaceous/Tertiary (K/T) extinction event 65 million years ago (1-3). Evidence is provided by the near-absence of fossils representing modern orders before the K/T boundary(4,5). However, fossil-based estimates of divergence time are known to be conservative because of sampling biases(6), and some molecular/time estimates point to earlier divergences among orders(7-10). In an attempt to resolve this controversy, we have estimated times of divergence among avian and mammalian orders with a comprehensive set of genes that exhibit a constant rate of substitution. Here we report molecular estimates of divergence times that average about 50-90% earlier than those predicted by the classical hypothesis, and show that the timing of these divergences coincides with the Mesozoic fragmentation of emergent land areas. This suggests that continental breakup may have been an important mechanism in the ordinal diversification of birds and mammals.	PENN STATE UNIV,INST MOLEC EVOLUT GENET,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hedges, SB (corresponding author), PENN STATE UNIV,DEPT BIOL,208 MUELLER LAB,UNIVERSITY PK,PA 16802, USA.		Kumar, Sudhir/F-1411-2011	Kumar, Sudhir/0000-0002-9918-8212				AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; CHIAPPE LM, 1995, NATURE, V378, P349, DOI 10.1038/378349a0; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; FEDUCCIA A, 1995, SCIENCE, V267, P637, DOI 10.1126/science.267.5198.637; HAY JM, 1995, MOL BIOL EVOL, V12, P928; HEDGES SB, 1994, P NATL ACAD SCI USA, V91, P9861, DOI 10.1073/pnas.91.21.9861; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JANKE A, 1994, GENETICS, V137, P243; LI WH, 1990, P NATL ACAD SCI USA, V87, P6703, DOI 10.1073/pnas.87.17.6703; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; OTA T, 1994, J MOL EVOL, V38, P642; Padian K., 1985, P41; PRAGER EM, 1974, J MOL EVOL, V3, P243, DOI 10.1007/BF01796041; RAMIREZ V, 1993, J MOL EVOL, V37, P296, DOI 10.1007/BF00175506; Russell Dale E., 1995, Historical Biology, V10, P3; SMITHSON TR, 1989, NATURE, V342, P676, DOI 10.1038/342676a0; TAJIMA F, 1993, GENETICS, V135, P599; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; XU XF, 1994, GENE, V148, P357, DOI 10.1016/0378-1119(94)90713-7	20	378	385	2	56	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					226	229		10.1038/381226a0	http://dx.doi.org/10.1038/381226a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622763				2022-12-28	WOS:A1996UL24900051
J	Lange, P; Ulrik, CS; Vestbo, J				Lange, P; Ulrik, CS; Vestbo, J			Mortality in adults with self-reported asthma	LANCET			English	Article							AIR-FLOW OBSTRUCTION; GENERAL-POPULATION; FOLLOW-UP; BRONCHIAL-ASTHMA; SAMPLE; QUESTIONNAIRES; PROGNOSIS; SYMPTOMS; DISEASE	Background On the question of whether asthma shortens survival the published work gives no clear answer. We have prospectively analysed overall and cause-specific mortality in persons with self-reported asthma. Methods A sample of 13 540 individuals (6104 men) 20 years of age or older, randomly selected from the general population of the city of Copenhagen, was followed for 17 years. Findings Survival in participants with self-reported asthma was significantly poorer than in non-asthmatics, the excess mortality being limited to pulmonary mortality. After statistical adjustment for age, length of school education, and smoking, women with asthma had a 1.7 higher risk of dying than women without asthma (95% confidence interval 1.3-2.2). Although the relative risk (RR) of dying with asthma was sightly lower in men (RR=1.5, 95% CI 1.2-1.9) the difference between sexes was not significant. The results were similar within smoking groups and the highest risk of death associated with asthma was seen among never-smokers (RR=2.1, 95% CI 1.6-2.3). Inclusion of one-second forced expiratory volume, in % predicted, in the mortality analyses showed that the increased risk of death associated with asthma was mediated mainly through reduced lung function. Interpretation We conclude that, in the general population, self-reported asthma is associated with a slight excess of mortality, mainly from respiratory diseases.	BISPEBJERG HOSP,DEPT PULM MED,DK-2400 COPENHAGEN,DENMARK; KOMMUNE HOSP COPENHAGEN,COPENHAGEN CTR PROSPECT POPULAT STUDIES,COPENHAGEN,DENMARK; KOMMUNE HOSP COPENHAGEN,INST PREVENT MED,COPENHAGEN,DENMARK	University of Copenhagen; Bispebjerg Hospital	Lange, P (corresponding author), RIGSHOSP,COPENHAGEN CITY HEART STUDY,EPIDEMIOL RES UNIT,DEPT 7121,DK-2200 COPENHAGEN N,DENMARK.		Vestbo, Jorgen/Y-2912-2019	Vestbo, Jorgen/0000-0001-6355-6362				ALDERSON M, 1977, BRIT J DIS CHEST, V71, P198, DOI 10.1016/0007-0971(77)90110-3; ALDERSON M, 1974, LANCET, V2, P1475; ALMIND M, 1992, DAN MED BULL, V39, P561; [Anonymous], 1984, Acta Med Scand Suppl, V682, P1; BEATY TH, 1985, J CHRON DIS, V38, P703, DOI 10.1016/0021-9681(85)90024-4; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BUIST AS, 1994, NEW ENGL J MED, V331, P1584, DOI 10.1056/NEJM199412083312309; BURNEY P, 1988, J EPIDEMIOL COMMUN H, V42, P316, DOI 10.1136/jech.42.4.316; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; BURROWS B, 1990, MED CLIN N AM, V74, P547, DOI 10.1016/S0025-7125(16)30539-9; COX DR, 1972, J R STAT SOC B, V34, P187; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; KOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; LANGE P, 1990, THORAX, V45, P579, DOI 10.1136/thx.45.8.579; MARKOWE HLJ, 1987, BRIT MED J, V295, P949, DOI 10.1136/bmj.295.6604.949; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721, DOI 10.1164/ajrccm/139.3.721; OPENSHAW PJM, 1989, RESP MED, V83, P25, DOI 10.1016/S0954-6111(89)80056-3; ROBINETTE CD, 1978, J CHRON DIS, V31, P619, DOI 10.1016/0021-9681(78)90022-X; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Toren K., 1994, European Respiratory Journal, V7, p253S; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330; ULRIK CS, 1995, CHEST, V108, P10, DOI 10.1378/chest.108.1.10; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; VESTBO J, 1988, AM REV RESPIR DIS, V137, P1114, DOI 10.1164/ajrccm/137.5.1114; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WU AH, 1995, AM J EPIDEMIOL, V141, P1023, DOI 10.1093/oxfordjournals.aje.a117366	30	98	99	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1285	1289		10.1016/S0140-6736(96)90937-X	http://dx.doi.org/10.1016/S0140-6736(96)90937-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622503				2022-12-28	WOS:A1996UK75800008
J	Neurath, MF; Branbrink, A; zumBuschenfelde, KHM; Lohse, AW				Neurath, MF; Branbrink, A; zumBuschenfelde, KHM; Lohse, AW			A new treatment for severe malabsorption due to radiation enteritis	LANCET			English	Article									UNIV MAINZ,DEPT MED,D-55101 MAINZ,GERMANY; UNIV MAINZ,DEPT ANESTHESIOL,D-55101 MAINZ,GERMANY	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz								BARNES MP, 1985, LANCET, V1, P297; BAUM CA, 1989, DIGEST DIS SCI, V34, P758, DOI 10.1007/BF01540349; BEVERS RFM, 1995, LANCET, V346, P803, DOI 10.1016/S0140-6736(95)91620-2; EARNEST DL, 1993, GASTROINTESTINAL DIS, P1257; LAK KH, 1978, INT J RADIAT ONCOL, V4, P457	5	13	13	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1302	1302		10.1016/S0140-6736(96)90942-3	http://dx.doi.org/10.1016/S0140-6736(96)90942-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622508				2022-12-28	WOS:A1996UK75800013
J	Jacobson, RH; Tjian, R				Jacobson, RH; Tjian, R			Transcription factor IIA: A structure with multiple functions	SCIENCE			English	Editorial Material							TFIIA; SUBUNITS; CDNA		UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Jacobson, RH (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.							DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313	11	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					827	828		10.1126/science.272.5263.827	http://dx.doi.org/10.1126/science.272.5263.827			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629011				2022-12-28	WOS:A1996UK75700040
J	Young, RE; Smith, MA; Sobeck, CK				Young, RE; Smith, MA; Sobeck, CK			Galileo probe: In situ observations of Jupiter's atmosphere	SCIENCE			English	Article							VOYAGER-2; WINDS; BELT	The Galileo probe performed the first in situ measurements of the atmosphere of Jupiter on 7 December 1995, The probe returned data until it reached a depth corresponding to an atmospheric pressure of similar to 24 bars. This report presents a brief overview of the origins and purpose of the mission. Science objectives, entry parameters and mission events, and results are described. The remaining reports address in more detail the individual experiments summarized here.			Young, RE (corresponding author), NASA,AMES RES CTR,MOFFETT FIELD,CA 94035, USA.							Atkinson DH, 1996, SCIENCE, V272, P842, DOI 10.1126/science.272.5263.842; Atreya S. K., 1985, Recent Advances in Planetary Meteorology. Seymour Hess Memorial Symposium at the 1983 IUGG General Assembly, P17; Beebe RF, 1996, SCIENCE, V272, P841, DOI 10.1126/science.272.5263.841; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; CONRATH B, 1987, J GEOPHYS RES, V92, P15006; DEPATER I, 1986, ICARUS, V68, P344, DOI 10.1016/0019-1035(86)90027-8; Fischer HM, 1996, SCIENCE, V272, P856, DOI 10.1126/science.272.5263.856; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; INGERSOLL AP, 1981, J GEOPHYS RES-SPACE, V86, P8733, DOI 10.1029/JA086iA10p08733; Lanzerotti LJ, 1996, SCIENCE, V272, P858, DOI 10.1126/science.272.5263.858; LIMAYE SS, 1982, J ATMOS SCI, V39, P1413, DOI 10.1175/1520-0469(1982)039<1413:JWFVPI>2.0.CO;2; LIMAYE SS, 1991, J GEOPHYS RES-PLANET, V96, P18941, DOI 10.1029/91JA01701; NEFF J, 1990, GLLMDT90195 JPL IOM; NEFF J, 1996, GLLNAV965 JPL IOM; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; Ragent B, 1996, SCIENCE, V272, P854, DOI 10.1126/science.272.5263.854; RUSSELL CT, 1992, SPACE SCI REV, V60; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; SMITH BA, 1981, SCIENCE, V212, P163, DOI 10.1126/science.212.4491.163; SMITH BA, 1986, SCIENCE, V233, P43, DOI 10.1126/science.233.4759.43; Sromovsky LA, 1996, SCIENCE, V272, P851, DOI 10.1126/science.272.5263.851; vonZahn U, 1996, SCIENCE, V272, P849, DOI 10.1126/science.272.5263.849; WEST RA, 1986, ICARUS, V65, P161, DOI 10.1016/0019-1035(86)90135-1; [No title captured]	25	47	47	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					837	838		10.1126/science.272.5263.837	http://dx.doi.org/10.1126/science.272.5263.837			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629015				2022-12-28	WOS:A1996UK75700044
J	Schrader, H; Obelieniene, D; Bovim, G; Surkiene, D; Mickeviciene, D; Miseviciene, I; Sand, T				Schrader, H; Obelieniene, D; Bovim, G; Surkiene, D; Mickeviciene, D; Miseviciene, I; Sand, T			Natural evolution of late whiplash syndrome outside the medicolegal context	LANCET			English	Article							SOFT-TISSUE INJURIES; CERVICAL-SPINE; NECK	Background In Lithuania, few car drivers and passengers are covered by insurance and there is little awareness among the general public about the potentially disabling consequences of a whiplash injury. We took this opportunity to study the natural course of head and neck symptoms after rear-end car collisions. Methods In a retrospective questionnaire-based cohort study, 202 individuals (157 men; 45 women) were identified from the records of the traffic police department in Kaunas, Lithuania. These individuals were interviewed 1-3 years after experiencing a rear-end car collision. Neck pain, headache, subjective cognitive dysfunction, psychological disorders, and low back pain in this group were compared with the same complaints in a sex-matched and age-matched control group of uninjured individuals selected randomly from the population register of the same geographic area. Findings Neck pain was reported by 71 (35% [95% CI 29-42]) accident victims and 67 (33% [27-40]) controls. Headache was reported by 107 (53% [46-60]) accident victims and 100 (50% [42-57]) controls. Chronic neck pain and chronic headache (more than 7 days per month) were also reported in similar proportions (17 [8 . 4%; 5-13] vs 14 [6 . 9%; 4-12] and 19 [9 . 4%; 6-15] vs 12 [5 . 9%; 3-10]) by the two groups, Of those who reported chronic neck pain or daily headache after the accident, substantial proportions had had similar symptoms before the accident (7/17 for chronic neck pain; 10/12 for daily headache). There was no significant difference found. No one in the study group had disabling or persistent symptoms as a result of the car accident. There was no relation between the impact severity and degree of pain. A family history of neck pain was the most important risk factor for current neck symptoms in logistic regression analyses. Interpretation Our results suggest that chronic symptoms were not usually caused by the car accident. Expectation of disability, a family history, and attribution of pre-existing symptoms to the trauma may be more important for the evolution of the late whiplash syndrome.	KAUNAS MED ACAD,DEPT NEUROL,KAUNAS,LITHUANIA; KAUNAS MED ACAD,DEPT PREVENT MED,KAUNAS,LITHUANIA	Lithuanian University of Health Sciences; Lithuanian University of Health Sciences	Schrader, H (corresponding author), UNIV TRONDHEIM HOSP,DEPT NEUROL,N-7006 TRONDHEIM,NORWAY.			Schrader, Harald/0000-0001-9975-1960; Obelieniene, Diana/0000-0002-7356-7150				AWERBUCH MS, 1992, MED J AUSTRALIA, V156, P193; Balla J, 1987, Clin Exp Neurol, V23, P179; BALLA JI, 1980, AUST NZ J SURG, V50, P610, DOI 10.1111/j.1445-2197.1980.tb04207.x; BALLA JI, 1982, CULT MED PSYCHIAT, V6, P191, DOI 10.1007/BF00051428; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008; BORCHGREVINK GE, 1995, ACTA RADIOL, V36, P425; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; CARETTE S, 1994, NEW ENGL J MED, V330, P1083, DOI 10.1056/NEJM199404143301512; CROWE H, 1928, ANN M W ORTH ASS SAN; DAVIS SJ, 1991, RADIOLOGY, V180, P245, DOI 10.1148/radiology.180.1.2052703; DEANS GT, 1987, INJURY, V18, P10, DOI 10.1016/0020-1383(87)90375-5; ELLERTSEN AB, 1978, ACTA NEUROL SCAND  S, V67, P269; GOBEL H, 1994, CEPHALALGIA, V14, P97, DOI 10.1046/j.1468-2982.1994.1402097.x; GOTTEN N, 1956, JAMA-J AM MED ASSOC, V162, P856; Hasvold Toralf, 1993, Scandinavian Journal of Primary Health Care, V11, P219, DOI 10.3109/02813439308994834; HILDINGSSON C, 1990, ACTA ORTHOP SCAND, V61, P357, DOI 10.3109/17453679008993536; HOHL M, 1974, J BONE JOINT SURG AM, VA 56, P1675, DOI 10.2106/00004623-197456080-00018; MACNAB I, 1964, J BONE JOINT SURG AM, V46, P1797, DOI 10.2106/00004623-196446080-00021; MAIMARIS C, 1988, INJURY, V19, P393, DOI 10.1016/0020-1383(88)90131-3; MAKELA M, 1991, AM J EPIDEMIOL, V134, P1356; MARSHALL PD, 1995, INJURY, V20, P17; Michler Ralf-Peter, 1993, Tidsskrift for den Norske Laegeforening, V113, P1104; MILES KA, 1988, SKELETAL RADIOL, V17, P493, DOI 10.1007/BF00364043; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NORRIS SH, 1983, J BONE JOINT SURG BR, V65, P608, DOI 10.1302/0301-620X.65B5.6643566; PEARCE JMS, 1989, J NEUROL NEUROSUR PS, V52, P1329, DOI 10.1136/jnnp.52.12.1329; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; WATKINSON A, 1991, INJURY, V22, P307, DOI 10.1016/0020-1383(91)90012-4; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950	29	278	282	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1207	1211		10.1016/S0140-6736(96)90733-3	http://dx.doi.org/10.1016/S0140-6736(96)90733-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622449				2022-12-28	WOS:A1996UJ59700008
J	Silverman, BG; Brown, SL; Bright, RA; Kaczmarek, RG; ArrowsmithLowe, JB; Kessler, DA				Silverman, BG; Brown, SL; Bright, RA; Kaczmarek, RG; ArrowsmithLowe, JB; Kessler, DA			Reported complications of silicone gel breast implants: An epidemiologic review	ANNALS OF INTERNAL MEDICINE			English	Review							CONNECTIVE-TISSUE DISEASE; CAPSULAR CONTRACTURE; AUGMENTATION MAMMAPLASTY; DEFINITIVE DIAGNOSIS; CANCER; MAMMOGRAPHY; PROSTHESES; RUPTURE; SMOOTH; RECONSTRUCTION	Data Sources: Epidemiologic studies of the potential risks of silicone breast implants identified by MEDLINE search and literature review. Study Selection: Epidemiologic studies with cohort, Ease-control, and cross-sectional designs. When epidemiologic studies were unavailable (as for estimates of local complications), case series were reviewed. Data Extraction: Epidemiologic studies evaluated for methodologic quality, including such characteristics as study design, sample size and selection, determination of silicone exposure and outcome variables, and duration of follow-up. Data Synthesis: The epidemiologic literature on the potential complications of silicone breast implants has concentrated primarily on connective tissue disorders and cancer. Estimates of the true incidence of local complications, such as rupture, capsular contracture, and breast pain, are unavailable. Studies of scleroderma and other defined connective tissue diseases suggest that implant recipients have no substantially increased risk for these disorders; however, the epidemiologic literature is insufficient to rule out an association between breast implants and connective tissue disease-like syndromes. Overall, the rate of breast cancer does not seem to be increased in women with silicone breast implants. However, the risk to women as they reach the postmenopausal years is not yet known. Conclusions: Information is insufficient to adequately advise women who currently have or are seeking to obtain breast implants about the overall risk of these devices. Mo epidemiologic study has indicated that the rate of well-defined connective tissue disease or breast cancer has greatly increased in women with silicone breast implants, but no studies have ruled out a moderately increased risk for these diseases. No studies have adequately addressed the crucial issue of local complications such as rupture and capsular contracture, although evidence increasingly points to a higher risk for rupture as implants age.	US FDA, HF 1, ROCKVILLE, MD 20857 USA; US FDA, CTR BIOL EVALUAT & RES, HFM 380, ROCKVILLE, MD 20852 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Silverman, BG (corresponding author), US FDA, CTR DEVICES & RADIOL HLTH, HFZ 541, 1350 PICCARD DR, ROCKVILLE, MD 20850 USA.		Bright, Roselie A/D-2240-2016	Silverman, Barbara/0000-0002-0337-4919				AHN CY, 1994, PLAST RECONSTR SURG, V94, P620, DOI 10.1097/00006534-199410000-00008; AHN CY, 1993, PLAST RECONSTR SURG, V92, P681, DOI 10.1097/00006534-199309001-00018; ANDERSEN B, 1989, PLAST RECONSTR SURG, V84, P903, DOI 10.1097/00006534-198912000-00006; Ashbell T S, 1980, Plast Reconstr Surg, V65, P239; ASPLUND O, 1984, PLAST RECONSTR SURG, V73, P270, DOI 10.1097/00006534-198402000-00022; BARKER DE, 1978, PLAST RECONSTR SURG, V61, P836, DOI 10.1097/00006534-197861060-00002; BASSETT L, 1994, CLIN PRACTICE GUIDEL, V13; BERKEL H, 1992, NEW ENGL J MED, V326, P1649, DOI 10.1056/NEJM199206183262501; BIGGS TM, 1982, PLAST RECONSTR SURG, V69, P445, DOI 10.1097/00006534-198203000-00007; BOSTWICK J, 1990, PLASTIC RECONSTRUCTI, P181; BOSTWICK J, 1990, PLAST RECONSTRUCTIVE, P272; BRIDGES AJ, 1993, ARCH INTERN MED, V153, P2638, DOI 10.1001/archinte.153.23.2638; BRIGHT RA, 1993, J LONG-TERM EFF MED, V3, P81; BRINTON LA, 1995, J CLIN EPIDEMIOL, V48, P557, DOI 10.1016/0895-4356(94)00213-A; BRINTON LA, 1990, OBSTET GYNECOL, V75, P859; BRODY GS, 1992, PLAST RECONSTR SURG, V90, P1102, DOI 10.1097/00006534-199212000-00029; BRYANT H, 1995, NEW ENGL J MED, V332, P1535, DOI 10.1056/NEJM199506083322302; BURKHARDT BR, 1988, CLIN PLAST SURG, V15, P521; BURKHARDT BR, 1986, PLAST RECONSTR SURG, V77, P919, DOI 10.1097/00006534-198606000-00008; BURNS CG, 1994, THESIS U MICHIGAN AN; CAIRNS TS, 1980, S AFR MED J, V57, P951; CAPOZZI A, 1982, PLAST RECONSTR SURG, V69, P904, DOI 10.1097/00006534-198205000-00054; CAPOZZI A, 1978, PLAST RECONSTR SURG, V62, P302, DOI 10.1097/00006534-197808000-00038; CARLSON GW, 1993, PLAST RECONSTR SURG, V91, P837, DOI 10.1097/00006534-199304001-00014; CHEN YM, 1993, AM REV RESPIR DIS, V147, P1299, DOI 10.1164/ajrccm/147.5.1299; COLEMAN DJ, 1991, BRIT J PLAST SURG, V44, P444, DOI 10.1016/0007-1226(91)90204-W; COOK RR, 1995, J CLIN EPIDEMIOL, V48, P519, DOI 10.1016/0895-4356(94)00208-8; COPELAND M, 1994, PLAST RECONSTR SURG, V94, P628, DOI 10.1097/00006534-199410000-00009; COPELAND M, 1994, PLAST RECONSTR SURG, V94, P634, DOI 10.1097/00006534-199410000-00010; CRONIN TD, 1964, 3RD T INT C PLAST SU, P41; DEAPEN DM, 1992, PLAST RECONSTR SURG, V89, P660, DOI 10.1097/00006534-199204000-00010; DECAMARA DL, 1993, PLAST RECONSTR SURG, V91, P828, DOI 10.1097/00006534-199304001-00012; DELAGE C, 1973, ARCH DERMATOL, V108, P104, DOI 10.1001/archderm.1973.01620220066018; DELOACH ED, 1994, ANN PLAS SURG, V33, P68, DOI 10.1097/00000637-199407000-00013; DESTOUET JM, 1992, AM J ROENTGENOL, V159, P973, DOI 10.2214/ajr.159.5.1414810; DOMANSKIS EJ, 1976, PLAST RECONSTR SURG, V58, P689, DOI 10.1097/00006534-197612000-00006; DOUGLAS KP, 1991, SOUTH MED J, V84, P49, DOI 10.1097/00007611-199101000-00013; DUGOWSON CE, 1992, ARHTRITIS RHEUM S, V35, P566; EISENBERG HV, 1977, PLAST RECONSTR SURG, V59, P849, DOI 10.1097/00006534-197706000-00024; EKLUND GW, 1988, AM J ROENTGENOL, V151, P469, DOI 10.2214/ajr.151.3.469; EKLUND GW, 1992, RADIOL CLIN N AM, V30, P21; ELLENBERG AH, 1980, PLAST RECONSTR SURG, V65, P307, DOI 10.1097/00006534-198003000-00006; ELLENBOGEN R, 1975, JAMA-J AM MED ASSOC, V234, P308, DOI 10.1001/jama.234.3.308; ENGLERT HJ, 1994, AUST NZ J MED, V24, P74, DOI 10.1111/j.1445-5994.1994.tb04439.x; ERSEK RA, 1991, PLAST RECONSTR SURG, V87, P879, DOI 10.1097/00006534-199105000-00012; GABRIEL SE, 1995, J CLIN EPIDEMIOL, V48, P527, DOI 10.1016/0895-4356(94)00209-9; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GILTAY EJ, 1994, ANN RHEUM DIS, V53, P194, DOI 10.1136/ard.53.3.194; GOLDMAN JA, 1995, J CLIN EPIDEMIOL, V48, P571, DOI 10.1016/0895-4356(94)00215-C; GRACE GT, 1990, ANN PLAS SURG, V25, P119, DOI 10.1097/00000637-199008000-00008; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P783, DOI 10.1093/oxfordjournals.aje.a117326; GRUBER RP, 1978, PLAST RECONSTR SURG, V62, P379, DOI 10.1097/00006534-197809000-00006; GYLBERT L, 1990, PLAST RECONSTR SURG, V85, P373, DOI 10.1097/00006534-199003000-00006; HARRIS KM, 1993, RADIOLOGY, V187, P761, DOI 10.1148/radiology.187.3.8497626; HAUSNER RJ, 1978, PLAST RECONSTR SURG, V62, P381, DOI 10.1097/00006534-197809000-00007; HAYES H, 1988, PLAST RECONSTR SURG, V82, P1, DOI 10.1097/00006534-198882010-00001; HOCHBERG MC, 1993, ANN INTERN MED, V118, P981, DOI 10.7326/0003-4819-118-12-199306150-00013; HOCHBERG MC, 1994, ARTHRITIS RHEUM, V37, P1177, DOI 10.1002/art.1780370811; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V270, P2607, DOI 10.1001/jama.270.21.2607; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; LEIBMAN AJ, 1990, RADIOLOGY, V174, P195, DOI 10.1148/radiology.174.1.2152981; LEVINE RA, 1991, PLAST RECONSTR SURG, V87, P1126, DOI 10.1097/00006534-199106000-00019; MALONE KE, 1992, LANCET, V339, P1365, DOI 10.1016/0140-6736(92)92021-7; *MAN LAB, 1992, SILT SMOOTH SURF LOW; MCKINNEY P, 1983, PLAST RECONSTR SURG, V72, P27, DOI 10.1097/00006534-198307000-00006; MCLAUGHLIN JK, 1994, J NATL CANCER I, V86, P1424, DOI 10.1093/jnci/86.18.1424; MCLAUGHLIN JK, 1995, JAMA-J AM MED ASSOC, V273, P116, DOI 10.1001/jama.273.2.116; ORTIZMONASTERIO F, 1972, PLAST RECONSTR SURG, V50, P42, DOI 10.1097/00006534-197207000-00007; Perkins LL, 1995, ANN PLAS SURG, V35, P561, DOI 10.1097/00000637-199512000-00001; PERSELLIN ST, 1992, MAYO CLIN PROC, V67, P891, DOI 10.1016/S0025-6196(12)60829-5; PETERS W, 1994, ANN PLAS SURG, V32, P449, DOI 10.1097/00000637-199405000-00001; PETERS W, 1993, ANN PLAS SURG, V31, P7; PETIT JY, 1994, PLAST RECONSTR SURG, V94, P115, DOI 10.1097/00006534-199407000-00011; POLLOCK H, 1993, PLAST RECONSTR SURG, V91, P404, DOI 10.1097/00006534-199303000-00002; ROBINSON OG, 1995, ANN PLAS SURG, V34, P1, DOI 10.1097/00000637-199501000-00001; Rohrich R J, 1993, Tex Med, V89, P52; SANCHEZGUERRERO J, 1994, ARTHRITIS RHEUM-US, V37, P158; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SCHIRBER S, 1993, SOUTHERN MED J, V86, P263, DOI 10.1097/00007611-199303000-00001; SCHUSTERMAN MA, 1993, ANN PLAS SURG, V31, P1; SHANKAR R, 1994, IMPLANTATION BIOL HO, P68; SHAPIRO MA, 1989, PLAST RECONSTR SURG, V84, P449, DOI 10.1097/00006534-198909000-00011; SHAPIRO S, 1994, AM J EPIDEMIOL, V140, P771, DOI 10.1093/oxfordjournals.aje.a117324; SHESTAK KC, 1993, PLAST RECONSTR SURG, V92, P209, DOI 10.1097/00006534-199308000-00003; SILMAN AJ, 1993, EPIDEMIOLOGY RHEUMAT, P193; SILVER RM, 1993, ARCH DERMATOL, V129, P63, DOI 10.1001/archderm.129.1.63; SILVERSTEIN MJ, 1992, EUR J CANCER, V28A, P635, DOI 10.1016/S0959-8049(05)80115-7; SILVERSTEIN MJ, 1990, ANN PLAS SURG, V25, P210, DOI 10.1097/00000637-199009000-00012; SMAHEL J, 1977, BRIT J PLAST SURG, V30, P324, DOI 10.1016/0007-1226(77)90132-1; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; TERRY MB, 1995, AM J PUBLIC HEALTH, V85, P1122, DOI 10.2105/AJPH.85.8_Pt_1.1122; *THET CORP, 1987, 606 THET CORP, P22; *THET CORP, 1991, 224 THET CORP, P5; THOMSEN JL, 1990, PLAST RECONSTR SURG, V85, P38, DOI 10.1097/00006534-199001000-00007; TRAVIS WD, 1985, HUM PATHOL, V16, P19, DOI 10.1016/S0046-8177(85)80209-4; VANRAPPARD JHA, 1988, ANN PLAS SURG, V21, P566, DOI 10.1097/00000637-198812000-00013; VARGAS A, 1979, PLAST RECONSTR SURG, V64, P252, DOI 10.1097/00006534-197908000-00025; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; WELLS KE, 1994, PLAST RECONSTR SURG, V93, P907, DOI 10.1097/00006534-199404001-00002; WIGLEY FM, 1992, ARTHRITIS RHEUM, V35, pS46; YUEN JC, 1994, IMPLANTATION BIOL HO, P192; 1993, JAMA-J AM MED ASSOC, V270, P2602	103	127	129	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					744	756		10.7326/0003-4819-124-8-199604150-00008	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00008			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633836				2022-12-28	WOS:A1996UD93600008
J	Serrano, M; Lee, HW; Chin, L; CordonCardo, C; Beach, D; DePinho, RA				Serrano, M; Lee, HW; Chin, L; CordonCardo, C; Beach, D; DePinho, RA			Role of the INK4a locus in tumor suppression and cell mortality	CELL			English	Article							ONCOGENES; MICE; CYCLINS; RAS; TRANSFORMATION; EXPRESSION; REQUIRES; KINASES	The cell cycle inhibitor p16(INK4a) is inactivated in many human tumors and in families with hereditary melanoma and pancreatic cancer. Tumor-associated alterations in the INK4a locus may also affect the overlapping gene encoding p19(ARF) and the adjacent gene encoding p15(INK4b), both negative regulators of cell proliferation. We report the phenotype of mice carrying a targeted deletion of the INK4a locus that eliminates both p-16(INK4a) and p19(ARF). The mice are viable but develop spontaneous tumors at an early age and are highly sensitive to carcinogenic treatments. INK4a-deficient primary fibroblasts proliferate rapidly and have a high colony-formation efficiency. in contrast with normal cells, the introduction of activated Ha-ras into INK4a-deficient fibroblasts can result in neoplastic transformation. These findings directly demonstrate that the INK4a locus functions to suppress neoplastic growth.	ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center	Serrano, M (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA.		Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER; NCI NIH HHS [CA09173] Funding Source: Medline; NEI NIH HHS [EY09300] Funding Source: Medline; NICHD NIH HHS [HD28317] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BATES S, 1994, ONCOGENE, V9, P71; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Conzen SD, 1995, ONCOGENE, V11, P2295; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; DEGRUIJL FR, 1991, CANCER RES, V51, P979; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; DURO D, 1995, ONCOGENE, V11, P21; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HE J, 1995, CANCER RES, V55, P4833; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAMA T, 1995, BLOOD, V86, P841; Holland EA, 1995, ONCOGENE, V11, P2289; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; KRIPKE ML, 1994, CANCER RES, V54, P6102; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MAO L, 1995, CANCER RES, V55, P2995; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; PALMIERI S, 1989, CURR TOP MICROBIOL, V148, P43; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Silver W. K., 1979, COAT COLORS MICE MOD; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Ueki K, 1996, CANCER RES, V56, P150; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOSHIDA S, 1995, CANCER RES, V55, P2756; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	76	1354	1403	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					27	37		10.1016/S0092-8674(00)81079-X	http://dx.doi.org/10.1016/S0092-8674(00)81079-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620534	Bronze			2022-12-28	WOS:A1996UE55900006
J	Sriramachari, S; Tandon, BN; Acharya, SK				Sriramachari, S; Tandon, BN; Acharya, SK			Excess zinc and progressive cholestasis: A new disease?	LANCET			English	Editorial Material							HEPATOTOXICITY		PUSHPAWATI SINGHANIA RES INST LIVER RENAL & DIGES,NEW DELHI,INDIA; ALL INDIA INST MED SCI,DEPT GASTROENTEROL,NEW DELHI,INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi	Sriramachari, S (corresponding author), ICMR,INST PATHOL,NEW DELHI,INDIA.							BOYER JL, 1989, ADV LIVER DISEASES, P149; CAGEN SZ, 1980, FED PROC, V39, P3124; *IND COUNC MED RES, 1997, IN PRESS REP ICMR MU; MCMILLAN DA, 1985, FUND APPL TOXICOL, V5, P297, DOI 10.1016/0272-0590(85)90077-6; PFEIFFER CJ, 1980, RES COMMUN CHEM PATH, V27, P587; SRIRAMACHARI S, 1991, INSA NEWS, V103, P24; SRIRAMACHARI S, 1993, INT J TOXICOL OCCUP, V2, P85; TANNER MS, 1979, LANCET, V1, P1203	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					845	846		10.1016/S0140-6736(96)91339-2	http://dx.doi.org/10.1016/S0140-6736(96)91339-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622385				2022-12-28	WOS:A1996UC45000003
J	Horton, R; Smith, R				Horton, R; Smith, R			Signing up for authorship	LANCET			English	Editorial Material									BMJ,LONDON,ENGLAND					Smith, Richard/0000-0001-9634-2918				Eastwood Susan, 1996, Sci Eng Ethics, V2, P89, DOI 10.1007/BF02639320; EPSTEIN RJ, 1993, BRIT MED J, V306, P765, DOI 10.1136/bmj.306.6880.765; GOODMAN NW, 1994, BRIT MED J, V309, P1482, DOI 10.1136/bmj.309.6967.1482; *INT COMM MED J ED, 1996, UN REQ MAN SUBM BIOM; SCHULMAN JL, 1995, NLM TECHNICAL B, V287, P17; SHAPIRO DW, 1994, JAMA-J AM MED ASSOC, V271, P438, DOI 10.1001/jama.271.6.438	6	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					780	780		10.1016/S0140-6736(96)90865-X	http://dx.doi.org/10.1016/S0140-6736(96)90865-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622331				2022-12-28	WOS:A1996UB15300006
J	Ferster, D; Chung, S; Wheat, H				Ferster, D; Chung, S; Wheat, H			Orientation selectivity of thalamic input to simple cells of cat visual cortex	NATURE			English	Article							RESPONSE PROPERTIES; RECEPTIVE-FIELDS; STRIATE CORTEX; AREA 17; NEURONS; PROJECTIONS; INHIBITION	MORE than 30 years after Hubel and Wiesel(1) first described orientation selectivity in the mammalian visual cortex, the mechanism that gives rise to this property is still controversial. Hubel and Wiesel(1) proposed a simple model for the origin of orientation tuning, in which the circularly symmetrical receptive fields of neurons in the lateral geniculate nucleus that excite a cortical simple cell are arranged in rows. Since this model was proposed, several experiments(2-6) and neuronal simulations(7,8) have suggested that the connectivity between the lateral geniculate nucleus and the cortex is not well organized in an orientation-specific fashion, and that orientation tuning arises instead from extensive interactions within the cortex. To test these models we have recorded visually evoked synaptic potentials in simple cells while cooling the cortex(9), which largely inactivates the cortical network, but leaves geniculate synaptic input functional. We report that the orientation tuning of these potentials is almost unaffected by cooling the cortex, in agreement with Hubel and Wiesel's original proposal(1).			Ferster, D (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,2153 N CAMPUS DR,EVANSTON,IL 60208, USA.							BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CREUTZFELDT OD, 1974, EXP BRAIN RES, V21, P251; CROOK JM, 1991, NEUROSCIENCE, V40, P1, DOI 10.1016/0306-4522(91)90169-O; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; FERSTER D, 1986, J NEUROSCI, V6, P1284; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P233, DOI 10.1113/jphysiol.1985.sp015822; FERSTER D, 1992, J NEUROSCI, V12, P1262; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1975, J COMP NEUROL, V163, P81, DOI 10.1002/cne.901630106; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; KALIL RE, 1970, J NEUROPHYSIOL, V33, P459, DOI 10.1152/jn.1970.33.3.459; KISVARDAY ZF, 1994, EUR J NEUROSCI, V6, P1619, DOI 10.1111/j.1460-9568.1994.tb00553.x; LEVAY S, 1976, BRAIN RES, V113, P1, DOI 10.1016/0006-8993(76)90002-0; MAEX R, 1994, THESIS KATHOLIEKE U; MILLER KD, 1994, J NEUROSCI, V14, P409; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; SAUL AB, 1990, J NEUROPHYSIOL, V64, P206, DOI 10.1152/jn.1990.64.1.206; SCHWARK HD, 1986, J NEUROPHYSIOL, V56, P1074, DOI 10.1152/jn.1986.56.4.1074; SHATZ CJ, 1977, J COMP NEUROL, V173, P497, DOI 10.1002/cne.901730307; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SOMERS DC, 1995, J NEUROSCI, V15, P5448; SUAREZ H, 1995, J NEUROSCI, V15, P6700; TANAKA K, 1983, J NEUROPHYSIOL, V49, P1303, DOI 10.1152/jn.1983.49.6.1303	30	412	416	0	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					249	252		10.1038/380249a0	http://dx.doi.org/10.1038/380249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637573				2022-12-28	WOS:A1996UB11700052
J	Goodie, AS; Fantino, E				Goodie, AS; Fantino, E			Learning to commit or avoid the base-rate error	NATURE			English	Article							CATEGORY	WHEN predicting an event, people neglect overall frequencies (base rates) of various possibilities(1). We have previously shown(2) that this base-rate occurs not only with word problems, but also in a procedure with repeated trials: a sample cue followed by two choice options, one of which the subject must choose, with feedback regarding the correctness of the choice. Perhaps this base-rate error depends on people's histories of matching physically similar items. In support of this suggestion, we begin by showing that the base-rate error is eliminated with physically unrelated items. We then show that when the relation between items is again arbitrary, but is a relation that subjects already know, the error reappears. Finally we show that teaching subjects new arbitrary relations reintroduces the error in later testing. These experiments demonstrate a fundamental base-rate error dependent on learned relationships: without interference from pre-existing associations between cues and options, predictions may be made more optimally.			Goodie, AS (corresponding author), UNIV CALIF SAN DIEGO,DEPT PSYCHOL,LA JOLLA,CA 92093, USA.							BARHILLEL M, 1980, ACTA PSYCHOL, V44, P211, DOI 10.1016/0001-6918(80)90046-3; CHAPMAN LJ, 1967, J ABNORM PSYCHOL, V72, P193, DOI 10.1037/h0024670; CHAPMAN LJ, 1969, J ABNORM PSYCHOL, V74, P271, DOI 10.1037/h0027592; GLUCK MA, 1988, J EXP PSYCHOL GEN, V117, P227, DOI 10.1037/0096-3445.117.3.227; GOODIE AS, 1995, PSYCHOL SCI, V6, P101, DOI 10.1111/j.1467-9280.1995.tb00314.x; HARTL JA, IN PRESS J EXP ANAL; HERRNSTEIN RJ, 1975, J EXP ANAL BEHAV, V24, P107, DOI 10.1901/jeab.1975.24-107; KAHNEMAN D, 1973, PSYCHOL REV, V80, P237, DOI 10.1037/h0034747; Kahneman Daniel, 1982, JUDGMENT UNCERTAINTY, P153, DOI DOI 10.1017/CBO9780511809477.011; MEDIN DL, 1988, J EXP PSYCHOL GEN, V117, P63; Myers J. L., 1976, HDB LEARNING COGNITI, P171; NOSOFSKY RM, 1992, J EXP PSYCHOL LEARN, V18, P211, DOI 10.1037/0278-7393.18.2.211	12	71	71	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					247	249		10.1038/380247a0	http://dx.doi.org/10.1038/380247a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UB117	8637572				2022-12-28	WOS:A1996UB11700051
J	Sil, A; Herskowitz, I				Sil, A; Herskowitz, I			Identification of an asymmetrically localized determinant, Ash1p, required for lineage-specific transcription of the yeast HO gene	CELL			English	Article							CELL-CYCLE REGULATION; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; LIFE-CYCLE; EXPRESSION; DNA; SW15; INTERCONVERSION; ENCODES; START	S. cerevisiae cells exhibit asymmetric determination of cell fate. Cell division yields a mother cell, which is competent to transcribe the HO gene and switch mating type, and a daughter cell, which is not. We have isolated a mutant in which daughters transcribe HO and switch mating type. This mutation defines the ASH1 gene (asymmetric synthesis of HO). Deletion and overexpression of ASH1 cause reciprocal cell fate transformations: in ash1 Delta strains, daughters switch mating type as efficiently as mothers. Conversely, overexpression of ASH1 inhibits switching in mother cells. Ash1p has a zinc finger motif related to those of GATA transcriptional regulators. Ash1p is localized to the daughter nucleus in cells that have undergone nuclear division. Thus, Ash1p is a cell fate determinant that is asymmetrically localized to the daughter nucleus where it inhibits HO transcription.			Sil, A (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NIAID NIH HHS [AI18738] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018738, R37AI018738] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ARIGONI F, 1995, SCIENCE, V270, P637, DOI 10.1126/science.270.5236.637; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DUNCAN L, 1995, SCIENCE, V270, P641, DOI 10.1126/science.270.5236.641; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; HADWIGER JA, 1990, NUCLEIC ACIDS RES, V18, P4025, DOI 10.1093/nar/18.13.4025; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HERSKOWITZ I, 1992, TRANSCRIPTIONAL REGU, P949; HICKS JB, 1976, GENETICS, V83, P245; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JENSEN R, 1983, P NATL ACAD SCI-BIOL, V80, P3035, DOI 10.1073/pnas.80.10.3035; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRUGER WD, 1991, THESIS U CALFORNIA S; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; ORKIN SH, 1992, BLOOD, V80, P575; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULTZ LD, 1983, J BACTERIOL, V155, P8, DOI 10.1128/JB.155.1.8-14.1983; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERN M, 1985, THESIS U CALIFORNIA; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; VOISARD C, 1993, MOL CELL BIOL, V13, P7091, DOI 10.1128/MCB.13.11.7091	49	216	219	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					711	722		10.1016/S0092-8674(00)81049-1	http://dx.doi.org/10.1016/S0092-8674(00)81049-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625409	Bronze			2022-12-28	WOS:A1996TZ99000009
J	Barbera, JA; Roger, N; Roca, J; Rovira, I; Higenbottam, TW; RodriguezRoisin, R				Barbera, JA; Roger, N; Roca, J; Rovira, I; Higenbottam, TW; RodriguezRoisin, R			Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease	LANCET			English	Article							RESPIRATORY-DISTRESS SYNDROME; VASOCONSTRICTION; HYPERTENSION	Background Inhalation of nitric oxide (NO) causes selective pulmonary vasodilation and improves arterial oxygenation in acute respiratory distress syndrome. But some patients do not respond or gas exchange worsens when inhaling NO. We hypothesised that this detrimental effect might be related to the reversion of hypoxic vasoconstriction in those patients where this mechanism contributes to ventilation-perfusion (V-A/Q) matching. Methods We studied 13 patients with advanced chronic obstructive pulmonary disease (COPD). We compared their responses to breathing room air, NO at 40 parts per million in air, and 100% O-2. Changes in pulmonary haemodynamics, blood gases, and V-A/Q distributions were assessed. Findings NO inhalation decreased the mean (SE) pulmonary artery pressure from 25.9 (2.0) to 21.5 (1.7) mm Hg (p=0.001) and PaO2 from 56 (2) to 53 (2) mm Hg (p=0.014). The decrease in PaO2 resulted from worsening of V-A/Q distributions, as shown by a greater dispersion of the blood-flow distribution (logSD Q) from 1.11 (0.1) to 1.22 (0.1) (p=0.018). O-2 breathing reduced the mean pulmonary arterial pressure to 23.4 (2.1) mm Hg and caused greater V-A/Q mismatch (logSD Q, 1.49 [0.1]). The intrapulmonary shunt on room air was small (2.7 [0.9]%) and did not change when beathing NO or O-2. Interpretation We conclude that in patients with COPD, in whom hypoxaemia is caused essentially by V-A/Q imbalance rather than by shunt, inhaled NO can worsen gas exchange because of impaired hypoxic regulation of the matching between ventilation and perfusion.	UNIV BARCELONA,HOSP CLIN,SERV ANESTESIA & REANIMACIO,DEPT MED,E-08036 BARCELONA,SPAIN; PAPWORTH HOSP,DEPT RESP PHYSIOL,CAMBRIDGE,ENGLAND	University of Barcelona; Hospital Clinic de Barcelona; Papworth Hospital	Barbera, JA (corresponding author), UNIV BARCELONA,HOSP CLIN,SERV PNEUMOL & ALLERGIA RESP,DEPT MED,E-08036 BARCELONA,SPAIN.		Roca, Josep/J-2583-2015; Roger, Núria/AAE-4040-2021	Roca, Josep/0000-0003-4768-8722; Barbera, Joan Albert/0000-0003-1469-4990				ADNOT S, 1993, AM REV RESPIR DIS, V148, P310, DOI 10.1164/ajrccm/148.2.310; AGUSTI AGN, 1990, CHEST, V97, P268, DOI 10.1378/chest.97.2.268; BARBERA JA, 1990, AM REV RESPIR DIS, V141, P895, DOI 10.1164/ajrccm/141.4_Pt_1.895; BARBERA JA, 1994, AM J RESP CRIT CARE, V149, P423, DOI 10.1164/ajrccm.149.2.8306040; DANTZKER DR, 1975, J APPL PHYSIOL, V38, P886, DOI 10.1152/jappl.1975.38.5.886; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; FROSTELL CG, 1993, ANESTHESIOLOGY, V78, P247; GERLACH H, 1993, EUR J CLIN INVEST, V23, P445; MELOT C, 1984, AM REV RESPIR DIS, V130, P612; MIRA JP, 1994, INTENS CARE MED, V20, P532, DOI 10.1007/BF01711913; MOINARD J, 1994, AM J RESP CRIT CARE, V149, P1482, DOI 10.1164/ajrccm.149.6.8004302; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; PISON U, 1993, J APPL PHYSIOL, V74, P1287, DOI 10.1152/jappl.1993.74.3.1287; REYES A, 1988, AM REV RESPIR DIS, V137, P1062, DOI 10.1164/ajrccm/137.5.1062; RICOU B, 1993, AM REV RESPIR DIS, V147, pA350; ROCA J, 1994, THORAX, V49, P815, DOI 10.1136/thx.49.8.815; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SPRAGUE RS, 1992, P NATL ACAD SCI USA, V89, P8711, DOI 10.1073/pnas.89.18.8711; WAGNER PD, 1987, AM REV RESPIR DIS, V136, P605, DOI 10.1164/ajrccm/136.3.605; WALMRATH D, 1995, AM J RESP CRIT CARE, V151, P724; WEITZENBLUM E, 1994, EUR RESPIR J, V7, P148, DOI 10.1183/09031936.94.07010148; 1987, AM REV RESPIR DIS, V136, P225	22	185	186	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					436	440		10.1016/S0140-6736(96)90011-2	http://dx.doi.org/10.1016/S0140-6736(96)90011-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618485				2022-12-28	WOS:A1996TV72200011
J	Dandona, P; Thusu, K; Cook, S; Snyder, B; Makowski, J; Armstrong, D; Nicotera, T				Dandona, P; Thusu, K; Cook, S; Snyder, B; Makowski, J; Armstrong, D; Nicotera, T			Oxidative damage to DNA in diabetes mellitus	LANCET			English	Article							BLOOMS SYNDROME	Background Increased production of reactive oxygen species (ROS) and lipid peroxidation may contribute to vascular complications in diabetes. To test whether DNA is also oxidatively damaged in diabetes, we measured 8-hydroxydeoxyguanosine (8-OHdG), an indicator of oxidative damage of DNA, in mononuclear cells. Methods For this laboratory-based study, 12 patients with insulin-dependent diabetes mellitus (IDDM) and 15 patients with non-insulin-dependent diabetes mellitus (NIDDM) were matched by age with ten healthy volunteers each. DNA was extracted from mononuclear cells from whole blood. 8-OHdG was assayed by high-pressure liquid chromatography, and ROS were assayed by chemiluminescence. Findings IDDM and NIDDM patients had significantly higher median concentrations (p<0.001, U test) of 8-OHdG in their mononuclear cells than their corresponding controls (in fmol/mu g DNA): 128.2 (interquartile range 96.0-223.2) and 95.2 (64.0-133.5) vs 28.2 (21.7-43.4) and 21.9 (18.0-24.4), respectively. ROS generation by mononuclear cells was also significantly greater (p<0.01) in diabetic their controls (in mV): 238.0 (107.0-243.0) and 101.3 (66.0-134.0) vs 69.5 (49.8-91.9) and 56.0 (38.8-62.5), respectively. Interpretation IDDM and NIDDM patients showed greater oxidative damage to DNA, with increased generation of ROS, than controls. Such changes might contribute to accelerated aging and atherogenesis in diabetes and to the microangiopathic complications of the disease.	SUNY BUFFALO,DEPT MED TECHNOL,BUFFALO,NY; ROSWELL PK CANC INST,DEPT BIOPHYS,BUFFALO,NY 14263	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute	Dandona, P (corresponding author), MILLARD FILLMORE HOSP,DEPT MED,DIABET ENDOCRINOL CTR WESTERN NEW YORK,BUFFALO,NY 14209, USA.							ARMSTRONG D, 1991, FREE RADICAL BIO MED, V11, P433, DOI 10.1016/0891-5849(91)90161-U; Cadet J, 1994, IARC Sci Publ, P245; GERMAN J, 1989, CLIN GENET, V35, P57; HATAHET Z, 1993, ANN NY ACAD SCI, V726, P346; KITAHARA M, 1980, DIABETES, V29, P251, DOI 10.2337/diab.29.4.251; NICOTERA T, 1993, CANCER RES, V53, P5104; NICOTERA TM, 1994, PHOTOCHEM PHOTOBIOL, V60, P295, DOI 10.1111/j.1751-1097.1994.tb05107.x; OMARA BA, 1985, J CHRON DIS, V38, P435, DOI 10.1016/0021-9681(85)90139-0; SAUL G, 1988, METHODS DETECTING DN, P407; SOHAL RS, 1994, SCIENCE, V263, P1128	10	622	647	1	43	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					444	445		10.1016/S0140-6736(96)90013-6	http://dx.doi.org/10.1016/S0140-6736(96)90013-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618487				2022-12-28	WOS:A1996TV72200013
J	Delbanco, TL; Daley, J				Delbanco, TL; Daley, J			A 72-year-old man with localized prostate cancer, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		ALBERTSEN P, 1995, JAMA-J AM MED ASSOC, V274, P69, DOI 10.1001/jama.274.1.69	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					485	485						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627972				2022-12-28	WOS:A1996TU63800039
J	Bortvin, A; Winston, F				Bortvin, A; Winston, F			Evidence that Spt6p controls chromatin structure by a direct interaction with histones	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PERIODIC TRANSCRIPTION; NUCLEAR-PROTEIN; ESSENTIAL GENE; YEAST; IDENTIFICATION; SNF2/SWI2; SUPPRESS; HOMOLOG; ENCODES	Genetic analysis has implicated SPT6, an essential gene of Saccharomyces cerevisiae, in the control of chromatin structure. Mutations in SPT6 and particular mutations in histone genes are able to overcome transcriptional defects in strains lacking the Snf/Swi protein complex. Here it is shown that an spt6 mutation causes changes in chromatin structure in vivo. In addition, both in vivo and in vitro experiments provide evidence that Spt6p interacts directly with histones and primarily with histone H3. Consistent with these findings, Spt6p is capable of nucleosome assembly in vitro.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School				Bortvin, Alex/0000-0003-0987-1905	NIGMS NIH HHS [GM32967] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032967, R37GM032967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBET FM, 1988, CURRENT PROTOCOLS MO; BORTVIN A, UNPUB; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CLARKADAMS CD, 1987, MOL CELL BIOL, V7, P679, DOI 10.1128/MCB.7.2.679; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; EDMONDSON DG, IN PRESS GENES DEV; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARTZOG GA, IN PRESS MOL CELL BI; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HEREFORD L, 1982, CELL, V30, P305, DOI 10.1016/0092-8674(82)90036-8; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1987, MOL CELL BIOL, V7, P672, DOI 10.1128/MCB.7.2.672; NISHIWAKI K, 1993, MOL GEN GENET, V239, P313, DOI 10.1007/BF00276929; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PRELICH G, 1993, GENETICS, V135, P665; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; Sherman F., 1978, METHODS YEAST GENETI; SWANSON MS, 1990, MOL CELL BIOL, V10, P4935, DOI 10.1128/MCB.10.9.4935; SWANSON MS, 1992, GENETICS, V132, P325; van Holde KE., 1989, SPRINGER SERIES MOL; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	40	282	282	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1473	1476		10.1126/science.272.5267.1473	http://dx.doi.org/10.1126/science.272.5267.1473			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633238				2022-12-28	WOS:A1996UP89900045
J	Strelnitski, V; Haas, MR; Smith, HA; Erickson, EF; Colgan, SWJ; Hollenbach, DJ				Strelnitski, V; Haas, MR; Smith, HA; Erickson, EF; Colgan, SWJ; Hollenbach, DJ			Far-infrared hydrogen lasers in the peculiar star MWC 349A	SCIENCE			English	Article							RECOMBINATION LINE MASER; MWC-349	Far-infrared hydrogen recombination lines H15 alpha (169.4 micrometers), H12 alpha (88.8 micrometers), and H10 alpha (52.5 micrometers) were detected in the peculiar luminous star MWC 349A from the Kuiper Airborne Observatory. Here it is shown that at least H15 alpha is strongly amplified, with the probable amplification factor being greater than or about equal to 10(3) and a brightness temperature that is greater than or about equal to 10(7) kelvin. The other two lines also show signs of amplification, although to a lesser degree. Beyond H10 alpha the amplification apparently vanishes. The newly detected amplified lines fall into the laser wavelength domain. These lasers, as well as the previously detected hydrogen masers, may originate in the photoionized circumstellar disk of MWC 349A and constrain the disk's physics and structure.	NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; SEARCH EXTRATERR INTELLIGENCE INST,MT VIEW,CA 94043	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Strelnitski, V (corresponding author), SMITHSONIAN INST,NATL AIR & SPACE MUSEUM,ASTROPHYS LAB,WASHINGTON,DC 20560, USA.		Colgan, Sean W J/M-4742-2014					ALTENHOFF WJ, 1981, ASTRON ASTROPHYS, V93, P48; BEZARD B, 1986, ASTRON ASTROPHYS, V161, P387; CHEUNG AC, 1969, NATURE, V221, P626, DOI 10.1038/221626a0; COHEN M, 1985, ASTROPHYS J, V292, P249, DOI 10.1086/163154; DICKINSON RE, 1986, J GEOPHYS RES, V91, P70, DOI 10.1029/JA091iA01p00070; ERICKSON EF, 1995, P AIRB ASTR S GAL EC, P707; ERICKSON EF, 1984, P SOC PHOTOOPT INSTR, V509, P129; Gordiets B. F., 1983, Cosmic Research, V21, P725; GORDON MA, 1992, ASTROPHYS J, V387, P701, DOI 10.1086/171117; GWINN CR, 1992, ASTROPHYS J, V393, P149, DOI 10.1086/171493; HAAS MR, 1982, ICARUS, V51, P476, DOI 10.1016/0019-1035(82)90141-5; HAMANN F, 1986, ASTROPHYS J, V311, P909, DOI 10.1086/164828; HOLLENBACH D, 1994, ASTROPHYS J, V428, P654, DOI 10.1086/174276; KIM KJ, 1990, SCIENCE, V250, P88, DOI 10.1126/science.250.4977.88; KROLIK JH, 1978, ASTROPHYS J SUPPL S, V37, P459, DOI 10.1086/190538; MARTINPINTADO J, 1989, ASTRON ASTROPHYS, V215, pL13; MARTINPINTADO J, 1989, A A, V229, pL9; MASERS, 1984, ENCY AM; MATTHEWS S, 1977, 73204 X NASA, P1; MENTEN KM, 1995, ASTROPHYS J, V450, pL67, DOI 10.1086/316776; Merrill PW, 1933, ASTROPHYS J, V78, P87, DOI 10.1086/143490; Mumma M. J., 1993, ASTROPHYSICAL MASERS, P455; MUMMA MJ, 1981, SCIENCE, V212, P45, DOI 10.1126/science.212.4490.45; POPOULAR R, 1983, ASTRON ASTROPHYS, V117, P46; RODRIGUEZ LF, 1994, ASTROPHYS J, V428, P324, DOI 10.1086/174243; SCOVILLE N, 1983, ASTROPHYS J, V275, P201, DOI 10.1086/161526; SEATON MJ, 1959, MON NOT R ASTRON SOC, V119, P90, DOI 10.1093/mnras/119.2.90; SHU FH, 1993, ICARUS, V106, P92, DOI 10.1006/icar.1993.1160; SMITH H, UNPUB; SMITH HA, 1979, ASTROPHYS J, V233, P132, DOI 10.1086/157374; STEPANOVA GI, 1985, SOV ASTRON LETT, V11, P390; STOREY PJ, 1995, MON NOT R ASTRON SOC, V272, P41, DOI 10.1093/mnras/272.1.41; STRELENITSKI VS, 1994, P AIRB ASTR S GAL EC; STRELNITSKI VS, IN PRESS ASTROPHYS J; STRELNITSKI VS, 1996, AMAZING LIGHT, P603; THOMPSON RI, 1977, ASTROPHYS J, V218, P170, DOI 10.1086/155668; THUM C, 1995, ASTRON ASTROPHYS, V300, P843; THUM C, 1994, ASTRON ASTROPHYS, V283, P582; THUM C, 1992, ASTRON ASTROPHYS, V256, P507; THUM C, 1994, ASTRON ASTROPHYS, V288, pL25; WEAVER H, 1965, NATURE, V208, P29, DOI 10.1038/208029a0	41	42	42	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1459	1461		10.1126/science.272.5267.1459	http://dx.doi.org/10.1126/science.272.5267.1459			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633236	Green Published			2022-12-28	WOS:A1996UP89900040
J	Petrie, KJ; Weinman, J; Sharpe, N; Buckley, J				Petrie, KJ; Weinman, J; Sharpe, N; Buckley, J			Role of patients' view of their illness in predicting return to work and functioning after myocardial infarction: Longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC REHABILITATION	Objective-To examine whether patients' initial perceptions of their myocardial infarction predict subsequent attendance at a cardiac rehabilitation course, return to work, disability, and sexual dysfunction. Design-Patients' perceptions of their illness were measured at admission with their first myocardial infarction and at follow up three and six months later. Setting-Two large teaching hospitals in Auckland, New Zealand. Subjects-143 consecutive patients aged under 65 with their first myocardial infarction. Main outcome measures-Attendance at rehabilitation course; time before returning to work; measures of disability with sickness impact profile questionnaire for sleep and rest, social interaction, recreational activity, and home management; and sexual dysfunction. Results-Attendance at the rehabilitation course was significantly related to a stronger belief during admission that the illness could be cured or controlled (t=2.08, P=0.04), Return to work within six weeks was significantly predicted by the perception that the illness would last a short time (t=-2.52, P=0.01) and have less grave consequences for the patient (t=-2.87, P=0.005), Patients' belief that their heart disease would have serious consequences was significantly related to later disability in work around the house, recreational activities, and social interaction, A strong illness identity was significantly related to greater sexual dysfunction at both three and six months. Conclusions-Patients' initial perceptions of illness are important determinants of different aspects of recovery after myocardial infarction, Specific illness perceptions need to be identified at an early stage as a basis for optimising outcomes from rehabilitation programmes.	UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,UNIT PSYCHOL,LONDON SE1 9RT,ENGLAND; UNIV AUCKLAND,SCH MED,DEPT MED,AUCKLAND,NEW ZEALAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Auckland	Petrie, KJ (corresponding author), UNIV AUCKLAND,SCH MED,DEPT PSYCHIAT & BEHAV SCI,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.			Buckley, Judith/0000-0003-0374-5369				ADES PA, 1992, ARCH INTERN MED, V152, P1033, DOI 10.1001/archinte.152.5.1033; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BYRNE DG, 1982, J PSYCHOSOM RES, V26, P105, DOI 10.1016/0022-3999(82)90028-9; DIEDERIKS JPM, 1991, J PSYCHOSOM RES, V35, P687, DOI 10.1016/0022-3999(91)90119-9; FLAPAN AD, 1994, BMJ-BRIT MED J, V309, P1129, DOI 10.1136/bmj.309.6962.1129; GARRITY TF, 1973, SOC SCI MED, V7, P705, DOI 10.1016/0037-7856(73)90004-8; GARRITY TF, 1975, PSYCHOL ASPECTS MYOC; GOBLE AJ, 1991, BRIT HEART J, V65, P126; Leventhal H., 1980, MED PSYCHOL, V2, P7; Ley P., 1988, COMMUNICATING PATIEN; LIPKIN DP, 1991, BRIT HEART J, V65, P237; LOGAN RL, 1986, NEW ZEAL MED J, V99, P368; MAELAND JG, 1987, J PSYCHOSOM RES, V31, P471, DOI 10.1016/0022-3999(87)90005-5; Skelton JA, 1991, MENTAL REPRESENTATIO; Stewart AL, 1992, MEASURING FUNCTIONIN; Weinman J, 1996, PSYCHOL HEALTH, V11, P114	16	464	472	0	28	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1191	1194						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UL058	8634561				2022-12-28	WOS:A1996UL05800016
J	Strachan, DP; Butland, BK; Anderson, HR				Strachan, DP; Butland, BK; Anderson, HR			Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort	BRITISH MEDICAL JOURNAL			English	Article							RISK FACTOR; NATURAL-HISTORY; BIRTH; PREMATURITY; CHILDREN	Objective-To describe the incidence and prognosis of wheezing illness from birth to age 33 and the relation of incidence to, perinatal, medical, social, environmental, and lifestyle factors. Design-Prospective longitudinal study. Setting-England, Scotland, and Wales. Subjects-18 559 people born on 3-9 March 1958. 5801 (31%) contributed information at ages 7, 11, 16, 23, and 33 years. Attrition bias was evaluated using information on 14 571 (79%) subjects. Main outcome measure-History of asthma, wheezy bronchitis, or wheezing obtained from interview with subjects' parents at ages 7, 11, and 16 and reported at interview by subjects at ages 23 and 33. Results-The cumulative incidence of wheezing illness was 18% by age 7, 24% by age 16, and 43% by age 33. Incidence during childhood was strongly and independently associated with pneumonia, hay fever, and eczema. There were weaker independent associations with male sex, third trimester antepartum haemorrhage, whooping cough, recurrent abdominal pain, and migraine. Incidence from age 17 to 33 was associated strongly with active cigarette smoking and a history of hay fever. There were weaker independent associations with female sex, maternal albuminuria during pregnancy, and histories of eczema and migraine. Maternal smoking during pregnancy was weakly and inconsistently related to childhood wheezing but was a stronger and significant independent predictor of incidence after age 16. Among 880 subjects who developed asthma or wheezy bronchitis from birth to age 7, 50% had attacks in the previous year at age 7; 18% at 11, 10% at 16, 10% at 23, and 27% at 33. Relapse at 33 after prolonged remission of childhood wheezing was more common among current smokers and atopic subjects. Conclusion-Atopy and active cigarette smoking are major influences on the incidence and recurrence of wheezing during adulthood.			Strachan, DP (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Anderson, Hugh R/A-7417-2016	Butland, Barbara/0000-0001-9952-3108				ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; ANDERSON HR, 1987, CHEST, V91, pS127, DOI 10.1378/chest.91.6.127S; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; BUTLER NR, 1969, PERINATAL PROBLEMS; Davie R., 1972, BIRTH 7 2 REPORT CHI; DOLOVICH J, 1981, THORAX, V36, P641, DOI 10.1136/thx.36.9.614; FERRI E, 1993, LIFE 33 5 FOLLOW UP; Fogelman K., 1976, BRITAINS 16 YEAR OLD; GILES GG, 1984, AUST NZ J MED, V14, P631, DOI 10.1111/j.1445-5994.1984.tb05015.x; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; JONES A, 1994, BRIT J GEN PRACT, V44, P127; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312, DOI 10.1164/ajrccm/143.2.312; RONA RJ, 1993, BMJ-BRIT MED J, V306, P817, DOI 10.1136/bmj.306.6881.817; *SAS SYST, 1990, SAS STAT US GUID VER; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584, DOI 10.1136/adc.66.5.584; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1985, J ROY COLL GEN PRACT, V35, P182; VONMUTIUS E, 1993, J PEDIATR-US, V123, P223, DOI 10.1016/S0022-3476(05)81692-0	21	476	478	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1195	1199						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634562				2022-12-28	WOS:A1996UL05800018
J	Duthie, DJR				Duthie, DJR			Aminoacid infusions to prevent postoperative hypothermia	LANCET			English	Editorial Material							ACID INFUSION				Duthie, DJR (corresponding author), PAPWORTH HOSP,DEPT ANAESTHESIA,CAMBRIDGE,ENGLAND.							CARLSON GL, 1994, AM J PHYSIOL, V266, pE848; GIOVANNINI I, 1988, CRIT CARE MED, V16, P667, DOI 10.1097/00003246-198807000-00004; HALL GM, 1978, ANAESTHESIA, V33, P924; HERSIO K, 1991, CRIT CARE MED, V19, P503, DOI 10.1097/00003246-199104000-00008; JEQUIER E, 1986, CLIN NUTR, V5, P181, DOI 10.1016/0261-5614(86)90022-1; SELIDEN E, 1994, CLIN SCI, V86, P611; SELLDEN E, 1996, BRIT J ANAESTH, V96, P227; SESSLER DI, 1993, FASEB J, V7, P638, DOI 10.1096/fasebj.7.8.8500688	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1199	1199		10.1016/S0140-6736(96)90728-X	http://dx.doi.org/10.1016/S0140-6736(96)90728-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622444				2022-12-28	WOS:A1996UJ59700003
J	Murphy, AW; Bury, G; Plunkett, PK; Gibney, D; Smith, M; Mullan, E; Johnson, Z				Murphy, AW; Bury, G; Plunkett, PK; Gibney, D; Smith, M; Mullan, E; Johnson, Z			Randomised controlled trial of general practitioner versus usual medical care in an urban accident and emergency department: Process, outcome, and comparative cost	BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL EMERGENCY	Objective-To see whether care provided by general practitioners to non-emergency patients in an accident and emergency department differs significantly from care by usual accident and emergency staff in terms of process, outcome, and comparative cost. Design-A randomised controlled trial. Setting-A busy inner city hospital's accident and emergency department which employed three local general practitioners on a sessional basis. Patients-All new attenders categorised by the triage system as ''semiurgent'' or ''delay acceptable.'' 66% of all attenders were eligible for inclusion. Main outcome measures-Numbers of patients undergoing investigation, referral, or prescription; types of disposal; consultation satisfaction scores; reattendance to accident and emergency department within 30 days of index visit; health status at one month; comparative cost differences. Results-4684 patients participated. For semiurgent patients, by comparison with usual accident and emergency staff, general practitioners investigated fewer patients (relative difference 20%; 95% confidence interval 16% to 25%), referred to other hospital services less often (39%; 28% to 47%), admitted fewer patients (45%; 32% to 56%), and prescribed more often (41%; 30% to 54%). A similar trend was found for patients categorised as delay acceptable and (in a separate analysis) by presenting complaint category. 393 (17%) patients who had been seen by general practitioner staff reattended the department within 30 days of the index visit; 418 patients (18%) seen by accident and emergency staff similarly reattended. 435 patients (72% of those eligible) completed the consultation satisfaction questionnaire and 258 (59% of those eligible) provided health status information one month after consultation. There were no differences between patients managed by general practitioners and those managed by usual staff regarding consultation satisfaction questionnaire scores or health status. For all patients seen by general practitioners during the study, estimated marginal and total savings were pound Ir1427 and pound Ir117 005 respectively. Conclusion-General practitioners working as an integral part of an accident and emergency department manage non-emergency accident and emergency attenders safely and use fewer resources than do usual accident and emergency staff.	ST JAMES HOSP,DEPT ACCID & EMERGENCY MED,DUBLIN 8,IRELAND; DR STEEVENS HOSP,EASTERN HLTH BOARD,HLTH INFORMAT UNIT,DUBLIN 8,IRELAND	Trinity College Dublin	Murphy, AW (corresponding author), NATL UNIV IRELAND UNIV COLL DUBLIN,COOMBE HEALTHCARE CTR,DEPT GEN PRACTICE,DUBLIN 8,IRELAND.		Bury, Gerard/D-2985-2019; Bury, Gerard/J-8813-2019	Bury, Gerard/0000-0002-4441-6724; Bury, Gerard/0000-0002-4441-6724; Plunkett, Patrick/0000-0003-0714-2717				ARMSTRONG AM, 1991, SCOT MED J, V36, P111, DOI 10.1177/003693309103600405; BADER JM, 1993, LANCET, V342, P857, DOI 10.1016/0140-6736(93)92706-Y; BAKER R, 1991, FAM PRACT, V8, P171, DOI 10.1093/fampra/8.2.171; Baker R, 1992, Qual Health Care, V1, P104, DOI 10.1136/qshc.1.2.104; BAKER R, 1990, BRIT J GEN PRACT, V40, P487; BINDMAN AB, 1995, BRIT MED J, V311, P404, DOI 10.1136/bmj.311.7002.404; BLISS HA, 1982, NEW ENGL J MED, V306, P998; BOERMA WGA, 1993, HLTH CARE GEN PRACT; BROOK RH, 1994, BRIT MED J, V308, P218, DOI 10.1136/bmj.308.6923.218; COURT C, 1994, BRIT MED J, V309, P132; DALE J, 1992, BRIT J GEN PRACT, V42, P90; DALE J, 1995, BRIT MED J, V311, P427, DOI 10.1136/bmj.311.7002.427; DALE J, 1995, BRIT MED J, V311, P423, DOI 10.1136/bmj.311.7002.423; DALY LE, 1991, INTERPRETATION USES, P426; DRISCOLL PA, 1987, ARCH EMERG MED, V4, P77; DUILLNER J, 1994, BR J GEN PRACT, V44, P251; FOLDES SS, 1994, ANN EMERG MED, V23, P833, DOI 10.1016/S0196-0644(94)70322-1; FOROUGHI D, 1989, PRACTITIONER, V233, P657; GEORGE S, 1993, J EPIDEMIOL COMMUN H, V47, P312, DOI 10.1136/jech.47.4.312; GREEN J, 1990, HLTH ED J, V49, P157, DOI DOI 10.1177/001789699004900402; HANSAGI H, 1987, PUBLIC HEALTH, V101, P99, DOI 10.1016/S0033-3506(87)80046-X; HOBBS R, 1995, BRIT MED J, V310, P207, DOI 10.1136/bmj.310.6974.207; HYNES M, 1990, ACCIDENT EMERGENCY R; KALISZER M, 1975, J IRISH MED ASSOC, V68, P159; *KINGS COLL HOSP A, 1991, PROV PRIM CAR PROGR; LAMBERTS H, 1993, INT CLASSIFICATION P; LERMAN B, 1987, PUBLIC HLTH, V101, P99; MCCABE JB, 1994, ANN EMERG MED, V23, P872, DOI 10.1016/S0196-0644(94)90004-3; OSHEA JS, 1984, CLIN PEDIATR, V23, P559, DOI 10.1177/000992288402301005; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; STRAUS JH, 1983, AM J PUBLIC HEALTH, V73, P57, DOI 10.2105/AJPH.73.1.57; *SUBC CENTR HLTH S, 1962, ACC EM SERV; WARE JE, 1993, BRIT MED J, V306, P1429, DOI 10.1136/bmj.306.6890.1429; Wilkinson A, 1977, J R Coll Gen Pract, V27, P727; World Health Organisation, 1991, GUID DEF DAIL DOS; 1975, J IRISH MED ASSOC, V68, P181; 1994, LANCET, V343, P305	38	83	84	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1135	1142						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620132				2022-12-28	WOS:A1996UK06900026
J	Thapa, S				Thapa, S			Challenges to improving maternal health in rural Nepal	LANCET			English	Article											Thapa, S (corresponding author), FAMILY HLTH INT,POPULAT & REPROD HLTH TECH SERV OFF,KATMANDU,NEPAL.		Thapa, Shyam/AAV-1700-2021					*FAM HLTH INT NEP, 1995, POP HLTH DAT BANK; Thapa S, 1995, Asia Pac Popul J, V10, P3; THAPA S, 1995, CORRELATES DETERMINA	3	10	10	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1244	1246		10.1016/S0140-6736(96)90748-5	http://dx.doi.org/10.1016/S0140-6736(96)90748-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622462				2022-12-28	WOS:A1996UJ59700022
J	Kamei, Y; Xu, L; Heinzel, T; Torchia, J; Kurokawa, R; Gloss, B; Lin, SC; Heyman, RA; Rose, DW; Glass, CK; Rosenfeld, MG				Kamei, Y; Xu, L; Heinzel, T; Torchia, J; Kurokawa, R; Gloss, B; Lin, SC; Heyman, RA; Rose, DW; Glass, CK; Rosenfeld, MG			A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors	CELL			English	Article							THYROID-HORMONE RECEPTORS; RETINOID X-RECEPTOR; GLUCOCORTICOID RECEPTOR; DNA-BINDING; FACTOR CREB; RXR-BETA; C-JUN; ACID; PROTEIN; FOS	Nuclear receptors regulate gene expression by direct activation of target genes and inhibition of AP-1. Here we report that, unexpectedly, activation by nuclear receptors requires the actions of CREB-binding protein (CBP) and that inhibition of AP-1 activity is the apparent result of competition for limiting amounts of CBP/p300 in cells. Utilizing distinct domains, CBP directly interacts with the ligand-binding domain of multiple nuclear receptors and with the p160 nuclear receptor coactivators, which upon cloning have proven to be variants of the SRC-1 protein. Because CBP represents a common factor, required in addition to distinct coactivators for function of nuclear receptors, CREB, and AP-1, we suggest that CBP/p300 serves as an integrator of multiple signal transduction pathways within the nucleus.	UNIV CALIF SAN DIEGO,SCH MED,BIOMED SCI GRAD PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,WHITTIER DIABET ASSOC DEPT,LA JOLLA,CA 92093; LIGAND PHARMACEUT INC,SAN DIEGO,CA 92121	University of California System; University of California San Diego; University of California System; University of California San Diego; Ligand Pharmaceuticals	Kamei, Y (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093, USA.		Heinzel, Thorsten/B-1013-2015; Glass, Christopher/AAI-3933-2021; Lin, SC/G-4666-2010	Glass, Christopher/0000-0003-4344-3592; 				Abate C, 1990, Semin Cancer Biol, V1, P19; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; Drapkin R, 1993, CURR OPIN CELL BIOL, V5, P469, DOI 10.1016/0955-0674(93)90013-G; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; ONATE SA, 1995, SCIENCE, V270, P1354; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAITOU M, 1994, J BIOL CHEM, V269, P19101; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	62	1889	1948	0	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					403	414		10.1016/S0092-8674(00)81118-6	http://dx.doi.org/10.1016/S0092-8674(00)81118-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616895	Green Published, Bronze			2022-12-28	WOS:A1996UK14000013
J	Yang, JY; Jayaram, M; Harshey, RM				Yang, JY; Jayaram, M; Harshey, RM			Positional information within the Mu transposase tetramer: Catalytic contributions of individual monomers	CELL			English	Article							PHAGE-MU; STRAND TRANSFER; DNA ENDS; SITE; PROTEIN; RECOMBINATION; DOMAINS; MECHANISM; COMPLEXES; CLEAVAGE	The strand cleavage and strand transfer reactions of Mu DNA transposition require structural/catalytic contributions from separate polypeptide domains of individual transposase (MuA) monomers within the functional MuA tetramer. Based on catalytic complementation between two inactive MuA variants, we have derived certain rules by which the physical location of a MuA monomer within the transposition complex specifies its role in DNA breakage and transfer. During strand transfer, MuA monomers contributing domain II to the reaction occupy R1 (the subsite proximal to the strand-transferred nucleotide), while those contributing domain III alpha occupy R2. The positions of the monomers contributing these two domains appear to be reversed during DNA cleavage.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								ALDAZ H, 1996, IN PRESS CELL, V85; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BETERMIER M, 1989, MOL MICROBIOL, V3, P1159, DOI 10.1111/j.1365-2958.1989.tb00266.x; CARVER TE, 1994, P NATL ACAD SCI USA, V91, P10670, DOI 10.1073/pnas.91.22.10670; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; JAYARAM M, 1994, TRENDS BIOCHEM SCI, V19, P78, DOI 10.1016/0968-0004(94)90039-6; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM K, 1995, NUCLEIC ACIDS RES, V23, P3937, DOI 10.1093/nar/23.19.3937; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE D, 1995, CURR TOP MICROBIOL, V204, P83; LEE J, 1993, J BIOL CHEM, V268, P17564; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEE J, 1996, IN PRESS J MOL BIOL; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NAMGOONG S, 1994, J MOL BIOL, V238, P514, DOI 10.1006/jmbi.1994.1311; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SAVILAHTI H, 1996, IN PRESS CELL, V85; SERRE MC, 1992, J MOL BIOL, V225, P621, DOI 10.1016/0022-2836(92)90390-6; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; WHANG I, 1994, MOL CELL BIOL, V14, P7492, DOI 10.1128/MCB.14.11.7492; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANGJY, 1995, GENE DEV, V9, P2545; ZOU A, 1991, J BIOL CHEM, V266, P20476	40	34	35	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					447	455		10.1016/S0092-8674(00)81122-8	http://dx.doi.org/10.1016/S0092-8674(00)81122-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616899	Bronze			2022-12-28	WOS:A1996UK14000017
J	Pringle, M; Rothera, I				Pringle, M; Rothera, I			Practicality of recording patient ethnicity in general practice: Descriptive intervention study and attitude survey	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the feasibility of recording patient ethnicity in primary care using the Office of Population Censuses and Surveys classification. Design-A descriptive intervention study and attitude survey in random samples of adults and primary care staff in randomly selected practices. Setting-Eight practices in Lincolnshire and seven in Leicester. Subjects and methods-When patients were asked their ethnicity by general practitioners, nurses, or receptionists data were collected for 863 of a possible 880 patients. Of 750 patients sent a questionnaire about their attitudes towards the collection of such data 489 responded. Ninety live primary care staff completed a similar questionnaire. Main outcome measures-Time taken to record a patient's ethnicity; attitudes of patients and staff towards such recording, including who should ask, who can respond for others, and whether data can be shared with secondary care. Results-Recording, the data took less than a minute for three quarters of patients, but even this would need an average of a week of receptionist time per general practitioner. 72% of patients and 57% of staff agreed that ethnic data could be shared with secondary care, and 73% of patients and 60% of staff felt that the data should probably be collected in general practice. Conclusions-Ethnicity recording in general practice is feasible and acceptable. Nevertheless, the role of ethnic data in assessing health need in primary care, an adequate recording system, and evidence that recording offers benefits greater than the costs need to be established.			Pringle, M (corresponding author), QUEENS MED CTR,SCH MED,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							ASPINALL PJ, 1995, BRIT MED J, V311, P1006; Audit Commission, 1994, WHAT SEEMS BE MATT C; AZUONYE IO, 1994, BRIT MED J, V309, P959; BALARAJAN R, 1993, ETHNICITY HLTH; BENZEVAL M, 1995, HEALTH SERV RES, V30, P163; BRADBY H, 1995, SOCIOL HEALTH ILL, V17, P405, DOI 10.1111/1467-9566.ep10933332; BULGER G, 1994, BR J GEN PRACT, V43, P351; Carr-Hill R, 1995, Health Serv J, V105, P28; *CHIEF MED OFF HLT, 1995, VAR HLTH WHAT CAN DE; GILL PS, 1995, BRIT MED J, V310, P890, DOI 10.1136/bmj.310.6984.890; GRIFFITHS C, 1994, BRIT J GEN PRACT, V44, P201; HAHN RA, 1992, JAMA-J AM MED ASSOC, V267, P268, DOI 10.1001/jama.267.2.268; HAWTHORNE K, 1994, FAM PRACT, V11, P453, DOI 10.1093/fampra/11.4.453; HEATH I, 1991, BRIT J GEN PRACT, V41, P310; KING M, 1994, BMJ-BRIT MED J, V309, P1115, DOI 10.1136/bmj.309.6962.1115; KLAJAKOVIC M, 1993, NZ MED J, V106, P103; LEE EC, 1994, BRIT J GEN PRACT, V44, P268; MALCOLM PN, 1995, BRIT MED J, V310, P910, DOI 10.1136/bmj.310.6984.910; MCKENNEY NR, 1994, PUBLIC HEALTH REP, V109, P16; MCKENZIE KJ, 1994, BRIT MED J, V309, P286, DOI 10.1136/bmj.309.6950.286; NAISH J, 1994, BRIT MED J, V309, P1126; NISHI C, 1994, J EPIDEMIOL COMMUNIT, V48, P107; ORME R, 1995, BRIT MED J, V310, P909, DOI 10.1136/bmj.310.6984.909; PARAMJIT S, 1995, BRIT MED J, V310, P890; Ranger C, 1994, Health Serv J, V104, P22; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RODERICK PJ, 1994, BRIT MED J, V309, P1111, DOI 10.1136/bmj.309.6962.1111; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; SHELDON TA, 1992, J PUBLIC HEALTH MED, V14, P104; SIMMONS D, 1989, BRIT MED J, V298, P18, DOI 10.1136/bmj.298.6665.18; SMAJE C, 1995, HLTH RACE ETHNICITY; WILKINSON RG, 1995, BRIT MED J, V311, P1177, DOI 10.1136/bmj.311.7014.1177	32	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1080	1082						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616418				2022-12-28	WOS:A1996UH81600029
J	GomezSkarmeta, JL; Diez del Corral, R; delaCalleMustienes, E; FerresMarco, D; Modolell, J				GomezSkarmeta, JL; Diez del Corral, R; delaCalleMustienes, E; FerresMarco, D; Modolell, J			araucan and caupolican, two members of the novel iroquois complex, encode homeoproteins that control proneural and vein-forming genes	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; ACHAETE-SCUTE COMPLEX; DROSOPHILA-MELANOGASTER; SUBSTRATE RECOGNITION; EXPRESSION; PROTEIN; SEGMENTATION; SEQUENCE; EXTRAMACROCHAETAE; SEARCH	In Drosophila imaginal wing discs, the achaete-scute (ac-sc) proneural genes and rhomboid (veinlet) are expressed in highly resolved patterns that prefigure the positions of sensory organs and wing veins, respectively. It is thought that these patterns are generated by a combination of factors (a prepattern) regulating these genes. We provide evidence for the existence of this prepattern by identifying two of its factors, Araucan and Caupolican. They are members of a novel family of homeoproteins, with homologs in vertebrates. Araucan and Caupolican, present in domains of the imaginal discs larger than those expressing as-sc and rhomboid, are necessary for expression of these genes in the overlapping domains. Araucan and Caupolican appear to be positive, direct regulators of ac-sc.			GomezSkarmeta, JL (corresponding author), UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOL SEVERO OCHOA, CANTOBLANCO, E-28049 MADRID, SPAIN.		Ferres-Marco, Maria/G-8364-2015; Gomez-Skarmeta, Jose Luis/B-5268-2014; DIEZ DEL CORRAL, RUTH/K-7974-2014	Ferres-Marco, Maria/0000-0002-0596-4891; Gomez-Skarmeta, Jose Luis/0000-0001-5125-4332; DIEZ DEL CORRAL, RUTH/0000-0003-2649-7214; de la Calle-Mustienes, Elisa/0000-0002-8975-6503				ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CHEN SM, 1993, DEV DROSOPHILA MELAN, P747; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1992, INT J DEV BIOL, V36, P85; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GOMEZSKARMETA JL, 1995, GENE DEV, V9, P1869, DOI 10.1101/gad.9.15.1869; GOMEZSKARMETA JL, 1995, THESIS U AUTONOMA MA; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; LEYNS L, 1991, THESIS U LIBRE BRUXE; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUIZGOMEZ M, 1987, GENE DEV, V1, P1238, DOI 10.1101/gad.1.10.1238; RUIZGOMEZ M, 1993, EMBO J, V12, P1121, DOI 10.1002/j.1460-2075.1993.tb05753.x; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN CURT, 1954, AMER SCI, V42, P213; STURTEVANT MA, 1995, DEVELOPMENT, V121, P785; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; XU T, 1993, DEVELOPMENT, V117, P1223	51	268	272	1	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					95	105		10.1016/S0092-8674(00)81085-5	http://dx.doi.org/10.1016/S0092-8674(00)81085-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620542	Bronze			2022-12-28	WOS:A1996UE55900012
J	Zhang, ZH; Vuori, K; Wang, HG; Reed, JC; Ruoslahti, E				Zhang, ZH; Vuori, K; Wang, HG; Reed, JC; Ruoslahti, E			Integrin activation by R-ras	CELL			English	Article							GLYCOPROTEIN-IIB-IIIA; FIBRONECTIN RECEPTOR; MONOCLONAL-ANTIBODIES; ALPHA-5-BETA-1 INTEGRIN; EXTRACELLULAR-MATRIX; SURFACE GLYCOPROTEIN; CYTOPLASMIC DOMAIN; CELL-ADHESION; AFFINITY; PROTEIN	Expression of a constitutively active R-ras converted two cell lines that grow in suspension into highly adherent cells. There was little change in cell surface expression of integrins, but attachment to surfaces coated with the integrin ligands was greatly enhanced. Cells transfected with activated R-ras bound integrin ligands from solution with higher affinities and assembled severalfold more fibronectin matrix than control transfectants. Introduction of a dominant negative R-ras into adherent cells reduced the adhesiveness of the cells, indicating that endogenous R-ras can control the ligand-binding activity of integrins. These results provide a mechanism for the modulation of integrin ligand-binding activity as well as a novel function for R-ras.	UNIV CALIF SAN DIEGO, SCH MED, MOL PATHOL PROGRAM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	Zhang, ZH (corresponding author), BURNHAM INST, LA JOLLA CANC RES CTR, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NCI NIH HHS [CA62042, CA67224, CA28896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028896, R01CA067224, R01CA062042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; AKIYAMA SK, 1990, CANCER RES, V50, P1601; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COX AD, 1994, ONCOGENE, V9, P3281; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1990, BLOOD, V76, P2017; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCNAMEE HM, 1992, J CELL BIOL, V121, P673; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; PIERSCHBACHER MD, 1981, CELL, V56, P281; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SAEZ R, 1994, ONCOGENE, V9, P2977; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMYTH SS, 1993, BLOOD, V81, P2827; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SYMONS MH, 1992, J CELL BIOL, V118, P1235, DOI 10.1083/jcb.118.5.1235; VAHERI A, 1974, INT J CANCER, V13, P579, DOI 10.1002/ijc.2910130502; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WU CY, 1993, J BIOL CHEM, V268, P21883; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; YANG JT, 1993, DEVELOPMENT, V119, P1093; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	56	365	368	1	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					61	69		10.1016/S0092-8674(00)81082-X	http://dx.doi.org/10.1016/S0092-8674(00)81082-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620538	Bronze			2022-12-28	WOS:A1996UE55900009
J	Stephens, NG; Parsons, A; Schofield, PM; Kelly, F; Cheeseman, K; Mitchinson, MJ; Brown, MJ				Stephens, NG; Parsons, A; Schofield, PM; Kelly, F; Cheeseman, K; Mitchinson, MJ; Brown, MJ			Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)	LANCET			English	Article							LOW-DENSITY LIPOPROTEIN; E CONSUMPTION; RISK; ATHEROSCLEROSIS; SELENIUM; LIPIDS	Background Vitamin E (alpha-tocopherol) is thought to have a role in prevention of atherosclerosis, through inhibition of oxidation of low-density lipoprotein. Some epidemiological studies have shown an association between high dietary intake or high serum concentrations of alpha-tocopherol and lower rates of ischaemic heart disease. We tested the hypothesis that treatment with a high dose of alpha-tocopherol would reduce subsequent risk of myocardial infarction (MI) and cardiovascular death in patients with established ischaemic heart disease, Methods In this double-blind, placebo-controlled study with stratified randomisation, 2002 patients with angiographically proven coronary atherosclerosis were enrolled and followed up for a median of 510 days (range 3-981), 1035 patients were assigned alpha-tocopherol (capsules containing 800 IU daily for first 546 patients; 400 IU daily for remainder); 967 received identical placebo capsules. The primary endpoints were a combination of cardiovascular death and non-fatal MI as well as non-fatal MI alone. Findings Plasma alpha-tocopherol concentrations (measured in subsets of patients) rose in the actively treated group (from baseline mean 34.2 mu mol/L to 51.1 mu mol/L with 400 IU daily and 64.5 mu mol/L with 800 IU daily) but did not change in the placebo group. alpha-tocopherol treatment significantly reduced the risk of the primary trial endpoint of cardiovascular death and non-fatal MI (41 vs 64 events; relative risk 0.53 [95% CI 0.34-0.83; p=0.005). The beneficial effects on this composite endpoint were due to a significant reduction in the risk of non-fatal MI (14 vs 41; 0.23 [0.11-0.47]; p=0005); however, there was a nonsignificant excess of cardiovascular deaths in the cr-tocopherol group (27 vs 23; 1.18 [0.62-2.27]; p=0.61). All-cause mortality was 36 of 1035 alpha-tocopherol-treated patients and 27 of 967 placebo recipients. Interpretation We conclude that in patients with angiographically proven symptomatic coronary atherosclerosis, alpha-tocopherol treatment substantially reduces the rate of non-fatal-MI, with beneficial effects apparent after 1 year of treatment, The effect of alpha-tocopherol treatment on cardiovascular deaths requires further study.	UNIV CAMBRIDGE, DEPT MED, CLIN PHARMACOL UNIT, CAMBRIDGE, ENGLAND; UNIV CAMBRIDGE, DEPT PATHOL, DIV CELLULAR PATHOL, CAMBRIDGE, ENGLAND; PAPWORTH HOSP, CARDIAC UNIT, CAMBRIDGE, ENGLAND; ST THOMAS HOSP, RAYNE INST, LONDON SE1 7EH, ENGLAND; BRUNEL UNIV, DEPT BIOL & BIOCHEM, UXBRIDGE UB8 3PH, MIDDX, ENGLAND	University of Cambridge; University of Cambridge; Papworth Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Brunel University	Stephens, NG (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR, DEPT CARDIOL, HARROW HA1 3UJ, MIDDX, ENGLAND.		Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392				BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; CARPENTER KLH, 1994, BIOCHEM J, V304, P625, DOI 10.1042/bj3040625; CARPENTER KLH, 1995, BBA-LIPID LIPID MET, V1256, P141, DOI 10.1016/0005-2760(94)00247-V; DAVIES MJ, 1981, BRIT HEART J, V46, P126; DOWD P, 1995, P NATL ACAD SCI USA, V92, P8171, DOI 10.1073/pnas.92.18.8171; Felton CV, 1993, J VASC MED BIOL, V4, P228; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HENSE HW, 1993, ATHEROSCLEROSIS, V103, P21, DOI 10.1016/0021-9150(93)90036-T; HODIS HN, 1995, JAMA-J AM MED ASSOC, V273, P1849, DOI 10.1001/jama.273.23.1849; HORWITT MK, 1972, ANN NY ACAD SCI, V203, P223, DOI 10.1111/j.1749-6632.1972.tb27878.x; KELLY FJ, 1990, BRIT J NUTR, V63, P631, DOI 10.1079/BJN19900149; KOK FJ, 1987, AM J CLIN NUTR, V45, P462, DOI 10.1093/ajcn/45.2.462; KRITCHEVSKY SB, 1995, CIRCULATION, V92, P2142, DOI 10.1161/01.CIR.92.8.2142; MITCHINSON MJ, 1994, BRIT J CLIN PRACT, V48, P149; MITCHINSON MJ, 1983, MED HYPOTHESES, V12, P171, DOI 10.1016/0306-9877(83)90079-8; MITCHINSON MJ, 1982, ATHEROSCLEROSIS, V45, P11, DOI 10.1016/0021-9150(82)90167-8; PALOMAKI P, 1994, J CLIN EPIDEMIOL, V47, P659, DOI 10.1016/0895-4356(94)90213-5; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALONEN JT, 1985, AM J CARDIOL, V56, P226, DOI 10.1016/0002-9149(85)90839-2; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; STEINBERG D, 1995, LANCET, V346, P36, DOI 10.1016/S0140-6736(95)92657-7; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STEINER M, 1991, J AM COLL NUTR, V10, P466; Wu H P, 1992, J Formos Med Assoc, V91, P270	31	1710	1761	0	75	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	1996	347	9004					781	786		10.1016/S0140-6736(96)90866-1	http://dx.doi.org/10.1016/S0140-6736(96)90866-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622332				2022-12-28	WOS:A1996UB15300007
J	Gash, DM; Zhang, ZM; Ovadia, A; Cass, WA; Yi, A; Simmerman, L; Russell, D; Martin, D; Lapchak, PA; Collins, F; Hoffer, BJ; Gerhardt, GA				Gash, DM; Zhang, ZM; Ovadia, A; Cass, WA; Yi, A; Simmerman, L; Russell, D; Martin, D; Lapchak, PA; Collins, F; Hoffer, BJ; Gerhardt, GA			Functional recovery in parkinsonian monkeys treated with GDNF	NATURE			English	Article							L-DOPA; NEURONS	PARKINSON's disease results from the progressive degeneration of dopamine neurons that innervate the striatum(1,2). In rodents, glial-cell-line-derived neurotrophic factor (GDNF) stimulates an increase in midbrain dopamine levels, protects dopamine neurons from some neurotoxins, and maintains injured dopamine neurons(3-9). Here we extend the rodent studies to an animal closer to the human in brain organization and function, by evaluating the effects of GDNF injected intracerebrally into rhesus monkeys that have had the symptomatology and pathophysiological features of Parkinson's disease induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)(10-14). The recipients of GDNF displayed significant improvements in three of the cardinal symptoms of parkinsonism: bradykinesia, rigidity and postural instability. GDNF administered every four weeks maintained functional recovery. On the lesioned side of GDNF-treated animals, dopamine levels in the midbrain and globus pallidus were twice as high, and nigral dopamine neurons were, on average, 20% larger, with an increased fibre density. The results indicate that GDNF may be of benefit in the treatment of Parkinson's disease.	AMGEN INC,THOUSAND OAKS,CA 91320; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,NEUROSCI TRAINING PROGRAM,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PSYCHIAT,NEUROSCI TRAINING PROGRAM,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,ROCKY MT CTR SENSOR TECHNOL,DENVER,CO 80262	Amgen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gash, DM (corresponding author), UNIV KENTUCKY,COLL MED,DEPT ANAT & NEUROBIOL,LEXINGTON,KY 40536, USA.		Lapchak, Paul/P-1845-2019	Lapchak, Paul/0000-0003-4413-7554; Gash, Don/0000-0002-2504-2528				BANKIEWICZ K, 1993, EXP NEUROL, V124, P140, DOI 10.1006/exnr.1993.1185; BANKIEWICZ KS, 1986, LIFE SCI, V39, P7, DOI 10.1016/0024-3205(86)90431-5; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BOWENKAMP KE, 1995, J COMP NEUROL, V355, P479, DOI 10.1002/cne.903550402; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DOUGLE KL, 1995, P NATL ACAD SCI USA, V92, P1669; GASH OM, 1995, J COMP NEUROL, V363, P345; GREENAMYRE JT, 1994, ANN NEUROL, V35, P655, DOI 10.1002/ana.410350605; HARDING AJ, 1994, J NEUROSCI METH, V51, P83, DOI 10.1016/0165-0270(94)90028-0; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; HOMYKIEWICZ O, 1986, ADV NEUROL, V45, P19; HUDSON J, 1995, BRAIN RES BULL, V36, P425, DOI 10.1016/0361-9230(94)00224-O; Jellinger K, 1986, ADV NEUROL, V45, P1; KEAMS CM, 1995, BRAIN RES, V672, P104; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; OVADIA A, 1995, NEUROBIOL AGING, V16, P931, DOI 10.1016/0197-4580(95)02012-8; ROBERTSON GS, 1988, NEUROSCI LETT, V89, P204, DOI 10.1016/0304-3940(88)90382-5; ROBERTSON GS, 1989, J NEUROSCI, V9, P3326; SMITH RD, 1993, NEUROSCIENCE, V52, P7, DOI 10.1016/0306-4522(93)90176-G; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O	22	810	853	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					252	255		10.1038/380252a0	http://dx.doi.org/10.1038/380252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637574				2022-12-28	WOS:A1996UB11700053
J	Bifani, PJ; Plikaytis, BB; Kapur, V; Stockbauer, K; Pan, X; Lutfey, ML; Moghazeh, SL; Eisner, W; Daniel, TM; Kaplan, MH; Crawford, JT; Musser, JM; Kreiswirth, BN				Bifani, PJ; Plikaytis, BB; Kapur, V; Stockbauer, K; Pan, X; Lutfey, ML; Moghazeh, SL; Eisner, W; Daniel, TM; Kaplan, MH; Crawford, JT; Musser, JM; Kreiswirth, BN			Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EPIDEMIOLOGY; POLYMORPHISM; TOOL	Objective.-To determine whether isolates of Mycobacterium tuberculosis from New York and elsewhere that are resistant to four or more primary antimicrobial agents and responsible for widespread disease in the 1990s represent a newly emerged clone or a heterogeneous array of unrelated organisms. Setting.-New York City area and selected locations in the United States. Patients.-M tuberculosis isolates from 1953 patients in New York and multidrug-resistant isolates from six patients from other US communities. Design.-Convenience sample of all M tuberculosis strains (M tuberculosis isolates resistant to rifampin, streptomycin, isoniazid, and ethambutol, and sometimes ethionamide, kanamycin, capreomycin, or ciprofloxacin) submitted to the Public Health Research Institute Tuberculosis Center since 1991 and samples submitted to the Centers for Disease Control and Prevention from throughout the United States, The samples submitted were representative of the New York City strains of M tuberculosis. Main Outcome Measure.-Characterization of resistant M tuberculosis strains studied by IS6110 and polymorphic CC-rich repetitive sequence (PGRS) hybridization patterns, multiplex polymerase chain reaction (PCR) analysis, and automated DNA sequencing of genes containing mutations associated with resistance to rifampin (rpoB), isoniazid (katG and inhA locus), and streptomycin (strA and rrs). Results.-Multidrug-resistant M tuberculosis isolates were recovered from 253 New York City patients and had the same or closely allied IS6110 and PGRS patterns, multiplex PCR type, and gene mutations associated with resistance to rifampin, isoniazid, and streptomycin. Isolates with these same molecular characteristics were recovered from patients in Florida and Nevada, health care workers in Atlanta, Ga, and Miami, Fla, and an individual who recently moved from New York City to Denver, Cole, and caused disease or skin test conversion in at least 12 people in a nursing home environment. Conclusions.-The results document the molecular origin and spread of progeny of a closely related family of multidrug-resistant M tuberculosis strains that have recently shared a common ancestor and undergone clonal expansion. The multidrug-resistant phenotype in these organisms arose by sequential acquisition of resistance-conferring mutations in several genes, most likely as a consequence of antibiotic selection of randomly occurring mutants in concert with inadequately treated infections. Dissemination of these difficult-to-treat bacteria throughout New York City and to at least four additional US cities has adverse implications for tuberculos control in the 21st century.	PUBL HLTH RES INST,TB CTR,NEW YORK,NY 10016; BAYLOR COLL MED,DEPT PATHOL,SECT MOLEC PATHOBIOL,HOUSTON,TX; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA 30341; N SHORE UNIV HOSP,MANHASSET,NY 11030; CASE WESTERN RESERVE UNIV,CTR INT HLTH,CLEVELAND,OH	Baylor College of Medicine; Centers for Disease Control & Prevention - USA; Northwell Health; North Shore University Hospital; Case Western Reserve University			Kapur, Vivek/F-7610-2013	Kapur, Vivek/0000-0002-9648-0138; Bifani, Pablo/0000-0001-9651-6439	NIAID NIH HHS [R01-AI37004] Funding Source: Medline; NIDA NIH HHS [R01-DA09238] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009238] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; HEWLETT D, 1995, INFECT DIS CLIN PRAC, V4, P389, DOI 10.1097/00019048-199509000-00020; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; HORN DL, IN PRESS INFECT DIS; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; LONGUET P, 1995, 35TH INT C ANT AG CH; MUSSER JM, 1995, CLIN MICROBIOL REV, V8, P496, DOI 10.1128/CMR.8.4.496; PLIKAYTIS BB, 1994, J CLIN MICROBIOL, V32, P1542, DOI 10.1128/JCM.32.6.1542-1546.1994; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; SEPKOWITZ KA, 1994, CLIN INFECT DIS, V18, P755, DOI 10.1093/clinids/18.5.755; SIDDIQI S, 1989, BACTEC TB SYSTEMS PR; SMALL PM, 1993, INFECT AGENT DIS, V2, P132; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702; 1991, MMWR MORBID MORTAL W, V40, P585; 1992, MMWR MORBID MORTAL W, V41, P507; 1990, NCCLS M24P NAT COMM	26	319	336	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					452	457		10.1001/jama.275.6.452	http://dx.doi.org/10.1001/jama.275.6.452			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627966				2022-12-28	WOS:A1996TU63800033
J	Haverkate, I; vanderWal, G				Haverkate, I; vanderWal, G			Policies on medical decisions concerning the end of life in Dutch health care institutions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe the prevalence and some features of policies on medical decisions concerning the end of life (MDELs) in Dutch hospitals, nursing homes, and institutions for the mentally disabled. Design.-A cross-sectional descriptive postal survey of 558 Dutch health care institutions. Setting.-All Dutch hospitals, nursing homes, and general institutions for the mentally disabled. Participants.-Directors of patient care of the institutions. Main Outcome Measures.-Respondents' reports on the existence of policies and guidelines on the following MDELs: euthanasia/assisted suicide (EAS), life-terminating acts without explicit request of the patient, refusal of treatment by patient, withholding or withdrawing treatment, symptom and pain control, and do-not-resuscitate (DNR) decisions. Results.-Of 558 health care institution managers, 86% responded. Most of the hospitals (69.2%) and nursing homes (73.9%) but only 16.3% of the institutions for the disabled had a written EAS policy. Nursing homes with a ban on EAS often had religious affiliations. In 37% of nursing homes, 15% of hospitals, and 15% of institutions for the disabled, the management had written policies on terminating life without request. Sixty percent of the hospitals, 35% of the nursing homes, and 17% of the institutions for the disabled had guidelines for one or more of four other distinct MDELs. Forty-five percent, 20%, and 8% of hospitals, nursing homes, and institutions of mentally disabled, respectively, had guidelines on DNR decisions. The management of 89% of the hospitals and 94% of the nursing homes communicated their policies on EAS to physicians and nurses in their institutions without being asked. Far fewer of these hospitals (3.9%) and nursing homes (30.5%) made their policies on EAS known to patients without being asked. Conclusions.-This study indicates that an important step toward policy development on EAS has been made by Dutch hospitals and nursing homes. Particularly with respect to policies on such decisions as withholding or withdrawing treatment, symptom and pain control, and DNR orders, an unexplored field is open to management for policy development in the Netherlands.	VRIJE UNIV AMSTERDAM,INST RES EXTRAMURAL MED,AMSTERDAM,NETHERLANDS; VRIJE UNIV AMSTERDAM,DEPT GEN PRACTICE NURSING HOME & SOCIAL MED INSPE,AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam								BASTELS LP, 1995, I INTRAMURAL HLTH CA; BRUNETTI LL, 1990, ARCH INTERN MED, V150, P121, DOI 10.1001/archinte.150.1.121; CHOUDHRY NK, 1994, J AM GERIATR SOC, V42, P1150, DOI 10.1111/j.1532-5415.1994.tb06980.x; KLEEMANS CHM, 1992, ZIEKENHUIS, V9, P438; KORTMAN FAM, 1993, MAANDBLAD GEESTELIJK, P787; MILES SH, 1985, J AM GERIATR SOC, V33, P707, DOI 10.1111/j.1532-5415.1985.tb01780.x; MILES SH, 1989, PROTOCOLS ELECTIVE U; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; RASOOLY I, 1994, CAN MED ASSOC J, V150, P1265; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDEBUNT C, 1995, REQUEST EUTHANASIA N; VANWIJMEN FCB, 1986, MED CONTACT, V41, P1065; 1992, 2ND CHAMB DUTCH PARL; 1992, MED CONTACT, V47, P29; 1987, BIOETHICS, V1, P163	15	28	28	2	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					435	439		10.1001/jama.275.6.435	http://dx.doi.org/10.1001/jama.275.6.435			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TU638	8627954				2022-12-28	WOS:A1996TU63800013
J	Hamvas, A; Wise, PH; Yang, RK; Wampler, NS; Noguchi, A; Maurer, MM; Walentik, CA; Schramm, WF; Cole, FS				Hamvas, A; Wise, PH; Yang, RK; Wampler, NS; Noguchi, A; Maurer, MM; Walentik, CA; Schramm, WF; Cole, FS			The influence of the wider use of surfactant therapy on neonatal mortality among blacks and whites	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY-DISTRESS SYNDROME; HYALINE-MEMBRANE DISEASE; PLACEBO-CONTROLLED TRIAL; SYNTHETIC SURFACTANT; INFANTS; BIRTH	Background. Surfactant therapy reduces morbidity and mortality among premature infants with the respiratory distress syndrome (RDS). Fetal pulmonary surfactant matures more slowly in white than in black fetuses, and therefore RDS is more prevalent among whites than among blacks. We reasoned that the increased use of surfactant after its approval by the Food and Drug Administration (FDA) in 1990 might have reduced neonatal mortality more among whites than among blacks. Methods. We merged vital-statistics information for all 1563 infants with very low birth weights (500 to 1500 g) born from 1987 through 1989 or in 1991 and 1992 to residents of St. Louis with clinical data from the four neonatal intensive care units in the St. Louis area; we then compared neonatal mortality during two periods, one before and one after the FDA's approval of surfactant for clinical use (1987 through 1989 and 1991 through 1992). Results. The use of surfactant increased by a factor of 10 between 1987 through 1989 and 1991 through 1992, The neonatal mortality rate among all very-low-birthweight infants decreased 17 percent, from 220.3 deaths per 1000 verv-low-birth-weight babies born alive (in 1987 through 1989) to 183.9 per 1000 (in 1991 through 1992; P = 0.07). This decrease was due to a 41 percent reduction in the mortality rate among white newborns with very low birth weights (from 261.5 per 1000 to 155.5 per 1000; P = 0.003). In contrast, among black infants, the mortality rate for very-low-birth-weight infants did not change significantly (195.6 per 1000 and 196.8 per 1000). The relative risk of death among black newborns with very low birth weights as compared with white newborns with similar weights was 0.7 from 1987 through 1989 and 1.3 from 1991 through 1992 (P = 0.02). The differences in mortality were not explained by differences in access to surfactant therapy, by differences in mortality between black and white infants who received surfactant, or by differences in the use of antenatal corticosteroid therapy. Conclusions. After surfactant therapy for RDS became generally available, neonatal mortality improved more for white than for black infants with very low birth weights. (C) 1996, Massachusetts Medical Society.	WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, ST LOUIS, MO 63110 USA; HARVARD UNIV, SCH MED, HARVARD INST REPROD & CHILD HLTH, JOINT PROGRAM NEONATOL, BOSTON, MA USA; ST LOUIS UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63104 USA; ST JOHNS MERCY MED CTR, ST LOUIS, MO 63141 USA; MISSOURI STATE DEPT HLTH, JEFFERSON, AR USA; ST LOUIS REG MED CTR, ST LOUIS, MO USA	Washington University (WUSTL); Harvard University; Harvard Medical School; Saint Louis University; Saint Johns Mercy Medical Center	Hamvas, A (corresponding author), ST LOUIS CHILDRENS HOSP, DIV NEWBORN MED, 1 CHILDRENS PL, ST LOUIS, MO 63110 USA.		Hamvas, Aaron/R-5721-2019	Cole, F. Sessions/0000-0002-3797-9369; Hamvas, Aaron/0000-0002-5749-7797				[Anonymous], 1994, NIH Consens Statement, V12, P1; [Anonymous], 1981, AM J OBSTET GYNECOL, V141, P276; Armitage P., 1987, STAT METHODS MED RES; AVERY ME, 1995, PEDIATRICS, V95, P133; FUJIKURA T, 1966, AM J OBSTET GYNECOL, V95, P572; GITLIN JD, 1987, PEDIATRICS, V79, P31; HORBAR JD, 1989, NEW ENGL J MED, V320, P959; HORBAR JD, 1993, PEDIATRICS, V92, P191; HULSEY TC, 1993, AM J OBSTET GYNECOL, V168, P572, DOI 10.1016/0002-9378(93)90496-6; JOBE AH, 1993, NEW ENGL J MED, V328, P861; LIECHTY EA, 1991, PEDIATRICS, V88, P19; LONG W, 1991, J PEDIATR-US, V118, P595, DOI 10.1016/S0022-3476(05)83388-8; LONG W, 1991, NEW ENGL J MED, V325, P1696, DOI 10.1056/NEJM199112123252404; MACDORMAN MF, 1993, VITAL HLTH STAT SERI, V20, P1; MAHER JE, 1994, AM J OBSTET GYNECOL, V170, P869, DOI 10.1016/S0002-9378(94)70300-0; MARTIN RJ, 1992, NEONATAL PERINATAL M, V2, P810; MERRITT TA, 1991, J PEDIATR-US, V118, P581, DOI 10.1016/S0022-3476(05)83387-6; OLOWE SA, 1978, PEDIATRICS, V62, P38; PALTA M, 1994, ARCH PEDIAT ADOL MED, V148, P1295, DOI 10.1001/archpedi.1994.02170120057009; RICHARDSON DK, 1994, AM J OBSTET GYNECOL, V170, P1273; ROSS S, 1981, PEDIATRICS, V68, P790; SCHWARTZ RM, 1994, NEW ENGL J MED, V330, P1476, DOI 10.1056/NEJM199405263302102; SPEER CP, 1992, PEDIATRICS, V89, P13; WEGMAN ME, 1991, PEDIATRICS, V88, P1081; WEGMAN ME, 1992, PEDIATRICS, V90, P835; WEGMAN ME, 1993, PEDIATRICS, V92, P743; WISE PH, 1985, NEW ENGL J MED, V313, P360, DOI 10.1056/NEJM198508083130605; 1994, INT CLASSIFICATION D, V1; 1994, INT CLASSIFICATION D, V2; 1994, INT CLASSIFICATION D, V3; 1993, MON VITAL STAT REP S, V42	31	83	85	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1996	334	25					1635	1640		10.1056/NEJM199606203342504	http://dx.doi.org/10.1056/NEJM199606203342504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ706	8628359				2022-12-28	WOS:A1996UQ70600004
J	Sarkisian, CA; Lachs, MS				Sarkisian, CA; Lachs, MS			''Failure to thrive'' in older adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PROTEIN-CALORIE UNDERNUTRITION; TO-THRIVE; ALZHEIMERS-DISEASE; ELDERLY PATIENTS; SOCIAL NETWORKS; ALAMEDA COUNTY; NURSING-HOME; POPULATION; MORTALITY; DEMENTIA	The term ''failure to thrive'' is frequently used to describe older adults whose independence is declining. The term was exported from pediatrics in the 1970s and is used to describe older adults with various concurrent chronic diseases, functional impairments, or both. Despite this heterogeneity, failure to thrive has had its own International Classification of Diseases, Ninth Revision (ICD-9) code since 1979 and has been approached as a clinically meaningful diagnosis in many review articles. This conceptual framework, however, can create barriers to proper evaluation and management. The most worrisome of these barriers is the reinforcement of both fatalism and intellectual laziness, which need to be balanced with a deconstructionist approach, wherein the major areas of impairment are identified and quantified and have their interactions considered. Four syndromes known to be individually predictive of adverse outcomes in older adults are repeatedly cited as prevalent in patients with failure to thrive: impaired physical functioning, malnutrition, depression, and cognitive impairment. The differential diagnosis of contributors to each of these syndromes includes the other three syndromes, and multiple contributors often exist concurrently. Some of these contributors are unmodifiable, some are easily modifiable, and some are potentially modifiable but only with the use of resource-intensive strategies. Initial interventions should be directed at easily remediable contributors in the hope of improving overall functional status, because a single contributor may simultaneously influence several other syndromes that conspire to create the phenotype of failure to thrive. How aggressively should more resource-intensive strategies for less easily modifiable contributors be pursued? This is a central clinical, ethical, and policy issue in geriatric medicine that cannot be settled without better process and outcome data. This paper examines the medical etymology of failure to thrive and proposes a rational approach to evaluation and management that is based on the limited medical literature.	CORNELL INTERNAL MED ASSOC, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, NEW YORK, NY 10021 USA; NEW YORK HOSP, CORNELL MED COLL, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital					PHS HHS [K00800580] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEXOPOULOS GS, 1991, PSYCHIAT CLIN N AM, V14, P327; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; Beers M, 1987, Clin Geriatr Med, V3, P17; BERKMAN B, 1989, GERONTOLOGIST, V29, P654, DOI 10.1093/geront/29.5.654; BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BOWERS J, 1990, MED J AUSTRALIA, V153, P192, DOI 10.5694/j.1326-5377.1990.tb136858.x; BRAUN JV, 1988, GERONTOLOGIST, V28, P809, DOI 10.1093/geront/28.6.809; BRODATY H, 1993, ARCH NEUROL-CHICAGO, V50, P643, DOI 10.1001/archneur.1993.00540060073021; CLARFIELD AM, 1988, ANN INTERN MED, V109, P476, DOI 10.7326/0003-4819-109-6-476; CLARK LP, 1990, J AM GERIATR SOC, V38, P967, DOI 10.1111/j.1532-5415.1990.tb04417.x; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; DOLGIN M, 1994, NOMENDATURE CRITERIA; Du W, 1993, J Geriatr Psychiatry Neurol, V6, P34; EGBERT AM, 1993, POSTGRAD MED, V94, P199, DOI 10.1080/00325481.1993.11945740; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FIRED LP, 1994, PRINCIPLES GERIATRIC, P1149; FITZ AG, 1994, J AM GERIATR SOC, V42, P186, DOI 10.1111/j.1532-5415.1994.tb04950.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIED LP, 1991, J AM GERIATR SOC, V39, P117, DOI 10.1111/j.1532-5415.1991.tb01612.x; FRIEDHOFF AJ, 1992, JAMA-J AM MED ASSOC, V268, P1018, DOI 10.1001/jama.1992.03490080092032; FRIEDMAN PJ, 1985, AGE AGEING, V14, P149, DOI 10.1093/ageing/14.3.149; GOODWIN JS, 1991, J AM GERIATR SOC, V39, P627, DOI 10.1111/j.1532-5415.1991.tb03607.x; Groom D D, 1993, J Gerontol Nurs, V19, P12; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; HANSON BS, 1989, AM J EPIDEMIOL, V130, P100, DOI 10.1093/oxfordjournals.aje.a115301; HEBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354, DOI 10.1001/jama.273.17.1354; HODKINSON HM, 1973, BMJ-BRIT MED J, V4, P94, DOI 10.1136/bmj.4.5884.94; HOWELL T, 1990, J GEN INTERN MED, V5, P431, DOI 10.1007/BF02599434; ISAACS B, 1971, LANCET, V1, P1115; KATZ IR, 1993, J GERIATR PSYCH NEUR, V6, P161, DOI 10.1177/089198879300600305; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KERSTETTER JE, 1992, J AM DIET ASSOC, V92, P1109; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LONERGAN ET, 1991, EXTENDING LIFE ENHAN, P60; MANT A, 1988, FAM PRACT, V5, P184, DOI 10.1093/fampra/5.3.184; MCCARTNEY JR, 1985, J AM GERIATR SOC, V33, P467, DOI 10.1111/j.1532-5415.1985.tb05457.x; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; MORLEY JE, 1994, J AM GERIATR SOC, V42, P583, DOI 10.1111/j.1532-5415.1994.tb06853.x; MOWE M, 1991, J AM GERIATR SOC, V39, P1089, DOI 10.1111/j.1532-5415.1991.tb02874.x; Newbern V B, 1992, J Gerontol Nurs, V18, P21; NEWBERN VB, 1994, J ADV NURS, V19, P840, DOI 10.1111/j.1365-2648.1994.tb01159.x; *NIH, 1993, NIH CONS DEV C STAT, V29, P87; ORY MG, 1993, J AM GERIATR SOC, V41, P283, DOI 10.1111/j.1532-5415.1993.tb06707.x; Osato E E, 1993, J Gerontol Nurs, V19, P28; PALMER RM, 1990, GERIATRICS, V45, P47; Palmer RM, 1990, GERIATRICS, V45, P53; PEARSON JL, 1989, J AM GERIATR SOC, V37, P1117, DOI 10.1111/j.1532-5415.1989.tb06674.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REUBEN DB, 1992, J GERONTOL, V47, pM106, DOI 10.1093/geronj/47.4.M106; REUBEN DB, 1990, J AM GERIATR SOC, V38, P1105, DOI 10.1111/j.1532-5415.1990.tb01373.x; RUDMAN D, 1989, J AM GERIATR SOC, V37, P173, DOI 10.1111/j.1532-5415.1989.tb05880.x; RUDOLPH AM, 1991, RUDOLPHS PEDIAT, P844; SIU AL, 1991, ANN INTERN MED, V115, P122, DOI 10.7326/0003-4819-115-2-122; STEINBACH U, 1992, J GERONTOL, V47, pS183, DOI 10.1093/geronj/47.4.S183; STRAWBRIDGE WJ, 1992, J AM GERIATR SOC, V40, P799, DOI 10.1111/j.1532-5415.1992.tb01852.x; SULLIVAN DH, 1991, AM J CLIN NUTR, V53, P599, DOI 10.1093/ajcn/53.3.599; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; VERDERY RB, 1991, J GERONTOL, V46, pM84, DOI 10.1093/geronj/46.3.M84; VERDERY RB, 1990, GERIATRICS, V45, P26; WEINER DK, 1992, J AM GERIATR SOC, V40, P203, DOI 10.1111/j.1532-5415.1992.tb02068.x; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WETLE T, 1987, JAMA-J AM MED ASSOC, V258, P516, DOI 10.1001/jama.1987.03400040114035; WILLIAMS ME, 1990, J AM GERIATR SOC, V38, P1120, DOI 10.1111/j.1532-5415.1990.tb01375.x; WINOGRAD CH, 1991, J AM GERIATR SOC, V39, P778, DOI 10.1111/j.1532-5415.1991.tb02700.x; WINOGRAD CH, 1986, J AM GERIATR SOC, V34, P295, DOI 10.1111/j.1532-5415.1986.tb04226.x; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	69	69	71	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1072	1078		10.7326/0003-4819-124-12-199606150-00008	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UQ658	8633822				2022-12-28	WOS:A1996UQ65800008
J	Marcus, CL				Marcus, CL			Periodic breathing in an infant with hydrocephalus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Marcus, CL (corresponding author), JOHNS HOPKINS UNIV,CHILDRENS CTR,600 N WOLFE ST,BALTIMORE,MD 21287, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1577	1577		10.1056/NEJM199606133342405	http://dx.doi.org/10.1056/NEJM199606133342405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP663	8628339				2022-12-28	WOS:A1996UP66300005
J	Treiman, A				Treiman, A			To see a world in 80 kilograms of rock	SCIENCE			English	Editorial Material							SNC				Treiman, A (corresponding author), LUNAR & PLANETARY INST,HOUSTON,TX 77058, USA.							Ash RD, 1996, NATURE, V380, P57, DOI 10.1038/380057a0; EUGSTER O, 1996, LUNAR PLANET SCI, V27, P345; Gladman BJ, 1996, SCIENCE, V271, P1387, DOI 10.1126/science.271.5254.1387; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; HARPER CL, 1995, SCIENCE, V267, P213, DOI 10.1126/science.7809625; HARVEY RP, 1996, LUNAR PLANET SCI, V27, P497; HARVEY RP, 1995, LUNAR PLANET SCI, V26, P555; JAGOUTZ E, 1996, LUNAR PLANET SCI, V27, P597; JAGOUTZ E, 1994, METEORITICS, V29, P479; KRING DA, 1996, LUNAR PLANET SCI, V27, P705; *LUN PLAN I, LUN PLAN I CONTR, V888; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; MITTLEFEHLDT DW, 1996, LUNAR PLANET SCI, V27, P1099; NYQUIST LE, 1995, LUNAR PLANET SCI, V26, P1065; ROMANEK CS, 1994, NATURE, V372, P665; SWINDLE TD, 1995, LUNAR PLANET SCI, V26, P1385; TREIMAN AH, 1993, METEORITICS, V28, P86, DOI 10.1111/j.1945-5100.1993.tb00251.x; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; TREIMAN AH, 1995, J GEOPHYS RES-PLANET, V100, P5329, DOI 10.1029/94JE02184; [No title captured]; [No title captured]	22	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1447	1448		10.1126/science.272.5267.1447	http://dx.doi.org/10.1126/science.272.5267.1447			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633232				2022-12-28	WOS:A1996UP89900034
J	Goldberger, AL				Goldberger, AL			Non-linear dynamics for clinicians: Chaos theory, fractals, and complexity at the bedside	LANCET			English	Article											Goldberger, AL (corresponding author), BETH ISRAEL HOSP,CARDIOVASC DIV GZ435,DEPT MED,HARVARD THORNDIKE LAB,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							BASSINGTHWAIGHT.JB, 1994, FRACTAL PHYSL; Glass L, 1988, CLOCKS CHAOS RHYTHMS; GOLDBERGER A L, 1990, Scientific American, V262, P42; GOLDBERGER AL, 1986, IEEE T BIO-MED ENG, V33, P874, DOI 10.1109/TBME.1986.325781; GOLDBERGER AL, 1988, EXPERIENTIA, V44, P983, DOI 10.1007/BF01939894; HAUSDORFF JM, 1995, J APPL PHYSIOL, V78, P349, DOI 10.1152/jappl.1995.78.1.349; LIPSITZ LA, 1992, JAMA-J AM MED ASSOC, V267, P1806, DOI 10.1001/jama.267.13.1806; MARSH DJ, 1990, AM J PHYSIOL, V258, pF1394, DOI 10.1152/ajprenal.1990.258.5.F1394; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; PENG CK, 1992, NATURE, V356, P168, DOI 10.1038/356168a0; REIMANN HA, 1963, PERIODIC DISEASES; RIGNEY DR, 1989, AM J PHYSIOL, V257, pH1292, DOI 10.1152/ajpheart.1989.257.4.H1292; ROSENBAUM DS, 1994, NEW ENGL J MED, V330, P235, DOI 10.1056/NEJM199401273300402; SKINNER JE, 1991, CIRC RES, V68, P966, DOI 10.1161/01.RES.68.4.966; SZETO HH, 1992, AM J PHYSIOL, V263, pR141, DOI 10.1152/ajpregu.1992.263.1.R141	15	577	612	2	40	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1312	1314		10.1016/S0140-6736(96)90948-4	http://dx.doi.org/10.1016/S0140-6736(96)90948-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622511	hybrid			2022-12-28	WOS:A1996UK75800016
J	Daley, J; Mennuti, M; Delbanco, TL				Daley, J; Mennuti, M; Delbanco, TL			A 35-year-old pregnant woman considering maternal serum screening and amniocentesis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FETAL DOWN-SYNDROME; UNCONJUGATED ESTRIOL; ALPHA-FETOPROTEIN; 2ND TRIMESTER; ABNORMALITIES; DECISIONS; HCG		UNIV PENN,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104	University of Pennsylvania								*AM COLL OBST GYN, 1994, 141 AM COLL OBST GYN; ATRASH HK, 1987, AM J OBSTET GYNECOL, V156, P605, DOI 10.1016/0002-9378(87)90061-5; BEEKHUIS JR, 1994, PRENATAL DIAG, V14, P199, DOI 10.1002/pd.1970140310; BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CANICK JA, 1990, PRENATAL DIAG, V10, P546, DOI 10.1002/pd.1970100813; CHARD T, 1984, LANCET, V2, P750; CHENG EY, 1993, OBSTET GYNECOL, V81, P72; Evans JA, 1996, LANCET, V347, P484, DOI 10.1016/S0140-6736(96)91131-9; FERGUSONSMITH MA, 1984, PRENATAL DIAG, V4, P5, DOI 10.1002/pd.1970040704; HADDOW JE, 1994, NEW ENGL J MED, V330, P1114, DOI 10.1056/NEJM199404213301603; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HOLMESSIEDLE M, 1987, PRENATAL DIAG, V7, P239, DOI 10.1002/pd.1970070403; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; ROBINSON A, 1989, AM J MED GENET, V34, P552, DOI 10.1002/ajmg.1320340420; ROSE NC, 1995, SEMIN PERINATOL, V19, P243, DOI 10.1016/S0146-0005(05)80038-2; ROSE NC, 1994, AM J OBSTET GYNECOL, V170, P1073, DOI 10.1016/S0002-9378(94)70100-8; ROSENSCHEIN JS, 1993, J EXP THEOR ARTIF IN, V5, P1, DOI 10.1080/09528139308953755; Verp MS, 1992, PRINCIPLES PRACTICE, V2nd, P159; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; 1996, GUIDANCE GENET COUNS, V6, P13; 1995, MMWR-MORBID MORTAL W, V44, P1; 1989, AM J OBSTET GYNECOL, V160, P575	24	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1440	1446						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618372				2022-12-28	WOS:A1996UJ30300032
J	Nellen, D; Burke, R; Struhl, G; Basler, K				Nellen, D; Burke, R; Struhl, G; Basler, K			Direct and long-range action of a DPP morphogen gradient	CELL			English	Article							DEVELOPING DROSOPHILA EYE; GENE-EXPRESSION; BETA FAMILY; PATTERN; PROTEIN; RECEPTOR; EMBRYO; CELLS; ACTS	During development of the Drosophila wing, the decapentaplegic (dpp) gene is expressed in a stripe of cells along the anteroposterior compartment boundary and gives rise to a secreted protein that exerts a long-range organizing influence on both compartments. Using clones of cells that express DPP, or in which DPP receptor activity has been constitutively activated or abolished, we show that DPP acts directly and at long range on responding cells, rather than by proxy through the short-range induction of other signaling molecules. Further, we show that two genes, optomotor-blind and spalt are transcriptionally activated at different distances from DPP-secreting cells and provide evidence that these genes respond to different threshold concentrations of DPP protein. We propose that DPP acts as a gradient morphogen during wing development.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	Nellen, D (corresponding author), UNIV ZURICH,INST ZOOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.			Basler, Konrad/0000-0003-3534-1529; Burke, Richard/0000-0003-0086-0767				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; Boveri T, 1903, VERHANDLUNGEN PHYSIK, V35, P67; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; INGHAM PW, 1994, CURR BIOL, V4, P374; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KOHNLEIN RP, 1994, EMBO J, V13, P168; LAWRENCE PA, 1966, J EXP BIOL, V44, P607; LAWRENCE PA, 1972, J CELL SCI, V11, P815; LAWRENCE PA, 1972, DEV SYSTEMS INSECTS, V2, P157; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; Morgan T.H., 1897, ROUX ARCH DEV BIOL, V5, P570; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; Spemann H., 1938, EMBRYONIC DEV INDUCT; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STUMPF HF, 1966, NATURE, V212, P430, DOI 10.1038/212430a0; SUN YH, 1995, GENETICS, V141, P1075; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; VINCENT JP, 1994, TRENDS GENET, V10, P383, DOI 10.1016/0168-9525(94)90040-X; WAGNERBERNHOLZ JT, 1991, GENE DEV, V5, P2467, DOI 10.1101/gad.5.12b.2467; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WOLPERT L, 1989, DEVELOPMENT S, P3; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	62	795	804	1	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					357	368		10.1016/S0092-8674(00)81114-9	http://dx.doi.org/10.1016/S0092-8674(00)81114-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616891	Green Accepted, hybrid			2022-12-28	WOS:A1996UK14000009
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Transformations, means, and confidence intervals	BRITISH MEDICAL JOURNAL			English	Article									IMPERIAL CANC RES FUND,MED STAT GRP,CTR STAT MED,INST HLTH SCI,OXFORD OX3 7LF,ENGLAND	University of Oxford	Bland, JM (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							Bland JM, 1996, BRIT MED J, V312, P700; Bland JM, 1996, BRIT MED J, V312, P770	2	321	328	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1079	1079						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616417				2022-12-28	WOS:A1996UH81600028
J	Fackler, ML; Huth, EJ; Pitkin, RM; Rennie, D; Begg, C; Greenland, S; Olkin, I; Stroup, DF; Deen, DF; Lau, J; Derish, P; Eastwood, S; Lang, T; Nichols, K				Fackler, ML; Huth, EJ; Pitkin, RM; Rennie, D; Begg, C; Greenland, S; Olkin, I; Stroup, DF; Deen, DF; Lau, J; Derish, P; Eastwood, S; Lang, T; Nichols, K			Checklist of information for inclusion in reports of clinical trials	ANNALS OF INTERNAL MEDICINE			English	Article							REQUIRING PROLONGED OBSERVATION; MEDICAL JOURNALS; GUIDELINES; QUALITY; PATIENT; DESIGN		UNIV CALIF SAN FRANCISCO, DEPT NEUROL SURG, ELS D, SAN FRANCISCO, CA 94143 USA; WOUND BALLIST REV, HAWTHORNE, FL USA; OBSTET & GYNECOL, LOS ANGELES, CA USA; JOURNAL AMER MED ASSOC, CHICAGO, IL USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; STANFORD UNIV, STANFORD, CA 94305 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA; UNIV CALIF SAN FRANCISCO, SCH MED, BRAIN TUMOR RES CTR, SAN FRANCISCO, CA 94143 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; ALZA CORP, PALO ALTO, CA USA	University of California System; University of California San Francisco; American Medical Association; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; Stanford University; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco; Tufts Medical Center; Cleveland Clinic Foundation; Johnson & Johnson; Johnson & Johnson USA								ALTMAN DG, 1983, BRIT MED J, V286, P1489, DOI 10.1136/bmj.286.6376.1489; ALTMAN DG, 1991, J R STAT SOC A STAT, V154, P223, DOI 10.2307/2983040; ANDREW E, 1994, JAMA-J AM MED ASSOC, V272, P1926, DOI 10.1001/jama.1994.03520240054041; BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; Bailar JC., 1992, MED USES STAT; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; Cox D. R., 1984, ANAL SURVIVAL DATA; Dawson-Saunders B., 1994, BASIC CLIN BIOSTATIS; FACKLER ML, 1994, ANN INTERN MED, V121, P894, DOI 10.7326/0003-4819-121-11-199412010-00015; FINNEY DJ, 1992, PHIL T R SOC LOND B, V337, P381; GLANTZ SA, 1993, JAMA-J AM MED ASSOC, V269, P2282; LANG TA, 1996, IN PRESS REPORTING S; MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122; MURRAY GD, 1988, BRIT J SURG, V75, P664, DOI 10.1002/bjs.1800750714; OLKIN I, 1992, SCIENCES         JUL, P30; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; REIDENBERG MM, 1990, CLIN PHARMACOL THER, V47, P669, DOI 10.1038/clpt.1990.91; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408	20	51	52	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					741	743		10.7326/0003-4819-124-8-199604150-00007	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633835				2022-12-28	WOS:A1996UD93600007
J	Sozzi, G; Veronese, ML; Negrini, M; Baffa, R; Cotticelli, MG; Inoue, H; Tornielli, S; Pilotti, S; DeGregorio, L; Pastorino, U; Pierotti, MA; Ohta, M; Huebner, K; Croce, CM				Sozzi, G; Veronese, ML; Negrini, M; Baffa, R; Cotticelli, MG; Inoue, H; Tornielli, S; Pilotti, S; DeGregorio, L; Pastorino, U; Pierotti, MA; Ohta, M; Huebner, K; Croce, CM			The FHIT gene at 3p14.2 is abnormal in lung cancer	CELL			English	Article							CHROMOSOMAL REGION 3P21; SMALL-CELL CARCINOMA; SHORT ARM; HOMOZYGOUS DELETION; P53 GENE; ADENOCARCINOMA; MUTATIONS; HETEROZYGOSITY; EXPRESSION; FREQUENT	To determine the role of the FHIT gene, which encompasses the fragile site at 3p14.2, we analyzed 59 tumors of the small cell and non-small cell type by reverse transcription of FHIT mRNA, followed by PCR amplification and sequencing of products. Allelic losses affecting the gene were evaluated by microsatellite polymorphism analysis and genomic alterations by hybridization using cDNA and genomic probes. Small cell lung tumors (80%) and non-small cell lung cancers (40%) showed abnormalities in RNA transcripts of FHIT, and 76% of the tumors exhibited loss of FHIT alleles. Abnormal lung tumor transcripts lack two or more exons of the FHIT gene. Small cell lung cancer tumors and cell lines were analyzed by Southern blotting and showed rearranged BamHI fragments. These data suggest a critical role of the FHIT gene in lung carcinogenesis.	IST NAZL TUMORI,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	Sozzi, G (corresponding author), JEFFERSON MED COLL,KIMMEL CANC CTR,PHILADELPHIA,PA 19107, USA.		Young, Richard A/F-6495-2012; sozzi, gabriella/G-8259-2011; Negrini, Massimo/J-2377-2016; Pastorino, Ugo/C-2712-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Young, Richard A/0000-0001-8855-8647; sozzi, gabriella/0000-0001-9360-6914; Negrini, Massimo/0000-0002-0007-1920; Pastorino, Ugo/0000-0001-9974-7902; Pierotti, Marco Alessandro/0000-0002-7431-8332	NATIONAL CANCER INSTITUTE [R35CA039860, P01CA021124] Funding Source: NIH RePORTER; NCI NIH HHS [CA56336, CA39860, P01CA21124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER JC, 1986, P NATL ACAD SCI USA, V83, P2350, DOI 10.1073/pnas.83.8.2350; BARSKY SH, 1994, MODERN PATHOL, V7, P633; BAXI MD, 1994, BIOCHEMISTRY-US, V33, P14601, DOI 10.1021/bi00252a028; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CHIBA I, 1990, ONCOGENE, V5, P1603; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DALY MC, 1993, ONCOGENE, V8, P1721; DRUCK T, 1995, CANCER RES, V55, P5348; EBINA M, 1994, CANCER RES, V54, P2496; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1992, ONCOGENE, V7, P445; HORIO Y, 1993, CANCER RES, V53, P1; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; *INT UN CANC, 1987, TNM CLASS MAL TUM; Kastury K, 1996, CANCER RES, V56, P978; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KIM SY, 1993, AM J PATHOL, V142, P307; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOK K, 1994, CANCER RES, V54, P4183; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURATA M, 1992, JPN J HUM GENET, V37, P205, DOI 10.1007/BF01900714; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Sambrook J., 2002, MOL CLONING LAB MANU; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SEKIDO Y, 1994, ONCOGENE, V9, P1599; SOZZI G, 1991, CANCER RES, V51, P400; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; WEINMANNDORSCH C, 1984, EUR J BIOCHEM, V138, P179, DOI 10.1111/j.1432-1033.1984.tb07897.x; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; World Health Organization, 1981, HIST TYP LUNG TUM; XU HJ, 1994, JNCI-J NATL CANCER I, V86, P695, DOI 10.1093/jnci/86.9.695; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOYAMA S, 1992, CANCER RES, V52, P873	40	538	573	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					17	26		10.1016/S0092-8674(00)81078-8	http://dx.doi.org/10.1016/S0092-8674(00)81078-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620533	Bronze			2022-12-28	WOS:A1996UE55900005
J	Abbas, AK				Abbas, AK			Die and let live: Eliminating dangerous lymphocytes	CELL			English	Review									HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	Abbas, AK (corresponding author), BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV IMMUNOL RES,BOSTON,MA 02115, USA.							BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; JACOBSON BA, 1995, IMMUNITY, V3, P509, DOI 10.1016/1074-7613(95)90179-5; KSANDER BR, 1994, CHEM IMMUNOL, V58, P117; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9	15	217	228	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					655	657		10.1016/S0092-8674(00)81042-9	http://dx.doi.org/10.1016/S0092-8674(00)81042-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625402	Bronze			2022-12-28	WOS:A1996TZ99000002
J	VanEssen, DC; Felleman, DJ				VanEssen, DC; Felleman, DJ			Indeterminate organization of the visual system - Response	SCIENCE			English	Editorial Material									UNIV TEXAS,SCH MED,HOUSTON,TX 77030	University of Texas System	VanEssen, DC (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.		Van Essen, David/ABA-8888-2020					Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Hilgetag CC, 1996, SCIENCE, V271, P776, DOI 10.1126/science.271.5250.776; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563	3	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					777	777						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628991				2022-12-28	WOS:A1996TU69400036
J	Belluzzi, A; Brignola, C; Campieri, M; Pera, A; Boschi, S; Miglioli, M				Belluzzi, A; Brignola, C; Campieri, M; Pera, A; Boschi, S; Miglioli, M			Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; UNSATURATED FATTY-ACIDS; ULCERATIVE-COLITIS; DIETARY SUPPLEMENTATION; MAINTENANCE TREATMENT; CONTROLLED TRIAL; BLOOD-PRESSURE; DOUBLE-BLIND; METAANALYSIS; PREVENTION	Background. Patients with Crohn's disease may have periods of remission, interrupted by relapses, Because fish oil has antiinflammatory actions, it could reduce the frequency of relapses, but it is often poorly tolerated because of its unpleasant taste and gastrointestinal side effects. Methods, We performed a one-year, double-blind, placebo-controlled study to investigate the effects of a new fish-oil preparation in the maintenance of remission in 78 patients with Crohn's disease who had a high risk of relapse, The patients received either nine fish-oil capsules containing a total of 2.7 g of n-3 fatty acids or nine placebo capsules daily, A special coating protected the capsules against gastric acidity for at least 30 minutes. Results. Among the 39 patients in the fish-oil group, 11 (28 percent) had relapses, 4 dropped out because of diarrhea, and 1 withdrew for other reasons, In contrast, among the 39 patients in the placebo group, 27 (69 percent) had relapses, 1 dropped out because of diarrhea, and 1 withdrew for other reasons (difference in relapse rate, 41 percentage points; 95 percent confidence interval, 21 to 61; P<0.001), After one year, 23 patients (59 percent) in the fish-oil group remained in remission, as compared with 10 (26 percent) in the placebo group (P=0.003). Logistic-regression analysis indicated that only fish oil and not sex, age, previous surgery, duration of disease, or smoking status affected the likelihood of relapse (odds ratio for the placebo group as compared with the fish-oil group, 4.2; 95 percent confidence interval, 1.6 to 10.7). Conclusions. In patients with Crohn's disease in remission, a novel enteric-coated fish-oil preparation is effective in reducing the rate of relapse. (C) 1996, Massachusetts Medical Society.	UNIV BOLOGNA,INST CLIN MED & GASTROENTEROL,BOLOGNA,ITALY; UNIV BOLOGNA,DEPT CLIN PHARMACOL,BOLOGNA,ITALY; SAN GIOVANNI BATTISTA HOSP,DEPT GASTROENTEROL,TURIN,ITALY	University of Bologna; University of Bologna; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette				belluzzi, andrea/0000-0002-9368-1014; Campieri, Massimo/0000-0001-8782-4245				APPEL LJ, 1993, ARCH INTERN MED, V153, P1429, DOI 10.1001/archinte.153.12.1429; ASLAN A, 1992, AM J GASTROENTEROL, V87, P432; BELLUZZI A, 1994, DIGEST DIS SCI, V39, P2589, DOI 10.1007/BF02087694; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BRIGNOLA C, 1986, GASTROENTEROLOGY, V91, P1490, DOI 10.1016/0016-5085(86)90206-4; BRIGNOLA C, 1994, EUR J GASTROEN HEPAT, V6, P955, DOI 10.1097/00042737-199410000-00020; BRIGNOLA C, 1992, DIGEST DIS SCI, V37, P29, DOI 10.1007/BF01308338; DONNELLY SM, 1992, J AM SOC NEPHROL, V2, P1634; ELBOUSTANI S, 1987, LIPIDS, V22, P711, DOI 10.1007/BF02533970; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FISHER M, 1986, INFLAMMATION, V10, P387, DOI 10.1007/BF00915822; GENDRE JP, 1993, GASTROENTEROLOGY, V104, P435, DOI 10.1016/0016-5085(93)90411-5; HAWTHORNE AB, 1992, GUT, V33, P922, DOI 10.1136/gut.33.7.922; HOSMER DW, 1989, APPL LOGISTIC REGRES; JASCHONEK K, 1991, THROMB RES, V63, P667, DOI 10.1016/0049-3848(91)90093-C; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAWSON LD, 1988, BIOCHEM BIOPH RES CO, V152, P328, DOI 10.1016/S0006-291X(88)80718-6; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; LORENZ R, 1989, J INTERN MED, V225, P225, DOI 10.1111/j.1365-2796.1989.tb01461.x; MACINTYRE DE, 1984, BLOOD, V63, P848; MATE J, 1991, Gastroenterology, V100, pA228; MESSORI A, 1994, AM J GASTROENTEROL, V89, P692; OCONNOR GT, 1992, AM J PREV MED, V8, P186, DOI 10.1016/S0749-3797(18)30830-4; PRANTERA C, 1992, GASTROENTEROLOGY, V103, P363, DOI 10.1016/0016-5085(92)90822-G; RAMPTON DS, 1993, ALIMENT PHARM THERAP, V7, P357; STENSON WF, 1992, ANN INTERN MED, V116, P609, DOI 10.7326/0003-4819-116-8-609; VANDERHOOF JA, 1994, GASTROENTEROLOGY, V106, P94, DOI 10.1016/S0016-5085(94)94589-6; WAKEFIELD AJ, 1989, LANCET, V2, P1057; WEBBERLEY MJ, 1993, GUT, V34, P247, DOI 10.1136/gut.34.2.247; WRIGHT JP, 1987, DIGEST DIS SCI, V32, P164, DOI 10.1007/BF01297104; 1990, ALIMENT PHARM THERAP, V4, P55	31	550	575	0	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1557	1560		10.1056/NEJM199606133342401	http://dx.doi.org/10.1056/NEJM199606133342401			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP663	8628335	Bronze			2022-12-28	WOS:A1996UP66300001
J	Blendon, RJ; Young, JT; Hemenway, D				Blendon, RJ; Young, JT; Hemenway, D			The American public and the gun control debate	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HARVARD UNIV,KENNEDY SCH GOVT,CAMBRIDGE,MA	Harvard University	Blendon, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,677 HUNTINGTON AVE,BOSTON,MA 02215, USA.							ADLER KP, 1994, JAMA-J AM MED ASSOC, V271, P1281, DOI 10.1001/jama.271.16.1281; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; DAVIS J, 1994, GENERAL SOCIAL SURVE; GOLSTEIN J, 1995, PACS PROFILE; HEMENWAY D, 1995, GUNS CONSTITUTION MY; KEY VO, 1961, PUBLIC OPINION AM DE; *L HARR ASS, 1996, HARR POLL; PAGE BI, 1992, RATIONAL PUBLIC 50 Y; *POLL REP INC, 1996, POLL REP; *ROP CTR PUBL OP R, 1994, MIT INT EX POLL; *ROP CTR PUBL OP R, 1995, CBS POLL; *ROP CTR PUBL OP R, 1994, NY TIM CBS POLL; *ROP CTR PUBL OP R, 1987, GALL POLL; *ROP CTR PUBL OP R, 1994, KRC COMM RES POLL; *ROP CTR PUBL OP R, 1993, GALL CNN USA TOD POL; *ROP CTR PUBL OP R, 1991, LOS ANG TIM POLL; *ROP CTR PUBL OP R, 1996, TIM CNN YANK PARTN I; Smith TW, 1995, J CRIM LAW CRIM, V86, P133, DOI 10.2307/1144003; Spitzer R. J., 1995, POLITICS GUN CONTROL; *US BUR CENS, 1994, 1994 STAT ABSTR US; *US DEP JUST, 1995, SOURC CRIM STAT 1994	21	32	32	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1719	1722		10.1001/jama.275.22.1719	http://dx.doi.org/10.1001/jama.275.22.1719			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP307	8637158				2022-12-28	WOS:A1996UP30700011
J	Vassar, MJ; Kizer, KW				Vassar, MJ; Kizer, KW			Hospitalizations for firearm-related injuries - A population-based study of 9562 patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URBAN TRAUMA CENTER; HOMICIDE	Objective.-To determine the incidence, nature, demographics, severity, and hospital charges associated with inpatient treatment of firearm-related injuries. Design.-A retrospective, 1-year, population-based study of firearm-related hospitalizations based on the 1991 California Hospital Discharge Abstract Data Tapes. Setting.-California acute care hospitals that reported firearm-related discharges. Patients.-A total of 9562 patients discharged with firearm-related injuries. Main Outcome Measures.-Per capita hospital discharge rates, according to age, race, and sex. Results.-A total of 9562 firearm-injured persons were discharged from California hospitals in 1991, representing a rate of 32 discharges per 100 000 population, Males aged 15 to 24 years accounted for 72% of the hospitalizations. For all causes of firearm-related injury, the highest age- and race-specific discharge rate was 439 per 100 000 for black persons aged 15 to 24 years, The highest county discharge rate was 55 per 100 000 for Los Angeles County. Statewide, there were 1.8 hospital discharges per firearm-related fatality (both in the hospital and in the community). Assaults accounted for 74% of cases, Among black males aged 15 to 24 years, assaults accounted for 598 discharges per 100 000 population. Hospital charges for 9193 patients exceeded $164 million; mean and median charges per patient discharged were $17 888 and $8535, respectively, Publicly financed health insurance programs sponsored 56% of patients; 25% had private insurance, and 19% were uninsured, Fifty-three percent of the discharges occurred at 13 of the 371 hospitals that discharged patients with firearm-related injuries. Conclusions.-Firearm-related violence is a major cause of hospitalization of young urban black males and represents a significant cost to publicly financed health care, The impact on individual hospitals is highly disproportionate, While hospital discharge data can be used for population-based surveillance of firearm-related trauma, there is need for improvement in local, state, and national surveillance of these injuries.	UNIV CALIF DAVIS,SCH MED,DAVIS,CA 95616	University of California System; University of California Davis			Vassar, Matt/AAD-5385-2020					ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; *CA DEP HLTH SERV, 1994, 4 EPIC CAL DEP HLTH; CLANCY TV, 1994, J TRAUMA, V37, P1, DOI 10.1097/00005373-199407000-00001; EASTMAN AB, 1994, J TRAUMA, V36, P835, DOI 10.1097/00005373-199406000-00014; FINE PR, 1994, J FORENSIC SCI, V39, P674; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; GRIFFITH EEH, 1989, JAMA-J AM MED ASSOC, V262, P2265, DOI 10.1001/jama.262.16.2265; HUTSON HR, 1994, NEW ENGL J MED, V330, P324, DOI 10.1056/NEJM199402033300506; *J HOPK HLTH SERV, 1989, DET INJ SEV HOSP DIS; KELLERMANN AL, 1992, J TRAUMA, V33, P1, DOI 10.1097/00005373-199207000-00001; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; KLEIN SR, 1991, AM SURGEON, V57, P793; LANGLOIS JA, 1995, AM J PUBLIC HEALTH, V85, P1261, DOI 10.2105/AJPH.85.9.1261; MARGANITT B, 1990, AM J PUBLIC HEALTH, V10, P1463; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; ORDOG GJ, 1995, J TRAUMA, V38, P291, DOI 10.1097/00005373-199502000-00029; OZONOFF V, 1995, MMWR-MORBID MORTAL W, V44, P160; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Rice DP, 1989, COST INJURY US REPOR; RIDDICK L, 1993, AM J FOREN MED PATH, V14, P216; ROPP L, 1992, JAMA-J AM MED ASSOC, V267, P2905, DOI 10.1001/jama.267.21.2905; RYAN M, 1993, AM SURGEON, V59, P831; SHELEY JF, 1995, PUBLIC HEALTH REP, V110, P18; SMITH RS, 1992, ARCH SURG-CHICAGO, V127, P668; SMITH SM, 1989, AM J PREV MED, V5, P296, DOI 10.1016/S0749-3797(18)31070-5; TARDIFF K, 1994, JAMA-J AM MED ASSOC, V272, P43, DOI 10.1001/jama.272.1.43; TARDIFF K, 1995, PUBLIC HEALTH REP, V110, P13; *US BUR CENS, 1990, 1990 CENS POP; *US DEP HHS, 1988, INT CLASS DIS 9 REV; *US GEN ACC OFF, 1991, TRAUM CAR LIF SYST; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; 1994, MONTHLY VITAL STAT R, V43, P1; 1994, MMWR-MORBID MORTAL W, V43, P37	37	35	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1734	1739		10.1001/jama.275.22.1734	http://dx.doi.org/10.1001/jama.275.22.1734			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP307	8637170				2022-12-28	WOS:A1996UP30700026
J	Wintemute, GJ				Wintemute, GJ			The relationship between firearm design and firearm violence - Handguns in the 1990s	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Wintemute, GJ (corresponding author), UNIV CALIF DAVIS,VIOLENCE PREVENT RES PROGRAM,2315 STOCKTON BLVD,SACRAMENTO,CA 95817, USA.							*APPL LAS SYST, 1995, PROD CAT; *AR TEK LTD, 1995, PROD CAT; AYOOB M, 1995, SHOOTING IND, V40, P65; AYOOB M, 1995, SHOOTING IND, V40, P20; AYOOB M, 1995, SHOOTING IND, V40, P68; Baker S P, 1980, J Public Health Policy, V1, P224, DOI 10.2307/3342086; *BUR ALC TOB FIR, 1977, FACT CRIT WEAP; *BUR ALC TOB FIR, 1976, BUR ALC TOB FIR PUBL; *CHARC INC, 1995, PROD CAT; CHRISTOFFEL T, 1993, PROTECTING PUBLIC LE; *GEN ACC OFF, 1991, US SEN PUBL; GROVER J, 1996, GUNS AMMO, V40, P36; Hargarten SW, 1996, JAMA-J AM MED ASSOC, V275, P42, DOI 10.1001/jama.275.1.42; HOGG IV, 1985, JANES DIRECTORY MILI; HUNNICUTT RW, 1995, AM RIFLEMAN, V143, P36; HUNNICUTT RW, 1995, AM RIFLEMAN, V143, P70; HUNNICUTT RW, 1995, AM RIFLEMAN, V143, P42; HUNNICUTT RW, 1995, AM RIFLEMAN, V143, P58; HUTSON HR, 1995, JAMA-J AM MED ASSOC, V274, P1031, DOI 10.1001/jama.274.13.1031; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; KOOP CE, 1994, JAMA-J AM MED ASSOC, V271, P1404; KOOP CE, 1992, JAMA-J AM MED ASSOC, V268, P3074; LORCIN, 1994, GUNT ESTS, V6, P10; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MERCY JA, 1993, HLTH AFF MILLWOOD, V12, P6; Robertson L. S., 1992, INJURY EPIDEMIOLOGY; SILVER V, 1995, NY TIMES        1102, pA8; SINGH GK, 1995, MONTHLY VITAL STAT R, V43, P1; *SPRINGF INC, 1994, PROD CAT; STONE JL, 1995, J TRAUMA, V38, P851, DOI 10.1097/00005373-199506000-00002; *SUND IND INC, 1994, PROM MAT; Teret SP, 1996, JAMA-J AM MED ASSOC, V275, P70, DOI 10.1001/jama.275.1.70; TERET SP, 1992, JAMA-J AM MED ASSOC, V267, P3073, DOI 10.1001/jama.267.22.3073; WEBSTER DW, 1992, ARCH SURG-CHICAGO, V127, P694; Wintemute G., 1994, RING FIRE HANDGUN MA; WINTEMUTE GJ, 1994, AM J PUBLIC HEALTH, V84, P561, DOI 10.2105/AJPH.84.4.561; WINTEMUTE GJ, 1995, TRAUMA TRANSITION TR; ZIMRING FE, 1972, J LEGAL STUDIES, V0001; 1996, FIREARMS BUSINESS, V5, P1; 1995, FIREARMS BUSINESS, V4, P7; 1995, GUN TESTS, V7, P30; 1995, AM FIREARMS IND, V23, P23; 1995, GUN TESTS, V7, P3; 1995, AM RIFLEMAN, V143, P48; 1994, PRODUCT CATALOG; 1995, FIREARMS BUSINESS, V4, P5; 1995, AM FIREARMS IND, V23, P72	48	50	50	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1749	1753		10.1001/jama.275.22.1749	http://dx.doi.org/10.1001/jama.275.22.1749			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP307	8637173				2022-12-28	WOS:A1996UP30700029
J	Frenette, PS; Wagner, DD				Frenette, PS; Wagner, DD			Adhesion molecules .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL		HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School			Frenette, Paul S/J-8272-2012	Frenette, Paul S/0000-0003-0862-9922				CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; RUOSLAHTI E, 1992, BRIT J CANCER, V66, P239, DOI 10.1038/bjc.1992.250	4	281	295	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1526	1529		10.1056/NEJM199606063342308	http://dx.doi.org/10.1056/NEJM199606063342308			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618609				2022-12-28	WOS:A1996UN79900008
J	Masuko, K; Mitsui, T; Iwano, K; Yamazaki, C; Okuda, K; Meguro, T; Murayama, N; Inoue, T; Tsuda, F; Okamoto, H; Miyakawa, Y; Mayumi, M				Masuko, K; Mitsui, T; Iwano, K; Yamazaki, C; Okuda, K; Meguro, T; Murayama, N; Inoue, T; Tsuda, F; Okamoto, H; Miyakawa, Y; Mayumi, M			Infection with hepatitis GB virus C in patients on maintenance hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FULMINANT-HEPATITIS; NON-A; PREVALENCE; REGION; RNA	Background. A recently discovered non-AE hepatitis virus has been designated hepatitis GB virus C (HGBV-C), but little is known about its mode of transmission and its clinical manifestations. We studied 519 patients on maintenance hemodialysis to determine whether they were infected with HGBV-C. Methods. HGBV-C RNA was identified in serum by a reverse-transcription-polymerase-chain-reaction assay with nested primers deduced from a nonstructural region. A nucleotide sequence of 100 bp in the nonstructural region was determined on HGBV-C clones. Results. HGBV-C RNA was detected in 3.1 percent of the patients on hemodialysis (16 of 519), as compared with 0.9 percent of healthy blood donors (4 of 448, P<0.03). None of the 16 patients had evidence of active liver disease, although 7 were also infected with hepatitis C virus. Eight patients with HGBV-C infection were followed for 7 to 16 years. In two patients the virus was present at the start of hemodialysis. One had a history of transfusion, and HGBV-C RNA persisted over a period of 16 years; the other became free of HGBV-C after 10 years. In five patients, HGBV-C RNA was first detected 3 to 20 weeks after blood transfusion and persisted for up to 13 years. One patient with no history of transfusion was infected with an HGBV-C variant with the same sequence as in two of the patients with post-transfusion HGBV-C infections. Conclusions. Patients on maintenance hemodialysis are at increased risk for HGBV-C infection. This virus produces persistent infections, which may be transmitted by transfusions but may also be transmitted by other means. (C) 1996, Massachusetts Medical Society.	JICHI MED SCH, DIV IMMUNOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; MASUKO HOSP, NAGOYA, AICHI, JAPAN; MASUKO INST MED RES, NAGOYA, AICHI, JAPAN; YAMANASHI MED UNIV, DEPT INTERNAL MED 1, TAMAHO, YAMANASHI, JAPAN; TOSHIBA GEN HOSP, DEPT MED SCI, TOKYO, JAPAN; MIYAKAWA MED RES FDN, TOKYO, JAPAN	Jichi Medical University; University of Yamanashi; Toshiba Corporation			Okamoto, Hiroaki/H-4371-2011	Okamoto, Hiroaki/0000-0003-0827-0964				Aikawa T, 1996, NEW ENGL J MED, V334, P195, DOI 10.1056/NEJM199601183340316; ALTER HJ, 1995, SEMIN LIVER DIS, V15, P110, DOI 10.1055/s-2007-1007268; CHAN TM, 1993, HEPATOLOGY, V17, P5, DOI 10.1016/0270-9139(93)90183-N; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; GOLDBLUM SE, 1980, ANN INTERN MED, V93, P597, DOI 10.7326/0003-4819-93-4-597; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; IIZUKA H, 1992, VOX SANG, V63, P107, DOI 10.1111/j.1423-0410.1992.tb02495.x; KOSAKA Y, 1991, GASTROENTEROLOGY, V100, P1087, DOI 10.1016/0016-5085(91)90286-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LONDON WT, 1969, NEW ENGL J MED, V281, P571, DOI 10.1056/NEJM196909112811101; Masuko K, 1994, J Viral Hepat, V1, P65, DOI 10.1111/j.1365-2893.1994.tb00063.x; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; OKAMOTO H, 1994, HEPATOLOGY, V20, P1131, DOI 10.1002/hep.1840200505; SATO S, 1995, ANN INTERN MED, V122, P241, DOI 10.7326/0003-4819-122-4-199502150-00001; SCHLAUDER GG, 1995, J MED VIROL, V46, P81, DOI 10.1002/jmv.1890460117; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; SZMUNESS W, 1974, JAMA-J AM MED ASSOC, V227, P901, DOI 10.1001/jama.227.8.901; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	27	449	454	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1485	1490		10.1056/NEJM199606063342301	http://dx.doi.org/10.1056/NEJM199606063342301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618602				2022-12-28	WOS:A1996UN79900001
J	Spector, SA; McKinley, GF; Lalezari, JP; Samo, T; Andruczk, R; Follansbee, S; Sparti, PD; Havlir, DV; Simpson, G; Buhles, W; Wong, R; Stempien, MJ				Spector, SA; McKinley, GF; Lalezari, JP; Samo, T; Andruczk, R; Follansbee, S; Sparti, PD; Havlir, DV; Simpson, G; Buhles, W; Wong, R; Stempien, MJ			Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CONTROLLED TRIAL; VIRUS RETINITIS; CLINICAL-TRIALS; INFECTION; PROPHYLAXIS; FOSCARNET; AUTOPSY; THERAPY	Background. In the advanced stages of the acquired immunodeficiency syndrome (AIDS), cytomegalovirus (CMV) disease, particularly vision-damaging retinitis due to CMV, is common. We evaluated prophylactic treatment with orally administered ganciclovir as a way to prevent CMV disease. Methods. We conducted a prospective, randomized, double-blind, placebo-controlled study of CMV-infected persons with AIDS with either CD4+ lymphocyte counts of less than or equal to 50 per cubic millimeter or counts of less than or equal to 100 per cubic millimeter in those with a history of an AIDS-defining opportunistic infection. Patients were randomly assigned, in a 2:1 ratio, to receive either oral ganciclovir (1000 mg three times daily) or placebo. Results. The study was stopped after a median of 367 days of follow-up. In an intention-to-treat analysis, the 12-month cumulative rates of confirmed CMV disease were 26 percent in the placebo group (n=239) and 14 percent in the ganciclovir group (n=486), representing an overall reduction in risk of 49 percent in the ganciclovir group (P<0.001). The incidence of CMV retinitis after 12 months was 24 percent in the placebo group and 12 percent in the ganciclovir group (P<0.001). The prevalence of CMV-positive urine cultures at base line was 42 percent; after two months it was 43 percent in the placebo group and 10 percent in the ganciclovir group (P<0.001). The one-year mortality rate was 26 percent in the placebo group and 21 percent in the ganciclovir group (P=0.14). Therapy with granulocyte colony-stimulating factor was more frequent in the ganciclovir group (24 percent) than in the placebo group (9 percent). Conclusions. In persons with advanced AIDS, prophylactic oral ganciclovir significantly reduces the risk of CMV disease. (C) 1996, Massachusetts Medical Society.	ST LUKES ROOSEVELT HOSP,NEW YORK,NY 10025; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; MT ZION HOSP & MED CTR,SAN FRANCISCO,CA; METHODIST HOSP,HOUSTON,TX 77030; OAKLAWN PHYSICIANS GRP,DALLAS,TX; RK DAVIES MED CTR,SAN FRANCISCO,CA; COMMUNITY RES INITIAT S FLORIDA,CORAL GABLES,FL; UNIV CALIF LOS ANGELES,HARBOR MED CTR,TORRANCE,CA 90509; ROCHE PHARMACEUT,PALO ALTO,CA	Mount Sinai St. Luke's; Mount Sinai West; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; The Methodist Hospital System; The Methodist Hospital - Houston; California Pacific Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Roche Holding	Spector, SA (corresponding author), UNIV CALIF SAN DIEGO,CLIN SCI BLDG,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							ALFORD CA, 1990, VIROLOGY, P1981; BLOOM JN, 1988, ANN INTERN MED, V109, P963, DOI 10.7326/0003-4819-109-12-963; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; BROSGART CL, 1995, 35 INT C ANT AG CHEM; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; DREW WL, 1992, CLIN INFECT DIS, V14, P608, DOI 10.1093/clinids/14.2.608-a; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; GALLANT JE, 1994, ANN INTERN MED, V120, P932, DOI 10.7326/0003-4819-120-11-199406010-00006; GERNA G, 1990, AIDS, V4, P1027, DOI 10.1097/00002030-199010000-00014; GOODGAME RW, 1993, ANN INTERN MED, V119, P924, DOI 10.7326/0003-4819-119-9-199311010-00010; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031; JACOBSON MA, 1989, ANTIMICROB AGENTS CH, V33, P736, DOI 10.1128/AAC.33.5.736; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; KALAYJIAN RC, 1993, MEDICINE, V72, P67, DOI 10.1097/00005792-199303000-00001; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIM K, 1990, BIOMETRICS, V46, P81, DOI 10.2307/2531632; LANE HC, 1994, ANN INTERN MED, V120, P945, DOI 10.7326/0003-4819-120-11-199406010-00007; LANE HC, 1995, ANN INTERN MED, V122, P317; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803; MORGELLO S, 1987, HUM PATHOL, V18, P289, DOI 10.1016/S0046-8177(87)80012-6; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; REICHERT CM, 1983, AM J PATHOL, V112, P357; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SPECTOR SA, 1995, J INFECT DIS, V171, P1431, DOI 10.1093/infdis/171.6.1431; SPECTOR SA, 1993, J INFECT DIS, V168, P557, DOI 10.1093/infdis/168.3.557; SPECTOR SA, 1992, J CLIN MICROBIOL, V30, P2359, DOI 10.1128/JCM.30.9.2359-2365.1992; 1995, AIDS, V9, P471; 1986, NEW ENGL J MED, V314, P801; 1987, MMWR-MORBID M      S, V36, pS1; 1992, NEW ENGL J MED, V326, P213; 1992, NEW ENGL J MED, V326, P1172	35	232	236	1	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1491	1497		10.1056/NEJM199606063342302	http://dx.doi.org/10.1056/NEJM199606063342302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618603				2022-12-28	WOS:A1996UN79900002
J	Chen, RT; Hausinger, S; Dajani, AS; Hanfling, M; Baughman, AL; Pallansch, MA; Patriarca, PA				Chen, RT; Hausinger, S; Dajani, AS; Hanfling, M; Baughman, AL; Pallansch, MA; Patriarca, PA			Seroprevalence of antibody against poliovirus in inner-city preschool children - Implications for vaccination policy in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARALYTIC POLIOMYELITIS; VACCINES; IMMUNOGENICITY; CHILDHOOD; RESPONSES; OUTBREAK; DISEASE; OMAN; LIVE	Objectives.-To assess susceptibility to poliomyelitis in selected inner-city preschool children in the United States and to estimate the contribution of secondary spread of live attenuated oral poliovirus vaccine virus to type-specific immunity, Design.-Cross-sectional seroprevalence study, Methods.-Serum neutralizing antibody levels against poliovirus types 1, 2, and 3 were analyzed according to vaccination status, agp, and other sociodemographic variables, Setting.-Hospital and satellite clinics serving inner-city populations in Houston, Tex, and Detroit, Mich, 1990 to 1991, Participants.-A total of 526 children aged 12 to 47 months seeking medical care were enrolled in the seroprevalence study; 144 children aged 12 to 35 months without a history of previous oral poliovirus vaccination were enrolled in the secondary spread study. Results.-Seropositive rates were similar in children in both cities, ranging from about 80% for types 1 and 3 in 12- to 23-month-old children to more than 90% in those aged 36 to 47 months. The most important predictor of seropositivity was the number of doses of oral poliovirus vaccine received (P<.01), with levels approximately 90% for all 3 serotypes among children who had received 3 or more doses. In children likely to have been unvaccinated, seropositive rates ranged from 9% to 18% for poliovirus types 1 and 3 and from 29% to 42% for type 2; secondary spread of vaccine virus appeared to have occurred among children who had previously received 1 dose or less but not those with 2 or more doses. Conclusions.-Levels of immunity to poliovirus among inner-city preschoolers are high and may be predicted by the number of doses of oral poliovirus vaccine received, Secondary spread of the vaccine virus plays a modest role in increasing polio immunity in inner-city populations, especially against types 1 and 3, This role will decrease in importance if the recently attained high levels of immunization coverage in the United States are sustained and if the risk of importation of wild poliovirus continues to diminish.	CTR DIS CONTROL & PREVENT, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA; BAYLOR COLL MED, SECT ACAD AMBULATORY PEDIAT, HOUSTON, TX 77030 USA; WAYNE STATE UNIV, SCH MED, DEPT PEDIAT, DETROIT, MI 48201 USA; CHILDRENS HOSP MICHIGAN, DIV INFECT DIS, DETROIT, MI 48201 USA	Centers for Disease Control & Prevention - USA; Wayne State University; Children's Hospital of Michigan	Chen, RT (corresponding author), CTR DIS CONTROL & PREVENT, NATL IMMUNIZATION PROGRAM E61, ATLANTA, GA 30333 USA.				PHS HHS [200-89-0735] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; BENYESHMELNICK M, 1976, AM J EPIDEMIOL, V86, P112; BOTTIGER M, 1984, REV INFECT DIS, V6, pS548; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P337; CIRNE MD, 1995, J INFECT DIS, V171, P1097, DOI 10.1093/infdis/171.5.1097; COHENABBO A, 1995, PEDIATR INFECT DIS J, V14, P100, DOI 10.1097/00006454-199502000-00004; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; FADEN H, 1990, J INFECT DIS, V162, P1291, DOI 10.1093/infdis/162.6.1291; Finney D., 1964, STAT METHOD BIOL ASS, P524; Fleiss JL, 1981, STAT METHODS RATES P; FOX JP, 1960, PAN AM SANITARY BURE, V50, P144; Francis Thomas, 1957, EVALUATION 1954 FIEL; GARD S, 1959, 1 INT C LIV POL VACC, P350; GELFAND HM, 1959, PAN AM SANITARY BURE, V44, P203; HARDEGREE M C, 1970, Bulletin of the World Health Organization, V43, P461; HINMAN AR, 1988, AM J PUBLIC HEALTH, V78, P291, DOI 10.2105/AJPH.78.3.291; HINMAN AR, 1993, AM J DIS CHILD, V147, P536, DOI 10.1001/archpedi.1993.02160290042020; HORSTMANN DM, 1959, JAMA-J AM MED ASSOC, V170, P1; HOVI T, 1986, LANCET, V1, P1427; *I MED, 1988, PUBL IOM, V8804; KIMBALL AC, 1960, PAN AM SANITARY BURE, V50, P161; KOPROWSKI H, 1960, PAN AM SANITARY BURE, V44, P159; KUCHARSKA Z, 1982, J HYG EPID MICROB IM, V26, P74; MARWICK C, 1995, JAMA-J AM MED ASSOC, V274, P203, DOI 10.1001/jama.1995.03530030025009; MCBEAN AM, 1988, AM J EPIDEMIOL, V128, P615, DOI 10.1093/oxfordjournals.aje.a115009; MODLIN JF, 1993, 33 INT C ANT AG CHEM; MORINIERE BJ, 1993, LANCET, V341, P1545, DOI 10.1016/0140-6736(93)90693-B; *NAT IMM PROGR, 1994, BIOL SURV SUMM; NIGHTINGALE EO, 1977, NEW ENGL J MED, V297, P249, DOI 10.1056/NEJM197708042970505; OGRA PL, 1984, REV INFECT DIS, V6, pS361; ONORATO IM, 1991, J INFECT DIS, V163, P1, DOI 10.1093/infdis/163.1.1; OOSTVOGEL PM, 1994, LANCET, V344, P665, DOI 10.1016/S0140-6736(94)92091-5; PATRIARCA PA, 1988, LANCET, V1, P429; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; PAUL JR, 1960, 5TH INT POL C COP, P359; PETER G, 1995, AAP NEWS, V11, P13; PLOTKIN SA, 1995, PEDIATR INFECT DIS J, V14, P835, DOI 10.1097/00006454-199510000-00003; SABIN AB, 1961, AM J DIS CHILD, V101, P546, DOI 10.1001/archpedi.1961.04020060004002; SHALALA DE, 1993, JAMA-J AM MED ASSOC, V269, P1844, DOI 10.1001/jama.269.14.1844; SPRENT P, 1993, APPL NONPARAMETRIC S, P28; STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; SUTTER RW, 1993, INT J EPIDEMIOL, V22, P936, DOI 10.1093/ije/22.5.936; Sutter RW, 1993, MEASLES POLIOMYELITI, P279; *US BUR CENS, 1994, COUNT CIT DAT BOOK 1; WRIGHT PF, 1991, NEW ENGL J MED, V325, P1774, DOI 10.1056/NEJM199112193252504; ZELL ER, 1994, JAMA-J AM MED ASSOC, V271, P833, DOI 10.1001/jama.271.11.833; 1995, MMWR-MORBID MORTAL W, V44, P613; 1995, MMWR-MORBID MORTAL W, V44, P273; 1994, MMWR-MORBID MORTAL W, V43, P720	50	60	61	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1639	1645		10.1001/jama.275.21.1639	http://dx.doi.org/10.1001/jama.275.21.1639			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637136				2022-12-28	WOS:A1996UN25200025
J	Birch, DE; Kolmodin, L; Laird, WJ; McKinney, N; Wong, J; Young, KKY; Zangenberg, GA; Zoccoli, MA				Birch, DE; Kolmodin, L; Laird, WJ; McKinney, N; Wong, J; Young, KKY; Zangenberg, GA; Zoccoli, MA			Simplified hot start PCR	NATURE			English	Article							ESCHERICHIA-COLI; GENE; DNA		ROCHE MOL SYST,DEPT INFECT DIS,ALAMEDA,CA 94501	Roche Holding	Birch, DE (corresponding author), ROCHE MOL SYST,DEPT PROD DEV,ALAMEDA,CA 94501, USA.							CHOU Q, 1992, NUCLEIC ACIDS RES, V20, P1717, DOI 10.1093/nar/20.7.1717; FALOONA F, 1990, 6 INT C AIDS SAN FRA; FINDLAY JB, 1993, CLIN CHEM, V39, P1927; HORTON RM, 1994, BIOTECHNIQUES, V16, P42; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KELLOGG DE, 1994, BIOTECHNIQUES, V16, P1134; KWOK S, 1992, 92 GEN M AM SOC MICR; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LYNCH CE, 1992, J ACQ IMMUN DEF SYND, V5, P433; TEVERE VJ, IN PRESS J CLIN MICR	10	108	115	3	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					445	446		10.1038/381445a0	http://dx.doi.org/10.1038/381445a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632804				2022-12-28	WOS:A1996UN47900057
J	Li, LM; Cohen, SN				Li, LM; Cohen, SN			tsg101: A novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells	CELL			English	Article							ANTI-SENSE RNA; ANCHORAGE-INDEPENDENT GROWTH; MULTIPLE SIGNAL-TRANSDUCTION; DNA-BINDING PROTEINS; SEQUENCES COMPLEMENTARY; RETROVIRAL VECTORS; SUPPRESSOR GENES; LEUCINE ZIPPER; LAC REPRESSOR; STEM-CELLS	Using a novel strategy that enables the isolation of previously unknown genes encoding selectable recessive phenotypes, we identified a gene (tsg101) whose homozygous functional disruption produces cell transformation. Antisense RNA from a transactivated promoter introduced randomly into transcribed genes throughout the genome of mouse 3T3 fibroblasts was used to knock out alleles of chromosomal genes adjacent to promoter inserts, generating clones that grew in 0.5% agar and formed metastatic tumors in nude mice. Removal of the transactivator restored normal growth. The protein encoded by tsg101 cDNA encodes a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated previously in tumorigenesis. Overexpression of tsg101 antisense transcripts in naive 3T3 cells resulted in cell transformation and increased stathmin-specific mRNA.	STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA	Stanford University; Stanford University								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BOOTH PM, 1994, GENE, V146, P303, DOI 10.1016/0378-1119(94)90310-7; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRENNER DG, 1989, P NATL ACAD SCI USA, V86, P5517, DOI 10.1073/pnas.86.14.5517; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; DETLOFF PJ, 1994, MOL CELL BIOL, V14, P6936, DOI 10.1128/MCB.14.10.6936; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; DOYE V, 1990, J BIOL CHEM, V265, P11650; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRATIOTDEANS J, 1992, J CLIN INVEST, V90, P1576, DOI 10.1172/JCI116026; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HAWLEY RG, 1987, P NATL ACAD SCI USA, V84, P2406, DOI 10.1073/pnas.84.8.2406; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NISHIGUCHI S, 1994, J BIOCHEM-TOKYO, V116, P128, DOI 10.1093/oxfordjournals.jbchem.a124485; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; ROOS G, 1993, LEUKEMIA, V7, P1538; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TEMSAMANI J, 1991, J BIOL CHEM, V266, P468; VOLLOCH V, 1991, BIOCHEM BIOPH RES CO, V179, P1593, DOI 10.1016/0006-291X(91)91756-3; VOLLOCH V, 1991, BIOCHEM BIOPH RES CO, V179, P1600, DOI 10.1016/0006-291X(91)91757-4; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819	63	296	344	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					319	329		10.1016/S0092-8674(00)81111-3	http://dx.doi.org/10.1016/S0092-8674(00)81111-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616888	Bronze			2022-12-28	WOS:A1996UK14000006
J	Lamb, FJ; Mitchell, IA; Bennett, ED				Lamb, FJ; Mitchell, IA; Bennett, ED			A woman with two young children and left chest pain	LANCET			English	Article							DISEASE				Lamb, FJ (corresponding author), ST GEORGE HOSP,DEPT INTENS CARE MED,LONDON SW17 0QT,ENGLAND.			Mitchell, Imogen/0000-0001-6013-4922				ALHO OP, 1995, ARCH OTOLARYNGOL, V121, P898; FARLEY MM, 1992, ANN INTERN MED, V116, P806, DOI 10.7326/0003-4819-116-10-806; HOWARD AJ, 1991, BRIT MED J, V303, P441, DOI 10.1136/bmj.303.6800.441; WENGER JD, 1989, J INFECT DIS, V21, P651	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					870	870		10.1016/S0140-6736(96)91349-5	http://dx.doi.org/10.1016/S0140-6736(96)91349-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622395				2022-12-28	WOS:A1996UC45000013
J	Brahams, D				Brahams, D			Unnatural death, AIDS, and coroners	LANCET			English	Editorial Material											Brahams, D (corresponding author), OLD SQ CHAMBERS,LONDON WC1,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					777	777		10.1016/S0140-6736(96)90862-4	http://dx.doi.org/10.1016/S0140-6736(96)90862-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622328				2022-12-28	WOS:A1996UB15300003
J	Brodie, MJ				Brodie, MJ			Antiepileptic drugs, clinical trials, and the marketplace	LANCET			English	Editorial Material							PHARMACOLOGICAL PROPERTIES; EPILEPSY; VIGABATRIN				Brodie, MJ (corresponding author), UNIV GLASGOW, WESTERN INFIRM, EPILEPSY RES UNIT, GLASGOW G61 1BD, LANARK, SCOTLAND.							BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; BRODIE MJ, 1993, LANCET, V341, P1445, DOI 10.1016/0140-6736(93)90888-N; Brodie MJ, 1996, NEW ENGL J MED, V334, P168, DOI 10.1056/NEJM199601183340308; BRODIE MJ, 1995, LANCET, V346, P918, DOI 10.1016/S0140-6736(95)91550-8; GOA KL, 1993, DRUGS, V46, P152, DOI 10.2165/00003495-199346010-00009; GOA KL, 1993, DRUGS, V46, P409, DOI 10.2165/00003495-199346030-00007; GRANT SM, 1991, DRUGS, V41, P889, DOI 10.2165/00003495-199141060-00007; KRAMER LD, 1993, EPILEPSIA, V34, P1075, DOI 10.1111/j.1528-1157.1993.tb02136.x; LEACH JP, 1995, SEIZURE-EUR J EPILEP, V4, P155, DOI 10.1016/S1059-1311(95)80098-0; LEPPIK IE, 1995, CNS DRUGS, V4, P294, DOI 10.2165/00023210-199504040-00006; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MATTSON RH, 1995, LANCET, V345, P467, DOI 10.1016/S0140-6736(95)90576-6; MCKEE PJW, 1993, EPILEPSIA, V34, P937, DOI 10.1111/j.1528-1157.1993.tb02115.x; SCHMIDT D, 1995, CNS DRUGS, V3, P194, DOI 10.2165/00023210-199503030-00005; 1995, LANCET, V346, P981	15	36	36	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	1996	347	9004					777	779		10.1016/S0140-6736(96)90863-6	http://dx.doi.org/10.1016/S0140-6736(96)90863-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622329				2022-12-28	WOS:A1996UB15300004
J	Harries, AD; Mbewe, LN; Salaniponi, FML; Nyangulu, DS; Veen, J; Ringdal, T; Nunn, P				Harries, AD; Mbewe, LN; Salaniponi, FML; Nyangulu, DS; Veen, J; Ringdal, T; Nunn, P			Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi	LANCET			English	Article							INFECTION; CHEMOTHERAPY; MORTALITY; NAIROBI; KENYA	Malawi is one of the poorest countries in the world. Despite the lack of resources, the country has a good tuberculosis (TB) recording and reporting system, developed in 1984 by the International Union against Tuberculosis and Lung Disease. Since 1985, Malawi has experienced an upsurge in TB notifications, mainly because of the HIV epidemic. The number of notified TB cases rose from 5334 in 1985 to 19 496 in 1994, according to the Malawi national TB programme. The national cure rate decreased from 80% in 1988 to 63% in 1992, as the TB programme struggled to cope with increasing numbers of patients while the economic situation worsened. The deterioration in treatment outcomes was more pronounced in the large cities of Blantyre and Lilongwe than elsewhere. This feature causes concern because Queen Elizabeth Central Hospital, Blantyre, and Kamuzu Central Hospital, Lilongwe, diagnose and treat 30-40% of all registered TB cases in Malawi. We have assessed the rates of TB notifications and treatment outcomes in Queen Elizabeth Central Hospital and the measures introduced to improve treatment outcomes.	MINIST HLTH,NATL TB PROGRAMME,LILONGWE,MALAWI; INT UNION AGAINST TB & LUNG DIS,PARIS,FRANCE; WHO,GLOBAL TB PROGRAMME,CH-1211 GENEVA,SWITZERLAND	World Health Organization	Harries, AD (corresponding author), QUEEN ELIZABETH CENT HOSP,DEPT MED,COLL MED,POB 95,BLANTYRE,MALAWI.							ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; BRINDLE RJ, 1993, AIDS, V7, P1469, DOI 10.1097/00002030-199311000-00010; ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1; KOOL HEJ, 1990, TROP GEOGR MED, V42, P128; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; REEVE PA, 1989, BRIT MED J, V298, P1567, DOI 10.1136/bmj.298.6687.1567; World Health Organization, 1993, TREATM TUB GUID NAT	9	34	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					807	809		10.1016/S0140-6736(96)90874-0	http://dx.doi.org/10.1016/S0140-6736(96)90874-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622340				2022-12-28	WOS:A1996UB15300015
J	Teunisse, RJ; Cruysberg, JR; Hoefnagels, WH; Verbeek, AL; Zitman, FG				Teunisse, RJ; Cruysberg, JR; Hoefnagels, WH; Verbeek, AL; Zitman, FG			Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome	LANCET			English	Article							BONNET,CHARLES SYNDROME; RELIABILITY; INTERVIEW	Background Bonnet's Syndrome (CBS) characterised by the presence of complex visual hallucinations in psychologically normal people, was considered for a long time to be rare. Systematic research on CBS has been limited. However, it has been realised that CBS occurs frequently in elderly, visually handicapped patients, and we have been able to study the syndrome in a large number of patients. Methods After screening 505 visually handicapped patients, 60 were found to meet proposed diagnostic criteria for CBS (generally, the existence of hallucinations without delusions or loss of insightful cognition.) Psychopathological characteristics, personal meaning, and the emotional impact of hallucinations, as well as factors influencing the hallucinations, were analysed. Findings Although diagnostic criteria demand merely ''partial insight'', all patients had full insight into the unreal nature of their hallucinations. Other characteristics varied. In 46 (77%) patients, hallucinations lacked a personal meaning. Sensory deprivation and a low level of arousal seemed to favour the occurrence of hallucinations. CBS caused considerable distress in only 17 (28%) patients. However, all patients were glad to be told that their hallucinations were not due to mental disease. The proper diagnosis had been made in only one of the 16 patients who had consulted a doctor. Interpretation Although largely unrecognised in clinical practice, CBS should be considered as a diagnosis in patients who complain of hallucinations and who meet defined diagnostic criteria. There is no proven treatment, but many patients will benefit from reassurance that their hallucinations do not imply mental illness.	UNIV NIJMEGEN HOSP, DEPT OPHTHALMOL, 6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN HOSP, DEPT GERIATR MED, 6500 HB NIJMEGEN, NETHERLANDS; UNIV NIJMEGEN HOSP, DEPT EPIDEMIOL, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Teunisse, RJ (corresponding author), UNIV NIJMEGEN HOSP, DEPT PSYCHIAT, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		Zitman, Frans G./E-7705-2010; Verbeek, A.L.M./H-8103-2014; Cruysberg, Johannes R. M./D-4313-2009	Verbeek, A.L.M./0000-0002-2319-5002; Cruysberg, Johannes R. M./0000-0002-5330-0774				*AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P398; BONNER C, 1760, ESSAI ANAL FACULTES; COLE MG, 1992, CAN J PSYCHIAT, V37, P267, DOI 10.1177/070674379203700411; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; DAMASMORA J, 1982, PSYCHOL MED, V12, P251, DOI 10.1017/S0033291700046584; de Morsier G, 1967, ANN MED PSYCHOL, V125, P677; FUCHS T, 1992, DELUSIONS HALLUCINAT, P187; GOLD K, 1989, COMPR PSYCHIAT, V30, P90, DOI 10.1016/0010-440X(89)90122-3; HOOIJER C, 1991, INT J GERIATR PSYCH, V6, P71, DOI 10.1002/gps.930060205; OLBRICH HM, 1987, GRAEF ARCH CLIN EXP, V225, P217, DOI 10.1007/BF02175452; PODOLL K, 1989, FORTSCHR NEUROL PSYC, V57, P43, DOI 10.1055/s-2007-1000744; SCHULTZ G, 1991, PERCEPTION, V20, P809, DOI 10.1068/p200809; SIATKOWSKI RM, 1990, J CLIN NEURO-OPHTHAL, V10, P215; TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254; TEUNISSE RJ, 1994, COMPR PSYCHIAT, V35, P70, DOI 10.1016/0010-440X(94)90172-4; WHITE NJ, 1980, BRIT J PSYCHIAT, V136, P284, DOI 10.1192/bjp.136.3.284	16	283	286	0	59	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	1996	347	9004					794	797		10.1016/S0140-6736(96)90869-7	http://dx.doi.org/10.1016/S0140-6736(96)90869-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UB153	8622335	Green Submitted			2022-12-28	WOS:A1996UB15300010
J	Jarvis, D; Chinn, S; Luczynska, C; Burney, P				Jarvis, D; Chinn, S; Luczynska, C; Burney, P			Association of respiratory symptoms and lung function in young adults with use of domestic gas appliances	LANCET			English	Article							INDOOR NITROGEN-DIOXIDE; PULMONARY-FUNCTION; IN-VITRO; CHILDREN; EXPOSURE; COOKING; DISEASE	Background There is evidence from some studies that people living in homes with gas stoves and other unvented gas appliances experience more respiratory symptoms than those who use other fuels for cooking and heating, but other studies have found no such association. We have investigated whether the use of gas appliances is associated with an increased risk of respiratory symptoms and whether sensitisation to common environmental allergens modifies any such association. Methods A stratified random sample of 15 000 adults aged 20-44 years, living in three towns in East Anglia, UK, were sent a questionnaire on asthma and hayfever. From those who responded, a random sample of 1864 were invited to complete an extended questionnaire that included questions on use of gas appliances, to give blood samples for measurements of total IgE and specific IgE to common allergens, and to undergo tests of respiratory function. 659 women and 500 men agreed to an interview. The association of the use of gas appliances with respiratory symptoms, total IgE, specific IgE, and respiratory function was assessed by logistic and multiple regression models. Findings Women who reported they mainly used gas for cooking had an increased risk of several asthma-like symptoms during the past 12 months including wheeze (odds ratio 2.07 [95% CI 1.41-3.05]), waking with shortness of breath (2.32 [1.25-4.34]), and asthma attacks (2.60 [1.20-5.65]). Gas cooking increased the risk of symptoms more in women who were atopic than in non-atopic women but the difference did not reach significance (p>0.05). Women who used a gas stove or had an open gas fire had reduced lung function (forced expiratory volume in 1 s [FEV(1)]) and increased airways obstruction (FEV, as a percentage of forced vital capacity) compared with women who did not. These associations were not observed in men. Interpretation In East Anglia, the use of gas cooking is significantly associated with subjective and objective markers of respiratory morbidity in women but not in men. Women may be more susceptible than men to the products of gas combustion or they may have greater exposure to high concentrations of these products because they cook more frequently than men.			Jarvis, D (corresponding author), UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND.		Jarvis, Deborah/E-6494-2011	Jarvis, Deborah/0000-0002-1753-3896; Burney, Peter/0000-0001-8635-5678				BRUNEKREEF B, 1990, J AIR WASTE MANAGE, V40, P1252, DOI 10.1080/10473289.1990.10466779; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; COMSTOCK GW, 1981, AM REV RESPIR DIS, V124, P143; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVALIA JL, 1993, EUR RESPIR J, V6, P1308; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; FLEISS JL, 1979, AM J EPIDEMIOL, V110, P103, DOI 10.1093/oxfordjournals.aje.a112794; HASSELBLAD V, 1992, J AIR WASTE MANAGE, V42, P662, DOI 10.1080/10473289.1992.10467018; HASSELBLAD V, 1981, AM REV RESPIR DIS, V123, P479; HELSING KT, 1982, ENVIRON INT, V8, P365; KELLER MD, 1979, ENVIRON RES, V19, P495, DOI 10.1016/0013-9351(79)90073-2; LAMBERT WE, 1993, 58 HLTH EFF I REP; MELIA RJW, 1977, BRIT MED J, V2, P149, DOI 10.1136/bmj.2.6080.149; MELIA RJW, 1978, ATMOS ENVIRON, V12, P1379, DOI 10.1016/0004-6981(78)90079-3; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204, DOI 10.1093/oxfordjournals.aje.a116073; NG TP, 1993, J EPIDEMIOL COMMUN H, V47, P454, DOI 10.1136/jech.47.6.454; NOY D, 1990, ATMOS ENVIRON A-GEN, V24, P2903, DOI 10.1016/0960-1686(90)90470-8; OGSTON SA, 1985, BRIT MED J, V290, P957, DOI 10.1136/bmj.290.6473.957; OSTRO BD, 1994, AM J RESP CRIT CARE, V149, P1400, DOI 10.1164/ajrccm.149.6.8004290; SPEIZER FE, 1980, AM REV RESPIR DIS, V121, P3; SPICER CW, 1993, J AIR WASTE MANAGE, V43, P1479, DOI 10.1080/1073161X.1993.10467221; STRACHAN DP, 1995, BRIT MED J, V311, P1053, DOI 10.1136/bmj.311.7012.1053; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; VOLKMER RE, 1995, J PAEDIATR CHILD H, V31, P116, DOI 10.1111/j.1440-1754.1995.tb00758.x; WARE J, 1984, AM REV RESPIR DIS, V129, P3266; 1993, 3RD HM STAT OFF REP; 1993, EUR RESPIR J S16, V6, P25	27	164	169	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					426	431		10.1016/S0140-6736(96)90009-4	http://dx.doi.org/10.1016/S0140-6736(96)90009-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618483				2022-12-28	WOS:A1996TV72200009
J	Reith, J; Jorgensen, HS; Pedersen, PM; Nakayama, H; Raaschou, HO; Jeppesen, LL; Olsen, TS				Reith, J; Jorgensen, HS; Pedersen, PM; Nakayama, H; Raaschou, HO; Jeppesen, LL; Olsen, TS			Body temperature in acute stroke: Relation to stroke severity, infarct size, mortality, and outcome	LANCET			English	Article							FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; HYPOTHERMIA; BRAIN; DAMAGE	Background In laboratory animals, cerebral ischaemia is worsened by hyperthermia and improved by hypothermia. Whether these observations apply to human beings with stroke is unknown. We therefore examined the relation between body temperature on admission with acute stroke and various indices of stroke severity and outcome. Methods In a prospective and consecutive study 390 stroke patients were admitted to hospital within 6 h after stroke (median 2.4 h). We determined body temperature on admission, initial stroke severity, infarct size, mortality, and outcome in survivors. Stroke severity was measured on admission, weekly, and at discharge on the Scandinavian Stroke Scale (SSS). Infarct size was determined by computed tomography. Multiple logistic and linear regression outcome analyses included relevant confounders and potential predictors such as age, gender, stroke severity on admission, body temperature, infections, leucocytosis, diabetes, hypertension, atrial fibrillation, ischaemic heart disease, smoking, previous stroke, and comorbidity. Findings Mortality was lower and outcome better in patients with mild hypothermia on admission; both were worse in patients with hyperthermia. Body temperature was independently related to initial stroke severity (p<0.009), infarct size (p<0.0001), mortality (p<0.02), and outcome in survivors (SSS at discharge) (p<0.003). For each 1 degrees C increase in body temperature the relative risk of poor outcome (death or SSS score on discharge <30 points) rose by 2.2 (95% CI 1.4-3.5) (p<0.002). Interpretation We have shown that, in acute human stroke, an association exists between body temperature and initial stroke severity, infarct size, mortality, and outcome. Only intervention trials of hypothermic treatment can prove whether this relation is causal.	BISPEBJERG HOSP, DEPT RADIOL, DK-2400 COPENHAGEN NV, DENMARK	University of Copenhagen; Bispebjerg Hospital	Reith, J (corresponding author), BISPEBJERG HOSP, DEPT NEUROL, DK-2400 COPENHAGEN NV, DENMARK.							[Anonymous], 1989, Stroke, V20, P1407; ASPLUND K, 1985, STROKE, V16, P885; BOISVERT DP, 1991, J CEREB BLOOD FLOW M, V11, pS637; BUCHAN A, 1992, NEUROL CLIN, V10, P49, DOI 10.1016/S0733-8619(18)30233-0; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CASTILLO J, 1994, CEREBROVASC DIS, V4, P66, DOI 10.1159/000108454; CHAMBERLAIN JM, 1991, CLIN PEDIATR, V30, P24, DOI 10.1177/0009922891030004S08; CHOPP M, 1992, STROKE, V23, P104, DOI 10.1161/01.STR.23.1.104; CHYATTE D, 1989, J NEUROSURG, V70, P489, DOI 10.3171/jns.1989.70.3.0489; Crowell RM, 1970, STROKE, V1, P439, DOI 10.1161/01.STR.1.6.439; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; HEISS WD, 1990, STROKE S1, V21, P2; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; JORGENSEN HS, 1994, LANCET, V344, P156; JORGENSEN HS, 1994, STROKE, V25, P97, DOI 10.1161/01.STR.25.1.97; JORGENSEN HS, 1992, STROKE, V23, P1701, DOI 10.1161/01.STR.23.12.1701; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MELLERGARD P, 1992, NEUROSURGERY, V31, P671; MELLERGARD P, 1994, ACTA NEUROCHIR, P485; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; NORUSIS MJ, 1992, LOGISTIC REGRESSION; NURSE S, 1994, J NEUROSCI, V14, P7726; OLSEN TS, 1983, STROKE, V14, P332, DOI 10.1161/01.STR.14.3.332; SACCANI S, 1992, J CARDIOVASC SURG, V33, P311; WISE RJS, 1983, BRAIN, V106, P197, DOI 10.1093/brain/106.1.197; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; 1992, STATISTCAL PACKAGE S; 1985, WHO TECH REP SER, V727	32	634	655	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 17	1996	347	8999					422	425		10.1016/S0140-6736(96)90008-2	http://dx.doi.org/10.1016/S0140-6736(96)90008-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618482				2022-12-28	WOS:A1996TV72200008
J	Stegeman, CA; Tervaert, JWC; deJong, PE; Kallenberg, CGM				Stegeman, CA; Tervaert, JWC; deJong, PE; Kallenberg, CGM			Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTICYTOPLASMIC AUTOANTIBODIES; DIAGNOSIS; ANTIBODIES; VASCULITIS; AGENTS	Background Respiratory tract infections may trigger relapses in patients with Wegener's granulomatosis in remission. Uncontrolled data have suggested that treatment with trimethoprim-sulfamethoxazole (co-trimoxazole) may be beneficial. Methods We conducted a prospective, randomized, placebo-controlled study of the efficacy of cotrimoxazole (800 mg of sulfamethoxazole and 160 mg of trimethoprim) given twice daily for 24 months in preventing relapses in patients with Wegener's granulomatosis in remission during or after treatment with cyclophosphamide and prednisolone. Relapses and infections were assessed with predefined criteria based on clinical, laboratory, and histopathological findings. Patients were evaluated at least once every three months for signs of disease activity, compliance with the treatment regimen, side effects of the therapy, and evidence of infections. Titers of serum antineutrophil cytoplasmic antibodies were measured serially. Results Forty-one patients were assigned to receive co-trimoxazole, and 40 to receive placebo. In 8 of the 41 patients in the co-trimoxazole group (20 percent), the drug had to be stopped because of side effects. According to life-table analysis, 82 percent of the patients in the co-trimoxazole group remained in remission at 24 months, as compared with 60 per cent of those in the placebo group (relative risk of relapse, 0.40; 95 percent confidence interval, 0.17 to 0.98). There were fewer respiratory tract infections (P = 0.005) and non-respiratory tract infections (P = 0.05) in the co-trimoxazole group than in the placebo group. There were no significant differences in antineutrophil cytoplasmic antibody titers at any time. Proportional-hazards regression analysis identified treatment with co-trimoxazole as an independent factor associated with prolonged disease-free survival and a positive antineutrophil cytoplasmic antibody test at the sta rt of treatment as a risk factor for relapse. Conclusions Treatment with co-trimoxazole reduces the incidence of relapses in patients with Wegener's granulomatosis in remission. (C)1996, Massachusetts Medical Society.	UNIV GRONINGEN HOSP,DEPT MED,DIV CLIN IMMUNOL,9713 EZ GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DIV NEPHROL,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen			tervaert, jan willem cohen/AAB-1111-2019	Stegeman, Coen/0000-0002-0224-0927				ARMITAGE P, 1987, STAT METHODS MED RES, P125; ARMITAGE P, 1987, STATISTICAL METHODS, P408; BERGLUND F, 1975, J UROLOGY, V114, P802, DOI 10.1016/S0022-5347(17)67149-0; BRADLEY JD, 1989, ARTHRITIS RHEUM, V32, P45, DOI 10.1002/anr.1780320108; BROUWER E, 1994, KIDNEY INT, V45, P1120, DOI 10.1038/ki.1994.149; COX DR, 1972, J R STAT SOC B, V34, P187; DEREMEE RA, 1985, MAYO CLIN PROC, V60, P27, DOI 10.1016/S0025-6196(12)65279-3; DEREMEE RA, 1988, ARTHRITIS RHEUM, V31, P1068, DOI 10.1002/art.1780310821; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; GODMAN GC, 1954, AMA ARCH PATHOL, V58, P533; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; ISRAEL HL, 1988, ARCH INTERN MED, V148, P2293, DOI 10.1001/archinte.148.10.2293; JAYNE D, 1990, NEPHROL DIAL TRANSPL, V5, P309; JUNG AC, 1994, ARCH INTERN MED, V154, P2402, DOI 10.1001/archinte.154.21.2402; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; MCRAE D, 1993, ARCH OTOLARYNGOL, V119, P103; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINCHING AJ, 1980, BRIT MED J, V281, P836, DOI 10.1136/bmj.281.6244.836; ROBERTS DE, 1990, ARTHRITIS RHEUM, V33, P1590, DOI 10.1002/art.1780331020; RUBIN RH, 1980, NEW ENGL J MED, V303, P426, DOI 10.1056/NEJM198008213030804; SAVAGE COS, 1987, LANCET, V1, P1389; SPECKS U, 1989, MAYO CLIN PROC, V64, P28, DOI 10.1016/S0025-6196(12)65300-2; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; STILLWELL TJ, 1988, ARTHRITIS RHEUM, V31, P465, DOI 10.1002/art.1780310402; TERVAERT JWC, 1989, ARCH INTERN MED, V149, P2461, DOI 10.1001/archinte.149.11.2461; TERVAERT JWC, 1990, LANCET, V336, P709; VALERIANOMARCET J, 1991, ARCH INTERN MED, V151, P1649, DOI 10.1001/archinte.151.8.1649; VANDERWOUDE FJ, 1985, LANCET, V1, P425; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265; YUASA K, 1988, AM J MED, V84, P371, DOI 10.1016/0002-9343(88)90450-0	32	581	603	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					16	20		10.1056/NEJM199607043350103	http://dx.doi.org/10.1056/NEJM199607043350103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637536				2022-12-28	WOS:A1996UU47900003
J	ConryCantilena, C; VanRaden, M; Gibble, J; Melpolder, J; Shakil, AO; Viladomiu, L; Cheung, L; DiBisceglie, A; Hoofnagle, J; Shih, JW; Kaslow, R; Ness, P; Alter, HJ				ConryCantilena, C; VanRaden, M; Gibble, J; Melpolder, J; Shakil, AO; Viladomiu, L; Cheung, L; DiBisceglie, A; Hoofnagle, J; Shih, JW; Kaslow, R; Ness, P; Alter, HJ			Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A-HEPATITIS; UNITED-STATES; TRANSMISSION; RISK; ANTIBODIES	Background. For many people infected with the hepatitis C virus (HCV), the route of exposure, risk of transmission, and severity of associated liver disease are unknown. We studied these variables in people who donated blood voluntarily. Methods. Blood donors who tested positive for HCV antibodies on enzyme immunoassay were classified according to whether the results of a confirmatory second-generation recombinant immunoblot assay (RIBA) for HCV were positive, negative, or indeterminate. The evaluations also included an assessment of risk factors, a physical examination, serial determinations of alanine aminotransferase levels and HCV serologic assays, a polymerase-chain-reaction assay for HCV RNA, testing of sexual contacts and family members, and liver biopsies in some participants who were HCV-positive by RIBA. Results. A total of 481 donors were studied, among whom 248 were positive for HCV by RIBA, 102 had indeterminate results, and 131 were HCV-negative. In a logistic-regression analysis, significant risk factors for HCV infection among the HCV-positive participants were a history of blood transfusion in 66 (27 percent; P<0.001 for the comparison with RIBA-negative donors), intranasal cocaine use in 169 (68 percent, P<0.001), intravenous drug use in 103 (42 percent, P=0.001), sexual promiscuity in 132 (53 percent, P= 0.002), and ear piercing among men (P<0.05). Nine of 85 sexual partners of HCV-positive donors were anti-HCV-positive; 8 had used intravenous drugs or received transfusions. HCV RNA was found in 213 HCV-positive donors (86 percent), 3 who had indeterminate results by RIBA (2 of these 3 tested positive with a more specific, third-generation RIBA), and none who were HCV-negative. Of the HCV-positive donors, 69 percent had biochemical evidence of chronic liver disease; among 77 donors positive for HCV by RIBA who underwent liver biopsy, 5 had severe chronic hepatitis or cirrhosis, 66 had mild-to-moderate chronic hepatitis, and 6 had no evidence of hepatitis. Conclusions. Among volunteer blood donors, prior blood transfusion, intranasal cocaine use, intravenous drug use, sexual promiscuity, and ear piercing in men are risk factors for HCV infection. The high frequency of intravenous drug use was unexpected, because these donors had denied such use when questioned directly at the time of their blood donations. (C) 1996, Massachusetts Medical Society.	NIAID, DIV MICROBIOL & INFECT DIS, NIH, BETHESDA, MD 20892 USA; NIDDKD, NIH, BETHESDA, MD 20892 USA; GREATER CHESAPEAKE & POTOMAC REG AMER RED CROSS, BALTIMORE, MD USA; HOSP GEN VALLE HEBRON, BARCELONA, SPAIN; ST LOUIS UNIV, HLTH SCI CTR, DEPT INTERNAL MED, ST LOUIS, MO 63103 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); American Red Cross; Hospital Universitari Vall d'Hebron; Saint Louis University	ConryCantilena, C (corresponding author), NIH, DEPT TRANSFUS MED, BLDG 10, RM 1C711, BETHESDA, MD 20892 USA.		Hug, Balthasar L./G-1568-2010; Shaikh, Obaid/AAL-5339-2021	Shaikh, Obaid/0000-0002-4955-9222; Viladomiu, Lluis/0000-0002-3434-9847				AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ABILDGAARD N, 1991, LANCET, V338, P460, DOI 10.1016/0140-6736(91)91095-C; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; ALTER MJ, 1993, INFECT AGENT DIS, V2, P155; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1994, GASTROENTEROL CLIN N, V23, P437; ALTER MJ, 1991, HEPATOLOGY, V14, P389, DOI 10.1016/0270-9139(91)91431-Y; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; BRETTLER DB, 1992, BLOOD, V80, P540; CONRYCANTILENA C, 1995, TRANSFUSION, V35, pS229; CUTHBERT JA, 1994, CLIN MICROBIOL REV, V7, P505, DOI 10.1128/CMR.7.4.505-532.1994; ESTEBAN JI, 1989, LANCET, V2, P294; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764; EYSTER ME, 1990, BLOOD, V76, pA398; Fleiss JL, 1981, STAT METHODS RATES P; HOSMER DW, 1989, APPL LOGISTIC REGRES; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KIYOSAWA K, 1994, GASTROENTEROLOGY, V106, P1596, DOI 10.1016/0016-5085(94)90416-2; LEITMAN SF, 1989, NEW ENGL J MED, V321, P917, DOI 10.1056/NEJM198910053211401; LISSEN E, 1993, EUR J CLIN MICROBIOL, V12, P827, DOI 10.1007/BF02000402; MCCULLOUGH J, 1993, JAMA-J AM MED ASSOC, V269, P2239, DOI 10.1001/jama.269.17.2239; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHAKIL AO, 1995, ANN INTERN MED, V123, P330, DOI 10.7326/0003-4819-123-5-199509010-00002; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; Snedecor GW, 1980, STAT METHODS, V7th; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; WEINSTOCK HS, 1993, JAMA-J AM MED ASSOC, V269, P392	33	490	508	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1691	1696		10.1056/NEJM199606273342602	http://dx.doi.org/10.1056/NEJM199606273342602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT400	8637513				2022-12-28	WOS:A1996UT40000002
J	Muto, Y; Moriwaki, H; Ninomiya, M; Adachi, S; Saito, A; Takasaki, KT; Tanaka, T; Tsurumi, K; Okuno, M; Tomita, E; Nakamura, T; Kojima, T				Muto, Y; Moriwaki, H; Ninomiya, M; Adachi, S; Saito, A; Takasaki, KT; Tanaka, T; Tsurumi, K; Okuno, M; Tomita, E; Nakamura, T; Kojima, T			Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-C VIRUS; INTRAHEPATIC RECURRENCE; CURATIVE RESECTION; ALPHA-FETOPROTEIN; BINDING PROTEIN; CLONAL ORIGIN; RISK-FACTORS; F-TYPE; CANCER; HEPATECTOMY	Background. In patients with hepatocellular carcinoma (hepatoma), the rate of recurrent and second primary hepatomas is high despite surgical resection and percutaneous ethanol-injection therapy. We developed an acyclic retinoid, polyprenoic acid, that inhibits hepatocarcinogenesis in the laboratory and induces differentiation and apoptosis in cell lines derived from human hepatoma. In a randomized, controlled study, we tested whether the compound reduced the incidence of recurrent and second primary hepatomas after curative treatment. Methods. We prospectively studied 89 patients who were free of disease after surgical resection of a primary hepatoma or the percutaneous injection of ethanol. We randomly assigned the patients to receive either polyprenoic acid (600 mg daily) or placebo for 12 months. We studied the remnant liver by ultrasonography every three months after randomization. The primary end point of the study was the appearance of a histologically confirmed recurrent or new hepatoma. Results. Treatment with polyprenoic acid significantly reduced the incidence of recurrent or new hepatomas. After a median follow-up of 38 months, 12 patients in the polyprenoic acid group (27 percent) had recurrent or new hepatomas as compared with 22 patients in the placebo group (49 percent, P = 0.04). The most striking difference was in the groups that had second primary hepatomas 7 in the group receiving polyprenoic acid as compared with 20 in the placebo group (P = 0.04 by the log-rank test). Cox proportional-hazards analysis demonstrated that as an independent factor, polyprenoic acid reduced the occurrence of second primary hepatomas (adjusted relative risk, 0.31; 95 percent confidence interval, 0.12 to 0.78). Conclusions. Oral polyprenoic acid prevents second primary hepatomas after surgical resection of the original tumor or the percutaneous injection of ethanol. (C) 1996, Massachusetts Medical Society.	GIFU UNIV,SCH MED,DEPT PATHOL,GIFU 500,JAPAN; GIFU UNIV,SCH MED,DEPT PHARMACOL,GIFU 500,JAPAN; TOKYO WOMENS MED COLL,INST GASTROENTEROL,TOKYO 162,JAPAN; GIFU MUNICIPAL HOSP,GASTROINTESTINAL DIS CTR,GIFU,JAPAN; GIHOKU HOSP,TAKATOMI,JAPAN; GIFU RED CROSS HOSP,GIFU,JAPAN; ASAHI UNIV,MURAKAMI MEM HOSP,GIFU,JAPAN	Gifu University; Gifu University; Tokyo Women's Medical University; Gifu Municipal Hospital; Asahi University	Muto, Y (corresponding author), GIFU UNIV,SCH MED,DEPT INTERNAL MED 1,40 TSUKASA MACHI,GIFU 500,JAPAN.							ADACHI E, 1995, GASTROENTEROLOGY, V108, P768, DOI 10.1016/0016-5085(95)90450-6; ARAKI H, 1995, BIOCHEM BIOPH RES CO, V209, P66, DOI 10.1006/bbrc.1995.1471; ARII S, 1992, CANCER, V69, P913, DOI 10.1002/1097-0142(19920215)69:4<913::AID-CNCR2820690413>3.0.CO;2-T; Armstrong Robert B., 1994, P545; BABA M, 1991, INT J CANCER, V49, P467, DOI 10.1002/ijc.2910490326; BELGHITI J, 1991, ANN SURG, V214, P114, DOI 10.1097/00000658-199108000-00004; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BOONE CW, 1990, CANCER RES, V50, P2; CHEN PJ, 1989, GASTROENTEROLOGY, V96, P527, DOI 10.1016/0016-5085(89)91581-3; CHIU JH, 1993, HEPATOLOGY, V18, P1292; CURPHEY TJ, 1988, PANCREAS, V3, P36, DOI 10.1097/00006676-198802000-00007; DAOUD AH, 1980, CANCER LETT, V9, P299, DOI 10.1016/0304-3835(80)90021-X; EBARA M, 1990, J GASTROEN HEPATOL, V5, P616, DOI 10.1111/j.1440-1746.1990.tb01115.x; EBARA M, 1989, Annals Academy of Medicine Singapore, V18, P83; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; ESUMI M, 1986, CANCER RES, V46, P5764; FUKUTOMI Y, 1990, JPN J CANCER RES, V81, P1281, DOI 10.1111/j.1349-7006.1990.tb02691.x; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; HATAKEYAMA H, IN PRESS CTR DETECT; Hong Waun Ki, 1994, P597; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; IKEDA K, 1993, CANCER, V71, P19, DOI 10.1002/1097-0142(19930101)71:1<19::AID-CNCR2820710105>3.0.CO;2-I; JWO SC, 1992, HEPATOLOGY, V16, P1367, DOI 10.1002/hep.1840160611; Kita K, 1994, Nihon Shokakibyo Gakkai Zasshi, V91, P1946; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KIYOSAWA K, 1991, J MED VIROL, V33, P114, DOI 10.1002/jmv.1890330209; *LIV CANC STUD GRO, 1992, GEN RUL CLIN PATH ST, P20; MACK DO, 1990, INT J BIOCHEM, V22, P359, DOI 10.1016/0020-711X(90)90138-S; MAIORANA A, 1980, J NATL CANCER I, V64, P655; MATSUMATA T, 1989, HEPATOLOGY, V9, P457, DOI 10.1002/hep.1840090320; Moon Richard C., 1994, P573; MORIWAKI H, 1988, Gastroenterologia Japonica, V23, P546; MORIWAKI H, 1982, ACTA HEPATOL JPN, V23, P523; MUTO Y, 1979, GANN, V70, P215; MUTO Y, 1981, ANN NY ACAD SCI, V359, P91, DOI 10.1111/j.1749-6632.1981.tb12740.x; MUTO Y, 1981, GANN, V72, P974; MUTO Y, 1984, J NATL CANCER I, V73, P1389; MUTO Y, 1991, PURE APPL CHEM, V63, P157, DOI 10.1351/pac199163010157; MUTO Y, 1985, RETINOIDS NEW TRENDS, P293; NAGAO T, 1990, ANN SURG, V211, P28, DOI 10.1097/00000658-199001000-00005; NAGASUE N, 1993, ANN SURG, V217, P375, DOI 10.1097/00000658-199304000-00009; NAGASUE N, 1993, GASTROENTEROLOGY, V105, P488, DOI 10.1016/0016-5085(93)90724-Q; NAKAMURA N, 1995, BIOCHEM BIOPH RES CO, V207, P382, DOI 10.1006/bbrc.1995.1199; OHTO M, 1988, JPN J MED IMAGING, V7, P25; SAKAMOTO M, 1989, AM J SURG PATHOL, V13, P1064, DOI 10.1097/00000478-198912000-00009; SATO Y, 1993, NEW ENGL J MED, V328, P1802, DOI 10.1056/NEJM199306243282502; SHINAGAWA T, 1984, GASTROENTEROLOGY, V86, P495; SHIRABE K, 1991, HEPATOLOGY, V14, P802, DOI 10.1002/hep.1840140510; SHIRAKI K, 1995, HEPATOLOGY, V22, P802, DOI 10.1002/hep.1840220317; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SPORN MB, 1979, FED PROC, V38, P2528; SPORN MB, 1991, CANCER RES, V51, P6215; SUGIOKA A, 1993, SURGERY, V113, P612; TAKETA K, 1993, CANCER RES, V53, P5419; TSUDA H, 1988, GASTROENTEROLOGY, V95, P1664, DOI 10.1016/S0016-5085(88)80093-3; TSURUMI H, 1993, INT J HEMATOL, V59, P9; Warren S., 1932, AM J CANCER, V16, P1358; YAMADA Y, 1994, MOL CARCINOGEN, V10, P151, DOI 10.1002/mc.2940100306; YAMANAKA N, 1990, CANCER, V65, P1104, DOI 10.1002/1097-0142(19900301)65:5<1104::AID-CNCR2820650511>3.0.CO;2-G; YAMASAKI S, 1992, PRIMARY LIVER CANC J, P345; YU MW, 1995, CANCER RES, V55, P1301; 1994, J HLTH WELFARE STA S, V41, P47; 1995, ACTA HEPATOL JPN, V36, P208; 1994, CANCER, V74, P2772; 1994, NEW ENGL J MED, V330, P1029; 1991, LANCET, V338, P1040	67	578	595	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1561	1567		10.1056/NEJM199606133342402	http://dx.doi.org/10.1056/NEJM199606133342402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP663	8628336				2022-12-28	WOS:A1996UP66300002
J	Goldman, L; Cook, EF; Johnson, PA; Brand, DA; Rouan, GW; Lee, TH				Goldman, L; Cook, EF; Johnson, PA; Brand, DA; Rouan, GW; Lee, TH			Prediction of the need for intensive care in patients who come to emergency departments with acute chest pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; LOW-RISK PATIENTS; PROSPECTIVE MULTICENTER; INITIAL ELECTROCARDIOGRAM; CLINICAL-CRITERIA; UNIT ADMISSION; DIAGNOSIS; IDENTIFICATION; INSTRUMENT; PROTOCOL	Background. Patients who come to the emergency department with chest pain are a heterogeneous group. Some have ischemic heart disease that may lead to serious complications, whereas others have minor disorders. We performed a study to identify clinical factors that predict which patients will have complications requiring intensive care. Methods. We first studied 10,682 patients with acute chest pain at seven hospitals between 1984 and 1986 (derivation set) to identify potential clinical predictors of the development of major complications, We then validated these predictors in a separate set of 4676 patients at one hospital between 1990 and 1994 (validation set). Results. In the derivation set of patients, we identified the following clinical features, which, if present in the emergency department, were associated with an increased risk of complications: ST-segment elevation or Q waves on the electrocardiogram thought to indicate acute myocardial infarction, other electrocardiographic changes indicating myocardial ischemia, low systolic blood pressure, pulmonary rales above the bases, or an exacerbation of known ischemic heart disease, On the basis of these criteria, the patients in the validation set were stratified into four groups, with the risk of major complications in the first 12 hours ranging from 0.15 to 8 percent, After 12 hours, the probability of a major complication could be updated on the basis of whether the patient had already had a complication of major severity, a complication of intermediate severity, or a myocardial infarction (independent relative risks, 18.9, 7.7, and 4.0, respectively, as compared with patients without prior complications or myocardial infarction). Conclusions, The risk of major complications in patients with acute chest pain can be estimated on the basis of the clinical presentation and new clinical observations made during the hospital course. These estimates of risk help in making rational decisions about the appropriate level of medical care for patients with acute chest pain. (C) 1996, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CLIN EPIDEMIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; NEW YORK MED COLL,PRIMARY CARE RES UNIT,VALHALLA,NY 10595; NEW YORK MED COLL,DEPT MED,VALHALLA,NY 10595; UNIV CINCINNATI,MED CTR,DIV GEN INTERNAL MED,CINCINNATI,OH 45267	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; New York Medical College; New York Medical College; University System of Ohio; University of Cincinnati	Goldman, L (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,505 PARNASUS AVE,SAN FRANCISCO,CA 94143, USA.							BAXT WG, 1992, ANN INTERN MED, V116, P94; BAXT WG, 1991, ANN INTERN MED, V115, P843, DOI 10.7326/0003-4819-115-11-843; Baxt WG, 1996, LANCET, V347, P12, DOI 10.1016/S0140-6736(96)91555-X; BERNING J, 1992, AM J CARDIOL, V69, P1538, DOI 10.1016/0002-9149(92)90699-Y; Breiman L., 1984, CLASSIFICATION REGRE; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; DAVISON G, 1990, J GEN INTERN MED, V5, P474, DOI 10.1007/BF02600872; EAGLE KA, 1990, JAMA-J AM MED ASSOC, V264, P992, DOI 10.1001/jama.264.8.992; FIEBACH NH, 1990, AM J MED, V89, P15, DOI 10.1016/0002-9343(90)90091-Q; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; GASPOZ JM, 1994, J AM COLL CARDIOL, V24, P1249, DOI 10.1016/0735-1097(94)90106-6; GIBLER WB, 1992, ANN EMERG MED, V21, P504; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HILTON TC, 1994, J AM COLL CARDIOL, V23, P1016, DOI 10.1016/0735-1097(94)90584-3; HOSMER DW, 1989, APPL LOGISTIC REGRES; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; LEE TH, 1995, ANN INTERN MED, V122, P434, DOI 10.7326/0003-4819-122-6-199503150-00006; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARK DB, 1991, CIRCULATION, V83, P1186, DOI 10.1161/01.CIR.83.4.1186; MULLEY AG, 1980, NEW ENGL J MED, V302, P943, DOI 10.1056/NEJM198004243021704; Newby LK, 1996, J AM COLL CARDIOL, V27, P625; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; RAVKILDE J, 1995, J AM COLL CARDIOL, V25, P574, DOI 10.1016/0735-1097(94)00430-X; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; SEKLER HP, 1991, MED CARE, V29, P1196; SELKER HP, 1987, JAMA-J AM MED ASSOC, V257, P1181, DOI 10.1001/jama.257.9.1181; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; STARK ME, 1987, ARCH INTERN MED, V147, P843, DOI 10.1001/archinte.147.5.843; TOSTESON ANA, IN PRESS CIRCULATION; WEINGARTEN S, 1990, ANN INTERN MED, V113, P283, DOI 10.7326/0003-4819-113-4-283; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; YUSUF S, 1984, EUR HEART J, V5, P690, DOI 10.1093/oxfordjournals.eurheartj.a061728	41	286	292	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1498	1504		10.1056/NEJM199606063342303	http://dx.doi.org/10.1056/NEJM199606063342303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618604				2022-12-28	WOS:A1996UN79900003
J	Dahlback, B				Dahlback, B			Are we ready for factor V Leiden screening?	LANCET			English	Editorial Material							POOR ANTICOAGULANT RESPONSE; ACTIVATED PROTEIN-C; THROMBOPHILIA				Dahlback, B (corresponding author), LUND UNIV,UNIV HOSP,DEPT CLIN CHEM,MALMO,SWEDEN.			Dahlback, Bjorn/0000-0003-1546-0328				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; DERONDE H, 1994, THROMB HAEMOSTASIS, V72, P880; JORQUERA JI, 1994, LANCET, V344, P1162, DOI 10.1016/S0140-6736(94)90673-4; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; TROSSAERT M, 1994, LANCET, V344, P1709, DOI 10.1016/S0140-6736(94)90494-4; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; ZOLLER B, 1994, J CLIN INVEST, V94, P2521, DOI 10.1172/JCI117623	13	44	45	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1346	1347		10.1016/S0140-6736(96)91004-1	http://dx.doi.org/10.1016/S0140-6736(96)91004-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637335				2022-12-28	WOS:A1996UL90400003
J	Wiznia, AA; Crane, M; Lambert, G; Sansary, J; Harris, A; Solomon, L				Wiznia, AA; Crane, M; Lambert, G; Sansary, J; Harris, A; Solomon, L			Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective:-To evaluate whether zidovudine treatment was accepted and used by pregnant women subsequent to the release of the results of a multicenter, randomized, placebo-controlled trial (AIDS Clinical Trial Group [ACTG] Protocol 076) that showed that zidovudine significantly reduced maternal-infant human immunodeficiency virus (HIV) type 1 transmission. Design.-Prospective study. Setting:-A community hospital with an integrated, multidisciplinary HIV-dedicated program located in an impoverished, HIV-endemic urban setting. Participants.-All HIV-infected pregnant women identified after the release of the ACTG 076 results who were offered zidovudine therapy to reduce maternal-infant transmission. Results.-Only 49 of the 125 HIV-infected pregnant women delivering at our site during this study period were identified prenatally. Perinatal zidovudine therapy was chosen by 37 (75%) of 49 women. Women refusing zidovudine were more likely to report injection drug use as their HIV risk factor and to continue to use drugs during their pregnancy. Of women choosing zidovudine and delivering, 24 of 36 received all components of their elected therapy. The intrapartum dose was missed by 12 women, 4 of whom also missed their prescribed prenatal oral therapy. Lack of adherence to chosen therapy was associated with continued cocaine use during pregnancy. Conclusions.-Zidovudine therapy to interrupt vertical transmission of HIV was not widely used by these HIV-infected pregnant women. Further studies evaluating factors affecting the acceptance and use of recently published public health recommendations are needed.	BRONX LEBANON HOSP CTR,DEPT OBSTET GYNECOL,BRONX,NY 10457; ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10467; ALBERT EINSTEIN COLL MED,DEPT OBSTET GYNECOL,BRONX,NY 10467	BronxCare Health System; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Wiznia, AA (corresponding author), BRONX LEBANON HOSP CTR,DIV PEDIAT INFECT DIS,1650 SELWYN AVE,APT 2C,BRONX,NY 10457, USA.				NIAID NIH HHS [AI32914-03] Funding Source: Medline; PHS HHS [U64/CCU206826-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032914] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAYER R, 1994, NEW ENGL J MED, V331, P1223, DOI 10.1056/NEJM199411033311811; BURKETT G, 1994, AM J OBSTET GYNECOL, V171, P372, DOI 10.1016/S0002-9378(94)70037-0; CDCP, 1994, EP INF VERS 6 WORD P; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; GIOVINO GA, 1995, EPIDEMIOL REV, V17, P48, DOI 10.1093/oxfordjournals.epirev.a036185; LESTER P, 1995, J ACQ IMMUN DEF SYND, V10, P341; Oxtoby MJ, 1994, PEDIATRIC AIDS CHALL, P3; PLESSINGER MA, 1993, CLIN OBSTET GYNECOL, V36, P267, DOI 10.1097/00003081-199306000-00008; Rodriguez EM, 1996, AIDS, V10, P273, DOI 10.1097/00002030-199603000-00006; ROGERS MF, 1994, NEW ENGL J MED, V331, P1223; *STAT NY DEP HLTH, 1994, CLIN GUID US ZID THE; *US DEP HHS, 1995, EX SUMM ACTG 152 RAN; *US DEP HHS, 1995, EX SUMM ACTG 175 RAN; WEHBEH H, 1995, AM J OBSTET GYNECOL, V172, P1014; 1995, MMWR-MORBID MORTAL W, V44, P1; 1994, MMWR-MORBID MORTAL W, V43, P1	17	55	55	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1504	1506		10.1001/jama.275.19.1504	http://dx.doi.org/10.1001/jama.275.19.1504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622226				2022-12-28	WOS:A1996UJ93700035
J	Reidenberg, MM				Reidenberg, MM			Barriers to controlling pain in patients with cancer	LANCET			English	Editorial Material							MANAGEMENT				Reidenberg, MM (corresponding author), CORNELL UNIV,COLL MED,DEPT PHARMACOL,ITHACA,NY 14853, USA.							[Anonymous], [No title captured]; BRANDT EN, 1984, JAMA-J AM MED ASSOC, V251, P1191; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Drayer RA, 1996, J INVEST MED, V44, pA311; HILL CS, 1993, SEMIN ONCOL, V20, P1; Lee LE, 1941, J AMER MED ASSOC, V116, P216, DOI 10.1001/jama.1941.02820030038009; MCGIVNEY WT, 1984, JAMA-J AM MED ASSOC, V251, P1182; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; *WHO EXP COMM, 1990, TECHN REP SERIES WHO, V804; ZENZ M, 1993, LANCET, V341, P1075, DOI 10.1016/0140-6736(93)92425-S; 1983, ANN INTERN MED, V99, P870; 1996, BRIT MED J, V312, P823	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1278	1278		10.1016/S0140-6736(96)90935-6	http://dx.doi.org/10.1016/S0140-6736(96)90935-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622501	hybrid			2022-12-28	WOS:A1996UK75800006
J	MacKie, RM; Hole, DJ				MacKie, RM; Hole, DJ			Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status	BRITISH MEDICAL JOURNAL			English	Article							RISK	Objective-To study incidence of and survival from cutaneous malignant melanoma in relation to socioeconomic status. Design-Application of Carstairs deprivation score to all malignant melanoma patients diagnosed in a geographically defined area over a 15 year period. Setting-West of Scotland (area population 2 716 900). Subjects-3142 patients first diagnosed with malignant melanoma in the period 1979-93. Interventions-Surgical excision of primary malignant melanoma with additional treatment as appropriate and follow up until December 1994. Main outcome measures-Malignant melanoma incidence, primary tumour thickness and five year survival by socioeconomic status Results-From 1979 to 1993, the age standardised incidence rate for cutaneous malignant melanoma was 9.1/100 000 for the most affluent men and 2.4/100 000 for the least affluent men and 16.1/100 000 and 5.0/100 000 respectively for most and least affluent women (P<0.001 for trend in both). The incidence increased steadily over time in both sexes in all socioeconomic groups. Good prognosis tumours (<1.5 mm thick) were most common in the most affluent men and women, and over the study period the proportion of such tumours increased most in the intermediate affluence group (both sexes) and in the least affluent women. Five year disease free survival from melanoma for the sexes combined was 81% for most affluent, 77% for intermediate, and 73% for least affluent groups. Even after adjustment for known prognostic factors of tumour thickness, ulceration, age, and body site of primary melanoma, the more affluent the group, the better the survival. Conclusion-Although the incidence of cutaneous malignant melanoma is higher among more affluent people, the prognosis is better in this group than for less affluent individuals. Early diagnosis campaigns should be targeted particularly to less affluent men and primary prevention campaigns should emphasise the greater risk in more affluent women.	RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GREATER GLASGOW HLTH BOARD,GLASGOW,LANARK,SCOTLAND	University of Glasgow	MacKie, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,LANARK,SCOTLAND.							BRESLOW A, 1975, ANN SURG, V182, P572, DOI 10.1097/00000658-197511000-00007; CARNON AG, 1994, BRIT MED J, V309, P1054, DOI 10.1136/bmj.309.6961.1054; Carstairs V., 1991, DEPRIVATION HLTH SCO; COX DR, 1972, J R STAT SOC B, V34, P187; KIRKPATRICK CS, 1990, INT J CANCER, V46, P1; LEE JAH, 1980, BRIT J CANCER, V41, P757, DOI 10.1038/bjc.1980.138; MACKIE R, 1992, LANCET, V339, P971, DOI 10.1016/0140-6736(92)91539-K; NELEMANS PJ, 1993, ENVIRON HEALTH PERSP, V101, P252, DOI 10.2307/3431552; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317	9	74	78	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1125	1128						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620127				2022-12-28	WOS:A1996UK06900020
J	Pavli, P; Cavanaugh, J; Grimm, M				Pavli, P; Cavanaugh, J; Grimm, M			Inflammatory bowel disease: Germs or genes?	LANCET			English	Editorial Material									AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research	Pavli, P (corresponding author), WODEN VALLEY HOSP,GASTROENTEROL UNIT,CANBERRA,ACT,AUSTRALIA.		Pavli, Paul/GZL-0607-2022; Cavanaugh, Juleen/C-9413-2009	Grimm, Michael/0000-0001-9426-3917				DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; ORHOLM M, 1993, BRIT MED J, V306, P20, DOI 10.1136/bmj.306.6869.20; ROTH MP, 1989, GASTROENTEROLOGY, V96, P1016, DOI 10.1016/0016-5085(89)91618-1; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; YANG H, 1992, CURRENT TOPICS GASTR, P17	6	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1198	1198		10.1016/S0140-6736(96)90727-8	http://dx.doi.org/10.1016/S0140-6736(96)90727-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622443				2022-12-28	WOS:A1996UJ59700002
J	Herlitze, S; Garcia, DE; Mackie, K; Hille, B; Scheuer, T; Catterall, WA				Herlitze, S; Garcia, DE; Mackie, K; Hille, B; Scheuer, T; Catterall, WA			Modulation of Ca2+ channels by G-protein beta gamma subunits	NATURE			English	Article							CALCIUM CHANNELS; SYNAPTIC TRANSMISSION; SYMPATHETIC NEURONS; RECEPTORS; INHIBITION	CALCIUM ions entering cells through voltage-gated Ca2+ channels initiate rapid release of neurotransmitters and secretion of hormones. Ca2+ currents can be inhibited in many cell types by neurotransmitters acting through G proteins via a membrane-delimited pathway independently of soluble intracellular messengers(1-4). Inhibition is typically caused by a positive shift in the voltage dependence and a slowing of channel activation and is relieved by strong depolarization resulting in facilitation of Ca2+ currents(1,4-6). This pathway regulates the activity of N-type and P/Q-type Ca2+ channels(1,2,7), which are localized in presynaptic terminals(8,9) and participate in neurotransmitter release(10-13). Synaptic transmission is inhibited by neurotransmitters through this mechanism(1,4). G-protein alpha subunits confer specificity in receptor coupling(1-4,14-17), but it is not known whether the G alpha or G beta gamma subunits are responsible for modulation of Ca2+ channels. Here we report that G beta gamma subunits can modulate Ca2+ channels. Transfection of G beta gamma into cells expressing P/Q-type Ca2+ channels induces modulation like that caused by activation of G protein-coupled receptors, but G alpha subunits do not. Similarly, injection or expression of G beta gamma subunits in sympathetic ganglion neurons induces facilitation and occludes modulation of N-type channels by noradrenaline, but G alpha subunits do not. In both cases, the G gamma subunit is ineffective by itself, but overexpression of exogenous G beta subunits is sufficient to cause channel modulation.	UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT ANESTHESIOL,SEATTLE,WA 98195; NATL AUTONOMOUS UNIV MEXICO,FAC MED,DEPT PHYSIOL,MEXICO CITY 04510,DF,MEXICO	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Universidad Nacional Autonoma de Mexico	Herlitze, S (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.		Mackie, Kenneth P/B-7358-2011; Mackie, Ken/E-3715-2013; Garcia, David/AAE-8176-2020; Garcia, David/A-7626-2008	Mackie, Ken/0000-0001-8501-6199; 				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BERNHEIM L, 1991, NEURON, V6, P859, DOI 10.1016/0896-6273(91)90226-P; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DOLPHIN AC, 1995, EXP PHYSIOL, V80, P1; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hescheler J, 1993, Curr Opin Neurobiol, V3, P360, DOI 10.1016/0959-4388(93)90129-M; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; HIMING LD, 1988, SCIENCE, V239, P57; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; LUEBKE JI, 1993, NEURON, V11, P895, DOI 10.1016/0896-6273(93)90119-C; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SHAPIRO MS, 1994, J NEUROSCI, V14, P7109; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WICKMAN KD, 1995, CURR OPIN NEUROBIOL, V5, P278, DOI 10.1016/0959-4388(95)80039-5; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WILKBLASZCZAK MA, 1994, NEURON, V13, P1215, DOI 10.1016/0896-6273(94)90059-0; ZHU Y, 1994, NEURON, V13, P657, DOI 10.1016/0896-6273(94)90033-7	30	674	686	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					258	262		10.1038/380258a0	http://dx.doi.org/10.1038/380258a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637576				2022-12-28	WOS:A1996UB11700055
J	Verkhovsky, MI; Morgan, JE; Puustinen, A; Wikstrom, M				Verkhovsky, MI; Morgan, JE; Puustinen, A; Wikstrom, M			Kinetic trapping of oxygen in cell respiration	NATURE			English	Article							CYTOCHROME-C-OXIDASE; LOW-SPIN HEME; ELECTRON-TRANSFER; ESCHERICHIA-COLI; FLOW-FLASH; SITE	CELL respiration in eukaryotes is catalysed by the mitochondri`al enzyme cytochrome c oxidase. In bacteria there are many variants of this enzyme, all of which have a binuclear haem iron-copper centre at which O-2 reduction occurs, and a low-spin haem, which serves as the immediate electron donor to this centre(1). It is essential that the components of the cell respiratory system have a high affinity for oxygen because of the low concentrations of dissolved O-2 in the tissues; however, the binding of O-2 to the respiratory haem-copper oxidases is very weak(2,3). This paradox has been attributed to kinetic trapping during fast reactions of O-2 bound within the enzyme's binuclear haem iron-copper centre(2). Our earlier work(3) indicated that electron transfer from the low-spin haem to the oxygen-bound binuclear centre may be necessary for such kinetic oxygen trapping. Here we show that a specific decrease of this haem-haem electron transfer rate in the respiratory haem-copper oxidase from Escherichia coli leads to a corresponding decrease in the enzyme's operational steady-state affinity for O-2. This demonstrates directly that fast electron transfer between the haem groups is a key process in achieving the high affinity for oxygen in cell respiration.	UNIV HELSINKI,BIOCENTRUM HELSINKI,SF-00014 HELSINKI,FINLAND	University of Helsinki	Verkhovsky, MI (corresponding author), UNIV HELSINKI,INST BIOMED SCI,DEPT MED CHEM,HELSINKI BIOENERGET GRP,PB 8,SF-00014 HELSINKI,FINLAND.		Wikstrom, Marten KF/A-4403-2008	Puustinen, Anne/0000-0002-0262-9975; Wikstrom, Marten/0000-0002-7527-4415				BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; CHANCE B, 1975, J BIOL CHEM, V250, P9226; CHANCE B, 1965, J GEN PHYSIOL, V49, P163, DOI 10.1085/jgp.49.1.163; HILL BC, 1984, BIOCHEM J, V218, P913, DOI 10.1042/bj2180913; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; MORGAN JE, 1993, BIOCHEMISTRY-US, V32, P11412; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; PETERSEN LC, 1974, BIOCHEM J, V142, P247, DOI 10.1042/bj1420247; PROVENCHER SW, 1983, PROGR SCI COMPUTING, V2, P304; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1992, BIOCHEMISTRY-US, V31, P10363, DOI 10.1021/bi00157a026; SVENSSON M, 1993, BIOCHEMISTRY-US, V32, P5442, DOI 10.1021/bi00071a021; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042	14	91	91	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					268	270		10.1038/380268a0	http://dx.doi.org/10.1038/380268a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637579				2022-12-28	WOS:A1996UB11700058
J	Werner, MH; Gronenborn, AM; Clore, GM				Werner, MH; Gronenborn, AM; Clore, GM			Intercalation, DNA kinking, and the control of transcription	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; CO-CRYSTAL STRUCTURE; TATA-BOX COMPLEX; NUCLEIC-ACIDS; TRANSACTIVATION DOMAIN; BINDING-AFFINITY; PROTEIN-BINDING; FORCE-FIELD; B-DNA; HELIX	Biological processes involved in the control and regulation of transcription are dependent on protein-induced distortions in DNA structure that enhance the recruitment of proteins to their specific DNA targets. This function is often accomplished by accessory factors that bind sequence specifically and locally bend or kink the DNA. The recent determination of the three-dimensional structures of several protein-DNA complexes, involving proteins that perform such architectural tasks, brings to light a common theme of side chain intercalation as a mechanism capable of driving the deformation of the DNA helix. The protein scaffolds orienting the intercalating side chain (or side chains) are structurally diverse, presently comprising four distinct topologies that can accomplish the same task. The intercalating side chain (or side chains), however, is exclusively hydrophobic. Intercalation can either kink or bend the DNA, unstacking one or more adjacent base pairs and locally unwinding the DNA over as much as a full turn of helix. Despite these distortions, the return to B-DNA helical parameters generally occurs within the adjacent half-turns of DNA.	NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				[Anonymous], COMMUNICATION; BAILLY C, 1995, J MOL BIOL, V253, P1, DOI 10.1006/jmbi.1995.0530; BALDWIN JP, 1975, NATURE, V253, P245, DOI 10.1038/253245a0; BERMAN HM, 1992, BIOPHYS J, V63, P751, DOI 10.1016/S0006-3495(92)81649-1; BHATTACHARYYA D, 1990, J BIOMOL STRUCT DYN, V8, P539, DOI 10.1080/07391102.1990.10507828; BOUTONNET N, 1993, BIOPOLYMERS, V33, P479, DOI 10.1002/bip.360330314; CALLADINE CR, 1986, J MOL BIOL, V192, P907, DOI 10.1016/0022-2836(86)90036-7; CALLADINE CR, 1992, UNDERSTANDING DNA MO; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHENG XD, 1995, CURR OPIN STRUC BIOL, V5, P4, DOI 10.1016/0959-440X(95)80003-J; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHEUNG S, 1984, P NATL ACAD SCI-BIOL, V81, P3665, DOI 10.1073/pnas.81.12.3665; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CRICK FHC, 1975, NATURE, V255, P530, DOI 10.1038/255530a0; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DALMAWEISZHAUSZ DD, 1991, NUCLEIC ACIDS RES, V19, P611, DOI 10.1093/nar/19.3.611; DEVARGAS LM, 1989, SCIENCE, V244, P1457; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; FISHER RA, UNPUB; FISHER RJ, 1994, PROTEIN SCI, V3, P257; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GEIERSTANGER BH, 1995, ANNU REV BIOPH BIOM, V24, P463, DOI 10.1146/annurev.bb.24.060195.002335; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GORIN AA, 1995, J MOL BIOL, V247, P34, DOI 10.1006/jmbi.1994.0120; GORIN AA, 1995, J BIOMOL STRUCT DYN, V12; GRIFFITH JD, 1975, SCIENCE, V187, P1202, DOI 10.1126/science.187.4182.1202; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HASSAN E, 1995, THESIS U CAMBRIDGE; HOGAN ME, 1989, P NATL ACAD SCI USA, V86, P9273, DOI 10.1073/pnas.86.23.9273; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; IRIKURA KK, 1985, SCIENCE, V229, P571, DOI 10.1126/science.3839596; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KEEPERS JW, 1982, P NATL ACAD SCI-BIOL, V79, P5537, DOI 10.1073/pnas.79.18.5537; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; KUMAR S, 1990, J BIOMOL STRUCT DYN, V8, P99, DOI 10.1080/07391102.1990.10507792; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEVITT M, 1982, COLD SPRING HARB SYM, V47, P251, DOI 10.1101/SQB.1983.047.01.030; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MCELREAVEY K, 1993, EUR J BIOCHEM, V218, P769, DOI 10.1111/j.1432-1033.1993.tb18432.x; MI S, 1995, NUCLEIC ACIDS RES, V23, P620, DOI 10.1093/nar/23.4.620; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NASH HA, IN PRESS REGULATION; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; OLINS AL, 1974, SCIENCE, V183, P330, DOI 10.1126/science.183.4122.330; PARKHURST KM, COMMUNICATION; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PETRI V, 1995, BIOCHEMISTRY-US, V34, P9977, DOI 10.1021/bi00031a020; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; QUAN X, 1993, BIOCHEMISTRY-US, V32, P9944; RAO SN, 1986, ISR J CHEM, V27, P189; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHELLMAN JA, 1974, BIOPOLYMERS, V13, P217, DOI 10.1002/bip.1974.360130115; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SEARLE MS, 1993, PROG NUCL MAG RES SP, V25, P403, DOI 10.1016/0079-6565(93)80005-E; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SINGH UC, 1985, P NATL ACAD SCI USA, V82, P755, DOI 10.1073/pnas.82.3.755; SOBELL HM, 1976, P NATL ACAD SCI USA, V73, P3068, DOI 10.1073/pnas.73.9.3068; STARR DB, 1995, J MOL BIOL, V250, P434; STOFER E, 1994, BIOPOLYMERS, V34, P337, DOI 10.1002/bip.360340305; SUN DY, 1995, CHEM BIOL, V2, P457, DOI 10.1016/1074-5521(95)90263-5; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TRAVERS AA, 1995, NAT STRUCT BIOL, V2, P615, DOI 10.1038/nsb0895-615; TRAVERS AA, 1995, DNA PROTEIN STRUCTUR, P49; VANHOLDE KE, 1974, NUCLEIC ACIDS RES, V1, P1579, DOI 10.1093/nar/1.11.1579; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Werner M. A., UNPUB; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; YANAGI K, 1991, J MOL BIOL, V217, P201, DOI 10.1016/0022-2836(91)90620-L; ZHU W, IN PRESS NATURE STRU; ZHURKIN VB, 1979, NUCLEIC ACIDS RES, V6, P1081, DOI 10.1093/nar/6.3.1081	100	258	258	3	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 9	1996	271	5250					778	784		10.1126/science.271.5250.778	http://dx.doi.org/10.1126/science.271.5250.778			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628992				2022-12-28	WOS:A1996TU69400038
J	Migliacci, R; Gresele, P				Migliacci, R; Gresele, P			Smoking and impaired endothelium-dependent dilatation	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							CIGARETTE-SMOKING; ADULTS		UNIV PERUGIA,I-06126 PERUGIA,ITALY	University of Perugia	Migliacci, R (corresponding author), CORTONA HOSP,I-52042 CORTONA,ITALY.		Gresele, Paolo/F-6775-2013; gresele, paolo/AAG-8019-2019	Gresele, Paolo/0000-0001-5365-8445; 				CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; MARTIN JL, 1984, AM J CARDIOL, V54, P56, DOI 10.1016/0002-9149(84)90303-5	4	12	12	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1996	334	25					1674	1674		10.1056/NEJM199606203342515	http://dx.doi.org/10.1056/NEJM199606203342515			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ706	8628376				2022-12-28	WOS:A1996UQ70600025
J	Ernst, M; Zametkin, AJ; Matochik, JA; Pascualvaca, D; Jons, PH; Hardy, K; Hankerson, JG; Doudet, DJ; Cohen, RM				Ernst, M; Zametkin, AJ; Matochik, JA; Pascualvaca, D; Jons, PH; Hardy, K; Hankerson, JG; Doudet, DJ; Cohen, RM			Presynaptic dopaminergic deficits in Lesch-Nyhan disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; F-18 DOPA; PARKINSONS-DISEASE; BRAIN; MODEL; BEHAVIOR; NEUROTRANSMITTERS; CARBIDOPA; MONKEYS	Background. Lesch-Nyhan disease is a rare, devastating, X-linked recessive disorder of purine synthesis. Patients present with hyperuricemia, choreoathetosis, dystonia, and aggressive and self-injurious behavior. Although the genetic and biochemical abnormalities have been identified, the causes of the neuropsychiatric syndrome remain unclear. Methods. We used positron-emission tomography to measure presynaptic accumulation of fluorodopa F 18 tracer in the dopaminergic regions of the brains of 12 patients with Lesch-Nyhan disease (age, 10 to 20 years) and 15 healthy controls (age, 12 to 23). The results were expressed as ratios of specific to nonspecific radioactive counts. A low ratio indicates decreased dopa decarboxylase activity and dopamine storage. Results. The fluorodopa F 18 ratio was significantly lower in the putamen (31 percent of control values), caudate nucleus (39 percent), frontal cortex (44 percent), and ventral tegmental complex (substantia nigra and ventral tegmentum; 57 percent) in the patients with Lesch-Nyhan disease than in the controls. Uptake of the tracer was abnormally low even in the youngest patients tested, and there was no overlap in the values between patients and controls. Conclusions. Patients with Lesch-Nyhan disease have abnormally few dopaminergic nerve terminals and cell bodies. The abnormality involves all dopaminergic pathways and is not restricted to the basal ganglia. These dopaminergic deficits are pervasive and appear to be developmental in origin, which suggests that they contribute to the characteristic neuropsychiatric manifestations of the disease. (C) 1996, Massachusetts Medical Society.	NIMH,PSYCHOL & PSYCHOPATHOL LAB,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT ANESTHESIOL,BETHESDA,MD 20892; UNIV BRITISH COLUMBIA,VANCOUVER,BC V5Z 1M9,CANADA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); University of British Columbia	Ernst, M (corresponding author), NIMH,CEREBRAL METAB LAB,BLDG 36,CONVENT DR,MSC 4030,BETHESDA,MD 20892, USA.			Hardy, Kristina/0000-0002-5479-5043				ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDERSON LT, 1992, J AUTISM DEV DISORD, V22, P189, DOI 10.1007/BF01058150; ANDERSON LT, 1994, J AUTISM DEV DISORD, V24, P67, DOI 10.1007/BF02172213; BOYES BE, 1986, LIFE SCI, V39, P2243, DOI 10.1016/0024-3205(86)90403-0; BREESE GR, 1984, PHARMACOL BIOCHEM BE, V21, P459, DOI 10.1016/S0091-3057(84)80110-0; BROOKS DJ, 1990, ANN NEUROL, V28, P547, DOI 10.1002/ana.410280412; CASASBRUGE M, 1985, LANCET, V1, P991; DOUDET DJ, 1992, J NUCL MED, V33, P1383; DOUDET DJ, 1992, PSYCHIAT RES-NEUROIM, V45, P153, DOI 10.1016/0925-4927(92)90023-W; DUNNETT SB, 1989, BRAIN RES, V501, P401, DOI 10.1016/0006-8993(89)90659-8; FREEMAN TB, 1991, EXP NEUROL, V113, P344, DOI 10.1016/0014-4886(91)90025-8; GJEDDE A, 1986, SOC NEUROSCI, V12; GOLDSTEIN M, 1986, BRAIN RES, V367, P114, DOI 10.1016/0006-8993(86)91584-2; HARRIS J, 1991, SOC NEUROSCI, V17; HARRIS J, 1994, 41 ANN M AM AC CHILD, V10; HOLLINGSHEAD AB, 1958, SOCIAL CLASS MENTAL, P387; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JANKOVIC J, 1988, ANN NEUROL, V23, P466, DOI 10.1002/ana.410230507; JINNAH HA, 1994, J NEUROSCI, V14, P1164; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LAKE CR, 1977, SCIENCE, V196, P905, DOI 10.1126/science.860124; LEENDERS KL, 1990, ARCH NEUROL-CHICAGO, V47, P1290, DOI 10.1001/archneur.1990.00530120034007; LESCH M, 1964, AM J MED, V36, P561, DOI 10.1016/0002-9343(64)90104-4; LLOYD KG, 1981, NEW ENGL J MED, V305, P1106, DOI 10.1056/NEJM198111053051902; MATSUI T, 1978, ATLAS HUMAN BRAIN CO; MCLELLAN CA, 1991, APPL RADIAT ISOTOPES, V42, P847; OLSON L, 1973, Z ANAT ENTWICKLUNGS, V139, P259, DOI 10.1007/BF00519968; Reich W., 1988, DIAGNOSTIC INTERVIEW; Sattler, 1986, STANFORD BINET INTEL; SAWLE GV, 1992, ANN NEUROL, V32, P609, DOI 10.1002/ana.410320503; SEMPLE WE, 1993, IMAGING DRUG ACTION, P297; SILANI V, 1994, EXP NEUROL, V128, P59, DOI 10.1006/exnr.1994.1113; SILVERSTEIN FS, 1985, NEUROLOGY, V35, P907, DOI 10.1212/WNL.35.6.907; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd; WATTS RWE, 1982, Q J MED, V201, P43; WECHSLER D, 1974, WISC 3 WECHSLER INTE; Wechsler D., 1981, WAIS R WECHSLER ADUL; WONG DF, 1992, SOC NEUROSCI, V18	39	134	138	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1568	1572		10.1056/NEJM199606133342403	http://dx.doi.org/10.1056/NEJM199606133342403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP663	8628337	Bronze			2022-12-28	WOS:A1996UP66300003
J	Ambros, IM; Zellner, A; Roald, B; Amann, G; Ladenstein, R; Printz, D; Gadner, H; Ambros, PF				Ambros, IM; Zellner, A; Roald, B; Amann, G; Ladenstein, R; Printz, D; Gadner, H; Ambros, PF			Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN NEURO-BLASTOMA; N-MYC AMPLIFICATION; ALPHA-SATELLITE DNA; GROWTH-FACTOR; INSITU HYBRIDIZATION; PARAFFIN SECTIONS; X-CHROMOSOME; FACTOR-BETA; SHORT ARM; SEQUENCE	Background. Neuroblastoma is a heterogeneous disease, with manifestations ranging from spontaneous regression to lethal spread. Sometimes the tumor spontaneously differentiates toward a benign ganglioneuroma (maturing neuroblastoma). The prognosis is frequently related to ploidy, deletions in the short arm of chromosome 1, and amplifications of the N-myc oncogene. Maturing neuroblastomas consist of both neuronal cells and Schwann cells. We investigated the genetic composition of both cell types in maturing neuroblastomas, to determine the relation between genetic abnormalities and maturation. Methods. We studied 20 maturing and mature neuroblastomas by in situ hybridization to count the chromosomes and evaluate possible deletions in the short arm of chromosome 1 in neuronal and Schwann cells. The DNA content of the cells was measured by flow cytometry. Results. Neuroblastic and ganglionic cells showed aberrations in the number of chromosomes. In situ hybridization and flow cytometry demonstrated near-triploidy in 18 of 19 tumors and pentaploidy in the remaining tumor. The Schwann cells in all 20 neuroblastomas contained normal numbers of chromosomes. In 18 tumors studied, there were no chromosome 1 deletions in either type of cell. Conclusions. The Schwann cells in maturing neuroblastomas differ genetically from the neuronal cells. The normal number of chromosomes in Schwann cells and the abnormal number in neuroblastic and ganglionic cells suggest that Schwann cells are a reactive population of normal cells that invade the neuroblastoma. Near-triploidy of neuroblastoma cells and intact chromosome 1 are presumably genetic prerequisites for spontaneous organoid maturation, because we found no diploidy or chromosome 1 deletions in the neuronal cells of spontaneously maturing neuroblastormas. (C) 1996, Massachusetts Medical Society.	ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST CLIN PATHOL,VIENNA,AUSTRIA; ULLEVAL UNIV HOSP,DEPT PATHOL,OSLO,NORWAY	Saint Anna Children's Hospital; University of Vienna; University of Oslo			Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211				AMBROS PF, 1995, EUR J CANCER, V31A, P510, DOI 10.1016/0959-8049(95)00044-J; BESSHO F, 1991, J PEDIATR-US, V119, P237, DOI 10.1016/S0022-3476(05)80733-4; BRESSLER JP, 1985, BRAIN RES, V344, P249, DOI 10.1016/0006-8993(85)90802-9; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; BUROKER N, 1987, HUM GENET, V77, P175, DOI 10.1007/BF00272388; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; COOKE HJ, 1979, NUCLEIC ACIDS RES, V6, P3177, DOI 10.1093/nar/6.10.3177; DANGIO GJ, 1971, LANCET, V1, P1046; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; DEVILEE P, 1988, Genomics, V3, P1, DOI 10.1016/0888-7543(88)90151-6; EVANS AE, 1980, CANCER, V45, P833, DOI 10.1002/1097-0142(19800301)45:5<833::AID-CNCR2820450502>3.0.CO;2-U; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GIANNAKUDIS J, 1987, CYTOGENET CELL GENET, V46, P619; GILBERT F, 1982, CANCER GENET CYTOGEN, V7, P33, DOI 10.1016/0165-4608(82)90105-4; HAAS D, 1988, CANCER, V62, P818, DOI 10.1002/1097-0142(19880815)62:4<818::AID-CNCR2820620430>3.0.CO;2-K; HAYASHI Y, 1989, CANCER, V63, P126, DOI 10.1002/1097-0142(19890101)63:1<126::AID-CNCR2820630120>3.0.CO;2-Z; HEIDEN T, 1991, CYTOMETRY, V12, P614, DOI 10.1002/cyto.990120705; HOPMAN AHN, 1991, MODERN PATHOL, V4, P503; JABS EW, 1984, P NATL ACAD SCI-BIOL, V81, P4884, DOI 10.1073/pnas.81.15.4884; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; KANEKO Y, 1987, CANCER RES, V47, P311; KOGNER P, 1993, CANCER RES, V53, P2044; Kushner BH, 1996, J CLIN ONCOL, V14, P373, DOI 10.1200/JCO.1996.14.2.373; LEMKE GE, 1984, J NEUROSCI, V4, P75; LIM R, 1989, P NATL ACAD SCI USA, V86, P3901, DOI 10.1073/pnas.86.10.3901; LIM R, 1990, DEV BIOL, V137, P444, DOI 10.1016/0012-1606(90)90269-O; LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MATTHAY KK, 1989, J CLIN ONCOL, V7, P236, DOI 10.1200/JCO.1989.7.2.236; MITELMAN F, 1994, CATALOG CHROMOSOME A; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NORDLUND M, 1992, GLIA, V5, P182, DOI 10.1002/glia.440050304; RATNER N, 1988, P NATL ACAD SCI USA, V85, P6992, DOI 10.1073/pnas.85.18.6992; Reynolds M L, 1993, Curr Opin Neurobiol, V3, P683, DOI 10.1016/0959-4388(93)90139-P; RIDLEY AJ, 1989, J CELL BIOL, V109, P3419, DOI 10.1083/jcb.109.6.3419; SALZER JL, 1980, J CELL BIOL, V84, P753, DOI 10.1083/jcb.84.3.753; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SIDELL N, 1986, EXP CELL BIOL, V54, P287; STOCK C, 1993, GENE CHROMOSOME CANC, V6, P1, DOI 10.1002/gcc.2870060103; STOCK C, 1994, GENE CHROMOSOME CANC, V11, P40, DOI 10.1002/gcc.2870110107; STREHL S, 1993, CYTOGENET CELL GENET, V63, P24, DOI 10.1159/000133494; TAYLOR SR, 1988, CANCER, V62, P749, DOI 10.1002/1097-0142(19880815)62:4<749::AID-CNCR2820620418>3.0.CO;2-W; TSOKOS M, 1987, AM J PATHOL, V128, P484; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; WAYE JS, 1986, MOL CELL BIOL, V6, P3156, DOI 10.1128/MCB.6.9.3156; WEINMASTER G, 1990, EMBO J, V9, P915, DOI 10.1002/j.1460-2075.1990.tb08189.x; WOOD PM, 1975, NATURE, V256, P662, DOI 10.1038/256662a0	53	177	179	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1505	1511		10.1056/NEJM199606063342304	http://dx.doi.org/10.1056/NEJM199606063342304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618605				2022-12-28	WOS:A1996UN79900004
J	Pine, DS; Tierney, L				Pine, DS; Tierney, L			A stressful interaction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; MYOCARDIAL-INFARCTION; ABNORMALITIES; HEART		VET AFFAIRS MED CTR,DEPT MED,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Pine, DS (corresponding author), KAISER PERMANENTE MED CTR,DEPT EMERGENCY MED,901 NEVIN AVE,RICHMOND,CA 94801, USA.		Pine, Daniel/Z-1601-2019					Ananthachari M D, 1967, Indian Heart J, V19, P105; BEARD EF, 1959, AM HEART J, V58, P755, DOI 10.1016/0002-8703(59)90235-2; BROUWERS PJAM, 1989, STROKE, V20, P1162, DOI 10.1161/01.STR.20.9.1162; CONNOR RCR, 1968, BRIT MED J, V3, P29; CROPP GJ, 1960, CIRCULATION, V22, P25, DOI 10.1161/01.CIR.22.1.25; DAVIES KR, 1991, BRIT J ANAESTH, V67, P58, DOI 10.1093/bja/67.1.58; DAVIS TP, 1993, PROG CARDIOVASC DIS, V36, P245, DOI 10.1016/0033-0620(93)90017-8; DIAMOND T, 1984, HEART LUNG, V13, P451; DIPASQUALE G, 1987, AM J CARDIOL, V59, P596, DOI 10.1016/0002-9149(87)91176-3; DOSHI R, 1980, J NEUROSURG, V52, P295, DOI 10.3171/jns.1980.52.3.0295; FABINYI G, 1977, J NEUROL NEUROSUR PS, V40, P818, DOI 10.1136/jnnp.40.8.818; FINK ME, 1993, NEUROLOGY, V43, pA341; GOLDBERGER AL, 1991, MYOCARDIAL INFARCTIO, P291; GREENHOO.JH, 1969, J NEUROSURG, V30, P521, DOI 10.3171/jns.1969.30.5.0521; HAMMERMEISTER KE, 1969, AM HEART J, V78, P94, DOI 10.1016/0002-8703(69)90264-6; HAWKINS WE, 1971, CARDIOVASC RES, V5, P524, DOI 10.1093/cvr/5.4.524; HUNT D, 1969, AM HEART J, V77, P479, DOI 10.1016/0002-8703(69)90157-4; KASTE M, 1978, BRIT HEART J, V40, P802; KETTUNEN P, 1983, CLIN CHIM ACTA, V134, P123, DOI 10.1016/0009-8981(83)90190-0; LANZINO G, 1994, J NEUROSURG ANESTH, V6, P156; MARION DW, 1986, NEUROSURGERY, V18, P101, DOI 10.1227/00006123-198601000-00019; MATSUMURA H, 1991, Neurological Surgery, V19, P349; MENON IS, 1964, LANCET, V2, P433; Neil-Dwyer G, 1990, Acta Neurochir Suppl (Wien), V47, P102; PFISTER CW, 1962, DIS CHEST, V42, P206; POLLICK C, 1988, J AM COLL CARDIOL, V12, P600, DOI 10.1016/S0735-1097(88)80044-5; PORTER RW, 1962, AM HEART J, V64, P815, DOI 10.1016/0002-8703(62)90180-1; RUDEHILL A, 1982, ACTA ANAESTH SCAND, V26, P344, DOI 10.1111/j.1399-6576.1982.tb01779.x; SCHELL AR, 1987, ARCH INTERN MED, V147, P591, DOI 10.1001/archinte.147.3.591; SZAKACS JE, 1958, AM J CLIN PATHOL, V30, P425; THEODORE J, 1976, AM REV RESPIR DIS, V113, P405; TODD GL, 1985, J MOL CELL CARDIOL, V17, P647, DOI 10.1016/S0022-2828(85)80064-X; YAMAGUCHI T, 1991, JPN J MED, V30, P142; YUKI K, 1991, J NEUROSURG, V75, P308, DOI 10.3171/jns.1991.75.2.0308	34	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1530	1534		10.1056/NEJM199606063342309	http://dx.doi.org/10.1056/NEJM199606063342309			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN799	8618610				2022-12-28	WOS:A1996UN79900009
J	Jiang, W; Babyak, M; Krantz, DS; Waugh, RA; Coleman, RE; Hanson, MM; Frid, DJ; McNulty, S; Morris, JJ; OConnor, CM; Blumenthal, JA				Jiang, W; Babyak, M; Krantz, DS; Waugh, RA; Coleman, RE; Hanson, MM; Frid, DJ; McNulty, S; Morris, JJ; OConnor, CM; Blumenthal, JA			Mental stress-induced myocardial ischemia and cardiac events	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; STABLE ANGINA-PECTORIS; SEGMENT DEPRESSION; PROGNOSTIC VALUE; SILENT ISCHEMIA; HEART-DISEASE; DAILY LIFE; INFARCTION; EXERCISE; ANGIOGRAPHY	Objective.-To assess the clinical significance of mental stress-induced myocardial ischemia in patients with coronary artery disease (CAD). Design and Setting.-Cohort study in outpatients in a tertiary care teaching hospital assessed at baseline and followed up for up to 5 years. Subjects.-A total of 126 volunteer patients (112 men, 14 women; mean age, 59 years) with documented CAD and exercise-induced myocardial ischemia. Outcome Measures.-Patients underwent baseline mental stress and exercise testing using radionuclide ventriculography and 48-hour Holter monitoring. Patients were subsequently contacted by mailed questionnaires or telephone to document cardiac events, including death, nonfatal myocardial infarction, and cardiac revascularization procedures, Logistic regression and Cox proportional hazards models were used to examine the prognostic value of the ischemic measures after adjusting for such potential confounding factors as age, baseline left ventricular ejection fraction (LVEF), and history of myocardial infarction. Results.-Twenty-eight patients (22%) experienced at least 1 cardiac event, Baseline mental stress-induced ischemia was associated with significantly higher rates of subsequent cardiac events (odds ratio, 2.8; 95% confidence interval [CI], 1.0-7.7; P<.05), The LVEF change during mental stress was significantly related to event-free survival (risk ratio [RR], 2.4; 95% CI, 1.12-5.14; P=.02), controlling for age, history of prior myocardial infarction, and baseline LVEF. This relationship remained significant after controlling for electrocardiogram (ECG)-defined ischemia during exercise (RR, 2.2; 95% CI, 1.01-4.81; P<.05). The RR for EGG-defined ischemia during exercise testing was 1,9 (95% CI, 0.95-3.96; P=.07) and the RR for ambulatory ECG ischemia was 0.75 (95% CI, 0.35-1.64; P=.47). Conclusions.-The presence of mental stress-induced ischemia is associated with significantly higher rates of subsequent fatal and nonfatal cardiac events, independent of age, baseline LVEF, and previous myocardial infarction, and predicted events over and above exercise-induced ischemia, These data suggest that the relationship between psychological stress and adverse cardiac events may be mediated by the occurrence of myocardial ischemia.	DUKE UNIV,CTR LIVING,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PSYCHIAT & BEHAV SCI,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT RADIOL,DURHAM,NC 27710; UNIFORMED SERV UNIV HLTH SCI,DEPT MED CLIN PSYCHOL,BETHESDA,MD 20814	Duke University; Duke University; Duke University; Duke University; Uniformed Services University of the Health Sciences - USA			Krantz, David S./L-5364-2015	Krantz, David/0000-0002-1671-1355	NHLBI NIH HHS [HL 43028, HL 49572, HL 47337] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047337, R01HL049572, R01HL043028] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM RD, 1986, AM J CARDIOL, V58, P423, DOI 10.1016/0002-9149(86)90008-1; BARRY J, 1988, AM J CARDIOL, V61, P989, DOI 10.1016/0002-9149(88)90112-9; BLUMENTHAL JA, 1995, CIRCULATION, V92, P2102, DOI 10.1161/01.CIR.92.8.2102; BLUMENTHAL JA, 1987, APPL BEHAV MED HLTH, P3; Burg MM, 1993, J AM COLL CARDIOL, V22, P440, DOI 10.1016/0735-1097(93)90048-6; CORBETT JR, 1981, CIRCULATION, V64, P535, DOI 10.1161/01.CIR.64.3.535; COX DR, 1972, J R STAT SOC B, V34, P187; DAKAK N, 1995, AM J CARDIOL, V76, P125, DOI 10.1016/S0002-9149(99)80043-5; DEANFIELD JE, 1984, LANCET, V2, P1001; DEANFIELD JE, 1983, LANCET, V2, P753; DEEDWANIA PC, 1990, CIRCULATION, V81, P748, DOI 10.1161/01.CIR.81.3.748; FRASURESMITH N, 1989, PSYCHOSOM MED, V51, P485, DOI 10.1097/00006842-198909000-00002; FRIEDMAN M, 1986, AM HEART J, V112, P653, DOI 10.1016/0002-8703(86)90458-8; FULLER CM, 1981, ANN INTERN MED, V94, P734, DOI 10.7326/0003-4819-94-6-734; Gabbay FH, 1996, J AM COLL CARDIOL, V27, P585, DOI 10.1016/0735-1097(95)00510-2; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; Gill JB, 1996, NEW ENGL J MED, V334, P65, DOI 10.1056/NEJM199601113340201; GOTTDIENER JS, 1994, J AM COLL CARDIOL, V24, P1645, DOI 10.1016/0735-1097(94)90169-4; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; IRONSON G, 1992, AM J CARDIOL, V70, P281, DOI 10.1016/0002-9149(92)90605-X; JAIN D, 1995, AM J CARDIOL, V76, P31, DOI 10.1016/S0002-9149(99)80796-6; JIANG W, 1995, AM J CARDIOL, V76, P350, DOI 10.1016/S0002-9149(99)80099-X; LEGAULT SE, 1995, AM J CARDIOL, V75, P1007, DOI 10.1016/S0002-9149(99)80713-9; MEISEL SR, 1991, LANCET, V338, P660, DOI 10.1016/0140-6736(91)91234-L; MILLER TQ, 1994, J BEHAV MED, V17, P567, DOI 10.1007/BF01857598; NEWMAN GF, 1980, CIRCULATION, V62, P1204, DOI 10.1161/01.CIR.62.6.1204; PETERSON ED, 1995, CIRCULATION, V92, P272; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; STERN S, 1974, BRIT HEART J, V36, P481; TALIERCIO CP, 1988, MAYO CLIN PROC, V63, P573, DOI 10.1016/S0025-6196(12)64887-3; TAVAZZI L, 1990, ADV CARDIOL, V37, P53; Trauner Michael A., 1994, Annals of Behavioral Medicine, V16, P24; TZIVONI D, 1989, AM J CARDIOL, V63, P273, DOI 10.1016/0002-9149(89)90329-9; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205; YEUNG AC, 1991, CIRCULATION, V83, P1598, DOI 10.1161/01.CIR.83.5.1598	38	252	260	3	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1651	1656		10.1001/jama.275.21.1651	http://dx.doi.org/10.1001/jama.275.21.1651			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637138				2022-12-28	WOS:A1996UN25200027
J	Lecuit, T; Brook, WJ; Ng, M; Calleja, M; Sun, H; Cohen, SM				Lecuit, T; Brook, WJ; Ng, M; Calleja, M; Sun, H; Cohen, SM			Two distinct mechanisms for long-range patterning by decapentaplegic in the Drosophila wing	NATURE			English	Article							OPTOMOTOR-BLIND; GENE-EXPRESSION; MELANOGASTER; MORPHOGENESIS; THRESHOLDS; ACTIVIN; HOMOLOG	Secreted signalling molecules provide cells with positional information that organizes long-range pattern during the development of multicellular animals. Evidence is presented that localized expression of Decapentaplegic instructs cells about their position along the anterior-posterior axis of the Drosophila wing in two distinct ways. One mechanism is based on the local concentration of the secreted protein; the other is based on the ability of the cells to retain an instruction received at an earlier time when their progenitors were in close proximity to the signal. Both mechanisms are involved in axis formation.	EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV AUTONOMA MADRID, E-28029 MADRID, SPAIN; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	European Molecular Biology Laboratory (EMBL); Autonomous University of Madrid; Academia Sinica - Taiwan			Cohen, Stephen M/G-9930-2011; Sun, Y. Henry/AAZ-7966-2021; Sun, Y. Henry/ABC-4614-2021	Cohen, Stephen M/0000-0003-2858-9163; Sun, Y. Henry/0000-0001-8279-5270				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DURINBORKOWSKI OA, 1995, DEV BIOL, V168, P689; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Ng M, 1996, NATURE, V381, P316, DOI 10.1038/381316a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PFLUGFELDER GO, 1990, GENETICS, V126, P91; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; RAFTERY LA, 1995, GENETICS, V139, P241; SANICOLA M, 1995, GENETICS, V139, P745; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SIMMONDS AJ, 1995, NATURE, V376, P424, DOI 10.1038/376424a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; WIERSDORFF V, IN PRESS DEVELOPMENT; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WOLPERT L, 1989, DEVELOPMENT, V107, P3; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036; ZECCA M, 1995, DEVELOPMENT, V121, P2265	44	559	565	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 30	1996	381	6581					387	393		10.1038/381387a0	http://dx.doi.org/10.1038/381387a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632795				2022-12-28	WOS:A1996UN47900041
J	[Anonymous]				[Anonymous]			How not to act on good advice	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					351	351						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632781				2022-12-28	WOS:A1996UN47900001
J	Cowley, AW; Roman, RJ				Cowley, AW; Roman, RJ			The role of the kidney in hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PAPILLARY BLOOD-FLOW; INTERSTITIAL HYDROSTATIC-PRESSURE; RENAL HEMODYNAMIC-RESPONSE; NITRIC-OXIDE INHIBITION; VOLUME-EXPANDED RATS; ANGIOTENSIN-II; SODIUM-REABSORPTION; PERFUSION-PRESSURE; NATRIURESIS RELATIONSHIP; VASOPRESSIN				Cowley, AW (corresponding author), MED COLL WISCONSIN, DEPT PHYSIOL, 8701 WATERTOWN PLANK RD, MILWAUKEE, WI 53226 USA.				NHLBI NIH HHS [HL42919, R37 HL036279, HL36279, HL29587] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042919, P01HL029587, R01HL036279, R37HL036279] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APERIA AC, 1971, AM J PHYSIOL, V220, P1205, DOI 10.1152/ajplegacy.1971.220.5.1205; ARENDSHORST WJ, 1979, CIRC RES, V44, P344, DOI 10.1161/01.RES.44.3.344; BARTTER FC, 1967, AM J MED, V42, P790, DOI 10.1016/0002-9343(67)90096-4; BAYLIS C, 1990, J AM SOC NEPHROL, V1, P875; BERECEK KH, 1980, AM J PHYSIOL, V238, pH287, DOI 10.1152/ajpheart.1980.238.3.H287; BIANCHI G, 1970, CLIN SCI, V38, P741, DOI 10.1042/cs0380741; BRAND PH, 1991, AM J PHYSIOL, V261, pR802, DOI 10.1152/ajpregu.1991.261.4.R802; CHEN PY, 1991, J CLIN INVEST, V88, P1559, DOI 10.1172/JCI115467; CHOU SY, 1990, KIDNEY INT, V37, P1, DOI 10.1038/ki.1990.1; CHURCHILL PC, 1992, AM J PHYSIOL, V262, pH1809; COWLEY AW, 1994, AM J PHYSIOL, V267, pH751, DOI 10.1152/ajpheart.1994.267.2.H751; COWLEY AW, 1985, HYPERTENSION, V7, pI151, DOI 10.1161/01.HYP.7.3_Pt_2.I151; COWLEY AW, 1975, CIRC RES, V36, P536, DOI 10.1161/01.RES.36.4.536; COWLEY AW, 1981, HYPERTENSION, V3, P93; CURTIS JJ, 1983, NEW ENGL J MED, V309, P1009, DOI 10.1056/NEJM198310273091702; DAHL LK, 1975, CIRC RES, V36, P692, DOI 10.1161/01.RES.36.6.692; DANANBERG J, 1993, HYPERTENSION, V21, P359, DOI 10.1161/01.HYP.21.3.359; DILLEY JR, 1984, AM J PHYSIOL, V247, pF672, DOI 10.1152/ajprenal.1984.247.4.F672; DUNN MJ, 1977, AM J PHYSIOL, V233, pF169, DOI 10.1152/ajprenal.1977.233.3.F169; EHMKE H, 1990, AM J PHYSIOL, V259, pF466, DOI 10.1152/ajprenal.1990.259.3.F466; EVAN AP, 1981, HYPERTENSION, V3, P154; FARRUGIA E, 1992, CIRC RES, V71, P1153, DOI 10.1161/01.RES.71.5.1153; FAUBERT PF, 1987, KIDNEY INT, V32, P472, DOI 10.1038/ki.1987.234; FENOY FJ, 1995, HYPERTENSION, V25, P408, DOI 10.1161/01.HYP.25.3.408; FENOY FJ, 1991, HYPERTENSION, V17, P1038, DOI 10.1161/01.HYP.17.6.1038; FENOY FJ, 1992, HYPERTENSION, V19, P49, DOI 10.1161/01.HYP.19.1.49; FINK GD, 1986, AM J PHYSIOL, V251, pH148, DOI 10.1152/ajpheart.1986.251.1.H148; FOLKOW B, 1977, ACTA PHYSIOL SCAND, V100, P270, DOI 10.1111/j.1748-1716.1977.tb05949.x; FOX U, 1976, CLIN EXP PHARMACOL P, P71; GARCIAESTAN J, 1990, AM J PHYSIOL, V258, pR1333, DOI 10.1152/ajpregu.1990.258.6.R1333; GARDINER SM, 1992, EUR J PHARMACOL, V213, P449, DOI 10.1016/0014-2999(92)90636-I; GEBREMEDHIN D, 1990, HYPERTENSION, V16, P648, DOI 10.1161/01.HYP.16.6.648; Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347; GONZALEZCAMPOY JM, 1991, AM J PHYSIOL, V260, pF643, DOI 10.1152/ajprenal.1991.260.5.F643; GOTTLIEB TB, 1972, CIRCULATION, V45, P571, DOI 10.1161/01.CIR.45.3.571; GRANGER JP, 1986, HYPERTENSION, V8, P112; GROSS V, 1994, J HYPERTENS, V12, P1029; Guarasci GR, 1996, AM J PHYSIOL-REG I, V270, pR469, DOI 10.1152/ajpregu.1996.270.2.R469; GUIDI E, 1985, NEPHRON, V41, P14, DOI 10.1159/000183539; GUYTON AC, 1972, AM J MED, V52, P584, DOI 10.1016/0002-9343(72)90050-2; GUYTON AC, 1974, CIRC RES, V35, P159, DOI 10.1161/01.RES.35.2.159; HAAS JA, 1986, AM J PHYSIOL, V250, pF425, DOI 10.1152/ajprenal.1986.250.3.F425; HALL JE, 1984, AM J PHYSIOL, V246, pF627, DOI 10.1152/ajprenal.1984.246.5.F627; HALL JE, 1986, AM J PHYSIOL, V250, pR960, DOI 10.1152/ajpregu.1986.250.6.R960; HALL JE, 1986, AM J PHYSIOL, V250, pF907, DOI 10.1152/ajprenal.1986.250.5.F907; HALL JE, 1984, HYPERTENSION, V6, pI183, DOI 10.1161/01.HYP.6.2_Pt_2.I183; HANSELL P, 1988, AM J PHYSIOL, V254, pF492, DOI 10.1152/ajprenal.1988.254.4.F492; HELLER J, 1993, PFLUG ARCH EUR J PHY, V425, P208, DOI 10.1007/BF00374168; HIGASHIHARA E, 1979, J CLIN INVEST, V64, P1277, DOI 10.1172/JCI109583; HOLLENBERG NK, 1978, MEDICINE, V57, P167, DOI 10.1097/00005792-197803000-00004; HOLLENBERG NK, 1976, AM J MED, V60, P773, DOI 10.1016/0002-9343(76)90891-3; HUANG CL, 1994, BRIT J PHARMACOL, V111, P111, DOI 10.1111/j.1476-5381.1994.tb14031.x; IKENAGA H, 1993, KIDNEY INT, V43, P205, DOI 10.1038/ki.1993.33; IMIG JD, 1993, HYPERTENSION, V22, P357, DOI 10.1161/01.HYP.22.3.357; JOHNSON BF, 1971, CLIN PHARMACOL THER, V12, P815; KAWABE K, 1978, JPN HEART J, V19, P886; KINOSHITA Y, 1989, CIRC RES, V64, P1013, DOI 10.1161/01.RES.64.5.1013; KIRCHNER KA, 1990, J AM SOC NEPHROL, V1, P180; KLINE RL, 1987, HYPERTENSION, V10, P590, DOI 10.1161/01.HYP.10.6.590; KLINE RL, 1994, HYPERTENSION, V24, P467, DOI 10.1161/01.HYP.24.4.467; KOPF D, 1993, AM J PHYSIOL, V265, pF104, DOI 10.1152/ajprenal.1993.265.1.F104; LEDINGHAM JM, 1964, CAN MED ASSOC J, V90, P292; LERMAN LO, 1995, AM J PHYSIOL-RENAL, V268, pF404, DOI 10.1152/ajprenal.1995.268.3.F404; LIU KL, 1994, AM J PHYSIOL, V266, pR1530, DOI 10.1152/ajpregu.1994.266.5.R1530; LU SH, 1992, AM J PHYSIOL, V263, pR1064, DOI 10.1152/ajpregu.1992.263.5.R1064; LU SH, 1994, HYPERTENSION, V23, P337, DOI 10.1161/01.HYP.23.3.337; MAJID DSA, 1993, AM J PHYSIOL, V264, pF79, DOI 10.1152/ajprenal.1993.264.1.F79; MANNING RD, 1993, HYPERTENSION, V22, P40, DOI 10.1161/01.HYP.22.1.40; MATTSON DL, 1991, AM J PHYSIOL, V260, pR1200, DOI 10.1152/ajpregu.1991.260.6.R1200; MATTSON DL, 1991, AM J PHYSIOL, V260, pF670, DOI 10.1152/ajprenal.1991.260.5.F670; MATTSON DL, 1993, HYPERTENSION, V21, P961, DOI 10.1161/01.HYP.21.6.961; MATTSON DL, 1994, AM J PHYSIOL, V266, pH1918, DOI 10.1152/ajpheart.1994.266.5.H1918; MORGAN DA, 1990, HYPERTENSION, V15, P436, DOI 10.1161/01.HYP.15.4.436; NAKANISHI K, 1995, AM J PHYSIOL-REG I, V269, pR193, DOI 10.1152/ajpregu.1995.269.1.R193; NAKANISHI K, 1995, AM J PHYSIOL-REG I, V268, pR317, DOI 10.1152/ajpregu.1995.268.2.R317; NIES AS, 1971, CIRCULATION, V44, P596, DOI 10.1161/01.CIR.44.4.596; NORMAN RA, 1978, AM J PHYSIOL, V234, pR98, DOI 10.1152/ajpregu.1978.234.3.R98; NORRELUND H, 1994, HYPERTENSION, V24, P301, DOI 10.1161/01.HYP.24.3.301; OLSEN ME, 1985, AM J PHYSIOL, V249, pF299, DOI 10.1152/ajprenal.1985.249.2.F299; OMVIK P, 1980, HYPERTENSION, V2, P515, DOI 10.1161/01.HYP.2.4.515; PADFIELD PL, 1977, AM HEART J, V94, P531, DOI 10.1016/S0002-8703(77)80049-5; PATEL AR, 1994, AM J PHYSIOL, V266, pR1730, DOI 10.1152/ajpregu.1994.266.6.R1730; PAWLOSKI CM, 1989, AM J PHYSIOL, V257, pH209, DOI 10.1152/ajpheart.1989.257.1.H209; PAWLOWSKA D, 1988, AM J PHYSIOL, V254, pF507, DOI 10.1152/ajprenal.1988.254.4.F507; RETTIG R, 1990, AM J PHYSIOL, V258, pF606, DOI 10.1152/ajprenal.1990.258.3.F606; RETTIG R, 1993, J HYPERTENS, V11, P883, DOI 10.1097/00004872-199309000-00001; ROAN RJ, 1993, AM J PHYSIOL, V265, pR963; ROMAN RJ, 1988, HYPERTENSION, V11, P657, DOI 10.1161/01.HYP.11.6.657; ROMAN RJ, 1988, HYPERTENSION, V12, P168, DOI 10.1161/01.HYP.12.2.168; ROMAN RJ, 1978, AM J PHYSIOL, V235, pF111, DOI 10.1152/ajprenal.1978.235.2.F111; ROMAN RJ, 1990, HYPERTENSION, V15, P29, DOI 10.1161/01.HYP.15.1.29; ROMAN RJ, 1991, HYPERTENSION, V17, P1018, DOI 10.1161/01.HYP.17.6.1018; ROMAN RJ, 1986, AM J PHYSIOL, V251, pF57, DOI 10.1152/ajprenal.1986.251.1.F57; ROMAN RJ, 1987, HYPERTENSION, V9, P130; ROMAN RJ, 1991, AM J PHYSIOL, V261, pR595, DOI 10.1152/ajpregu.1991.261.3.R595; ROMAN RJ, 1985, AM J PHYSIOL, V248, pF190, DOI 10.1152/ajprenal.1985.248.2.F190; ROMAN RJ, 1988, HYPERTENSION, V12, P177, DOI 10.1161/01.HYP.12.2.177; ROMAN RJ, 1988, AM J PHYSIOL, V255, pF690, DOI 10.1152/ajprenal.1988.255.4.F690; SACERDOTI D, 1989, SCIENCE, V243, P388, DOI 10.1126/science.2492116; SALOM MG, 1992, AM J PHYSIOL, V262, pF718, DOI 10.1152/ajprenal.1992.262.5.F718; SCHORK NJ, 1995, GENOME RES, V5, P164, DOI 10.1101/gr.5.2.164; Selye H, 1943, CAN MED ASSOC J, V49, P88; SMITH MJ, 1979, AM J PHYSIOL, V237, pF232, DOI 10.1152/ajprenal.1979.237.3.F232; STEC DE, IN PRESS HYPERTENSIO; STEIN JH, 1972, J CLIN INVEST, V51, P1709, DOI 10.1172/JCI106972; STRANDGAARD S, 1986, BRIT MED J, V292, P1041, DOI 10.1136/bmj.292.6527.1041; STRICK DM, 1994, AM J PHYSIOL, V267, pR253, DOI 10.1152/ajpregu.1994.267.1.R253; SZCZEPANSKASADOWSKA E, 1994, AM J PHYSIOL-REG I, V267, pR1217, DOI 10.1152/ajpregu.1994.267.5.R1217; TAKEZAWA K, 1987, AM J PHYSIOL, V252, pF992, DOI 10.1152/ajprenal.1987.252.6.F992; TOBIAN L, 1978, CIRC RES, V43, pI92; VANDERMARK J, 1994, AM J PHYSIOL, V266, pR739, DOI 10.1152/ajpregu.1994.266.3.R739; ZATZ R, 1991, AM J PHYSIOL, V261, pF360	112	225	230	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1581	1589		10.1001/jama.275.20.1581	http://dx.doi.org/10.1001/jama.275.20.1581			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622250				2022-12-28	WOS:A1996UL02900031
J	Dawson, C; Whitfield, H				Dawson, C; Whitfield, H			ABC of urology - Common paediatric problems	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON NW10 7NS,ENGLAND; INST UROL & NEPHROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	Dawson, C (corresponding author), EDITH CAVELL HOSP,PETERBOROUGH,CAMBS,ENGLAND.							BIANCHI A, 1995, ANN ROY COLL SURG, V77, P3; DHILLON HK, 1995, CURRENT OPINION UROL, V75, P75	2	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1291	1294		10.1136/bmj.312.7041.1291	http://dx.doi.org/10.1136/bmj.312.7041.1291			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634623	Green Published			2022-12-28	WOS:A1996UM40400032
J	Nkata, M				Nkata, M			Rupture of the uterus: A review of 32 cases in a general hospital in Zambia	BRITISH MEDICAL JOURNAL			English	Article							MATERNAL MORTALITY				Nkata, M (corresponding author), MANSA GEN HOSP,POB 710156,MANSA,ZAMBIA.							CHIPHANGWI JD, 1992, E AFR MED J, V69, P675; FALEYIMU BL, 1990, TROP DOCT, V20, P188, DOI 10.1177/004947559002000425; SUNDARI TK, 1992, INT J HEALTH SERV, V22, P513, DOI 10.2190/91YH-A52T-AFBB-1LEA; VEALE DJH, 1992, J ETHNOPHARMACOL, V36, P185, DOI 10.1016/0378-8741(92)90043-Q	4	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1204	1205						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634565				2022-12-28	WOS:A1996UL05800022
J	Rizzoli, R; Bonjour, JP				Rizzoli, R; Bonjour, JP			Pregnancy-associated osteoporosis	LANCET			English	Editorial Material							BONE MASS ACCUMULATION; LACTATION; DENSITY; WOMEN				Rizzoli, R (corresponding author), UNIV HOSP GENEVA,DIV CLIN PATHOPHYSIOL,WHO,COLLABORATING CTR OSTEOPOROSIS & BONE DIS,GENEVA,SWITZERLAND.							BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; Chevalley T, 1991, Osteoporos Int, V1, P147, DOI 10.1007/BF01625444; COURTNEY AC, 1994, CALCIFIED TISSUE INT, V55, P55; DRINKWATER BL, 1991, BONE MINER, V14, P153, DOI 10.1016/0169-6009(91)90092-E; DUNNE F, 1993, CLIN ENDOCRINOL, V39, P487, DOI 10.1111/j.1365-2265.1993.tb02398.x; GALLACHER SJ, 1994, EUR J ENDOCRINOL, V131, P369, DOI 10.1530/eje.0.1310369; KRITZSILVERSTEIN D, 1992, AM J EPIDEMIOL, V136, P1052, DOI 10.1093/oxfordjournals.aje.a116570; LAKHANPAL S, 1987, ANN INTERN MED, V106, P444, DOI 10.7326/0003-4819-106-3-444; MAILIS A, 1992, J RHEUMATOL, V19, P758; PECK WA, 1993, AM J MED, V94, P646; Smith R, 1995, QJM-MON J ASSOC PHYS, V88, P865; THEINTZ G, 1992, J CLIN ENDOCR METAB, V75, P1060, DOI 10.1210/jc.75.4.1060	12	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1274	1276		10.1016/S0140-6736(96)90932-0	http://dx.doi.org/10.1016/S0140-6736(96)90932-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622498				2022-12-28	WOS:A1996UK75800003
J	Knottnerus, JA				Knottnerus, JA			Research in general practice	LANCET			English	Article											Knottnerus, JA (corresponding author), UNIV LIMBURG,DEPT GEN PRACTICE,6200 MD MAASTRICHT,NETHERLANDS.								0	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1236	1238						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622459				2022-12-28	WOS:A1996UJ59700019
J	Kolde, G; Bachus, R; Ludolph, AC				Kolde, G; Bachus, R; Ludolph, AC			Skin involvement in amyotrophic lateral sclerosis	LANCET			English	Article								Background Patients with sporadic amyotrophic lateral sclerosis (ALS) show disorganised collagen and elastin of the dermis. We looked for inflammatory alterations to cutaneous blood vessels. Patients and findings Seven patients with sporadic ALS were investigated; five were confined to bed, but none had bedsores. Light and electron microscopy of skin showed an oedematous dermis with collagen fibrils of irregular diameter. Small blood vessels were characterised by duplicated basement membranes and deposition of beta-amyloid protein, the main component of the neuronal and non-neuronal amyloid deposits in Alzheimer's disease. These skin changes were seen in all degrees of disability, but none was found in age-matched and sex-matched controls. Interpretation The skin in ALS is characterised by a distinctive pattern of alterations of connective tissue and blood vessels. Examination of skin is an additional and easily accessible investigation which may help elucidate the pathogenesis of ALS.	HUMBOLDT UNIV BERLIN,DEPT NEUROL,D-10117 BERLIN,GERMANY	Humboldt University of Berlin	Kolde, G (corresponding author), HUMBOLDT UNIV BERLIN,DEPT DERMATOL,VIRCHOW CLIN,DEPT DERMATOL,D-13353 BERLIN,GERMANY.							CHARCOT JM, 1880, LECON MALADIES SYSTE, V2; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; DANIEL RK, 1981, ARCH PHYS MED REHAB, V62, P492; FURUKAWA T, 1976, LANCET, V1, P862; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; KNIFFEN JC, 1969, NEUROLOGY, V19, P312; LUDOLPH AC, 1987, BRAIN, V110, P149, DOI 10.1093/brain/110.1.149; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; NORRIS FH, 1974, NEUROLOGY, V24, P721, DOI 10.1212/WNL.24.8.721; ONO S, 1994, J NEUROL NEUROSUR PS, V57, P94, DOI 10.1136/jnnp.57.1.94; ROY DN, 1990, TOXICANTS PLANT ORIG, P170; WILLIAMS DB, 1991, MAYO CLIN PROC, V66, P54, DOI 10.1016/S0025-6196(12)61175-6	12	48	48	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1226	1227		10.1016/S0140-6736(96)90737-0	http://dx.doi.org/10.1016/S0140-6736(96)90737-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622453				2022-12-28	WOS:A1996UJ59700012
J	Murphy, JJ				Murphy, JJ			Current practice and complications of temporary transvenous cardiac pacing	BRITISH MEDICAL JOURNAL			English	Article											Murphy, JJ (corresponding author), DARLINGTON MEM HOSP,DEPT MED,DARLINGTON DL3 6HX,DURHAM,ENGLAND.							ANDREWS R, 1992, BRIT HEART J, V68, P91; MURPHY JJ, 1995, BRIT J CLIN PRACT, V49, P126; SZNAJDER JI, 1986, ARCH INTERN MED, V146, P259, DOI 10.1001/archinte.146.2.259; WINNER S, 1989, J ROY COLL PHYS LOND, V23, P161	4	66	68	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1134	1134						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620131				2022-12-28	WOS:A1996UK06900025
J	Panis, Y; Poupard, B; Nemeth, J; Lavergne, A; Hautefeuille, P; Valleur, P				Panis, Y; Poupard, B; Nemeth, J; Lavergne, A; Hautefeuille, P; Valleur, P			Ileal pouch anal anastomosis for Crohn's disease	LANCET			English	Article							RESTORATIVE PROCTOCOLECTOMY; COLITIS; COMPLICATIONS	Background Patients with Crohn's disease (CD) are not commonly considered as candidates for ileal pouch/anal anastomosis (IPAA). This approach has been avoided because of the poor results observed, retrospectively, in patients with an initial diagnosis of ulcerative colitis who were found to have CD on examination of the resected specimen. However, in 1985, we decided to investigate an alternative to coloproctectomy with definitive end-ileostomy by a prospective study of IPAA for selected patients with CD. Methods Between 1985 and 1992, 31 patients with CD, but with no evidence of anoperineal or small-bowel disease, were recruited to our study. They comprised 15 men and 16 women whose mean age was 36 years (SD 14; range 16-72). All CD patients underwent IPAA. The short-term and long-term functional results of this procedure were compared with those of 71 ulcerative colitis patients who also underwent IPAA during the same period in our unit. Mean follow-up was 59 (SD 25) months. Findings No significant differences were observed between patients with CD and ulcerative colitis in the postoperative complication rate. Of the 31 CD patients, six (19%) experienced specific complications 9 months to 6 years after surgery: three had pouch-perineal fistulas, which required pouch excision in two cases; one had a pouch-vaginal fistula that was treated by gracilis muscle interposition; and one had an extrasphincteric abscess, which was treated surgically. Two patients (6%), one of whom was treated for an extrasphincteric abscess, experienced CD recurrence on the reservoir, and were treated successfully with azathioprine. At 5-year follow-up, there were no significant differences between patients with CD and ulcerative colitis in stool frequency (5.0 [2.0] vs 4.7 [1.4] per day; p=0.68), continence, gas/stool discrimination, leak or need for protective pads, and sexual activity. Interpretation Our results show that in selected cases of CD without anoperineal or small-bowel manifestations, IPAA can be recommended as an alternative to coloprotectomy with definitive end-ileostomy, when rectal resection is essential.	HOP LARIBOISIERE,DEPT SURG,F-75475 PARIS 10,FRANCE; HOP LARIBOISIERE,DEPT PATHOL,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite								BERREBI W, 1993, DIGEST DIS SCI, V38, P1558, DOI 10.1007/BF01308621; DEUTSCH AA, 1991, DIS COLON RECTUM, V34, P475, DOI 10.1007/BF02049932; DOZOIS RR, 1989, ANN SURG, V210, P268, DOI 10.1097/00000658-198909000-00002; GALANDIUK S, 1990, ANN SURG, V212, P446, DOI 10.1097/00000658-199010000-00007; GORENSTEIN L, 1988, DIS COLON RECTUM, V31, P730, DOI 10.1007/BF02552595; GROBLER SP, 1993, GUT, V34, P1384, DOI 10.1136/gut.34.10.1384; HAUTEFEUILLE P, 1988, ANN SURG, V207, P61, DOI 10.1097/00000658-198801000-00012; HYMAN NH, 1991, DIS COLON RECTUM, V34, P653, DOI 10.1007/BF02050345; KEIGHLEY MRB, 1993, BRIT J SURG, V80, P1065, DOI 10.1002/bjs.1800800849; KOLTUN WA, 1991, DIS COLON RECTUM, V34, P857, DOI 10.1007/BF02049696; LEONG APK, 1994, BRIT J SURG, V81, P727, DOI 10.1002/bjs.1800810536; MCINTYRE PB, 1995, DIS COLON RECTUM, V38, P51; MORSON BC, 1990, MORSON DAWSONS GASTR; PEMBERTON JH, 1989, ANN SURG, V209, P620, DOI 10.1097/00000658-198905000-00015; PEZIM ME, 1989, DIS COLON RECTUM, V32, P653, DOI 10.1007/BF02555768; SCAMMELL BE, 1987, BRIT J SURG, V74, P671, DOI 10.1002/bjs.1800740805; WEXNER SD, 1989, DIS COLON RECTUM, V32, P275, DOI 10.1007/BF02553479	17	143	145	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					854	857		10.1016/S0140-6736(96)91344-6	http://dx.doi.org/10.1016/S0140-6736(96)91344-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622390				2022-12-28	WOS:A1996UC45000008
J	Hasan, A; Fortune, F; Wilson, A; Warr, K; Shinnick, T; Mizushima, Y; vanderZee, R; Stanford, MR; Sanderson, J; Lehner, T				Hasan, A; Fortune, F; Wilson, A; Warr, K; Shinnick, T; Mizushima, Y; vanderZee, R; Stanford, MR; Sanderson, J; Lehner, T			Role of gamma delta T cells in pathogenesis and diagnosis of Behcet's disease	LANCET			English	Article							HEAT-SHOCK PROTEIN; RECURRENT ORAL ULCERS; LYMPHOCYTES-T; EXPRESSION; ACTIVATION; MYCOBACTERIAL; ANTIGENS; RECEPTOR; IGA	Background Behcet's disease (BD) is a multisystem disorder of unknown pathogenesis. The diagnosis is based on a set of international clinical criteria. Previous investigations have suggested that immunological crossreactivity between peptides within streptococcal heat-shock proteins and human peptides might be involved in the pathogenesis of BD. We tested four peptides from mycobacterial heat-shock proteins to see if they specifically stimulated gamma delta T cells from ED patients. We then investigated this response to see whether it could be used as a laboratory test to diagnose BD. Methods We used a T-cell proliferative test to assay responses to four mycobacterial 65 kDa heat-shock-protein peptides and to four homologous peptides derived from the sequence of the human 60 kDa heat-shock protein. Findings We elicited significant gamma delta T-cell responses to the mycobacterial peptides in 25 (76%) of 33 patients with BD, compared with 2 (3.6%) of 55 controls with recurrent oral ulcers, systemic disease, or no disorders. The proportion of BD patients who had false-negative results decreased if the test was done during clinical manifestation of disease activity. There was a correlation between disease activity and T-cell responses. Four homologous peptides from human 60 kDa heat-shock protein also specifically stimulated T cells from patients with ED but with lower stimulation indices. Interpretation Activation of peripheral-blood mononuclear cells with the four heat-shock-protein peptides elicited significant T-cell proliferative responses by the gamma delta subset of T cells, which may regulate alpha beta T cells. Because these peptides have a high specificity for BD, this assay can be used as a laboratory diagnostic test for BD.	UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DEPT IMMUNOL,LONDON SE1 9RT,ENGLAND; UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DEPT GASTROENTEROL,LONDON SE1 9RT,ENGLAND; CTR DIS CONTROL,DEPT BACTERIAL DIS,ATLANTA,GA 30333; ST MARIANNA UNIV,INST MED SCI,KAWASAKI,KANAGAWA,JAPAN; INST INFECT DIS & IMMUNOL,DEPT IMMUNOL,UTRECHT,NETHERLANDS	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Centers for Disease Control & Prevention - USA; Saint Marianna University			van der Zee, Ruurd/O-5256-2015	van der Zee, Ruurd/0000-0002-4331-2755; Wilson, Amanda/0000-0001-5681-9611				BOISMENU R, 1994, SCIENCE, V266, P1253, DOI 10.1126/science.7973709; Bonass WA, 1986, INT C S SERIES ROYAL, V103, P37; DENMAN AM, 1979, BEHCETS SYNDROME, P91; EGLIN RP, 1982, LANCET, V2, P1356; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FORTUNE F, 1990, CLIN EXP IMMUNOL, V82, P326; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; HAMZAOUI K, 1994, J RHEUMATOL, V21, P2301; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; HASAN A, 1995, CLIN EXP IMMUNOL, V99, P392; International Study Group for Behcet's Disease, 1990, LANCET, V335, P1078; KANEKO F, 1985, BRIT J DERMATOL, V113, P303, DOI 10.1111/j.1365-2133.1985.tb02082.x; KAUFMANN SHE, 1993, P NATL ACAD SCI USA, V90, P9620, DOI 10.1073/pnas.90.20.9620; LEHNER T, 1968, P ROY SOC MED, V61, P515, DOI 10.1177/003591576806100543; LEHNER T, 1991, INFECT IMMUN, V59, P1434, DOI 10.1128/IAI.59.4.1434-1441.1991; LEHNER T, 1964, LANCET, V2, P1154; LEHNER T, 1979, CLIN IMMUNOLOGICAL F, P1; Lehner T, 1979, BEHCETS SYNDROME CLI, P13; MIZUSHIMA Y, 1989, J RHEUMATOL, V16, P506; MUNK ME, 1990, J IMMUNOL, V145, P2434; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; OHNO S, 1985, RECENT ADV BEHCETS D, P181; OSHIMA Y, 1963, ANN RHEUM DIS, V22, P36, DOI 10.1136/ard.22.1.36; PERVIN K, 1993, J IMMUNOL, V151, P2273; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; SANDOR M, 1992, J IMMUNOL, V148, P2363; SIRCUS W, 1957, Q J MED, V26, P235; STANFORD MR, 1994, CLIN EXP IMMUNOL, V97, P226; STUDD M, 1991, J MED MICROBIOL, V34, P39, DOI 10.1099/00222615-34-1-39; SUZUKI Y, 1992, J RHEUMATOL, V16, P588	30	145	149	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					789	794		10.1016/S0140-6736(96)90868-5	http://dx.doi.org/10.1016/S0140-6736(96)90868-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622334				2022-12-28	WOS:A1996UB15300009
J	Riemersma, RA				Riemersma, RA			Coronary heart disease and vitamin E	LANCET			English	Editorial Material							E CONSUMPTION; RISK		UNIV TROMSO,DEPT MED PHYSIOL,TROMSO,NORWAY	UiT The Arctic University of Tromso	Riemersma, RA (corresponding author), UNIV EDINBURGH,CARDIOVASC RES UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND.							HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HODIS HN, 1995, JAMA-J AM MED ASSOC, V273, P1849, DOI 10.1001/jama.273.23.1849; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; KARDINAAL AFM, 1995, AM J EPIDEMIOL, V141, P440, DOI 10.1093/oxfordjournals.aje.a117446; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; MORRIS DL, 1994, JAMA-J AM MED ASSOC, V272, P1439, DOI 10.1001/jama.272.18.1439; Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STREET DA, 1994, CIRCULATION, V90, P1154, DOI 10.1161/01.CIR.90.3.1154; 1994, NEW ENGL J MED, V330, P1029	13	19	19	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					776	777		10.1016/S0140-6736(96)90861-2	http://dx.doi.org/10.1016/S0140-6736(96)90861-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622327				2022-12-28	WOS:A1996UB15300002
J	Horowitz, HW				Horowitz, HW			Poetry on rounds: A model for the integration of humanities into residency training	LANCET			English	Editorial Material							MEDICINE; PHYSICIAN				Horowitz, HW (corresponding author), WESTCHESTER CTY MED CTR,DIV INFECT DIS,ROOM 209 MACY PAVIL,VALHALLA,NY 10595, USA.							ALMY TP, 1992, ANN INTERN MED, V116, P569, DOI 10.7326/0003-4819-116-7-569; American Board of Internal Medicine (ABIM), 1983, ANN INTERN MED, V99, P720; ARNOLD RM, 1987, ANN INTERN MED, V106, P313, DOI 10.7326/0003-4819-106-2-313; BAKER NJ, 1990, MINN MED, V73, P19; BARNARD D, 1994, ACAD MED, V69, P628, DOI 10.1097/00001888-199408000-00004; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; MCMANUS IC, 1995, LANCET, V346, P1143, DOI 10.1016/S0140-6736(95)91806-X; POVAR GJ, 1984, J MED EDUC, V59, P714; RISSE GB, 1992, WESTERN J MED, V156, P431; VERGHESE A, 1994, ANN INTERN MED, V121, P821; 1984, J MED ED S, V59, P177	11	22	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					447	449		10.1016/S0140-6736(96)90015-X	http://dx.doi.org/10.1016/S0140-6736(96)90015-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618489				2022-12-28	WOS:A1996TV72200015
J	Graham, NMH; Hoover, DR; Park, LP; Stein, DS; Phair, JP; Mellors, JW; Detels, R; Saah, AJ; Taylor, E; Margolick, JB; Markham, R; McArthur, J; Farzadegan, H; Armenian, H; Chmiel, JS; Cohen, B; Wesch, J; Wolinsky, S; Visscher, BR; Fahey, JL; Giorgi, JV; Dudley, J; Lee, M; Nishanian, P; Rinaldo, CR; Kingsley, LA; Kingsley, A; Mellors, J; Winkelstein, A; Munoz, A; Park, L; Gange, S; Nelson, K; Jacobson, LP; Su, S				Graham, NMH; Hoover, DR; Park, LP; Stein, DS; Phair, JP; Mellors, JW; Detels, R; Saah, AJ; Taylor, E; Margolick, JB; Markham, R; McArthur, J; Farzadegan, H; Armenian, H; Chmiel, JS; Cohen, B; Wesch, J; Wolinsky, S; Visscher, BR; Fahey, JL; Giorgi, JV; Dudley, J; Lee, M; Nishanian, P; Rinaldo, CR; Kingsley, LA; Kingsley, A; Mellors, J; Winkelstein, A; Munoz, A; Park, L; Gange, S; Nelson, K; Jacobson, LP; Su, S			Survival in HIV-infected patients who have received zidovudine: Comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; MULTICENTER AIDS COHORT; CONTROLLED TRIAL; DIDANOSINE; COMPLEX	Background: Among patients who begin receiving zidovudine during intermediate-stage human immunodeficiency virus (HIV) infection, it is unclear whether changing to combination therapy (adding didanosine or zalcitabine) or sequential monotherapy (changing to didanosine or zalcitabine) significantly improves survival. Objective: To determine, among patients who began receiving zidovudine during intermediate-stage HIV infection, the differential effects of changing to combination therapy (zidovudine with didanosine or zalcitabine) or sequential monotherapy (with didanosine or zalcitabine) or continuing zidovudine monotherapy. Patients: 1077 HIV-seropositive men in the Multicenter AIDS (acquired immunodeficiency syndrome) Cohort Study who began receiving zidovudine before an AIDS-defining illness developed. Setting: University-affiliate clinics in Baltimore, Chicago, Los Angeles, and Pittsburgh. Design: Longitudinal cohort study. Treatment groups and important prognostic variables were modeled as time-dependent covariates in Cox proportional hazards models. Measurements: Progression to AIDS and death. Results: Compared with patients receiving continued zidovudine monotherapy, patients receiving combination therapy had a 45% improvement in survival (relative risk, 0.55 [95% CI, 0.41 to 0.74; P < 0.001]) and patients who changed to sequential monotherapy had a 32% improvement in survival (relative risk, 0.68 [CI, 0.52 to 0.89; P = 0.005]). In the landmark analyses, the median prolongation of survival associated with changing therapy was, at best, 3 to 6 months. Survival curves converged at 3.5 years for the 50 cells/mm(3) disease-stage landmark, at 4.4 years for the 100 cells/mm(3) landmark, and at 4.9 years for the 150 cells/mm(3) landmark. Mortality within these periods was 100%, regardless of treatment group or landmark. Conclusions: For patients who began receiving zidovudine during intermediate-stage disease, changing to either combination therapy or sequential monotherapy was associated with a statistically significant survival benefit compared with continuation of zidovudine monotherapy. The absolute increase in survival was modest, however, and long-term survival remained poor. Simultaneous time-dependent adjustment for changes in therapy and in important prognostic variables is necessary to derive relatively unbiased estimates of treatment effects in observational studies of HIV infection.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27157 USA; ALBANY MED COLL, DEPT MED, ALBANY, NY 12208 USA; ALBANY MED COLL, DEPT PHARMACOL, ALBANY, NY 12208 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, PITTSBURGH, PA 15261 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT EPIDEMIOL, LOS ANGELES, CA 90095 USA; UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA USA; NORTHWESTERN UNIV, SCH MED, DEPT MED, CHICAGO, IL 60611 USA; JOHNS HOPKINS UNIV, SCH PUBL HLTH, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA	Wake Forest University; Wake Forest Baptist Medical Center; Albany Medical College; Albany Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; Johns Hopkins University; Johns Hopkins University	Graham, NMH (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, 624 N BROADWAY, ROOM 895, BALTIMORE, MD 21205 USA.		Wolinsky, Steven/B-2893-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035039, U01AI035042, U01AI035043] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI-35042, U01-AI-35039, U01-AI-35043] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS DI, 1994, NEW ENGL J MED, V330, P657, DOI 10.1056/NEJM199403103301001; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BROOKMEYER R, 1987, AM J EPIDEMIOL, V126, P14, DOI 10.1093/oxfordjournals.aje.a114646; COLLIER AC, 1993, ANN INTERN MED, V119, P786, DOI 10.7326/0003-4819-119-8-199310150-00003; DARBYSHIRE JH, 1992, LANCET, V340, P1346, DOI 10.1016/0140-6736(92)92524-J; DOLIN R, 1995, ARCH INTERN MED, V155, P961, DOI 10.1001/archinte.155.9.961; DRUSANO GL, 1994, ANTIMICROB AGENTS CH, V38, P1726, DOI 10.1128/AAC.38.8.1726; DRUSANO GL, 1992, ANN INTERN MED, V116, P562, DOI 10.7326/0003-4819-116-7-562; DUDLEY J, 1995, AM J EPIDEMIOL, V142, P323, DOI 10.1093/oxfordjournals.aje.a117638; DUDLEY MN, 1992, 32 INT C ANT AG CHEM; FISCHL MA, 1995, ANN INTERN MED, V122, P24, DOI 10.7326/0003-4819-122-1-199501010-00004; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1993, ANN INTERN MED, V118, P762, DOI 10.7326/0003-4819-118-10-199305150-00002; GAZZARD B, 1996, 3 C RETR OPP INF WAS; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GRAHAM NMH, 1995, CLIN INFECT DIS, V20, P352, DOI 10.1093/clinids/20.2.352; GRAHAM NMH, 1994, J CLIN EPIDEMIOL, V47, P1003, DOI 10.1016/0895-4356(94)90115-5; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HAMMER S, 1995, 35 INT C ANT AG CHEM; HOOVER DR, 1995, DRUGS, V49, P20, DOI 10.2165/00003495-199549010-00003; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KATZENSTEIN D, 1995, 35 INT C ANT AG CHEM; LONGINI IM, 1993, AM J EPIDEMIOL, V137, P1229, DOI 10.1093/oxfordjournals.aje.a116625; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; *NAT I ALL INF DIS, 1993, EX SUMM ACTG PROT 11; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; PARK LP, 1995, CLIN INFECT DIS, V21, P930, DOI 10.1093/clinids/21.4.930; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; SALE M, 1993, CLIN PHARMACOL THER, V54, P556, DOI 10.1038/clpt.1993.188; SARAVOLATZ L, 1996, 3 C RETR OPP INF WAS; *SAS I, 1991, SZS SOFTW VERS 6 09; SAS Institute, 1991, SAS STAT SOFTW PHREG; SCHOOLEY R, 1994, 4 EUR C CLIN ASP TRE; SELIGMANN M, 1994, LANCET, V343, P871; SPRUANCE SL, 1994, ANN INTERN MED, V120, P360, DOI 10.7326/0003-4819-120-5-199403010-00002; STEIN DS, 1994, ANN INTERN MED, V121, P100, DOI 10.7326/0003-4819-121-2-199407150-00004; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9	46	28	31	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1031	1038		10.7326/0003-4819-124-12-199606150-00002	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633816				2022-12-28	WOS:A1996UQ65800002
J	Sadowski, LS; Munoz, SR				Sadowski, LS; Munoz, SR			Nonfatal and fatal firearm injuries in a rural county	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To measure the incidence of fatal and nonfatal firearm injuries in a rural setting. Design.-A prospective, population-based surveillance system using information from medical and legal records, newspapers, and members of the community. Setting.-A rural county in North Carolina. Main Outcome Measures.-Incidence rates and case-fatality ratios (fatal:nonfatal). Results.-Of the 114 firearm injuries detected by the surveillance system from January 1, 1990, through December 31, 1991, nearly two thirds were nonfatal, The overall age-adjusted annual incidence of firearm injuries was 66.4 per 100 000 population, and the incidence of nonfatal firearm injuries was 41.2 per 100 000 population, Subgroup annual incidence rates were greatest for African Americans. The overall case-fatality ratio was 1:1.8 (fatal:nonfatal). Conclusions.-Incidence rates and case-fatality ratios for firearm injury in this rural setting were greater than expected, based on national estimates, perhaps because of greater proportions of rifle injuries and self-inflicted injuries.	UNIV LA FRONTERA, SCH MED, CLIN EPIDEMIOL UNIT, TEMUCO, CHILE	Universidad de La Frontera	Sadowski, LS (corresponding author), UNIV N CAROLINA, DEPT MED, CB 7110, CHAPEL HILL, NC 27599 USA.				PHS HHS [R49/CCR402444] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEXANDER GR, 1985, AM J PUBLIC HEALTH, V75, P165, DOI 10.2105/AJPH.75.2.165; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; Rothman K, 1986, MODERN EPIDEMIOLOGY; *STAT GRAPH DAT MA, 1992, STATA REF MAN REL 3, V3, P66; *US BUR CENS, 1987, 1987 CURR POP SURV; *US BUR CENS, 1992, 1990 COUNT POP AG SE; *US CTR HLTH STAT, 1988, 1988 US DET MORT DAT; *US NAT CTR HLTH S, 1976, VIT HLTH STAT, V10; WINTEMUTE GJ, 1987, J TRAUMA, V27, P530; ZWERLING C, 1993, AM J PREV MED, V9, P21, DOI 10.1016/S0749-3797(18)30674-3	13	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1762	1764		10.1001/jama.275.22.1762	http://dx.doi.org/10.1001/jama.275.22.1762			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP307	8637176				2022-12-28	WOS:A1996UP30700032
J	Shigemoto, R; Kulik, A; Roberts, JDB; Ohishi, H; Nusser, Z; Kaneko, T; Somogyi, P				Shigemoto, R; Kulik, A; Roberts, JDB; Ohishi, H; Nusser, Z; Kaneko, T; Somogyi, P			Target-cell-specific concentration of a metabotropic glutamate receptor In the presynaptic active zone	NATURE			English	Article							SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; CALCIUM CURRENTS; MODULATION	THE probability of synaptic neurotransmitter release from nerve terminals is regulated by presynaptic receptors responding to transmitters released from the same nerve terminal or from terminals of other neurons. The release of glutamate, the major excitatory neurotransmitter, is suppressed by presynaptic autoreceptors(1-3). Here we show that a metabotropic glutamate receptor (mGluR7) in the rat hippocampus is restricted to the presynaptic grid, the site of synaptic vesicle fusion. Pyramidal cell terminals presynaptic to mGluR1 alpha-expressing interneurons have at least a ten-fold higher level of presynaptic mGluR7 than terminals making synapses with pyramidal cells and other types of interneuron. Distinct levels of mGluR7 are found at different synapses made by individual pyramidal axons or even single boutons. These results raise the possibility that presynaptic neurons could regulate the probability of transmitter release at individual synapses according to the postsynaptic target.	UNIV OXFORD,MRC,ANAT NEUROPHARMACOL UNIT,DEPT PHARMACOL,OXFORD OX1 3TH,ENGLAND; KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,SAKYO KU,KYOTO 606,JAPAN	University of Oxford; Kyoto University			Nusser, Zoltan/K-8587-2014; Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444; Nusser, Zoltan/0000-0001-7004-4111				BAUDE A, 1995, NEUROSCIENCE, V69, P1031, DOI 10.1016/0306-4522(95)00350-R; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BLASCOIBANEZ JM, 1995, EUR J NEUROSCI, V7, P2170, DOI 10.1111/j.1460-9568.1995.tb00638.x; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; CHARPAK S, 1995, EUR J NEUROSCI, V7, P1548, DOI 10.1111/j.1460-9568.1995.tb01150.x; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; GEREAU RW, 1995, J NEUROSCI, V15, P6879; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; KOERBER HR, 1991, J NEUROPHYSIOL, V65, P590, DOI 10.1152/jn.1991.65.3.590; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MACCAFERRI G, 1995, J NEURON, V15, P137; Manzoni O, 1995, EUR J NEUROSCI, V7, P2518, DOI 10.1111/j.1460-9568.1995.tb01051.x; MCBAIN CJ, 1994, J NEUROSCI, V14, P4433; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; Ohishi H, 1995, NEUROSCI LETT, V202, P85, DOI 10.1016/0304-3940(95)12207-9; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; SAHARA Y, 1993, J NEUROSCI, V13, P3041; Shigemoto R., 1995, Society for Neuroscience Abstracts, V21, P846; SOMOGYI P, 1984, J NEUROSCI, V4, P2590; TAREILUS E, 1995, NEUROCHEM INT, V26, P539, DOI 10.1016/0197-0186(94)00149-O; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; VIGNES M, 1995, NEUROPHARMACOLOGY, V34, P973, DOI 10.1016/0028-3908(95)00093-L	31	337	359	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					523	525		10.1038/381523a0	http://dx.doi.org/10.1038/381523a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP435	8632825				2022-12-28	WOS:A1996UP43500060
J	OKeefe, J; Burgess, N				OKeefe, J; Burgess, N			Geometric determinants of the place fields of hippocampal neurons	NATURE			English	Article							FREELY-MOVING RATS; UNIT-ACTIVITY; CELLS; DIRECTION; POSITION; LESIONS; MEMORY	THE human hippocampus has been implicated in memory(1), in particular episodic(2,3) or declarative(4) memory. In rats, hippocampal lesions cause selective spatial deficits(2,5-7), and hippocampal complex spike cells (place cells) exhibit spatially localized firing(8,9), suggesting a role in spatial memory(2), although broader functions have also been suggested(10,11). Here we report the identification of the environmental features controlling the location and shape of the receptive fields (place fields) of the place cells. This was done by recording from the same cell in four rectangular boxes that differed solely in the length of one or both sides. Most of our results are explained by a model in which the place field is formed by the summation of gaussian tuning curves, each oriented perpendicular to a box wall and peaked at a fixed distance from it.			OKeefe, J (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT,TORRINGTON PL,LONDON WC1E 6BT,ENGLAND.		Burgess, Neil/B-2420-2009	Burgess, Neil/0000-0003-0646-6584				[Anonymous], 1983, CANADIAN PSYCHOL; BURGESS N, 1994, NEURAL NETWORKS, V7, P1065, DOI 10.1016/S0893-6080(05)80159-5; CHENG K, 1986, COGNITION, V23, P149, DOI 10.1016/0010-0277(86)90041-7; COLLETT TS, 1986, J COMP PHYSIOL A, V158, P835, DOI 10.1007/BF01324825; EICHENBAUM H, 1992, J COGNITIVE NEUROSCI, V4, P217, DOI 10.1162/jocn.1992.4.3.217; Gothard KM, 1996, J NEUROSCI, V16, P823; GOTHARD KM, 1995, SOC NEUR ABSTR, V21, P911; KNIERIM JJ, 1995, J NEUROSCI, V15, P1648, DOI 10.1523/JNEUROSCI.15-03-01648.1995; MARGULES J, 1988, ANIM LEARN BEHAV, V16, P404, DOI 10.3758/BF03209379; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; MCNAUGHTON BL, 1994, COGNITIVE NEUROSCIEN, P585; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MULLER RU, 1987, J NEUROSCI, V7, P1951; MULLER RU, 1989, J NEUROSCI, V9, P4101; MULLER RU, 1994, J NEUROSCI, V14, P7235; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1975, EXP NEUROL, V48, P152, DOI 10.1016/0014-4886(75)90230-7; OKEEFE J, 1979, PROG NEUROBIOL, V13, P419, DOI 10.1016/0301-0082(79)90005-4; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; OKeefe J, 1991, BRAIN SPACE, P273, DOI DOI 10.1016/j.neuron.2015.06.011; REDISH AD, IN PRESS SYMBOLIC VI; Rudy JW, 1995, HIPPOCAMPUS, V5, P375, DOI 10.1002/hipo.450050502; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHARP PE, 1991, PSYCHOBIOLOGY, V19, P103; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TAUBE JS, 1990, J NEUROSCI, V10, P420; ZIPSER D, 1985, BEHAV NEUROSCI, V99, P1006, DOI 10.1037/0735-7044.99.5.1006	30	734	742	3	75	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					425	428		10.1038/381425a0	http://dx.doi.org/10.1038/381425a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632799				2022-12-28	WOS:A1996UN47900052
J	Saad, TF				Saad, TF			Dysmorphic urinary erythrocytes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Saad, TF (corresponding author), UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284, USA.			Saad, Theodore/0000-0002-8066-6990					0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1996	334	22					1440	1440		10.1056/NEJM199605303342205	http://dx.doi.org/10.1056/NEJM199605303342205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM493	8618583				2022-12-28	WOS:A1996UM49300005
J	Obarzanek, E; Velletri, PA; Cutler, JA				Obarzanek, E; Velletri, PA; Cutler, JA			Dietary protein and blood pressure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RENAL FUNCTIONAL RESERVE; SPONTANEOUSLY HYPERTENSIVE RATS; NITRIC-OXIDE PATHWAY; AMINO-ACIDS; VEGETARIANS; CHOLESTEROL; DISEASE; HEMODYNAMICS; MECHANISMS; RELEASE	Objective.-To review published and presented data on the relationship between dietary protein and blood pressure in humans and animals. Data Sources.-Bibliographies from review articles and books on diet and blood pressure that had references to dietary protein. The bibliographies were supplemented with computerized MEDLINE search restricted to English language and abstracts presented at epidemiologic meetings. Study Selection.-Observational and intervention studies in humans and experimental studies in animals. Data Extraction.-In human studies, systolic or diastolic blood pressure were outcome measures, and dietary protein was measured by dietary assessment methods or by urine collections. In animal studies, blood pressure and related physiological effects were outcome measures, and experimental treatment included protein or amino acids. Data Synthesis.-Historically, dietary protein has been thought to raise blood pressure; however, studies conducted in japan raised the possibility of an inverse relationship. Data analyses from subsequent observational studies in the United States and elsewhere have provided evidence of an inverse relationship between protein and blood pressure. However, intervention studies have mostly found no significant effects of protein on blood pressure. Few animal studies have specifically examined the effects of increased dietary protein on blood pressure. Conclusions.-Because of insufficient data and limitations in previous investigations, better controlled and adequately powered human studies are needed to assess the effect of dietary protein on blood pressure. In addition, more research using animal models, in which experimental conditions are highly controlled and detailed mechanistic studies can be performed, is needed to help provide experimental support for or against the protein-blood pressure hypothesis.	NHLBI,DIV HEART & VASC DIS,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Obarzanek, E (corresponding author), NHLBI,DIV EPIDEMIOL & CLIN APPLICAT,2 ROCKLEDGE CTR,MSC 7936,6701 ROCKLEDGE DR,ROOM 8,BETHESDA,MD 20892, USA.							[Anonymous], 1989, AM J EPIDEMIOL, V129, P687; Appel Lawrence J., 1995, Annals of Epidemiology, V5, P149, DOI 10.1016/1047-2797(94)00059-3; ARNOLDA L, 1992, KIDNEY INT, V41, pS2; BEILIN LJ, 1994, AM J CLIN NUTR, V59, p1130S, DOI 10.1093/ajcn/59.5.1130S; BOSCH JP, 1983, AM J MED, V75, P943, DOI 10.1016/0002-9343(83)90873-2; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BRUSSAARD JH, 1981, AM J CLIN NUTR, V34, P2023, DOI 10.1093/ajcn/34.10.2023; CHALMERS J, 1992, J HYPERTENS, V10, pS27; CHAPMAN CB, 1950, NEW ENGL J MED, V243, P899, DOI 10.1056/NEJM195012072432301; *COMM DIET HLTH FO, 1989, DIET HLTH IMPL RED C, P259; DENICOLA L, 1992, HYPERTENSION, V19, P790, DOI 10.1161/01.HYP.19.6.790; DENICOLA L, 1991, KIDNEY INT, V40, P406, DOI 10.1038/ki.1991.226; DYER A, 1992, J HYPERTENS, V10, pS122; ELLIOTT P, 1991, CIRCULATION S2, V84, P698; ELLIOTT P, 1992, J HYPERTENS       S4, V10, pP105; Finot P A, 1992, Bibl Nutr Dieta, P83; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; HATCH FT, 1954, AM J MED, V17, P499, DOI 10.1016/0002-9343(54)90125-4; HAVLIK RJ, 1990, PREV MED, V19, P31, DOI 10.1016/0091-7435(90)90004-4; HISHIKAWA K, 1993, J HYPERTENS, V11, P639, DOI 10.1097/00004872-199306000-00008; HISHIKAWA K, 1992, JPN HEART J, V33, P41; KEMPNER W, 1948, AM J MED, V4, P545, DOI 10.1016/0002-9343(48)90441-0; KESTIN M, 1989, AM J CLIN NUTR, V50, P280, DOI 10.1093/ajcn/50.2.280; KIHARA M, 1984, HYPERTENSION, V6, P736, DOI 10.1161/01.HYP.6.5.736; KIMURA N, 1977, ATHEROSCL REV, V2, P209; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LIU K, 1993, CIRCULATION, V87, P679; LIU K, 1992, CIRCULATION, V85, P867; MEYER TW, 1985, NIH WORKSH NUTR HYP; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NAKAKI T, 1990, LANCET, V336, P696, DOI 10.1016/0140-6736(90)92196-O; *NAT HIGH BLOOD PR, 1993, WORK GROUP REP PRIM; PELLUM LK, 1983, NUTR REP INT, V227, P1277; PRESCOTT SL, 1987, CLIN EXP PHARMACOL P, V14, P159, DOI 10.1111/j.1440-1681.1987.tb00368.x; REED D, 1985, HYPERTENSION, V7, P405, DOI 10.1161/01.HYP.7.3_Pt_1.405; SACKS FM, 1988, AM J CLIN NUTR, V48, P795, DOI 10.1093/ajcn/48.3.795; SACKS FM, 1984, HYPERTENSION, V6, P193, DOI 10.1161/01.HYP.6.2_Pt_1.193; SACKS FM, 1984, HYPERTENSION, V6, P199, DOI 10.1161/01.HYP.6.2_Pt_1.199; SACKS FM, 1981, JAMA-J AM MED ASSOC, V246, P640, DOI 10.1001/jama.246.6.640; SACKS FM, 1974, AM J EPIDEMIOL, V100, P390, DOI 10.1093/oxfordjournals.aje.a112050; STAMLER J, 1992, CIRCULATION, V85, P867; SVED AF, 1982, J PHARMACOL EXP THER, V221, P329; SVED AF, 1979, P NATL ACAD SCI USA, V76, P3511, DOI 10.1073/pnas.76.7.3511; TAKEMOTO Y, 1991, JPN J PHYSIOL, V41, P717, DOI 10.2170/jjphysiol.41.717; Whelton P K, 1992, Ann Epidemiol, V2, P295, DOI 10.1016/1047-2797(92)90062-U; WOODS LL, 1986, AM J PHYSIOL, V251, pF303, DOI 10.1152/ajprenal.1986.251.2.F303; Yamori Y, 1981, Lancet, V1, P1204; YAMORI Y, 1984, HYPERTENSION, V6, P49, DOI 10.1161/01.HYP.6.1.49; Yamori Y, 1981, Adv Nephrol Necker Hosp, V10, P51; ZHOU BF, 1994, INT J EPIDEMIOL, V23, P716, DOI 10.1093/ije/23.4.716; ZHOU BF, 1989, CHINESE MED J-PEKING, V102, P257; 1992, AM J PUBLIC HEALTH, V82, P1613	52	116	121	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1598	1603		10.1001/jama.275.20.1598	http://dx.doi.org/10.1001/jama.275.20.1598			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622252				2022-12-28	WOS:A1996UL02900033
J	Gardlund, B				Gardlund, B			Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases	LANCET			English	Article							DEEP-VEIN THROMBOSIS; LOW-MOLECULAR-WEIGHT; DOUBLE-BLIND TRIAL; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; SUBCUTANEOUS HEPARIN; MEDICAL INPATIENTS; STANDARD HEPARIN; ACUTE STROKE; SURGERY	Background Fatal pulmonary embolism and other thromboembolic complications are common in hospital inpatients. However, there is little evidence on the routine use of pharmacological thromboprophylaxis in non-surgical patients. We assessed the efficacy and safety of low-dose heparin in the prevention of hospital-acquired, clinically relevant, fatal pulmonary embolism in patients with infectious diseases. Methods Our study used the postrandomisation consent older, admitted to departments of infectious diseases in six design. 19 751 consecutive patients, aged 55 years or Swedish hospitals, were screened for inclusion in the randomised, controlled, unblinded, multicentre trial. Of the eligible patients, 5776 were assigned subcutaneous standard heparin (5000 IU every 12 h) until hospital discharge or for a maximum of 3 weeks; 5917 were assigned no prophylactic treatment (control group). We sought consent only from the heparin group. Follow-up was for 3 weeks after discharge from hospital or for a maximum of 60 days from randomisation. The primary endpoint was necropsy-verified pulmonary embolism of predefined clinical relevance. Findings By intention-to-treat analysis mortality was similar in the heparin and control groups (5.3 vs 5.6%, p=0.39) and the median time from admission to death was 16 days in both groups (IQR 8-31 vs 6-28 days). Necropsy-verified pulmonary embolism occurred in 15 heparin-treated and 16 control-group patients. There was a significant difference between heparin and control groups in median time from randomisation to fatal pulmonary embolism (28 [24-36] vs 12.5 [10-20] days, p=0.007). This difference corresponds to the duration of heparin prophylaxis. Nonfatal thromboembolic complications occurred in more of the control than of the heparin group (116 vs 70, p=0.0012). Interpretation Our findings do not support the routine use of heparin prophylaxis for 3 weeks or less in large groups of non-surgical patients. Further studies are needed to investigate whether heparin prophylaxis of longer duration may prevent fatal pulmonary embolism.			Gardlund, B (corresponding author), KAROLINSKA HOSP,INFECT DIS SECT,S-17176 STOCKHOLM,SWEDEN.							ARCELUS JI, 1993, SEMIN THROMB HEMOST, V19, P142; BELCH JJ, 1981, SCOT MED J, V26, P115, DOI 10.1177/003693308102600205; CADE JF, 1982, CRIT CARE MED, V10, P448, DOI 10.1097/00003246-198207000-00006; CHONG BH, 1995, BRIT J HAEMATOL, V89, P431, DOI 10.1111/j.1365-2141.1995.tb08346.x; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COON WW, 1959, SURG GYNECOL OBSTET, V109, P487; DAHAN R, 1986, HAEMOSTASIS, V16, P159; EMERSON PA, 1977, BRIT MED J, V1, P18, DOI 10.1136/bmj.1.6052.18; Gallus A S, 1990, Baillieres Clin Haematol, V3, P651, DOI 10.1016/S0950-3536(05)80023-X; GARDLUND B, 1985, ACTA MED SCAND, V218, P417; GINSBERG JS, 1990, THROMB HAEMOSTASIS, V64, P286; GREEN D, 1994, PHARMACOL REV, V46, P89; HALKIN H, 1982, ANN INTERN MED, V96, P561, DOI 10.7326/0003-4819-96-5-561; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; HAVIG O, 1977, ACTA CHIR SCAND    S, V478, P48; HIRSH J, 1992, AUST NZ J MED, V22, P487; KAKKAR AK, 1995, INT J ONCOL, V6, P885; KAKKAR VV, 1993, LANCET, V341, P259, DOI 10.1016/0140-6736(93)92614-Y; KAKKAR VV, 1993, HAEMOSTASIS, V23, P42; LINDBLAD B, 1991, BRIT MED J, V302, P709, DOI 10.1136/bmj.302.6778.709; MCCARTHY ST, 1977, LANCET, V2, P800; MCCARTHY ST, 1986, AGE AGEING, V15, P84, DOI 10.1093/ageing/15.2.84; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; PITT A, 1980, AM HEART J, V99, P574, DOI 10.1016/0002-8703(80)90729-2; SAEGER W, 1994, PATHOL RES PRACT, V190, P394; SANDLER DA, 1989, J ROY SOC MED, V82, P203, DOI 10.1177/014107688908200407; TURPIE AGG, 1987, LANCET, V1, P523; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; WARLOW C, 1973, LANCET, V2, P934; WRAY R, 1973, NEW ENGL J MED, V288, P815, DOI 10.1056/NEJM197304192881604; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; 1986, JAMA-J AM MED ASSOC, V256, P744; 1992, BRIT MED J, V305, P567; 1992, INT ANGIOL, V11, P151	34	184	189	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1357	1361						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637340				2022-12-28	WOS:A1996UL90400008
J	Jackson, MA; Lodwick, R; Hutchinson, SG				Jackson, MA; Lodwick, R; Hutchinson, SG			Lesson of the week - Hyperkalaemic cardiac arrest successfully treated with peritoneal dialysis	BRITISH MEDICAL JOURNAL			English	Article									QUEEN ALEXANDRA HOSP,PORTSMOUTH,HANTS,ENGLAND	Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	Jackson, MA (corresponding author), NEW CROSS HOSP,DEPT GEN MED & NEPHROL,WOLVERHAMPTON WV10 0QP,W MIDLANDS,ENGLAND.							ETTINGER PO, 1974, AM J CARDIOL, V33, P876, DOI 10.1016/0002-9149(74)90635-3; GENEVER EE, 1971, BRIT J ANAESTH, V43, P984, DOI 10.1093/bja/43.10.984; LYNN JL, 1990, CRIT CARE MED, V18, P342; MATCH WE, 1982, AM J MED, V72, P536; MILLNER M, 1987, KLIN PADIATR, V199, P122, DOI 10.1055/s-2008-1026777; SMITH CL, 1983, BRIT J ANAESTH, V55, P923; TORRECILLA C, 1989, INTENS CARE MED, V15, P325, DOI 10.1007/BF00263870	7	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1289	1290		10.1136/bmj.312.7041.1289	http://dx.doi.org/10.1136/bmj.312.7041.1289			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634622	Green Published			2022-12-28	WOS:A1996UM40400030
J	Marshall, D; Johnell, O; Wedel, H				Marshall, D; Johnell, O; Wedel, H			Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures	BRITISH MEDICAL JOURNAL			English	Article							HIP FRACTURE; POSTMENOPAUSAL WOMEN; FRAGILITY FRACTURES; ELDERLY WOMEN; RISK-FACTORS; MASS; FOREARM; SITES; AGE	Objective-To determine the ability of measurements of bone density in women to predict later fractures. Design-Meta-analysis of prospective cohort studies published between 1985 and end of 1994 with a baseline measurement of bone density in women and subsequent follow up for fractures. For comparative purposes, we also reviewed case control studies of hip fractures published between 1990 and 1994. Subjects-Eleven separate study populations with about 90 000 person years of observation time and over 2000 fractures. Main outcome measures-Relative risk of fracture for a decrease in bone mineral density of one standard deviation below age adjusted mean. Results-All measuring sites had similar predictive abilities (relative risk 1.5 (95% confidence interval 1.4 to 1.6)) for decrease in bone mineral density except for measurement at spine for predicting vertebral fractures (relative risk 2.3 (1.9 to 2.8)) and measurement at hip for hip fractures (2.6 (2.0 to 3.5)). These results are in accordance with results of case-control studies. Predictive ability of decrease in bone mass was roughly similar to (or, for hip or spine measurements, better than) that of a 1 SD increase in blood pressure for stroke and better than a 1 SD increase in serum cholesterol concentration for cardiovascular disease. Conclusions-Measurements of bone mineral density can predict fracture risk but cannot identify individuals who will have a fracture. We do not recommend a programme of screening menopausal women for osteoporosis by measuring bone density.	NORD SCH PUBL HLTH,DEPT BIOSTAT & EPIDEMIOL,S-40242 GOTHENBURG,SWEDEN; SWEDISH COUNCIL TECHNOL ASSESSMENT HLTH CARE,S-10324 STOCKHOLM,SWEDEN; MALMO GEN HOSP,DEPT ORTHOPAED,S-21401 MALMO,SWEDEN				YAMAMOTO, MASAHIRO/F-9094-2011; Marshall, Deborah/J-7248-2015	YAMAMOTO, MASAHIRO/0000-0003-3859-0125; Marshall, Deborah/0000-0002-8467-8008				BLACK DM, 1992, J BONE MINER RES, V7, P633; CHENG S, 1994, OSTEOPOROSIS INT, V4, P48, DOI 10.1007/BF02352261; Chevalley T, 1991, Osteoporos Int, V1, P147, DOI 10.1007/BF01625444; CLEGHORN DB, 1991, CALCIFIED TISSUE INT, V49, P161, DOI 10.1007/BF02556110; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; CUMMINGS SR, 1985, AM J MED, V78, P487, DOI 10.1016/0002-9343(85)90343-2; GARDSELL P, 1991, CALCIFIED TISSUE INT, V49, P90, DOI 10.1007/BF02565127; GARDSELL P, 1993, CALCIFIED TISSUE INT, V52, P348, DOI 10.1007/BF00310197; GLUER CC, 1994, J BONE MINER RES, V9, pS153; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; HEANEY RP, 1977, AM J CLIN NUTR, V30, P1603, DOI 10.1093/ajcn/30.10.1603; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; KANBARA Y, 1992, Kobe Journal of Medical Sciences, V38, P21; KARLSSON MK, 1993, BONE, V14, P161, DOI 10.1016/8756-3282(93)90243-4; KELSEY JL, 1992, AM J EPIDEMIOL, V135, P477, DOI 10.1093/oxfordjournals.aje.a116314; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; LESTER GE, 1990, J ORTHOPAED RES, V8, P220, DOI 10.1002/jor.1100080210; LIBANATI CR, 1992, J CLIN ENDOCR METAB, V74, P351, DOI 10.1210/jc.74.2.351; MELTON LJ, 1993, J BONE MINER RES, V8, P1227; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; NAKAMURA N, 1992, J BONE MINER RES, V7, P755; NEVITT MC, 1994, OSTEOPOROSIS INT, V4, P325, DOI 10.1007/BF01622192; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; NORDIN BEC, 1987, MED J AUSTRALIA, V146, P300; Perloff J J, 1991, Orthop Rev, V20, P690; PITT F, 1990, COSTS BENEFITS SCREE; PORTER RW, 1990, BMJ-BRIT MED J, V301, P638, DOI 10.1136/bmj.301.6753.638; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SELMER R, 1992, AM J EPIDEMIOL, V136, P428, DOI 10.1093/oxfordjournals.aje.a116516; STEGMAN MR, 1992, OSTEOPOROSIS INT, V2, P290, DOI 10.1007/BF01623185; SUGIMOTO T, 1994, OSTEOPOROSIS INT, V4, P144, DOI 10.1007/BF01623059; *SWED COUNC TECHN, IN PRESS BON DENS ME; Thompson S G, 1993, Stat Methods Med Res, V2, P173, DOI 10.1177/096228029300200205; *U LEEDS, 1992, B EFF HLTH SERV INT, V1; *US C, 1994, OTABPH120 OFF TECHN; VOGEL J, 1994, J BONE MINER RES, V9, pS154; Wasnich R.D., 1987, CLIN ORTHOP RELAT R, V216, P262; WASNICH RD, 1989, J NUCL MED, V30, P1166; *WHO, 1994, WHO TECN SER, V843; WINDELER J, 1995, BRIT MED J, V310, P454, DOI 10.1136/bmj.310.6977.454; YANO K, 1984, AM J EPIDEMIOL, V119, P751, DOI 10.1093/oxfordjournals.aje.a113796	48	2604	2689	7	164	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1254	1259		10.1136/bmj.312.7041.1254	http://dx.doi.org/10.1136/bmj.312.7041.1254			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634613	Green Published			2022-12-28	WOS:A1996UM40400018
J	Black, N				Black, N			Why we need observational studies to evaluate the effectiveness of health care	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIALS	The view is widely held that experimental methods (randomised controlled trials) are the ''gold standard'' for evaluation and that observational methods (cohort and case control studies) have little or no value. This ignores the limitations of randomised trials, which may prove unnecessary, inappropriate, impossible, or inadequate. Many of the problems of conducting randomised trials could often, in theory, be overcome, but the practical implications for researchers and funding bodies mean that this is often not possible. The false conflict between those who advocate randomised trials in all situations and those who believe observational data provide sufficient evidence needs to be replaced with mutual recognition of the complementary roles of the two approaches. Researchers should be united in their quest for scientific rigour in evaluation, regardless of the method used.			Black, N (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH SERV RES UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; BLACK N, 1992, J PUBLIC HEALTH MED, V14, P361, DOI 10.1093/oxfordjournals.pubmed.a042773; Black N, 1990, Health Serv Manage Res, V3, P108; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; CHALMERS I, 1986, BIRTH-ISS PERINAT C, V13, P155, DOI 10.1111/j.1523-536X.1986.tb01037.x; *CLIN STAND ADV GR, 1993, ACC AV COR ART BYP G; DIXON J, 1995, BRIT MED J, V311, P727, DOI 10.1136/bmj.311.7007.727; DOLL S, 1994, ANN NY ACAD SCI, V703, P313; DOREY F, 1994, J BONE JOINT SURG BR, V76B, P1; DOWNS SH, 1996, ANN R COLL SURG ENGL, V78, P211; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; Hennekens CH, 1994, ANN NY ACAD SCI, V703, P22; HLATKY MA, 1988, J AM COLL CARDIOL, V11, P237, DOI 10.1016/0735-1097(88)90086-1; KORN EL, 1991, LANCET, V337, P149, DOI 10.1016/0140-6736(91)90809-4; Lilford RJ, 1995, J ROY SOC MED, V88, P552; MAW R, 1993, BMJ-BRIT MED J, V306, P756, DOI 10.1136/bmj.306.6880.756; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; Oxman A., 1994, COCHRANE COLLABORATI; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SOWDEN AJ, 1995, BRIT MED J, V311, P115; STAUFFER RN, 1982, J BONE JOINT SURG AM, V64, P983, DOI 10.2106/00004623-198264070-00003; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; WARD LC, 1992, BRIT J CANCER, V66, P943, DOI 10.1038/bjc.1992.390; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202; WENNBERG JE, 1994, ANN NY ACAD SCI, V703, P56; WHITE HD, 1995, LANCET, V346, P1174, DOI 10.1016/S0140-6736(95)92892-8; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; 1992, LANCET, V340, P944; 1983, LANCET, V1, P219	31	1081	1102	0	49	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1215	1218						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634569				2022-12-28	WOS:A1996UL05800026
J	Ragent, B; Colburn, DS; Avrin, P; Rages, KA				Ragent, B; Colburn, DS; Avrin, P; Rages, KA			Results of the Galileo probe nephelometer experiment	SCIENCE			English	Article								The nephelometer experiment carried on the Galileo probe was designed to measure the jovian cloud structure and its microphysical characteristics from entry down to atmospheric pressure levels greater than 10 bars. Before this mission there was no direct evidence for the existence of the clouds below the uppermost cloud layer, and only theoretical models derived from remote sensing observations were available for describing such clouds. Only one significant cloud structure with a base at about 1.55 bars was found along the probe descent trajectory below an ambient pressure of about 0.4 bar, although many indications of small densities of particle concentrations were noted during much of the descent.	AEROSP CORP,COLORADO SPRINGS,CO 80912; SPACE PHYS RES INST,SUNNYVALE,CA 94087	Aerospace Corporation - USA	Ragent, B (corresponding author), SAN JOSE STATE UNIV FDN,SAN JOSE,CA 95172, USA.							ATREYA SK, 1985, PLANETARY METEOROLOG, P17; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; GIVENS JJ, 1983, P AIAA 21 AER SCI M, P1; JOHNSON TV, 1992, SPACE SCI REV, V60, P3, DOI 10.1007/BF00216848; MAROV MY, 1980, ICARUS, V44, P608, DOI 10.1016/0019-1035(80)90131-1; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; ONEILL WJ, 1983, P AIAA 21 AER SCI M, P1; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; RAGENT B, 1992, SPACE SCI REV, V60, P179, DOI 10.1007/BF00216854; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; Sromovsky LA, 1996, SCIENCE, V272, P851, DOI 10.1126/science.272.5263.851; WEIDENSCHILLING SJ, 1973, ICARUS, V61, P311	12	35	35	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					854	856		10.1126/science.272.5263.854	http://dx.doi.org/10.1126/science.272.5263.854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629019				2022-12-28	WOS:A1996UK75700052
J	Stiell, IG; Hebert, PC; Wells, GA; Laupacis, A; Vandemheen, K; Dreyer, JF; Eisenhauer, MA; Gibson, J; Higginson, LAJ; Kirby, AS; Mahon, JL; Maloney, JP; Weitzman, BN				Stiell, IG; Hebert, PC; Wells, GA; Laupacis, A; Vandemheen, K; Dreyer, JF; Eisenhauer, MA; Gibson, J; Higginson, LAJ; Kirby, AS; Mahon, JL; Maloney, JP; Weitzman, BN			The Ontario trial of active compression-decompression cardiopulmonary resuscitation for in-hospital and prehospital cardiac arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DOSE EPINEPHRINE; CORONARY PERFUSION-PRESSURE; MYOCARDIAL BLOOD-FLOW; CPR; CHEST; AUGMENTATION; SWINE; VEST; PIGS	Objective.-To compare the impact of active compression-decompression (ACD) cardiopulmonary resuscitation (CPR) and standard CPR on the outcomes of in-hospital and prehospital victims of cardiac arrest. Design.-Randomized controlled trial with blinding of allocation using a sealed container. Settings.-(1) Emergency departments, wards, and intensive care units of 5 university hospitals and (2) all locations outside hospitals in 2 midsized cities. Patients.-A total of 1784 adults who had cardiac arrest, Intervention.-Patients received either standard or ACD CPR throughout resuscitation. Main Outcome Measures.-Survival for 1 hour and to hospital discharge and the modified Mini-Mental State Examination (MMSE). Results.-All characteristics were similar in the standard and ACD CPR groups for the 773 in-hospital patients and the 1011 prehospital patients. For in-hospital patients, there were no significant differences between the standard (n=368) and ACD (n=405) CPR groups in survival for 1 hour (35.1% vs 34.6%; P=.89), in survival until hospital discharge (11.4% vs 10.4%; P=.64), or in the median MMSE score of survivors (37 in both groups). For patients who collapsed outside the hospital, there were also no significant differences between the standard (n=510) and ACD (n=501) CPR groups in survival for 1 hour (16.5% vs 18.2%; P=.48), in survival to hospital discharge (3.7% vs 4.6%; P=.49), or in the median MMSE score of survivors (35 in both groups). Exploration of clinically important subgroups failed to identify any patients who appeared to benefit from ACD CPR. Conclusions.-ACD CPR did not improve survival or neurologic outcomes in any group of patients with cardiac arrest.	OTTAWA CIVIC HOSP,DIV EMERGENCY MED,OTTAWA,ON K1Y 4E9,CANADA; OTTAWA CIVIC HOSP,DEPT MED,OTTAWA,ON K1Y 4E9,CANADA; UNIV WESTERN ONTARIO,DIV EMERGENCY MED,LONDON,ON,CANADA; UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON,CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Western University (University of Western Ontario); Western University (University of Western Ontario)	Stiell, IG (corresponding author), OTTAWA CIVIC HOSP,CLIN EPIDEMIOL UNIT,LOEB MED RES INST,1053 CARLING AVE,OTTAWA,ON K1Y 4E9,CANADA.		Mahon, Jeff/G-3324-2011	Stiell, Ian/0000-0002-2583-6408				BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; CARLI PA, 1994, ANN EMERG MED, V24, P890, DOI 10.1016/S0196-0644(54)00211-9; CHANDRA N, 1981, AM J CARDIOL, V48, P1053, DOI 10.1016/0002-9149(81)90320-9; CHANG MW, 1993, CIRCULATION, V88, P193; CHANG MW, 1994, CHEST, V106, P1250, DOI 10.1378/chest.106.4.1250; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; COHEN TJ, 1992, AM HEART J, V124, P1145, DOI 10.1016/0002-8703(92)90393-A; COHEN TJ, 1993, NEW ENGL J MED, V329, P1918, DOI 10.1056/NEJM199312233292603; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; GULY UM, 1994, RESUSCITATION, V28, pS27; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; HALPERIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2940, DOI 10.1001/jama.267.21.2940; HALPERIN HR, 1994, CIRCULATION, V90, P5; HOSMER DW, 1989, APPL LOGISTIC REGRES; IDRIS AH, 1994, ACAD EMERG MED, V1, pA17; KERN KB, 1990, AM HEART J, V120, P324, DOI 10.1016/0002-8703(90)90076-A; KOSNIK JW, 1985, ANN EMERG MED, V14, P204, DOI 10.1016/S0196-0644(85)80440-6; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; LINDNER KH, 1993, CIRCULATION, V88, P1254, DOI 10.1161/01.CIR.88.3.1254; LURIE KG, 1994, JAMA-J AM MED ASSOC, V271, P1405, DOI 10.1001/jama.271.18.1405; LURIE KG, 1990, JAMA-J AM MED ASSOC, V264, P1661, DOI 10.1001/jama.1990.03450130031020; LURIE KG, 1994, RESUSCITATION, V28, P115, DOI 10.1016/0300-9572(94)90083-3; MALZER R, 1994, RESUSCITATION, V28, pS5; NIEMANN JT, 1992, NEW ENGL J MED, V327, P1075; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; ORLIAGUET GA, 1995, ANN EMERG MED, V25, P48, DOI 10.1016/S0196-0644(95)70354-3; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; PARADIS NA, 1991, JAMA-J AM MED ASSOC, V265, P1139, DOI 10.1001/jama.265.9.1139; PELL ACH, 1994, RESUSCITATION, V27, P137, DOI 10.1016/0300-9572(94)90006-X; RIVERS EP, 1994, ACAD EMERG MED, V1, pA19; RUDIKOFF MT, 1980, CIRCULATION, V61, P345, DOI 10.1161/01.CIR.61.2.345; SACK JB, 1992, JAMA-J AM MED ASSOC, V267, P379; SCHWAB TM, 1995, JAMA-J AM MED ASSOC, V273, P1261, DOI 10.1001/jama.273.16.1261; SHULTZ JJ, 1995, RESUSCITATION, V29, P23, DOI 10.1016/0300-9572(94)00812-T; SHULTZ JJ, 1994, CIRCULATION, V89, P684, DOI 10.1161/01.CIR.89.2.684; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; STIELL IG, 1995, ACAD EMERG MED, V2, P264, DOI 10.1111/j.1553-2712.1995.tb03220.x; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TUCKER KJ, 1993, J AM COLL CARDIOL, V22, P1485, DOI 10.1016/0735-1097(93)90561-E; TUCKER KJ, 1993, RESUSCITATION, V26, P125, DOI 10.1016/0300-9572(93)90172-M; TUCKER KJ, 1994, ANN EMERG MED, V24, P895, DOI 10.1016/S0196-0644(54)00229-6; TUCKER KJ, 1994, J AM COLL CARDIOL, V24, P201, DOI 10.1016/0735-1097(94)90564-9; TUCKER KJ, 1994, RESUSCITATION, V28, P1, DOI 10.1016/0300-9572(94)90048-5; WIK L, 1994, RESUSCITATION, V28, P55, DOI 10.1016/0300-9572(94)90055-8; Zar JH., 1999, BIOSTAT ANAL; 1991, CONTROL CLIN TRIALS, V12, P525; 1992, JAMA-J AM MED ASSOC, V268, P2171	51	95	97	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1417	1423		10.1001/jama.275.18.1417	http://dx.doi.org/10.1001/jama.275.18.1417			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618367				2022-12-28	WOS:A1996UJ30300027
J	Fell, JME; Reynolds, AP; Meadows, N; Khan, K; Long, SG; Quaghebeur, G; Taylor, WJ; Milla, PJ				Fell, JME; Reynolds, AP; Meadows, N; Khan, K; Long, SG; Quaghebeur, G; Taylor, WJ; Milla, PJ			Manganese toxicity in children receiving long-term parenteral nutrition	LANCET			English	Article							CHOLESTASIS	Background In patients receiving long-term parenteral nutrition (PN), cholestatic disease acid nervous system disorders have been associated with high blood concentrations of manganese. In such patients, the normal homoeostatic mechanisms of the liver and gut ate bypassed and the requirement for this trace element is not known; nor has it been certain whether hypermanganesaemia causes the cholestasis or vice versa. We explored the direction of effect by serial tests of liver function after withdrawal of manganese supplements from children receiving long-term PN. We also examined the relation between blood manganese concentrations and brain lesions, as indicated by clinical examination and magnetic resonance imaging (MRI). Methods From a combined group of 57 children receiving PN we identified 11 with the combination of hypermanganesaemia and cholestasis; one also had a movement disorder. Manganese supplements were reduced in the first three and withdrawn in the remainder. MRI was done in two of these children. We also looked at manganese concentrations and MRI scans in six children who had received PN for more than 2 years without developing liver disease. Findings In the hypermanganesaemia/cholestasis group, four of the 11 patients died. In the seven survivors baseline whole-blood manganese was 615-1840 nmol/L, and after 4 months it had declined by a median of 643 nmol/L (p<0 . 01). Over the same interval total bilirubin declined by a median of 70 mu mol/L (p<0 . 05). Two of these children had movement disorders, one of whom survived to have an MRI scan; this showed, with T1 weighted images, bilateral symmetrically increased signal intensity in the globus pallidus and subthalamic nuclei. Such changes were also seen in five other children-one from the hypermanganesaemia/cholestasis group and four of six in the long-term PN group without liver disease (in all of whom blood manganese was above normal). Interpretation The cholestasis complicating PN is multifactorial, but these results add to the evidence that manganese contributes. In view of the additional hazard of basal ganglia damage from high manganese levels in children receiving long-term PN, we recommend a low dose regimen of not more than 0 . 018 mu mol/kg per 24 h together with regular examination of the nervous system.	GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT GASTROENTEROL,LONDON WC1N 3JH,ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT CHEM PATHOL,LONDON WC1N 3JH,ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT NEURORADIOL,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust				Lalpour, Abdollah/0000-0002-7134-9395				AYOTTE P, 1985, BIOCHEM PHARMACOL, V34, P3857, DOI 10.1016/0006-2952(85)90435-6; BALL PA, 1994, PAEDIAT PARENTERAL N; DEVENYI AG, 1994, GASTROENTEROLOGY, V106, P1068, DOI 10.1016/0016-5085(94)90769-2; EJAMA A, 1992, LANCET, V339, P426; GRAEF JW, 1982, LEAD ABSORPTION CHIL, P153; HAMBIDGE KM, 1989, JPEN-PARENTER ENTER, V13, P168, DOI 10.1177/0148607189013002168; HUANG CC, 1989, ARCH NEUROL-CHICAGO, V46, P1104, DOI 10.1001/archneur.1989.00520460090018; KRIEGER D, 1995, LANCET, V346, P270, DOI 10.1016/S0140-6736(95)92164-8; LUSTIG S, 1982, ARCH INTERN MED, V142, P405, DOI 10.1001/archinte.142.2.405; MIROWITZ SA, 1992, RADIOLOGY, V185, P535, DOI 10.1148/radiology.185.2.1410368; MIROWITZ SA, 1991, RADIOLOGY, V181, P117, DOI 10.1148/radiology.181.1.1909445; NELSON K, 1993, BRIT J IND MED, V50, P510; PLAA GL, 1982, BIOCHEM PHARMACOL, V31, P3698, DOI 10.1016/0006-2952(82)90602-5; QUIGLEY EMM, 1993, GASTROENTEROLOGY, V104, P286, DOI 10.1016/0016-5085(93)90864-9; REYNOLDS AP, 1994, ARCH DIS CHILD, V71, P527, DOI 10.1136/adc.71.6.527; SINGH J, 1974, ENVIRON PHYSIOL BIOC, V4, P16; UNDERWOOD EJ, 1977, TRACE ELEMENTS HUMAN, P170; 1988, AM J CLIN NUTR, V48, P1324; 1979, JAMA-J AM MED ASSOC, V241, P2051	19	227	230	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1218	1221		10.1016/S0140-6736(96)90735-7	http://dx.doi.org/10.1016/S0140-6736(96)90735-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622451				2022-12-28	WOS:A1996UJ59700010
J	Bodenheimer, MM				Bodenheimer, MM			Noncardiac surgery in the cardiac patient: What is the question?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PERIOPERATIVE MYOCARDIAL-ISCHEMIA; PERIPHERAL VASCULAR-SURGERY; RISK; INFARCTION; ANESTHESIA; MORBIDITY; MEN	Before having major noncardiac surgery, patients with known or suspected coronary artery disease frequently have noninvasive cardiac testing to better define their cardiac risk. The rationale for this approach is that prophylactic coronary revascularization will significantly reduce the number of adverse cardiac events. No randomized studies support this conclusion. Furthermore, recent studies have suggested that adverse cardiac events result from postoperative stress and excess catecholamine levels, which cause an imbalance between myocardial oxygen supply and demand. Plaque rupture in this setting, if it occurs, is secondary and not primary, in contrast to its pivotal role in spontaneous myocardial infarction. Therefore, improved clinical outcomes are more likely to result from preventing excess oxygen demand after surgery rather than from deciding which tests optimally predict adverse events. The exception is the patient with a clinical syndrome consistent with existing plaque rupture who requires active therapy for the cardiac disease independent of the need for noncardiac surgery. Otherwise, the tests should be skipped acid the patient cleared.			Bodenheimer, MM (corresponding author), LONG ISL JEWISH MED CTR, HARRIS CHASANOFF HEART INST, ROONM 2135, NEW HYDE PK, NY 11042 USA.							ANDERSON TJ, 1993, MAYO CLIN PROC, V68, P713, DOI 10.1016/S0025-6196(12)60612-0; ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; CARLINER NH, 1985, AM J CARDIOL, V56, P51, DOI 10.1016/0002-9149(85)90565-X; COHEN MC, 1995, CONTROL CLIN TRIALS, V16, P89, DOI 10.1016/0197-2456(94)00068-E; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; DOMANSKI M, 1995, AM J CARDIOL, V75, P829, DOI 10.1016/S0002-9149(99)80422-6; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; FLEISHER LA, 1995, J CLIN ANESTH, V7, P97, DOI 10.1016/0952-8180(94)00030-8; GOLDMAN L, 1994, NEW ENGL J MED, V330, P707, DOI 10.1056/NEJM199403103301010; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; KEHLET H, 1991, CAN J SURG, V34, P565; LANDESBERG G, 1993, LANCET, V341, P715, DOI 10.1016/0140-6736(93)90486-Z; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANTHA S, 1994, ANESTH ANALG, V79, P422; POHOST GM, 1991, CIRCULATION, V84, P931, DOI 10.1161/01.CIR.84.2.931; RABY KE, 1992, JAMA-J AM MED ASSOC, V268, P222, DOI 10.1001/jama.268.2.222; RAO TLK, 1983, ANESTHESIOLOGY, V59, P499, DOI 10.1097/00000542-198312000-00003; TARHAN S, 1972, J AMER MED ASSOC, V220, P1451, DOI 10.1001/jama.220.11.1451; WENGER NK, 1990, AM J CARDIOL, V66, P1375, DOI 10.1016/0002-9149(90)91172-3; WONG T, 1992, ANN INTERN MED, V116, P743, DOI 10.7326/0003-4819-116-9-743	22	38	40	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					763	766		10.7326/0003-4819-124-8-199604150-00010	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633838				2022-12-28	WOS:A1996UD93600010
J	Olson, EN; Arnold, HH; Rigby, PWJ; Wold, BJ				Olson, EN; Arnold, HH; Rigby, PWJ; Wold, BJ			Know your neighbors: Three phenotypes in null mutants of the myogenic bHLH gene MRF4	CELL			English	Review							MUSCLE; MICE; DEFECTS; MYF-5; DEATH		TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,INST BIOCHEM & BIOTECHNOL,W-3300 BRAUNSCHWEIG,GERMANY; NATL INST MED RES,MRC,DIV EUKARYOT MOL GENET,LONDON NW7 1AA,ENGLAND; CALTECH,DIV BIOL 156 29,PASADENA,CA 91125	Braunschweig University of Technology; MRC National Institute for Medical Research; California Institute of Technology	Olson, EN (corresponding author), UNIV TEXAS,SW MED CTR,HAMON CTR BASIC CANC RES,DALLAS,TX 75235, USA.							BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; BRAUN T, 1994, DEVELOPMENT, V120, P3083; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; Floss T, 1996, DEV BIOL, V174, P140, DOI 10.1006/dbio.1996.0058; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HORAN GSB, 1994, P NATL ACAD SCI USA, V91, P12644, DOI 10.1073/pnas.91.26.12644; HORAN GSB, 1995, DEV BIOL, V169, P359, DOI 10.1006/dbio.1995.1150; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; KOSTIC D, 1994, MECH DEVELOP, V46, P231, DOI 10.1016/0925-4773(94)90073-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; PATAPOUTIAN A, 1993, DEVELOPMENT, V118, P61; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIJLI FM, 1994, DEV DYNAM, V201, P366, DOI 10.1002/aja.1002010408; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	20	413	429	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					1	4		10.1016/S0092-8674(00)81073-9	http://dx.doi.org/10.1016/S0092-8674(00)81073-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620528	Bronze			2022-12-28	WOS:A1996UE55900001
J	Sieweke, MH; Tekotte, H; Frampton, J; Graf, T				Sieweke, MH; Tekotte, H; Frampton, J; Graf, T			MafB is an interaction partner and repressor of Ets-1 that inhibits erythroid differentiation	CELL			English	Article							TRANSCRIPTION FACTOR NF-E2; TRANSFERRIN RECEPTOR GENE; LEUCINE ZIPPER PROTEIN; V-ETS; SACCHAROMYCES-CEREVISIAE; ERYTHROLEUKEMIC CELLS; ESCHERICHIA-COLI; TS MUTANTS; C-JUN; EXPRESSION	Using a yeast one-hybrid screen with a DNA-bound Ets-1 protein, we have identified MafB, an AP-1 like protein, as a direct interaction partner. MafB is specifically expressed in myelomonocytic cells and binds to the DNA-binding domain of Ets-1 via its basic region or leucine-zipper domain. Furthermore, it represses Ets-1 transactivation of synthetic promoters containing Ets binding sites and inhibits Ets-1-mediated transactivation of the transferrin receptor, which is known to be essential for erythroid differentiation, Accordingly, overexpression of MafB in an erythroblast cell line down-regulates the endogenous transferrin receptor gene and inhibits differentiation without affecting cell proliferation. These results highlight the importance of inhibitory interactions between transcription factors in regulating lineage-specific gene expression.			Sieweke, MH (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTRASSEL 69117, HEIDELBERG, GERMANY.		Graf, Thomas/B-4252-2015; Sieweke, Michael/AAR-7515-2020	Graf, Thomas/0000-0003-2774-4117; Sieweke, Michael/0000-0002-3228-9537; Tekotte, Hille/0000-0003-2164-7412				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAN LNL, 1989, NUCLEIC ACIDS RES, V17, P3763, DOI 10.1093/nar/17.10.3763; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GRAF T, 1978, NATURE, V275, P496, DOI 10.1038/275496a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIGGS DR, 1993, CURR BIOL, V3, P548, DOI 10.1016/0960-9822(93)90054-R; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HORTON MA, 1983, EXP CELL RES, V144, P361, DOI 10.1016/0014-4827(83)90415-9; HU HYY, 1977, SCIENCE, V197, P559, DOI 10.1126/science.267327; IACOPETTA BJ, 1982, BIOCHIM BIOPHYS ACTA, V687, P204, DOI 10.1016/0005-2736(82)90547-8; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; IOTH K, 1995, MOL CELL BIOL, V15, P4184; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KILLISCH I, 1992, J CELL SCI, V103, P211; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; METZ T, 1992, ONCOGENE, V7, P597; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NERLOV C, 1991, ONCOGENE, V6, P1583; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OMARY MB, 1980, NATURE, V286, P888, DOI 10.1038/286888a0; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; QUEVA C, 1993, ONCOGENE, V8, P2511; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMIDT JA, 1986, CELL, V46, P41, DOI 10.1016/0092-8674(86)90858-5; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1993, ONCOGENE, V8, P1783; SIEFF C, 1982, BLOOD, V60, P703; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x	79	245	252	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					49	60		10.1016/S0092-8674(00)81081-8	http://dx.doi.org/10.1016/S0092-8674(00)81081-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620536	Bronze			2022-12-28	WOS:A1996UE55900008
J	Mason, JK; Mulligan, D				Mason, JK; Mulligan, D			Euthanasia by stages	LANCET			English	Article									VOLUNTARY EUTHANASIA SOC SCOTLAND,EDINBURGH,MIDLOTHIAN,SCOTLAND		Mason, JK (corresponding author), UNIV EDINBURGH,FAC LAW,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.							ANDREWS K, 1992, BRIT MED J, V305, P486, DOI 10.1136/bmj.305.6852.486; CRANFORD RE, 1995, BRIT MED J, V311, P464, DOI 10.1136/bmj.311.7003.464; HARRIGAN P, 1995, LANCET, V346, P494, DOI 10.1016/S0140-6736(95)91332-7; *HM STAT OFF, 1994, GOV RESP REP SEL COM; HOWARD RS, 1995, BRIT MED J, V310, P341, DOI 10.1136/bmj.310.6976.341; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; WALL M, 1995, LANCET, V346, P368, DOI 10.1016/S0140-6736(95)92243-1; 1995, LANCET, V346, P259; [No title captured]	9	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					810	811		10.1016/S0140-6736(96)90875-2	http://dx.doi.org/10.1016/S0140-6736(96)90875-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622341				2022-12-28	WOS:A1996UB15300016
J	Allen, JP; Davis, RM; Genel, M; Howe, JP; Karlan, MS; Kennedy, WR; Numann, PA; Riggs, JA; Skelton, WD; Slanetz, PJ; Spillman, MA; Williams, MA; Young, DC; Allen, JR; Rinaldi, RC; Schwartzberg, JG				Allen, JP; Davis, RM; Genel, M; Howe, JP; Karlan, MS; Kennedy, WR; Numann, PA; Riggs, JA; Skelton, WD; Slanetz, PJ; Spillman, MA; Williams, MA; Young, DC; Allen, JR; Rinaldi, RC; Schwartzberg, JG			Good care of the dying patient	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ILL CANCER-PATIENTS; TERMINALLY ILL; CRITICALLY ILL; INTENSIVE-CARE; HOSPICE CARE; LIFE; PAIN; DEATH; MANAGEMENT; ATTITUDES				Allen, JP (corresponding author), AMER MED ASSOC, COUNCIL SCI AFFAIRS, GRP SCI TECHNOL & PUBL HLTH STAND, 515 N STATE ST, CHICAGO, IL 60610 USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014; Slanetz, Priscilla/0000-0003-1248-5116				ACHTE KA, 1971, OMEGA-J DEATH DYING, V2, P46; [Anonymous], 1992, J Clin Oncol, V10, P1976; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BERRY ZS, 1992, CLIN RES, V40, pA552; BREITBART W, 1990, ADV PAIN RES THER, V16, P399; Breitbart W, 1987, Oncology (Williston Park), V1, P49; BROCK DB, 1987, P AM STAT ASS SOC ST, P306; BRODY H, 1984, NEW ENGL J MED, V310, P920; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; BRUERA E, 1993, OXFORD TXB PALLIATIV, P87; BUKBERG J, 1984, PSYCHOSOM MED, V46, P199, DOI 10.1097/00006842-198405000-00002; CARTWRIGHT A, 1973, LIFE DEATH; CHIARELLO RJ, 1987, ARCH GEN PSYCHIAT, V44, P286; Coyle N, 1990, J Pain Symptom Manage, V5, P83; DESBIENS NA, IN PRESS CRIT CARE M; Doyle D., 1993, OXFORD TXB PALLIATIV; EMANUEL EJ, 1993, AM J MED, V95, P619, DOI 10.1016/0002-9343(93)90358-V; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; EXTONSMITH A, 1961, LANCET, V2, P305; FIELD MJ, 1994, SUMMARY COMMITTEE VI; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; Glaser BG, 1965, AWARENESS DYING; Gomez Carlos F., 1991, REGULATING DEATH EUT; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; HAAS JS, 1993, ARCH INTERN MED, V153, P1241, DOI 10.1001/archinte.153.10.1241; KANE RL, 1984, LANCET, V1, P890; Katz J., 1984, SILENT WORLD DOCTOR; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LOUHIVUORI KA, 1979, AM J EPIDEMIOL, V109, P59, DOI 10.1093/oxfordjournals.aje.a112659; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; LYNN J, 1991, THEOR MED, V12, P325, DOI 10.1007/BF00489892; LYNN J, 1993, NEW ENGL J MED, V328, P964; LYNN J, 1989, REV DAXS CASE ESSAYS, P63; MARTINI CJM, 1993, JAMA-J AM MED ASSOC, V270, P1053, DOI 10.1001/jama.270.9.1053; MASSIE MJ, 1990, J CLIN PSYCHIAT, V51, P12; MASSIE MJ, 1983, AM J PSYCHIAT, V140, P1048; MCCUSKER J, 1983, PUBLIC HEALTH REP, V98, P170; MCGIVNEY WT, 1984, JAMA-J AM MED ASSOC, V251, P1182; MELZACK R, 1976, CAN MED ASSOC J, V115, P125; MERRILL D, 1993, AGING HLTH, V5, P516; MOR V, 1983, J HEALTH SOC BEHAV, V24, P375, DOI 10.2307/2136403; MORRIS JN, 1986, J CHRON DIS, V39, P47, DOI 10.1016/0021-9681(86)90106-2; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; OKEN D, 1961, JAMA-J AM MED ASSOC, V175, P1120, DOI 10.1001/jama.1961.03040130004002; OSLER W, 1908, SCI IMMORTALITY, P18; PARKES CM, 1980, POSTGRAD MED J, V56, P685, DOI 10.1136/pgmj.56.660.685; PARKES CM, 1985, LANCET, V1, P155; PLUMB MM, 1977, PSYCHOSOM MED, V39, P264, DOI 10.1097/00006842-197707000-00007; POLLACK MM, 1987, NEW ENGL J MED, V316, P134, DOI 10.1056/NEJM198701153160304; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; PRITCHARD R, 1994, J GEN INTERN MED, V9, pA146; QUILL TE, 1993, NEW ENGL J MED, V328, P965; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; Roy D J, 1990, J Palliat Care, V6, P3; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; SAUNDERS CM, 1978, MANAGEMENT TERMINAL, P194; SAUNDERS CM, 1981, THERAPY PAIN, P215; SCHMITZ P, 1994, PRINCIPLES GERIATRIC, P383; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SEEMAN I, 1992, VITAL HLTH STAT, V19, P20; SILBERFARB PM, 1980, AM J PSYCHIAT, V137, P450; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SUDNOW D, 1965, PASSING ON SOCIAL OR; Sugarman J, 1993, Kennedy Inst Ethics J, V3, P387; Takeda F., 1986, PAIN CLINIC, V1, P83; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; TENO J, 1993, CLIN RES, V41, pA582; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TENO JM, 1994, J CLIN ETHIC, V5, P23; Tomlinson Tom, 1990, Bioethics, V4, P253, DOI 10.1111/j.1467-8519.1990.tb00088.x; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; Ventafridda V, 1990, J Palliat Care, V6, P7; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WILKES E, 1984, LANCET, V1, P950; 1989, PRINCIPLES ANAL USE; 1987, GUIDELINES TERMINATI; 1993, CHOOSING DEATH HLTH; 1990, WHO TECHNICAL REPORT, V809; 1995, POLICY COMPENDIUM, P292; 1993, CAMB Q HLTH ETHICS, V2, P275; [No title captured]; 1991, GUIDELINES STATE COU	93	171	171	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					474	478						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TU638	8627970				2022-12-28	WOS:A1996TU63800037
J	Joneson, T; White, MA; Wigler, MH; BarSagi, D				Joneson, T; White, MA; Wigler, MH; BarSagi, D			Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; PROTEIN	The RAS guanine nucleotide binding proteins activate multiple signaling events that regulate cell growth and differentiation. In quiescent fibroblasts, ectopic expression of activated H-RAS (H-RAS(V12), where V12 indicates valine-12) induces membrane ruffling, mitogen-activated protein (MAP) kinase activation, and stimulation of DNA synthesis. A mutant of activated H-RAS, H-RAS(V12C40) (where C40 indicates cysteine-40), was identified that was defective for MAP kinase activation and stimulation of DNA synthesis, but retained the ability to induce membrane ruffling. Another mutant of activated H-RAS, H-RAS(V12S35) (where S35 indicates serine-35), which activates MAP kinase, was defective for stimulation of membrane ruffling and induction of DNA synthesis. Expression of both mutants resulted in a stimulation of DNA synthesis that was comparable to that induced by H-RAS(V12). These results indicate that membrane ruffling and activation of MAP kinase represent distinct RAS effector pathways and that input from both pathways is required for the mitogenic activity of RAS.	SUNY STONY BROOK,DEPT MICROBIOL & MOLEC GENET,STONY BROOK,NY 11794; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cold Spring Harbor Laboratory				Wigler, Michael/0000-0003-4396-1971; Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [R37CA055360, R01CA055360] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; JONESON T, UNPUB; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THORBURN J, 1994, J BIOL CHEM, V269, P30580; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITE MG, UNPUB	18	362	363	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					810	812		10.1126/science.271.5250.810	http://dx.doi.org/10.1126/science.271.5250.810			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628998				2022-12-28	WOS:A1996TU69400047
J	Baba, TW; Trichel, AM; An, L; Liska, V; Martin, LN; MurpheyCorb, M; Ruprecht, RM				Baba, TW; Trichel, AM; An, L; Liska, V; Martin, LN; MurpheyCorb, M; Ruprecht, RM			Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL BISEXUAL MEN; RHESUS-MONKEYS; HIV SEROCONVERSION; HTLV-III; ACID-SECRETION; DISEASE STAGE; RISK-FACTORS; HUMAN SALIVA; TRANSMISSION	Unprotected receptive anal intercourse is a well-recognized risk factor for infection with human immunodeficiency virus-type 1 (HIV-1). Isolated human case reports have implicated HIV-1 transmission by oral-genital exposure. Adult macaques exposed nontraumatically to cell-free simian immunodeficiency virus (SIV) through the oral route became infected and developed acquired immunodeficiency syndrome (AIDS). The minimal virus dose needed to achieve systemic infection after oral exposure was 6000 times lower than the minimal dose required to achieve systemic infection after rectal exposure. Thus, unprotected receptive oral intercourse, even in the absence of mucosal lesions, should be added to the list of risk behaviors for HIV-1 transmission.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, LAB VIRAL PATHOGENESIS, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, DEPT PEDIAT, DIV NEWBORN MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; TULANE UNIV, TULANE REG PRIMATE RES CTR, COVINGTON, LA 70433 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School; Tulane University					NIAID NIH HHS [U01-AI24345, R01-AI34266, R01-AI32330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024345, R01AI034266, R01AI032330, R37AI024345] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN JS, 1991, J VIROL, V65, P2816, DOI 10.1128/JVI.65.6.2816-2828.1991; AMEDEE AM, 1995, J VIROL, V69, P7982, DOI 10.1128/JVI.69.12.7982-7990.1995; AMORY J, 1992, CLIN RES, V40, pA51; ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; ARCHIBALD DW, 1990, AIDS RES HUM RETROV, V6, P1425, DOI 10.1089/aid.1990.6.1425; BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BABA TW, 1993, J WOMENS HEALTH, V2, P231; BASKIN GB, 1988, VET PATHOL, V25, P456, DOI 10.1177/030098588802500609; BASKIN GB, 1986, J NATL CANCER I, V77, P127; BERGEY EJ, 1994, J ACQ IMMUN DEF SYND, V7, P995; BERTHIER A, 1986, LANCET, V2, P598; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; CONWAY MD, 1991, J MED PRIMATOL, V20, P152; COPPENHAVER DH, 1994, NEW ENGL J MED, V330, P1314, DOI 10.1056/NEJM199405053301815; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; FRANCHINI G, 1989, ANN NY ACAD SCI, V554, P81, DOI 10.1111/j.1749-6632.1989.tb22412.x; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; FRIEDLAND G, 1990, AIDS, V4, P639, DOI 10.1097/00002030-199007000-00005; FULTZ PN, 1986, J INFECT DIS, V154, P896, DOI 10.1093/infdis/154.5.896; FULTZ PN, 1986, LANCET, V2, P1215; GIBB D, 1994, AIDS S1, V8, pS275; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; HAMED KA, 1993, J INFECT DIS, V167, P798, DOI 10.1093/infdis/167.4.798; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1984, SCIENCE, V226, P451, DOI 10.1126/science.6208608; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; KINGSLEY LA, 1987, LANCET, V1, P345; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; LAIRMORE MD, 1993, AIDS RES HUM RETROV, V9, P565, DOI 10.1089/aid.1993.9.565; LANE HC, 1991, AM J PUBLIC HEALTH, V81, P658, DOI 10.2105/AJPH.81.5.658; LARSSON H, 1983, GASTROENTEROLOGY, V85, P900; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; Levy JA, 1994, HIV PATHOGENESIS AID; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; LIND T, 1983, GUT, V24, P270, DOI 10.1136/gut.24.4.270; MALAMUD D, 1993, AIDS RES HUM RETROV, V9, P633, DOI 10.1089/aid.1993.9.633; MARTHAS ML, 1992, J MED PRIMATOL, V21, P99; MARTIN LN, 1994, ANTIMICROB AGENTS CH, V38, P1277, DOI 10.1128/AAC.38.6.1277; MARTIN LN, 1993, J INFECT DIS, V168, P825, DOI 10.1093/infdis/168.4.825; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; MCTAVISH D, 1991, DRUGS, V42, P138, DOI 10.2165/00003495-199142010-00008; MILLER CJ, 1994, J VIROL, V68, P6391, DOI 10.1128/JVI.68.10.6391-6400.1994; MILLER CJ, 1990, J MED PRIMATOL, V19, P401; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; MILLER CJ, 1994, AM J REPROD IMMUNOL, V31, P52, DOI 10.1111/j.1600-0897.1994.tb00847.x; MILLER CJ, 1994, AM J REPROD IMMUNOL, V188, P107; MURRAY AB, 1991, LANCET, V338, P830, DOI 10.1016/0140-6736(91)90726-6; ONKAWA S, 1990, FASEB J, V4, pA2264; PAUZA CD, 1994, AIDS RES HUM RETROV, V10, pS7; PAUZA CD, 1993, J MED PRIMATOL, V22, P154; POURTOIS M, 1991, AIDS, V5, P598, DOI 10.1097/00002030-199105000-00022; ROGERS MF, 1990, PEDIATRICS, V85, P210; ROZENBAUM W, 1988, LANCET, V1, P1395; SPOUGE JL, 1992, P NATL ACAD SCI USA, V89, P7581, DOI 10.1073/pnas.89.16.7581; SU H, 1991, MOL IMMUNOL, V28, P811, DOI 10.1016/0161-5890(91)90044-K; VANGRIENSVEN GJP, 1987, AM J EPIDEMIOL, V125, P1048, DOI 10.1093/oxfordjournals.aje.a114620; VANVOORHIS BJ, 1991, FERTIL STERIL, V55, P588; WILLIAMSHERMANN D, 1993, INT C AIDS JUN; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607; ZHANG JY, 1988, J INFECT DIS, V158, P1277, DOI 10.1093/infdis/158.6.1277	66	130	133	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1486	1489		10.1126/science.272.5267.1486	http://dx.doi.org/10.1126/science.272.5267.1486			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633242				2022-12-28	WOS:A1996UP89900049
J	Bayer, R				Bayer, R			AIDS prevention - Sexual ethics and responsibility	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HIV; INFECTION; PARTNERS				Bayer, R (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY 10032, USA.				NIMH NIH HHS [K05 MH01376-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001376] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAYER R, 1992, AM J PUBLIC HEALTH, V82, P1158, DOI 10.2105/AJPH.82.8.1158; BAYER R, 1993, AM J PUBLIC HEALTH, V83, P1471, DOI 10.2105/AJPH.83.10.1471; CHAMBERS DL, 1994, HARVARD CIVIL RIGHTS, V29, P353; COCHRAN SD, 1990, NEW ENGL J MED, V322, P774, DOI 10.1056/NEJM199003153221111; EKSTRAND M, 1993, AIDS, V7, P281, DOI 10.1097/00002030-199302000-00020; ILLINGWORTH P, 1990, AIDS GOOD SOC; KEGELES SM, 1988, JAMA-J AM MED ASSOC, V259, P216, DOI 10.1001/jama.259.2.216; MARKS G, 1992, PUBLIC HEALTH REP, V107, P100; MARKS G, 1991, AM J PUBLIC HEALTH, V81, P1321, DOI 10.2105/AJPH.81.10.1321; MASON HRC, 1995, HEALTH PSYCHOL, V14, P6, DOI 10.1037/0278-6133.14.1.6; MASS L, 1995, NATION          0417, P540; MOHR RD, 1986, RARITAN, V6, P38; PERRY SW, 1994, AIDS EDUC PREV, V6, P403; PILKINGTON CJ, 1994, J SEX RES, V31, P203, DOI 10.1080/00224499409551753; ROTELLO G, 1995, NATION          0417, P510; SIGNORILE M, 1995, NY TIMES        0226, V4, P15; SIMONI JM, 1995, J CONSULT CLIN PSYCH, V63, P474, DOI 10.1037/0022-006X.63.3.474; SOBO EJ, 1995, CHOOSING UNSAFE SEX; WILLIG C, 1995, J COMMUNITY APPL PSY, V4, P74; YEO M, 1991, PERSPECTIVES AIDS ET, P75	20	55	57	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 6	1996	334	23					1540	1542		10.1056/NEJM199606063342312	http://dx.doi.org/10.1056/NEJM199606063342312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UN799	8618613	Green Published			2022-12-28	WOS:A1996UN79900012
J	Vega, KJ; Pina, I; Krevsky, B				Vega, KJ; Pina, I; Krevsky, B			Heart transplantation is associated with an increased risk for pancreaticobiliary disease	ANNALS OF INTERNAL MEDICINE			English	Article							GENERAL SURGICAL COMPLICATIONS; CARDIAC TRANSPLANTATION; CYCLOSPORINE THERAPY; CHOLELITHIASIS; RECIPIENTS; CHOLESTASIS; MANAGEMENT; BILE	Objective: To determine the risk factors for and the incidence, morbidity, mortality, and outcome of pancreaticobiliary disease in patients who have had orthotopic heart transplantation. Design: Retrospective case-control analysis. Setting: University hospital-based heart transplantation center. Patients: 20 case-patients with pancreaticobiliary disease and 40 controls; all patients received heart transplants between 1985 and 1994. Controls were matched to case-patients by time of transplantation and length of survival. Measurements: Charts were reviewed and data were extracted using a structured data abstraction protocol. Risk factors assessed before transplantation were cause of heart disease, history of diabetes, reproductive history, and sex. Risk factors assessed at presentation of pancreaticobiliary disease were weight change after transplantation, alcohol use, use of medications, recent total parenteral nutrition, age at symptom onset, recent rejection episode, cyclosporine level, complete blood count, time between transplantation and onset of symptoms, body mass index, calcium level, liver function test results before and at symptom onset, and lipid profile. Results: Pancreaticobiliary disease occurred in 20 of 255 transplant recipients (7.8%). The incidence of disease in these patients within 1 year after transplantation was 3.9% compared with an expected rate of 0.2% per year (P < 0.01). A decreased serum calcium level was the only risk factor found to differ significantly between the two groups (mean +/- SD, 2.19 +/- 0.17 mmol/L in case-patients and 2.31 +/- 0.14 mmol/L in controls; P = 0.005). The duration of hospitalization for the treatment of pancreaticobiliary disease was longer for patients who received transplants than for patients who did not receive transplants and were treated at Temple University Hospital during a similar period (17.1 days compared with 7.2 days; P < 0.001). However, the outcome was excellent in most patients. Conclusions: Pancreaticobiliary disease occurs 17.4 times (95% CI, 9.2 to 32.7 times) more frequently in patients receiving transplants than in the general population. It is a seldom recognized but apparently common complication of orthotopic heart transplantation that results in substantial morbidity and health care resource use. Further study is needed to ascertain why this condition occurs and how the risk for developing it can be reduced.	TEMPLE UNIV HOSP & MED SCH, GASTROENTEROL SECT, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV HOSP & MED SCH, CARDIOL SECT, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								BORTNICHAK EA, 1985, AM J EPIDEMIOL, V121, P19, DOI 10.1093/oxfordjournals.aje.a113978; BURCKART GJ, 1988, TRANSPLANT P, V20, P190; COLON R, 1988, SURGERY, V103, P32; CSENDES A, 1978, ACTA CHIR SCAND, V144, P289; DISESA VJ, 1989, ARCH SURG-CHICAGO, V124, P539; EVERHART JE, 1994, DIGESTIVE DIS US EPI, P647; GIRARDET RE, 1989, J HEART TRANSPLANT, V8, P391; IZSAK EM, 1980, GASTROENTEROLOGY, V79, P555; LORBER MI, 1987, TRANSPLANT P, V19, P1808; MERRELL SW, 1989, ARCH SURG-CHICAGO, V124, P889; PARASCANDOLA SA, 1989, J HEART TRANSPLANT, V8, P400; ROTOLO FS, 1986, AM J SURG, V151, P35, DOI 10.1016/0002-9610(86)90008-5; SAPALA MA, 1979, SURG GYNECOL OBSTET, V148, P36; SCHADE RR, 1983, TRANSPLANT P, V15, P2757; SPES CH, 1990, J HEART TRANSPLANT, V9, P404; STECK TB, 1991, J HEART LUNG TRANSPL, V10, P1029; STEED DL, 1985, SURGERY, V98, P739; STONE B, 1988, TRANSPLANT P, V20, P841; *UN NETW ORG SHAR, 1995, 1994 UN NETW ORG SHA; VOGELBERG KH, 1984, DEUT MED WOCHENSCHR, V109, P1712, DOI 10.1055/s-2008-1069440	20	16	16	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1996	124	11					980	983		10.7326/0003-4819-124-11-199606010-00005	http://dx.doi.org/10.7326/0003-4819-124-11-199606010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL905	8624065				2022-12-28	WOS:A1996UL90500005
J	Desmarais, S; deMoerloose, P; Reber, G; Minazio, P; Perrier, A; Bounameaux, H				Desmarais, S; deMoerloose, P; Reber, G; Minazio, P; Perrier, A; Bounameaux, H			Resistance to activated protein C in an unselected population of patients with pulmonary embolism	LANCET			English	Article								Background Resistance to activated protein C (APC) is the most frequent cause of inherited thrombophilia. This phenomenon has been reported in 10-50% of selected patients with venous thromboembolism, a variation that might result from different degrees of selection in different reports. Methods We measured the APC sensitivity ratio in 494 frozen blood samples from unselected consecutive outpatients suspected of pulmonary embolism and referred over a 30-month period to the emergency ward of the University Hospital of Geneva, the only public primary-tertiary care hospital in the region of Geneva (400 000 inhabitants). Findings Prevalence of resistance to APC was 55% (95% CI 2.4-10.5%) (8/146) in patients with confirmed pulmonary embolism and 4.0% (2.2-6.7%) (14/348) in patients in whom the diagnosis could be ruled out (p=0.66), giving an odds ratio of 1.36 (0.56-3.32). Interpretation The very different risks of venous thromboembolism in the presence of resistance to APC that have been reported in trials published so far are probably due to variable recruitment conditions. The lower prevalence observed in our totally unselected population of patients with pulmonary embolism may be more representative of the real risk with which clinicians will be confronted. Therefore, more data are needed from various populations of patients with venous thromboembolism to help decide which patients will benefit from screening for resistance to APC.	UNIV HOSP GENEVA, DIV ANGIOL & HAEMOSTASIS, DEPT INTERNAL MED, CH-1211 GENEVA 14, SWITZERLAND; UNIV HOSP GENEVA, MED CLIN 1, DEPT INTERNAL MED, CH-1211 GENEVA 14, SWITZERLAND	University of Geneva; University of Geneva			Perrier, Arnaud/M-2263-2014					BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4	7	86	87	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	1996	347	9012					1374	1375		10.1016/S0140-6736(96)91013-2	http://dx.doi.org/10.1016/S0140-6736(96)91013-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637344				2022-12-28	WOS:A1996UL90400012
J	Hanneman, RL				Hanneman, RL			Intersalt: Hypertension rise with age revisited	BRITISH MEDICAL JOURNAL			English	Article											Hanneman, RL (corresponding author), SALT INST,700 N FAIRFAX ST,ALEXANDRIA,VA 22314, USA.							SWALES JD, 1988, BRIT MED J, V297, P307, DOI 10.1136/bmj.297.6644.307; 1988, BRIT MED J, V297, P319	2	30	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1283	1284		10.1136/bmj.312.7041.1283	http://dx.doi.org/10.1136/bmj.312.7041.1283			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634620	Green Published			2022-12-28	WOS:A1996UM40400026
J	Harrison, PJ; Geddes, JR				Harrison, PJ; Geddes, JR			Schizophrenia and the 5-HT2A receptor gene	LANCET			English	Editorial Material											Harrison, PJ (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD,ENGLAND.			Harrison, Paul/0000-0002-6719-1126; Geddes, John/0000-0002-5281-5960				ARRANZ M, 1995, LANCET, V346, P281, DOI 10.1016/S0140-6736(95)92168-0; HALLMAYER J, 1992, ARCH GEN PSYCHIAT, V49, P216; Inayama Y, 1996, AM J MED GENET, V67, P103, DOI 10.1002/(SICI)1096-8628(19960216)67:1<103::AID-AJMG18>3.0.CO;2-S; KOHURY MJ, 1993, FUNDAMENTALS GENETIC; MELTZER HY, 1991, PHARMACOL REV, V43, P587; MORRIS AG, 1995, HUM MOL GENET, V4, P1957, DOI 10.1093/hmg/4.10.1957; ODONOVAN MC, 1995, NAT GENET, V10, P380, DOI 10.1038/ng0895-380; PELTONEN L, 1995, NATURE, V378, P665, DOI 10.1038/378665a0; Roth Bryan L., 1995, P1215; WEINBERGER DR, 1995, LANCET, V346, P552, DOI 10.1016/S0140-6736(95)91386-6	10	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1274	1274		10.1016/S0140-6736(96)90931-9	http://dx.doi.org/10.1016/S0140-6736(96)90931-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622497				2022-12-28	WOS:A1996UK75800002
J	Papadakis, MA; Grady, D; Black, D; Tierney, MJ; Gooding, GAW; Schambelan, M; Grunfeld, C				Papadakis, MA; Grady, D; Black, D; Tierney, MJ; Gooding, GAW; Schambelan, M; Grunfeld, C			Growth hormone replacement in healthy older men improves body composition but not functional ability	ANNALS OF INTERNAL MEDICINE			English	Article						body composition; insulin-like growth factor I; health status; muscle weakness; age factors	SOMATOMEDIN-C; DEFICIENT ADULTS; FACTOR-I; AGE; PERFORMANCE; METABOLISM; SECRETION; ADIPOSITY	Objective: To determine whether growth hormone replacement in older men improves functional ability. Design: Randomized, controlled, double-blind trial. Setting: General community. Patients: 52 healthy men older than 69 years of age with well-preserved functional ability but low baseline insulin-like growth factor 1 levels. Intervention: Growth hormone (0.03 mg/kg of body weight) or placebo given three times a week for 6 months. Measurements: Body composition, knee and hand grip muscle strength, systemic endurance, and cognitive function. Results: The participants' mean age was 75.0 years (range, 70 to 85 years). At 6 months, lean mass had increased on average by 4.3% in the growth hormone group and had decreased by 0.1 % in the placebo group, a difference of 4.4 percentage points (95% CI, 2.1 to 6.8 percentage points). Fat mass decreased by an average of 13.1% in the growth hormone group and by 0.3% in the placebo group, a difference of 12.8 percentage points (CI, 8.6 to 17.0 percentage points). No statistically or clinically significant differences were seen between the groups in knee or hand grip strength or in systemic endurance. The mean Trails B score in the growth hormone group improved by 8.5 seconds, whereas scores in the placebo group deteriorated by 5.0 seconds, a difference of 13.5 seconds (CI, 3.1 seconds to 23.9 seconds; P = 0.01) However, the growth hormone group's score on the Mini-Mental Status Examination deteriorated by 0.4, whereas the placebo group's score improved by 0.2, a difference of 0.6 (P = 0.11). The two treatment groups had almost identical scores on the Digit Symbol Substitution Test (P > 0.2). Twenty-six men in the growth hormone group had 48 incidents of side effects, and 26 placebo recipients had 14 incidents of side effects (P = 0.002). Dose reduction was required in 26% of the growth hormone recipients and in none of the placebo recipients (P < 0.001). Conclusions: Physiologic doses of growth hormone given for 6 months to healthy older men with well-preserved functional abilities increased lean tissue mass and decreased fat mass. Although body composition improved with growth hormone use, functional ability did not improve. Side effects occurred frequently.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Papadakis, MA (corresponding author), VET ADM MED CTR, 4150 CLEMENT ST 111A1, SAN FRANCISCO, CA 94121 USA.				NCRR NIH HHS [M01RR00083] Funding Source: Medline; NIDDK NIH HHS [DK45833, DK40990] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045833, R01DK040990] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK JC, 1960, METABOLISM, V9, P699; BERGENSTAL DM, 1960, J CLIN ENDOCR METAB, V20, P1427, DOI 10.1210/jcem-20-11-1427; CHATELAIN PG, 1983, J CLIN ENDOCR METAB, V56, P376, DOI 10.1210/jcem-56-2-376; CLEMMONS DR, 1984, CLIN ENDOCRINOL META, V13, P113, DOI 10.1016/S0300-595X(84)80011-0; COPELAND KC, 1990, METABOLISM, V39, P584, DOI 10.1016/0026-0495(90)90022-5; CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; DRAPER NR, 1966, APPLIED REGRESSION A; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FLAIM KE, 1978, AM J PHYSIOL, V234, pE38, DOI 10.1152/ajpendo.1978.234.1.E38; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRISANCHO AR, 1984, AM J CLIN NUTR, V40, P808, DOI 10.1093/ajcn/40.4.808; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; HOLLOWAY L, 1994, J CLIN ENDOCR METAB, V79, P470, DOI 10.1210/jc.79.2.470; JORGENSEN JOL, 1989, LANCET, V1, P1221; JORGENSEN JOL, 1994, EUR J ENDOCRINOL, V130, P224, DOI 10.1530/eje.0.1300224; MULLIGAN K, 1993, J CLIN ENDOCR METAB, V77, P956, DOI 10.1210/jc.77.4.956; NOVAK LP, 1972, J GERONTOL, V27, P438, DOI 10.1093/geronj/27.4.438; ORY MG, 1993, J AM GERIATR SOC, V41, P283, DOI 10.1111/j.1532-5415.1993.tb06707.x; PAPADAKIS MA, 1995, J AM GERIATR SOC, V43, P1350, DOI 10.1111/j.1532-5415.1995.tb06613.x; POEHLMAN ET, 1990, J CLIN ENDOCR METAB, V71, P1468, DOI 10.1210/jcem-71-6-1468; PYKA G, 1994, J GERONTOL, V49, pM22, DOI 10.1093/geronj/49.1.M22; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; REUBEN DB, 1990, J AM GERIATR SOC, V38, P1105, DOI 10.1111/j.1532-5415.1990.tb01373.x; RUDMAN D, 1981, J CLIN INVEST, V67, P1361, DOI 10.1172/JCI110164; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; RUDMAN D, 1985, J AM GERIATR SOC, V33, P800, DOI 10.1111/j.1532-5415.1985.tb04195.x; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SALTHOUSE TA, 1992, J GERONTOL, V47, pP121, DOI 10.1093/geronj/47.3.P121; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; TAAFFE DR, 1994, J CLIN ENDOCR METAB, V79, P1361, DOI 10.1210/jc.79.5.1361; THOMPSON JL, 1995, J CLIN ENDOCR METAB, V80, P1845, DOI 10.1210/jc.80.6.1845; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; Vandervoort AA, 1986, PHYSIOTHER CAN, V38, P167; VERMEULEN A, 1987, J CLIN ENDOCR METAB, V64, P884, DOI 10.1210/jcem-64-5-884; WOLFSON L, 1984, BIOL BEHAVIORAL ASPE, P17; ZIEGLER TR, 1991, CLIN ENDOCRINOL, V34, P281, DOI 10.1111/j.1365-2265.1991.tb03767.x	38	340	365	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					708	+		10.7326/0003-4819-124-8-199604150-00002	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UD936	8633830				2022-12-28	WOS:A1996UD93600002
J	Thea, DM; Porat, R; Nagimbi, K; Baangi, M; StLouis, ME; Kaplan, G; Dinarello, CA; Keusch, GT				Thea, DM; Porat, R; Nagimbi, K; Baangi, M; StLouis, ME; Kaplan, G; Dinarello, CA; Keusch, GT			Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1	ANNALS OF INTERNAL MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; HUMAN MONONUCLEAR-CELLS; IMMUNODEFICIENCY-VIRUS TYPE-1; FACTOR-ALPHA; SOLUBLE RECEPTORS; HIV-1-INFECTED PATIENTS; BLOOD MONOCYTES; TNF-ALPHA; IL-1	Objectives: To examine the relation of circulating cytokines and cytokine antagonists to the progression of human immunodeficiency virus type 1 (HIV-1) disease. Design: Cross-sectional analysis. Setting: An ambulatory acquired immunodeficiency syndrome (AIDS) research clinic in Kinshasa, Zaire. Patients: 48 women with AIDS, 51 women with HIV infection who were clinically asymptomatic, and 11 female controls who did not have HIV infection, all from Zaire. Measurements: Plasma levels of interleukin-1 beta, tumor necrosis factor-alpha (TNF-alpha), interleukin-6, interleukin-8, interferon-gamma, interleukin-1 beta receptor antagonist (interleukin-1Ra), and TNF soluble receptor p55 (TNFsRp55) were assayed by specific radioimmunoassays. Plasma levels of interferon-gamma were assayed by commercial enzyme-linked immunosorbent assay. The Wilcoxon rank-sum test was used to assess the significance of mean and median differences between groups. Results: Of the 48 patients with AIDS, circulating interleukin-1 beta was detected in 2, TNF-alpha in 4, interleukin-6 in 3, and interleukin-8 in 12. None of these factors were seen in any of the 11 controls. Median values of interleukin-lp (320 pg/ml), TNF-alpha (210 pg/mL), and interleukin-8 (750 pg/mL) were elevated in HIV-infected asymptomatic patients compared with patients with AIDS (2-, 2.6-, and 18.7-fold higher, respectively; P < 0.001). Interleukin-1Ra and TNFsRp55 levels were substantially higher than interleukin-1 beta and TNF-alpha levels in HIV-infected asymptomatic patients (73- and 14-fold, respectively) and were higher than those in patients with AIDS (17.8- and 1.74-fold, respectively). Conclusion: High circulating levels of the proinflammatory cytokines interleukin-1 beta and TNF-alpha, combined with an excess of their natural inhibitors interleukin-1Ra and TNFsRp55, were seen in clinically asymptomatic HIV-1-positive African women but not in African women with AIDS or in HIV-negative controls. Circulating cytokine antagonists may play a clinical role in modulating cytokine-associated symptoms in the early phases of HIV infection.	TUFTS UNIV NEW ENGLAND MED CTR, DIV GEOGRAPH MED & INFECT DIS, BOSTON, MA 02111 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA 30333 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; MINIST HLTH, AIDS RES UNIT, KINSHASA, DEM REP CONGO	Tufts Medical Center; Centers for Disease Control & Prevention - USA; Rockefeller University				/0000-0001-5724-2965; Thea, Donald/0000-0002-6933-1030	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024755, R01AI024755, R37AI015614, P01AI026698, R01AI015614] Funding Source: NIH RePORTER; NIAID NIH HHS [P01-AI-26698, AI-24755, AI-15614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; BARGETZI MJ, 1993, CANCER RES, V53, P4010; BREEN EC, 1990, J IMMUNOL, V144, P480; CANNON JG, 1992, CRIT CARE MED, V20, P1414, DOI 10.1097/00003246-199210000-00009; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; DINARELLO CA, 1991, BLOOD, V77, P1627; FERRETTI M, 1994, J CLIN INVEST, V94, P449, DOI 10.1172/JCI117345; GIRARDIN E, 1992, IMMUNOLOGY, V76, P20; GODFRIED MH, 1994, J INFECT DIS, V169, P739, DOI 10.1093/infdis/169.4.739; GODFRIED MH, 1993, AIDS, V7, P33, DOI 10.1097/00002030-199301000-00005; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; GRANOWITZ EV, 1992, BLOOD, V79, P2356; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; KAUFFMAN CA, 1986, AM J CLIN NUTR, V44, P449, DOI 10.1093/ajcn/44.4.449; KIKUTA H, 1990, J INFECT DIS, V162, P35, DOI 10.1093/infdis/162.1.35; LISI PJ, 1987, LYMPHOKINE RES, V6, P229; LOWRY SF, 1993, ARCH SURG-CHICAGO, V128, P1235; MILLER LC, 1993, LANCET, V341, P146, DOI 10.1016/0140-6736(93)90006-3; MOLINA JM, 1990, J INFECT DIS, V161, P888, DOI 10.1093/infdis/161.5.888; OKAMOTO T, 1989, AIDS RES HUM RETROV, V5, P131, DOI 10.1089/aid.1989.5.131; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POLI G, 1994, P NATL ACAD SCI USA, V91, P108, DOI 10.1073/pnas.91.1.108; PORAT R, 1992, FASEB J, V6, P2482, DOI 10.1096/fasebj.6.7.1532945; POUTSIAKA DD, 1991, BLOOD, V78, P1275; RAMBALDI A, 1991, BLOOD, V78, P3248; RAUTONEN J, 1991, AIDS, V5, P1319, DOI 10.1097/00002030-199111000-00006; REKA S, 1994, LYMPHOKINE CYTOK RES, V13, P391; ROUXLOMBARD P, 1989, CLIN IMMUNOL IMMUNOP, V50, P374, DOI 10.1016/0090-1229(89)90144-X; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCHINDLER R, 1990, BLOOD, V75, P40; SCOTTALGARA D, 1991, AIDS RES HUM RETROV, V7, P381, DOI 10.1089/aid.1991.7.381; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SHAPIRO L, 1993, J INFECT DIS, V167, P1344, DOI 10.1093/infdis/167.6.1344; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; SUTTMANN U, 1994, CLIN SCI, V86, P461; VANDERMEER JWM, 1988, J LEUKOCYTE BIOL, V43, P216, DOI 10.1002/jlb.43.3.216; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VONSYDOW M, 1991, AIDS RES HUM RETROV, V7, P375, DOI 10.1089/aid.1991.7.375; 1989, MMWR MORB MORT WK S7, V38, P1	40	72	74	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					757	762		10.7326/0003-4819-124-8-199604150-00009	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633837				2022-12-28	WOS:A1996UD93600009
J	McNamara, JM; Houston, AI				McNamara, JM; Houston, AI			State-dependent life histories	NATURE			English	Review							CLUTCH SIZE; REPRODUCTIVE EFFORT; PHENOTYPIC PLASTICITY; REACTION NORMS; GREAT TIT; AGE; EVOLUTION; NUMBER; STRATEGIES; SELECTION	Life-history theory is concerned with strategic decisions over an organism's lifetime. Evidence is accumulating about the way in which these decisions depend on the organism's physiological state and other components such as external circumstances. Phenotypic plasticity may be interpreted as an organism's response to its state. The quality of offspring may depend on the state and behaviour of the mother. Recent theoretical advances allow these and other state-dependent effects to be modelled within the same framework.	UNIV BRISTOL, SCH BIOL SCI, BRISTOL BS8 1UG, AVON, ENGLAND	University of Bristol	McNamara, JM (corresponding author), UNIV BRISTOL, SCH MATH, UNIV WALK, BRISTOL BS8 1TW, AVON, ENGLAND.							Altmann J., 1988, P403; BERRIGAN D, 1994, J EVOLUTION BIOL, V7, P549, DOI 10.1046/j.1420-9101.1994.7050549.x; BLARER A, 1995, P R SOC LOND B, V262, P303; BOYCE MS, 1987, ECOLOGY, V68, P142, DOI 10.2307/1938814; BRAULT S, 1993, ECOLOGY, V74, P1444, DOI 10.2307/1940073; Caswell H, 1989, MATRIX POPULATION MO; CHANDRA RK, 1975, SCIENCE, V190, P289, DOI 10.1126/science.1179211; CHARLESWORTH B, 1976, AM NAT, V110, P449, DOI 10.1086/283079; Charlesworth B., 1994, EVOLUTION AGE STRUCT, DOI [10.1017/CBO9780511525711, DOI 10.1017/CBO9780511525711]; Clutton-Brock T.H., 1988, P325; CLUTTONBROCK TH, 1984, AM NAT, V123, P212, DOI 10.1086/284198; CLUTTONBROCK TH, 1985, J ANIM ECOL, V54, P831, DOI 10.2307/4381; CLUTTONBROCK TH, 1982, RED DEER BEHAVIOR EC; COCHRAN ME, 1992, ECOL MONOGR, V62, P345, DOI 10.2307/2937115; DAAN S, 1990, BEHAVIOUR, V114, P83, DOI 10.1163/156853990X00068; ELLNER S, 1986, J THEOR BIOL, V123, P173, DOI 10.1016/S0022-5193(86)80151-5; Fisher, 1958, GENETICAL THEORY NAT; FRANK LG, 1986, ANIM BEHAV, V34, P1510, DOI 10.1016/S0003-3472(86)80221-4; GREEN WCH, 1991, OECOLOGIA, V86, P521, DOI 10.1007/BF00318318; GUSTAFSSON L, 1994, PHILOS T R SOC B, V346, P323, DOI 10.1098/rstb.1994.0149; HARCOURT AH, 1989, TRENDS ECOL EVOL, V4, P101, DOI 10.1016/0169-5347(89)90055-4; HEINSOHN RG, 1991, AM NAT, V137, P864, DOI 10.1086/285198; HOLEKAMP KE, 1993, ANIM BEHAV, V46, P451, DOI 10.1006/anbe.1993.1214; HOUSTON A, 1988, NATURE, V332, P29, DOI 10.1038/332029a0; HOUSTON AI, 1992, EVOL ECOL, V6, P243, DOI 10.1007/BF02214164; HOUSTON DC, 1995, IBIS, V137, P322, DOI 10.1111/j.1474-919X.1995.tb08028.x; KAWECKI TJ, 1993, EVOL ECOL, V7, P155, DOI 10.1007/BF01239386; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; LANDE R, 1990, GENET RES, V55, P189, DOI 10.1017/S0016672300025520; LEFKOVITCH LP, 1965, BIOMETRICS, V21, P1, DOI 10.2307/2528348; LEIMAR O, IN PRESS BEHAV ECOL; LLOYD DG, 1987, AM NAT, V129, P800, DOI 10.1086/284676; Lumey L H, 1992, Paediatr Perinat Epidemiol, V6, P240, DOI 10.1111/j.1365-3016.1992.tb00764.x; LUNN NJ, 1993, J ZOOL, V229, P55, DOI 10.1111/j.1469-7998.1993.tb02620.x; MANGEL M, 1994, BEHAV ECOL, V5, P412, DOI 10.1093/beheco/5.4.412; Marrow P, 1996, PHILOS T R SOC B, V351, P17, DOI 10.1098/rstb.1996.0002; MCNAMARA JM, 1993, J THEOR BIOL, V161, P23, DOI 10.1006/jtbi.1993.1037; MCNAMARA JM, 1992, EVOL ECOL, V6, P170, DOI 10.1007/BF02270710; MCNAMARA JM, 1991, THEOR POPUL BIOL, V40, P230, DOI 10.1016/0040-5809(91)90054-J; MCNAMARA JM, 1995, EVOL ECOL, V9, P185, DOI 10.1007/BF01237756; MCNAMARA JM, 1993, ACTA BIOTHEOR, V41, P165, DOI 10.1007/BF00712164; MCNAMARA JM, IN PRESS THEOR POP B; MECH LD, 1991, J MAMMAL, V72, P146, DOI 10.2307/1381989; METZ JAJ, 1992, TRENDS ECOL EVOL, V7, P198, DOI 10.1016/0169-5347(92)90073-K; MOLLER AP, 1993, J ANIM ECOL, V62, P309, DOI 10.2307/5362; MOUSSEAU TA, 1991, ANNU REV ENTOMOL, V36, P511, DOI 10.1146/annurev.en.36.010191.002455; NORRIS K, 1994, J ANIM ECOL, V63, P601, DOI 10.2307/5226; PARTRIDGE L, 1988, SCIENCE, V241, P1449, DOI 10.1126/science.241.4872.1449; PARTRIDGE L, 1993, NATURE, V362, P305, DOI 10.1038/362305a0; PERRIN N, 1993, EVOL ECOL, V7, P576, DOI 10.1007/BF01237822; PERRINS CM, 1965, J ANIM ECOL, V34, P601, DOI 10.2307/2453; PERRINS CM, 1975, J ANIM ECOL, V44, P695, DOI 10.2307/3712; PETTIFOR RA, 1988, NATURE, V336, P160, DOI 10.1038/336160a0; PETTIFOR RA, 1993, J ANIM ECOL, V62, P131, DOI 10.2307/5488; PIANKA ER, 1975, AM NAT, V109, P453, DOI 10.1086/283013; PRICE K, 1993, BEHAV ECOL, V4, P144, DOI 10.1093/beheco/4.2.144; PRINCE PA, 1981, CONDOR, V83, P238, DOI 10.2307/1367315; REITER J, 1991, BEHAV ECOL SOCIOBIOL, V28, P153, DOI 10.1007/BF00172166; REZNICK DN, 1990, J EVOLUTION BIOL, V3, P185, DOI 10.1046/j.1420-9101.1990.3030185.x; RISCH TS, 1995, ECOLOGY, V76, P1643, DOI 10.2307/1938165; ROACH DA, 1987, ANNU REV ECOL SYST, V18, P209, DOI 10.1146/annurev.ecolsys.18.1.209; Roff Derek A., 1992; SAETHER BE, 1993, J ANIM ECOL, V62, P482, DOI 10.2307/5197; SILK JB, 1983, AM NAT, V121, P56, DOI 10.1086/284039; SMITH CC, 1974, AM NAT, V108, P499, DOI 10.1086/282929; Steams S. C., 1992, EVOLUTION LIFE HIST; STEARNS SC, 1986, EVOLUTION, V40, P893, DOI 10.1111/j.1558-5646.1986.tb00560.x; TANNER JE, 1994, ECOLOGY, V75, P2204, DOI 10.2307/1940877; TRIVERS RL, 1973, SCIENCE, V179, P90, DOI 10.1126/science.179.4068.90; VAN NOORDWIJK AJ, 1986, AM NAT, V128, P137, DOI 10.1086/284547; WEIMERSKIRCH H, 1992, OIKOS, V64, P464, DOI 10.2307/3545162; WITTER MS, 1993, PHILOS T R SOC B, V340, P73, DOI 10.1098/rstb.1993.0050; ZAMENHOF S, 1971, SCIENCE, V172, P850, DOI 10.1126/science.172.3985.850	73	603	606	1	205	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	1996	380	6571					215	221		10.1038/380215a0	http://dx.doi.org/10.1038/380215a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637568				2022-12-28	WOS:A1996UB11700042
J	Brenman, JE; Chao, DS; Gee, SH; McGee, AW; Craven, SE; Santillano, DR; Wu, ZQ; Huang, F; Xia, HH; Peters, MF; Froehner, SC; Bredt, DS				Brenman, JE; Chao, DS; Gee, SH; McGee, AW; Craven, SE; Santillano, DR; Wu, ZQ; Huang, F; Xia, HH; Peters, MF; Froehner, SC; Bredt, DS			Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha 1-syntrophin mediated by PDZ domains	CELL			English	Article							L-ARGININE; DYSTROPHIN; TISSUE; SYSTEM; BRAIN; CELLS	Neuronal nitric oxide synthase (nNOS) is concentrated at synaptic junctions in brain and motor endplates in skeletal muscle. Here, we show that the N-terminus of nNOS, which contains a PDZ protein motif, interacts with similar motifs in postsynaptic density-95 protein (PSD-95) and a related novel protein, PSD-93. nNOS and PSD-95 are coexpressed in numerous neuronal populations, and a PSD-95/nNOS complex occurs in cerebellum. PDZ domain interactions also mediate binding of nNOS to skeletal muscle syntrophin, a dystrophin-associated protein. nNOS isoforms lacking a PDZ domain, identified in nNOS(Delta/Delta) mutant mice, do not associate with PSD-95 in brain or with skeletal muscle sarcolemma. Interaction of PDZ-containing domains therefore mediates synaptic association of nNOS and may play a more general role in formation of macromolecular signaling complexes.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599	University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill	Brenman, JE (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.							ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; AOKI C, 1993, BRAIN RES, V620, P97, DOI 10.1016/0006-8993(93)90275-R; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HALL AV, 1994, J BIOL CHEM, V269, P33082; HECKER M, 1994, J NEUROCHEM, V62, P1524; HIBBS JB, 1987, J IMMUNOL, V138, P550; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; KIM E, 1995, IN PRESS NATURE; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHMIDT HHHW, 1992, J HISTOCHEM CYTOCHEM, V40, P1439, DOI 10.1177/40.10.1382087; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242; YANG B, 1994, J BIOL CHEM, V269, P6040	37	1393	1455	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					757	767		10.1016/S0092-8674(00)81053-3	http://dx.doi.org/10.1016/S0092-8674(00)81053-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625413	Bronze			2022-12-28	WOS:A1996TZ99000013
J	Ehlers, MD; Zhang, S; Bernhardt, JP; Huganir, RL				Ehlers, MD; Zhang, S; Bernhardt, JP; Huganir, RL			Inactivation of NMDA receptors by direct interaction of calmodulin with the NR1 subunit	CELL			English	Article							RAT HIPPOCAMPAL-NEURONS; SPINAL-CORD NEURONS; PROTEIN-KINASE-C; GLUTAMATE RECEPTORS; CALCIUM; CHANNELS; RESPONSES; CLONING; ACID	NMDA (N-methyl-D-aspartate) receptors are excitatory neurotransmitter receptors in the brain critical for synaptic plasticity and neuronal development. These receptors are Ca2+-permeable glutamate-gated ion channels whose physiological properties are regulated by intracellular Ca2+. We report here the purification of a 20 kDa protein identified as calmodulin that interacts with the NR1 subunit of the NMDA receptor. Calmodulin binding to the NR1 subunit is Ca2+ dependent and occurs with homomeric NR1 complexes, heteromeric NR1/NR2 subunit complexes, and NMDA receptors from brain. Furthermore, calmodulin binding to NR1 causes a 4-fold reduction in NMDA channel open probability. These results demonstrate that NMDA receptor function can be regulated by direct binding of calmodulin to the NR1 subunit, and suggest a possible mechanism for activity-dependent feedback inhibition and Ca2+-dependent inactivation of NMDA receptors.			Ehlers, MD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BAER MF, 1995, NEURON, V15, P1; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KATSUWADA T, 1992, NATURE, V358, P36; KINCAID RL, 1982, J BIOL CHEM, V267, P10638; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MEDINA I, 1995, J PHYSIOL-LONDON, V482, P567, DOI 10.1113/jphysiol.1995.sp020540; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; VYKLICKY L, 1993, J PHYSIOL-LONDON, V470, P575, DOI 10.1113/jphysiol.1993.sp019876; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; ZORUMSKI CF, 1989, CELL MOL NEUROBIOL, V9, P95, DOI 10.1007/BF00711446	41	462	479	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					745	755		10.1016/S0092-8674(00)81052-1	http://dx.doi.org/10.1016/S0092-8674(00)81052-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625412	hybrid			2022-12-28	WOS:A1996TZ99000012
J	Symons, M; Derry, JMJ; Karlak, B; Jiang, S; Lemahieu, V; McCormick, F; Francke, U; Abo, A				Symons, M; Derry, JMJ; Karlak, B; Jiang, S; Lemahieu, V; McCormick, F; Francke, U; Abo, A			Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; T-CELLS; GROWTH; LYMPHOCYTES; GENE; NCK; SH2	The Rho family of GTPases control diverse biological processes, including cell morphology and mitogenesis. We have identified WASP, the protein that is defective in Wiskott-Aldrich syndrome (WAS), as a novel effector for CDC42Hs, but not for the other Rho family members, Pac and Rho. This interaction is dependent on the presence of the G protein-binding domain. Cellular expression of epitope-tagged WASP produces clusters of WASP that are highly enriched in polymerized actin. This clustering is not observed with a C-terminally deleted WASP and is inhibited by coexpression with dominant negative CDC42Hs-N17, but not with dominant negative forms of Rac or Rho. Thus, WASP provides a novel link between CDC42Hs and the actin cytoskeleton, which suggests a molecular mechanism for many of the cellular abnormalities in WAS. The WASP sequence contains two novel domains that are homologous to other proteins involved in actin organization.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University	Symons, M (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.							Ammann AJ, 1989, IMMUNOLOGIC DISORDER, P257; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DERRY JMJ, 1995, GENOMICS, V29, P471, DOI 10.1006/geno.1995.9979; DERRY JMJ, 1995, HUM MOL GENET, V4, P1127, DOI 10.1093/hmg/4.7.1127; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DONNELLY SFH, 1993, MOL MICROBIOL, V10, P585, DOI 10.1111/j.1365-2958.1993.tb00930.x; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KENNEY D, 1986, BLOOD, V68, P1329; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOLLURI R, 1995, HUM MOL GENET, V4, P1119, DOI 10.1093/hmg/4.7.1119; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARTIN GA, 1995, EMBO J, V14, P4385, DOI 10.1002/j.1460-2075.1995.tb00113.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; MULLEN CA, 1993, BLOOD, V82, P2961; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OCHS HD, 1980, BLOOD, V55, P243; PARSEY MV, 1993, J IMMUNOL, V151, P1881; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; POLLARD TD, 1995, CURR BIOL, V5, P837, DOI 10.1016/S0960-9822(95)00167-9; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; STEPHEN F, 1990, J MOL BIOL, V215, P403, DOI DOI 10.1006/JMBI.1990.9999; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; WENGLER GS, 1995, BLOOD, V86, P3684; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHU QL, 1995, BLOOD, V86, P3797, DOI 10.1182/blood.V86.10.3797.bloodjournal86103797	55	738	741	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					723	734		10.1016/S0092-8674(00)81050-8	http://dx.doi.org/10.1016/S0092-8674(00)81050-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625410	Bronze			2022-12-28	WOS:A1996TZ99000010
J	Mallonee, S; Istre, GR; Rosenberg, M; ReddishDouglas, M; Jordan, F; Silverstein, P; Tunell, W				Mallonee, S; Istre, GR; Rosenberg, M; ReddishDouglas, M; Jordan, F; Silverstein, P; Tunell, W			Surveillance and prevention of residential-fire injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POPULATION	Background The majority of severe and fatal burn injuries result from residential fires. We studied the effectiveness of a smoke-alarm-giveaway program in the prevention of burn injuries in an area with a high rate of such injuries. Methods We collected data on burn injuries in Oklahoma City from September 1987 through April 1990. The target area for the intervention was an area of 24 square miles (62 km(2)) with the highest rate of injuries related to residential fires in the city. We distributed smoke alarms door to door in the target area and then surveyed alarm use and function in a sample of the homes that had received an alarm. We also calculated the rates of fire injury per 100,000 population and per 100 fires for both the target area and the rest of the city before and after the smoke-alarm giveaway. Results Before the intervention the rate of burn injuries per 100,000 population was 4.2 times higher in the target area than in the rest of Oklahoma City. An initial survey indicated that 11,881 of the 34,945 homes in the target area (34 percent) did not have smoke alarms. A total of 10,100 smoke alarms were distributed to 9291 homes; 45 percent were functioning four years later. The annualized fire-injury rates declined by 80 percent in the target area during the four years after the intervention (from 15.3 to 3.1 per 100,000 population), as compared with a small increase in the rest of the city (from 3.6 to 3.9 per 100,000 population). There was also a 74 percent de dine in the target area in the injury rate per 100 fires (from 5.0 to 1.3; rate ratio, 0.3; 95 percent confidence interval, 0.1 to 0.6), as compared with a small in crease in the rest of the city. Conclusions A targeted intervention involving a smoke-alarm-giveaway program can reduce the incidence of injuries from residential fires. (C)1996, Massachusetts Medical Society.	OKLAHOMA DEPT HLTH,EPIDEMIOL SERV,OKLAHOMA CITY,OK 73117; CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341; OFF CHIEF MED EXAMINER,OKLAHOMA CITY,OK; BAPTIST MED CTR OKLAHOMA,OKLAHOMA CITY,OK; CHILDRENS HOSP OKLAHOMA,OKLAHOMA CITY,OK	Centers for Disease Control & Prevention - USA	Mallonee, S (corresponding author), OKLAHOMA DEPT HLTH,INJURY PREVENT SERV 0307,1000 NE 10TH,OKLAHOMA CITY,OK 73117, USA.				PHS HHS [R49/CCR603696] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], COST INJURY US; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BALLARD JE, 1992, PUBLIC HEALTH REP, V107, P402; BARILLO DJ, 1986, AM SURGEON, V52, P641; BIRKY MM, 1979, FIRE MATER, V3, P211, DOI 10.1002/fam.810030406; Dean A. G., 1990, EPI INFO VERSION 5 W; HALL JR, 1983, FIRE SERV TODAY, V50, P18; HEMENWAY D, 1990, Q J ECON, V105, P1063, DOI 10.2307/2937886; ISTRE GR, 1992, PUBLIC HEALTH SURVEILLANCE, P42; JAMES KE, 1973, BIOMETRICS, V29, P121, DOI 10.2307/2529681; JERNIGAN W, 1987, FIRE J, V81, P57; Karter M J Jr, 1994, NFPA J, V88, P57; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LEVINE MS, 1977, AM J PUBLIC HEALTH, V67, P1077, DOI 10.2105/AJPH.67.11.1077; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MIERLEY MC, 1983, JAMA-J AM MED ASSOC, V249, P1466, DOI 10.1001/jama.249.11.1466; *NAT FIR PROT AG, 1990, 901 NFPA FIR FACTS; PATETTA MJ, 1990, AM J PUBLIC HEALTH, V80, P1116, DOI 10.2105/AJPH.80.9.1116; ROSSOMANDO C, 1995, COMMUNITY BASED FIRE; Rothman K, 1986, MODERN EPIDEMIOLOGY; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; Thacker SB, 1996, FIELD EPIDEMIOLOGY, P16; *US FIR ADM, 1990, FIR US 1983 1987; *US FIR ADM FED EM, 1980, EV RES SMOK DET PERF; 1987, JAMA-J AM MED ASSOC, V257, P1618; 1985, MMWR-MORBID MORTAL W, V34, P623; 1987, MMWR-MORBID MORTAL W, V36, P644	27	132	135	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					27	31		10.1056/NEJM199607043350106	http://dx.doi.org/10.1056/NEJM199607043350106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UU479	8637539				2022-12-28	WOS:A1996UU47900006
J	Chemello, L; Cavalletto, L; Casarin, C; Bonetti, P; Bernardinello, E; Pontisso, P; Donada, C; Belussi, F; Martinelli, S; Alberti, A				Chemello, L; Cavalletto, L; Casarin, C; Bonetti, P; Bernardinello, E; Pontisso, P; Donada, C; Belussi, F; Martinelli, S; Alberti, A			Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED TRIAL; THERAPY; ALFA; RNA	Objective: To define long-term outcome in patients with chronic hepatitis C who remain viremic after sustained biochemical response to interferon-alpha therapy. Design: Prospective evaluation of an outpatient cohort. Setting: University hospital. Patients: 107 patients with chronic hepatitis C who maintained normal aminotransferase levels as long as 12 months after interferon-alpha therapy. Patients were followed prospectively for an additional 6 to 36 months. Measurements: Aminotransferase levels were monitored at 3-month intervals. Serum hepatitis C virus (HCV) RNA was tested by polymerase chain reaction before therapy, at the end of therapy, and 12 months after therapy. The HCV genotype was defined by spot hybridization using serum specimens obtained before treatment, Results: Hepatitis C virus RNA was detected in 27 (25%) patients with sustained biochemical response; 80 (75%) patients were negative for HCV RNA. Patients positive for HCV RNA were older (P < 0.001), had received a smaller interferon-a dose (P = 0.02), and were more frequently infected with HCV genotype 2 (P < 0.01). Liver histologic findings were active in 57% of patients positive for HCV RNA, despite normal alanine aminotransferase levels, compared with only 12% of patients who were negative for HCV RNA (P = 0.01). The estimated probability of hepatitis relapse by 4 years after therapy was 53% in viremic patients and 0% in patients negative for HCV RNA (P < 0.001). Conclusion: Patients with chronic hepatitis C should be tested for serum HCV RNA 1 year after a sustained biochemical response to interferon-alpha therapy to determine whether the response is complete and permanent.	UNIV PADUA, MED CLIN 2, I-35100 PADUA, ITALY; OSPED CIVILE, DIV MED 3, I-33170 PORDENONE, ITALY; OSPED LE GRAZIE, DIV MALATTIE INFETT, I-30124 VENICE, ITALY; OSPED CIVILE CITTADELLA, DIV MED, I-35013 CITTADELLA, PD, ITALY	University of Padua; ULSS 6 Euganea; Ospedale di Cittadella			chemello, liliana/AAU-9414-2020; PONTISSO, PATRIZIA/K-3574-2018	PONTISSO, PATRIZIA/0000-0003-2077-9202; ALBERTI, ALFREDO/0000-0001-9926-2382				Casarin C., 1994, Journal of Hepatology, V21, pS62; CHEMELLO L, 1995, J VIRAL HEPATITIS, V2, P91, DOI 10.1111/j.1365-2893.1995.tb00012.x; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; KASAHARA A, 1995, HEPATOLOGY, V21, P291, DOI 10.1016/0270-9139(95)90083-7; LAU JYN, 1993, LANCET, V342, P1208, DOI 10.1016/0140-6736(93)92187-X; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; TISMINETZKY SG, 1994, INT HEPATOL COMMUN, V2, P105, DOI 10.1016/0928-4346(94)90020-5	12	107	108	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1058	1060		10.7326/0003-4819-124-12-199606150-00005	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633819				2022-12-28	WOS:A1996UQ65800005
J	Ash, P; Kellermann, AL; FuquaWhitley, D; Johnson, A				Ash, P; Kellermann, AL; FuquaWhitley, D; Johnson, A			Gun acquisition and use by juvenile offenders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VIOLENCE; YOUTH	Objective.-To learn how, when, where, and why juvenile offenders acquire guns. Design.-Following acquisition of informed consent, we conducted semistructured interviews between June and November 1995 with a convenience sample of 63 juvenile offenders aged 13 through 18 years, each of whom was incarcerated at a detention center in metropolitan Atlanta, Ga. Setting.-Five detention centers in metropolitan Atlanta. Main Outcome Measures.-Frequency of handgun acquisition and use, age at and method of first handgun acquisition, feelings experienced when carrying guns, development of gun-carrying behavior, drug use, and gang membership. Results.-The mean age of respondents was 15.7 years. Forty-one male and 12 female respondents had owned a gun, Eighty-four percent of gun carriers acquired their first gun before the age of 15 years; more than half received their first gun passively, without any specific plan to do so. Adolescents who purposefully obtained their first handgun were more likely to become frequent or constant carriers. Forty percent felt safer and 40% said they felt more energized, excited, or powerful while carrying a gun, However, 34% reported increased anxiety about getting caught. Almost all stated that guns are readily available from a wide range of sources. Conclusion.-Knowledge of the developmental patterns of gun carrying by delinquent adolescents could be useful in formulating effective strategies to reduce firearm violence.	EMORY UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,PSYCHIAT & LAW SERV,ATLANTA,GA 30322	Emory University	Ash, P (corresponding author), EMORY UNIV,ROLLINS SCH PUBL HLTH,EMORY CTR INJURY CONTROL,1518 CLIFTON RD NE,ATLANTA,GA 30322, USA.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; American Psychological Association, 1993, VIOL YOUTH PSYCH RES, V1; Anderson, 1994, ATLANTIC MONTHLY MAY, V273, P80; Blumstein A, 1995, J CRIM LAW CRIM, V86, P10, DOI 10.2307/1143998; CALLAHAN CM, 1993, J ADOLESCENT HEALTH, V14, P350, DOI 10.1016/S1054-139X(08)80006-7; Cook PJ, 1995, J CRIM LAW CRIM, V86, P59, DOI 10.2307/1144000; FINGERHUT LA, 1993, ADV DATA VITAL HLTH, V231; GREENFIELD LA, 1995, NCJ155284 US DEP JUS; HECHINGER F, 1992, CARNEGIE Q, V37, P2; HUIZINGA D, 1986, J QUANTITATIVE CRIMI, V0002; KENNEDY DM, 1994, AM PROSPECT      SUM, P74; *NAT I MENT HLTH, 1992, DIAGN INT SCHED CHIL; PIACENTINI J, 1993, J AM ACAD CHILD PSY, V32, P658, DOI 10.1097/00004583-199305000-00025; RAND MR, 1994, NCJ147003 US DEP JUS; REISS AJ, 1993, UNDERSTANDING CONTRO; Rich JA, 1996, J GEN INTERN MED, V11, P77, DOI 10.1007/BF02599582; SCHUBINER H, 1993, J ADOLESCENT HEALTH, V14, P214, DOI 10.1016/1054-139X(93)90008-D; SHELEY JF, 1992, AM J DIS CHILD, V146, P677, DOI 10.1001/archpedi.1992.02160180035012; SHELEY JF, 1993, NCJ145326 US DEP JUS; WEBSTER DW, 1993, HEALTH AFFAIR, V12, P126, DOI 10.1377/hlthaff.12.4.126; WILSON JJ, 1994, COMPREHENSIVE STRATE; 1991, MMWR MROB MORTAL WKL, V40, P681; 1995, MMWR-MORBID MORTAL W, V44, P1	23	76	77	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1754	1758		10.1001/jama.275.22.1754	http://dx.doi.org/10.1001/jama.275.22.1754			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP307	8637174				2022-12-28	WOS:A1996UP30700030
J	Frobert, O; FunchJensen, P; Bagger, JP				Frobert, O; FunchJensen, P; Bagger, JP			Diagnostic value of esophageal studies in patients with angina-like chest pain and normal coronary angiograms	ANNALS OF INTERNAL MEDICINE			English	Article						chest pain; esophageal motility disorders; gastroesophageal reflux; hydrogen-ion concentration; electrocardiography	SYNDROME-X; MICROVASCULAR ANGINA; ACID PERFUSION; FOLLOW-UP; VASODILATOR RESERVE; MYOCARDIAL-ISCHEMIA; ARTERY DISEASE; PH; MOTILITY; PECTORIS	Objective: To study 1) variations in esophageal motility and pH values and 2) electrocardiographic ST-segment changes in patients with angina-like chest pain but normal coronary angiograms. Design: Cross-sectional study. Setting: Tertiary cardiologic referral center. Patients: 63 consecutive patients referred to the study center over a 3-year period and 22 healthy controls. Patients were grouped according to the results of exercise electrocardiography: normal response to exercise (n = 28) and ischemic response to exercise (n = 35). Measurements: 1) 24-hour three-channel esophageal manometry and two-channel pH monitoring, 2) provocation testing with intravenous edrophonium chloride and esophageal acid perfusion, and 3) Holter electrocardiography conducted during the first two tests. In conventional time-weighted analyses, values during periods of pain and the 2 minutes before pain developed were compared with baseline values. Results: Regardless of the outcome of exercise testing, no differences were seen in 24-hour esophageal variables between patients and controls. Forty-six patients had a total of 248 spontaneous episodes of chest pain. Only minor differences were seen between baseline and the prepain and pain periods. Edrophonium chloride provocation and acid perfusion caused chest pain in 9 patients (14%) and 10 patients (16%), respectively. Esophageal monitoring variables did not differ between patients with a positive response to one or both provocation tests (n = 16 [25%]) and controls and did not change between baseline and the prepain or pain periods. Forty-eight ST-segment depressions were recorded on Hotter monitoring in 16 patients (25%), but these depressions were associated with one prepain period and four pain periods. No ST-segment changes were seen during esophageal provocation testing. Conclusions: The rationale for routine esophageal investigations in this patient group is questionable.	AARHUS UNIV, AARHUS, DENMARK; UNIV COPENHAGEN, COPENHAGEN, DENMARK	Aarhus University; University of Copenhagen				Frobert, Ole/0000-0002-5846-345X				AKSGLAEDE K, 1992, GASTROINTEST RADIOL, V17, P1, DOI 10.1007/BF01888495; ANDERSON KO, 1989, DIGEST DIS SCI, V34, P83, DOI 10.1007/BF01536159; ANDREWS PLR, 1986, PROG BRAIN RES, V67, P65; BAGGER JP, 1990, PHARMACOL TOXICOL, V66, P6; BERNERSEN B, 1990, GUT, V31, P989, DOI 10.1136/gut.31.9.989; BERNSTEIN LM, 1958, GASTROENTEROLOGY, V34, P760; BRAND DL, 1977, AM J DIG DIS, V22, P300, DOI 10.1007/BF01072186; Bremner Ross M., 1993, Biomedical Instrumentation and Technology, V27, P49; BREUMELHOF R, 1990, GASTROENTEROLOGY, V99, P1257, DOI 10.1016/0016-5085(90)91147-X; CAMICI PG, 1992, CIRCULATION, V86, P179, DOI 10.1161/01.CIR.86.1.179; CAMICI PG, 1991, J AM COLL CARDIOL, V17, P1461, DOI 10.1016/0735-1097(91)90632-J; CANNON RO, 1990, J AM COLL CARDIOL, V16, P1359, DOI 10.1016/0735-1097(90)90377-2; CANNON RO, 1990, AM J MED, V88, P217, DOI 10.1016/0002-9343(90)90145-4; CANNON RO, 1985, CIRCULATION, V71, P218, DOI 10.1161/01.CIR.71.2.218; CANNON RO, 1988, AM J CARDIOL, V62, P306, DOI 10.1016/0002-9149(88)90229-9; CANNON RO, 1988, AM J CARDIOL, V61, P1338, DOI 10.1016/0002-9149(88)91180-0; CASTELL DO, 1990, GASTROENTEROLOGY, V98, P1103, DOI 10.1016/0016-5085(90)90055-6; CHAUHAN A, 1993, LANCET, V341, P1309, DOI 10.1016/0140-6736(93)90817-Z; CHAUHAN A, 1994, J AM COLL CARDIOL, V24, P329, DOI 10.1016/0735-1097(94)90284-4; CLOUSE RE, 1987, GASTROENTEROLOGY, V92, P1027, DOI 10.1016/0016-5085(87)90979-6; COHEN S, 1989, DIGEST DIS SCI, V34, P1649, DOI 10.1007/BF01540038; DAVIES HA, 1985, LANCET, V1, P1011; DECAESTECKER JS, 1988, GUT, V29, P1029, DOI 10.1136/gut.29.8.1029; DECAESTECKER JS, 1985, LANCET, V2, P1143; DEMEESTER TR, 1982, ANN SURG, V196, P488, DOI 10.1097/00000658-198210000-00013; DUCROTTE P, 1984, DIGEST DIS SCI, V29, P305, DOI 10.1007/BF01318514; EMDE C, 1991, GASTROENTEROLOGY, V100, P1630, DOI 10.1016/0016-5085(91)90662-5; FROBERT O, 1995, ENDOSCOPY, V27, P365, DOI 10.1055/s-2007-1005715; FROBERT O, 1996, IN PRESS BR HEART J; GHILLEBERT G, 1990, GUT, V31, P738, DOI 10.1136/gut.31.7.738; HEWSON EG, 1990, DIGEST DIS SCI, V35, P302, DOI 10.1007/BF01537406; HEWSON EG, 1989, GUT, V30, P305, DOI 10.1136/gut.30.3.305; HICK DG, 1992, GUT, V33, P79, DOI 10.1136/gut.33.1.79; HOWARD PJ, 1991, GUT, V32, P128, DOI 10.1136/gut.32.2.128; JANSSENS J, 1986, GASTROENTEROLOGY, V90, P1978, DOI 10.1016/0016-5085(86)90270-2; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; KATZ PO, 1987, ANN INTERN MED, V106, P593, DOI 10.7326/0003-4819-106-4-593; KEMP HG, 1986, J AM COLL CARDIOL, V7, P479, DOI 10.1016/S0735-1097(86)80456-9; KRUSEANDERSEN S, 1991, GUT, V32, P1270, DOI 10.1136/gut.32.11.1270; LAM HGT, 1994, DIGEST DIS SCI, V39, P402, DOI 10.1007/BF02090215; LAM HGT, 1992, GASTROENTEROLOGY, V102, P453, DOI 10.1016/0016-5085(92)90090-L; LIMBURG AJ, 1990, SCAND J GASTROENTERO, V25, P793, DOI 10.3109/00365529008999217; LONDON RL, 1981, GASTROENTEROLOGY, V81, P10; MASERI A, 1991, J AM COLL CARDIOL, V17, P499, DOI 10.1016/S0735-1097(10)80122-6; MELLOW MH, 1983, GASTROENTEROLOGY, V85, P306; MESHKINPOUR H, 1982, DIGEST DIS SCI, V27, P772, DOI 10.1007/BF01391368; NEVENS F, 1991, DIGEST DIS SCI, V36, P229, DOI 10.1007/BF01300762; OPHERK D, 1981, CIRCULATION, V63, P817, DOI 10.1161/01.CIR.63.4.817; OPHERK D, 1989, CIRCULATION, V80, P1610, DOI 10.1161/01.CIR.80.6.1610; PETERS L, 1988, GASTROENTEROLOGY, V94, P878, DOI 10.1016/0016-5085(88)90542-2; POOLEWILSON PA, 1989, INT J MICROCIRC, V8, P423; PROUDFIT WL, 1980, CIRCULATION, V62, P712, DOI 10.1161/01.CIR.62.4.712; RASMUSSEN K, 1984, EUR HEART J, V5, P354, DOI 10.1093/oxfordjournals.eurheartj.a061668; RICHTER JE, 1987, GASTROENTEROLOGY, V93, P21, DOI 10.1016/0016-5085(87)90308-8; RICHTER JE, 1989, GUT, V30, P1040, DOI 10.1136/gut.30.8.1040; RICHTER JE, 1985, ANN INTERN MED, V103, P14, DOI 10.7326/0003-4819-103-1-14; RICHTER JE, 1991, BAILLI RES CLIN GAST, P281; ROSEN SD, 1994, CIRCULATION, V90, P50, DOI 10.1161/01.CIR.90.1.50; SAX FL, 1987, NEW ENGL J MED, V317, P1366, DOI 10.1056/NEJM198711263172202; SCHOFIELD PM, 1987, BRIT HEART J, V58, P218; SCHOFIELD PM, 1989, DIGESTION, V42, P70, DOI 10.1159/000199828; SINGH S, 1992, AM J GASTROENTEROL, V87, P967; SMOUT AJPM, 1992, AM J MED, V92, pS74, DOI 10.1016/0002-9343(92)80060-D; SOFFER EE, 1989, DIGEST DIS SCI, V34, P1651, DOI 10.1007/BF01540039; TIBBLING L, 1976, ACTA MED SCAND, V200, P391; VANTRAPPEN G, 1993, GUT, V34, P1013, DOI 10.1136/gut.34.8.1013; WARD BW, 1987, AM J GASTROENTEROL, V82, P215; WIENER GJ, 1988, AM J GASTROENTEROL, V83, P358	68	40	42	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1996	124	11					959	+		10.7326/0003-4819-124-11-199606010-00003	http://dx.doi.org/10.7326/0003-4819-124-11-199606010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL905	8624063				2022-12-28	WOS:A1996UL90500003
J	Hurny, C; Bernhard, J; Coates, AS; CastiglioneGertsch, M; Peterson, HF; Gelber, RD; Forbes, JF; Rudenstam, CM; Simoncini, E; Crivellari, D; Goldhirsch, A; Senn, HJ				Hurny, C; Bernhard, J; Coates, AS; CastiglioneGertsch, M; Peterson, HF; Gelber, RD; Forbes, JF; Rudenstam, CM; Simoncini, E; Crivellari, D; Goldhirsch, A; Senn, HJ			Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer	LANCET			English	Article							OF-LIFE; RECEIVING END; CHEMOTHERAPY; TRIAL; ADJUSTMENT	Background Adjuvant therapy for early breast cancer is effective but may be toxic. Our aim was to investigate the impact of the presence, timing, and duration of adjuvant chemotherapy on patients' perceptions of their quality of life (QL). Methods International Breast Cancer Study Group trial VI assessed adjuvant chemotherapy in 1475 premenopausal and perimenopausal patients, and trial VII assessed adjuvant tamoxifen or chemoendocrine therapy in 1212 postmenopausal patients with node-positive breast cancer. Patients were asked to complete a QL questionnaire-single-item linear analogue self-assessment scales measured physical wellbeing, mood, appetite, and perceived adjustment/coping. QL was assessed in this way at the beginning of treatment, 2 months after the start of treatment, every 3 months, and at 1 and 6 months after recurrence. Findings Baseline QL scores decreased as the number of involved axillary nodes increased (for example, mean mood score: 66.1 for women with one positive node, 66.4 for two to four positive nodes, 61.3 for five to nine positive nodes, and 59.1 for ten or more positive nodes; p=0.008 for trends), and were lower in patients with oestrogen-receptor-negative than in patients with oestrogen-receptor-positive tumours (61.4 vs 66.3, p=0.0009). AII treatment groups showed substantial improvement in QL scores during adjuvant therapy. Patterns of QL scores reflected presence, duration, and timing of cytotoxic treatment. Longer initial cytotoxic therapy delayed improvement in QL scores. Later cytotoxic therapy had transient adverse effects. Anticipation of future therapy also affected QL scores. Interpretation Overall, chemotherapy had a measurable adverse effect on QL, but this effect was transient and minor compared with patients' adaptation/coping after diagnosis and surgery. This finding should encourage patients and doctors to choose appropriate adjuvant therapy with less concern for initial toxicity.	ROYAL PRINCE ALFRED HOSP, DEPT MED ONCOL, CAMPERDOWN, NSW 2050, AUSTRALIA; UNIV BERN, INSELSPITAL, MED DIV LORY, CH-3010 BERN, SWITZERLAND; IBCSG, COORDINATING CTR, BERN, SWITZERLAND; HARVARD UNIV, SCH PUBL HLTH,DANA FARBER CANC INST, IBCSG STAT CTR,DIV BIOSTAT & EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; MATER MISERICORDIAE HOSP, HUNTER ONCOL CTR, WARATAH, NSW, AUSTRALIA; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT SURG, S-41345 GOTHENBURG, SWEDEN; SPEDALE CIVILLI, SERV ONCOL, FDN BERETTA, BRESCIA, ITALY; CTR RIFERIMENTO ONCOL, I-33081 AVIANO, ITALY; OSPED CIVICO, SERV ONCOL, LUGANO, SWITZERLAND; KANTONSSPITAL, ST GALLEN, SWITZERLAND	University of Sydney; University of Bern; University Hospital of Bern; Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Sahlgrenska University Hospital; University of Gothenburg; Hospital Spedali Civili Brescia; IRCCS Aviano (CRO); Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen								ABE O, 1992, LANCET, V339, P71; [Anonymous], 1995, LANCET, V346, P1; [Anonymous], 1992, Lancet, V339, P1; BERAL V, 1995, LANCET, V345, P1642, DOI 10.1016/S0140-6736(95)90151-5; BERNHARD J, 1996, QUALITY LIFE PHARMAC, P693; BUTOW P, 1991, ANN ONCOL, V2, P597, DOI 10.1093/oxfordjournals.annonc.a058027; COATES A, 1990, ANN ONCOL, V1, P213, DOI 10.1093/oxfordjournals.annonc.a057724; COATES A, 1993, EUR J CANCER, V29A, P1731, DOI 10.1016/0959-8049(93)90115-V; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; COATES A, 1992, J CLIN ONCOL, V10, P1833, DOI 10.1200/JCO.1992.10.12.1833; COATES A, 1983, EUR J CANCER CLIN ON, V19, P1633, DOI 10.1016/0277-5379(83)90096-2; DONOVAN K, 1989, J CLIN ONCOL, V7, P959, DOI 10.1200/JCO.1989.7.7.959; FAIRCLOUGH DL, 1996, QUALITY LIFE PHARMAC, P427; FETTING JH, 1988, J CLIN ONCOL, V6, P1795, DOI 10.1200/JCO.1988.6.12.1795; FRASER SCA, 1993, BRIT J CANCER, V67, P402, DOI 10.1038/bjc.1993.74; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GOLDHIRSCH A, 1989, J CLIN ONCOL, V7, P36, DOI 10.1200/JCO.1989.7.1.36; Horny C, 1996, MED CARE, V34, P234; HURNY C, 1992, ANN ONCOL, V3, P825; HURNY C, 1992, EUR J CANCER, V28A, P118, DOI 10.1016/0959-8049(92)90399-M; HURNY C, 1993, SUPPORT CARE CANCER, V1, P200, DOI 10.1007/BF00366447; HURNY C, 1994, ANN ONCOL, V5, P65; IRVINE D, 1991, CANCER, V67, P1097, DOI 10.1002/1097-0142(19910215)67:4<1097::AID-CNCR2820670438>3.0.CO;2-Z; MOR V, 1994, MONOGR NATL CANC I, V16, P191; PRIESTMAN T, 1977, BRIT MED J, V1, P1248, DOI 10.1136/bmj.1.6071.1248; PRIESTMAN TJ, 1976, LANCET, V1, P899; RAZAVI D, 1990, LANCET, V335, P931, DOI 10.1016/0140-6736(90)90996-I; ROBERTS CS, 1994, CANCER, V74, P336, DOI 10.1002/cncr.2820741319; TANNOCK IF, 1988, J CLIN ONCOL, V6, P1377, DOI 10.1200/JCO.1988.6.9.1377; VANKNIPPENBERG FCE, 1988, J CLIN EPIDEMIOL, V41, P1043, DOI 10.1016/0895-4356(88)90073-X; ZERSSEN D, 1986, ASSESSMENT DEPRESSIO, P270; 1996, IN PRESS J CLIN ONCO	32	147	147	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	1996	347	9011					1279	1284						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622502				2022-12-28	WOS:A1996UK75800007
J	Murch, SH; Winyard, PJD; Koletzko, S; Wehner, B; Cheema, HA; Risdon, RA; Phillips, AD; Meadows, N; Klein, NJ; WalkerSmith, JA				Murch, SH; Winyard, PJD; Koletzko, S; Wehner, B; Cheema, HA; Risdon, RA; Phillips, AD; Meadows, N; Klein, NJ; WalkerSmith, JA			Congenital enterocyte heparan sulphate deficiency with massive albumin loss, secretory diarrhoea, and malnutrition	LANCET			English	Article							CELLS; GLYCOSAMINOGLYCANS; SURFACE	Background The molecular basis of protein-losing enteropathy is unknown. However it has been shown that sulphated glycosaminoglycans may be important in regulating vascular and renal albumin loss. Methods We describe three baby boys who presented within the first weeks of life with massive enteric protein loss, secretory diarrhoea, and intolerance of enteral feeds. All required total parenteral nutrition and repeated albumin infusions. No cause could be found in any case despite extensive investigations, including small intestinal biopsy sampling, which were repeatedly normal. Findings By specific histochemistry, we detected gross abnormality in the distribution of small intestinal glycosaminoglycans in all three infants, with complete absence of enterocyte heparan sulphate. The distribution of vascular and lamina propria glycosaminoglycans was, however, normal. Interpretation The presentation of these infants suggests that enterocyte heparan sulphate is important in normal small intestinal function.	QUEEN ELIZABETH HOSP CHILDREN,LONDON,ENGLAND; UNIV MUNICH,KINDERPOLIKLIN,MUNICH,GERMANY; KING SAUD UNIV HOSP,DEPT PEDIAT,ABHA,SAUDI ARABIA; HOSP SICK CHILDREN,DEPT HISTOPATHOL,LONDON WC1N 3JH,ENGLAND; INST CHILD HLTH,MOLEC IMMUNOL UNIT,LONDON,ENGLAND	University of London; University College London; University of Munich; King Saud University; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Murch, SH (corresponding author), UNIV LONDON,ROYAL FREE HOSP,DEPT PAEDIAT GASTROENTEROL,LONDON NW3 2QG,ENGLAND.		Phillips, Alan D/C-8700-2009	Klein, Nigel/0000-0003-3925-9258				Alberts B., 1994, MOL BIOL CELL, VVolume 19, P949; CURRAN PF, 1960, J GEN PHYSIOL, V43, P1137, DOI 10.1085/jgp.43.6.1137; Gupta B L, 1989, Symp Soc Exp Biol, V43, P81; GUPTA BL, 1978, NATURE, V272, P70, DOI 10.1038/272070a0; HENNEKAM RCM, 1989, AM J MED GENET, V34, P593, DOI 10.1002/ajmg.1320340429; KLEIN NJ, 1992, J CELL SCI, V102, P821; KLEIN NJ, 1993, HISTOCHEM J, V25, P291, DOI 10.1007/BF00159120; MURCH SH, 1993, LANCET, V341, P711, DOI 10.1016/0140-6736(93)90485-Y; MURCH SH, 1995, J GASTROEN HEPATOL, V10, P210, DOI 10.1111/j.1440-1746.1995.tb01081.x; SAHAGUN G, 1990, AM J PHYSIOL, V259, pH162, DOI 10.1152/ajpheart.1990.259.1.H162; SUNERGREN KP, 1987, J APPL PHYSIOL, V63, P1987; VERNIER RL, 1983, NEW ENGL J MED, V309, P1001, DOI 10.1056/NEJM198310273091701	12	89	92	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1299	1301		10.1016/S0140-6736(96)90941-1	http://dx.doi.org/10.1016/S0140-6736(96)90941-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622507				2022-12-28	WOS:A1996UK75800012
J	Feldman, M				Feldman, M			Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-THERAPY; ANTAGONISTS; LIQUID	Objective.-To compare an over-the-counter histamine(2)-receptor antagonist with an antacid as gastric acid reducers, Design.-Randomized, double-blind, placebo-controlled crossover trial. Setting.-Gastric secretory research laboratory in a Veterans Affairs medical center. Participants.-Eighteen healthy volunteers (10 men and 8 women) aged 25 to 62 years with normal gastric acid secretion rates. Interventions.-The subjects received the histamine(2)-receptor antagonist famotidine (Pepcid AC, 10 mg), calcium carbonate antacid tablets (Tums, 1000 mg), or placebo medications 1 hour after a test meal. Two identical meals were taken 2.5 and 6.0 hours after the medication was given. Main Outcome Measures.-Intragastric pH was maintained at 4.0 by in vivo intragastric titration with 0.3N sodium bicarbonate for 10 hours (1 hour before and 9 hours after medication). Reduction in sodium bicarbonate titrant use in the 2 treatment groups compared with titrant use with placebo was reflective of acid secretion inhibited by famotidine or acid neutralized by calcium carbonate tablets. Results.-When evaluated in increments of 30 minutes, calcium carbonate had a rapid onset of action, neutralizing 6.7 mmol of acid in the first 30 minutes, However, its duration of effect was only 60 minutes. Famotidine had a delayed onset of action compared with antacid, beginning after 90 minutes. However, famotidine had a duration of effect of at least 540 minutes. At its peak effect, 210 minutes after administration, famotidine reduced acid secretion by 7.3 mmol per 30 minutes. Conclusions.-Recommended over-the-counter doses of famotidine and calcium carbonate tablets have different pharmacokinetic profiles when taken in the postprandial period. The antacid has a rapid onset and short duration of action, while the histamine(2)-receptor antagonist has a delayed onset and a prolonged duration. Their peak potencies are similar.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Feldman, M (corresponding author), VET AFFAIRS MED CTR,MED SERV,111,4500 S LANCASTER RD,DALLAS,TX 75216, USA.							BARNETT CC, 1985, DIGEST DIS SCI, V30, P1049, DOI 10.1007/BF01315602; BARZAGHI N, 1989, J CLIN PHARMACOL, V29, P670, DOI 10.1002/j.1552-4604.1989.tb03399.x; FELDMAN M, 1990, NEW ENGL J MED, V323, P1672; FELDMAN M, 1993, ARCH INTERN MED, V153, P2415, DOI 10.1001/archinte.153.21.2415; FORDTRAN JS, 1973, J CLIN INVEST, V52, P645, DOI 10.1172/JCI107226; FORDTRAN JS, 1968, NEW ENGL J MED, V279, P900, DOI 10.1056/NEJM196810242791702; FORDTRAN JS, 1966, NEW ENGL J MED, V274, P921, DOI 10.1056/NEJM196604282741701; FORDTRAN JS, 1973, NEW ENGL J MED, V288, P923, DOI 10.1056/NEJM197305032881801; *GALL ORG, 1988, GALL ORG GALL SURV H; GOLDSCHMIEDT M, 1993, TXB GASTROINTESTINAL, P524; KIRSNER JOSEPH B., 1941, AMER JOUR DIGEST DIS, V8, P53; LASKIN OL, 1993, J CLIN PHARMACOL, V33, P636, DOI 10.1002/j.1552-4604.1993.tb04716.x; MATON PN, 1991, NEW ENGL J MED, V324, P965; *MED EC DAT PROD C, 1995, PHYS DESK REF NONPR; Simon Thomas J., 1995, Am J Ther, V2, P304, DOI 10.1097/00045391-199505000-00003; 1995, MED LETT, V37, P63	16	27	27	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1428	1431		10.1001/jama.275.18.1428	http://dx.doi.org/10.1001/jama.275.18.1428			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618369				2022-12-28	WOS:A1996UJ30300029
J	Lucas, A; Morley, R; Fewtrell, MS				Lucas, A; Morley, R; Fewtrell, MS			Low triiodothyronine concentration in preterm infants and subsequent intelligence quotient (IQ) at 8 year follow up	BRITISH MEDICAL JOURNAL			English	Article											Lucas, A (corresponding author), MRC,DUNN NUTR UNIT,INFANT & CHILD NUTR GRP,CAMBRIDGE CB4 1XJ,ENGLAND.							BAKER BA, 1988, ARCH DIS CHILD, V63, P1198, DOI 10.1136/adc.63.10.1198; BRASEL JA, 1975, PERINATAL THYROID PH, P59; LUCAS A, 1994, ARCH DIS CHILD, V71, P288, DOI 10.1136/adc.71.4.288; LUCAS A, 1990, ARCH DIS CHILD, V65, P977, DOI 10.1136/adc.65.9.977; LUCAS A, 1988, ARCH DIS CHILD, V63, P1202	5	90	90	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1132	1133						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620130				2022-12-28	WOS:A1996UK06900023
J	Pell, J; Gruer, L; Christie, P; Goldberg, D				Pell, J; Gruer, L; Christie, P; Goldberg, D			Management of HIV infected health care workers: Lessons from three cases	BRITISH MEDICAL JOURNAL			English	Article								Three cases in which doctors in Glasgow were diagnosed as having HIV infection were all handled differently in relation to telling patients and the media. In the first patients were not told because the doctor had been doing administrative work and there was thought to be no risk to patients; although the media did report the case, it accepted the assurances given. In the second case, where a doctor had done many jobs in different specialities and places, the media identified the doctor before most patients had been informed: most calls to the helpline subsequently set up by the health authority were fi om patients who had not been treated bg this doctor. This episode, however, allowed the incident team to be prepared for the next case, enabling the helpline to be established swiftly. In this case the doctor voluntarily identified himself, and this served to allay public fears and reduce the number of inappropriate calls to the helpline.	RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW J20 9NB,LANARK,SCOTLAND		Pell, J (corresponding author), GREATER GLASGOW HLTH BOARD,DEPT PUBL HLTH,GLASGOW G1 1ET,LANARK,SCOTLAND.			Gruer, Laurence/0000-0002-1089-2896				BEIL DM, 1991, 7 INT C AIDS FLOR I; CHRISTIE P, 1994, HIV INFECTED HEALTHC; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Heptonstall J, 1995, OCCUPATIONAL TRANSMI; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; PELL J, 1995, LANCET, V346, P1425, DOI 10.1016/S0140-6736(95)92439-6; PELL JP, 1994, HIV INFECTED HLTH CA; STARK C, 1994, BRIT MED J, V309, P44, DOI 10.1136/bmj.309.6946.44; *UK DEP HLTH, 1993, AIDS HIV INF HLTH CA; 1990, MMWR-MORBID MORTAL W, V39, P489	10	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1150	1152						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620136	Green Published			2022-12-28	WOS:A1996UK06900031
J	vanGijn, J				vanGijn, J			Randomised trials	LANCET			English	Article											vanGijn, J (corresponding author), UNIV UTRECHT,DEPT NEUROL,3584 CX UTRECHT,NETHERLANDS.								0	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1234	1235		10.1016/S0140-6736(96)90743-6	http://dx.doi.org/10.1016/S0140-6736(96)90743-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622457				2022-12-28	WOS:A1996UJ59700017
J	Rudel, T; Schmid, A; Benz, R; Kolb, HA; Lang, F; Meyer, TF				Rudel, T; Schmid, A; Benz, R; Kolb, HA; Lang, F; Meyer, TF			Modulation of Neisseria porin (PorB) by cytosolic ATP/GTP of target cells: Parallels between pathogen accommodation and mitochondrial endosymbiosis	CELL			English	Article							OUTER-MEMBRANE PROTEINS; DEPENDENT ANION CHANNEL; HUMAN EPITHELIAL-CELLS; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; LIPID BILAYERS; GONOCOCCAL-INFECTION; SELECTIVE CHANNELS; RECEPTOR PROTEIN; BACTERIAL PORIN	PorB of the pathogenic Neisseria species belongs to the large family of pore-forming proteins (porins) produced by gram-negative bacteria. PorB is exceptional in that it is capable of translocating vectorially into membranes of infected target cells and functions in the infection process. Here we report on an unexpected similarity between Neisserial PorB and mitochondrial porins. Both porin classes interact with purine nucleoside triphosphates, which down-regulate pore size and cause a shift in voltage dependence and ion selectivity. Patch-clamp analyses indicate that PorB channel activity is tightly regulated in intact epithelial cells. In light of recent findings on the pivotal role of PorB in virulence and the prevention of phagosome lysosome fusion, these data provide important mechanistic clues on the intracellular pathogen accommodation reminiscent of mitochondrial endosymbiosis.	MAX PLANCK INST BIOL, INFEKT BIOL ABT, D-72076 TUBINGEN, GERMANY; MAX PLANCK INST INFEKT BIOL, MOLEK BIOL ABT, D-10117 BERLIN, GERMANY; UNIV WURZBURG, THEODOR BOVERI INST BIOZENTRUM, LEHRSTUHL BIOTECHNOL, D-97074 WURZBURG, GERMANY; UNIV TUBINGEN, INST PHYSIOL 1, D-72076 TUBINGEN, GERMANY	Max Planck Society; Max Planck Society; University of Wurzburg; Eberhard Karls University of Tubingen			Meyer, Thomas F. F/J-2485-2013	Meyer, Thomas F. F/0000-0002-6120-8679; Benz, Roland/0000-0002-9510-9265				BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BENZ R, 1992, BIOL CHEM H-S, V373, P295, DOI 10.1515/bchm3.1992.373.1.295; Benz R., 1994, BACTERIAL CELL WALL, P397; BETTENDORFF L, 1993, J NEUROCHEM, V60, P423, DOI 10.1111/j.1471-4159.1993.tb03168.x; Blake M.S., 1985, PATHOGENESIS BACTERI, P51; BLAKE MS, 1987, BACTERIAL OUTER MEMB, P377; BLATZ AL, 1983, BIOPHYS J, V43, P237, DOI 10.1016/S0006-3495(83)84344-6; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; FISCHER K, 1994, J BIOL CHEM, V269, P25754; FLORKE H, 1994, BIOL CHEM H-S, V375, P513, DOI 10.1515/bchm3.1994.375.8.513; GRAY PTA, 1984, PROC R SOC SER B-BIO, V221, P395, DOI 10.1098/rspb.1984.0041; HA HJ, 1993, J BIOL CHEM, V268, P12143; HAINES KA, 1991, J CELL BIOL, V114, P433, DOI 10.1083/jcb.114.3.433; HAINES KA, 1988, J BIOL CHEM, V263, P945; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANCOCK REW, 1982, J BACTERIOL, V150, P730, DOI 10.1128/JB.150.2.730-738.1982; HANCOCK REW, 1992, J BACTERIOL, V174, P471, DOI 10.1128/jb.174.2.471-476.1992; HITCHCOCK PJ, 1989, CLIN MICROBIOL REV, V2, pS64, DOI 10.1128/CMR.2.Suppl.S64-S65.1989; HOLDEN MJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P396, DOI 10.1016/0005-2728(93)90126-Z; JALONEN T, 1989, ACTA PHYSIOL SCAND, V136, P611, DOI 10.1111/j.1748-1716.1989.tb08709.x; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KOLB HA, 1991, REV PHYSIOL BIOCH P, V118, P1; KOLB HA, 1987, BIOCHIM BIOPHYS ACTA, V899, P239, DOI 10.1016/0005-2736(87)90405-6; KOLB HA, 1985, PFLUG ARCH EUR J PHY, V403, P262, DOI 10.1007/BF00583597; KONIG U, 1991, BIOL CHEM H-S, V372, P565, DOI 10.1515/bchm3.1991.372.2.565; KORCHAK HM, 1978, P NATL ACAD SCI USA, V75, P3818, DOI 10.1073/pnas.75.8.3818; KRIEGERBRAUER HJ, 1980, ARCH MICROBIOL, V124, P233, DOI 10.1007/BF00427732; KUPSCH EM, 1993, EMBO J, V12, P641, DOI 10.1002/j.1460-2075.1993.tb05697.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; LUDWIG O, 1988, EUR BIOPHYS J BIOPHY, V15, P269, DOI 10.1007/BF00256477; LYNCH EC, 1984, BIOPHYS J, V45, P104, DOI 10.1016/S0006-3495(84)84127-2; MAIER C, 1988, J BIOL CHEM, V263, P2493; MAKINO S, 1991, EMBO J, V10, P1307, DOI 10.1002/j.1460-2075.1991.tb07649.x; MARRERO H, 1991, EUR J NEUROSCI, V3, P813, DOI 10.1111/j.1460-9568.1991.tb01677.x; MAURO A, 1988, P NATL ACAD SCI USA, V85, P1071, DOI 10.1073/pnas.85.4.1071; MCGEE ZA, 1981, J INFECT DIS, V143, P413, DOI 10.1093/infdis/143.3.413; MEYER TF, 1984, P NATL ACAD SCI-BIOL, V81, P6110, DOI 10.1073/pnas.81.19.6110; MEYERS KM, 1982, AM J PHYSIOL, V243, pR454, DOI 10.1152/ajpregu.1982.243.3.R454; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NELSON DJ, 1984, J MEMBRANE BIOL, V80, P81, DOI 10.1007/BF01868692; NEWHALL WJ, 1980, INFECT IMMUN, V28, P785; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; PETER ME, 1992, EMBO J, V11, P933, DOI 10.1002/j.1460-2075.1992.tb05132.x; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; SANDSTROM EG, 1984, SEX TRANSM DIS, V11, P77, DOI 10.1097/00007435-198404000-00005; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; SCHWARZE W, 1984, PFLUG ARCH EUR J PHY, V402, P281, DOI 10.1007/BF00585511; SHAFER WM, 1989, ANNU REV MICROBIOL, V43, P121; SIEHNEL RJ, 1988, MOL MICROBIOL, V2, P347, DOI 10.1111/j.1365-2958.1988.tb00038.x; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; THINNES FP, 1989, BIOL CHEM H-S, V370, P1253; TOKUNAGA H, 1981, J BIOL CHEM, V256, P8024; TRIAS J, 1990, J BIOL CHEM, V265, P15680; TRIAS J, 1988, BIOCHIM BIOPHYS ACTA, V938, P493, DOI 10.1016/0005-2736(88)90148-4; TROLL H, 1992, J BIOL CHEM, V267, P21072; TSAI CM, 1981, J BACTERIOL, V146, P69, DOI 10.1128/JB.146.1.69-78.1981; VANDERLEY P, 1991, INFECT IMMUN, V59, P2963, DOI 10.1128/IAI.59.9.2963-2971.1991; VANPUTTEN JPM, 1993, EMBO J, V12, P4043, DOI 10.1002/j.1460-2075.1993.tb06088.x; VIRJI M, 1992, MOL MICROBIOL, V6, P2785, DOI 10.1111/j.1365-2958.1992.tb01458.x; WARD MJ, 1992, FEMS MICROBIOL LETT, V94, P283, DOI 10.1111/j.1574-6968.1992.tb05332.x; WEEL JFL, 1991, RES MICROBIOL, V142, P985, DOI 10.1016/0923-2508(91)90009-Y; WEEL JFL, 1991, J EXP MED, V174, P705, DOI 10.1084/jem.174.3.705; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W; WHITIN JC, 1980, J BIOL CHEM, V255, P1874; ZIZI M, 1994, J BIOL CHEM, V269, P1614	81	95	99	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					391	402		10.1016/S0092-8674(00)81117-4	http://dx.doi.org/10.1016/S0092-8674(00)81117-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616894	Bronze, Green Published			2022-12-28	WOS:A1996UK14000012
J	Tisch, R; McDevitt, H				Tisch, R; McDevitt, H			Insulin-dependent diabetes mellitus	CELL			English	Review							GLUTAMIC-ACID DECARBOXYLASE; T-CELL; NOD MICE; MOUSE; CD4+; MHC; SUSCEPTIBILITY; AUTOANTIGEN; PREVENTION; RESISTANCE		STANFORD UNIV,SCH MED,DEPT MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University	Tisch, R (corresponding author), UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599, USA.							ACHAORBEA H, 1987, P NATL ACAD SCI USA, V84, P2435, DOI 10.1073/pnas.84.8.2435; AKHTAR L, 1995, J EXP MED, V182, P87; ATKINSON MA, 1993, J CLIN INVEST, V92, P1608, DOI 10.1172/JCI116745; ATKINSON MA, 1994, J CLIN INVEST, V94, P2125, DOI 10.1172/JCI117567; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BARNETT AH, 1981, DIABETOLOGIA, V20, P404; BOITARD C, 1988, P NATL ACAD SCI USA, V85, P9719, DOI 10.1073/pnas.85.24.9719; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123; CHRISTIE MR, 1994, DIABETES, V43, P1254, DOI 10.2337/diabetes.43.10.1254; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; CUCCA F, 1995, HUM IMMUNOL, V43, P301, DOI 10.1016/0198-8859(95)00042-3; DANIEL D, 1995, EUR J IMMUNOL, V25, P1056, DOI 10.1002/eji.1830250430; ELIAS D, 1994, LANCET, V343, P704, DOI 10.1016/S0140-6736(94)91582-2; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; ELLIOTT JF, 1994, DIABETES, V43, P1494, DOI 10.2337/diabetes.43.12.1494; ERLICH HA, 1993, NAT GENET, V3, P358, DOI 10.1038/ng0493-358; FOWELL D, 1993, J EXP MED, V177, P627, DOI 10.1084/jem.177.3.627; HAGOPIAN WA, 1993, J CLIN INVEST, V91, P368, DOI 10.1172/JCI116195; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; HASKINS K, 1990, SCIENCE, V249, P1433, DOI 10.1126/science.2205920; IKEGAMI H, 1993, BIOCHEM BIOPH RES CO, V192, P677, DOI 10.1006/bbrc.1993.1468; JARPE A, 1991, REG IMMUNOL, V3, P305; KATZ J, 1993, EUR J IMMUNOL, V23, P3358, DOI 10.1002/eji.1830231244; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KELLER RJ, 1993, LANCET, V341, P927, DOI 10.1016/0140-6736(93)91215-8; LARGER E, 1995, J EXP MED, V181, P1635, DOI 10.1084/jem.181.5.1635; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; MUIR A, 1995, J CLIN INVEST, V95, P628, DOI 10.1172/JCI117707; NEPOM GT, 1990, DIABETES, V39, P1153, DOI 10.2337/diabetes.39.10.1153; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; PASSINI N, 1995, P NATL ACAD SCI USA, V92, P9412, DOI 10.1073/pnas.92.20.9412; PENNLINE KJ, 1994, CLIN IMMUNOL IMMUNOP, V71, P169, DOI 10.1006/clin.1994.1068; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; QUARTEYPAPAFIO R, 1995, J IMMUNOL, V154, P5567; RABINOVITCH A, 1994, DIABETES, V43, P613, DOI 10.2337/diabetes.43.5.613; RAMENSEE HG, 1995, IMMUNOGENETICS, V41, P178; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; REICH EP, 1994, J IMMUNOL, V152, P2279; ROEP BO, 1990, NATURE, V345, P632, DOI 10.1038/345632a0; SCOTT B, 1994, IMMUNITY, V1, P73, DOI 10.1016/1074-7613(94)90011-6; SEMPE P, 1991, EUR J IMMUNOL, V21, P1163, DOI 10.1002/eji.1830210511; SERREZE DV, 1994, DIABETES, V43, P505, DOI 10.2337/diabetes.43.3.505; SHEHADEH NN, 1993, J AUTOIMMUN, V6, P291, DOI 10.1006/jaut.1993.1025; SHIMIZU J, 1993, J IMMUNOL, V151, P1723; SHIZURU JA, 1988, SCIENCE, V240, P659, DOI 10.1126/science.2966437; SINGER SM, 1993, P NATL ACAD SCI USA, V90, P9566, DOI 10.1073/pnas.90.20.9566; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; THAI AC, 1993, DIABETES REV, V123, P37; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; WICKER LS, 1992, J EXP MED, V176, P67, DOI 10.1084/jem.176.1.67; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; WICKER LS, 1994, DIABETES, V43, P500, DOI 10.2337/diabetes.43.3.500; WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597; YANG XD, 1993, P NATL ACAD SCI USA, V90, P10494, DOI 10.1073/pnas.90.22.10494; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	60	792	818	0	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					291	297		10.1016/S0092-8674(00)81106-X	http://dx.doi.org/10.1016/S0092-8674(00)81106-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616883	Bronze			2022-12-28	WOS:A1996UK14000001
J	Lorincz, AL				Lorincz, AL			Cutaneous T-cell lymphoma (mycosis fungoides)	LANCET			English	Article							SEZARY-SYNDROME; DIAGNOSIS; EXPERIENCE; THERAPY; BLOOD				Lorincz, AL (corresponding author), UNIV CHICAGO, DERMATOL SECT, 5841 S MARYLAND, MC 5067, CHICAGO, IL 60637 USA.							ABEL EA, 1993, CA-CANCER J CLIN, V43, P93, DOI 10.3322/canjclin.43.2.93; BARNHILL RL, 1988, J AM ACAD DERMATOL, V19, P25, DOI 10.1016/S0190-9622(88)70147-4; BRAVERMAN IM, 1991, CURR PROBL DERMATOL, V3, P181; BREATHNACH SM, 1982, BRIT J DERMATOL, V106, P340; EDELSON R, 1987, NEW ENGL J MED, V316, P297, DOI 10.1056/NEJM198702053160603; EDELSON R, 1974, NEW ENGL J MED, V291, P293, DOI 10.1056/NEJM197408082910608; GREENE MH, 1982, CANCER, V49, P737, DOI 10.1002/1097-0142(19820215)49:4<737::AID-CNCR2820490423>3.0.CO;2-R; HALL WW, 1991, SCIENCE, V253, P317, DOI 10.1126/science.1857968; HOPPE RT, 1979, CANCER TREAT REP, V63, P691; KEIL H, 1937, ARCH DERMATOL SYPHIL, V37, P465; KUPPER T S, 1987, Journal of Dermatology (Tokyo), V14, P517; KUZEL TM, 1991, J CLIN ONCOL, V9, P1298, DOI 10.1200/JCO.1991.9.7.1298; LONG JC, 1974, CANCER, V34, P1745, DOI 10.1002/1097-0142(197411)34:5<1745::AID-CNCR2820340524>3.0.CO;2-W; LUTZNER MA, 1968, BLOOD, V31, P719, DOI 10.1182/blood.V31.6.719.719; MANZARI V, 1987, SCIENCE, V238, P1581, DOI 10.1126/science.2825353; MCNUTT NS, 1981, CANCER, V47, P698, DOI 10.1002/1097-0142(19810215)47:4<698::AID-CNCR2820470413>3.0.CO;2-Z; O'LOUGHLIN S, 1977, Archives of Dermatology, V113, P309, DOI 10.1001/archderm.113.3.309; RAPPAPORT H, 1974, CANCER-AM CANCER SOC, V34, P1198, DOI 10.1002/1097-0142(197410)34:4<1198::AID-CNCR2820340431>3.0.CO;2-E; RATNER AC, 1968, CANCER, V21, P83, DOI 10.1002/1097-0142(196801)21:1<83::AID-CNCR2820210113>3.0.CO;2-8; ROENIGK HH, 1990, J INVEST DERMATOL, V95, pS198, DOI 10.1111/1523-1747.ep12875523; SAUSVILLE EA, 1985, HUM PATHOL, V16, P1098, DOI 10.1016/S0046-8177(85)80177-5; SAUSVILLE EA, 1988, ANN INTERN MED, V109, P372, DOI 10.7326/0003-4819-109-5-372; Sezary A., 1938, B SOC FR DERMATOL SY, V45, P254; VONDERHEID EC, 1989, J AM ACAD DERMATOL, V20, P416, DOI 10.1016/S0190-9622(89)70051-7; WEINSTOCK MA, 1988, JAMA-J AM MED ASSOC, V260, P42, DOI 10.1001/jama.260.1.42; WHITTEMORE AS, 1989, J NATL CANCER I, V81, P1560, DOI 10.1093/jnci/81.20.1560; WIESELTHIER JS, 1990, J AM ACAD DERMATOL, V22, P381, DOI 10.1016/0190-9622(90)70054-L; ZACKHEIM HS, 1990, J AM ACAD DERMATOL, V22, P802, DOI 10.1016/0190-9622(90)70112-U; ZUCKERFRANKLIN D, 1991, P NATL ACAD SCI USA, V88, P7630, DOI 10.1073/pnas.88.17.7630; 1979, CANC TREAT REP, V63, P561	30	49	54	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 30	1996	347	9005					871	876		10.1016/S0140-6736(96)91350-1	http://dx.doi.org/10.1016/S0140-6736(96)91350-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622396				2022-12-28	WOS:A1996UC45000014
J	Jansen, RP; Dowzer, C; Michaelis, C; Galova, M; Nasmyth, K				Jansen, RP; Dowzer, C; Michaelis, C; Galova, M; Nasmyth, K			Mother cell-specific HO expression in budding yeast depends on the unconventional myosin myo4p and other cytoplasmic proteins	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CYCLE REGULATION; TRANSCRIPTION; GENE; ASYMMETRY; DIVISION	Certain cell types give rise to progeny that adopt different patterns of gene expression in the absence of any differences in their environment. Cells of budding yeast give birth to mother and daughter cells that differ in that only mother cells express the HO endonuclease gene and thereby switch mating types. We describe the identification of five genes, called SHE1-SHE5, that encode cytoplasmic proteins required for mother-specific HO expression. She1p, which is identical to the minimyosin Myo4p, and She3p are not, however, mother-specific proteins. On the contrary, they accumulate in growing buds. She proteins might be required for the transport of factors that promote HO repression from the mother cell into its bud. In an accompanying paper, we show that SHE genes are needed for the accumulation in daughter nuclei of Ash1p, a repressor of HO.			Jansen, RP (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403				BECAM AM, 1994, YEAST, V10, P1; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; HAARER BK, 1994, J CELL SCI, V107, P1055; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SANDERS SL, 1994, CURR BIOL, V4, P907, DOI 10.1016/S0960-9822(00)00201-3; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927	36	260	262	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					687	697		10.1016/S0092-8674(00)81047-8	http://dx.doi.org/10.1016/S0092-8674(00)81047-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625407	Bronze			2022-12-28	WOS:A1996TZ99000007
J	Wiertz, EJHJ; Jones, TR; Sun, L; Bogyo, M; Geuze, HJ; Ploegh, HL				Wiertz, EJHJ; Jones, TR; Sun, L; Bogyo, M; Geuze, HJ; Ploegh, HL			The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol	CELL			English	Article							COMPLEX CLASS-I; TRANSLOCATION; EXPRESSION; STABILITY; ANTIGENS; SEC61P	Human cytomegalovirus (HCMV) down-regulates expression of MHC class I products by selective proteolysis. A single HCMV gene, US11, which encodes an endoplasmic reticulum (ER) resident type-I transmembrane glycoprotein, is sufficient to cause this effect. In US11(+) cells, MHC class I molecules are core-glycosylated and therefore inserted into the ER. They are degraded with a half-time of less than 1 min. A full-length breakdown intermediate that has lost the single N-linked glycan in an N-glycanase-catalyzed reaction transiently accumulates in cells exposed to the protease inhibitors LLnL, Cbz-LLL, and lactacystin, identifying the proteasome as a key protease. Subcellular fractionation experiments show this intermediate to be cytosolic. Thus, US11 dislocates newly synthesized class I molecules from the ER to the cytosol, where they are acted upon by an N-glycanase and the proteasome.	WYETH AYERST RES, DEPT BIOL MOLEC, INFECT DIS SECT, PEARL RIVER, NY 10965 USA; UNIV UTRECHT, SCH MED, DEPT CELL BIOL, 3584 CX UTRECHT, NETHERLANDS	Pfizer; Utrecht University	Wiertz, EJHJ (corresponding author), MIT, CTR CANC RES, DEPT BIOL, CAMBRIDGE, MA 02139 USA.			Bogyo, Matthew/0000-0003-3753-4412	NCI NIH HHS [5-P30-CA14501] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; DELVAL M, 1992, J EXP MED, V176, P729, DOI 10.1084/jem.176.3.729; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EICHHOLTZ T, 1992, J BIOL CHEM, V267, P22490; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HILL A, 1995, P NATL ACAD SCI USA, V92, P341, DOI 10.1073/pnas.92.2.341; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; JONES TR, 1994, J VIROL, V68, P3742, DOI 10.1128/JVI.68.6.3742-3752.1994; JONES TR, 1991, J VIROL, V65, P3742; KIM HJ, 1995, J VIROL, V69, P2565, DOI 10.1128/JVI.69.4.2565-2573.1995; KIM YJ, 1994, CELL, V78, P845; LARDY HENRY A., 1965, P245; LIOU W, 1994, IMPROVED FINE STRUCT, P1; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; NEEFJES JJ, 1993, EUR J IMMUNOL, V23, P840, DOI 10.1002/eji.1830230411; NEEFJES JJ, 1986, IMMUNOGENETICS, V23, P164, DOI 10.1007/BF00373817; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PLOEGH HL, 1995, CURRENT PROTOCOLS PR; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STAM NJ, 1986, J IMMUNOL, V137, P2299; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	43	898	919	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					769	779		10.1016/S0092-8674(00)81054-5	http://dx.doi.org/10.1016/S0092-8674(00)81054-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625414	Bronze			2022-12-28	WOS:A1996TZ99000014
J	Willett, WC; Stampfer, MJ; Manson, JE; Colditz, GA; Rosner, BA; Speizer, FE; Hennekens, CH				Willett, WC; Stampfer, MJ; Manson, JE; Colditz, GA; Rosner, BA; Speizer, FE; Hennekens, CH			Coffee consumption and coronary heart disease in women - A ten-year follow-up	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; DEATH; QUESTIONNAIRE; MEN	Objective.-To assess the relationship between coffee consumption and risk of coronary heart disease (CHD) among women. Design.-Prospective cohort study with coffee consumption measured in 1980, 1984, and 1986, and follow-up through 1990. Setting.-Female registered nurses in the United States. Participants.-A total of 85 747 US women 34 to 59 years of age in 1980 and without history of CHD, stroke, or cancer. Main Outcome Measure.-Ten-year incidence of CHD (defined as nonfatal myocardial infarction or fatal CHD). Results.-During 10 years of follow-up we documented 712 cases of CHD. After adjustment for age, smoking, and other CHD risk factors, we found no evidence for any positive association between coffee consumption and risk of subsequent CHD. For women drinking six or more cups of caffeine-containing coffee per day in 1980, the relative risk was 0.95 (95% confidence interval, 0.73 to 1.26) compared with women who did not consume this beverage. Similarly, there was no association when the first 4 years of follow-up were excluded, when nonfatal and fatal CHD end points were examined separately, or when we updated coffee consumption in 1984 or 1986 and examined only CHD during the next 2-year interval. Further, there was no association with caffeine intake from all sources combined or with decaffeinated coffee consumption. Conclusions.-These data indicate that coffee as consumed by US women is not an important cause of CHD.	BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Willett, WC (corresponding author), CHANNING LABS,818 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594, HL 24074] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		GABH Rose, 1982, WHO MONOGRAPH SERIES; GREENLAND S, 1993, EPIDEMIOLOGY, V4, P366, DOI 10.1097/00001648-199307000-00013; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HENNEKENS CH, 1976, NEW ENGL J MED, V294, P633, DOI 10.1056/NEJM197603182941203; KALANDIDI A, 1993, INT J EPIDEMIOL, V21, P174; KAWACHI I, 1994, BRIT HEART J, V72, P269; Klag Michael J., 1994, Annals of Epidemiology, V4, P425, DOI 10.1016/1047-2797(94)90001-9; KLATSKY AL, 1990, AM J EPIDEMIOL, V132, P479, DOI 10.1093/oxfordjournals.aje.a115684; MANN JI, 1975, LANCET, V2, P1215; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MYERS MG, 1992, ARCH INTERN MED, V152, P1767, DOI 10.1001/archinte.152.9.1767; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; TVERDAL A, 1990, BRIT MED J, V300, P566, DOI 10.1136/bmj.300.6724.566; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; ZOCK PL, 1990, LANCET, V335, P1235, DOI 10.1016/0140-6736(90)91302-Q	18	79	84	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					458	462		10.1001/jama.275.6.458	http://dx.doi.org/10.1001/jama.275.6.458			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627967				2022-12-28	WOS:A1996TU63800034
J	Levy, D; Larson, MG; Vasan, RS; Kannel, WB; Ho, KKL				Levy, D; Larson, MG; Vasan, RS; Kannel, WB; Ho, KKL			The progression from hypertension to congestive heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR DYSFUNCTION; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; DIASTOLIC DYSFUNCTION; UNITED-STATES; FRAMINGHAM; MORTALITY; DISEASE; POPULATION; PREVALENCE	Objectives.-To study the relative and population-attributable risks of hypertension for the development of congestive heart failure (CHF), to assess the time course of progression from hypertension to CHF, and to identify risk factors that contribute to the development of overt heart failure in hypertensive subjects. Design.-Inception cohort study. Setting.-General community. Participants.-Original Framingham Heart Study and Framingham Offspring Study participants aged 40 to 89 years and free of CHF. To reflect more contemporary experience, the starting point of this study was January 1, 1970. Exposure Measures.-Hypertension (blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic or current use of medications for treatment of high blood pressure) and other potential CHF risk factors were assessed at periodic clinic examinations. Outcome Measure.-The development of CHF. Results.-A total of 5143 eligible subjects contributed 72 422 person-years of observation. During up to 20.1 years of follow-up (mean, 14.1 years), there were 392 new cases of heart failure; in 91% (357/392), hypertension antedated the development of heart failure. Adjusting for age and heart failure risk factors in proportional hazards regression models, the hazard for developing heart failure in hypertensive compared with normotensive subjects was about 2-fold in men and 3-fold in women. Multivariable analyses revealed that hypertension had a high population-attributable risk for CHF, accounting for 39% of cases in men and 59% in women. Among hypertensive subjects, myocardial infarction, diabetes, left ventricular hypertrophy, and valvular heart disease were predictive of increased risk for CHF in both sexes. Survival following the onset of hypertensive CHF was bleak; only 24% of men and 31% of women survived 5 years. Conclusions.-Hypertension was the most common risk factor for CHF, and it contributed a large proportion of heart failure cases in this population-based sample. Preventive strategies directed toward earlier and more aggressive blood pressure control are likely to offer the greatest promise for reducing the incidence of CHF and its associated mortality.	NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, SCH MED, PREVENT MED & EPIDEMIOL SECT, BOSTON, MA 02118 USA; BETH ISRAEL HOSP, DIV CARDIOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Levy, D (corresponding author), FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA.		Levy, Daniel/ABB-2752-2021; Ramachandran, Vasan/Y-2527-2019; Levy, Daniel/ABF-6873-2021	Ramachandran, Vasan/0000-0001-7357-5970; Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELMANN WH, 1989, J AM COLL CARDIOL, V13, P1219, DOI 10.1016/0735-1097(89)90293-3; AGUIRRE FV, 1989, AM J CARDIOL, V63, P1098, DOI 10.1016/0002-9149(89)90085-4; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1970, JAMA, V213, P1143; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1007; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Cox DR, 1984, ANAL SURVIVAL DATA, P48; Cutler Jeffrey A., 1995, P253; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DOUGHERTY AH, 1984, AM J CARDIOL, V54, P778, DOI 10.1016/S0002-9149(84)80207-6; ECHEVERRIA HH, 1983, AM J MED, V75, P750, DOI 10.1016/0002-9343(83)90403-5; ERIKSSON H, 1988, ACTA MED SCAND, V223, P197; ERIKSSON H, 1989, EUR HEART J, V10, P647, DOI 10.1093/oxfordjournals.eurheartj.a059542; Furberg C D, 1986, Adv Cardiol, V34, P124; GALDERISI M, 1991, AM J CARDIOL, V68, P85, DOI 10.1016/0002-9149(91)90716-X; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; GLYNN JR, 1993, LANCET, V342, P530, DOI 10.1016/0140-6736(93)91651-2; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; IRIARTE M, 1993, AM J CARDIOL, V71, P308, DOI 10.1016/0002-9149(93)90796-F; KANNEL W, 1988, FRAMINGHAM STUDY, P5; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1972, NEW ENGL J MED, V287, P782; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KANNEL WB, 1987, AM J CARDIOL, V60, pI85; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RODEHEFFER RJ, 1993, MAYO CLIN PROC, V68, P1143, DOI 10.1016/S0025-6196(12)60063-9; *SAS I INC, 1992, P229 SAS I INC, P433; *SAS I INC, 1989, SAS STAT US GUID VER, V2, P1027; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; SOUFER R, 1985, AM J CARDIOL, V55, P1032, DOI 10.1016/0002-9149(85)90741-6; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TEERLINK JR, 1991, AM HEART J, V121, P1852, DOI 10.1016/0002-8703(91)90072-P; TOPOL EJ, 1985, NEW ENGL J MED, V312, P277, DOI 10.1056/NEJM198501313120504; VANHOEVEN KH, 1990, CIRCULATION, V82, P848, DOI 10.1161/01.CIR.82.3.848; Vasan RS, 1996, ARCH INTERN MED, V156, P146, DOI 10.1001/archinte.156.2.146; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; VASAN RS, 1995, CIRCULATION S1, V92, P665; WACKERS FJ, 1976, BRIT HEART J, V38, P906; WONG WF, 1989, AM J CARDIOL, V63, P1526, DOI 10.1016/0002-9149(89)90022-2; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1989, HYPERTENSION, V0013; 1994, MMWR-MORBID MORTAL W, V43, P77	55	1428	1490	3	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1557	1562		10.1001/jama.275.20.1557	http://dx.doi.org/10.1001/jama.275.20.1557			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622246				2022-12-28	WOS:A1996UL02900027
J	Staessen, JA; Roels, H; Fagard, R				Staessen, JA; Roels, H; Fagard, R			Lead exposure and conventional and ambulatory blood pressure - A prospective population study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR RISK; RENAL-FUNCTION; UNITED-STATES; HYPERTENSION; ASSOCIATION; FRAMINGHAM; ALCOHOL; HEALTH; TRIALS	Objective.-To evaluate in a prospective fashion the association between low-level lead exposure and blood pressure. Design.-Prospective cohort study. Setting.-General population. Participants.-A random population sample (N=728; 49% men; age range, 20-82 years) was studied in Belgium for 1985 through 1989 and reexamined for 1991 through 1995. Mean Outcome Measures.-At baseline and follow-up, blood pressure was measured by conventional sphygmomanometry (15 total readings) and at followup also by 24-hour ambulatory monitoring. Lead exposure was estimated from blood lead and zinc protoporphyrin concentrations. Multivariate analyses controlled for sex, age, body mass index, smoking and drinking habits, physical activity, exposure at work, social class, menopausal status, use of medications (antihypertensive medication, oral contraceptives, hormonal replacement therapy), hematocrit or hemoglobin, serum total calcium concentration, 24-hour urinary sodium and potassium excretion, and gamma-glutamyltransferase activity. Results.-At baseline, mean (SD) systolic/diastolic conventional blood pressure was 130 (17)/77 (9) mm Hg. The mean blood lead concentration was 0.42 mu mol/L (8.7 mu g/dL), and the mean zinc protoporphyrin concentration was 1.0 mu g per gram of hemoglobin. Over the 5.2-year median follow-up, the mean blood lead concentration dropped by 32% (0.14 mu mol/L [2.9 mu g/dL]) (P<.001). Small but significant (P<.01) changes occurred in systolic (-1.5 mm Hg) and diastolic (+1.7 mm Hg) conventional blood pressure and in zinc protoporphyrin concentration (+0.5 mu g per gram of hemoglobin). Over the follow-up period, no consistent associations emerged between the changes in conventional blood pressure and in blood lead or zinc protoporphyrin concentrations. In addition, after adjustment for sex, age, and body mass index, blood lead and zinc protoporphyrin concentrations at baseline did not predict the development of hypertension in 47 patients (risk ratio for doubling of the initial lead concentration, 1.2; 95% confidence interval, 0.7-2.0). In a time-integrated analysis in which each person was characterized by all available measurements, conventional blood pressure did not correlate with blood lead or zinc protoporphyrin concentrations in a consistent manner. Similarly, the mean (SD) 24-hour blood pressure at follow-up (119 [11]/71 [8] mm Hg; N=684) did not show a consistent relationship with blood lead or zinc protoporphyrin concentrations at baseline or at follow-up. Conclusions.-Lead exposure at the intensity studied (<1.45 mu mol/L [<30 mu g/dL]) was not consistently associated with increased conventional or 24-hour blood pressure in the general population or with increased risk of hypertension. These findings argue against the hypothesis that current lead exposure levels are associated with excess cardiovascular morbidity and mortality caused by hypertension.	UNIV LOUVAIN, DEPT MOL & CARDIOVASC RES, HYPERTENS & CARDIOVASC REHABIL UNIT, LOUVAIN, BELGIUM; UNIV LOUVAIN, IND TOXICOL & OCCUPAT MED UNIT, BRUSSELS, BELGIUM	Universite Catholique Louvain			Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				ANNEST JL, 1983, NEW ENGL J MED, V308, P1373, DOI 10.1056/NEJM198306093082301; Astrand PO., 1986, TXB WORK PHYSL PHYSL, P486; CHABANEL A, 1995, HYPERTENSION PATHOPH, V1, P365; CLAEYS F, 1992, CADMIUM HUMAN ENV TO, P83; COATE D, 1989, J HEALTH ECON, V8, P173, DOI 10.1016/0167-6296(89)90002-7; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CONWAY J, 1988, J HYPERTENS, V6, P111; COOPER WC, 1985, SCAND J WORK ENV HEA, V11, P331, DOI 10.5271/sjweh.2215; ELLIOTT P, 1988, BRIT MED J, V297, P319; GARTSIDE PS, 1988, ENVIRON HEALTH PERSP, V78, P31, DOI 10.2307/3430495; GRANDJEAN P, 1989, AM J EPIDEMIOL, V129, P732, DOI 10.1093/oxfordjournals.aje.a115188; HARLAN WR, 1985, JAMA-J AM MED ASSOC, V253, P530, DOI 10.1001/jama.253.4.530; HARLAN WR, 1984, AM J EPIDEMIOL, V120, P17, DOI 10.1093/oxfordjournals.aje.a113870; HJORTLAND MC, 1976, AM J EPIDEMIOL, V103, P304, DOI 10.1093/oxfordjournals.aje.a112228; KANNEL WB, 1978, B NEW YORK ACAD MED, V54, P573; Kannel WB, 1975, EPIDEMIOLOGY CONTROL, P553; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; LIU K, 1979, AM J EPIDEMIOL, V110, P219, DOI 10.1093/oxfordjournals.aje.a112806; LOCKETT CJ, 1987, B ENVIRON CONTAM TOX, V38, P975, DOI 10.1007/BF01609083; Machin D, 1987, STAT TABLES DESIGN C, P89; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAHAFFEY KR, 1982, NEW ENGL J MED, V307, P573, DOI 10.1056/NEJM198209023071001; MANCIA G, 1983, LANCET, V2, P695; MCARDLE WD, 1991, EXERCISE PHYSL ENERG, P804; MOLLER L, 1992, AM J EPIDEMIOL, V136, P1091, DOI 10.1093/oxfordjournals.aje.a116574; NERI LC, 1988, ENVIRON HEALTH PERSP, V78, P123, DOI 10.2307/3430512; OBRIEN E, 1991, J HUM HYPERTENS, V5, P223; Office of Population Censuses and Surveys, 1980, CLASS OCC COD IND; OLSEN NB, 1981, DAN MED BULL, V28, P168; PERSIJN JP, 1976, J CLIN CHEM CLIN BIO, V14, P421; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; Pickering TG., 1991, AMBULATORY MONITORIN; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; POCOCK SJ, 1984, BRIT MED J, V289, P872, DOI 10.1136/bmj.289.6449.872; RABINOWITZ M, 1987, HYPERTENSION, V10, P447, DOI 10.1161/01.HYP.10.4.447; SCHMID RW, 1957, ANAL CHEM, V29, P264, DOI 10.1021/ac60122a026; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; SIEGEL S, 1988, NONPARAMETRIC STAT B, P73; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; STAESSEN J, 1991, J HUM HYPERTENS, V5, P355; STAESSEN J, 1990, BRIT J IND MED, V47, P442; STAESSEN J, 1984, ACTA CARDIOL, V39, P55; Staessen J A, 1994, J Cardiovasc Risk, V1, P87; Staessen J.A., 1993, J HYPERTENS S2, V11, pS35; STAESSEN JA, 1995, J HUM HYPERTENS, V9, P303; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P1313, DOI 10.1056/NEJM198811173192004; Thijs L, 1992, HIGH BLOOD PRESSURE, V1, P17; *US EPA, 1986, US EPA PUBL, P1; WEISS ST, 1986, AM J EPIDEMIOL, V123, P800, DOI 10.1093/oxfordjournals.aje.a114309; YAMADA Y, 1991, HYPERTENSION, V18, P819, DOI 10.1161/01.HYP.18.6.819; 1990, J HYPERTENS       S6, V8, pS135	53	59	62	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1563	1570		10.1001/jama.275.20.1563	http://dx.doi.org/10.1001/jama.275.20.1563			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622247				2022-12-28	WOS:A1996UL02900028
J	Nehls, M; Kyewski, B; Messerle, M; Waldschutz, R; Schuddekopf, K; Smith, AJH; Boehm, T				Nehls, M; Kyewski, B; Messerle, M; Waldschutz, R; Schuddekopf, K; Smith, AJH; Boehm, T			Two genetically separable steps in the differentiation of thymic epithelium	SCIENCE			English	Article							STROMAL CELL-TYPES; MICE; MICROENVIRONMENT; MATURATION; ALPHA	The development oi the thymus depends initially on epithelial-mesenchymal and subsequently on reciprocal lympho-stromal interactions. The genetic steps governing development and differentiation of the thymic microenvironment are unknown. With the use of a targeted disruption of the whn gene, which recapitulates the phenotype of the athymic nude mouse, the WHN transcription factor was shown to be the product of the nude locus. Formation of the thymic epithelial primordium before the entry of lymphocyte progenitors did not require the activity of WHN. However, subsequent differentiation of primitive precursor cells into subcapsular, cortical, and medullary epithelial cells of the postnatal thymus did depend on activity of the whn gene. These results define the first geneticallyd separable steps during thymic epithelial differentiation.	DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Helmholtz Association; German Cancer Research Center (DKFZ); MRC Laboratory Molecular Biology				Messerle, Martin/0000-0002-1227-3933				ALTEVOGT P, 1989, EUR J IMMUNOL, V19, P1509, DOI 10.1002/eji.1830190826; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; AUERBACH R, 1960, DEV BIOL, V2, P271, DOI 10.1016/0012-1606(60)90009-9; CORDIER AC, 1980, AM J ANAT, V157, P227, DOI 10.1002/aja.1001570303; HOLLANDER GA, 1995, NATURE, V373, P350, DOI 10.1038/373350a0; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; KISHIHARA K, 1987, EUR J IMMUNOL, V17, P477, DOI 10.1002/eji.1830170407; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KUBO RT, 1989, J IMMUNOL, V142, P2736; LASTER AJ, 1986, DIFFERENTIATION, V31, P67, DOI 10.1111/j.1432-0436.1986.tb00385.x; LEDOUARIN NM, 1984, AM J ANAT, V170, P261, DOI 10.1002/aja.1001700305; MACDONALD HR, 1981, J IMMUNOL, V126, P885; MESSERLE M, UNPUB; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; NEHLS M, 1995, MAMM GENOME, V6, P321, DOI 10.1007/BF00364794; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; NEHLS M, 1994, BIOTECHNIQUES, V17, P770; RICH BE, 1995, J EXP MED, V181, P1223, DOI 10.1084/jem.181.3.1223; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VANVLIET E, 1985, EUR J IMMUNOL, V15, P675, DOI 10.1002/eji.1830150707; WARREN A, 1994, CELL, V15, P45; [No title captured]	28	368	437	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					886	889		10.1126/science.272.5263.886	http://dx.doi.org/10.1126/science.272.5263.886			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629026				2022-12-28	WOS:A1996UK75700063
J	Fest, T; Pron, B; Lefranc, MP; Pierre, C; Angonin, R; deWazieres, B; Soua, Z; Dupond, JL				Fest, T; Pron, B; Lefranc, MP; Pierre, C; Angonin, R; deWazieres, B; Soua, Z; Dupond, JL			Detection of a clonal BCL2 gene rearrangement in tissues from a patient with Whipple disease	ANNALS OF INTERNAL MEDICINE			English	Article							FOLLICULAR LYMPHOMAS; IMMUNE-RESPONSE; MUCOSA; PYLORI		HOP NECKER ENFANTS MALAD, MICROBIOL SERV, F-75743 PARIS 15, FRANCE; INST GENET MOLEC, UMR CNRS 9942, IMMUNOGENET MOLEC LAB, F-34033 MONTPELLIER 1, FRANCE; HOP UNIV JEAN MINJOZ, SERV ANATOMOPATHOL, F-25030 BESANCON, FRANCE; HOP UNIV JEAN MINJOZ, SERV MED INTERNE, F-25030 BESANCON, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Franche-Comte; CHU Besancon; Universite de Franche-Comte; CHU Besancon	Fest, T (corresponding author), NEI, PATHOL LAB, 9000 ROCKVILLE PIKE, BLDG 10, ROOM 2N109, BETHESDA, MD 20892 USA.			fest, thierry/0000-0002-6437-4189				ECTORS N, 1992, HISTOPATHOLOGY, V21, P1; GILLEN CD, 1993, GUT, V34, P1627, DOI 10.1136/gut.34.11.1627; GUPTA S, 1986, GASTROENTEROLOGY, V90, P1286, DOI 10.1016/0016-5085(86)90398-7; MIKRAKI V, 1991, GENE CHROMOSOME CANC, V3, P117, DOI 10.1002/gcc.2870030206; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; RICKMAN LS, 1995, NEW ENGL J MED, V332, P363, DOI 10.1056/NEJM199502093320604; SOUA Z, 1995, EXP CLIN IMMUNOGENET, V12, P16; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; VONHERBAY A, 1989, DEUT MED WOCHENSCHR, V114, P2028; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; YANO T, 1992, BLOOD, V80, P758	11	12	12	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					738	740		10.7326/0003-4819-124-8-199604150-00006	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633834				2022-12-28	WOS:A1996UD93600006
J	Huh, YB; Rose, S; Schoen, RE; Hunt, S; Whitcomb, DC; Finkelstein, S				Huh, YB; Rose, S; Schoen, RE; Hunt, S; Whitcomb, DC; Finkelstein, S			Colonic bacillary angiomatosis	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; EPITHELIOID ANGIOMATOSIS; ROCHALIMAEA; BARTONELLA; INFECTION; DISEASE; CELLS		UNIV PITTSBURGH, PRESBYTERIAN HOSP, MED CTR, DIV GASTROENTEROL & HEPATOL, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, PITTSBURGH, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ADAL KA, 1994, NEW ENGL J MED, V330, P1509, DOI 10.1056/NEJM199405263302108; BRENNER DJ, 1993, INT J SYST BACTERIOL, V43, P777, DOI 10.1099/00207713-43-4-777; COCKERELL CJ, 1991, J INVEST DERMATOL, V97, P812, DOI 10.1111/1523-1747.ep12487507; COCKERELL CJ, 1987, LANCET, V2, P654; CONLEY T, 1994, J LAB CLIN MED, V124, P521; GARCIA FU, 1990, AM J PATHOL, V136, P1125; GRISHAM MB, 1988, DIGEST DIS SCI, V33, pS6, DOI 10.1007/BF01538126; JAMES SP, 1988, GASTROENTEROLOGY, V95, P1667, DOI 10.1016/S0016-5085(88)80094-5; KOEHLER JE, 1995, GASTROENTEROLOGY, V109, P2011, DOI 10.1016/0016-5085(95)90770-X; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; SCHREIBER S, 1991, GASTROENTEROLOGY, V101, P1020, DOI 10.1016/0016-5085(91)90729-5; STOLER MH, 1983, AM J CLIN PATHOL, V80, P714, DOI 10.1093/ajcp/80.5.714; WALFORD N, 1990, HISTOPATHOLOGY, V16, P83	13	10	11	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					735	737		10.7326/0003-4819-124-8-199604150-00005	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633833				2022-12-28	WOS:A1996UD93600005
J	Dickason, RR; Huston, DP				Dickason, RR; Huston, DP			Creation of a biologically active interleukin-5 monomer	NATURE			English	Article							COLONY-STIMULATING FACTOR; BINDING	INTERLEUKIN-5 (IL-5) specifically induces the differentiation of eosinophils, which are important in host defence and the patho genesis of allergies and asthma(1,2). Structurally, IL-5 is a unique member of the short-chain helical-bundle subfamily of cytokines whose canonical motif contains four helices (A-D) arranged in an up-up-down-down topology(3,4). In contrast to other subfamily members, which fold unimolecularly into a single helical bundle(5-8), IL-5 forms a pair of helical bundles by the interdigitation of two identical monomers that contribute a D helix to the other's A-C helices(3). We predicted that the lack of bioactivity by an IL-5 monomer(9) was due to a short loop between helices C and D which physically prevents unimolecular folding of helix D into a functionally obligate structural motif. Here we report that, by lengthening this loop, we have engineered an insertional mutant of IL-5 that was expressed as a monomer with biological activity similar to that of native IL-5. These studies demonstrate that all of the structural features necessary for IL-5 to function are contained within a single helical bundle.	BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA	Baylor College of Medicine	Dickason, RR (corresponding author), BAYLOR COLL MED, DEPT MED, 1 BAYLOR PLAZA, FBRN B567, HOUSTON, TX 77030 USA.			Huston, David/0000-0002-2332-0010				BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; DEVOS R, 1993, J BIOL CHEM, V268, P6581; DICKASON RR, 1994, CYTOKINE, V6, P647, DOI 10.1016/1043-4666(94)90053-1; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KORKE M, 1994, INT ARCH ALLER A IMM, V104, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKENZIE ANJ, 1991, MOL IMMUNOL, V28, P155, DOI 10.1016/0161-5890(91)90099-6; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; Sanderson C J, 1992, Adv Pharmacol, V23, P163, DOI 10.1016/S1054-3589(08)60965-5; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; Summers MD, 1987, MANUAL METHODS BACUL; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194	19	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					652	655		10.1038/379652a0	http://dx.doi.org/10.1038/379652a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628400				2022-12-28	WOS:A1996TV68800056
J	Eidelman, LA; Putterman, D; Putterman, C; Sprung, CL				Eidelman, LA; Putterman, D; Putterman, C; Sprung, CL			The spectrum of septic encephalopathy - Definitions, etiologies, and mortalities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEPSIS; SYSTEM; COMA	Objective.-To determine whether the severity of septic encephalopathy is correlated with gram-negative bacteremia and mortality and whether there exists a single or combination of metabolic derangement(s) that cause septic encephalopathy. Design and Setting.-Prospective case series in an academic medical center. Patients.-Fifty patients selected according to clinical and laboratory criteria for severe sepsis. The criteria included temperature, heart rate, respiratory rate, and hypotension and/or signs of systemic hypoperfusion. Main Outcome Measures.-A single or combination of metabolic and laboratory derangements and organ failures, three different methods to grade the severity of septic encephalopathy, Acute Physiology and Chronic Health Evaluation II (APACHE II) scores, gram-negative bacteremia and infection, and mortality. Results.-Encephalopathy was associated with an increase in mortality when graded by the Glasgow Coma Score; a score of 15 had 16% mortality, 13 to 14 had 20%, 9 to 12 had 50%, and 3 to 8 had 63% mortality (P<.05). Bacteremia was associated with encephalopathy; 13% of septic patients without encephalopathy vs 59% of patients with encephalopathy had bacteremia (P<.001) when graded by altered mental status. Septic encephalopathic patients had elevated serum urea nitrogen and bilirubin levels, increased APACHE II scores, and a higher incidence of renal failure. Conclusions.-The severity of septic encephalopathy correlated with mortality, bacteremia, and renal and hepatic dysfunction. The Glasgow Coma Score is a useful tool for characterizing septic encephalopathy. Considerable variations can be found according to different criteria used to classify septic encephalopathy.	HEBREW UNIV JERUSALEM,HADASSAH UNIV HOSP,DEPT ANESTHESIOL & CRIT CARE MED,IL-91120 JERUSALEM,ISRAEL; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY	Hebrew University of Jerusalem; Yeshiva University; Albert Einstein College of Medicine								[Anonymous], 1992, CRIT CARE MED, V20, P864; BATES DW, 1995, ARCH INTERN MED, V155, P593, DOI 10.1001/archinte.155.6.593; Bleck Thomas P., 1993, P193; BLECK TP, 1993, CRIT CARE MED, V21, P98, DOI 10.1097/00003246-199301000-00019; Bolton CF, 1986, NEW HORIZONS PERSPEC, P157; BOLTON CF, 1993, ANN NEUROL, V33, P4; BOWTON DL, 1989, CRIT CARE CLIN, V5, P785; Freedman D. A., 1980, STATISTICS; JACKSON AC, 1985, CAN J NEUROL SCI, V12, P303, DOI 10.1017/S0317167100035381; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOPPEL JD, 1989, TXB NEPHROLOGY, P1238; KREGER BE, 1980, AM J MED, V68, P332, DOI 10.1016/0002-9343(80)90101-1; LUCE JM, 1987, CHEST, V91, P883, DOI 10.1378/chest.91.6.883; Martin M A, 1991, Infect Dis Clin North Am, V5, P739; MERRILL JP, 1953, AM J MED, V14, P519; MULLIE A, 1988, LANCET, V1, P137; PENDLEBURY WW, 1989, J NEUROPATH EXP NEUR, V48, P290, DOI 10.1097/00005072-198905000-00006; PINE RW, 1983, ARCH SURG-CHICAGO, V118, P242; Plum F, 1980, DIAGNOSIS STUPOR COM, Vthird; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; TEASDALE G, 1974, LANCET, V2, P81; WIJDICKS EFM, 1992, ARCH NEUROL-CHICAGO, V49, P653, DOI 10.1001/archneur.1992.00530300093015; YOUNG GB, 1990, CLIN INVEST MED, V13, P297; YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016; ZEIGLER EJ, 1991, NEW ENGL J MED, V324, P429	25	269	287	2	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					470	473		10.1001/jama.275.6.470	http://dx.doi.org/10.1001/jama.275.6.470			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627969				2022-12-28	WOS:A1996TU63800036
J	Rodewald, HR; Dessing, M; Dvorak, AM; Galli, SJ				Rodewald, HR; Dessing, M; Dvorak, AM; Galli, SJ			Identification of a committed precursor for the mast cell lineage	SCIENCE			English	Article							BONE-MARROW; PERIPHERAL-BLOOD; MICE; HYPERSENSITIVITY; INTERLEUKIN-4; ESTABLISHMENT; MATURATION; EXPRESSION; RECEPTORS; BASOPHILS	Mast cells originate from hematopoietic stem cells, but the mast cell-committed precursor has not been identified. In the study presented here, a cell population in murine fetal blood that fulfills the criteria of progenitor mastocytes was identified. It is defined by the phenotype Thy-1(lo)c-Kit(hi), contains cytoplasmic granules, and expresses RNAs encoding mast cell-associated proteases but lacks expression of the high-affinity immunoglobulin E receptor. Thy-1(lo)c-Kit(hi) cells generated functionally competent mast cells at high frequencies in vitro but lacked developmental potential for other hematopoietic lineages. When transferred intraperitoneally, this population reconstituted the peritoneal mast cell compartment of genetically mast cell-deficient W/W-v mice to wild-type levels.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rodewald, HR (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.				NCI NIH HHS [CA/AI-72074] Funding Source: Medline; NIAID NIH HHS [AI-33372, AI/CA-23990] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023990, R01AI023990, R01AI033372] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN JW, 1991, EUR J IMMUNOL, V21, P2559, DOI 10.1002/eji.1830211037; DVORAK AM, 1993, LAB INVEST, V68, P708; DVORAK AM, 1982, BLOOD, V59, P1279; DVORAK AM, 1994, AM J PATHOL, V144, P160; ENERBACK L, 1974, HISTOCHEMISTRY, V42, P301, DOI 10.1007/BF00492678; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GALLI SJ, 1982, J CELL BIOL, V95, P435, DOI 10.1083/jcb.95.2.435; HUFF TF, 1995, BIOLOGICAL AND MOLECULAR ASPECTS OF MAST CELL AND BASOPHIL DIFFERENTIATION AND FUNCTION, P105; ISCOVE NN, 1979, IMMUNOLOGICAL METHOD, P379; ISHIZAKA K, 1989, CURR OPIN IMMUNOL, V1, P625, DOI 10.1016/0952-7915(89)90031-9; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KINZER CA, 1995, J EXP MED, V182, P575, DOI 10.1084/jem.182.2.575; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P1085; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; KODAMA HA, 1982, J CELL PHYSIOL, V112, P89, DOI 10.1002/jcp.1041120114; KSUGAI T, 1995, BLOOD, V85, P1334; LANTZ CS, 1995, J IMMUNOL, V155, P4024; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Miller H. R. P., 1992, Allergy and immunity to helminths: common mechanisms or divergent pathways., P228; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; OGAWA M, 1991, J EXP MED, V174, P631; PAUL WE, 1993, ADV IMMUNOL, V53, P1, DOI 10.1016/S0065-2776(08)60496-4; RA C, 1989, J BIOL CHEM, V264, P15323; RODEWALD HR, 1994, EMBO J, V13, P4229, DOI 10.1002/j.1460-2075.1994.tb06743.x; RODEWALD HR, 1995, CURR OPIN IMMUNOL, V7, P176, DOI 10.1016/0952-7915(95)80002-6; ROLINK A, 1993, BLOOD, V81, P2290; ROTTEM M, 1992, BLOOD, V79, P972; SCUDAMORE CL, 1995, J EXP MED, V182, P1871, DOI 10.1084/jem.182.6.1871; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SONODA T, 1982, J CELL PHYSIOL, V112, P136, DOI 10.1002/jcp.1041120120; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TSAI M, 1995, AM J PATHOL, V146, P335; TSUJI K, 1991, J CELL PHYSIOL, V148, P362, DOI 10.1002/jcp.1041480306; ZUCKERFRANKLIN D, 1981, BLOOD, V58, P544	45	283	287	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					818	822		10.1126/science.271.5250.818	http://dx.doi.org/10.1126/science.271.5250.818			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8629001				2022-12-28	WOS:A1996TU69400050
J	Olshausen, BA; Field, DJ				Olshausen, BA; Field, DJ			Emergence of simple-cell receptive field properties by learning a sparse code for natural images	NATURE			English	Article							CORTEX	THE receptive fields of simple cells in mammalian primary visual cortex can be characterized as being spatially localized, oriented(1-4) and bandpass (selective to structure at different spatial scales), comparable to the basis functions of wavelet transforms(5,6), One approach to understanding such response properties of visual neurons has been to consider their relationship to the statistical structure of natural images in terms of efficient coding(7-12), Along these lines, a number of studies have attempted to train unsupervised learning algorithms on natural images in the hope of developing receptive fields with similar properties(13-18), but none has succeeded in producing a full set that spans the image space and contains all three of the above properties. Here we investigate the proposal(8,12) that a coding strategy that maximizes sparseness is sufficient to account for these properties, We show that a learning algorithm that attempts to find sparse linear codes for natural scenes will develop a complete family of localized, oriented, bandpass receptive fields, similar to those found in the primary visual cortex, The resulting sparse image code provides a more efficient representation for later stages of processing because it possesses a higher degree of statistical independence among its outputs.	CORNELL UNIV,DEPT PSYCHOL,ITHACA,NY 14853; UNIV CALIF DAVIS,CTR NEUROSCI,DAVIS,CA 95616	Cornell University; University of California System; University of California Davis			Field, David j/B-9211-2008					Aticky JJ, 2011, NETWORK-COMP NEURAL, V22, P4, DOI [10.1088/0954-898X/3/2/009, 10.3109/0954898X.2011.638888]; Barlow HB, 1989, NEURAL COMPUT, V1, P295, DOI 10.1162/neco.1989.1.3.295; BARROW HG, 1994, IEEE 1 INT C NEUR NE, V4, P115; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; DAUGMAN JG, 1989, IEEE T BIO-MED ENG, V36, P107, DOI 10.1109/10.16456; DAUGMAN JG, 1990, COMPUTATIONAL NEUROS, P403; DEVALOIS RL, 1982, VISION RES, V22, P545, DOI 10.1016/0042-6989(82)90113-4; FIELD DJ, 1994, NEURAL COMPUT, V6, P559, DOI 10.1162/neco.1994.6.4.559; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; Field DJ, 1993, WAVELETS FRACTALS FO, P151; FOLDIAK P, 1990, BIOL CYBERN, V64, P165, DOI 10.1007/BF02331346; FYFE C, 1995, NETWORK-COMP NEURAL, V6, P333, DOI 10.1088/0954-898X/6/3/002; HANCOCK PJB, 1992, NETWORK-COMP NEURAL, V3, P61, DOI 10.1088/0954-898X/3/1/008; Harpur GF, 1996, NETWORK-COMP NEURAL, V7, P277, DOI 10.1088/0954-898X/7/2/007; HINTON GE, 1995, SCIENCE, V268, P1158, DOI 10.1126/science.7761831; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; INTRATOR N, 1992, NEURAL COMPUT, V4, P98, DOI 10.1162/neco.1992.4.1.98; JONES JP, 1987, J NEUROPHYSIOL, V58, P1233, DOI 10.1152/jn.1987.58.6.1233; LAW CC, 1994, P NATL ACAD SCI USA, V91, P7797, DOI 10.1073/pnas.91.16.7797; LINSKER R, 1988, COMPUTER         MAR, P105; LU ZL, 1996, 9615 U CAL IRV I MAT; Olshausen BA, 1996, NETWORK-COMP NEURAL, V7, P333, DOI 10.1088/0954-898X/7/2/014; PARKER AJ, 1988, J OPT SOC AM A, V5, P598, DOI 10.1364/JOSAA.5.000598; RUDERMAN DL, 1994, NETWORK-COMP NEURAL, V5, P517, DOI 10.1088/0954-898X/5/4/006; Sanger T. D., 1989, ADV NEURAL INFORMATI, V1, P11; SAUND E, 1995, NEURAL COMPUT, V7, P51, DOI 10.1162/neco.1995.7.1.51; SRINIVASAN MV, 1982, PROC R SOC SER B-BIO, V216, P427, DOI 10.1098/rspb.1982.0085; VANHATEREN JH, 1992, NATURE, V360, P68, DOI 10.1038/360068a0; Zemel R, 1993, THESIS U TORONTO	30	3389	3610	25	305	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1996	381	6583					607	609		10.1038/381607a0	http://dx.doi.org/10.1038/381607a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637596				2022-12-28	WOS:A1996UQ65700051
J	Burns, R				Burns, R			A piece of my mind - Frozen in time	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1775	1775						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP307	8637178				2022-12-28	WOS:A1996UP30700034
J	Dobner, T; Horikoshi, N; Rubenwolf, S; Shenk, T				Dobner, T; Horikoshi, N; Rubenwolf, S; Shenk, T			Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor	SCIENCE			English	Article							LATE GENE-EXPRESSION; WILD-TYPE; DNA-BINDING; EARLY REGION-4; TRANSFORMED-CELLS; PROTEIN; SEQUENCE; ANTIGEN; DOMAIN; TRANSACTIVATION	The adenovirus E4orf6 protein is shown here to interact with the cellular tumor suppressor protein p53 and to block p53-mediated transcriptional activation. The adenovirus protein inhibited the ability of p53 to bind to human TAF(II)31, a component of transcription factor IID (TFIID). Earlier work demonstrated that the interaction of p53 with TAF(II)31 involves a sequence near the NH2-terminus of p53, whereas the E4orf6-p53 interaction occurs within amino acids 318 to 360 of p53. Thus, the E4orf6 protein interacts at a site on p53 distinct from the domain that binds to TAF(II)31 but nevertheless inhibits the p53-TAF(II)31 interaction.	PRINCETON UNIV, DEPT MOLEC BIOL, HOWARD HUGHES MED INST, PRINCETON, NJ 08544 USA; UNIV REGENSBURG, INST MED MIKROBIOL & HYG, D-93042 REGENSBURG, GERMANY	Howard Hughes Medical Institute; Princeton University; University of Regensburg			Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178				BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BRAIN R, 1994, ONCOGENE, V9, P1775; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KAO CC, 1990, VIROLOGY, V52, P456; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; PRIVES C, 1994, COLD SPRING HARB SYM, V59, P207, DOI 10.1101/SQB.1994.059.01.025; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	39	256	263	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 7	1996	272	5267					1470	1473		10.1126/science.272.5267.1470	http://dx.doi.org/10.1126/science.272.5267.1470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633237				2022-12-28	WOS:A1996UP89900044
J	Thorpe, S; Fize, D; Marlot, C				Thorpe, S; Fize, D; Marlot, C			Speed of processing in the human visual system	NATURE			English	Article							EVENT-RELATED POTENTIALS; FACES; PICTURES; RECOGNITION; TIME	How long does it take for the human visual system to process a complex natural image? Subjectively, recognition of familiar objects and scenes appears to be virtually instantaneous, but measuring this processing time experimentally has proved difficult. Behavioural measures such as reaction times can be used(1), but these include not only visual processing but also the time required for response execution. However, event-related potentials (ERPs) can sometimes reveal signs of neural processing well before the motor output(2). Here we use a go/no-go categorization task in which subjects have to decide whether a previously unseen photograph, flashed on for just 20 ms, contains an animal. ERP analysis revealed a frontal negativity specific to no-go trials that develops roughly 150 ms after stimulus onset. We conclude that the visual processing needed to perform this highly demanding task can be achieved in under 150 ms.			Thorpe, S (corresponding author), CTR RECH CERVEAU & COGNIT,UMR 5549,F-31062 TOULOUSE,FRANCE.		THORPE, Simon J/A-5661-2008; Fize, Denis/F-4525-2011	THORPE, Simon J/0000-0003-4997-3367; 				ALLISON T, 1994, CEREB CORTEX, V4, P544, DOI 10.1093/cercor/4.5.544; ALLISON T, 1994, J NEUROPHYSIOL, V71, P821, DOI 10.1152/jn.1994.71.2.821; BARRETT SE, 1988, NEUROPSYCHOLOGIA, V26, P105, DOI 10.1016/0028-3932(88)90034-6; BARRETT SE, 1989, NEUROPSYCHOLOGIA, V27, P913, DOI 10.1016/0028-3932(89)90067-5; BARRETT SE, 1990, BRAIN COGNITION, V14, P201, DOI 10.1016/0278-2626(90)90029-N; BARRETT SE, 1990, BRAIN LANG, V38, P424, DOI 10.1016/0093-934X(90)90125-Z; BOBES MA, 1994, BRAIN COGNITION, V26, P1, DOI 10.1006/brcg.1994.1039; BULTHOFF HH, 1995, CEREB CORTEX, V5, P247, DOI 10.1093/cercor/5.3.247; CELEBRINI S, 1993, VISUAL NEUROSCI, V10, P811, DOI 10.1017/S0952523800006052; GEMBA DH, 1989, NEUROSCI LETT, V101, P263, DOI 10.1016/0304-3940(89)90543-0; HALGREN E, 1994, J PHYSIOL-PARIS, V88, P1, DOI 10.1016/0928-4257(94)90092-2; HOLCOMB PJ, 1994, BRAIN COGNITION, V24, P259, DOI 10.1006/brcg.1994.1014; HUMMEL JE, 1992, PSYCHOL REV, V99, P480, DOI 10.1037/0033-295X.99.3.480; INTRAUB H, 1981, J EXP PSYCHOL HUMAN, V7, P604, DOI 10.1037/0096-1523.7.3.604; JEFFREYS DA, 1992, EXP BRAIN RES, V91, P340; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; ORAM MW, 1992, J NEUROPHYSIOL, V68, P70, DOI 10.1152/jn.1992.68.1.70; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; POTTER MC, 1975, NATURE, V253, P437, DOI 10.1038/253437a0; PRATARELLI ME, 1994, BRAIN COGNITION, V24, P137, DOI 10.1006/brcg.1994.1008; ROLLS ET, 1994, P ROY SOC B-BIOL SCI, V257, P9, DOI 10.1098/rspb.1994.0087; RUDELL AP, 1992, ELECTROEN CLIN NEURO, V83, P77, DOI 10.1016/0013-4694(92)90135-5; RUGG MC, 1995, ELECTROPHYSIOLOGY MI; RUGG MD, 1995, J COGNITIVE NEUROSCI, V7, P209, DOI 10.1162/jocn.1995.7.2.209; SASAKI K, 1993, NEUROSCI RES, V18, P249, DOI 10.1016/0168-0102(93)90062-U; SEECK M, 1992, EXP BRAIN RES, V92, P338; THORPE SJ, 1989, CONNECTIONISM IN PERSPECTIVE, P63; VETTER T, 1995, CEREB CORTEX, V5, P261, DOI 10.1093/cercor/5.3.261	28	2360	2433	12	307	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 6	1996	381	6582					520	522		10.1038/381520a0	http://dx.doi.org/10.1038/381520a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UP435	8632824				2022-12-28	WOS:A1996UP43500059
J	Grimm, RH; Flack, JM; Grandits, GA; Elmer, PJ; Neaton, JD; Cutler, JA; Lewis, C; McDonald, R; Schoenberger, J; Stamler, J				Grimm, RH; Flack, JM; Grandits, GA; Elmer, PJ; Neaton, JD; Cutler, JA; Lewis, C; McDonald, R; Schoenberger, J; Stamler, J			Long-term effects on plasma lipids of diet and drugs to treat hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FACTOR INTERVENTION TRIAL; CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; BLOOD-PRESSURE; MILD HYPERTENSION; RISK; LIPOPROTEINS; MRFIT; PARTICIPANTS; DIURETICS	Objective.-To compare long-term plasma lipid changes among 6 antihypertensive treatment interventions for stage I (mild) hypertension. Design.-Multicenter, randomized, double-blind, parallel-group clinical trial. Setting.-Four academic clinical research units in the United States. Participants.-A total of 902 men and women, aged 45 to 69 years, with stage I diastolic hypertension (diastolic blood pressure <100 mm Hg), recruited from 11 914 persons screened in their communities. Interventions.-Participants were randomized to 1 of 6 treatment groups: (1) placebo, (2) beta-blocker (acebutolol), (3) calcium antagonist (amlodipine), (4) diuretic (chlorthalidone), (5) alpha(1)-antagonist (doxazosin), and (6) angiotensin-converting enzyme inhibitor (enalapril). All groups received intensive lifestyle counseling to achieve weight loss, dietary sodium and alcohol reduction, and increased physical activity. Main Outcomes Measures.-Changes in plasma total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides from baseline to annual visits through 4 years. Results.-Mean changes in all plasma lipids were favorable in all groups. The degree of weight loss with fat-modified diet and exercise was significantly related to favorable lipid changes. Significant differences (P<.01) among groups for average changes during follow-up in each lipid were observed. Decreases in plasma total cholesterol and LDL cholesterol were greater with doxazosin and acebutolol (for plasma total cholesterol, 0.36 and 0.30 mmol/L [13.8 and 11.7 mg/dL], respectively), less with chlorthalidone and placebo (0.12 and 0.13 mmol/L [4.5 and 5.1 mg/dL], respectively). Decreases in triglycerides were greater with doxazosin and enalapril, least with acebutolol. Increases in HDL cholesterol were greater with enalapril and doxazosin, least with acebutolol. Significant relative increases in plasma total cholesterol with chlorthalidone compared with placebo at 12 months were no longer present at 24 months and beyond, when mean plasma total cholesterol for the chlorthalidone group fell below baseline. Analyses of participants continuing to receive chlorthalidone throughout the 4 years of follow-up indicated this was not due solely to an increasing percentage of participants changing or discontinuing use of medication during follow-up. Conclusions.-Weight loss with a fat-modified diet plus increased exercise produces favorable long-term effects on blood pressure and all plasma lipid fractions of adults with stage I hypertension; blood pressure reduction is enhanced to a similar degree by addition of a drug from any one of 5 classes of antihypertensive medication. These drugs differ quantitatively in influencing the degree of long-term favorable effects on blood lipids obtained with nutritional-hygienic treatment.	UNIV MINNESOTA,SCH MED,DIV CARDIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT INTERNAL MED,DIV GEN MED,MINNEAPOLIS,MN 55455; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR HYPERTENS,WINSTON SALEM,NC; UNIV MINNESOTA,SCH PUBL HLTH,DIV BIOSTAT,MINNEAPOLIS,MN; UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN; NHLBI,DIV EPIDEMIOL & CLIN APPLICAT,BETHESDA,MD 20892; UNIV ALABAMA,SCH MED,DEPT MED,BIRMINGHAM,AL; UNIV PITTSBURGH,DEPT MED,PITTSBURGH,PA; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PREVENT MED,CHICAGO,IL 60612; NORTHWESTERN UNIV,SCH MED,DEPT PREVENT MED,CHICAGO,IL	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Wake Forest University; Wake Forest Baptist Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Rush University; Northwestern University					NHLBI NIH HHS [R01-HL34767] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034767] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES RP, 1976, LANCET, V1, P721; [Anonymous], 1994, Circulation, V89, P1333; CAGGIULA AW, 1981, PREV MED, V10, P443, DOI 10.1016/0091-7435(81)90060-8; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Grimm R. H., 1989, HYPERTENSION S1, V13, P131; GRIMM RH, 1981, ANN INTERN MED, V94, P7, DOI 10.7326/0003-4819-94-1-7; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; LARDINOIS CK, 1988, ARCH INTERN MED, V148, P1280, DOI 10.1001/archinte.148.6.1280; LASSER NL, 1984, AM J MED, V76, P52, DOI 10.1016/0002-9343(84)90957-4; LEHTONEN A, 1984, ACTA MED SCAND, V216, P57; Lewis CE, 1996, ARCH INTERN MED, V156, P377, DOI 10.1001/archinte.156.4.377; LIU K, 1978, J CHRON DIS, V31, P399, DOI 10.1016/0021-9681(78)90004-8; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MASCIOLI SR, 1990, AM J CARDIOL, V66, pC32, DOI 10.1016/0002-9149(90)90760-X; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; SNEDECOR CW, 1967, STATISTICAL METHODS; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STAMLER J, IN PRESS AM J CLIN N; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; TILLOTSON JL, 1981, J AM DIET ASSOC, V78, P235; WEIDMANN P, 1988, ARCH INTERN MED, V148, P1280; WILLIAMS WR, 1986, AM J PREV MED, V2, P248; 1993, ARCH INTERN MED, V153, P154; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1988, ARCH INTERN MED, V148, P36; 1974, LIPID RES CLIN PROGR, V1, P74; 1992, BRIT MED J, V304, P405; 1984, JAMA-J AM MED ASSOC, V251, P365; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1991, ARCH INTERN MED, V151, P1413	33	121	124	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	1996	275	20					1549	1556		10.1001/jama.275.20.1549	http://dx.doi.org/10.1001/jama.275.20.1549			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL029	8622245				2022-12-28	WOS:A1996UL02900026
J	MacGregor, GA; Sever, PS				MacGregor, GA; Sever, PS			Salt - Overwhelming evidence but still no action: Can a consensus be reached with the food industry?	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; ESSENTIAL-HYPERTENSION; ETIOLOGY; KIDNEY; TRIAL		UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,LONDON W2 7PG,ENGLAND	Imperial College London	MacGregor, GA (corresponding author), ST GEORGE HOSP,SCH MED,BLOOD PRESSURE UNIT,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.							ANTONIOS TFT, IN PRESS LANCET; Cardiovascular Review Group Great Britain-Department of Health, 1994, NUTR ASP CARD DIS; DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009; DEWARDENER HE, 1990, CLIN SCI, V79, P193, DOI 10.1042/cs0790193; DEWARDENER HE, 1990, CLIN SCI, V79, P289, DOI 10.1042/cs0790289; FORTE JG, 1989, J HUM HYPERTENS, V3, P179; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; MACGREGOR GA, 1989, LANCET, V2, P1244, DOI 10.1016/S0140-6736(89)91852-7; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; *ROWL CO, 1991, LIF FACTS SALT; SEVER PS, 1989, J HYPERTENS, V7, pS9, DOI 10.1097/00004872-198902001-00004; SINGER DRJ, 1995, HYPERTENSION, V25, P1042, DOI 10.1161/01.HYP.25.5.1042; UZODIKE VO, 1993, THESIS U LONDON LOND	14	64	68	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1287	1289		10.1136/bmj.312.7041.1287	http://dx.doi.org/10.1136/bmj.312.7041.1287			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634621	Green Published			2022-12-28	WOS:A1996UM40400029
J	Sporn, MB				Sporn, MB			The war on cancer	LANCET			English	Review							PROMYELOCYTIC LEUKEMIA; RETINOIC ACID; DIFFERENTIATION; CARCINOGENESIS; CELLS	25 years ago, then President Nixon ''declared'' War on Cancer. In this personal commentary, the war is reviewed. There have been obvious triumphs, for instance in cure of acute lymphocytic leukaemia and other childhood cancers, Hodgkin's disease, and testicular cancer. However, substantial advances in molecular oncology have yet to impinge on mortality statistics. Too many adults still die from common epithelial cancers. Failure to appreciate that local invasion and distant metastasis rather then cell proliferation itself are lethal, obsession with cure of advanced disease rather than prevention of early disease, and neglect of the need to arrest preneoplastic lesions may all have served to make victory elusive.	DARTMOUTH COLL SCH MED,DEPT MED,HANOVER,NH 03755	Dartmouth College	Sporn, MB (corresponding author), DARTMOUTH COLL SCH MED,DEPT PHARMACOL,HANOVER,NH 03755, USA.							BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; BOONE CW, 1992, CANCER RES, V52, P1651; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHEN C, 1995, CANCER RES, V55, P4230; CLARK WH, 1995, ACTA ONCOL, V34, P3, DOI 10.3109/02841869509093632; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; Costa Alberto, 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P655; Cutler Jeffrey A., 1995, P253; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FARBER E, 1991, CANCER RES, V51, P2751; FARBER E, 1995, CANCER RES, V55, P3759; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FOULDS L, 1969, NEOPLASTIC DEV; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GREENWALD P, 1995, CA-CANCER J CLIN, V45, P31, DOI 10.3322/canjclin.45.1.31; Hermon C, 1996, BRIT J CANCER, V73, P955, DOI 10.1038/bjc.1996.171; Hong WK, 1995, CLIN CANCER RES, V1, P677; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Jordan VC, 1995, CLIN CANCER RES, V1, P467; JORDAN VC, 1994, LONGTERM TAMOSIFEN T; Knudson AG, 1995, ADV CANCER RES, V67, P1, DOI 10.1016/S0065-230X(08)60708-3; KOOP CE, 1995, AM J PUBLIC HEALTH, V85, P759, DOI 10.2105/AJPH.85.6.759; KOSARY CL, 1995, NCI NIH PUB; Levi F, 1996, EUR J CANCER, V32A, P652, DOI 10.1016/0959-8049(95)00582-X; LI FP, 1995, CANCER EPIDEM BIOMAR, V4, P579; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mintz B, 1981, Adv Cancer Res, V34, P211, DOI 10.1016/S0065-230X(08)60243-2; MITELMAN F, 1994, CATALOG CHROMOSOME A; PEDERSENBJERGAARD J, 1994, BLOOD, V83, P2780, DOI 10.1182/blood.V83.10.2780.2780; PEDTERSEN TR, 1995, NEW ENGL J MED, V333, P1350; POSTE G, 1982, Invasion and Metastasis, V2, P137; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Smith G A, 1995, Important Adv Oncol, P201; Smith MA, 1996, JNCI-J NATL CANCER I, V88, P407, DOI 10.1093/jnci/88.7.407; Sporn M. B., 1990, PEPTIDE GROWTH FACTO; SPORN MB, 1991, CANCER RES, V51, P6215; SPORN MB, 1983, CANCER RES, V43, P3034; SPORN MB, IN PRESS CANC MED; SPORN MB, 1980, NATURE, V280, P107; VOGELSTEIN B, 1994, COLD SPRING HARB SYM, V59, P517, DOI 10.1101/SQB.1994.059.01.057; WATTENBERG LW, 1993, CANCER RES, V53, P5890; Weinberg RA, 1995, CANCER SURV, V25, P3; [No title captured]; 1992, LANCET, V339, P71; 1976, CANCER RES, V36, P2475	49	492	513	0	39	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1377	1381		10.1016/S0140-6736(96)91015-6	http://dx.doi.org/10.1016/S0140-6736(96)91015-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637346	hybrid			2022-12-28	WOS:A1996UL90400014
J	Ebert, M; Grossmann, T; Heil, W; Otten, WE; Surkau, R; Leduc, M; Bachert, P; Knopp, MV; Schad, LR; Thelen, M				Ebert, M; Grossmann, T; Heil, W; Otten, WE; Surkau, R; Leduc, M; Bachert, P; Knopp, MV; Schad, LR; Thelen, M			Nuclear magnetic resonance imaging with hyperpolarised helium-3	LANCET			English	Article								Background Magnetic resonance imaging (MRI) relies on magnetisation of hydrogen nuclei (protons) of water molecules in tissue as source of the signal. This technique has been valuable for studying tissues that contain significant amounts of water, but biological settings with low proton content, notably the lungs, are difficult to image. We report use of spin-polarised helium-3 for lung MRI. Methods A volunteer inhaled hyperpolarised He-3 to fill the lungs, which were imaged with a conventional MRI detector assembly. The nuclear spin polarisation of helium, and other noble gases, can be greatly enhanced by laser optical pumping and is about 10(5) times larger than the polarisation of water protons, This enormous gain in polarisation easily overcomes the loss in signal due to the lower density of the gas. Findings The in-vivo experiment was done in a whole-body MRI scanner. The He-3 image showed clear demarcation of the lung against diaphragm, heart, chest wall, and blood vessels (which gave no signal). The signal intensity within the air spaces was greatest in lung regions that are preferentially ventilated in the supine position; less well ventilated areas, such as the apices, showed a weaker signal. Interpretation MRI with hyperpolarised He-3 gas could be an alternative to established nuclear medicine methods, The ability to image air spaces offers the possibility of investigating physiological and pathophysiological processes in pulmonary ventilation and differences in its regional distribution.	UNIV MAINZ,INST PHYS,D-55099 MAINZ,GERMANY; UNIV MAINZ,KLIN POLIKLIN RADIOL,D-55099 MAINZ,GERMANY; ECOLE NORMALE SUPER,F-75231 PARIS,FRANCE; DEUTSCH KREBSFORSCHUNGSZENTRUM,FORSCH SCHWERPUNKT RADIOL DIAGNOST & THERAPIE,HEIDELBERG,GERMANY	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Helmholtz Association; German Cancer Research Center (DKFZ)								ALBERT MS, 1994, NATURE, V370, P199, DOI 10.1038/370199a0; AMINOFF CG, 1989, REV PHYS APPL, V24, P827, DOI 10.1051/rphysap:01989002408082700; BECKER J, 1994, NUCL INSTRUM METH A, V346, P45, DOI 10.1016/0168-9002(94)90687-4; ECKERT G, 1992, NUCL INSTRUM METH A, V320, P53, DOI 10.1016/0168-9002(92)90769-Z; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; HEIL W, 1995, PHYS LETT A, V201, P337, DOI 10.1016/0375-9601(95)00243-V; HEIL W, IN PRESS J NEUTRON R; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; SAAM B, 1995, PHYS REV A, V52, P862, DOI 10.1103/PhysRevA.52.862; WEST JB, 1971, LANCET, V1, P839; WEST JB, 1972, J APPL PHYSIOL, V32, P332, DOI 10.1152/jappl.1972.32.3.332	11	168	175	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1297	1299		10.1016/S0140-6736(96)90940-X	http://dx.doi.org/10.1016/S0140-6736(96)90940-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622506				2022-12-28	WOS:A1996UK75800011
J	vanGent, DC; Ramsden, DA; Gellert, M				vanGent, DC; Ramsden, DA; Gellert, M			The RAG1 and RAG2 proteins establish the 12/23 rule in V(D)J recombination	CELL			English	Article							MOUSE THYMOCYTES; SIGNALS; DNA	V(D)J recombination requires a pair of signal sequences with spacer lengths of 12 and 23 base pairs. Cleavage by the RAG1 and RAG2 proteins was previously shown to demand only a single signal sequence. Here, we establish conditions where 12- and 23-spacer signal sequences are both necessary for cleavage. Coupled cutting at both sites requires only the RAG1 and RAG2 proteins, but depends on the metal ion. In Mn2+, a single signal sequence supports efficient double strand cleavage, but cutting in Mg2+ requires two signal sequences and is best with the canonical 12/23 pair. Thus, the RAG proteins determine both aspects of the specificity of V(D)J recombination, the recognition of a single signal sequence and the correct 12/23 coupling in a pair of signals.			vanGent, DC (corresponding author), NIDDKD,MOLEC BIOL LAB,NIH,BETHESDA,MD 20892, USA.			Ramsden, Dale/0000-0003-1575-4748				BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; GELLERT M, 1992, ANNU REV GENET, V22, P425; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; RAMSDEN DA, 1996, IN PRESS EMBO J; Roberts R, 1993, NUCLEASES, P35; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592	18	239	240	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					107	113		10.1016/S0092-8674(00)81086-7	http://dx.doi.org/10.1016/S0092-8674(00)81086-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620529	Bronze			2022-12-28	WOS:A1996UE55900013
J	Basade, MM; Gulati, SC				Basade, MM; Gulati, SC			High-dose chemotherapy with autologous bone marrow stem-cell rescue in lung cancer	LANCET			English	Editorial Material							THERAPY; CARCINOMA; SUPPORT		NARGIS DUTT MEM CANC HOSP,BARSHI,INDIA; CORNELL UNIV,MED CTR,NEW YORK HOSP,DIV HEMATOL ONCOL,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital	Basade, MM (corresponding author), TATA MEM HOSP,DEPT MED ONCOL,BARSHI,INDIA.							BRUGGER W, 1995, SEMIN ONCOL, V22, P3; CANON JL, 1988, EUR J CANCER CLIN ON, V24, P147, DOI 10.1016/0277-5379(88)90245-3; ELIAS A, 1995, HIGH DOSE CANC THERA, P824; ELIAS AD, 1993, CHEST, V103, pS433, DOI 10.1378/chest.103.4.433S; LEONARD RCF, 1990, CANCER RES, V50, P6545; MARANGOLO M, 1989, BONE MARROW TRANSPL, V4, P405; SEIFTER EJ, 1988, SEMIN ONCOL, V15, P278; SPITZER G, 1986, J CLIN ONCOL, V4, P4, DOI 10.1200/JCO.1986.4.1.4; STAHEL RA, 1985, J CLIN ONCOL, V3, P455, DOI 10.1200/JCO.1985.3.4.455; WARDE P, 1992, J CLIN ONCOL, V10, P890, DOI 10.1200/JCO.1992.10.6.890	10	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					847	848		10.1016/S0140-6736(96)91341-0	http://dx.doi.org/10.1016/S0140-6736(96)91341-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622387				2022-12-28	WOS:A1996UC45000005
J	Ericsson, CG; Hamsten, A; Nilsson, J; Grip, L; Svane, B; deFaire, U				Ericsson, CG; Hamsten, A; Nilsson, J; Grip, L; Svane, B; deFaire, U			Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients	LANCET			English	Article							MYOCARDIAL-INFARCTION; MALE SURVIVORS; REGRESSION; PREVENTION; THERAPY	Background Bezafibrate has effects on lipid metabolism and haemostatic function. We undertook a double-blind, placebo-controlled intervention trial, the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT), to establish whether bezafibrate (200 mg three times daily) could retard or prevent the progression of atherosclerotic lesions in dyslipidaemic male survivors of myocardial infarction who were younger than 45 years at the time of the event. Methods 92 patients completed an initial 3-month period of dietary intervention and were randomly assigned to treatment with bezafibrate or placebo. Dietary intervention continued throughout the trial. Coronary angiography was done at baseline and after 2 and 5 years. 81 patients (42 bezafibrate treated and 39 placebo treated) who underwent baseline angiography and at least one post treatment angiogram were included in the efficacy analysis, The primary endpoint was change in mean minimum lumen diameter. Findings The mean minimum lumen diameter decreased from baseline to the last angiographic assessment (2 or 5 years) by 0.06 mm (95% CI 0.15 reduction to 0.01 increase) in the bezafibrate group and by 0.17 mm (0.33 reduction to 0.09 increase) in the placebo group. The treatment effect was therefore 0 13 mm (95% CI 0.10 to 0.15; p=0.049). Parallel treatment effects, although not statistically significant, were observed for the secondary angiographic endpoints (mean segment diameter 0.02 mm [0.01-0.04] and percentage stenosis -3.41% [-4.00 to -2.98]). The cumulative coronary event rate was significantly lower among bezafibrate-treated than among placebo-treated patients (three vs 11 patients; p=0.02). There were significant treatment effects of bezafibrate for serum concentrations of cholesterol (-9%; p<0.001), very-low-density-lipoprotein (VLDL) cholesterol (-35%; p<0.001), serum triglycerides (-31%; p<0.001), VLDL triglycerides (-37%; p<0.001), and plasma fibrinogen (-12%; p=0.001), whereas low-density (LDL) cholesterol concentrations did not change. High density lipoprotein (HDL) cholesterol increased significantly with bezafibrate (9%; p=0.02). Interpretation The results show that bezafibrate improves dyslipidaemia, lowers plasma fibrinogen, slows the progression of focal coronary atherosclerosis, and reduces coronary events in young survivors of myocardial infarction.	KAROLINSKA HOSP,DEPT MED,DIV CARDIOVASC MED,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT CARDIOL,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT THORAC RADIOL,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,ATHEROSCLEROSIS RES UNIT,KING GUSTAF V RES INST,S-17176 STOCKHOLM,SWEDEN; DANDERYD HOSP,DIV CARDIOL,DEPT MED,STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Danderyds Hospital								[Anonymous], 1994, LANCET, V344, P633; Austen W G, 1975, Circulation, V51, P5; Austin Melissa A., 1994, Current Opinion in Lipidology, V5, P395, DOI 10.1097/00041433-199412000-00002; BERGSTRAND R, 1982, EUR HEART J, V3, P130, DOI 10.1093/oxfordjournals.eurheartj.a061274; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; DEFAIRE U, 1995, DRUG EXP CLIN RES, V21, P105; GOLDBOURT U, 1993, AM J CARDIOL, V71, P909, DOI 10.1016/0002-9149(93)90905-R; HAMSTEN A, 1986, ATHEROSCLEROSIS, V59, P223, DOI 10.1016/0021-9150(86)90051-1; HAMSTEN A, 1986, BRIT HEART J, V55, P58; HAMSTEN A, 1987, AM HEART J, V113, P917, DOI 10.1016/0002-8703(87)90052-4; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HAMSTEN A, 1987, AM J CARDIOL, V59, P14, DOI 10.1016/S0002-9149(87)80061-9; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HODIS HN, 1995, CURR OPIN LIPIDOL, V6, P209, DOI 10.1097/00041433-199508000-00004; HODIS HN, 1994, CIRCULATION, V90, P42, DOI 10.1161/01.CIR.90.1.42; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; LEHMANN EL, 1986, TESTING STATISTICAL; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; MALMBERG K, 1994, J AM COLL CARDIOL, V24, P592, DOI 10.1016/0735-1097(94)90002-7; MONK JP, 1987, DRUGS, V33, P539, DOI 10.2165/00003495-198733060-00002; REIBER J, 1991, QUANTITATIVE CORONAR; STAHLBERG D, 1992, CARDIOVASC DRUG REV, V10, P259, DOI 10.1111/j.1527-3466.1992.tb00250.x; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; TORNVALL P, 1991, ATHEROSCLEROSIS, V90, P67, DOI 10.1016/0021-9150(91)90245-X; 1993, EUR HEART J, V14, P8	27	422	437	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					849	853		10.1016/S0140-6736(96)91343-4	http://dx.doi.org/10.1016/S0140-6736(96)91343-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622389				2022-12-28	WOS:A1996UC45000007
J	Rivers, JK				Rivers, JK			Melanoma	LANCET			English	Article							MALIGNANT-MELANOMA; DIAGNOSIS; GENE		BRITISH COLUMBIA CANC AGCY, VANCOUVER, BC V5Z 4E8, CANADA	British Columbia Cancer Agency	Rivers, JK (corresponding author), UNIV BRITISH COLUMBIA, DIV DERMATOL, VANCOUVER HOSP & HLTH SCI CTR, 835 W 10TH AVE, VANCOUVER, BC V5Z 4E8, CANADA.		Rivers, Jason/K-1031-2019	Rivers, Jason/0000-0002-0131-1607				ARMSTRONG BK, 1993, MELANOMA RES, V3, P395, DOI 10.1097/00008390-199311000-00002; ARMSTRONG BK, 1994, CANCER SURV, V20, P219; AVRIL MF, 1994, WHO MELANOMA PUBLICA, V3; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BARTH A, 1995, CANCER, V75, P726, DOI 10.1002/1097-0142(19950115)75:2+<726::AID-CNCR2820751417>3.0.CO;2-R; BINDER M, 1995, ARCH DERMATOL, V131, P286, DOI 10.1001/archderm.131.3.286; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CEBALLOS PI, 1995, NEW ENGL J MED, V332, P656, DOI 10.1056/NEJM199503093321007; COATES AS, 1995, J AM COLL SURGEONS, V180, P402; GARBE C, 1994, J INVEST DERMATOL, V102, P695, DOI 10.1111/1523-1747.ep12374280; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1994, J NATL CANCER I, V86, P1385, DOI 10.1093/jnci/86.18.1385; GREEN A, 1994, J AM ACAD DERMATOL, V31, P958, DOI 10.1016/S0190-9622(94)70264-0; GRIN CM, 1990, ARCH DERMATOL, V126, P763, DOI 10.1001/archderm.126.6.763; GRITTERS LS, 1993, J NUCL MED, V34, P1420; HALL PN, 1995, BRIT J DERMATOL, V132, P325, DOI 10.1111/j.1365-2133.1995.tb08664.x; HEALSMITH MF, 1994, BRIT J DERMATOL, V130, P48, DOI 10.1111/j.1365-2133.1994.tb06881.x; HO RCS, 1995, CANCER, V75, P735, DOI 10.1002/1097-0142(19950115)75:2+<735::AID-CNCR2820751418>3.0.CO;2-Q; HUGHES DG, 1992, CLIN RADIOL, V46, P290, DOI 10.1016/S0009-9260(05)80176-X; *INT AG RES CANC, 1992, IARC MON EV CARC RIS, V55; JOHNSON TM, 1995, J AM ACAD DERMATOL, V32, P689, DOI 10.1016/0190-9622(95)91443-9; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIRKPATRICK CS, 1994, EPIDEMIOLOGICAL ASPE, P243; Kirkwood John M., 1994, Current Opinion in Oncology, V6, P204, DOI 10.1097/00001622-199403000-00014; KREMENTZ ET, 1994, ANN SURG, V220, P520, DOI 10.1097/00000658-199410000-00010; MACKIE RM, 1992, BRIT MED J, V304, P1012, DOI 10.1136/bmj.304.6833.1012; MARGHOOB AA, 1995, CANCER-AM CANCER SOC, V75, P707, DOI 10.1002/1097-0142(19950115)75:2+<707::AID-CNCR2820751415>3.0.CO;2-W; MARKS R, 1995, ARCH DERMATOL, V131, P474, DOI 10.1001/archderm.131.4.474; MELIA J, 1995, BRIT J DERMATOL, V132, P405, DOI 10.1111/j.1365-2133.1995.tb08674.x; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; *NAT CANC I CAN, 1995, CAN CANC STAT 1995; PION IA, 1995, CANCER, V75, P637, DOI 10.1002/1097-0142(19950115)75:2+<637::AID-CNCR2820751404>3.0.CO;2-#; RIGEL DS, 1989, CANCER, V63, P386, DOI 10.1002/1097-0142(19890115)63:2<386::AID-CNCR2820630231>3.0.CO;2-6; RIVERS JK, 1992, ARCH DERMATOL, V128, P537, DOI 10.1001/archderm.128.4.537; VOIGT H, 1995, CANCER, V75, P981, DOI 10.1002/1097-0142(19950215)75:4<981::AID-CNCR2820750413>3.0.CO;2-A; WENDER RC, 1995, CANCER, V75, P691, DOI 10.1002/1097-0142(19950115)75:2+<691::AID-CNCR2820751412>3.0.CO;2-G; WESTERDAHL J, 1994, EUR J CANCER, V30A, P1647, DOI 10.1016/0959-8049(94)00337-5; WHITEMAN D, 1994, CANCER CAUSE CONTROL, V5, P564, DOI 10.1007/BF01831385; WILLIAMS ML, 1994, WESTERN J MED, V160, P343	39	47	50	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	1996	347	9004					803	806		10.1016/S0140-6736(96)90873-9	http://dx.doi.org/10.1016/S0140-6736(96)90873-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622339				2022-12-28	WOS:A1996UB15300014
J	Spiller, RC				Spiller, RC			Cholesterol, fibre, and bile acids	LANCET			English	Editorial Material							DIETARY FIBER; LIPIDS; SERUM; MEN				Spiller, RC (corresponding author), UNIV HOSP,QUEENS MED CTR,DEPT THERAPEUT,NOTTINGHAM,ENGLAND.		spiller, robin/ABE-6690-2021	spiller, robin/0000-0001-6371-4500				DAVIDSON MH, 1991, JAMA-J AM MED ASSOC, V265, P1833, DOI 10.1001/jama.265.14.1833; EVERSON GT, 1992, J LIPID RES, V33, P1183; GELISSEN IC, 1995, BRIT J NUTR, V74, P221, DOI 10.1079/BJN19950125; JENKINS DJA, 1975, LANCET, V1, P1116, DOI 10.1016/S0140-6736(75)92503-9; KESANIEMI YA, 1990, AM J CLIN NUTR, V51, P1007, DOI 10.1093/ajcn/51.6.1007; MIETTINEN TA, 1987, AM J CLIN NUTR, V45, P1237, DOI 10.1093/ajcn/45.5.1237; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; TOPPING DL, 1991, NUTR REV, V49, P195, DOI 10.1111/j.1753-4887.1991.tb03021.x; VAHOUNY GV, 1980, LIPIDS, V15, P1012, DOI 10.1007/BF02534316	9	12	12	2	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					415	416		10.1016/S0140-6736(96)90005-7	http://dx.doi.org/10.1016/S0140-6736(96)90005-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618479				2022-12-28	WOS:A1996TV72200005
J	Meydan, N; Grunberger, T; Dadi, H; Shahar, M; Arpaia, E; Lapidot, Z; Leeder, JS; Freedman, M; Cohen, A; Gazit, A; Levitzki, A; Roifman, CM				Meydan, N; Grunberger, T; Dadi, H; Shahar, M; Arpaia, E; Lapidot, Z; Leeder, JS; Freedman, M; Cohen, A; Gazit, A; Levitzki, A; Roifman, CM			Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor	NATURE			English	Article							PROTEIN-TYROSINE KINASES; DEFICIENT SCID MICE; SRC FAMILY; LEUKEMIA; LYMPHOCYTES; CELLS; PHOSPHORYLATION; INTERLEUKIN-7; EXPRESSION; ACTIVATION	ACUTE lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Despite the progress achieved in its treatment, 20% of cases relapse and no longer respond to chemotherapy. The most common phenotype of ALL cells share surface antigens with very early precursors of B cells and are therefore believed to originate from this lineage(1,3). Characterization of the growth requirement of ALL cells indicated that they were dependent on various cytokines, suggesting paracrine and/or autocrine growth regulation(4-6). Because many cytokines induce tyrosine phosphorylation in lymphoid progenitor cells, and constitutive tyrosine phosphorylation is commonly observed in B-lineage leukaemias(7,8), attempts have been made to develop protein tyrosine kinase (PTK) blockers of leukaemia cell growth(9,10). Here we show that leukaemic cells from patients in relapse have constitutively activated Jak-2 PTK. Inhibition of Jak-2 activity by a specific tyrosine kinase blocker, AG-490, selectively blocks leukaemic cell growth in vitro and in vivo by inducing programmed cell death, with no deleterious effect on normal haematopoiesis.	HOSP SICK CHILDREN, DIV ALLERGY IMMUNOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DIV HAEMATOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DIV PHARMACOL, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT PEDIAT, TORONTO, ON M5G 1X8, CANADA; WEIZMANN INST SCI, DEPT IMMUNOL, IL-76100 REHOVOT, ISRAEL; HEBREW UNIV JERUSALEM, INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Weizmann Institute of Science; Hebrew University of Jerusalem			Leeder, James Steven/ABD-5438-2021	Leeder, James Steven/0000-0001-6688-0504				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKE TR, 1993, J MED CHEM, V36, P425, DOI 10.1021/jm00056a001; COHEN A, 1991, BLOOD, V78, P94; CUSHMAN M, 1994, J MED CHEM, V37, P3353, DOI 10.1021/jm00046a020; DADI HK, 1993, BIOCHEM BIOPH RES CO, V192, P459, DOI 10.1006/bbrc.1993.1437; ESTROV Z, 1991, EXP HEMATOL, V19, P221; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; GRIMALDI JC, 1989, BLOOD, V73, P2081; HARPUR AG, 1992, ONCOGENE, V7, P1347; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAMELREID S, 1992, LEUKEMIA, V6, P8; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; NADLER LM, 1983, J IMMUNOL, V131, P244; OSAMU M, 1994, BLOOD, V84, P1501; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; ROIFMAN CM, 1992, J IMMUNOL, V148, P1136; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1993, NEW ENGL J MED, V329, P1296, DOI 10.1056/NEJM199310283291802; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	30	841	932	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					645	648		10.1038/379645a0	http://dx.doi.org/10.1038/379645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628398				2022-12-28	WOS:A1996TV68800054
J	Oliver, SG				Oliver, SG			From DNA sequence to biological function	NATURE			English	Article							HUMAN GENOME PROJECT; SACCHAROMYCES-CEREVISIAE; CHROMOSOME-III; YEAST; GENE; PROTEINS; GROWTH; SYSTEM; CELL	Genome sequencing is leading to the discovery of new genes at a rate 50-100 times greater than that achieved by classical genetics, but the biological function of almost half of these genes is completely unknown. In order fully to exploit genome sequence data, a systematic approach to the discovery of gene function is required. Possible strategies are discussed here in the context of functional analysis in the yeast Saccharomyces cerevisiae, a model eukaryote whose genome sequence will soon be completed.			Oliver, SG (corresponding author), UMIST, DEPT BIOCHEM & APPL MOLEC BIOL, POB 88, MANCHESTER M60 1QD, LANCS, ENGLAND.							ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Bassett DE, 1996, NATURE, V379, P589, DOI 10.1038/379589a0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BLATTNER FR, 1993, JOHN INN S, P43; BODMER W, 1994, NAT GENET, V6, P217, DOI 10.1038/ng0394-217; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHADWICK DJ, 1992, CIBA F S, V171; CHATER KF, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P277; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DANG VD, 1994, YEAST, V10, P1273, DOI 10.1002/yea.320101004; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DEVINE KM, 1995, TRENDS BIOTECHNOL, V13, P210, DOI 10.1016/S0167-7799(00)88948-9; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DULBECCO R, 1993, GENE, V135, P259, DOI 10.1016/0378-1119(93)90074-D; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; Hammond J. R. M., 1993, YEASTS, P7; HAVUKKALA I, 1995, J BIOTECHNOL, V41, P139, DOI 10.1016/0168-1656(95)00038-R; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; JIA Y, 1993, THESIS U P M CURIE P; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KABACK DB, 1979, NUCLEIC ACIDS RES, V6, P2499, DOI 10.1093/nar/6.7.2499; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; KREUDTZFELDT C, 1991, BIOTECH HDB, V4, P5; LALO D, 1993, CR HEBD ACAD SCI, V316, P137; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LEONGMORGENTHALER P, 1994, BIOCHIMIE, V76, P45, DOI 10.1016/0300-9084(94)90061-2; LIN YS, 1993, MOL MICROBIOL, V10, P923, DOI 10.1111/j.1365-2958.1993.tb00964.x; MEHTA PK, 1993, EUR J BIOCHEM, V211, P373, DOI 10.1111/j.1432-1033.1993.tb19907.x; MORTIMER RK, 1986, GENETICS, V113, P35; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLIVER SG, 1993, JOHN INN S, P233; Olson M., 1991, MOL CELLULAR BIOL YE, P1; OLSON MV, 1993, P NATL ACAD SCI USA, V90, P4338, DOI 10.1073/pnas.90.10.4338; OUZOUNIS C, 1993, FEBS LETT, V322, P159, DOI 10.1016/0014-5793(93)81559-I; QUANT PA, 1993, TRENDS BIOCHEM SCI, V18, P26; RENDUELES PS, 1988, FEMS MICROBIOL LETT, V54, P17; RIEGER K, IN PRESS YEAST; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMIDT R, 1993, BIOESSAYS, V15, P63, DOI 10.1002/bies.950150110; SCHWARTZ K, 1994, NAT GENET, V8, P110, DOI 10.1038/ng1094-110; SHORT N, 1995, NATURE, V377, P1; SMITH HO, 1995, SCIENCE, V269, P538, DOI 10.1126/science.7542802; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; TANAKA S, 1993, NUCLEIC ACIDS RES, V21, P1149, DOI 10.1093/nar/21.5.1149; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TUGENDREICH S, 1994, HUM MOL GENET, V3, P1509, DOI 10.1093/hmg/3.suppl_1.1509; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WARD R, 1990, HYPERTENSION PATHOPH, P81; WATERSTON B, 1995, NATURE, V376, P111, DOI 10.1038/376111d0; Weinstock Keith G., 1994, Current Opinion in Biotechnology, V5, P599, DOI 10.1016/0958-1669(94)90081-7; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOSHIKAWA A, 1990, YEAST, V6, P383, DOI 10.1002/yea.320060504; ZHENG L, 1958, P NATL ACAD SCI USA, V90, P2754	61	245	249	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					597	600		10.1038/379597a0	http://dx.doi.org/10.1038/379597a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TV688	8628394				2022-12-28	WOS:A1996TV68800040
J	Hilgetag, CC; ONeill, MA; Young, MP				Hilgetag, CC; ONeill, MA; Young, MP			Indeterminate organization of the visual system	SCIENCE			English	Editorial Material							CORTICAL CONNECTIONS; AREAS				Hilgetag, CC (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT PSYCHOL,NEURAL SYST GRP,RIDLEY BLDG,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND.		Hilgetag, Claus C/L-7282-2013; Hilgetag, Claus C/AAH-1760-2020	Hilgetag, Claus C/0000-0003-2129-8910; Hilgetag, Claus C/0000-0003-2129-8910				BOUSSAOUD D, 1990, J COMP NEUROL, V296, P462, DOI 10.1002/cne.902960311; COOGAN TA, 1993, J NEUROSCI, V13, P3749; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; MANUNSELL JHR, 1983, ANN REV NEUROSCI, V10, P363; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; ROCKLAND KS, 1979, BRAIN RES, V179, P3, DOI 10.1016/0006-8993(79)90485-2	7	123	125	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					776	777		10.1126/science.271.5250.776	http://dx.doi.org/10.1126/science.271.5250.776			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628990				2022-12-28	WOS:A1996TU69400035
J	Bhasin, S; Storer, TW; Berman, N; Callegari, C; Clevenger, B; Phillips, J; Bunnell, TJ; Tricker, R; Shirazi, A; Casaburi, R				Bhasin, S; Storer, TW; Berman, N; Callegari, C; Clevenger, B; Phillips, J; Bunnell, TJ; Tricker, R; Shirazi, A; Casaburi, R			The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANABOLIC-STEROIDS; BODY-COMPOSITION; WEIGHT; MASS	Background Athletes often take androgenic steroids in an attempt to increase their strength. The efficacy of these substances for this purpose is unsubstantiated, however. Methods We randomly assigned 43 normal men to one of four groups: placebo with no exercise, testosterone with no exercise, placebo plus exercise, and testosterone plus exercise. The men received injections of 600 mg of testosterone enanthate or placebo weekly for 10 weeks. The men in the exercise groups performed standardized weight-lifting exercises three times weekly. Before and after the treatment period, fat-free mass was determined by underwater weighing, muscle size was measured by magnetic resonance imaging, and the strength of the arms and legs was assessed by bench-press and squatting exercises, respectively. Results Among the men in the no-exercise groups, those given testosterone had greater increases than those given placebo in muscle size in their arms (mean [+/-SE] change in triceps area, 424+/-104 vs. -81+/-109 mm(2); P<0.05) and legs (change in quadriceps area, 607+/-123 vs. -131+/-111 mm(2); P<0.05) and greater increases in strength in the bench-press (9+/-4 vs. -1+/-1 kg, P<0.05) and squatting exercises (16+/-4 vs. 3+/-1 kg, P<0.05). The men assigned to testosterone and exercise had greater increases in fat-free mass (6.1+/-0.6 kg) and muscle size (triceps area, 501+/-104 mm(2); quadriceps area, 1174+/-91 mm(2)) than those assigned to either no-exercise group, and greater increases in muscle strength (bench-press strength, 22+/-2 kg; squatting-exercise capacity, 38+/-4 kg) than either no-exercise group. Neither mood nor behavior was altered in any group. Conclusions Supraphysiologic doses of testosterone, especially when combined with strength training, increase fat-free mass and muscle size and strength in normal men. (C)1996, Massachusetts Medical Society.	EL CAMINO COLL, EXERCISE SCI LAB, TORRANCE, CA USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, DEPT MED, TORRANCE, CA 90509 USA; OREGON STATE UNIV, DEPT PUBL HLTH, CORVALLIS, OR 97331 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Oregon State University	Bhasin, S (corresponding author), CHARLES R DREW UNIV MED & SCI, DIV ENDOCRINOL METAB & MOL MED, DEPT MED, 1621 E 120TH ST, MP 2, LOS ANGELES, CA 90059 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045211] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR11145-01] Funding Source: Medline; NIDDK NIH HHS [1 RO1 DK 45211] Funding Source: Medline; PHS HHS [MO-00543] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1987, Med Sci Sports Exerc, V19, P534; ARIEL G, 1973, J SPORT MED PHYS FIT, V13, P187; BHASIN S, 1992, J CLIN ENDOCR METAB, V74, P75, DOI 10.1210/jc.74.1.75; BHASIN S, 1994, AM SOC ANDR M SPRING; BOWERS RW, 1972, MED SCI SPORT EXER, V4, P54; BUCKLEY WE, 1988, JAMA-J AM MED ASSOC, V260, P3441; BYERLEY LO, 1993, ENDOCR J, V1, P253; Casaburi R, 1996, PHARMACOLOGY, BIOLOGY, AND CLINICAL APPLICATIONS OF ANDROGENS, P283; Casner S W Jr, 1971, J Sports Med Phys Fitness, V11, P98; COWART V, 1987, JAMA-J AM MED ASSOC, V257, P421; CRIST DM, 1983, J APPL PHYSIOL, V54, P366, DOI 10.1152/jappl.1983.54.2.366; ELASHOFF JD, 1991, ANN INTERN MED, V115, P387, DOI 10.7326/0003-4819-115-5-387; FAHEY TD, 1973, MED SCI SPORT EXER, V5, P272; FORBES GB, 1985, METABOLISM, V34, P571, DOI 10.1016/0026-0495(85)90196-9; FREED DLJ, 1975, BRIT MED J, V2, P471, DOI 10.1136/bmj.2.5969.471; Golding L, 1974, PHYSICIAN SPORTSMED, V2, P39; GRIGGS RC, 1989, J APPL PHYSIOL, V66, P498, DOI 10.1152/jappl.1989.66.1.498; HAUPT HA, 1984, AM J SPORT MED, V12, P469, DOI 10.1177/036354658401200613; HERVEY GR, 1981, CLIN SCI, V60, P457, DOI 10.1042/cs0600457; JOHNSON LC, 1972, MED SCI SPORT EXER, V4, P43; JOHNSON LC, 1969, SCIENCE, V164, P957, DOI 10.1126/science.164.3882.957; KATZNELSON L, 1994, 76 ANN M END SOC AN, P581; Kenyon AT, 1940, ENDOCRINOLOGY, V26, P26, DOI 10.1210/endo-26-1-26; KOCHAKIAN CD, 1950, AM J PHYSIOL, V160, P53, DOI 10.1152/ajplegacy.1949.160.1.53; LOUGHTON SJ, 1977, J SPORT MED PHYS FIT, V17, P285; MATSUMOTO AM, 1988, FERTIL STERIL, V50, P324; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; O'Shea J., 1970, NUTR REP INT, V2, P351; Samuels LT, 1942, J CLIN ENDOCRINOL, V2, P649, DOI 10.1210/jcem-2-11-649; SIEGEL JM, 1986, J PERS SOC PSYCHOL, V51, P191, DOI 10.1037/0022-3514.51.1.191; STAMFORD BA, 1974, J SPORT MED PHYS FIT, V14, P191; STONE MH, 1987, WEIGHT TRAINING SCI; STRAUSS RH, 1991, ANNU REV MED, V42, P449, DOI 10.1146/annurev.me.42.020191.002313; STROMME SB, 1974, MED SCI SPORT EXER, V6, P203; TAHMINDJIS AJ, 1976, MED J AUSTRALIA, V1, P991, DOI 10.5694/j.1326-5377.1976.tb128921.x; TOM L, 1992, J CLIN ENDOCR METAB, V75, P476, DOI 10.1210/jc.75.2.476; WADE N, 1972, SCIENCE, V176, P1399, DOI 10.1126/science.176.4042.1399; WARD P, 1973, MED SCI SPORT EXER, V5, P277; WILSON JD, 1988, ENDOCR REV, V9, P181, DOI 10.1210/edrv-9-2-181; Win-May M, 1975, J Sports Med Phys Fitness, V15, P266	40	1079	1101	7	145	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					1	7		10.1056/NEJM199607043350101	http://dx.doi.org/10.1056/NEJM199607043350101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637535				2022-12-28	WOS:A1996UU47900001
J	Bazzoni, F; Beutler, B				Bazzoni, F; Beutler, B			The tumor necrosis factor ligand and receptor families	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ADIPOCYTE GENE-EXPRESSION; FACTOR TNF RECEPTOR; ENDOTOXIC-SHOCK; FACTOR-ALPHA; HYPER-IGM; MICE; CACHECTIN; LPR; LYMPHOTOXIN; OBESITY		UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Bazzoni, Flavia/AAB-7674-2019	Bazzoni, Flavia/0000-0001-6768-8012	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042582] Funding Source: NIH RePORTER; NIDDK NIH HHS [5-POIDK42582] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; AGGARWAL BB, 1984, J BIOL CHEM, V259, P686; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAZZONI F, 1995, P NATL ACAD SCI USA, V92, P5376, DOI 10.1073/pnas.92.12.5376; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; BEUTLER B, 1994, ANN NY ACAD SCI, V730, P118, DOI 10.1111/j.1749-6632.1994.tb44244.x; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FARROW SN, 1995, NATURE, V375, P431, DOI 10.1038/375431a0; FELDMANN M, 1994, CIRC SHOCK, V43, P179; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; IZUI S, 1984, J IMMUNOL, V133, P227; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P968, DOI 10.1073/pnas.87.3.968; JACOB CO, 1988, NATURE, V331, P356, DOI 10.1038/331356a0; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P1979; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; MARIATHASAN S, 1995, J INFLAMM, V45, P72; MATSUZAWA A, 1990, J EXP MED, V171, P519, DOI 10.1084/jem.171.2.519; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PEKALA PH, 1984, T ASSOC AM PHYSICIAN, V97, P251; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRUEB R, 1996, J INFLAMM, V45, P239; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WHERRY JC, 1993, CRIT CARE MED, V21, pS436, DOI 10.1097/00003246-199310001-00004; XU J, 1994, IMMUNITY, V1, pA613; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YANG XD, 1994, J EXP MED, V180, P995, DOI 10.1084/jem.180.3.995; YANG XD, 1994, CIRC SHOCK, V43, P198	83	968	1041	0	29	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1717	1725		10.1056/NEJM199606273342607	http://dx.doi.org/10.1056/NEJM199606273342607			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT400	8637518				2022-12-28	WOS:A1996UT40000007
J	Fried, M; Duffy, PE				Fried, M; Duffy, PE			Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta	SCIENCE			English	Article							INFECTED ERYTHROCYTES; MALARIA; PREGNANCY; AFRICA; ICAM-1	Women are particularly susceptible to malaria during first and second pregnancies, even though they may have developed immunity over years of residence in endemic areas. Plasmodium falciparum-infected red blood cells (IRBCs) were obtained from human placentas. These IRBCs bound to purified chondroitin sulfate A (CSA) but not to other extracellular matrix proteins or to other known IRBC receptors. IRBCs from nonpregnant donors did not bind to CSA. Placental IRBCs adhered to sections of fresh-frozen human placenta with an anatomic distribution similar to that of naturally infected placentas, and this adhesion was competitively inhibited by purified CSA. Thus, adhesion to CSA appears to select for a subpopulation of parasites that causes maternal malaria.	KENYA GOVT MED RES CTR,KISUMU,KENYA	Kenya Medical Research Institute	Fried, M (corresponding author), USA,MED RES UNIT KENYA,POB 54,KISUMU,KENYA.							Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BRABIN BJ, 1985, REV INFECT DIS, V7, P579; BRABIN BJ, 1990, ANN TROP MED PARASIT, V84, P1; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; FRIED M, UNPUB; GUPTA S, 1994, P NATL ACAD SCI USA, V91, P3715, DOI 10.1073/pnas.91.9.3715; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; McGregor I A, 1987, Parassitologia, V29, P153; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; RASHEED FN, 1993, AM J TROP MED HYG, V48, P154, DOI 10.4269/ajtmh.1993.48.154; REILLY K, 1993, PRIMARY CARE, V20, P665; RIGANTI M, 1990, IMMUNOL LETT, V25, P199, DOI 10.1016/0165-2478(90)90115-7; RINDWALD P, 1993, INFECT IMMUN, V61, P5198; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; WALTER PR, 1982, AM J PATHOL, V109, P330; WEINBERG ED, 1984, REV INFECT DIS, V6, P814; ZHU ZL, 1995, P NATL ACAD SCI USA, V92, P3546, DOI 10.1073/pnas.92.8.3546	26	874	884	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1502	1504		10.1126/science.272.5267.1502	http://dx.doi.org/10.1126/science.272.5267.1502			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633247				2022-12-28	WOS:A1996UP89900054
J	Elliott, P; Stamler, J; Nichols, R; Dyer, AR; Stamler, R; Kesteloot, H; Marmot, M				Elliott, P; Stamler, J; Nichols, R; Dyer, AR; Stamler, R; Kesteloot, H; Marmot, M			Intersalt revisited: Further analyses of 24 hour sodium excretion and blood pressure within and across populations	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIETARY SALT; OBSERVATIONAL DATA; REDUCTION; POTASSIUM; CORONARY	Objectives-To assess further the relation in Intersalt of 24 hour urinary sodium to blood pressure of individuals and populations, and the difference it blood pressure from young adulthood into middle age. Design-Standardised cross sectional study within and across populations. Setting-52 population samples in 32 countries. Subjects-10 074 men and women aged 20-59. Main outcome measures-Association of sodium and blood pressure from within population and cross population multiple linear regression analyses with multivariate correction for regression dilution bias. Relation of sample median daily urinary sodium excretion to difference in blood pressure with age. Results-In within population analyses (n=10 074), individual 24 hour urinary sodium excretion higher by 100 mmol (for example, 170 v 70 mmol) was associated with systolic/diastolic blood pressure higher on average by 3/0 to 6/3 mm Hg (with and without body mass in analyses). Associations were larger at ages 40-59. In cross population analyses (n=52), sample median 24 hour sodium excretion higher by 100 mmol was associated with median systolic/diastolic pressure higher on average by 5-7/2-4 mm Hg, and estimated mean difference in systolic/diastolic pressure at age 55 compared with age 25 greater by 10-11/6 mm Hg. Conclusions-The strong, positive association of urinary sodium with systolic pressure of individuals concurs with Intersalt cross population findings and results of other studies. Higher urinary sodium is also associated with substantially greater differences in blood pressure in middle age compared with young adulthood. These results support recommendations for reduction of high salt intake in populations for prevention and control of adverse blood pressure levels.	NORTHWESTERN UNIV, SCH MED, DEPT PREVENT MED, CHICAGO, IL 60611 USA; ST RAPHAEL UNIV HOSP, DEPT EPIDEMIOL, LOUVAIN, BELGIUM; UNIV LONDON UNIV COLL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND	Northwestern University; University of London; University College London; UCL Medical School	Elliott, P (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON W2 1PG, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		CUTLER JA, 1991, HYPERTENSION, V17, pI27, DOI 10.1161/01.HYP.17.1_Suppl.I27; DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009; Department of Health, 1994, 46 DEP HLTH CARD REV; DYER AR, 1994, AM J EPIDEMIOL, V139, P927, DOI 10.1093/oxfordjournals.aje.a117099; DYER AR, 1989, J HUM HYPERTENS, V3, P299; DYER AR, 1995, NAT MED, V1, P994, DOI 10.1038/nm1095-994; DYER AR, 1994, HYPERTENSION, V23, P729, DOI 10.1161/01.HYP.23.6.729; DYER AR, 1994, AM J EPIDEMIOL, V139, P940, DOI 10.1093/oxfordjournals.aje.a117100; ELLIOTT P, 1988, BRIT MED J, V297, P319; ELLIOTT P, 1989, J HUM HYPERTENS, V3, P289; ELLIOTT P, 1988, CONTROL CLIN TRIALS, V9, pS1, DOI 10.1016/0197-2456(88)90028-1; ELLIOTT P, 1989, J HUM HYPERTENS, V3, P323; ELLIOTT P, 1991, HYPERTENSION, V17, pI3, DOI 10.1161/01.HYP.17.1_Suppl.I3; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; GELEIJNSE JM, 1994, BRIT MED J, V309, P436, DOI 10.1136/bmj.309.6952.436; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; JOOSSENS JV, 1994, J AM COLL NUTR, V13, P179; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; KLEINBAUM DG, 1987, APPLIED REGRESSION A; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LIU K, 1988, AM J EPIDEMIOL, V127, P864, DOI 10.1093/oxfordjournals.aje.a114870; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; *NAT RES COUNC COM, 1989, DIET HLTH IMPL RED C, V15, P413; PAFFENBARGER RS, 1968, AM J EPIDEMIOL, V88, P25, DOI 10.1093/oxfordjournals.aje.a120864; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; PRIOR IAM, 1980, EPIDEMIOLOGY ARTERIA, P243; ROSE G, 1986, J HYPERTENS, V4, P781; SANCHEZCASTILLO CP, 1987, CLIN SCI, V72, P95, DOI 10.1042/cs0720095; Snedecor GW, 1980, STAT METHODS, V7th; STAMLER J, 1989, HYPERTENSION, V14, P570, DOI 10.1161/01.HYP.14.5.570; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; STAMLER J, 1960, PATHOGENESIS ESSENTI, P67; STAMLER J, 1967, LECTURES PREVENTIVE, P242; STAMLER J, 1979, HYPERTENSION UPDATE, P23; *US DHHS, 1991, DHHS PUBL; [No title captured]; [No title captured]	39	631	648	1	39	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 18	1996	312	7041					1249	1253		10.1136/bmj.312.7041.1249	http://dx.doi.org/10.1136/bmj.312.7041.1249			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634612	Green Published			2022-12-28	WOS:A1996UM40400016
J	Hublin, JJ; Spoor, F; Braun, M; Zonneveld, F; Condemi, S				Hublin, JJ; Spoor, F; Braun, M; Zonneveld, F; Condemi, S			A Late Neanderthal associated with Upper Palaeolithic artefacts	NATURE			English	Article								THE French site of Arcy-sur-Cure is a key locality in documenting the Middle-Upper Palaeolithic transition in Europe. Reliable attribution of the fragmentary hominid fossils associated with its early Upper Palaeolithic Chatelperronian industry has not been possible. Here we report the first conclusive identification of one of these fossils as Neanderthal on the basis of newly discovered derived features of the bony labyrinth. Dated at about thirty-four thousand years (34 kyr) ago, the fossil is representative of the youngest known Neanderthal populations, and its archaeological context indicates that these hominids used a rich bone industry as well as personal ornaments. The evidence supports the hypothesis of a long term coexistence with technocultural interactions between the first modern humans and the last Neanderthals in Europe. However, the complete absence of the derived Neanderthal traits in labyrinths of modern Upper Palaeolithic specimens from western Europe argues against phylogenetic continuity between the two populations in this region.	UNIV NANCY 1, DEPT ANAT, F-54505 VANDOEUVRE LES NANCY, FRANCE; UNIV UTRECHT HOSP, DEPT DIAGNOST RADIOL, 3584 CX UTRECHT, NETHERLANDS; INST PALEONTOL HUMAINE, F-75013 PARIS, FRANCE; MUSEE HOMME PARIS, LAB ANTHROPOL, F-75116 PARIS, FRANCE; UCL, DEPT ANAT & DEV BIOL, EVOLUT ANAT UNIT, LONDON WC1E 6JJ, ENGLAND	Universite de Lorraine; Utrecht University; Utrecht University Medical Center; Museum National d'Histoire Naturelle (MNHN); University of London; University College London			Spoor, Fred/C-1718-2008; Condemi, Silvana/ABE-2701-2021	Condemi, Silvana/0000-0002-6516-0879				BISCHOFF JL, 1994, J ARCHAEOL SCI, V21, P541, DOI 10.1006/jasc.1994.1053; BISCHOFF JL, 1989, J ARCHAEOL SCI, V16, P553; Cabrera-Valdes V., 1989, J ARCHAEOL SCI, V16, P577, DOI [10.1016/0305-4403(89)90023-X, DOI 10.1016/0305-4403(89)90023-X]; CLARK GA, 1989, HUMAN REVOLUTION, P621; DEMARS PY, 1989, ERAUL LIEGE, V34, P29; Girard M., 1990, PALEOLITHIQUE MOYEN, V3, P295; HARROLD FB, 1989, HUMAN REVOLUTION, P677; Hedges R.E., 1994, ARCHAEOMETRY, V36, P337, DOI DOI 10.1111/J.1475-4754.1994.TB00975.X; HOWELL FC, 1994, INTERD CONT, P253; HUBLIN JJ, 1995, CR ACAD SCI II A, V321, P931; Leroi-Gourhan A., 1958, ANN PALEONTOL, V44, P87; Leroyer C, 1983, B SOC PREHIST FRANC, V80, P41; LEROYER C, 1988, ERAUL LIEGE, V35, P103; LEUJEUNE M, 1987, ART MOBILIER PALEOLI, V4; LEVEQUE F, 1980, CR ACAD SCI D NAT, V291, P187; MAFFIER D, 1990, PALEOLITHIQUE MOYEN, P329; MELLARS PA, 1992, PHILOS T ROY SOC B, V337, P225, DOI 10.1098/rstb.1992.0100; MERCIER N, 1991, NATURE, V351, P735; Pelegrin J., 1995, CAHIERS QUATERNAIRE, V20, P297; RAK Y, 1994, SPECIES SPECIES CONC, P523; Ruff Christopher B., 1994, Yearbook of Physical Anthropology, V37, P65; Spoor C.E, 1993, COMP MORPHOLOGY PHYL; SPOOR CF, 1994, COUR FORSCH SENCKENB, V171, P251; SPOOR CF, 1995, J ANAT, V186, P271; SPOOR F, 1994, NATURE, V369, P645, DOI 10.1038/369645a0; Straus L.G., 1993, EVOLUTIONARY ANTHR, V2, P195; STRINGER CB, 1991, NATURE, V351, P701, DOI 10.1038/351701a0; TABORIN Y, 1990, PALEOLITHIQUE MOYEN, P335; VANVARK GN, 1984, MULTIVARIATE STATIST, P323; WOLPOFF MH, 1992, NATURE, V356, P200, DOI 10.1038/356200b0	30	259	270	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					224	226		10.1038/381224a0	http://dx.doi.org/10.1038/381224a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UL249	8622762				2022-12-28	WOS:A1996UL24900050
J	Feng, Y; Broder, CC; Kennedy, PE; Berger, EA				Feng, Y; Broder, CC; Kennedy, PE; Berger, EA			HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BACTERIOPHAGE-T7 RNA-POLYMERASE; MOLECULAR-CLONING; HUMAN CD4; REGULATED EXPRESSION; CD4-MEDIATED FUSION; MEMBRANE-FUSION; VACCINIA VIRUS; HUMAN HOMOLOG; MURINE CELLS	A cofactor for HIV-1 (human immunodeficiency virus-type 1) fusion and entry was identified with the use of a novel functional complementary DNA (cDNA) cloning strategy. This protein, designated ''fusin,'' is a putative G protein-coupled receptor with seven transmembrane segments. Recombinant fusin enabled CD4-expressing nonhuman cell types to support HIV-1 Env-mediated cell fusion and HIV-1 infection. Antibodies to fusin blocked cell fusion and infection with normal CD4-positive human target cells. Fusin messenger RNA levels correlated with HIV-1 permissiveness in diverse human cell types. Fusin acted preferentially for T cell line-tropic isolates, in comparison to its activity with macrophage-tropic HIV-1 isolates.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Broder, Christopher/E-1169-2013					ALEXANDER WA, 1992, J VIROL, V66, P2934, DOI 10.1128/JVI.66.5.2934-2942.1992; ALKHATIB G, IN PRESS J VIROL; [Anonymous], COMMUNICATION; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BERGER EA, 1996, KEYST S CELL BIOL VI, P8; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; CHAKRABARTI SK, COMMUNICATION; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; Cho SG, 1995, AIDS RES HUM RETROV, V11, P1487, DOI 10.1089/aid.1995.11.1487; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1994, AIDS RES HUM RETROV, V10, P321, DOI 10.1089/aid.1994.10.321; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DRAGIC T, 1993, J VIROL, V67, P2355, DOI 10.1128/JVI.67.4.2355-2359.1993; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; DRAGIC T, 1995, J VIROL, V69, P1013, DOI 10.1128/JVI.69.2.1013-1018.1995; DUNN CS, 1995, J GEN VIROL, V76, P1327, DOI 10.1099/0022-1317-76-6-1327; EARL PL, 1991, CURRENT PROTOCOL S15, V2; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; FENG Y, 1996, KEYST S IMM HIV INF, P21; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GILLESPIE FP, 1993, MOL CELL BIOL, V13, P2952, DOI 10.1128/MCB.13.5.2952; HANNA Z, 1994, MOL CELL BIOL, V14, P1084, DOI 10.1128/MCB.14.2.1084; HARRINGTON RD, 1993, J VIROL, V67, P5939, DOI 10.1128/JVI.67.10.5939-5947.1993; HERZOG H, 1993, DNA CELL BIOL, V12, P465, DOI 10.1089/dna.1993.12.465; HOXIE JA, 1988, J VIROL, V62, P2557, DOI 10.1128/JVI.62.8.2557-2568.1988; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOENIG S, 1989, P NATL ACAD SCI USA, V86, P2443, DOI 10.1073/pnas.86.7.2443; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Planelles Vincente, 1993, P17; RAMARLI D, 1993, AIDS RES HUM RETROV, V9, P1269, DOI 10.1089/aid.1993.9.1269; Richardson TM, 1996, J VIROL, V70, P753, DOI 10.1128/JVI.70.2.753-762.1996; SNYDER BW, 1995, MOL REPROD DEV, V40, P419, DOI 10.1002/mrd.1080400405; TRONO D, 1994, CLIN LAB MED, V14, P203, DOI 10.1016/S0272-2712(18)30375-5; VALENTIN A, 1994, J VIROL, V68, P6684, DOI 10.1128/JVI.68.10.6684-6689.1994; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679	44	3535	3779	1	202	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					872	877		10.1126/science.272.5263.872	http://dx.doi.org/10.1126/science.272.5263.872			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629022				2022-12-28	WOS:A1996UK75700059
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Statistics notes - The use of transformation when comparing two means	BMJ-BRITISH MEDICAL JOURNAL			English	Article									IMPERIAL CANC RES FUND, MED STAT GRP, CTR STAT MED, INST HLTH SCI, OXFORD OX3 7LF, ENGLAND	University of Oxford	Bland, JM (corresponding author), UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND.							Bland JM, 1996, BRIT MED J, V312, P700; Bland JM, 1996, BRIT MED J, V312, P1079; Bland JM, 1996, BRIT MED J, V312, P770	3	206	207	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 4	1996	312	7039					1153	1153						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620137				2022-12-28	WOS:A1996UK06900033
J	[Anonymous]				[Anonymous]			Ethnicity, race, and culture: Guidelines for research, audit, and publication	BRITISH MEDICAL JOURNAL			English	Article								The following guidelines on the use of ethnic, racial, and cultural descriptions in published research were produced with the help of Drs Kwame McKenzie and Natasha Crowcroft (see also editorial). We hope that authors will use them in describing patients individually and in groups and that both authors and readers will find them helpful.						mckenzie, kwame/0000-0001-6419-8130					0	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1094	1094						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UH816	8616423				2022-12-28	WOS:A1996UH81600036
J	Hatala, R; Dinh, T; Cook, DJ				Hatala, R; Dinh, T; Cook, DJ			Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article						meta-analysis; dose-response relationship, drug; antibiotics, aminoglycoside; drug administration schedule; bacterial infections	GRAM-NEGATIVE INFECTIONS; DAILY NETILMICIN REGIMENS; CRITICALLY ILL ADULT; DAILY AMIKACIN; SYSTEMIC INFECTIONS; SERIOUS INFECTIONS; PEDIATRIC-PATIENTS; CLINICAL-TRIALS; RISK-FACTORS; A-DAY	Objective: To compare the efficacy, nephrotoxicity, and ototoxicity of once-daily aminoglycoside dosing with those of standard aminoglycoside regimens in immunocompetent adults. Data Sources: A structured MEDLINE search from 1966 to April 1995 using the keywords aminoglycosides, drug administration schedule, and adult; bibliographic searching of review articles, position papers, and references of the selected articles; contact with primary authors of selected articles to obtain information not in the published reports and lists of potentially relevant articles. Study Selection: Randomized, controlled trials that 1) compared an intravenous once-daily aminoglycoside regimen with a standard aminoglycoside regimen in infected immunocompetent adults and 2) examined efficacy, mortality, or toxicity. Data Extraction: For each selected study, two indepen dent reviewers assessed methodologic quality and abstracted data. The heterogeneity of individual study risk ratios was assessed and data were pooled using a random-effects model. Results: Forty-two studies were reviewed for possible inclusion. Thirteen independent studies met the selection criteria, and their results were pooled. The trials had a mean methodologic quality score of 0.69 (range, 0.50 to 0.91). Heterogeneity exists among the individual risk ratios for clinical cure (P = 0.07); significant heterogeneity does not exist for the other outcomes. For the pooled efficacy outcomes, the risk ratio for bacteriologic cure is 1.02 (95% CI, 0.99 to 1.05), and the risk ratio for mortality is 0.91 (CI, 0.63 to 1.31). For the pooled toxicity outcomes, the risk ratio for nephrotoxicity is 0.87 (CI, 0.60 to 1.26), and the risk ratio for ototoxicity is 0.67 (CI, 0.35 to 1.28). Conclusions: Standard and once-daily aminoglycoside dosing regimens are equivalent with regard to bacteriologic cure, and once-daily dosing shows a trend toward reduced mortality and toxicity. However, additional studies are needed for more precise estimates of mortality and toxicity risk ratios. The equivalency of the dosing regimens, the ease of administration, reduced nursing time, and reduced variability in the timing of drug administration that are associated with once-daily dosing may mean that the once-daily regimen is clinically advantageous.	MCMASTER UNIV, HAMILTON, ON, CANADA	McMaster University	Hatala, R (corresponding author), HENDERSON GEN HOSP, DEPT MED, 711 CONCESS ST, HAMILTON, ON L8V 1C3, CANADA.							AGUADO JM, 1994, INT C ANT AG CHEM NE, P1154; BARRIERE SL, 1988, CLIN PHARMACY, V7, P385; BLASER J, 1994, INT C ANT AG CHEM 19, P1153; BOURGET P, 1991, J CLIN PHARM THER, V16, P167, DOI 10.1111/j.1365-2710.1991.tb00300.x; BURTON ME, 1986, CLIN PHARMACY, V5, P143; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHAN GLC, 1989, DICP ANN PHARMAC, V23, P788, DOI 10.1177/106002808902301010; Conly J, 1994, Can J Infect Dis, V5, P205; DACOSTA PM, 1992, HEPATO-GASTROENTEROL, V39, P350; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEVRIES PJ, 1990, EUR J CLIN MICROBIOL, V9, P161; DEZIELEVANS LM, 1986, CLIN PHARMACY, V5, P319; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; EDSON RS, 1983, MAYO CLIN PROC, V58, P99; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; FAN ST, 1988, J ANTIMICROB CHEMOTH, V22, P69, DOI 10.1093/jac/22.1.69; FRENCH MA, 1981, ANTIMICROB AGENTS CH, V19, P147, DOI 10.1128/AAC.19.1.147; Freund D A, 1992, Pharmacoeconomics, V1, P20, DOI 10.2165/00019053-199201010-00006; GARRISON MW, 1990, DICP ANN PHARMAC, V24, P267, DOI 10.1177/106002809002400312; GERBER A U, 1988, Journal of Drug Development, V1, P17; GIAMARELLOU H, 1991, J ANTIMICROB CHEMOTH, V27, P73, DOI 10.1093/jac/27.suppl_C.73; GIBEY R, 1981, CLIN CHIM ACTA, V116, P25, DOI 10.1016/0009-8981(81)90165-0; GILBERT D, 1995, INT C ANT AG CHEM WA, pM86; GILBERT DN, 1991, ANTIMICROB AGENTS CH, V35, P399, DOI 10.1128/AAC.35.3.399; GONZALEZ P, 1993, LANCET, V341, P895; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HILF M, 1989, AM J MED, V87, P540, DOI 10.1016/S0002-9343(89)80611-4; HOLLENDER LF, 1989, J ANTIMICROB CHEMOTH, V23, P773, DOI 10.1093/jac/23.5.773; HOOTON TM, 1984, ANTIMICROB AGENTS CH, V26, P535, DOI 10.1128/AAC.26.4.535; HUSTINX WNM, 1993, CLIN PHARMACOKINET, V25, P427, DOI 10.2165/00003088-199325060-00002; JACKSON GG, 1990, J INFECT DIS, V162, P408, DOI 10.1093/infdis/162.2.408; KARLOWSKY JA, 1994, ANTIMICROB AGENTS CH, V38, P1165, DOI 10.1128/AAC.38.5.1165; KOVARIK JM, 1989, EUR J CLIN MICROBIOL, V8, P761, DOI 10.1007/BF02185842; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LESAR TS, 1982, JAMA-J AM MED ASSOC, V248, P1190, DOI 10.1001/jama.248.10.1190; MALLER R, 1990, SCAND J INFECT DIS, V22, P575, DOI 10.3109/00365549009027099; MALLER R, 1991, J ANTIMICROB CHEMOTH, V27, P121, DOI 10.1093/jac/27.suppl_C.121; MALLER R, 1988, J ANTIMICROB CHEMOTH, V22, P75, DOI 10.1093/jac/22.1.75; MALLER R, 1993, J ANTIMICROB CHEMOTH, V31, P939, DOI 10.1093/jac/31.6.939; MARIK PE, 1991, J ANTIMICROB CHEMOTH, V27, P81, DOI 10.1093/jac/27.suppl_C.81; MARIK PE, 1991, J ANTIMICROB CHEMOTH, V28, P753, DOI 10.1093/jac/28.5.753; MATTIE H, 1989, J ANTIMICROB CHEMOTH, V24, P281, DOI 10.1093/jac/24.3.281; MAURACHER EH, 1989, CLIN THER, V11, P604; MEYER RD, 1986, AM J MED, V80, P119, DOI 10.1016/0002-9343(86)90489-4; MOELLERING RC, 1992, CLIN INFECT DIS, V14, P1173, DOI 10.1093/clinids/14.6.1173; MOORE RD, 1987, J INFECT DIS, V155, P93, DOI 10.1093/infdis/155.1.93; MUIJSKEN M A, 1988, Journal of Drug Development, V1, P145; NICOLAU DP, 1995, ANTIMICROB AGENTS CH, V39, P650, DOI 10.1128/AAC.39.3.650; NICOLAU DP, 1994, INT C ANT AG CHEM 19, P85; NORDSTROM L, 1991, J HOSP INFECT, V18, P117, DOI 10.1016/0195-6701(91)90013-X; NORDSTROM L, 1990, J ANTIMICROB CHEMOTH, V25, P159, DOI 10.1093/jac/25.1.159; NORDSTROM L, 1985, RECENT ADV CHEMOTHER, P2653; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; PARKER SE, 1993, J ANTIMICROB CHEMOTH, V31, P4, DOI 10.1093/jac/31.1.4; PECHERE JC, 1991, J ANTIMICROB CHEMOTH, V27, P149, DOI 10.1093/jac/27.suppl_C.149; PETTY B, 1987, 26 INT C ANT AG CHEM, P30; PIERRE C, 1988, CLIN PHARMACOL THER, V44, P458, DOI 10.1038/clpt.1988.180; POWELL SH, 1983, J INFECT DIS, V147, P918, DOI 10.1093/infdis/147.5.918; PRINS JM, 1993, LANCET, V341, P335, DOI 10.1016/0140-6736(93)90137-6; PROCTOR L, 1987, LARYNGOSCOPE, V97, P1443; RAJKUMAR SV, 1993, LANCET, V341, P895; SANDERS WE, 1988, REV INFECT DIS, V10, P830; SCHENTAG JJ, 1980, APPL PHARMACOKINETIC, P184; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SMITH CR, 1980, NEW ENGL J MED, V302, P1106, DOI 10.1056/NEJM198005153022002; STURM A W, 1988, Journal of Drug Development, V1, P125; STURM AW, 1989, J INFECT DIS, V159, P931, DOI 10.1093/infdis/159.5.931; TERBRAAK EW, 1990, AM J MED, V89, P58, DOI 10.1016/0002-9343(90)90099-Y; TULKENS P M, 1988, Journal of Drug Development, V1, P71; TULKENS PM, 1991, J ANTIMICROB CHEMOTH, V27, P49, DOI 10.1093/jac/27.suppl_C.49; VANDERAUWERA P, 1991, J ANTIMICROB CHEMOTH, V27, P63; VANHAEVERBEEK M, 1993, J ANTIMICROB CHEMOTH, V31, P185, DOI 10.1093/jac/31.1.185; VANHAEVERBEEK M, 1993, INT J CLIN PHARM TH, V31, P153; VELLUTI G, 1988, Journal of Drug Development, V1, P137; VERPOOTEN GA, 1989, CLIN PHARMACOL THER, V45, P22, DOI 10.1038/clpt.1989.4; VREEDE E, 1988, INFECT GRAM NEGATIVE, P143; WATLING SM, 1993, ANN PHARMACOTHER, V27, P151, DOI 10.1177/106002809302700202; WATLING SM, 1993, ANN PHARMACOTHER, V27, P351, DOI 10.1177/106002809302700319	79	215	218	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					717	+		10.7326/0003-4819-124-8-199604150-00003	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633831				2022-12-28	WOS:A1996UD93600003
J	Margolese, R				Margolese, R			Screening mammography in young women: A different perspective	LANCET			English	Editorial Material							BREAST-CANCER DETECTION				Margolese, R (corresponding author), MCGILL UNIV,JEWISH GEN HOSP,DEPT ONCOL,3755 CHEM COTE ST CATHERINE,MONTREAL,PQ H3T 1E2,CANADA.							BAINES CJ, 1994, ANN INTERN MED, V120, P326, DOI 10.7326/0003-4819-120-4-199402150-00011; DEKONING HJ, 1995, JNCI-J NATL CANCER I, V87, P1217; FEIG SA, 1995, CANCER, V75, P2412, DOI 10.1002/1097-0142(19950515)75:10<2412::AID-CNCR2820751005>3.0.CO;2-4; HARRIS R, 1994, J NATL CANCER I, V86, P1721; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KOPANS DB, 1993, AM J ROENTGENOL, V161, P755, DOI 10.2214/ajr.161.4.8372752; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; SHAPIRO S, 1989, CANCER, V63, P1873, DOI 10.1002/1097-0142(19890515)63:10<1873::AID-CNCR2820631002>3.0.CO;2-6; SHAPIRO S, 1985, NCI MONO, V85, P2; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; SMART CR, 1993, CANCER, V72, P1449, DOI 10.1002/1097-0142(19930815)72:4+<1449::AID-CNCR2820721406>3.0.CO;2-C; TABAR L, 1995, CANCER, V75, P2507, DOI 10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-H	12	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					881	882		10.1016/S0140-6736(96)91352-5	http://dx.doi.org/10.1016/S0140-6736(96)91352-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622398				2022-12-28	WOS:A1996UC45000016
J	Bochkarev, A; Barwell, JA; Pfuetzner, RA; Bochkareva, E; Frappier, L; Edwards, AM				Bochkarev, A; Barwell, JA; Pfuetzner, RA; Bochkareva, E; Frappier, L; Edwards, AM			Crystal structure of the DNA-Binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA	CELL			English	Article							NUCLEAR ANTIGEN EBNA-1; REPLICATION ORIGIN; HUMAN-CELLS; SITES; ORIP; PLASMIDS; ENHANCER; REFINEMENT; TARGET	The Epstein-Barr virus nuclear antigen 1 (EBNA1) protein binds to and activates DNA replication from oriP, the latent origin of DNA replication in Epstein-Barr virus. The crystal structure of the DNA-binding domain of EBNA1 bound to an 18 bp binding site was solved at 2.4 Angstrom resolution. EBNA1 comprises two domains, a flanking and a core domain. The flanking domain, which includes a helix that projects into the major groove and an extended chain that travels along the minor groove, makes all of the sequence-determining contacts with the DNA. The core domain, which is structurally homologous to the complete DNA-binding domain of the bovine papilloma virus E2 protein, makes no direct contacts with the DNA bases. A model for origin unwinding is proposed that incorporates the known biochemical and structural features of the EBNA1-origin interaction.	MCMASTER UNIV,DEPT PATHOL,CANC RES GRP,INST MOLEC BIOL & BIOTECHNOL,HAMILTON,ON L8N 3Z5,CANADA	McMaster University				Edwards, Aled/0000-0002-4782-6016				AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FUREY W, 1995, MACROMOLECULAR CRYST; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; HARRISON S, 1994, J VIROL, V68, P1913, DOI 10.1128/JVI.68.3.1913-1925.1994; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEIMAN Z, 1994, CURR OPIN GENE DEV, V4, P185; Kornberg A., 1992, DNA REPLICATION; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; Summers H, 1996, J VIROL, V70, P1228, DOI 10.1128/JVI.70.2.1228-1231.1996; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	30	183	192	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					791	800		10.1016/S0092-8674(00)81056-9	http://dx.doi.org/10.1016/S0092-8674(00)81056-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625416	Bronze			2022-12-28	WOS:A1996TZ99000016
J	Drancourt, M; Birtles, R; Chaumentin, G; Vandenesch, F; Etienne, J; Raoult, D				Drancourt, M; Birtles, R; Chaumentin, G; Vandenesch, F; Etienne, J; Raoult, D			New serotype of Bartonella henselae in endocarditis and cat-scratch disease	LANCET			English	Article							AFIPIA-FELIS; IDENTIFICATION	Background The fastidious nature of Bartonella henselae is such that demonstration of clinical infection relies mainly on serological or molecular biological methods. Only five isolates have been obtained from patients with cat-scratch disease (CSD) and none from endocarditis. Methods We isolated B henselae from a CSD patient and, for the first time, from a patient with endocarditis. The isolates were characterised on the basis of morphology, biochemistry, cell-wall fatty-acid analysis, PCR-restriction fragment length polymorphism analysis of the 16-23S intragenic spacer region, and 16S rRNA gene sequences. Characterisation of these isolates indicated them to belong to a new serogroup, which we have called ''Marseille'', and to a new genotype based on the 16S rRNA gene sequence. The new variant was incorporated into an immunofluorescence antibody test (IFAT), which was used to reassess serum samples from 113 CSD patients who were seronegative with the conventional IFAT. Findings 18 (16%) of these apparently seronegative patients yielded significantly raised titres. 20 CSD patients who were seropositive as judged by the conventional IFAT remained seropositive with the new IFAT. Interpretation Antigenic variability within the species is one possible reason for inconsistent results in the serological diagnosis of CSD.	CNRS,EP J0054,UNITE RICHETTSIES,F-13385 MARSEILLE 05,FRANCE; HOP CROIX ROUSSE,SERV MALAD INFECT & TROP,F-69317 LYON,FRANCE; HOP LOUIS PRADEL,BACTERIOL LAB,F-69500 BRON,FRANCE	Centre National de la Recherche Scientifique (CNRS); CHU Lyon; CHU Lyon			ETIENNE, Jerome/C-5471-2014; RAOULT, Didier/A-8434-2008; Vandenesch, Francois/C-7209-2014	ETIENNE, Jerome/0000-0002-3348-3315; RAOULT, Didier/0000-0002-0633-5974; Vandenesch, Francois/0000-0001-9412-7106; Birtles, Richard/0000-0002-4216-5044				ALKAN S, 1995, LANCET, V345, P385, DOI 10.1016/S0140-6736(95)90370-4; ANDREWS DM, 1992, NEW ENGL J MED, V327, P1600; BERGMANS AMC, 1995, J INFECT DIS, V171, P916, DOI 10.1093/infdis/171.4.916; BRENNER DJ, 1991, J CLIN MICROBIOL, V29, P2450, DOI 10.1128/JCM.29.11.2450-2460.1991; CLARRIDGE JE, 1995, J CLIN MICROBIOL, V33, P2107, DOI 10.1128/JCM.33.8.2107-2113.1995; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; DRANCOURT M, 1992, LANCET, V340, P558, DOI 10.1016/0140-6736(92)91761-V; ENGLISH CK, 1988, JAMA-J AM MED ASSOC, V259, P1347, DOI 10.1001/jama.259.9.1347; JOBLET C, 1995, J CLIN MICROBIOL, V33, P1879, DOI 10.1128/JCM.33.7.1879-1883.1995; MARULLO S, 1992, J INFECT DIS, V166, P1462, DOI 10.1093/infdis/166.6.1462-a; RAOULT D, 1994, CLIN INFECT DIS, V19, P355, DOI 10.1093/clinids/19.2.355; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; WONG MT, 1995, CLIN INFECT DIS, V21, P352, DOI 10.1093/clinids/21.2.352	14	166	170	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					441	443		10.1016/S0140-6736(96)90012-4	http://dx.doi.org/10.1016/S0140-6736(96)90012-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618486				2022-12-28	WOS:A1996TV72200012
J	White, K; Tahaoglu, E; Steller, H				White, K; Tahaoglu, E; Steller, H			Cell killing by the Drosophila gene reaper	SCIENCE			English	Article							DEATH	The reaper gene (rpr) is important for the activation of apoptosis in Drosophila. To investigate whether rpr expression is sufficient to induce apoptosis, transgenic flies were generated that express rpr complementary DNA or the rpr open reading frame in cells that normally live. Transcription of rpr from a heat-inducible promoter rapidly caused widespread ectopic apoptosis and organismal death. Ectopic overexpression of rpr in the developing retina resulted in eye ablation. The occurrence of cell death was highly sensitive to the dosage of the transgene. Because cell death induced by the protein encoded by rpr(RPR)could be blocked by the baculovirus p35 protein, RPR appears to activate a death program mediated by a ced-3/ICE (interleukin-1 converting enzyme)-like protease.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	White, K (corresponding author), MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129, USA.		White, Kristin/D-7936-2013					ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CLEM RJ, 1994, APOPTOSIS, V2, P89; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; NEWCOMBCARBOY C, UNPUB; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; SONG HY, 1994, J BIOL CHEM, V269, P22492; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WHITE K, 1995, TRENDS CELL BIOL, V5, P74, DOI 10.1016/S0962-8924(00)88950-3; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	20	326	340	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					805	807		10.1126/science.271.5250.805	http://dx.doi.org/10.1126/science.271.5250.805			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628996				2022-12-28	WOS:A1996TU69400045
J	Chen, CR; Cheng, TO; Huang, T; Zhou, UL; Chen, JY; Huang, YG; Li, HJ				Chen, CR; Cheng, TO; Huang, T; Zhou, UL; Chen, JY; Huang, YG; Li, HJ			Percutaneous balloon valvuloplasty for pulmonic stenosis in adolescents and adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VALVE STENOSIS	Background Percutaneous balloon valvuloplasty has been the accepted first-line treatment for congenital pulmonic stenosis in children. Its efficacy in adolescents and adults is less well defined. Methods Between December 1985 and July 1995 we performed percutaneous pulmonic valvuloplasty with a single Inoue balloon catheter in 53 adolescent or adult patients 13 to 55 years of age (mean [+/-SD], 26+/-11). Follow-up studies were performed 0.2 to 9.8 years after the procedure (mean, 6.9+/-3.1) by Doppler echocardiography (in all the patients) and by cardiac catheterization and angiography (in nine patients). Results After balloon valvuloplasty, the systolic pressure gradient across the pulmonic valve decreased from 91+/-46 mm Hg to 38+/-32 mm Hg (P<0.001), and the diameter of the pulmonic-valve orifice increased from 8.9+/-3.6 mm to 17.4+/-4.6 mm (P<0.001). In the nine patients catheterized at followup, the systolic gradient decreased from 107+/-48 mm Hg before valvuloplasty to 50+/-29 mm Hg after valvuloplasty and to 30+/-16 mm Hg at follow-up (P<0.001 for the comparison of the gradient before and after valvuloplasty; P<0.001 for the comparison before valvuloplasty and at follow-up; and P<0.05 for the comparison after valvuloplasty and at followup). In the same nine patients, the diameter of the pulmonic valve, as measured by right ventricular angiography, increased from 8.3+/-1.4 mm before valvuloplasty to 17.2+/-2.0 mm after valvuloplasty (P<0.001) and to 18.4+/-1.4 mm at follow-up (P=0.08). Incompetence of the pulmonic valve was noted in 7 of the 53 patients (13 percent) after balloon valvuloplasty, but it had disappeared at followup in all of them. Conclusions Patients with congenital pulmonic stenosis who present in late adolescence or adult life can be treated with percutaneous balloon valvuloplasty with excellent short-term and long-term results that are similar to those in young children. (C)1996, Massachusetts Medical Society.	GUANGDONG CARDIOVASC INST,DEPT CARDIOL,GUANGZHOU,PEOPLES R CHINA; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DEPT MED,DIV CARDIOL,WASHINGTON,DC 20052	George Washington University								ALKASAB S, 1988, AM J CARDIOL, V62, P822, DOI 10.1016/0002-9149(88)91234-9; BARRAUD P, 1992, ARCH MAL COEUR VAISS, V85, P435; BENSHACHAR G, 1985, J AM COLL CARDIOL, V5, P754, DOI 10.1016/S0735-1097(85)80407-1; BOUTAUD P, 1990, ARCH MAL COEUR VAISS, V83, P969; Carminati M, 1993, Cardiologia, V38, P361; CHEN CR, 1988, CATHETER CARDIO DIAG, V15, P55, DOI 10.1002/ccd.1810150113; CHEN CR, 1995, AM HEART J, V129, P1197, DOI 10.1016/0002-8703(95)90404-2; CHEN CR, 1987, CHIN J CARDIOL, V15, P234; CHENG TO, 1994, CIRCULATION, V89, P896, DOI 10.1161/01.CIR.89.2.896; Eckert S., 1994, European Heart Journal, V15, P265; FAIT F, 1995, J INFASIVE CARDIO SC, V7, pC16; FAWZY ME, 1990, CATHETER CARDIO DIAG, V21, P77, DOI 10.1002/ccd.1810210204; GUTGESELL HP, 1992, J AM COLL CARDIOL, V20, P174, DOI 10.1016/0735-1097(92)90155-G; HERRMANN HC, 1991, AM J CARDIOL, V68, P1111, DOI 10.1016/0002-9149(91)90510-R; KAN JS, 1984, CIRCULATION, V69, P554, DOI 10.1161/01.CIR.69.3.554; KAN JS, 1982, NEW ENGL J MED, V307, P540, DOI 10.1056/NEJM198208263070907; KAUL UA, 1993, AM HEART J, V126, P1152, DOI 10.1016/0002-8703(93)90668-Y; LANDZBERG MJ, 1993, CIRCULATION, V88, P341; Lau K W, 1993, J Heart Valve Dis, V2, P321; LAU KW, 1993, CATHETER CARDIO DIAG, V29, P99, DOI 10.1002/ccd.1810290203; MAATOUK F, 1995, ARCH MAL COEUR VAISS, V88, P63; MCCRINDLE BW, 1991, CIRCULATION, V83, P1915, DOI 10.1161/01.CIR.83.6.1915; NUGENT EW, 1977, CIRCULATION, V56, P38; OCONNOR BK, 1992, J AM COLL CARDIOL, V20, P169, DOI 10.1016/0735-1097(92)90154-F; PRESBITERO P, 1988, Giornale Italiano di Cardiologia, V18, P155; RAO PS, 1988, AM J CARDIOL, V62, P979, DOI 10.1016/0002-9149(88)90909-5; RAO PS, 1992, PERCUTANEOUS BALLOON, P365; SADRAMELI MA, 1995, J AM COLL CARDIOL, P25; SHERMAN W, 1990, AM HEART J, V119, P186, DOI 10.1016/S0002-8703(05)80100-0; SIEVERT H, 1989, EUR HEART J, V10, P712, DOI 10.1093/oxfordjournals.eurheartj.a059555; STANGER P, 1990, AM J CARDIOL, V65, P775, DOI 10.1016/0002-9149(90)91387-L; TEUPE CHJ, 1995, CIRCULATION S1, V92, P357	32	100	109	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					21	25		10.1056/NEJM199607043350104	http://dx.doi.org/10.1056/NEJM199607043350104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637537				2022-12-28	WOS:A1996UU47900004
J	Wolinsky, AP				Wolinsky, AP			The illusion of certainty	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERMITTENT CLAUDICATION											CRIADO E, 1991, SURG GYNECOL OBSTET, V173, P163; DEWEESE JA, 1960, NEW ENGL J MED, V262, P1214, DOI 10.1056/NEJM196006162622403; HALL S, 1985, ANN INTERN MED, V103, P271, DOI 10.7326/0003-4819-103-2-271; SOX HC, 1988, MED DECIS MAKING, P27; SOX HC, 1988, MED DECIS MAKING, P67; WARREN R, 1976, ARCH SURG-CHICAGO, V111, P739	6	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 4	1996	335	1					46	48		10.1056/NEJM199607043350109	http://dx.doi.org/10.1056/NEJM199607043350109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UU479	8637542				2022-12-28	WOS:A1996UU47900009
J	Lindner, KH; Prengel, AW; Brinkmann, A; Strohmenger, HU; Lindner, IM; Lurie, KG				Lindner, KH; Prengel, AW; Brinkmann, A; Strohmenger, HU; Lindner, IM; Lurie, KG			Vasopressin administration in refractory cardiac arrest	ANNALS OF INTERNAL MEDICINE			English	Article							HIGH-DOSE EPINEPHRINE; CARDIOPULMONARY-RESUSCITATION; BLOOD-FLOW	Background: Successful outcomes after cardiopulmonary resuscitation remain disappointingly infrequent. In animal studies, administration of exogenous vasopressin during closed- and open-chest cardiopulmonary resuscitation has recently been shown to be more effective than optimal doses of epinephrine in improving vital organ blood flow. Objective: To describe the clinical effects and outcomes of administering vasopressin to patients in cardiac arrest refractory to current medical therapies. Design: Case reports. Setting: University hospital. Patients: 8 adults with in-hospital cardiac arrest. Interventions: After intravenous epinephrine (administered according to American Heart Association guidelines) and defibrillation efforts had failed, patients in cardiac arrest who were having cardiopulmonary resuscitation received 40 U of vasopressin intravenously and then defibrillation. Measurements: Return of spontaneous circulation and hospital discharge rates. Results: After administration of vasopressin, spontaneous circulation was promptly restored in all patients. Three patients were discharged from the hospital with intact neurologic function; the other five lived for between 30 minutes and 82 hours. Conclusion: In the presence of ventricular fibrillation with severe hypoxia and acidosis, vasopressin seems to be more potent and effective than adrenergic vasopressors for restoring spontaneous cardiovascular function. These results do not justify the widespread use of vasopressin for refractory cardiac arrest. However, on the basis of these cases, further studies comparing vasopressin with epinephrine are warranted in an effort to improve the currently dismal prognosis of patients after cardiac arrest.	UNIV ULM KLINIKUM, ANASTHESIOL KLIN, D-89075 ULM, GERMANY; UNIV MINNESOTA, SCH MED, CARDIAC ARRHYTHMIA CTR, MINNEAPOLIS, MN 55455 USA	Ulm University; University of Minnesota System; University of Minnesota Twin Cities								BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; FOREMAN BW, 1991, CIRC RES, V69, P657, DOI 10.1161/01.RES.69.3.657; LINDNER KH, 1993, ANESTH ANALG, V77, P427; LINDNER KH, 1992, ANESTHESIOLOGY, V77, P662, DOI 10.1097/00000542-199210000-00008; LINDNER KH, 1995, CIRCULATION, V91, P215, DOI 10.1161/01.CIR.91.1.215; LINDNER KH, 1992, RESUSCITATION, V24, P147, DOI 10.1016/0300-9572(92)90021-4; LINDNER KH, 1996, BRIT HEART J, V75, P145; PARADIS NA, 1990, ANN EMERG MED, V19, P1288, DOI 10.1016/S0196-0644(05)82289-9; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; Woodhouse SP, 1995, RESUSCITATION, V30, P243, DOI 10.1016/0300-9572(95)00890-X	10	154	162	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1061	1064		10.7326/0003-4819-124-12-199606150-00006	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633820				2022-12-28	WOS:A1996UQ65800006
J	Simons, SS				Simons, SS			Environmental estrogens: Can two ''alrights'' make a wrong?	SCIENCE			English	Editorial Material							HORMONE-BINDING; RECEPTOR				Simons, SS (corresponding author), NIDDKD,STEROID HORMONES SECT,NIH,ROOM B2A-07,BLDG 8,BETHESDA,MD 20892, USA.							Arnold SF, 1996, SCIENCE, V272, P1489, DOI 10.1126/science.272.5267.1489; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Foster WG, 1995, ENVIRON HEALTH PERSP, V103, P63, DOI 10.2307/3432724; HEINZ GH, 1991, ENVIRON MONIT ASSESS, V16, P277, DOI 10.1007/BF00397615; LOEB JN, 1987, MOL ENDOCRINOL, V1, P75, DOI 10.1210/mend-1-1-75; MARTIN PM, 1988, P NATL ACAD SCI USA, V85, P2533, DOI 10.1073/pnas.85.8.2533; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; NOTIDES AC, 1981, P NATL ACAD SCI-BIOL, V78, P4926, DOI 10.1073/pnas.78.8.4926; RUH TS, 1977, ENDOCRINOLOGY, V100, P420, DOI 10.1210/endo-100-2-420; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	14	28	28	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1451	1451		10.1126/science.272.5267.1451	http://dx.doi.org/10.1126/science.272.5267.1451			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633235				2022-12-28	WOS:A1996UP89900037
J	Glesby, MJ; Hoover, DR				Glesby, MJ; Hoover, DR			Survivor treatment selection bias in observational studies: Examples from the AIDS literature	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION; HIV-INFECTION; CONTROLLED TRIAL; NATURAL-HISTORY; ZIDOVUDINE; PROGRESSION; COMPLEX; THERAPY; TIME; MEN	Unlike patients in a randomized, clinical trial, patients in an observational study choose if and when to begin treatment. Patients who live longer have more opportunities to select treatment; those who die earlier may be untreated by default. These facts are the essence of an often over-looked bias, termed ''survivor treatment selection bias,'' which can erroneously lead to the conclusion that an ineffective treatment prolongs survival. Unfortunately, misanalysis of survivor treatment selection bias has been prevalent in the recent literature on the acquired immunodeficiency syndrome. Approaches to mitigating this bias involve complex statistical models. At a minimum, initiation of therapy should be treated as a time-dependent covariate in a proportional hazards model. Investigators and readers should be on the alert for survivor treatment selection bias and should be cautious when interpreting the results of observational treatment studies.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DIV INFECT DIS, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					PHS HHS [IU0135042-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BROOKMEYER R, 1987, AM J EPIDEMIOL, V126, P14, DOI 10.1093/oxfordjournals.aje.a114646; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; CDC, 1993, MMWR-MORBID MORTAL W, V42, P1; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; COLE P, 1980, JNCI-J NATL CANCER I, V64, P1263; COLFORD JM, 1994, AM J EPIDEMIOL, V139, P206, DOI 10.1093/oxfordjournals.aje.a116982; COX DR, 1972, J R STAT SOC B, V34, P187; DEGRUTTOLA V, 1993, J ACQ IMMUN DEF SYND, V6, P359; FATKENHEUER G, 1991, NEW ENGL J MED, V325, P1311, DOI 10.1056/NEJM199110313251812; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GAIL MH, 1992, NEW ENGL J MED, V327, P815; GALLANT JE, 1995, J INFECT DIS, V172, P346, DOI 10.1093/infdis/172.2.346; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; GRAHAM NMH, 1992, NEW ENGL J MED, V327, P815; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HIRSCHEL B, 1992, NEW ENGL J MED, V327, P814, DOI 10.1056/NEJM199209103271116; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIRBY AJ, 1994, J ACQ IMMUN DEF SYND, V7, P1242; KOPECSCHRADER E, 1993, AIDS, V7, P1009, DOI 10.1097/00002030-199307000-00016; LEMP GF, 1992, J INFECT DIS, V166, P74, DOI 10.1093/infdis/166.1.74; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; MARK SD, 1993, STAT MED, V12, P1605, DOI 10.1002/sim.4780121707; MARTINEZ MM, 1992, HAEMOSTASIS, V22, P281; MONFORTE AD, 1992, J ACQ IMMUN DEF SYND, V5, P1276; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOORE RD, 1994, JAMA-J AM MED ASSOC, V272, P1001, DOI 10.1001/jama.1994.03520130035018; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; PHILLIPS AN, 1992, J ACQ IMMUN DEF SYND, V5, P1065; PIKE MC, 1991, NEW ENGL J MED, V325, P1312; PORTEGIES P, 1993, AIDS, V7, P669, DOI 10.1097/00002030-199305000-00010; RAGNI MV, 1992, J ACQ IMMUN DEF SYND, V5, P120; ROBINS JM, 1992, EPIDEMIOLOGY, V3, P319, DOI 10.1097/00001648-199207000-00007; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; SANTOS B, 1994, INT J STD AIDS, V5, P279, DOI 10.1177/095646249400500410; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P124; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; STEIN DS, 1994, ANN INTERN MED, V121, P100, DOI 10.7326/0003-4819-121-2-199407150-00004; TSAI WY, 1987, BIOMETRIKA, V74, P883; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1994, LANCET, V871, P81; 1994, CLIN INVESTIGATOR, V72, P111	46	146	147	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1996	124	11					999	1005		10.7326/0003-4819-124-11-199606010-00008	http://dx.doi.org/10.7326/0003-4819-124-11-199606010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL905	8624068				2022-12-28	WOS:A1996UL90500008
J	Rao, SSC; Gregersen, H; Hayek, B; Summers, RW; Christensen, J				Rao, SSC; Gregersen, H; Hayek, B; Summers, RW; Christensen, J			Unexplained chest pain: The hypersensitive, hyperreactive, and poorly compliant esophagus	ANNALS OF INTERNAL MEDICINE			English	Article						chest pain; esophagus; neuromuscular diseases; impedance planimetry; balloon dilation	CROSS-SECTIONAL AREA; NORMAL CORONARY ARTERIOGRAMS; BALLOON DISTENSION; FOLLOW-UP; DIAGNOSIS; PRESSURE; PROVOCATION; EXPERIENCE; MOTILITY; ARTERIES	Objective: To determine whether neuromuscular dysfunction of the esophagus causes chest pain in patients in whom no disease is found on cardiac work-up, upper gastrointestinal endoscopy, esophageal manometry, and 24-hour pH studies. Design: Prospective study. Setting: Tertiary referral center. Patients: 24 consecutive patients and 12 healthy controls. Measurements: A new technique, impedance planimetry, was used to measure the sensory, motor, and biomechanical properties of the human esophagus. The impedance planimeter, which consists of a probe with four ring electrodes, three pressure sensors, and a balloon, simultaneously measures intraluminal pressure and cross-sectional areas. This allows calculation of the biomechanical variables of the esophageal wall. Results: Stepwise balloon distentions from 5 to 50 cm H2O induced a first sensation at a mean pressure (+/- SD) of 15 +/- 9 cm H2O in patients and 30 +/- 11 cm H2O in controls (P < 0.001). Moderate discomfort and pain were reported by 20 of 24 patients (83%) at 26 +/- 9 cm H2O and at 36 +/- 9 cm H2O, respectively, but by none of the controls (P < 0.001). Typical chest pain was reproduced in 20 of 24 patients (83%). In patients, the reactivity of the esophagus to balloon distention was greater (P = 0.01), the pressure elastic modulus was higher (P = 0.02), and the tension-strain association showed that the esophageal wall was less distensible (P = 0.02). Distention excited tertiary contractions and secondary peristalsis at a lower threshold of pressure (P = 0.05) and with a higher motility index in patients than in controls (P = 0.04). Conclusion: In patients with chest pain and normal cardiac and esophageal evaluations, impedance planimetry of the esophagus reproduces pain and is associated with a 50% lower sensory threshold for pain, a 50% lower threshold for reactive contractions, and reduced esophageal compliance.	UNIV IOWA HOSP & CLIN, INTERNAL MED GI DIV, IOWA CITY, IA 52242 USA; UNIV IOWA HOSP & CLIN, DEPT INTERNAL MED, DIV GI HEPATOL, IOWA CITY, IA 52242 USA; DEPT VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA; AARHUS UNIV, AARHUS, DENMARK	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Aarhus University			Gregersen, Hans/AAH-3723-2021	Gregersen, Hans/0000-0002-5792-2845				BARISH CF, 1986, DIGEST DIS SCI, V31, P1292, DOI 10.1007/BF01299805; BEITMAN BD, 1989, AM J CARDIOL, V63, P1399, DOI 10.1016/0002-9149(89)91056-4; BLACKWELL JN, 1984, GUT, V25, P1, DOI 10.1136/gut.25.1.1; CANNON RO, 1990, AM J MED, V88, P217, DOI 10.1016/0002-9343(90)90145-4; CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CANNON RO, 1994, NEW ENGL J MED, V330, P1411, DOI 10.1056/NEJM199405193302003; CERVERO F, 1992, TRENDS NEUROSCI, V15, P374, DOI 10.1016/0166-2236(92)90182-8; CLOUSE RE, 1983, NEW ENGL J MED, V309, P1337, DOI 10.1056/NEJM198312013092201; COLSTRUP H, 1983, UROL RES, V11, P139; DEMEESTER TR, 1982, ANN SURG, V196, P488, DOI 10.1097/00000658-198210000-00013; DESCHNER WK, 1990, AM J GASTROENTEROL, V85, P938; GHILLEBERT G, 1990, GUT, V31, P738, DOI 10.1136/gut.31.7.738; GREGERSEN H, 1991, MED BIOL ENG COMPUT, V29, P108, DOI 10.1007/BF02446307; Gregersen H, 1988, Clin Phys Physiol Meas, V9 Suppl A, P61, DOI 10.1088/0143-0815/9/4A/011; GREGERSEN H, 1991, DIGEST DIS, V9, P332, DOI 10.1159/000171320; GREGERSEN H, 1992, J GASTROINTEST MOTIL, V4, P125; Harris J, 1971, URODYNAMICS, P465; HOWARD PJ, 1991, GUT, V32, P128, DOI 10.1136/gut.32.2.128; KATZ PO, 1987, ANN INTERN MED, V106, P593, DOI 10.7326/0003-4819-106-4-593; KEMP HG, 1973, AM J MED, V54, P735, DOI 10.1016/0002-9343(73)90060-0; LANDOWNE M, 1957, TISSUE ELASTICITY, P191; LOSE G, 1986, MED BIOL ENG COMPUT, V24, P488, DOI 10.1007/BF02443964; MAYER EA, 1994, GASTROENTEROLOGY, V107, P271, DOI 10.1016/0016-5085(94)90086-8; MAYER EA, 1993, BASIC CLIN ASPECTS C, P3; MAYRAND S, 1993, GASTROENTEROLOGY, V105, P1411, DOI 10.1016/0016-5085(93)90146-4; NEVENS F, 1991, DIGEST DIS SCI, V36, P229, DOI 10.1007/BF01300762; OCKENE IS, 1980, NEW ENGL J MED, V303, P1249, DOI 10.1056/NEJM198011273032201; ORVAR KB, 1993, DIGEST DIS SCI, V38, P197, DOI 10.1007/BF01307535; RAO SSC, 1995, AM J GASTROENTEROL, V90, P431; Richter J E, 1988, Adv Intern Med, V33, P311; RICHTER JE, 1989, ANN INTERN MED, V110, P66, DOI 10.7326/0003-4819-110-1-66; RICHTER JE, 1986, GASTROENTEROLOGY, V91, P845, DOI 10.1016/0016-5085(86)90685-2; RICHTER JE, 1991, TXB GASTROENTEROLOGY, P1083; ROTHSTEIN RD, 1989, GASTROENTEROL CLIN N, V18, P257; SOFFER EE, 1989, DIGEST DIS SCI, V34, P1651, DOI 10.1007/BF01540039; WARD BW, 1987, AM J GASTROENTEROL, V82, P215	36	145	148	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1996	124	11					950	958		10.7326/0003-4819-124-11-199606010-00002	http://dx.doi.org/10.7326/0003-4819-124-11-199606010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL905	8624062				2022-12-28	WOS:A1996UL90500002
J	Fey, R; Pearson, N				Fey, R; Pearson, N			Statins and coronary heart disease	LANCET			English	Editorial Material									AVON HLTH, DIST HLTH AUTHOR, BRISTOL BS2 8EE, AVON, ENGLAND		Fey, R (corresponding author), AVON HLTH, AVON FAMILY HLTH SERV AUTHOR, 10 DIGHTON ST, BRISTOL BS2 8EE, AVON, ENGLAND.							ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; DEAN M, 1995, LANCET, V346, P1415, DOI 10.1016/S0140-6736(95)92414-0; FOULDS J, 1995, BRIT MED J, V311, P1152, DOI 10.1136/bmj.311.7013.1152; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; *OFF POP CENS SURV, 1995, SER PP2, V19; OLIVER MF, 1995, LANCET, V346, P1378, DOI 10.1016/S0140-6736(95)92399-3; *OPCS SOC SURV DIV, 1995, 1993 HLTH SURV ENGL; PEDERSEN TR, 1994, LANCET, V344, P1383; PEDERSEN TR, 1995, NEW ENGL J MED, V333, P1350, DOI 10.1056/NEJM199511163332010; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SHEPHERD J, 1995, AM J CARDIOL, V76, P485; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; 1996, ANN INTERN MED, V14, P515; 1995, BRIT NATL FORMUL SEP	17	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	1996	347	9012					1389	1390		10.1016/S0140-6736(96)91019-3	http://dx.doi.org/10.1016/S0140-6736(96)91019-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637349				2022-12-28	WOS:A1996UL90400018
J	Hotvedt, R; Kristiansen, IS; Forde, OH; Thoner, J; Almdahl, SM; Bjorsvik, G; Berge, L; Magnus, AC; Mamen, K; Sparr, T; YtreArne, K				Hotvedt, R; Kristiansen, IS; Forde, OH; Thoner, J; Almdahl, SM; Bjorsvik, G; Berge, L; Magnus, AC; Mamen, K; Sparr, T; YtreArne, K			Which groups of patients benefit from helicopter evacuation?	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; TRAUMA MORTALITY; TRANSPORT; SERVICE; IMPACT	Background The evacuation of emergency cases by air, usually by helicopter, is controversial because of the cost of the programme, the possibility of an accident (especially in an urban area), and unproven benefit. But such evacuations cannot be studied by a random intervention leg, air versus ground ambulance). We used an expert-panel approach to estimate the health outcome for patients transferred by emergency helicopter compared with the potential outcome if they had gone by surface ambulance. Methods The helicopter programme is based at the University Hospital of Tromso in northern Norway. 370 case-reports of helicopter evacuation from rural areas were screened by anaesthetists for routine and case-specific data. Two expert panels assessed the cases for potential additional health benefit arising from the fact of helicopter evacuation. The panels used a modified Delphi technique to reach consensus in life-years gained. One panel met for cases aged under 15 and pregnant women, the other for older cases. Findings 240 of the 370 cases were male (65%); the age range for both sexes was 0-86 years. The most common diagnosis for the 55 cases aged under 15 was infection (49%); in older patients, cardiovascular disease dominated (50%). Trauma accounted for just under a fifth of cases in both groups. On average, the patients arrived 69 min (range 0-615) earlier in hospital than if they had gone by ground transport. For 283 cases, the initial screening by the anaesthetists indicated no additional benefit compared with that obtainable by ground-ambulance transport. The main reason was that no treatment was given during the flight or early on in hospital that could not have been given otherwise. 90 cases entered the expert panel system. Of these 90, 49 cases were judged to have received no additional benefit. This left 41 (11% of the total of 370 evacuated) who were judged to have benefited, gaining 290.6 life-years. 96% of the total number of life-years gained was achieved in nine patients, six of whom were aged below 7 (four were aged 0-7 months). The life-year-gain per adult patient with cardiovascular disease was 0.54. Interpretation We conclude that an emergency helicopter service can provide considerable health benefits for selected patients, at least in this rural setting. Given the costs and risks of such a service, the benefits for most patients are small.	UNIV TROMSO, INST COMMUNITY MED, N-9001 TROMSO, NORWAY; MUNICIPAL HLTH AUTHOR, HANSNES, NORWAY; MUNICIPAL HLTH AUTHOR, FINNSNES, NORWAY	UiT The Arctic University of Tromso	Hotvedt, R (corresponding author), UNIV TROMSO HOSP, DEPT ANAESTHESIOL, N-9038 TROMSO, NORWAY.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BAXT WG, 1983, JAMA-J AM MED ASSOC, V249, P3047, DOI 10.1001/jama.249.22.3047; BAXT WG, 1985, ANN EMERG MED, V14, P859, DOI 10.1016/S0196-0644(85)80634-X; BAXT WG, 1987, JAMA-J AM MED ASSOC, V257, P3246, DOI 10.1001/jama.257.23.3246; BELLINGER RL, 1988, AM J CARDIOL, V61, P718, DOI 10.1016/0002-9149(88)91054-5; BLACK RE, 1982, NEW ENGL J MED, V307, P1465, DOI 10.1056/NEJM198212023072342; CARTER GL, 1986, ANN EMERG MED, V15, P1117, DOI 10.1016/S0196-0644(86)80141-X; *CENTR BUR STAT NO, 1986, 1986 STAT YB; *CENTR BUR STAT NO, 1986, INT CLASS DIS; CUSACK SC, 1991, INJURY, V22, P54, DOI 10.1016/0020-1383(91)90165-B; DEMELLO WF, 1990, BRIT J HOSP MED, V43, P328; ELLIOTT JP, 1982, AM J OBSTET GYNECOL, V143, P157, DOI 10.1016/0002-9378(82)90646-9; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; HARBOE S, 1985, Tidsskrift for den Norske Laegeforening, V105, P1863; HOTVEDT R, 1994, EMERGENCY AMBULANCE; KAPLAN L, 1987, ANN EMERG MED, V16, P55, DOI 10.1016/S0196-0644(87)80287-1; KARPER S, 1990, EMERGENCY HELICOPTER; LOW R B, 1988, Journal of Emergency Medicine, V6, P41, DOI 10.1016/0736-4679(88)90250-8; MOYLAN JA, 1988, ANN SURG, V207, P679, DOI 10.1097/00000658-198806000-00006; RHEE KJ, 1990, ANN EMERG MED, V19, P552, DOI 10.1016/S0196-0644(05)82188-2; RHEE KJ, 1990, AVIAT SPACE ENVIR MD, V61, P750; SCHNEIDER S, 1988, AM J EMERG MED, V6, P449, DOI 10.1016/0735-6757(88)90243-4; Schwartz R J, 1988, Conn Med, V52, P203; Torrance GW, 1987, METHODS EC EVALUATIO; TYSON AA, 1988, AM J EMERG MED, V6, P435, DOI 10.1016/0735-6757(88)90240-9; URDANETA LF, 1987, ARCH SURG-CHICAGO, V122, P992; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Westlund K, 1972, J Oslo City Hosp, V22, P77; WESTLUND K, 1956, ACTA MED SCAND S315, V154, P1; 1988, SAFETY STUDY COMMERC	31	76	76	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	1996	347	9012					1362	1366		10.1016/S0140-6736(96)91010-7	http://dx.doi.org/10.1016/S0140-6736(96)91010-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637341	Bronze			2022-12-28	WOS:A1996UL90400009
J	Verheugt, FWA				Verheugt, FWA			Primary angioplasty for acute myocardial infarction: Is the balloon half full or half empty?	LANCET			English	Editorial Material							IMMEDIATE ANGIOPLASTY				Verheugt, FWA (corresponding author), UNIV NIJMEGEN HOSP, DEPT CARDIOL, 6500 HB NIJMEGEN, NETHERLANDS.		Verheugt, F.W.A./H-8105-2014					AHMAD T, 1995, AM J CARDIOL, V76, P77, DOI 10.1016/S0002-9149(99)80807-8; Elizaga J., 1993, European Heart Journal, V14, P118; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Grinfeld Liliana, 1996, Journal of the American College of Cardiology, V27, p222A; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; Ribichini Flavio, 1996, Journal of the American College of Cardiology, V27, p221A; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	9	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	1996	347	9011					1276	1277		10.1016/S0140-6736(96)90933-2	http://dx.doi.org/10.1016/S0140-6736(96)90933-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622499	Green Submitted			2022-12-28	WOS:A1996UK75800004
J	Geiger, JH; Hahn, S; Lee, S; Sigler, PB				Geiger, JH; Hahn, S; Lee, S; Sigler, PB			Crystal structure of the yeast TFIIA/TBP/DNA complex	SCIENCE			English	Article							TRANSCRIPTION INITIATION SITES; SACCHAROMYCES-CEREVISIAE; FACTOR-IIA; TFIIA; SUBUNITS; ACTIVATION; CDNA; GENE	The crystal structure of the yeast TFIIA/TBP/TATA promoter complex was solved to 3 angstrom resolution by double-edge multiple wavelength anomalous diffraction from two different species of anomalous scattering elements in the same crystal. The large and small subunits of TFIIA associate intimately to form both domains of a two-domain folding pattern. TFIIA binds as a heterodimer to the side of the TBP/TATA complex opposite to the side that binds TFIIB and does not alter the TBP/DNA interaction. The six-stranded beta-sandwich domain interacts with the amino-terminal end of TBP through a stereospecific parallel beta-strand interface and with the backbone of the TATA box and the 5'-flanking B-DNA segment. The four-helix-bundle domain projects away from the TBP/TATA complex, thereby presenting a substantial surface for further protein-protein interactions.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Yale University; Howard Hughes Medical Institute; Yale University; Fred Hutchinson Cancer Center				Geiger, James/0000-0002-9443-4488				AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BRYANT GW, COMMUNICATION; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; GE H, 1994, J BIOL CHEM, V269, P17136; GuzikevichGuerstein G, 1996, NAT STRUCT BIOL, V3, P32, DOI 10.1038/nsb0196-32; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; LAGRANGE T, COMMUNICATION; LEE DK, 1992, MOL CELL BIOL, V12, P96; MA D, COMMUNICATION; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Ozer J, 1996, J BIOL CHEM, V271, P11182, DOI 10.1074/jbc.271.19.11182; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RANISH J, COMMUNICATION; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; RANISH JA, UNPUB; RANISH JA, IN PRESS CURR OPIN G; REED RJ, 1986, ACTA CRYSTALLOGR A, V42, P140; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313	46	233	236	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					830	836		10.1126/science.272.5263.830	http://dx.doi.org/10.1126/science.272.5263.830			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629014				2022-12-28	WOS:A1996UK75700043
J	Voloshin, ON; Wang, LJ; CameriniOtero, RD				Voloshin, ON; Wang, LJ; CameriniOtero, RD			Homologous DNA pairing promoted by a 20-amino acid peptide derived from RecA	SCIENCE			English	Article							SINGLE-STRANDED FRAGMENTS; ESCHERICHIA-COLI; SUPERHELICAL DNA; BRANCH MIGRATION; UVSX PROTEIN; BACTERIOPHAGE-T4; RECOMBINATION; BINDING; YEAST	The molecular structure of the Escherichia coli RecA protein in the absence of DNA revealed two disordered or mobile loops that were proposed to be DNA binding sites. A short peptide spanning one of these loops was shown to carry out the key reaction mediated by the whole RecA protein: pairing (targeting) of a single-stranded DNA to its homologous site on a duplex DNA. In the course of the reaction the peptide bound to both substrate DNAs, unstacked the single-stranded DNA, and assumed a beta structure. These events probably recapitulate the underlying molecular pathway or mechanism used by homologous recombination proteins.	NIDDKD,GENET BIOMED BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CameriniOtero RD, 1995, ANNU REV GENET, V29, P509, DOI 10.1146/annurev.genet.29.1.509; CAZAUX C, 1994, J BIOL CHEM, V269, P8246; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; COX MM, 1995, J BIOL CHEM, V270, P26021, DOI 10.1074/jbc.270.44.26021; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARRIS LD, 1988, BIOCHEMISTRY-US, V27, P6954, DOI 10.1021/bi00418a042; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; KANSY JW, 1986, J BIOMOL STRUCT DYN, V3, P1079, DOI 10.1080/07391102.1986.10508487; KASLIN E, 1994, J BIOL CHEM, V269, P14103; KMIEC EB, 1994, J BIOL CHEM, V269, P10163; KOLLER T, 1983, MECHANISMS DNA REPLI, P723; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KOWALCZYKOWSKI C, 1994, ANN REV BIOCH, V63, P991; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P538; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; MARABOEUF O, 1995, J BIOL CHEM, V270, P30927; Maxam A M, 1980, Methods Enzymol, V65, P499; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; RADDING CM, 1977, J MOL BIOL, V116, P825, DOI 10.1016/0022-2836(77)90273-X; RAO BJ, 1995, TRENDS BIOCHEM SCI, V20, P109, DOI 10.1016/S0968-0004(00)88976-8; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIKORAV JL, 1991, J MOL BIOL, V222, P1085, DOI 10.1016/0022-2836(91)90595-W; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; VOLOSHIN ON, UNPUB; Wang L., UNPUB; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YU X, 1993, J MOL BIOL, V232, P1, DOI 10.1006/jmbi.1993.1363; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	42	75	88	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					868	872		10.1126/science.272.5263.868	http://dx.doi.org/10.1126/science.272.5263.868			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629021				2022-12-28	WOS:A1996UK75700058
J	Beevers, DG; Sleight, P				Beevers, DG; Sleight, P			Fortnightly review - Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: Is there a risk?	BRITISH MEDICAL JOURNAL			English	Article							INFARCTION; NIFEDIPINE; TRIAL		JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; CITY HOSP,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND	University of Oxford; University of Birmingham								Barnett AA, 1996, LANCET, V347, P313; BORHANI NO, 1992, J CARDIOVASC PHARM, V19, pS16; BURING JE, 1995, JAMA-J AM MED ASSOC, V274, P654, DOI 10.1001/jama.274.8.654; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; DAVIS BR, IN PRESS AM J HYPERT; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; MCCARTHY M, 1995, LANCET, V346, P689, DOI 10.1016/S0140-6736(95)92289-X; MESSERLI FH, 1991, LANCET, V338, P881, DOI 10.1016/0140-6736(91)91530-8; OMAILIA JJ, 1987, ANN INTERN MED, V107, P185, DOI 10.7326/0003-4819-107-2-185; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; PAHOR M, IN PRESS LANCET; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; REHNQVIST N, IN PRESS EUR HEART J; Sleight P, 1996, DRUGS, V51, P216, DOI 10.2165/00003495-199651020-00003; WAGENKNECHT LE, 1995, BRIT MED J, V310, P776, DOI 10.1136/bmj.310.6982.776; WATERS D, 1991, CIRCULATION, V84, P2598, DOI 10.1161/01.CIR.84.6.2598; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G; Yusuf S, 1996, AM J CARDIOL, V77, P421, DOI 10.1016/S0002-9149(97)89376-9; 1990, AM J CARDIOL, V66, P779	19	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1143	1145						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK069	8620133				2022-12-28	WOS:A1996UK06900028
J	Bauer, CE; Bird, TH				Bauer, CE; Bird, TH			Regulatory circuits controlling photosynthesis gene expression	CELL			English	Review							RHODOBACTER-SPHAEROIDES; OPERON; LIGHT; CAPSULATUS; OXYGEN				Bauer, CE (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.				NIGMS NIH HHS [R01 GM040941, R37 GM040941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040941, R37GM040941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberti M, 1995, ANOXYGENIC PHOTOSYNT, P1083; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; Beatty J. T., 1995, ANOXYGENIC PHOTOSYNT, P1209; BUGGY J, 1995, J BACTERIOL, V177, P6958, DOI 10.1128/jb.177.23.6958-6965.1995; BUGGY JJ, 1994, J BACTERIOL, V176, P6936, DOI 10.1128/JB.176.22.6936-6943.1994; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; ERASO JM, 1995, J BACTERIOL, V177, P2695, DOI 10.1128/jb.177.10.2695-2706.1995; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; Gest H, 1995, PHOTOSYNTH RES, V46, P473, DOI 10.1007/BF00032302; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; KLUG G, 1995, ANOXYGENIC PHOTOSYNT, P1235; LEE JK, 1992, J BACTERIOL, V174, P1146, DOI 10.1128/jb.174.4.1146-1157.1992; LEE JK, 1993, J BIOL CHEM, V268, P24491; MA D, 1993, J BACTERIOL, V175, P2037, DOI 10.1128/JB.175.7.2037-2045.1993; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; PENFOLD RJ, 1994, J BACTERIOL, V176, P2869, DOI 10.1128/JB.176.10.2869-2876.1994; PONNAMPALAM SN, 1995, J BACTERIOL, V177, P2990, DOI 10.1128/jb.177.11.2990-2997.1995; Qian YL, 1996, J BACTERIOL, V178, P12, DOI 10.1128/jb.178.1.12-18.1996; SHIMADA H, 1992, PLANT CELL PHYSIOL, V33, P471; ZUCCONI AP, 1988, J BACTERIOL, V170, P877, DOI 10.1128/jb.170.2.877-882.1988	20	74	75	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					5	8		10.1016/S0092-8674(00)81074-0	http://dx.doi.org/10.1016/S0092-8674(00)81074-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620537	Bronze			2022-12-28	WOS:A1996UE55900002
J	Heichman, KA; Roberts, JM				Heichman, KA; Roberts, JM			The yeast CDC16 and CDC27 genes restrict DNA replication to once per cell cycle	CELL			English	Article							POLE BODY DUPLICATION; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; BUDDING YEAST; ASPERGILLUS-NIDULANS; NUCLEAR DIVISION; LICENSING FACTOR; MITOSIS; ANAPHASE; MUTANTS	CDC16 and CDC27 were identified as genes in S. cerevisiae necessary to limit DNA replication to once per cell cycle. A screen for mutants that overreplicated their DNA uncovered new conditional alleles that cause accumulation of up to 8C DNA. DNA overreplication involves all chromosomes and does not require passage through mitosis or another START. It occurs within a single cell cycle and can cause arrest at the MEC1 checkpoint. Remarkably, CIb2-Cdc28 activity remains elevated in the overreplicating cells. These observations distinguish CDC16 and CDC27 from other mutants that accumulate extra DNA after completing an aberrent mitosis, or skipping mitosis altogether, and entering a second, inappropriate G1 and S phase. CDC16 and CDC27 may contribute to replication control by targeted proteolysis of an S phase initiator.			Heichman, KA (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.							ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; CREANOR J, 1990, J CELL SCI, V96, P435; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUBERMAN JA, 1995, NATURE, V375, P360, DOI 10.1038/375360a0; IMIGER S, 1995, CELL, V81, P269; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KLYCE HR, 1973, EXP CELL RES, V82, P47, DOI 10.1016/0014-4827(73)90243-7; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MAY GS, 1992, J BIOL CHEM, V267, P15737; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; ODONNELL KL, 1991, J CELL SCI, V99, P711; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745	53	79	81	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	1996	85	1					39	48		10.1016/S0092-8674(00)81080-6	http://dx.doi.org/10.1016/S0092-8674(00)81080-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620535	Bronze			2022-12-28	WOS:A1996UE55900007
J	Konig, P; Giraldo, R; Chapman, L; Rhodes, D				Konig, P; Giraldo, R; Chapman, L; Rhodes, D			The crystal structure of the DNA-binding domain of yeast RAP1 in complex with telomeric DNA	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ANTENNAPEDIA HOMEODOMAIN; PROTEIN; SILENCER; LENGTH; TRANSCRIPTION; RESOLUTION; SEQUENCES; STABILITY; ERRORS	Telomeres, the nucleoprotein complexes at the ends of eukaryotic chromosomes, are essential for chromosome stability. In the yeast S. cerevisiae, telomeric DNA is bound in a sequence-specific manner by RAP1, a multifunctional protein also involved in transcriptional regulation. Here we report the crystal structure of the DNA-binding domain of RAP1 in complex with a telomeric DNA site at 2.25 Angstrom resolution. The protein contains two similar domains that bind DNA in a tandem orientation, recognizing a tandemly repeated DNA sequence. The domains are structurally related to the homeodomain and the proto-oncogene Myb, but show novel features in their DNA-binding mode. A structured linker between the domains and a long C-terminal tail contribute to the binding specificity. This structure provides insight into the recognition of the conserved telomeric DNA sequences by a protein.	CSIC,CTR INVEST BIOL,MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Konig, P (corresponding author), MRC,MOLEC BIOL LAB,LONDON W1N 4AL,ENGLAND.		Giraldo, Rafael/P-3289-2014	Giraldo, Rafael/0000-0002-5358-7488				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAIRALL L, 1989, EMBO J, V8, P1809, DOI 10.1002/j.1460-2075.1989.tb03575.x; FREEMAN K, 1995, GENETICS, V141, P1253; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GILSON E, 1995, NUCLEIC ACIDS MOL BI, V9, P308; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GRAHAM IR, 1994, NUCLEIC ACIDS RES, V22, P124, DOI 10.1093/nar/22.2.124; GREIDER CW, 1994, CURR OPIN GENET DEV, V4, P203, DOI 10.1016/S0959-437X(05)80046-2; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HENRY YAL, 1990, NUCLEIC ACIDS RES, V18, P2617, DOI 10.1093/nar/18.9.2617; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P110; HUET J, 1985, EMBO J, V4, P3539, DOI 10.1002/j.1460-2075.1985.tb04114.x; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LARSON GP, 1994, GENE, V150, P35, DOI 10.1016/0378-1119(94)90854-0; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCEACHERN MJ, 1994, P NATL ACAD SCI USA, V91, P3453, DOI 10.1073/pnas.91.8.3453; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MULLER T, 1994, J STRUCT BIOL, V113, P1, DOI 10.1006/jsbi.1994.1027; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; QIAN YQ, 1993, J MOL BIOL, V234, P1070, DOI 10.1006/jmbi.1993.1660; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RHODES D, 1995, CURR OPIN STRUC BIOL, V5, P311, DOI 10.1016/0959-440X(95)80092-1; SCHWABE JWR, 1995, STRUCTURE, V3, P201, DOI 10.1016/S0969-2126(01)00150-2; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; TSANG JSH, 1990, NUCLEIC ACIDS RES, V18, P7331, DOI 10.1093/nar/18.24.7331; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; YUAN H, 1992, BIOCHEMISTRY-US, V31, P8009, DOI 10.1021/bi00149a035; ZAKIAN AV, 1995, SCIENCE, V270, P1601	64	251	254	4	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	1996	85	1					125	136		10.1016/S0092-8674(00)81088-0	http://dx.doi.org/10.1016/S0092-8674(00)81088-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UE559	8620531	Bronze			2022-12-28	WOS:A1996UE55900015
J	Green, AR				Green, AR			Pathogenesis of polycythaemia vera	LANCET			English	Editorial Material							POLYCYTHEMIA-VERA; ERYTHROPOIETIN				Green, AR (corresponding author), UNIV CAMBRIDGE,DEPT HAEMATOL,MRC CTR,CAMBRIDGE,ENGLAND.			Green, Anthony/0000-0002-9795-0218				ADAMSON JW, 1976, NEW ENGL J MED, V295, P913, DOI 10.1056/NEJM197610212951702; Aldred M. A., 1995, American Journal of Human Genetics, V57, pA255; ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; CORREA PN, 1994, BLOOD, V83, P99; DAI CH, 1992, BLOOD, V80, P891; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; FISHER MJ, 1994, BLOOD, V84, P1982; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; KRALOVICS R, 1995, BLOOD, V86, P733; KRALOVICS R, 1995, BLOOD, V86, P270; NUNEZ C, 1994, BLOOD, V85, P635; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; WHITE NJ, 1994, BLOOD, V83, P2809, DOI 10.1182/blood.V83.10.2809.2809; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	15	20	20	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					844	845		10.1016/S0140-6736(96)91338-0	http://dx.doi.org/10.1016/S0140-6736(96)91338-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC450	8622384				2022-12-28	WOS:A1996UC45000002
J	Tarn, WY; Steitz, JA				Tarn, WY; Steitz, JA			A novel spliceosome containing U11, U12, and U5 snRNPs excises a minor class (AT-AC) intron in vitro	CELL			English	Article							SMALL NUCLEAR-RNA; CROSS-LINKING; ACTIVE-SITE; U6 SNRNA; RIBONUCLEOPROTEIN; MUTATIONS; PROBES; U4/U6; YEAST; CAP	A minor class of introns with noncanonical splice (AT-AC) and branch site sequences exists in metazoan protein coding genes. We have established a HeLa cell in vitro system that accurately splices a pre-mRNA substrate containing such an intron from the human P120 gene. Splicing occurs via a lariat intermediate whose branch site A residue is predicted to bulge from a duplex formed with the low abundance U12 small nuclear ribonucleoprotein (snRNP), which we confirm by psoralen cross-linking. Native gel electrophoresis reveals that U11, U12, and U5 snRNPs assemble onto the P120 pre-mRNA to form splicing complexes. Inhibition of P120 splicing by 2'-O-methyl oligonucleotides complementary to U12 or U5 demonstrates that U12 and U5 snRNPs perform essential roles in the AT-AC spliceosome.			Tarn, WY (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW HAVEN, CT 06536 USA.		Tarn, Woan-Yuh/N-8464-2018		NIGMS NIH HHS [GM26154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026154, R37GM026154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; CHANFREAU G, 1994, NUCLEIC ACIDS RES, V22, P1981, DOI 10.1093/nar/22.11.1981; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; CRISPINO JD, 1995, GENE DEV, V9, P2314, DOI 10.1101/gad.9.18.2314; GILLIAM AC, 1993, P NATL ACAD SCI USA, V90, P6781, DOI 10.1073/pnas.90.14.6781; GONTAREK RR, 1993, GENE DEV, V7, P1926, DOI 10.1101/gad.7.10.1926; GUPTA S, 1990, J BIOL CHEM, V265, P19137; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; HALL SL, 1986, IN PRESS SCIENCE; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1989, METHOD ENZYMOL, V180, P442; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; LAMM GM, 1993, BIOCHIM BIOPHYS ACTA, V1173, P247, DOI 10.1016/0167-4781(93)90122-T; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; LARSON RG, 1990, CANCER COMMUN, V2, P63, DOI 10.3727/095535490820874704; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; LINGNER J, 1993, NUCLEIC ACIDS RES, V21, P2917, DOI 10.1093/nar/21.12.2917; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; RUSKIN B, 1990, METHOD ENZYMOL, V181, P180; SCADDEN ADJ, 1995, EMBO J, V14, P3236; SONTHEIMER EJ, 1992, MOL CELL BIOL, V12, P734, DOI 10.1128/MCB.12.2.734; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; TARN WY, 1995, RNA, V1, P644; TARN WY, 1994, P NATL ACAD SCI USA, V8, P2704; WASSARMAN DA, 1993, MOL BIOL REP, V17, P143, DOI 10.1007/BF00996222; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542	41	185	188	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 8	1996	84	5					801	811		10.1016/S0092-8674(00)81057-0	http://dx.doi.org/10.1016/S0092-8674(00)81057-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625417	hybrid			2022-12-28	WOS:A1996TZ99000017
J	Vladeck, BC				Vladeck, BC			The past, present, and future of nursing home quality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Vladeck, BC (corresponding author), US HLTH CARE FINANCING ADM,BALTIMORE,MD 21207, USA.								0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					425	425						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627949				2022-12-28	WOS:A1996TU63800006
J	Cluzel, P; Lebrun, A; Heller, C; Lavery, R; Viovy, JL; Chatenay, D; Caron, F				Cluzel, P; Lebrun, A; Heller, C; Lavery, R; Viovy, JL; Chatenay, D; Caron, F			DNA: An extensible molecule	SCIENCE			English	Article							RECA PROTEIN; SINGLE	The force-displacement response of a single duplex DNA molecule was measured. The force saturates at a plateau around 70 piconewtons, which ends when the DNA has been stretched about 1.7 times its contour length. This behavior reveals a highly cooperative transition to a state here termed S-DNA. Addition of an intercalator suppresses this transition. Molecular modeling of the process also yields a force plateau and suggests a structure for the extended form. These results may shed light on biological processes involving DNA extension and open the route for mechanical studies on individual molecules in a previously unexplored range.	ECOLE NORMALE SUPER,CNRS,URA 1302,GENET MOLEC LAB,F-75230 PARIS,FRANCE; INST CURIE,CNRS,URA 448,F-75005 PARIS,FRANCE; INST CURIE,CNRS,URA 1379,F-75005 PARIS,FRANCE; INST BIOL PHYSICOCHIM,CNRS,URA 77,LAB BIOCHIM THEOR,F-75005 PARIS,FRANCE; INST PHYS,LUDFC,F-67084 STRASBOURG,FRANCE; MAX PLANCK INST MOLEC GENET,D-14195 BERLIN,GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Max Planck Society			Lavery, Richard/G-1422-2011	Lavery, Richard/0000-0001-9901-6640; Heller, Christoph/0000-0002-9434-8192; Viovy, Jean-Louis/0000-0002-8223-4040				BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; Cox R. G., 1970, Journal of Fluid Mechanics, V44, P791, DOI 10.1017/S002211207000215X; CRICK FHC, 1954, PROC R SOC LON SER-A, V223, P80, DOI 10.1098/rspa.1954.0101; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRASER MJ, 1951, NATURE, V167, P760; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; HILL TL, 1959, J CHEM PHYS, V30, P383, DOI 10.1063/1.1729961; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; LAVERY R, 1995, COMPUT PHYS COMMUN, V91, P135, DOI 10.1016/0010-4655(95)00046-I; LAVERY R, 1994, ADV COMP BIOL, V1, P69; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Smith Steven B., 1995, Biophysical Journal, V68, pA250; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; Sundaralingam M., 1988, STRUCTURE EXPRESSION, P191; VIOVY JL, 1994, CR ACAD SCI III-VIE, V317, P795; WILKINS MHF, 1951, NATURE, V167, P759, DOI 10.1038/167759a0; WILKINS MHF, 1953, NATURE, V171, P738, DOI 10.1038/171738a0; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390	23	859	892	1	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 9	1996	271	5250					792	794		10.1126/science.271.5250.792	http://dx.doi.org/10.1126/science.271.5250.792			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8628993				2022-12-28	WOS:A1996TU69400041
J	Pijls, NHJ; DeBruyne, B; Peels, K; VanderVoort, PH; Bonnier, HJRM; Bartunek, J; Koolen, JJ				Pijls, NHJ; DeBruyne, B; Peels, K; VanderVoort, PH; Bonnier, HJRM; Bartunek, J; Koolen, JJ			Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOBUTAMINE STRESS ECHOCARDIOGRAPHY; BAYES THEOREM; BLOOD-FLOW; DISEASE; ANGIOPLASTY; DIAGNOSIS; PRESSURE; THALLIUM; ADENOSINE; INTERVENTIONS	Background. The clinical significance of coronary-artery stenoses of moderate severity can be difficult to determine. Myocardial fractional flow reserve (FFR) is a new index of the functional severity of coronary stenoses that is calculated from pressure measurements made during coronary arteriography. We compared this index with the results of noninvasive tests commonly used to detect myocardial ischemia, to determine the usefulness of the index. Methods. In 45 consecutive patients with moderate coronary stenosis and chest pain of uncertain origin, we performed bicycle exercise testing, thallium scintigraphy, stress echocardiography with dobutamine, and quantitative coronary arteriography and compared the results with measurements of FFR. Results. In all 21 patients with an FFR of less than 0.75, reversible myocardial ischemia was demonstrated unequivocally on at least one noninvasive test. After coronary angioplasty or bypass surgery was performed, all the positive test results reverted to normal. In contrast, 21 of the 24 patients with an FFR of 0.75 or higher tested negative for reversible myocardial ischemia on all the noninvasive tests. No revascularization procedures were performed in these patients, and none were required during 14 months of follow-up. The sensitivity of FFR in the identification of reversible ischemia was 88 percent, the specificity 100 percent, the positive predictive value 100 percent, the negative predictive value 88 percent, and the accuracy 93 percent. Conclusions. In patients with coronary stenosis of moderate severity, FFR appears to be a useful index of the functional severity of the stenoses and the need for coronary revascularization. (C) 1996, Massachusetts Medical Society.	CTR CARDIOVASC, AALST, BELGIUM		Pijls, NHJ (corresponding author), CATHARINA HOSP, DEPT CARDIOL, POB 1350, 5602 ZA EINDHOVEN, NETHERLANDS.							ANDERSON HV, 1993, AM J CARDIOL, V71, pD62, DOI 10.1016/0002-9149(93)90135-Y; BOURASSA MG, 1988, CIRCULATION, V78, P780, DOI 10.1161/01.CIR.78.3.780; BOURDILLON PDV, 1989, J AM SOC ECHOCARDIOG, V2, P398; DEBRUYNE B, 1995, CIRCULATION, V92, P39, DOI 10.1161/01.CIR.92.1.39; DEBRUYNE B, 1994, CIRCULATION, V89, P1013, DOI 10.1161/01.CIR.89.3.1013; DEBRUYNE B, 1994, CATHETER CARDIO DIAG, V33, P250, DOI 10.1002/ccd.1810330312; DETRANO R, 1986, CIRCULATION, V73, P970, DOI 10.1161/01.CIR.73.5.970; DETRANO R, 1988, AM J MED, V84, P699, DOI 10.1016/0002-9343(88)90107-6; DILSIZIAN V, 1990, NEW ENGL J MED, V323, P141, DOI 10.1056/NEJM199007193230301; EMANUELSSON H, 1991, CATHETER CARDIO DIAG, V24, P137, DOI 10.1002/ccd.1810240213; FRYBACK DG, 1978, COMPUT BIOMED RES, V11, P423, DOI 10.1016/0010-4809(78)90001-0; GOULD KL, 1990, J AM COLL CARDIOL, V15, P459, DOI 10.1016/S0735-1097(10)80078-6; GOULD KL, 1991, CORONARY ARTERY STEN, P197; HAMILTON GW, 1978, SEMIN NUCL MED, V8, P358, DOI 10.1016/S0001-2998(78)80021-X; KERN MJ, 1995, J AM COLL CARDIOL, V25, P178, DOI 10.1016/0735-1097(94)00328-N; KERN MJ, 1991, J AM COLL CARDIOL, V18, P718, DOI 10.1016/0735-1097(91)90795-B; KIRKEEIDE RL, 1986, J AM COLL CARDIOL, V7, P103, DOI 10.1016/S0735-1097(86)80266-2; KIRKLIN JW, 1991, CIRCULATION, V83, P1125; KLOCKE FJ, 1990, J AM COLL CARDIOL, V16, P763, DOI 10.1016/S0735-1097(10)80319-5; LAMM C, 1993, AM HEART J, V126, P66, DOI 10.1016/S0002-8703(07)80011-1; MARWICK T, 1993, CIRCULATION, V87, P345, DOI 10.1161/01.CIR.87.2.345; MARWICK T, 1993, J AM COLL CARDIOL, V22, P159, DOI 10.1016/0735-1097(93)90830-T; MCNEILL AJ, 1992, AM J CARDIOL, V70, P41, DOI 10.1016/0002-9149(92)91387-J; MELIN JA, 1981, CIRCULATION, V63, P1019, DOI 10.1161/01.CIR.63.5.1019; NABEL EG, 1988, CIRCULATION, V77, P43, DOI 10.1161/01.CIR.77.1.43; NAHSER PJ, 1995, CIRCULATION, V91, P635, DOI 10.1161/01.CIR.91.3.635; OFILI EO, 1993, J AM COLL CARDIOL, V21, P308, DOI 10.1016/0735-1097(93)90668-Q; PATTERSON RE, 1989, J AM COLL CARDIOL, V13, P1653, DOI 10.1016/0735-1097(89)90361-6; PICANO E, 1994, CIRCULATION, V89, P753, DOI 10.1161/01.CIR.89.2.753; PIJLS NHJ, 1995, CIRCULATION, V92, P3183, DOI 10.1161/01.CIR.92.11.3183; PIJLS NHJ, 1995, J AM COLL CARDIOL, V25, P1522, DOI 10.1016/0735-1097(95)00111-G; PIJLS NHJ, 1993, CIRCULATION, V87, P1354, DOI 10.1161/01.CIR.87.4.1354; REDBERG RF, 1995, CIRCULATION, V92, P190, DOI 10.1161/01.CIR.92.2.190; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; RITCHIE JL, 1995, CIRCULATION, V91, P1278; SALUSTRI A, 1992, EUR HEART J, V13, P70, DOI 10.1093/oxfordjournals.eurheartj.a060051; SAWADA SG, 1991, CIRCULATION, V83, P1605, DOI 10.1161/01.CIR.83.5.1605; SERRUYS PW, 1993, AM J CARDIOL, V71, pD41, DOI 10.1016/0002-9149(93)90133-W; TOPOL EJ, 1993, CIRCULATION, V87, P1489, DOI 10.1161/01.CIR.87.5.1489; UREN NG, 1994, NEW ENGL J MED, V330, P1782, DOI 10.1056/NEJM199406233302503; WEINTRAUB WS, 1984, AM J CARDIOL, V54, P43, DOI 10.1016/0002-9149(84)90301-1; WILSON RF, 1990, CIRCULATION, V82, P1595, DOI 10.1161/01.CIR.82.5.1595	42	1552	1721	3	82	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1703	1708		10.1056/NEJM199606273342604	http://dx.doi.org/10.1056/NEJM199606273342604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT400	8637515				2022-12-28	WOS:A1996UT40000004
J	Paton, JH				Paton, JH			A young man who liked lizards and lost his job	LANCET			English	Article											Paton, JH (corresponding author), BURTON HOSP NHS TRUST, BURTON UPON TRENT DE13 0RB, STAFFS, ENGLAND.							CHIODINI RJ, 1981, AM J EPIDEMIOL, V113, P494, DOI 10.1093/oxfordjournals.aje.a113124; *DEP HLTH, 1995, FOOD HANDL FITN WORK, P8; HAMEL FAD, 1971, J HYG-CAMB, V69, P247, DOI 10.1017/S0022172400021471; PLUMMER RAS, 1992, LANCET, V339, P440, DOI 10.1016/0140-6736(92)90136-Q; 1992, MMWR-MORBID MORTAL W, V41, P610	5	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	1996	347	9012					1376	1376		10.1016/S0140-6736(96)91014-4	http://dx.doi.org/10.1016/S0140-6736(96)91014-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637345	Bronze			2022-12-28	WOS:A1996UL90400013
J	Sniderman, AD				Sniderman, AD			The governance of clinical trials	LANCET			English	Editorial Material											Sniderman, AD (corresponding author), ROYAL VICTORIA HOSP, MCGILL UNIT PREVENT CARDIOVASC DIS, 687 PINE AVE W, MONTREAL, PQ H3A 1A1, CANADA.							PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383	2	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 18	1996	347	9012					1387	1388		10.1016/S0140-6736(96)91018-1	http://dx.doi.org/10.1016/S0140-6736(96)91018-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637348	Bronze			2022-12-28	WOS:A1996UL90400017
J	Wokke, JHJ				Wokke, JHJ			Diseases that masquerade as motor neuron disease	LANCET			English	Editorial Material											Wokke, JHJ (corresponding author), UNIV UTRECHT HOSP,DEPT NEUROL,UTRECHT,NETHERLANDS.							BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BLEXRUD MD, 1993, ANN NEUROL, V34, P622, DOI 10.1002/ana.410340419; BRAAKMAN R, 1994, J NEUROL NEUROSUR PS, V57, P257, DOI 10.1136/jnnp.57.3.257; Davenport RJ, 1996, J NEUROL NEUROSUR PS, V60, P147, DOI 10.1136/jnnp.60.2.147; NIGHTINGALE SL, 1995, JAMA-J AM MED ASSOC, V274, P292; SWASH M, 1992, NEUROMUSCULAR DISORD, V2, P7, DOI 10.1016/0960-8966(92)90020-7; SWASH M, 1988, J NEUROL NEUROSUR PS, V51, P165, DOI 10.1136/jnnp.51.2.165; VANDENBERG LH, 1995, NEUROLOGY, V45, P987, DOI 10.1212/WNL.45.5.987; 1992, J NEUROL NEUROSUR PS, V55, P536	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1347	1348		10.1016/S0140-6736(96)91005-3	http://dx.doi.org/10.1016/S0140-6736(96)91005-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637336	Bronze			2022-12-28	WOS:A1996UL90400004
J	Rice, WR				Rice, WR			Sexually antagonistic male adaptation triggered by experimental arrest of female evolution	NATURE			English	Article								EACH sex is part of the environment of the other sex. This may lead to perpetual coevolution between the sexes, when adaptation by one sex reduces fitness of the other. Indirect evidence comes from experiments with Drosophila melanogaster indicating that seminal fluid reduces the competitive ability of sperm from other males, thereby increasing male fitness(1,2). It also reduces a female's propensity to remate and increases her egg-laying rate(3). In contrast to these benefits to males, seminal fluid has substantial toxic side effects in females, with increasing quantity leading to decreasing female survival(4,5). Here I show that when female D. melanogaster are experimentally prevented from coevolving with males, males rapidly adapt to the static female phenotype. This male adaptation leads to a reduction in female survivorship, which is mediated by an increased rate of remating and increased toxicity of seminal fluid.			Rice, WR (corresponding author), UNIV CALIF SANTA CRUZ,DEPT BIOL,SANTA CRUZ,CA 95064, USA.							BARTON NH, 1995, GENETICS, V140, P821; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; CHARLESWORTH B, 1994, GENET RES, V63, P213, DOI 10.1017/S0016672300032365; CHARLESWORTH D, 1993, GENET RES, V61, P1289; CHEN PS, 1988, CELL, V54, P291, DOI 10.1016/0092-8674(88)90192-4; CLARK AG, 1995, GENETICS, V139, P189; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; MANNING JT, 1984, ACTA BIOTHEOR, V33, P219, DOI 10.1007/BF00048429; Muller HJ, 1942, BIOL S, V6, P71; ORR HA, 1995, GENETICS, V139, P1805; Palopoli M.F., 1994, ANNU REV GENET, V27, P283, DOI 10.1146/annurev.ge.28.120194.001435; PECK JR, 1994, GENETICS, V137, P597; RICE WR, 1994, TRENDS ECOL EVOL, V9, P235, DOI 10.1016/0169-5347(94)90258-5; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; Van Valen L., 1973, EVOL THEORY REV, V1, P1, DOI DOI 10.1038/344864A0	17	767	776	0	173	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					232	234		10.1038/381232a0	http://dx.doi.org/10.1038/381232a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622764				2022-12-28	WOS:A1996UL24900053
J	Surks, MI; DeFesi, CR				Surks, MI; DeFesi, CR			Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine - A paradox resolved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM PHENYTOIN; EPILEPTIC PATIENTS; ANTICONVULSANT DRUGS; EQUILIBRIUM DIALYSIS; FUNCTION TESTS; FREE-THYROXINE; DIPHENYLHYDANTOIN; TRIIODOTHYRONINE; BINDING; 5,5'-DIPHENYLHYDANTOIN	Objective.-To address the paradox that phenytoin- and carbamazepine-treated patients have decreased serum free thyroxine (T-4) and triiodothyronine (T-3) concentrations but appear clinically euthyroid and have normal serum thyroid-stimulating hormone (TSH) concentrations. Design.-In vitro studies comparing measurements of total and free T-4 and T-3 by ultrafiltration assay (undiluted serum) and a commercial free T-4 estimate kit in control serum samples or serum samples containing added therapeutic levels of phenytoin or carbamazepine. These measurements were made in serum samples diluted 1:5 with either identical serum or phosphate buffer, pH 7.4, and in serum samples from patients with seizure disorders who were treated with phenytoin or carbamazepine. Setting.-A 650-bed teaching hospital. Patients.-Selected patients (n=19) who were in good health except for seizure disorder, with stable anticonvulsant drug levels in the upper half of the therapeutic range, and were not taking any other drugs that could affect thyroid parameters. Main Outcome Measure.-Serum concentrations of free T-4 and free T-3 in patients taking phenytoin or carbamazepine vs normal controls. Results-Addition of phenytoin or carbamazepine to normal human serum in vitro resulted in a significant increase in free T-4 fraction and free T-4 (P<.001). In patients taking phenytoin or carbamazepine, serum total T-4 decreased significantly to 60% and 74%, respectively, of the control serum concentration (P<.001 for both phenytoin and carbamazepine); free T-4 fraction (by ultrafiltration assay) increased 65% and 44%, respectively (P<.001 for phenytoin, P<.01 for carbamazepine); and free T-4 remained unchanged. Free T-4 concentration measured by a commercial kit (1.5 serum dilution) was significantly lower than the control concentration in both phenytoin- and carbamazepine-treated patients. Serum free T-3 and serum TSH were also normal in phenytoin- and carbamazepine-treated patients. Conclusions.-Therapeutic levels of phenytoin and carbamazepine displace T-4 and T-3 from serum binding proteins. When added to serum, the drugs effect an increase in free hormone fractions and free T-4 and T-3. In drug-treated patients, increased free T-4 and free T-3 fractions offset the significant decrease in serum T-4 and T-3, resulting in normal free T-4 and free T-3 concentrations. Since currently available clinical tests will continue to show decreased free T-4 concentrations in patients taking phenytoin or carbamazepine, clinicians should rely on serum TSH measurements to confirm the euthyroid status of these patients.	ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Surks, MI (corresponding author), MONTEFIORE MED CTR, DEPT MED & PATHOL, DIV ENDOCRINOL & METAB, 111 E 210TH ST, BRONX, NY 10467 USA.							BENTSEN KD, 1983, ACTA NEUROL SCAND, V67, P235, DOI 10.1111/j.1600-0404.1983.tb04569.x; BLACKSHEAR JL, 1983, ANN INTERN MED, V99, P341, DOI 10.7326/0003-4819-99-3-341; CAVALIERI RR, 1979, METABOLISM, V28, P1161, DOI 10.1016/0026-0495(79)90156-2; CHIN W, 1968, J CLIN ENDOCR METAB, V28, P181, DOI 10.1210/jcem-28-2-181; Cochran W.G., 1967, STAT METHODS; CONNELL JMC, 1984, EUR J CLIN PHARMACOL, V26, P453, DOI 10.1007/BF00542140; EKINS R, 1990, ENDOCR REV, V11, P5, DOI 10.1210/edrv-11-1-5; FICHSEL H, 1978, EPILEPSIA, V19, P323, DOI 10.1111/j.1528-1157.1978.tb04498.x; FRANKLYN JA, 1985, J ENDOCRINOL, V104, P201, DOI 10.1677/joe.0.1040201; FRANKLYN JA, 1984, EUR J CLIN PHARMACOL, V26, P633, DOI 10.1007/BF00543499; HANSEN JM, 1974, J CLIN ENDOCR METAB, V39, P785, DOI 10.1210/jcem-39-4-785; HEGEDUS L, 1985, CLIN ENDOCRINOL, V23, P423, DOI 10.1111/j.1365-2265.1985.tb01100.x; HERMAN R, 1991, BIOL PSYCHIAT, V29, P779, DOI 10.1016/0006-3223(91)90197-T; HEYMA P, 1977, CLIN ENDOCRINOL, V6, P369, DOI 10.1111/j.1365-2265.1977.tb02023.x; ISOJARVI JIT, 1990, ARCH NEUROL-CHICAGO, V47, P670, DOI 10.1001/archneur.1990.00530060082023; ISOJARVI JIT, 1993, J NEUROL NEUROSUR PS, V56, P710, DOI 10.1136/jnnp.56.6.710; ISOJARVI JIT, 1989, ARCH NEUROL-CHICAGO, V46, P1175, DOI 10.1001/archneur.1989.00520470029021; LARSEN PR, 1970, J CLIN INVEST, V49, P1266, DOI 10.1172/JCI106339; LIEWENDAHL K, 1976, SCAND J CLIN LAB INV, V36, P141, DOI 10.3109/00365517609055240; LIEWENDAHL K, 1978, CLIN ENDOCRINOL, V8, P185, DOI 10.1111/j.1365-2265.1978.tb01493.x; LIEWENDAHL K, 1985, CLIN CHEM, V31, P1993; LIM CF, 1988, J CLIN ENDOCR METAB, V67, P682, DOI 10.1210/jcem-67-4-682; MANN DN, 1983, ENDOCRINOLOGY, V112, P1723, DOI 10.1210/endo-112-5-1723; OPPENHEIMER J, 1961, J CLIN ENDOCR METAB, V21, P252, DOI 10.1210/jcem-21-3-252; OPPENHEIMER JH, 1962, ENDOCRINOLOGY, V71, P496, DOI 10.1210/endo-71-3-496; ROOTWELT K, 1978, SCAND J CLIN LAB INV, V38, P731, DOI 10.3109/00365517809104880; SMITH PJ, 1984, ENDOCR REV, V5, P514, DOI 10.1210/edrv-5-4-514; STJERNHOLM MR, 1975, CLIN CHEM, V21, P1388; SURKS MI, 1988, J CLIN ENDOCR METAB, V67, P1031, DOI 10.1210/jcem-67-5-1031; YEO PPB, 1978, BRIT MED J, V1, P1581, DOI 10.1136/bmj.1.6127.1581	30	70	72	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1495	1498		10.1001/jama.275.19.1495	http://dx.doi.org/10.1001/jama.275.19.1495			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622224				2022-12-28	WOS:A1996UJ93700033
J	Kelly, P; Lungu, F; Keane, E; Baggaley, R; Kazembe, F; Pobee, J; Farthing, M				Kelly, P; Lungu, F; Keane, E; Baggaley, R; Kazembe, F; Pobee, J; Farthing, M			Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: A randomised double blind controlled trial	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the value of short course, high dose albendazole chemotherapy in the treatment of persistent diarrhoea related to HIV in unselected patients in urban Zambia. Design-A randomised double blind placebo controlled trial of albendazole 800 mg twice daily for two weeks. Patients were monitored intensively for one month and followed for up to six months. Setting-Home care AIDS services in Lusaka and Ndola. Patients-174 HIV seropositive patients with persistent diarrhoea (defined as loose but not bloody stools three or more times a day for three weeks or longer). No investigations were undertaken except HIV testing after counselling. Main outcome measures-Proportion of time periods during which diarrhoea was experienced after completion of treatment; proportion of patients with full remission after completion of treatment; mortality. Results-The patients taking albendazole had diarrhoea on 29% fewer days than those taking placebo (P<0.0001) in the two weeks after treatment. The benefit of albendazole was maintained over six months. In patients with a Karnofsky score of 50 to 70 (needing help with activities of daily living and unable to work, but not needing admission to hospital) diarrhoea was reduced by 50%. Remission was obtained in 26% of all patients who received albendazole (P=0.004 against 9% receiving placebo), and this difference was maintained over six months (log rank test, P=0.003). Albendazole had no effect on mortality. Minimal adverse effects were noted. Conclusions-For HIV infected Zambians with diarrhoea of more than three weeks' duration albendazole offers substantial relief from symptoms and may be used empirically, without prior investigation.	UNIV LUSAKA,TEACHING HOSP,LUSAKA,ZAMBIA; NDOLA CENT HOSP,AIDS HOME CARE SERV,NDOLA,ZAMBIA; KARA COUNSELLING & TRAINING TRUST,LUSAKA,ZAMBIA		Kelly, P (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,DIGEST DIS RES CTR,LONDON EC1M 6BQ,ENGLAND.			Kelly, Paul/0000-0003-0844-6448				ARCHIBALD LK, 1993, Q J MED, V86, P191; BLANSHARD C, 1992, AIDS, V6, P311, DOI 10.1097/00002030-199203000-00008; BYAR DP, 1990, NEW ENGL J MED, V323, P1343, DOI 10.1056/NEJM199011083231912; CALI A, 1993, J EUKARYOT MICROBIOL, V40, P101, DOI 10.1111/j.1550-7408.1993.tb04889.x; CHELA CM, 1991, AIDS, V5, pS157; COLEBUNDERS RL, 1991, AIDS, V5, pS103; CONLON CP, 1990, AM J TROP MED HYG, V42, P83, DOI 10.4269/ajtmh.1990.42.83; DROBNIEWSKI F, 1995, J INFECT DIS, V171, P515, DOI 10.1093/infdis/171.2.515; FOSTER S, 1993, HEALTH POLICY PLANN, V8, P247, DOI 10.1093/heapol/8.3.247; Foster S. D., 1990, Tropical Diseases Bulletin, V87, pR1; FYLKESNES K, 1994, SOCIOECONOMIC IMPACT, V1; GARNETT GP, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90522-R; GAZZARD B, 1993, BAILLIERE CLIN GASTR, V7, P387, DOI 10.1016/0950-3528(93)90047-V; GILKS C, 1993, LANCET, V342; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KELLY P, 1993, AIDS, V7, P91, DOI 10.1097/00002030-199301000-00014; KELLY P, IN PRESS ACTA TROPIC; LUCAS SB, 1994, BRIT MED J, V308, P1531, DOI 10.1136/bmj.308.6943.1531; MELONI BP, 1990, T ROY SOC TROP MED H, V84, P375, DOI 10.1016/0035-9203(90)90324-8; MOLINA JM, 1995, J INFECT DIS, V171, P245, DOI 10.1093/infdis/171.1.245; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; PIOT P, 1991, AIDS, V5, pS1; SHANSON DC, 1990, T ROY SOC TROP MED H, V84, P14, DOI 10.1016/0035-9203(90)90449-O	23	29	29	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1187	1191						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634560	Green Published			2022-12-28	WOS:A1996UL05800015
J	Sromovsky, LA; Best, FA; Collard, AD; Fry, PM; Revercomb, HE; Freedman, RS; Orton, GS; Hayden, JL; Tomasko, MG; Lemmon, MT				Sromovsky, LA; Best, FA; Collard, AD; Fry, PM; Revercomb, HE; Freedman, RS; Orton, GS; Hayden, JL; Tomasko, MG; Lemmon, MT			Solar and thermal radiation in Jupiter's atmosphere: Initial results of the Galileo probe net flux radiometer	SCIENCE			English	Article								The Galileo probe net flux radiometer measured radiation within Jupiter's atmosphere over the 125-kilometer altitude range between pressures of 0.44 bar and 14 bars. Evidence for the expected ammonia cloud was seen in solar and thermal channels down to 0.5 to 0.6 bar. Between 0.6 and 10 bars large thermal fluxes imply very low gaseous opacities and provide no evidence for a deep water cloud. Near 8 bars the water vapor abundance appears to be about 10 percent of what would be expected for a solar abundance of oxygen. Below 8 bars, measurements suggest an increasing water abundance with depth or a deep cloud layer. Ammonia appears to follow a significantly subsaturated profile above 3 bars. Unexpectedly high absorption of sunlight was found at wavelengths greater than 600 nanometers.	NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; CALTECH,JET PROP LAB,PASADENA,CA 91109; LOCKHEED MARTIN ASTRONAUT,DENVER,CO 80201; UNIV ARIZONA,TUCSON,AZ 85721	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Lockheed Martin; University of Arizona	Sromovsky, LA (corresponding author), UNIV WISCONSIN,MADISON,WI 53706, USA.		Lemmon, Mark/X-2333-2019; Orton, Glenn/AAD-9862-2020; Lemmon, Mark T/E-9983-2010	Lemmon, Mark/0000-0002-4504-5136; Lemmon, Mark T/0000-0002-4504-5136				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; DEPATER I, 1993, J GEOPHYS RES-PLANET, V98, P5471, DOI 10.1029/92JE02810; GIVER LP, 1989, B AM ASTRON SOC, V21, P947; KARKOSCHKA E, 1994, ICARUS, V111, P174, DOI 10.1006/icar.1994.1139; LANZEROTTI LJ, COMMUNICATION; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; RAGENT B, 1996, SCIENCE, V272, P855; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; SROMOVSKY LA, 1992, SPACE SCI REV, V60, P233, DOI 10.1007/BF00216856; SROMOVSKY LA, 1994, P 4 INFR SENS CAL S; WEST RA, 1986, ICARUS, V65, P161, DOI 10.1016/0019-1035(86)90135-1; Young RE, 1996, SCIENCE, V272, P837, DOI 10.1126/science.272.5263.837	14	34	34	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					851	854		10.1126/science.272.5263.851	http://dx.doi.org/10.1126/science.272.5263.851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629018				2022-12-28	WOS:A1996UK75700051
J	Welch, WP; Verrilli, D; Katz, SJ; Latimer, E				Welch, WP; Verrilli, D; Katz, SJ; Latimer, E			A detailed comparison of physician services for the elderly in the United States and Canada	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPENDITURES; SURGERY	Objective.-To assess the relative volume and price of physician services in Canada and the United States. Design.-A comparative analysis of 1992 claims data from Canadian provincial ministries of health and from the US Health Care Financing Administration. Patients.-All elderly individuals in the 3 largest Canadian provinces, Ontario, Quebec, and British Columbia, and a 1% random sample of US elderly Medicare beneficiaries not enrolled in health maintenance organizations. Main Outcome Measure.-The volume of physician services measured in terms of the relative value units used in the Medicare fee schedule to calculate payments, with services disaggregated into clinically meaningful categories. Results.-Canadian elderly receive a higher volume of physician services than US elderly. Because the provinces examined paid a much lower price per service, Canada had overall lower expenditures per elderly person than the United States, Canadian elderly received 44% more evaluation and management services, but 25% fewer procedures. Canada has a disproportionately lower volume of procedures for which there is low clinical consensus as to when they are indicated. Such procedures include cataract extractions and knee replacements. Conclusion.-The lower prices for physician services in Canada permit Canadian elderly to receive a higher volume of evaluation and management services with lower expenditures than US elderly. Expenditures for procedural services, on the other hand, are constrained by both price and volume. These differences in the volume of physician services may be the result of differences in facility and physician supply.	URBAN INST,WASHINGTON,DC 20037; UNIV MICHIGAN,SCH MED,DIV GEN MED,ANN ARBOR,MI; HARVARD UNIV,DEPT HLTH POLICY & MANAGEMENT,CAMBRIDGE,MA 02138	Urban Institute; University of Michigan System; University of Michigan; Harvard University	Welch, WP (corresponding author), CONGRESS BUDGET OFF,FORD HOUSE OFF BLDG,ROOM 425A,WASHINGTON,DC 20515, USA.		KATZ, STEVEN/ABH-8886-2020	Latimer, Eric/0000-0002-4485-1056				American Medical Association, 1994, PHYS CHAR DISTR US; ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; BERENSON R, 1992, JAMA-J AM MED ASSOC, V267, P687, DOI 10.1001/jama.267.5.687; *BRIT COL MED ASS, 1991, GUID FEES; COUTTS J, 1995, TORONTO GLOBE M 0328, pA3; COUTTS J, 1994, TORONTO GLOBE M 1221, pA3; COYTE PC, 1994, NEW ENGL J MED, V331, P1068, DOI 10.1056/NEJM199410203311607; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; *HLTH CAN, 1992, HLTH PERS CAN 1992; *HLTH CAN, 1996, NAT HLTH EXP CAN 197; KATZ SJ, 1994, JAMA-J AM MED ASSOC, V272, P530, DOI 10.1001/jama.272.7.530; Katz SJ, 1996, MED CARE, V34, P117, DOI 10.1097/00005650-199602000-00004; KATZ SJ, 1991, JAMA-J AM MED ASSOC, V266, P1108, DOI 10.1001/jama.266.8.1108; Katz SJ, 1996, AM J PUBLIC HEALTH, V86, P520, DOI 10.2105/AJPH.86.4.520; LEVIT KR, 1994, HEALTH CARE FINANC R, V16, P247; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MENDELSSOHN DC, 1993, CON DIAL NEPHROL OCT, P27; MICHLEBURGH R, 1993, TORONTO GLOBE M 0213, pA6; *MIN HLTH, 1991, PAYM SCHED; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; *ONT MIN HLTH, 1992, SCHED BEN; *ORG EC COOP DEV, 1992, NAT ACC MAIN AGGR, V1; PICARD A, 1992, TORONTO GLOBE M 0428, pA11; *PROSP PAYM ASS CO, 1993, MED AM HLTH CAR SYST, P92; REDELMEIER DA, 1993, NEW ENGL J MED, V328, P772, DOI 10.1056/NEJM199303183281107; *REG ASS MAL, 1991, MED SPEC MAN; Roos N P, 1988, Health Care Financ Rev, V9, P53; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; RUBLEE DA, 1994, HEALTH AFFAIR, V13, P113, DOI 10.1377/hlthaff.13.4.113; SCHIEBER GJ, 1991, HEALTH AFFAIR, V10, P22, DOI 10.1377/hlthaff.10.3.22; Welch W P, 1993, Health Care Financ Rev, V14, P41; WELCH WP, 1994, CLAIMS LEVEL FILE PH; WELCH WP, 1995, 643300402 URB I; WHITCOMB ME, 1992, NEW ENGL J MED, V326, P1469, DOI 10.1056/NEJM199205283262205; 1992, FED REG         1125, V57, P55914	35	23	24	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1410	1416		10.1001/jama.275.18.1410	http://dx.doi.org/10.1001/jama.275.18.1410			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UJ303	8618366				2022-12-28	WOS:A1996UJ30300026
J	Prescher, G; Bornfeld, N; Hirche, H; Horsthemke, B; Jockel, KH; Becher, R				Prescher, G; Bornfeld, N; Hirche, H; Horsthemke, B; Jockel, KH; Becher, R			Prognostic implications of monosomy 3 in uveal melanoma	LANCET			English	Article							ENUCLEATION; CHROMOSOME-3	Background A high proportion of patients with uveal melanoma die of metastatic disease. In a subgroup of uveal melanomas there is the loss of one chromosome 3, To assess the prognostic implications of this genetic anomaly, we studied 54 patients for a median of 3 . 4 years. Methods 180 patients underwent primary enucleation for malignant uveal melanoma at the Ophthalmology Department of the Universitatskiinikum Essen between 1987 and 1993. Tumour material was available for chromosome analysis and DNA preparation from 69 of these patients (for logistic reasons unlikely, we believe, to introduce bias), 15 patients were excluded from our study: nine because the methods for assessment of monosomy 3 were unsuccessful; five because of insufficient information about their relapse status; one because histopathological data were incomplete. Of the 54 remaining patients, the tumours of 16 were assessed for copy number of chromosome 3 by karyotype analysis, of 30 by comparative genomic hybridisation, and of eight by both techniques. Clinical status was assessed by contact with family doctor or a clinical check up. Statistical analysis was by the log-rank test and Cox proportional-hazard regression. Findings The tumours of 30 patients had monosomy 3. 17 (57%) of these patients relapsed with metastatic disease, and the 3-year relapse-free survival rate was 50%. By contrast, of the 24 patients whose tumours had retained both chromosomes 3, none developed metastatic disease, In univariate analysis monosomy 3 was the most significant (p<0 . 0001) predictor of poor prognosis in uveal melanoma, followed by tumour location (p<0 . 0007) and tumour diameter (p<0 . 0021). Histopathological subtype, age, sex, extrascleral growth, and tumour thickness had no additional predictive value. Interpretation In uveal melanoma, monosomy 3 is a significant predictor of both relapse-free and overall survival.	UNIV KLINIKUM ESSEN,INNERE KLIN & POLIKLIN,D-45122 ESSEN,GERMANY; UNIV KLINIKUM ESSEN,INST MED INFORMAT BIOMETRIE & EPIDEMIOL,D-45122 ESSEN,GERMANY; UNIV KLINIKUM ESSEN,INST HUMAN GENET,D-45122 ESSEN,GERMANY; FREE UNIV BERLIN,AUGENKLIN & POLIKLIN,UNIV KLINIKUM BENJAMIN FRANKLIN,W-1000 BERLIN,GERMANY	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								ALBERT DM, 1992, SURV OPHTHALMOL, V36, P429, DOI 10.1016/S0039-6257(05)80024-4; COLEMAN K, 1993, BRIT J OPHTHALMOL, V77, P688, DOI 10.1136/bjo.77.11.688; DIENERWEST M, 1992, ARCH OPHTHALMOL-CHIC, V110, P245, DOI 10.1001/archopht.1992.01080140101036; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; FOLBERG R, 1993, OPHTHALMOLOGY, V100, P1389; GORDON KB, 1994, CANCER RES, V54, P4764; HORSMAN DE, 1993, CANCER, V71, P811, DOI 10.1002/1097-0142(19930201)71:3<811::AID-CNCR2820710325>3.0.CO;2-F; HORSTHEMKE B, 1992, GENE CHROMOSOME CANC, V4, P217, DOI 10.1002/gcc.2870040305; JENSEN OA, 1982, ACTA OPHTHALMOL, V60, P161; MCLEAN IW, 1982, HUM PATHOL, V13, P123; MCLEAN IW, 1995, OPHTHALMOLOGY, V102, P1060; PRESCHER G, 1992, LANCET, V339, P691, DOI 10.1016/0140-6736(92)90861-V; PRESCHER G, 1990, J NATL CANCER I, V82, P1765, DOI 10.1093/jnci/82.22.1765; RUMMELT V, 1995, OPHTHALMOLOGY, V102, P844, DOI 10.1016/S0161-6420(95)30947-5; SEDDON JM, 1983, ARCH OPHTHALMOL-CHIC, V101, P1894; SHIELDS JA, 1993, CANCER, V72, P2067, DOI 10.1002/1097-0142(19931001)72:7<2067::AID-CNCR2820720702>3.0.CO;2-0; SISLEY K, 1990, GENE CHROMOSOME CANC, V2, P205, DOI 10.1002/gcc.2870020307; Soulen M C, 1994, Oncology (Williston Park), V8, P77; SPEICHER MR, 1994, CANCER RES, V54, P3817	19	540	549	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1222	1225						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622452				2022-12-28	WOS:A1996UJ59700011
J	Satsangi, J; Welsh, KI; Bunce, M; Julier, C; Farrant, JM; Bell, JI; Jewell, DP				Satsangi, J; Welsh, KI; Bunce, M; Julier, C; Farrant, JM; Bell, JI; Jewell, DP			Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease	LANCET			English	Article							PRIMARY SCLEROSING CHOLANGITIS; PRIMERS PCR-SSP; ULCERATIVE-COLITIS; CROHNS-DISEASE; HLA; LINKAGE	Background Despite strong evidence implicating immune dysfunction and genetic predisposition in the pathogenesis of the chronic inflammatory bower diseases Crohn's disease and ulcerative colitis, the importance of the genes of the major histocompatibility complex remains uncertain, We have investigated the contribution of HLA DRB1 and DQB genes by the strategies of non-parametric linkage analysis (affected sibling pair method) as well as association study. The relation between genotype and phenotype was examined in detail. Methods For linkage analysis 74 families in whom two or more siblings had inflammatory bowel disease were studied. A total of 83 affected sibling pairs were involved: in 42 pairs both siblings had Crohn's disease; in 29 both had ulcerative colitis; in 12 one sibling had Crohn's disease, the other ulcerative colitis. for the association study there were 175 patients with ulcerative colitis, 173 with Crohn's disease, and 472 controls. Details of sex, age of onset, disease extent, and family history were analysed. 24 patients with ulcerative colitis and 92 with Crohn's disease required surgery for refractory disease, HLA DRB1 and DQB1 gene-typing was performed by polymerase chain reaction with sequence-specific primers. Findings in ulcerative colitis, the sharing of alleles among affected sibling pairs provided evidence for linkage with DRB1 locus (p=0 . 017, chi(2)=5 . 32). Of 29 affected sibling pairs studied, only one pair shared no DRB1 DQB haplotypes. 15 shared two DRB DQB haplotypes. In contrast, no linkage was noted for Crohn's disease (42 sibling pairs; p=0 . 30, chi 2=0 . 16) or for inflammatory bowel disease overall (83 sibling pairs, p=0 . 16, chi(2)=2 . 28), In the association study the rare DRB1*103 (8 . 3% vs 3 . 2% in controls) and DRB1*12 (8 . 6% vs 2 . 1% in controls) alleles were associated with ulcerative colitis (p=0 . 0074, chi(2)=7 . 22, odds ratio OR=2 . 9 [95% CI 1 . 3-6-4] and p=0 . 0056, chi(2)=12 . 63, OR=4 . 33 [1 . 8-11 . 0] respectively). No association with alleles representing DR2 (p=0 . 55, chi(2)=0 . 34) was noted, No overall association was seen in Crohn's disease, In ulcerative colitis, the frequency of DRB1*0301 DQB*0201 (DR3 DQ2) was reduced in females (9 . 8% vs 26 . 3% in controls, p=0 . 037, chi(2)=8 . 39 OR=0 . 34 (0 . 15-0 . 71]), particularly in those with distal disease (2 . 3%, p=0 . 001 vs controls, chi(2)=11 . 35, OR=0 . 07 [0 . 00-0 . 39]). In both males and females, the DR3 DQ2 haplotype was predictive of extensive ulcerative colitis (32 . 9% vs 10 . 7% in distal disease, p<0 . 01, chi(2)=10 . 94, OR 4 . 09 [1 . 70-10 . 6]) but not of need for surgery (p=0 . 93, chi(2)=0 . 01), Interpretation These data provide strong evidence for genetic heterogeneity in inflammatory bower disease. Genes of the major histocompatibility complex are implicated as important inherited determinants of susceptibility to ulcerative colitis and may also influence the pattern of disease. In Crohn's disease, important susceptibility genes are likely to exist outside the HLA region.	OXFORD RADCLIFFE HOSP,GASTROENTEROL UNIT,OXFORD,ENGLAND; OXFORD RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD,ENGLAND; OXFORD RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD,ENGLAND; WELLCOME TRUST CTR HUMAN GENET,OXFORD,ENGLAND	University of Oxford; University of Oxford; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics			JULIER, Cécile/M-9824-2017	JULIER, Cécile/0000-0002-1538-0240	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASAKURA H, 1982, GASTROENTEROLOGY, V82, P413; BISHOP DT, 1990, AM J HUM GENET, V46, P254; BRIGGS DC, 1991, LANCET, V338, P661, DOI 10.1016/0140-6736(91)91235-M; BUNCE M, 1993, HUM IMMUNOL, V37, P201, DOI 10.1016/0198-8859(93)90502-R; BUNCE M, IN PRESS TISSUE ANTI; CHAPMAN RW, 1991, GUT, V32, P1433, DOI 10.1136/gut.32.12.1433; DUERR RH, 1995, GASTROENTEROLOGY, V108, P423, DOI 10.1016/0016-5085(95)90069-1; FARMER RG, 1985, GASTROENTEROLOGY, V88, P1818, DOI 10.1016/0016-5085(85)90006-X; FARRANT JM, 1992, HEPATOLOGY, V16, P390, DOI 10.1002/hep.1840160217; HASHIMOTO M, 1994, TISSUE ANTIGENS, V44, P166, DOI 10.1111/j.1399-0039.1994.tb02375.x; HUGOT JP, 1994, AM J MED GENET, V52, P207, DOI 10.1002/ajmg.1320520216; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; MCCONNELL RB, 1992, GENETIC BASIS COMMON, P326; MERRETT M, 1992, Gastroenterology, V102, pA935; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NAOM IS, 1994, GUT, V35, pS30; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; REIJONEN H, 1994, TISSUE ANTIGENS, V43, P1, DOI 10.1111/j.1399-0039.1994.tb02289.x; RISCH N, 1987, AM J HUM GENET, V40, P1; ROITBERGTAMBUR A, 1994, TISSUE ANTIGENS, V43, P219, DOI 10.1111/j.1399-0039.1994.tb02328.x; ROTTER JI, 1984, CLIN GENET, V26, P529; SATSANGI J, 1994, GUT, V35, P696, DOI 10.1136/gut.35.5.696; SATSANGI J, 1994, EUR J GASTROEN HEPAT, V6, P413; SUAREZ BK, 1978, ANN HUM GENET, V42, P87, DOI 10.1111/j.1469-1809.1978.tb00933.x; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TOYODA H, 1993, GASTROENTEROLOGY, V104, P741, DOI 10.1016/0016-5085(93)91009-7; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; WASSMUTH R, 1994, EUR J GASTROEN HEPAT, V6, P405; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049	29	319	334	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1212	1217		10.1016/S0140-6736(96)90734-5	http://dx.doi.org/10.1016/S0140-6736(96)90734-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622450				2022-12-28	WOS:A1996UJ59700009
J	vanLonden, J				vanLonden, J			Dutch health care - A study in purple	LANCET			English	Article											vanLonden, J (corresponding author), PUBL HLTH COUNCIL,ZOETERMEER,NETHERLANDS.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1229	1231		10.1016/S0140-6736(96)90740-0	http://dx.doi.org/10.1016/S0140-6736(96)90740-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622454				2022-12-28	WOS:A1996UJ59700014
J	Light, DW				Light, DW			Betrayal by the surgeons	LANCET			English	Editorial Material											Light, DW (corresponding author), UNIV MED & DENT NEW JERSEY,DEPT PSYCHIAT,DIV SOCIAL & BEHAV SCI,STRATFORD,NJ 08084, USA.							*AM MED ASS, 1992, PHYS MARK STAT 1991; *AUD COMM, 1995, DOCT TAL WORK HOSP D; CHADDA D, 1994, HLTH SERV J     0804, P5; HARLEY M, 1995, HLTH SERV J     1012, P26; JOHNSON J, 1995, HLTH SERV J     0706, P30; Light D, 1990, Health Serv J, V100, P1648; Light D, 1990, Health Serv J, V100, P1552; LIGHT DW, 1991, LANCET, V338, P102, DOI 10.1016/0140-6736(91)90088-7; LIGHT DW, 1995, FUTURE FUNDHOLDING; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510; YATES J, 1995, PRIVATE EYE HLTH HIP	11	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					812	813		10.1016/S0140-6736(96)90876-4	http://dx.doi.org/10.1016/S0140-6736(96)90876-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622342				2022-12-28	WOS:A1996UB15300017
J	Euling, S; Ambros, V				Euling, S; Ambros, V			Heterochronic genes control cell cycle progress and developmental competence of C-elegans vulva precursor cells	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; ENCODES; EXPRESSION; LINEAGES; FATES; MUTANTS; LIN-14; LOCUS; IDENTIFICATION; PROLIFERATION	Heterochronic genes control the timing of vulval development in the C. elegans hermaphrodite. lin-14 or lin-28 loss-of-function mutations cause the vulval precursor cells (VPCs) to enter S phase and to divide one larval stage earlier than in the wild type. A precocious vulva is formed by essentially normal cell lineage patterns, governed by the same intercellular signals as in the wild type. Mutations that prevent the normal developmental down-regulation of lin-14 activity delay or block VPC division and prevent vulval differentiation. A genetic pathway that includes lin-4, lin-14, and lin-28 controls when VPCs complete G1 and also controls when VPCs acquire the competence to respond to the intercellular patterning signals and express vulval fates.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University	Euling, S (corresponding author), DARTMOUTH COLL,DEPT BIOL SCI,HANOVER,NH 03755, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034028] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34028] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTSON D, 1987, DEV BIOL, V63, P165; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AMBROS V, 1987, GENE DEV, V1, P398, DOI 10.1101/gad.1.4.398; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1981, CELL, V24, P56; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CLARK SG, 1994, GENETICS, V137, P987; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; EULING S, 1993, THESIS HARVARD U CAM; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FREYD G, 1991, THESIS MIT CAMBRIDGE; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HILL RJ, 1993, DEVELOPMENT S, V119, P9; HORVITZ HR, 1980, GENETICS, V96, P435; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KENYON C, 1995, CELL, V82, P171, DOI 10.1016/0092-8674(95)90302-X; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; Kornberg A., 1992, DNA REPLICATION; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LIU ZC, 1989, GENE DEV, V3, P2039, DOI 10.1101/gad.3.12b.2039; LIU ZC, 1995, DEVELOPMENT, V121, P2471; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; ROUGVIE AE, 1995, DEVELOPMENT, V121, P2491; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; Sokal R. R, 1981, BIOMETRY; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TUCK S, 1995, GENE DEV, V9, P347; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8; WILKINSON HA, 1995, GENETICS, V141, P513; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	57	86	94	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					667	676		10.1016/S0092-8674(00)81045-4	http://dx.doi.org/10.1016/S0092-8674(00)81045-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625405	Bronze			2022-12-28	WOS:A1996TZ99000005
J	Merskey, H				Merskey, H			Influences of the media: A powerful what?	LANCET			English	Editorial Material											Merskey, H (corresponding author), LONDON PSYCHIAT HOSP,LONDON,ON,CANADA.							PLATT S, 1987, BRIT MED J, V294, P954, DOI 10.1136/bmj.294.6577.954; Simkin S, 1995, BRIT J PSYCHIAT, V167, P754, DOI 10.1192/bjp.167.6.754	2	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					416	416		10.1016/S0140-6736(96)90006-9	http://dx.doi.org/10.1016/S0140-6736(96)90006-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618480	Bronze			2022-12-28	WOS:A1996TV72200006
J	DErchia, AM; Gissi, C; Pesole, G; Saccone, C; Arnason, U				DErchia, AM; Gissi, C; Pesole, G; Saccone, C; Arnason, U			The guinea-pig is not a rodent	NATURE			English	Article							MITOCHONDRIAL-DNA; NUCLEOTIDE-SEQUENCE; EVOLUTION; PHYLOGENY; MAMMALS; GENE; SEAL	IN 1991 Graur et al. raised the question of whether the guinea-pig, Cavia porcellus, is a rodent(1). They suggested that the guinea-pig and myomorph rodents diverged before the separation between myormorph rodents and a lineage leading to primates and artiodactyls. Several findings have since been reported, both for and against this phylogeny, thereby highlighting the issue of the validity of molecular analysis in mammalian phylogeny. Here we present findings based on the sequence of the complete mitochondrial genome of the guinea-pig, which strongly contradict rodent monophyly. The conclusions are based on the cumulative evidence provided by orthologically inherited genes and the use of three different analytic al methods, none of which joins the guinea-pig with myomorph rodents. In addition to the phylogenetic conclusions, we also draw attention to several factors that are important for the validity of phylogenetic analysis based on molecular data.	UNIV BARI, DIPARTMENTO BIOCHIM & BIOL MOLEC, I-70125 BARI, ITALY; LUND UNIV, DEPT EVOLUTIONARY MOL SYSTEMAT, S-22362 LUND, SWEDEN; UNIV BASILICATA, DIPARTIMENTO BIOL DBAF, I-30100 POTENZA, ITALY; CNR, CTR STUDIO MITOCONDRI & METAB ENERGET, I-70125 BARI, ITALY	Universita degli Studi di Bari Aldo Moro; Lund University; University of Basilicata; Consiglio Nazionale delle Ricerche (CNR)			Pesole, Graziano/K-5283-2019; D'Erchia, Anna maria/K-9001-2016; Pesole, Graziano/E-9051-2014; Pesole, Graziano/C-1408-2009	Pesole, Graziano/0000-0003-3663-0859; Pesole, Graziano/0000-0003-3663-0859; D'ERCHIA, Anna Maria/0000-0002-4627-0626; Gissi, Carmela/0000-0002-2269-079X				ARNASON U, 1993, J MOL EVOL, V37, P323; Arnason U, 1996, J MOL EVOL, V42, P145, DOI 10.1007/BF02198840; ARNASON U, 1991, J MOL EVOL, V33, P556, DOI 10.1007/BF02102808; ARNASON U, 1992, J MOL EVOL, V34, P493, DOI 10.1007/BF00160463; CAO Y, 1994, MOL BIOL EVOL, V11, P593; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Felsestein J., 1993, PHYLIP PHYLOGENY INF; FRYE MS, 1995, MOL BIOL EVOL, V12, P168, DOI 10.1093/oxfordjournals.molbev.a040186; GRAUR D, 1992, COMP BIOCHEM PHYS B, V101, P495, DOI 10.1016/0305-0491(92)90327-N; GRAUR D, 1994, MOL BIOL EVOL, V11, P357; Graur D, 1996, NATURE, V379, P333, DOI 10.1038/379333a0; GRAUR D, 1991, NATURE, V351, P649, DOI 10.1038/351649a0; GRAUR D, 1993, FEBS LETT, V325, P152, DOI 10.1016/0014-5793(93)81432-Y; Hasegawa, 1992, COMPUTER SCI MONOGRA, V27; HASEGAWA M, 1992, NATURE, V355, P595, DOI 10.1038/355595a0; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; Krettek A, 1995, J MOL EVOL, V41, P952; KUMA K, 1994, JPN J GENET, V69, P555, DOI 10.1266/jjg.69.555; LI WH, 1992, J HERED, V83, P174, DOI 10.1093/oxfordjournals.jhered.a111188; MA DP, 1993, J MOL EVOL, V36, P327; MARTIGNETTI JA, 1993, P NATL ACAD SCI USA, V90, P9698, DOI 10.1073/pnas.90.20.9698; NOGUCHI T, 1994, COMP BIOCHEM PHYS B, V107, P179, DOI 10.1016/0305-0491(94)90037-X; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; SACCONE C, 1990, METHOD ENZYMOL, V183, P570; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Swofford D., 1998, PAUP PHYLOGENETIC AN; WOLF B, 1993, BIOL CHEM H-S, V374, P641, DOI 10.1515/bchm3.1993.374.7-12.641; XU XF, 1994, GENE, V148, P357, DOI 10.1016/0378-1119(94)90713-7	28	272	280	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					597	600		10.1038/381597a0	http://dx.doi.org/10.1038/381597a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637593				2022-12-28	WOS:A1996UQ65700048
J	Diem, SJ; Lantos, JD; Tulsky, JA				Diem, SJ; Lantos, JD; Tulsky, JA			Cardiopulmonary resuscitation on television - Miracles and misinformation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; PARAMEDIC SERVICES; METROPOLITAN-AREA; SURVIVAL; OUTCOMES; YOUNGER; OLDER; AGE	Background. Responsible, shared decision making on the part of physicians and patients about the potential use of cardiopulmonary resuscitation (CPR) requires patients who are educated about the procedure's risks and benefits, Television is an important source of information about CPR for patients, We analyzed how three popular television programs depict CPR, Methods. We watched all the episodes of the television programs ER and Chicago Hope during the 1994-1995 viewing season and 50 consecutive episodes of Rescue 911 broadcast over a three-month period in 1995, We identified all occurrences of CPR in each episode and recorded the causes of cardiac arrest, the identifiable demographic characteristics of the patients, the underlying illnesses, and the outcomes. Results. There were 60 occurrences of CPR in the 97 television episodes - 31 on ER, 11 on Chicago Hope, and 18 on Rescue 911, In the majority of cases, cardiac arrest was caused by trauma; only 28 percent were due to primary cardiac causes, Sixty-five percent of the cardiac arrests occurred in children, teenagers, or young adults, Seventy-five percent of the patients survived the immediate arrest, and 67 percent appeared to have survived to hospital discharge. Conclusions. The survival rates in our study are significantly higher than the most optimistic survival rates in the medical literature, and the portrayal of CPR on television may lead the viewing public to have an unrealistic impression of CPR and its chances for success, Physicians discussing the use of CPR with patients and families should be aware of the images of CPR depicted on television and the misperceptions these images may foster. (C) 1996, Massachusetts Medical Society.	DUKE UNIV,MED CTR,CTR HLTH POLICY RES & EDUC,DURHAM,NC; DUKE UNIV,MED CTR,CTR STUDY AGING & HUMAN DEV,DURHAM,NC; UNIV CHICAGO,MACLEAN CTR MED ETH,CHICAGO,IL	Duke University; Duke University; University of Chicago	Diem, SJ (corresponding author), VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,508 FULTON ST,DURHAM,NC 27705, USA.		Diem, Susan/B-6479-2013					ANNAS GJ, 1995, HASTINGS CENT REP, V25, P40, DOI 10.2307/3562794; APRAHAMIAN C, 1985, ANN EMERG MED, V14, P583, DOI 10.1016/S0196-0644(85)80785-X; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; COPASS MK, 1984, AM J SURG, V148, P20, DOI 10.1016/0002-9610(84)90284-8; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1980, LANCET, V1, P812; GUZY PM, 1983, AM J PUBLIC HEALTH, V73, P766, DOI 10.2105/AJPH.73.7.766; KARETZKY M, 1995, ARCH INTERN MED, V155, P1277, DOI 10.1001/archinte.155.12.1277; LAVELLE JM, 1993, CRIT CARE MED, V21, P368, DOI 10.1097/00003246-199303000-00013; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; PONS PT, 1985, J TRAUMA, V25, P828, DOI 10.1097/00005373-198509000-00003; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAK HLTH CAR DEC REP; ROSEMURGY AS, 1993, J TRAUMA, V35, P468, DOI 10.1097/00005373-199309000-00022; ROTH R, 1984, ANN EMERG MED, V13, P237, DOI 10.1016/S0196-0644(84)80470-9; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TRESCH DD, 1988, AM J CARDIOL, V61, P1120, DOI 10.1016/0002-9149(88)90141-5; TRESCH DD, 1990, AM J CARDIOL, V65, P453, DOI 10.1016/0002-9149(90)90809-F; Turow Joseph, 1989, PLAYING DOCTOR TELEV; VERTESI L, 1983, CAN MED ASSOC J, V128, P809; 1995, JAMA-J AM MED ASSOC, V274, P1591	27	315	323	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 13	1996	334	24					1578	1582		10.1056/NEJM199606133342406	http://dx.doi.org/10.1056/NEJM199606133342406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UP663	8628340				2022-12-28	WOS:A1996UP66300006
J	Rhodes, CJ; Anderson, RM				Rhodes, CJ; Anderson, RM			Power laws governing epidemics in isolated populations	NATURE			English	Article							FOREST-FIRE MODEL; MEASLES DYNAMICS; TIME-SERIES; CHAOS; ERROR	TEMPORAL changes in the incidence of measles virus infection within large urban communities in the developed world have been the focus of much discussion in the context of the identification and analysis of nonlinear and chaotic patterns in biological time series(1-11). In contrast, the measles records for small isolated island populations are highly irregular, because of frequent fade-outs of infection(12-14), and traditional analysis(15) does not yield useful insight. Here we use measurements of the distribution of epidemic sizes and duration to show that regularities in the dynamics of such systems do become apparent. Specifically, these biological systems are characterized by well-defined power laws in a manner reminiscent of other nonlinear, spatially extended dynamical systems in the physical sciences(16-19). We further show that the observed power-law exponents are well described by a simple lattice-based model which reflects the social interaction between individual hosts.			Rhodes, CJ (corresponding author), UNIV OXFORD, DEPT ZOOL, CTR EPIDEMIOL INFECT DIS, S PARKS RD, OXFORD OX1 3PS, ENGLAND.			Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; BAK P, 1988, PHYS REV A, V38, P364, DOI 10.1103/PhysRevA.38.364; BAK P, 1990, PHYS LETT A, V147, P297, DOI 10.1016/0375-9601(90)90451-S; BARTLETT MS, 1960, J R STAT SOC SER A-G, V123, P37, DOI 10.2307/2343186; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; BLACK FL, 1966, J THEOR BIOL, V11, P207, DOI 10.1016/0022-5193(66)90161-5; BOLKER BM, 1993, P ROY SOC B-BIOL SCI, V251, P75, DOI 10.1098/rspb.1993.0011; CHEN K, 1991, PHYS REV A, V43, P625, DOI 10.1103/PhysRevA.43.625; CLAR S, 1994, PHYS REV E, V50, P1009, DOI 10.1103/PhysRevE.50.1009; Cliff Andrew, 1993, HIST GEOGRAPHY MAJOR; DROSSEL B, 1992, PHYS REV LETT, V69, P1629, DOI 10.1103/PhysRevLett.69.1629; FERGUSON N, IN PRESS PRINCETON M; GRENFELL BT, 1995, P ROY SOC B-BIOL SCI, V259, P97, DOI 10.1098/rspb.1995.0015; GRENFELL BT, 1992, J ROY STAT SOC B MET, V54, P383; GRENFELL BT, 1994, PHILOS T R SOC A, V348, P515, DOI 10.1098/rsta.1994.0108; Gutenberg B., 1956, ANN GEOFIS, V9, P1, DOI DOI 10.4401/AG-5590; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MAY RM, 1987, PROC R SOC LON SER-A, V413, P27, DOI 10.1016/0920-5632(87)90020-X; OLSEN LF, 1988, THEOR POPUL BIOL, V33, P344, DOI 10.1016/0040-5809(88)90019-6; OLSEN LF, 1990, SCIENCE, V249, P499, DOI 10.1126/science.2382131; SOMETTE A, 1989, EPL-EUROPHYS LETT, V9, P197; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0; SUGIHARA G, 1990, PHILOS T R SOC B, V330, P235, DOI 10.1098/rstb.1990.0195; TIDD CW, 1993, P ROY SOC B-BIOL SCI, V254, P257, DOI 10.1098/rspb.1993.0155	24	132	140	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 13	1996	381	6583					600	602		10.1038/381600a0	http://dx.doi.org/10.1038/381600a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UQ657	8637594				2022-12-28	WOS:A1996UQ65700049
J	Delbanco, TL; Daley, J; Walzer, J				Delbanco, TL; Daley, J; Walzer, J			A 79-year-old musician with asymptomatic carotid artery disease, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		CAPLAN LR, 1995, JAMA-J AM MED ASSOC, V74, P1383	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	1996	275	21					1681	1681						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN252	8637144				2022-12-28	WOS:A1996UN25200033
J	Anzueto, A; Baughman, RP; Guntupalli, KK; Weg, JG; Wiedemann, HP; Raventos, AA; Lemaire, F; Long, W; Zaccardelli, DS; Pattishall, EN				Anzueto, A; Baughman, RP; Guntupalli, KK; Weg, JG; Wiedemann, HP; Raventos, AA; Lemaire, F; Long, W; Zaccardelli, DS; Pattishall, EN			Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							END-EXPIRATORY PRESSURE; SYNTHETIC SURFACTANT; SURVIVAL	Background. Patients with acute respiratory distress syndrome (ARDS) have a deficiency of surfactant, Surfactant replacement improves physiologic function in such patients, and preliminary data suggest that it may improve survival. Methods. We conducted a prospective, multicenter, double-blind, randomized, placebo-controlled trial involving 725 patients with sepsis-induced ARDS. Patients were stratified according to the risk of death at base line (indicated by their score on the Acute Physiologic and Chronic Health Evaluation [APACHE III] index) and randomly assigned to receive either continuously administered synthetic surfactant (13.5 mg of dipalmitoylphosphatidylcholine per milliliter; 364 patients) or placebo (0.45 percent saline; 361 patients) in aerosolized form for up to five days. Results. The demographic and physiologic characteristics of the two treatment groups were similar at base line, The mean (+/-SD) age was 50+/-17 years in the surfactant group and 53+/-18 years in the placebo group, and the mean APACHE III scores at randomization were 70.4+/-25 and 70.5+/-25, respectively, Hemodynamic measures, measures of oxygenation, duration of mechanical ventilation, and length of stay in the intensive care unit did not differ significantly in the two groups. Survival at 30 days was 60 percent for both groups, Survival was similar in the groups when analyzed according to APACHE III score, cause of death, time of onset and severity of ARDS, presence or absence of documented sepsis, underlying disease, whether or not there was a do-not-resuscitate order, and medical center. Increased secretions were significantly more frequent in the surfactant group; the rates of other complications were similar in the two groups. Conclusions. The continuous administration of aerosolized synthetic surfactant to patients with sepsis-induced ARDS had no significant effect on 30-day survival, length of stay in the intensive care unit, duration of mechanical ventilation, or physiologic function. (C) 1996, Massachusetts Medical Society.	UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA; OHIO UNIV, CINCINNATI, OH USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV MICHIGAN, MED CTR, ANN ARBOR, MI USA; CLEVELAND CLIN, CLEVELAND, OH 44106 USA; CONSORCI HOSP PARC TAVLI, SABADELL, SPAIN; HENRI MONDOR HOSP, PARIS, FRANCE; UNIV N CAROLINA, CHAPEL HILL, NC USA; GLAXO WELLCOME, RES TRIANGLE PK, NC USA	University of Texas System; University of Texas Health San Antonio; University System of Ohio; Ohio University; Baylor College of Medicine; University of Michigan System; University of Michigan; Cleveland Clinic Foundation; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline	Anzueto, A (corresponding author), S TEXAS VET HLTH CARE SYST, AUDIE L MURPHY MEM VET HOSP DIV, PULM DIS SECT 111E, SAN ANTONIO, TX 78284 USA.			Wiedemann, Herbert/0000-0002-4587-4401				ALLEN JN, 1995, J LAB CLIN MED, V125, P356; ASHBAUGH DG, 1967, LANCET, V2, P319; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CHAN CYJ, 1992, CLIN PHARMACY, V11, P880; COLEMAN RE, 1994, CHEST, V105, P1765, DOI 10.1378/chest.105.6.1765; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; DREYFUSS D, 1995, AM J RESP CRIT CARE, V151, P1568, DOI 10.1164/ajrccm.151.5.7735616; DURAND DJ, 1985, J PEDIATR-US, V107, P775, DOI 10.1016/S0022-3476(85)80416-9; FROESE AB, 1993, AM REV RESPIR DIS, V148, P569, DOI 10.1164/ajrccm/148.3.569; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; GREGORY TJ, 1994, AM J RESP CRIT CARE, V149, pA567; HALLMAN M, 1982, J CLIN INVEST, V70, P673, DOI 10.1172/JCI110662; Hyers TM, 1991, LUNG BIOL HEAL DIS, V50, P23; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOBAYASHI T, 1984, J APPL PHYSIOL, V57, P995, DOI 10.1152/jappl.1984.57.4.995; LACHMANN B, 1989, EUR RESPIR J, V3, P98; LEWIS J, 1991, J APPL PHYSIOL, V71, P1270, DOI 10.1152/jappl.1991.71.4.1270; LEWIS JF, 1993, AM REV RESPIR DIS, V148, P1187, DOI 10.1164/ajrccm/148.5.1187; MacIntyre NR, 1994, AM J RESP CRIT CARE, V149, pA125; MANTEL N, 1959, J NATL CANCER I, V22, P719; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MITCHELL DR, 1993, AM REV RESPIR DIS, V147, pA348; PETTY TL, 1990, DM-DIS MON, V36, P3; PETTY TL, 1979, CHEST, V75, P571, DOI 10.1378/chest.75.5.571; PETTY TL, 1977, AM REV RESPIR DIS, V115, P531; Reines HD, 1992, CRIT CARE MED, V20, pS61; Richman P.S., 1989, EUR RESPIR J, V2, P109; ROTH MD, 1993, AM J RESP CELL MOL, V9, P652, DOI 10.1165/ajrcmb/9.6.652; SLOANE PJ, 1992, AM REV RESPIR DIS, V146, P419, DOI 10.1164/ajrccm/146.2.419; SPRAGG RG, 1994, CHEST, V105, P195, DOI 10.1378/chest.105.1.195; SUCHYTA MR, 1992, CHEST, V101, P1074, DOI 10.1378/chest.101.4.1074; THOMASSEN MJ, 1992, AM J RESP CELL MOL, V7, P257, DOI 10.1165/ajrcmb/7.3.257; THOMASSEN MJ, 1994, AM J RESP CELL MOL, V10, P399, DOI 10.1165/ajrcmb.10.4.8136155; WEG JG, 1994, JAMA-J AM MED ASSOC, V272, P1433, DOI 10.1001/jama.272.18.1433	36	397	420	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1996	334	22					1417	1421		10.1056/NEJM199605303342201	http://dx.doi.org/10.1056/NEJM199605303342201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM493	8618579	Bronze, Green Published			2022-12-28	WOS:A1996UM49300001
J	Venter, JC; Smith, HO; Hood, L				Venter, JC; Smith, HO; Hood, L			A new strategy for genome sequencing	NATURE			English	Editorial Material							FACTOR-BASED VECTOR; HUMAN DNA		JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; UNIV WASHINGTON,DEPT MOLEC BIOTECHNOL,SEATTLE,WA 98195	Johns Hopkins University; University of Washington; University of Washington Seattle	Venter, JC (corresponding author), INST GENOM RES,9712 MED CTR DR,ROCKVILLE,MD 20850, USA.							CHUMAKOV IM, 1995, NATURE, V377, P175; CRAIG C, 1996, BIOWORLD TODAY  0925, V7, P1; CRAIG C, 1996, BIOWORLD TODAY, V7, P3; DICKSON D, 1995, NATURE, V378, P120, DOI 10.1038/378120a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; KIM UJ, 1992, NUCLEIC ACIDS RES, V20, P1083, DOI 10.1093/nar/20.5.1083; MACILWAIN C, 1996, NATURE, V380, P471; Marshall E, 1996, SCIENCE, V272, P188, DOI 10.1126/science.272.5259.188; MARSHALL E, 1995, SCIENCE, V268, P1270, DOI 10.1126/science.7761844; Marshall E, 1996, SCIENCE, V272, P477; Natl. Res. Council, 1988, MAPP SEQ HUM GEN; OLSEN MV, 1995, SCIENCE, V270, P394; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; WATSON JD, 1990, SCIENCE, V248, P49	15	236	254	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 30	1996	381	6581					364	366		10.1038/381364a0	http://dx.doi.org/10.1038/381364a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632789				2022-12-28	WOS:A1996UN47900021
J	RobertsThomson, IC; Ryan, P; Khoo, KK; Hart, WJ; McMichael, AJ; Butler, RN				RobertsThomson, IC; Ryan, P; Khoo, KK; Hart, WJ; McMichael, AJ; Butler, RN			Diet, acetylator phenotype, and risk of colorectal neoplasia	LANCET			English	Article							CANCER; ACETYLTRANSFERASE; POLYMORPHISM; CARCINOMA; COLON	Background Inherited or acquired differences in metabolic pathways that activate or inactivate dietary carcinogens may influence the risk of developing cancer. A polymorphism in N-acetyltransferase classifies people into fast and slow acetylators. This enzyme catalyses the formation of mutagenic products from foodstuffs, especially cooked meat and fish. Some data suggest that fast acetylators are at higher risk of colorectal cancer. We have studied the adenoma and cancer risk in relation to meat intake and acetylator status. Methods In a case-control study, we compared 110 patients with colorectal cancer, 89 patients with colorectal adenomatous polyps, and 110 controls. Acetylator status was assessed by the rate of acetylation of sulphamethazine given orally. Findings The fast-acetylator phenotype was associated with odds ratios of 1.1 (95% CI 0.6-2.1) and 1.8 (1.0-3.3) for adenoma and colorectal cancer, respectively. The highest risk occurred in the youngest tertile (<64 years) of cases (2.5 [0.7-9.4] and 8.9 [2.6-30.4], respectively). There was no difference between the sexes. The risk of adenoma or cancer increased with increasing intake of meat in fast but not in slow acetylators: covariate-adjusted odds of disease over three levels of meat consumption were 2.1 (0.9-4.7) for adenoma, 1.7 (0.9-3.5) for cancer, and 1.9 (1.0-3.7) for all tumours. Interpretation Our findings indicate that acetylator status modulates the risk of colorectal neoplasia associated with meat intake.	UNIV ADELAIDE,DEPT COMMUNITY MED,ADELAIDE,SA,AUSTRALIA	University of Adelaide	RobertsThomson, IC (corresponding author), QUEEN ELIZABETH HOSP,DEPT GASTROENTEROL,WOODVILLE,SA 5011,AUSTRALIA.							[Anonymous], 1990, NUTR EPIDEMIOLGY; Demant P, 1992, Semin Cancer Biol, V3, P159; HICKMAN D, 1991, BIOCHEM PHARMACOL, V42, P1007, DOI 10.1016/0006-2952(91)90282-A; ILETT KF, 1987, CANCER RES, V47, P1466; KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910; LADERO JM, 1991, CANCER RES, V51, P2098; LANG NP, 1994, CANCER EPIDEM BIOMAR, V3, P675; LANG NP, 1986, ARCH SURG-CHICAGO, V121, P1259, DOI 10.1001/archsurg.121.11.1259; NAGAO M, 1993, MUTAT RES, V290, P43, DOI 10.1016/0027-5107(93)90031-A; POTTER JD, 1986, JNCI-J NATL CANCER I, V76, P557, DOI 10.1093/jnci/76.4.557	10	167	174	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1372	1374		10.1016/S0140-6736(96)91012-0	http://dx.doi.org/10.1016/S0140-6736(96)91012-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637343				2022-12-28	WOS:A1996UL90400011
J	Morris, RS; Gleicher, N				Morris, RS; Gleicher, N			Genetic abnormalities, male infertility, and ICSI	LANCET			English	Editorial Material											Morris, RS (corresponding author), CTR HUMAN REPROD,DIV REPROD ENDOCRINOL & INFERTIL,CHICAGO,IL, USA.							DEVROEY P, 1995, HUM REPROD, V10, P1457, DOI 10.1093/HUMREP/10.6.1457; HARARI O, 1995, FERTIL STERIL, V63, P182, DOI 10.1016/S0015-0282(16)57315-4; MERCIER B, 1995, AM J HUM GENET, V56, P272; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; PRITCHARD JA, 1985, MED SURGICAL ILLNESS, P561; SILBER SJ, 1995, HUM REPROD, V10, P503, DOI 10.1093/oxfordjournals.humrep.a135977; SILBER SJ, 1995, HUM REPROD, V10, P2031, DOI 10.1093/oxfordjournals.humrep.a136231; TEMPLESMITH PD, 1985, J IN VITRO FERTIL EM, V2, P850; TERZOLI G, 1992, FERTIL STERIL, V58, P821	9	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1277	1277		10.1016/S0140-6736(96)90934-4	http://dx.doi.org/10.1016/S0140-6736(96)90934-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK758	8622500				2022-12-28	WOS:A1996UK75800005
J	Hautvast, JGAJ				Hautvast, JGAJ			The Wageningen approach to human nutrition	LANCET			English	Article											Hautvast, JGAJ (corresponding author), AGR UNIV WAGENINGEN,DEPT HUMAN NUTR,WAGENINGEN,NETHERLANDS.								0	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1235	1236		10.1016/S0140-6736(96)90744-8	http://dx.doi.org/10.1016/S0140-6736(96)90744-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622458				2022-12-28	WOS:A1996UJ59700018
J	HowdenChapman, P; Carter, J; Woods, N				HowdenChapman, P; Carter, J; Woods, N			Blood money: Blood donors' attitudes to changes in the New Zealand blood transfusion service	BRITISH MEDICAL JOURNAL			English	Article											HowdenChapman, P (corresponding author), WELLINGTON SCH MED,POB 7343,WELLINGTON,NEW ZEALAND.							HOWDENCHAPMAN P, 1994, HEALTH POLICY, V27, P35, DOI 10.1016/0168-8510(94)90156-2; POZO PR, 1994, J MED ETHICS, V20, P31; Titmuss R., 1971, GIFT RELATIONSHIP HU; VONSCHUBERT H, 1994, SOC SCI MED, V39, P201, DOI 10.1016/0277-9536(94)90328-X; [No title captured]	5	17	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 4	1996	312	7039					1131	1132						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UK069	8620129				2022-12-28	WOS:A1996UK06900022
J	Brosnan, CM; Gowing, NFC				Brosnan, CM; Gowing, NFC			Addison's disease	BRITISH MEDICAL JOURNAL			English	Article							ADRENAL INSUFFICIENCY; DIAGNOSIS		ROYAL MARSDEN HOSP,LONDON SW3 6JJ,ENGLAND	Royal Marsden NHS Foundation Trust	Brosnan, CM (corresponding author), ST HELIER HOSP,CARSHALTON SM5 1AA,SURREY,ENGLAND.							BURKE CW, 1985, CLIN ENDOCRINOL META, V14, P947, DOI 10.1016/S0300-595X(85)80084-0; BURKE CW, 1983, OXFORD TXB MED, V10, P58; CLAYTON RN, 1989, BRIT MED J, V298, P271, DOI 10.1136/bmj.298.6669.271; DONIACH D, 1982, RECENT ADV ENDOCRINO, V2, P100; DRUCKER D, 1985, CRIT CARE MED, V13, P477, DOI 10.1097/00003246-198506000-00007; LESHIN M, 1982, UROL CLIN N AM, V9, P229; LIDDLE GW, 1981, ADRENALS TXB ENDOCRI; MORAN JL, 1994, INTENS CARE MED, V20, P489, DOI 10.1007/BF01711901; MULLIGAN TM, 1985, CUTIS, V36, P317; NERUP J, 1974, ACTA ENDOCRINOL-COP, V76, P127, DOI 10.1530/acta.0.0760127; NEVILLE AM, 1992, OXFORD TXB PATHOLOGY, P1968; OLSSON RG, 1989, AM J GASTROENTEROL, V84, P1302; PATERSON JR, 1990, ANN CLIN BIOCHEM, V27, P378, DOI 10.1177/000456329002700416; RAMEY ER, 1957, PHYSIOL REV, V37, P155, DOI 10.1152/physrev.1957.37.2.155; RAO RH, 1995, MED CLIN N AM, V79, P107, DOI 10.1016/S0025-7125(16)30087-6; RINGSTAD J, 1991, J INTERN MED, V230, P465, DOI 10.1111/j.1365-2796.1991.tb00475.x; ROTH DN, 1992, WILLIAMS TXB ENDOCRI, P489; RUNCIE CJ, 1986, SCOT MED J, V31, P111, DOI 10.1177/003693308603100212; TOBIN MV, 1989, AM J GASTROENTEROL, V84, P1302; VARADARAJ R, 1986, AM J PSYCHIAT, V143, P553	20	37	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1085	1087						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616420				2022-12-28	WOS:A1996UH81600033
J	Danziger, R				Danziger, R			An epidemic like any other? Rights and responsibilities in HIV prevention	BRITISH MEDICAL JOURNAL			English	Article								Throughout the 1980s and into the 1990s, HIV prevention has been closely associated with the protection of individual human rights. Traditional public health measures such as compulsory testing and isolation have largely been rejected as ineffective in public health terms and inappropriate in the context of human rights protection. HIV prevention has been based instead chiefly on elective measures -information, education, counselling, and voluntary testing. In the past five years there have been important clinical, epidemiological, and social developments in the AIDS epidemic. These changes, combined with a growing recognition of possible weaknesses inherent in a strictly voluntarist approach to HIV prevention, may herald a new approach to AIDS control which places more weight on social responsibility in the context of HIV prevention.			Danziger, R (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND.							Bayer Ronald, 1992, ADIS IND DEMOCRACIES, P1; BERRIDGE V, 1992, AIDS MAKING CHRONIC, P299; CHRYSTIE IL, 1995, BRIT MED J, V311, P928, DOI 10.1136/bmj.311.7010.928; CLARKE A, 1994, SOC SCI MED, V39, P591, DOI 10.1016/0277-9536(94)90102-3; DILLNER L, 1995, BRIT MED J, V311, P827, DOI 10.1136/bmj.311.7009.827; ETZIONI A, 1993, TIME MAGAZINE    DEC, V13, P60; JOSEPH SC, 1992, DRAGON GATES ONCE FU, P82; MINKOFF H, 1995, JAMA-J AM MED ASSOC, V274, P1165, DOI 10.1001/jama.274.14.1165; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; SCHEPERHUGHES N, 1994, SOC SCI MED, V39, P991, DOI 10.1016/0277-9536(94)90210-0; SIGNORILE M, 1995, GUARDIAN        0301; *UN COMM HUM RIGHT, 1993, DISCR HIV INF PEOPL; VEEKEN H, 1995, BRIT MED J, V311, P935; WILFERT CM, 1994, CLIN INFECT DIS, V19, P664, DOI 10.1093/clinids/19.4.664	14	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1083	1084						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UH816	8616419				2022-12-28	WOS:A1996UH81600031
J	Fleisher, LA; Eagle, KA				Fleisher, LA; Eagle, KA			Screening for cardiac disease in patients having noncardiac surgery	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PERIPHERAL VASCULAR-SURGERY; CORONARY-ARTERY DISEASE; RISK; ISCHEMIA	The preoperative evaluation of the cardiac patient having noncardiac surgery offers an opportunity to identify occult and further define known cardiovascular disease to modify both perioperative and long-term care. The baseline probability of cardiovascular disease should initially be assessed using clinical variables and identifying unstable symptoms, including unstable angina and congestive heart failure. The decision about whether to obtain noninvasive testing to further define cardiovascular status should be made on the basis of the testing's potential to modify perioperative care, the prior probability of advanced coronary disease based on clinical history, and the magnitude of the surgical procedure. Noninvasive testing is best done in selected patients who are at moderate clinical risk. Otherwise, testing loses its predictive value because of a high incidence of fa Ise-negative and false-positive results. Quantitative imaging can also be used to identify those patients in whom coronary angiography is indicated, The value of coronary revascularization before noncardiac surgery has not been studied in a randomized, prospective manner, but several cohort studies have suggested that patients who survive coronary artery bypass grafting have decreased risk during subsequent noncardiac surgery. Given the potential short-term increase in morbidity from two surgical procedures, it is prudent to reserve coronary revascularization before noncardiac surgery for those patients in whom it is associated with improved long-term survival. If coronary revascularization is reserved for these patients, then the overall evaluation should prove cost-effective from the perspective of both perioperative and long-term cardiovascular care.	UNIV MICHIGAN, CTR MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	Fleisher, LA (corresponding author), JOHNS HOPKINS UNIV HOSP, DEPT ANESTHESIOL, 600 N WOLFE ST, CARNEGIE 442, BALTIMORE, MD 21287 USA.		Lee A, Fleisher/Q-9894-2019					BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; EAGLE KA, 1996, IN PRESS CIRCULATION; FLEISHER LA, 1995, ANESTHESIOLOGY, V83, P906, DOI 10.1097/00000542-199511000-00003; FLEISHER LA, 1994, ANESTH ANALG, V79, P661; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HUBER KC, 1992, MAYO CLIN PROC, V67, P15, DOI 10.1016/S0025-6196(12)60271-7; ISAACSON IJ, 1990, J VASC SURG, V12, P754, DOI 10.1067/mva.1990.24456; LITALIEN GL, 1996, IN PRESS J AM COLL C; MANGANO DT, 1991, CIRCULATION, V84, P493, DOI 10.1161/01.CIR.84.2.493; MASON JJ, 1995, JAMA-J AM MED ASSOC, V273, P1919, DOI 10.1001/jama.273.24.1919; MCPHAIL N, 1988, J VASC SURG, V7, P60, DOI 10.1067/mva.1988.avs0070060; PASTERNACK PF, 1989, AM J SURG, V158, P113, DOI 10.1016/0002-9610(89)90357-7; POLDERMANS D, 1995, J AM COLL CARDIOL, V26, P648, DOI 10.1016/0735-1097(95)00240-5; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; RIHAL CS, 1995, CIRCULATION, V91, P46, DOI 10.1161/01.CIR.91.1.46; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3; Vanzetto G, 1996, AM J CARDIOL, V77, P143, DOI 10.1016/S0002-9149(96)90585-8	20	21	22	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					767	772		10.7326/0003-4819-124-8-199604150-00011	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633839				2022-12-28	WOS:A1996UD93600011
J	Vercoulen, JHMM; Swanink, CMA; Zitman, FG; Vreden, SGS; Hoofs, MPE; Fennis, JFM; Galama, JMD; vanderMeer, JWM; Bleijenberg, G				Vercoulen, JHMM; Swanink, CMA; Zitman, FG; Vreden, SGS; Hoofs, MPE; Fennis, JFM; Galama, JMD; vanderMeer, JWM; Bleijenberg, G			Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome	LANCET			English	Article							DEPRESSION; THERAPY	Background No somatic treatment has been found to be effective for chronic fatigue syndrome (CFS). Antidepressant therapy is commonly used. Fluoxetine is recommended in preference to tricyclic agents because it has fewer sedative and autonomic nervous system effects. However, there have been no randomised, placebo-controlled, double-blind studies showing the effectiveness of antidepressant therapy in CFS. We have carried out such a study to assess the effect of fluoxetine in depressed and non-depressed CFS patients. Methods In this randomised, double-blind study, we recruited 44 patients to the depressed CFS group, and 52 to the non-depressed CFS group. In each group participants were randomly assigned to receive either fluoxetine (20 mg once daily) or placebo for 8 weeks. The effect of fluoxetine was assessed by questionnaires, self-observation lists, standard neuropsychological tests, and a motion-sensing device (Actometer), which were applied on the day treatment started and on the last day. Findings The two groups were well matched in terms of age, sex distribution, employment and marital status, and duration of CFS. There were no significant differences between the placebo and fluoxetine-treated groups in the change during the 8-week treatment period for any dimension of CFS. There was no change in subjective assessments of fatigue, severity of depression, functional impairment, sleep disturbances, neuropsychological function, cognitions, or physical activity in the depressed or the non-depressed subgroup. Interpretation Fluoxetine in a 20 mg daily dose does not have a beneficial effect on any characteristic of CFS. The lack of effect of fluoxetine on depressive symptoms in CFS suggests that processes underlying the presentation of depressive symptoms in CFS may differ from those in patients with major depressive disorder.	UNIV NIJMEGEN HOSP,DEPT GEN INTERNAL MED,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT MED MICROBIOL,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT PSYCHIAT,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Vercoulen, JHMM (corresponding author), UNIV NIJMEGEN HOSP,DEPT PSYCHOL MED,POSTBUS 9101,6500 HB NIJMEGEN,NETHERLANDS.		Vercoulen, J.H.M.M./L-4706-2015; Zitman, Frans G./E-7705-2010; Bleijenberg, Gijs/E-6984-2010; van der Meer, Jos W.M./C-8521-2013	van der Meer, Jos W.M./0000-0001-5120-3690				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BLONDELHILL E, 1993, DRUGS, V46, P639, DOI 10.2165/00003495-199346040-00005; DORNSEIF BE, 1989, PSYCHOPHARMACOL BULL, V25, P71; DUNLOP SR, 1990, PSYCHOPHARMACOL BULL, V26, P173; Ettema J, 1986, SCL 90 HANDLEIDING B; GANTZ NM, 1989, DRUGS, V38, P855, DOI 10.2165/00003495-198938060-00003; GOODNICK PJ, 1993, J CLIN PSYCHIAT, V54, P13; GRAM LF, 1994, NEW ENGL J MED, V331, P1354; Halfens R., 1988, TIJDSCHRIFT SOCIALE, V66, P399; Jacobs H M, 1990, Ned Tijdschr Geneeskd, V134, P1950; LYNCH S, 1991, BRIT J GEN PRACT, V41, P339; LYNCH S, 1990, PSYCHIAT B R COLL PH, V3, P43; SCHWEIZER E, 1990, J CLIN PSYCHIAT, V51, P8; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; VLAEYEN JWS, 1989, PIJN COGNITIE LIJST; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; WERNICKE JF, 1988, PSYCHOPHARMACOL BULL, V24, P183; WERNICKE JF, 1987, PSYCHOPHARMACOL BULL, V23, P164; WERNICKE JF, 1989, INT CLIN PSYCHOPHARM, V4, P63; WILSON A, 1994, AM J MED, V96, P544, DOI 10.1016/0002-9343(94)90095-7; YATHAM LN, 1995, CAN J PSYCHIAT, V40, P93	25	178	180	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 30	1996	347	9005					858	861		10.1016/S0140-6736(96)91345-8	http://dx.doi.org/10.1016/S0140-6736(96)91345-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UC450	8622391	Green Submitted			2022-12-28	WOS:A1996UC45000009
J	SelaHerman, S; Scharschmidt, BF				SelaHerman, S; Scharschmidt, BF			Choledochal cyst, a disease for all ages	LANCET			English	Editorial Material									UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	SelaHerman, S (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143, USA.							Chaudhary A, 1996, BRIT J SURG, V83, P186, DOI 10.1046/j.1365-2168.1996.02042.x; IWAI N, 1992, ANN SURG, V215, P27, DOI 10.1097/00000658-199201000-00003; LIPSETT PA, 1994, ANN SURG, V220, P644, DOI 10.1097/00000658-199411000-00007; STAIN SC, 1995, ANN SURG, V222, P128, DOI 10.1097/00000658-199508000-00004; Stringer MD, 1995, ARCH DIS CHILD, V73, P528, DOI 10.1136/adc.73.6.528	5	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					779	779		10.1016/S0140-6736(96)90864-8	http://dx.doi.org/10.1016/S0140-6736(96)90864-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622330				2022-12-28	WOS:A1996UB15300005
J	Verdonck, LF; Lokhorst, HM; Dekker, AW; Nieuwenhuis, HK; Petersen, EJ				Verdonck, LF; Lokhorst, HM; Dekker, AW; Nieuwenhuis, HK; Petersen, EJ			Graft-versus-myeloma effect in two cases	LANCET			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; BONE-MARROW TRANSPLANTATION; HOST DISEASE; IMMUNOTHERAPY	Background Allogeneic bone-marrow transplantation (BMT) is associated with the graft-versus-leukaemia effect because of the antileukaemic action of donor lymphocytes. We describe a graft-versus-myeloma effect after BMT in multiple myeloma. Methods Two patients with recurrent multiple myeloma after allogeneic BMT (T cells partly depleted, 10(5) T cells infused per kg) received leucocyte infusions obtained by leukapheresis from their original marrow donors. The patients were a 48-year-old woman and a 49-year-old man. Findings Both patients developed graft-versus-host disease and achieved complete remission of myeloma. Chimerism was complete in both patients in that all peripheral blood cells were of donor origin. Interpretation We see our results as evidence for a graft-versus-myeloma effect. Using this form of adoptive immunotherapy, we could administer 1000-3000 times more T cells than with the earlier BMT.			Verdonck, LF (corresponding author), UNIV UTRECHT HOSP,DEPT HAEMATOL,POB 85500,3508 GA UTRECHT,NETHERLANDS.							BORTIN MM, 1979, NATURE, V281, P490, DOI 10.1038/281490a0; DROBYSKI WR, 1993, BLOOD, V82, P2310; HOROWITZ MM, 1990, BLOOD, V75, P555; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; MARMOST AM, 1989, BLOOD, V78, P2120; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204; SULLIVAN KM, 1989, NEW ENGL J MED, V320, P828, DOI 10.1056/NEJM198903303201303; VERDONCK LF, 1994, BLOOD, V83, P3090, DOI 10.1182/blood.V83.10.3090.3090; VERDONCK LF, 1991, TRANSPLANTATION, V51, P1120; WEIDEN PL, 1979, NEW ENGL J MED, V300, P1068, DOI 10.1056/NEJM197905103001902	10	177	182	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					800	801		10.1016/S0140-6736(96)90871-5	http://dx.doi.org/10.1016/S0140-6736(96)90871-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622337				2022-12-28	WOS:A1996UB15300012
J	Maruyama, H; Raphael, JH; Djerassi, C				Maruyama, H; Raphael, JH; Djerassi, C			Why Japan ought to legalize the pill	NATURE			English	Editorial Material											Maruyama, H (corresponding author), STANFORD UNIV, ASIA PACIFIC RES CTR, STANFORD, CA 94305 USA.							ANDERSON A, 1985, NATURE, V317, P760, DOI 10.1038/317760c0; Coleman Samuel, 1983, FAMILY PLANNING JAPA; JITSUKAWA M, 1994, SCIENCE, V265, P1048, DOI 10.1126/science.8066442; MURAMATSU M, 1973, B I PUBL HLTH, V22, P228; MURAMATSU M, 1974, ABORTION RES INT EXP, P133; NATHAN R, 1995, NAT MED, V1, P1115, DOI 10.1038/nm1195-1115; RIPHAGEN FE, 1987, WIEN MED WOCHENSCHR, V137, P488; TRUSSELL J, 1990, STUD FAMILY PLANN, V21, P51, DOI 10.2307/1966591; WEINSTEIN M, 1990, POP STUD-J DEMOG, V44, P447, DOI 10.1080/0032472031000144846; 1993, 1992 YUSEI HOGO TOKE, P20; 1994, SUMMARY 22ND NATIONA; 1992, SUMMARY 21ST NATIONA; 1995, NIKKEI UERUNESU, V12, P10; 1995, WORLD POPULATION DAT	14	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 15	1996	379	6566					579	580		10.1038/379579a0	http://dx.doi.org/10.1038/379579a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	TV688	8628389				2022-12-28	WOS:A1996TV68800021
J	Rawlings, DJ; Scharenberg, AM; Park, H; Wahl, MI; Lin, SQ; Kato, RM; Fluckiger, AC; Witte, ON; Kinet, JP				Rawlings, DJ; Scharenberg, AM; Park, H; Wahl, MI; Lin, SQ; Kato, RM; Fluckiger, AC; Witte, ON; Kinet, JP			Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; TYROSINE KINASE; B-CELLS; CHROMOSOME; PP60C-SRC; MUTATION; GENES; MICE	Bruton's tyrosine kinase (BTK) is pivotal in B cell activation and development through its participation in the signaling pathways of multiple hematopoietic receptors. The mechanisms controlling BTK activation were studied here by examination of the biochemical consequences of an interaction between BTK and SRC family kinases. This interaction of BTK with SRC kinases transphosphorylated BTK on tyrosine at residue 551, which led to BTK activation. BTK then autophosphorylated at a second site. The same two sites were phosphorylated upon B cell antigen receptor cross-linking. The activated BTK was predominantly membrane-associated, which suggests that BTK integrates distinct receptor signals resulting in SRC kinase activation and BTK membrane targeting.	BETH ISRAEL HOSP, LAB ALLERGY & IMMUNOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036834, K11AR001912] Funding Source: NIH RePORTER; NCI NIH HHS [CA09120-20] Funding Source: Medline; NIAMS NIH HHS [AR36834, AR01912] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P4204, DOI 10.1073/pnas.91.10.4204; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER MD, 1993, PROGR IMMUNOLOGY, P535; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; EARL PL, 1987, CURRENT PROTOCOLS MO; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; Harian J. E., 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASBOLD J, 1994, EUR J IMMUNOL, V24, P152, DOI 10.1002/eji.1830240123; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HITOSHI Y, 1993, INT IMMUNOL, V5, P1183, DOI 10.1093/intimm/5.9.1183; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOIKE M, 1995, INT IMMUNOL, V7, P21, DOI 10.1093/intimm/7.1.21; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Park H., UNPUB; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SCRIBNER CL, 1987, J IMMUNOL, V138, P3611; SHIMAOKA J, UNPUB; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; YAMASHITA Y, 1995, IMMUNOLOGY, V85, P248; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	45	378	384	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 9	1996	271	5250					822	825		10.1126/science.271.5250.822	http://dx.doi.org/10.1126/science.271.5250.822			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TU694	8629002				2022-12-28	WOS:A1996TU69400051
J	Fisher, CJ; Agosti, JM; Opal, SM; Lowry, SF; Balk, RA; Sadoff, JC; Abraham, E; Schein, RMH; Benjamin, E				Fisher, CJ; Agosti, JM; Opal, SM; Lowry, SF; Balk, RA; Sadoff, JC; Abraham, E; Schein, RMH; Benjamin, E			Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FACTOR-BINDING-PROTEIN; FACTOR-ALPHA; MONOCLONAL-ANTIBODY; SEPSIS SYNDROME; CANCER-PATIENTS; TNF-ALPHA; SERUM; CACHECTIN; INTERLEUKIN-1; ENDOTOXIN	Background, A recombinant, soluble fusion protein that is a dimer of an extracellular portion of the human tumor necrosis factor (TNF) receptor and the Fc portion of IgG1 (TNFR:Fc) binds and neutralizes TNF-alpha and prevents death in animal models of bacteremia and endotoxemia. Methods. To evaluate the safety and efficacy of TNFR:Fc in the treatment of septic shock, we conducted a randomized, double-blind, placebo-controlled, multicenter trial. A total of 141 patients were randomly assigned to receive either placebo or a single intravenous infusion of one of three doses of TNFR:Fc (0.15, 0.45, or 1.5 mg per kilogram of body weight). The primary end point was mortality from all causes at 28 days. Results. There were 10 deaths among the 33 patients in the placebo group (30 percent mortality), 9 deaths among the 30 patients receiving the low dose of TNFR:Fc (30 percent mortality), 14 deaths among the 29 receiving the middle dose (48 percent mortality), and 26 deaths among the 49 receiving the high dose (53 percent mortality) (P=0.02 for the dose-response relation). Baseline differences in the severity of illness did not account for the increased mortality in the groups receiving the higher doses of TNFR:Fc. Conclusions. In patients with septic shock, treatment with the TNFR:Fc fusion protein does not reduce mortality, and higher doses appear to be associated with increased mortality. (C) 1996, Massachusetts Medical Society.	IMMUNEX CORP, DIV RES & DEV, SEATTLE, WA USA; BROWN UNIV, SCH MED, DEPT MED, PAWTUCKET, RI USA; BROWN UNIV, MEM HOSP RHODE ISL, PAWTUCKET, RI 02860 USA; CORNELL UNIV, MED CTR, DEPT SURG, NEW YORK, NY 10021 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, SECT PULM, CHICAGO, IL 60612 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, SECT CRIT CARE MED, CHICAGO, IL 60612 USA; WALTER REED ARMY MED CTR, WALTER REED ARMY INST RES, DIV COMMUNICABLE DIS & IMMUNOL, WASHINGTON, DC 20307 USA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA; VET AFFAIRS MED CTR, MIAMI, FL 33125 USA; UNIV MIAMI, DEPT MED, MIAMI, FL USA; MT SINAI MED CTR, DEPT SURG, NEW YORK, NY 10029 USA	Immunex Corporation; Brown University; Brown University; Cornell University; Rush University; Rush University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; Icahn School of Medicine at Mount Sinai	Fisher, CJ (corresponding author), CLEVELAND CLIN FDN, DEPT PULM & CRIT CARE MED, CRIT CARE RES UNIT, MAIL CODE G-62, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BAGBY GJ, 1991, J INFECT DIS, V163, P83, DOI 10.1093/infdis/163.1.83; BAUMGARTNER S, 1996, BIOM 96 MED RES BENC; BAUSS F, 1987, INFECT IMMUN, V55, P1622, DOI 10.1128/IAI.55.7.1622-1625.1987; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; CARLET J, 1994, 34TH INT C ANT AG CH, P7; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P31; CROSS AS, 1989, J EXP MED, V169, P2021, DOI 10.1084/jem.169.6.2021; DAMAS P, 1989, CRIT CARE MED, V17, P975, DOI 10.1097/00003246-198910000-00001; DEBETS JMH, 1989, CRIT CARE MED, V17, P489, DOI 10.1097/00003246-198906000-00001; DHAINAUT JFA, 1994, CRIT CARE MED, V22, P1720, DOI 10.1097/00003246-199422110-00005; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; ESKANDARI MK, 1992, J IMMUNOL, V148, P2724; EVANS T, 1993, 33RD INT C ANT AG CH, P378; EVANS TJ, 1994, J EXP MED, V180, P2173, DOI 10.1084/jem.180.6.2173; FEINBERG B, 1988, J CLIN ONCOL, V6, P1328, DOI 10.1200/JCO.1988.6.8.1328; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CJ, 1993, CRIT CARE MED, V21, P318, DOI 10.1097/00003246-199303000-00006; GATANAGA T, 1990, P NATL ACAD SCI USA, V87, P8781, DOI 10.1073/pnas.87.22.8781; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; GIRARDIN E, 1992, IMMUNOLOGY, V76, P20; HAVELL EA, 1992, J IMMUNOL, V148, P1486; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; JIN HK, 1994, J INFECT DIS, V170, P1323, DOI 10.1093/infdis/170.5.1323; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MACVITTIE T, 1992, P 2 C INT END SOC VI, P229; MARANO MA, 1990, SURG GYNECOL OBSTET, V170, P32; MARKS JD, 1990, AM REV RESPIR DIS, V141, P94, DOI 10.1164/ajrccm/141.1.94; MASTROENI P, 1991, MICROB PATHOGENESIS, V11, P33, DOI 10.1016/0882-4010(91)90091-N; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MOHLER KM, 1993, J IMMUNOL, V151, P1548; OFFNER F, 1990, J LAB CLIN MED, V116, P100; OLSSON I, 1989, EUR J HAEMATOL, V42, P270, DOI 10.1111/j.1600-0609.1989.tb00111.x; OPAL SM, 1990, J INFECT DIS, V161, P1148, DOI 10.1093/infdis/161.6.1148; OPAL SM, 1993, 33 INT C ANT AG CHEM, P379; SCHUTZE S, 1989, J BIOL CHEM, V264, P3562; SECKINGER P, 1988, J EXP MED, V167, P1511, DOI 10.1084/jem.167.4.1511; SILVA AT, 1990, J INFECT DIS, V162, P421, DOI 10.1093/infdis/162.2.421; SUFFREDINI AF, 1994, INT CARE MED S1, V20, pS147; SUITTERS AJ, 1994, J EXP MED, V179, P849, DOI 10.1084/jem.179.3.849; TENAILLON A, 1994, P 1 AUT INT M SEPS D, P31; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, SURG GYNECOL OBSTET, V164, P415; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; VANFURTH R, 1994, J INFECT DIS, V170, P234, DOI 10.1093/infdis/170.1.234; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WAAGE A, 1987, LANCET, V1, P355; WALSH CJ, 1992, ARCH SURG-CHICAGO, V127, P138; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	57	907	976	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1697	1702		10.1056/NEJM199606273342603	http://dx.doi.org/10.1056/NEJM199606273342603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT400	8637514				2022-12-28	WOS:A1996UT40000003
J	Schreiber, GB; Busch, MP; Kleinman, SH; Korelitz, JJ				Schreiber, GB; Busch, MP; Kleinman, SH; Korelitz, JJ			The risk of transfusion-transmitted viral infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; NON-B-HEPATITIS; STATES BLOOD-DONORS; NON-A-HEPATITIS; UNITED-STATES; LONG-TERM; RECIPIENTS; ANTIBODY; TRANSMISSION	Background. Accurate estimates of the risk of transfusion-transmitted infectious disease are essential for monitoring the safety of the blood supply and evaluating the potential effect of new screening tests. We estimated the risk of transmitting the human immunodeficiency virus (HIV), the human T-cell lymphotropic virus (HTLV), the hepatitis C virus (HCV), and the hepatitis B virus (HBV) from screened blood units donated during the window period following a recent, undetected infection. Methods. Using data on 586,507 persons who each donated blood more than once between 1991 and 1993 at five blood centers (for a total of 2,318,356 allogeneic blood donations), we calculated the incidence rates of seroconversion among those whose donations passed all the screening tests used. We adjusted these rates for the estimated duration of the infectious window period for each virus. We then estimated the further reductions in risk that would result from the use of new and more sensitive viral-antigen or nucleic acid screening tests. Results. Among donors whose units passed all screening tests, the risks of giving blood during an infectious window period were estimated as follows: for HIV, 1 in 493,000 (95 percent confidence interval, 202,000 to 2,778,000); for HTLV, 1 in 641,000 (256,000 to 2,000,000); for HCV, 1 in 103,000 (28,000 to 288,000); and for HBV, 1 in 63,000 (31,000 to 147,000). HBV and HCV accounted for 88 percent of the aggregate risk of 1 in 34,000. New screening tests that shorten the window periods for the four viruses should reduce the risks by 27 to 72 percent. Conclusions. The risk of transmitting HIV, HTLV, HCV, or HBV infection by the transfusion of screened blood is very small, and new screening tests will reduce the risk even further. (C) 1996, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; IRWIN MEM BLOOD CTR, SAN FRANCISCO, CA USA; UNIV CALIF LOS ANGELES, BLOOD & PLATELET CTR, LOS ANGELES, CA USA	University of California System; University of California San Francisco; University of California System; University of California Los Angeles	Schreiber, GB (corresponding author), WESTAT CORP, 1650 RES BLVD, ROCKVILLE, MD 20850 USA.				DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097078, N01HB097077] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-97114, N01-HB-97078, N01-HB-97077] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1981, JAMA-J AM MED ASSOC, V246, P630, DOI 10.1001/jama.246.6.630; ALTER HJ, 1995, BLOOD, V85, P1681, DOI 10.1182/blood.V85.7.1681.bloodjournal8571681; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; Aubuchon J. P., 1995, Transfusion (Bethesda), V35, p43S; BUSCH MP, 1994, BLOOD, V83, P1143; BUSCH MP, 1993, TRANSFUSION, V33, P84, DOI 10.1046/j.1537-2995.1993.33193142316.x; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; Busch MP, 1995, TRANSFUSION, V35, P903, DOI 10.1046/j.1537-2995.1995.351196110893.x; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DODD RY, 1994, BLOOD SUPPLY RISKS P, P1; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; HJELLE B, 1993, BLOOD, V81, P1641; HOOFNAGLE JH, 1978, VIRAL HEPATITIS, P219; HUGHES W, 1995, TRANSFUSION MED, V5, P225, DOI 10.1111/j.1365-3148.1995.tb00232.x; IWARSON S, 1995, CLIN INFECT DIS, V20, P1361, DOI 10.1093/clinids/20.5.1361; JAGODZINSKI L, 1994, TRANSFUSION, V34, pS37; KLEINMAN S, 1992, TRANSFUSION, V32, P805, DOI 10.1046/j.1537-2995.1992.32993110750.x; KLEINMAN S, 1992, BLOOD SAFETY CURRENT, P169; KLEINMAN SH, 1994, J CLIN MICROBIOL, V32, P603, DOI 10.1128/JCM.32.3.603-607.1994; KLEINMAN SH, 1996, CLIN PRACTICE TRANSF, P809; KORELITZ JJ, 1994, TRANSFUSION, V34, P870, DOI 10.1046/j.1537-2995.1994.341095026972.x; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; LELIE PN, 1992, J MED VIROL, V37, P203, DOI 10.1002/jmv.1890370310; MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609; MIMMS LT, 1993, BRIT MED J, V307, P1095, DOI 10.1136/bmj.307.6912.1095; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; RENZULLO PO, 1995, J ACQ IMMUN DEF SYND, V10, P177, DOI 10.1097/00042560-199510020-00011; Sayre KR, 1996, TRANSFUSION, V36, P45, DOI 10.1046/j.1537-2995.1996.36196190514.x; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; STRAUSS D, 1994, TRANSFUSION, V34, pS34; Zuck TF, 1995, TRANSFUSION, V35, P944, DOI 10.1046/j.1537-2995.1995.351196110900.x; 1994, MMWR-MORBID MORTAL W, V42, P1	41	1367	1444	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1685	1690		10.1056/NEJM199606273342601	http://dx.doi.org/10.1056/NEJM199606273342601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UT400	8637512	Bronze			2022-12-28	WOS:A1996UT40000001
J	Gregory, KWP; Davis, RC				Gregory, KWP; Davis, RC			Angioedema of the intestine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Gregory, KWP (corresponding author), VANDERBILT UNIV,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.								0	29	29	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1996	334	25					1641	1641		10.1056/NEJM199606203342505	http://dx.doi.org/10.1056/NEJM199606203342505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ706	8628360				2022-12-28	WOS:A1996UQ70600005
J	Tibbles, PM; Edelsberg, JS				Tibbles, PM; Edelsberg, JS			Medical progress - Hyperbaric-oxygen therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CARBON-MONOXIDE; NECROTIZING FASCIITIS; AIR-EMBOLISM; RADIATION NECROSIS; SKELETAL-MUSCLE; BRAIN; OSTEOMYELITIS; BIOSYNTHESIS; INHIBITION; TOXICITY				Tibbles, PM (corresponding author), UNIV MASSACHUSETTS, MED CTR, DEPT EMERGENCY MED, 55 LAKE AVE N, WORCESTER, MA 01655 USA.							BASKIN SE, 1975, NEW ENGL J MED, V293, P184, DOI 10.1056/NEJM197507242930407; Bernard C., 1857, LECONS EFFETS SUBSTA; BLUMEN IJ, 1992, CRIT CARE CLIN, V8, P597, DOI 10.1016/S0749-0704(18)30243-4; BOEHME DE, 1976, NATURE, V262, P418, DOI 10.1038/262418a0; Boerema I, 1960, J CARDIOVASC SURG TO, V1, P133; Bowersox J.C., 1986, J HYPERBARIC MED, V1, P141; BRANNEN AL, 1995, UNDERSEA HYPERB ME S, V22, P11; BROWN DR, 1994, AM J SURG, V167, P485, DOI 10.1016/0002-9610(94)90240-2; BROWN OR, 1972, MICROBIOS, V5, P7; BROWN SD, 1990, J APPL PHYSIOL, V68, P604, DOI 10.1152/jappl.1990.68.2.604; Cianci P, 1988, J HYPERBAR MED, V3, P97; CLARK JM, 1971, PHARMACOL REV, V23, P37; COBB N, 1991, JAMA-J AM MED ASSOC, V266, P659, DOI 10.1001/jama.266.5.659; DAVIS JC, 1986, J BONE JOINT SURG AM, V68A, P1210, DOI 10.2106/00004623-198668080-00010; DEMELLO FJ, 1973, SURGERY, V73, P936; Doctor N, 1992, J Postgrad Med, V38, P112; DUCASSE JL, 1995, UNDERSEA HYPERBAR M, V22, P9; *DUK U MED CTR, 1995, DIV AL NETW REP 1993; ESTERHAI JL, 1987, J TRAUMA, V27, P763, DOI 10.1097/00005373-198707000-00013; Euing J, 1926, ACTA RADIOL, V6, P399; Francis TJR, 1993, PHYSL MED DIVING, P454; FYKE FE, 1985, AM J MED, V78, P333; GABB G, 1987, CHEST, V92, P1074, DOI 10.1378/chest.92.6.1074; GOLDBAUM LR, 1975, AVIAT SPACE ENVIR MD, V46, P1289; GOZAL D, 1986, ARCH SURG-CHICAGO, V121, P233; Haapaniemi T, 1996, PLAST RECONSTR SURG, V97, P602, DOI 10.1097/00006534-199603000-00017; HAMMARLUND C, 1994, PLAST RECONSTR SURG, V93, P829, DOI 10.1097/00006534-199404000-00026; HART GB, 1974, SURG GYNECOL OBSTET, V139, P693; HART GB, 1976, CANCER-AM CANCER SOC, V37, P2580, DOI 10.1002/1097-0142(197606)37:6<2580::AID-CNCR2820370603>3.0.CO;2-H; HART GB, 1994, HYPERBARIC MED PRACT, P57; HART GB, 1994, HYPERBARIC MED PRACT, P517; HARWARD TRS, 1985, J VASC SURG, V2, P220, DOI 10.1067/mva.1985.avs0020220; Heimbach RD, 1994, HYPERBARIC MED PRACT, P373; HILL GB, 1972, J INFECT DIS, V125, P17, DOI 10.1093/infdis/125.1.17; HUNT TK, 1988, ANN EMERG MED, V17, P1265, DOI 10.1016/S0196-0644(88)80351-2; HUNT TK, 1972, SURG GYNECOL OBSTETR, V135, P561; JURELL G, 1973, SCAND J PLAST RECONS, V7, P25, DOI 10.3109/02844317309072414; KAYE D, 1967, P SOC EXP BIOL MED, V124, P360; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KINDWALL EP, 1993, CLIN PLAST SURG, V20, P473; KNIGHTON DR, 1981, SURGERY, V90, P262; KNIGHTON DR, 1986, ARCH SURG-CHICAGO, V121, P191; KULONEN E, 1968, ACTA PHYSIOL SCAND, V73, P383, DOI 10.1111/j.1748-1716.1968.tb04116.x; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471, DOI 10.1152/jappl.1953.5.9.471; Lee H.C., 1987, J HYPERBARIC MED, V2, P75; MADER JT, 1978, J INFECT DIS, V138, P312, DOI 10.1093/infdis/138.3.312; MADER JT, 1980, J INFECT DIS, V142, P915, DOI 10.1093/infdis/142.6.915; MAINOUS EG, 1974, INT J ORAL MAXILLOF, V3, P297, DOI 10.1016/S0300-9785(74)80066-9; MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002-9610(05)81019-0; MARX RE, 1982, J ORAL MAXIL SURG, V40, P412, DOI 10.1016/0278-2391(82)90076-3; MARX RE, 1987, ORAL SURG ORAL MED O, V64, P379, DOI 10.1016/0030-4220(87)90136-8; MARX RE, 1985, J AM DENT ASSOC, V111, P49, DOI 10.14219/jada.archive.1985.0074; Marx RE, 1994, HYPERBARIC MED PRACT, P447; Marx RE, 1988, PROBLEM WOUNDS ROLE, P65; Moon RE, 1993, PHYSL MED DIVING, P506; MURPHY BP, 1985, ANN SURG, V201, P242, DOI 10.1097/00000658-198502000-00019; MUSTOE TA, 1993, CLIN PLAST SURG, V20, P465; *NAT CTR HLTH STAT, 1994, VIT STAT US 1990, V2; NYLANDER G, 1984, BURNS, V10, P193, DOI 10.1016/0305-4179(84)90026-3; Oriani G, 1990, J HYPERB MED, V5, P171; PACE N, 1950, SCIENCE, V111, P652, DOI 10.1126/science.111.2894.652; PALMQUIST BM, 1984, BRIT J OPHTHALMOL, V68, P113, DOI 10.1136/bjo.68.2.113; PARK MK, 1991, ANTIMICROB AGENTS CH, V35, P691, DOI 10.1128/AAC.35.4.691; PECORARO RE, 1991, DIABETES, V40, P1305, DOI 10.2337/diabetes.40.10.1305; PERRINS DJD, 1967, LANCET, V1, P868; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P77, DOI 10.1056/NEJM197907123010204; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104; RAPHAEL JC, 1989, LANCET, V2, P414; RISEMAN JA, 1990, SURGERY, V108, P847; ROTH RN, 1994, CLIN DERMATOL, V12, P141, DOI 10.1016/0738-081X(94)90265-8; SHULMAN AG, 1967, SURGERY, V62, P1051; SKYHAR MJ, 1986, J BONE JOINT SURG AM, V68A, P1218, DOI 10.2106/00004623-198668080-00011; STRAUSS MB, 1983, J BONE JOINT SURG AM, V65, P656, DOI 10.2106/00004623-198365050-00011; Strauss MB, 1994, HYPERBARIC MED PRACT, P525; TEHRANI MA, 1977, POSTGRAD MED J, V53, P237, DOI 10.1136/pgmj.53.619.237; THOM SR, 1992, J APPL PHYSIOL, V73, P1584, DOI 10.1152/jappl.1992.73.4.1584; THOM SR, 1993, TOXICOL APPL PHARM, V123, P248, DOI 10.1006/taap.1993.1243; THOM SR, 1993, TOXICOL APPL PHARM, V123, P234, DOI 10.1006/taap.1993.1242; THOM SR, 1994, TOXICOL APPL PHARM, V128, P105, DOI 10.1006/taap.1994.1186; THORN SR, 1995, ANN EMERG MED, V25, P474, DOI 10.1016/S0196-0644(95)70261-X; TIBBLES PM, 1994, ANN EMERG MED, V24, P269, DOI 10.1016/S0196-0644(94)70141-5; UHL E, 1994, PLAST RECONSTR SURG, V93, P835, DOI 10.1097/00006534-199404000-00028; *UND HYP MED SOC, 1996, DIR HYP CHAMB US CAN; *UND HYP MED SOC, 1992, HYP OX THER COMM REP; Van UNNIK A. J. M., 1965, ANTONIE LEEUWENHOEK J MICROBIOL SEROL, V31, P181; WATTEL F, 1990, ANGIOLOGY, V41, P59, DOI 10.1177/000331979004100109; Weaver LK, 1995, UNDERSEA HYPERB ME S, V22, P14; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; ZAMBONI W A, 1989, Journal of Reconstructive Microsurgery, V5, P343, DOI 10.1055/s-2007-1006884; ZAMBONI WA, 1993, PLAST RECONSTR SURG, V91, P1110, DOI 10.1097/00006534-199305000-00022	90	618	639	0	63	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1996	334	25					1642	1648		10.1056/NEJM199606203342506	http://dx.doi.org/10.1056/NEJM199606203342506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ706	8628361				2022-12-28	WOS:A1996UQ70600006
J	Ellis, RJ				Ellis, RJ			The ''bio'' in biochemistry: Protein folding inside and outside the cell	SCIENCE			English	Editorial Material							GROEL				Ellis, RJ (corresponding author), UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.							ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P11; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9	15	17	18	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1448	1449						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633233				2022-12-28	WOS:A1996UP89900035
J	Jayaraman, T; Ondrias, K; Ondriasova, E; Marks, AR				Jayaraman, T; Ondrias, K; Ondriasova, E; Marks, AR			Regulation of the inositol 1,4,5-trisphosphate receptor by tyrosine phosphorylation	SCIENCE			English	Article							T-CELL RECEPTOR; ANTIGEN RECEPTOR; PROTEIN-KINASE; BINDING-SITE; MUTANT MICE; CHANNELS; TRANSDUCTION; CEREBELLUM	Tyrosine kinases indirectly raise intracellular calcium concentration ([Ca2+](i)) by activating phospholipases that generate inositol 1,4,5-trisphosphate (IP3). IP3 activates the IP3 receptor (IP(3)R), an intracellular calcium release channel on the endoplasmic reticulum. T cell receptor stimulation triggered a physical association between the nonreceptor protein tyrosine kinase Fyn and the IP(3)R, which induced tyrosine phosphorylation of the IP(3)R. Fyn activated an IP3-gated calcium channel in vitro, and tyrosine phosphorylation of the IP(3)R during T cell activation was reduced in thymocytes from fyn(-/-) mice. Thus, activation of the IP(3)R by tyrosine phosphorylation may play a role in regulating [Ca2+](i).	CUNY MT SINAI SCH MED,DEPT MED,MOLEC CARDIOL LAB,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai				Ondriasova, Elena/0000-0002-2990-990X; Ondrias, Karol/0000-0001-8329-3563	PHS HHS [N529814] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BEZPROZVANNY I, 1993, NEURON, V10, P1175, DOI 10.1016/0896-6273(93)90065-Y; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; JAYARAMAN T, UNPUB; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKADE S, 1994, J BIOL CHEM, V269, P6735; ONDRIAS K, UNPUB; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; WATRAS J, 1991, J NEUROSCI, V11, P3239; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	27	190	197	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1492	1494		10.1126/science.272.5267.1492	http://dx.doi.org/10.1126/science.272.5267.1492			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633244				2022-12-28	WOS:A1996UP89900051
J	Kharasch, ED; Hankins, D; Mautz, D; Thummel, KE				Kharasch, ED; Hankins, D; Mautz, D; Thummel, KE			Identification of the enzyme responsible for oxidative halothane metabolism: Implications for prevention of halothane hepatitis	LANCET			English	Article							HEPATOTOXICITY; MICROSOMES; 2E1; DEFLUORINATION; METHOXYFLURANE; NEOANTIGENS; CIMETIDINE; TOXICITY	Background Fulminant hepatic necrosis (''halothane hepatitis'') is an unusual and often fatal complication of halothane anaesthesia, It is mediated by immune sensitisation in susceptible individuals to trifluoroacetylated liver protein neoantigens, formed by oxidative halothane metabolism. The seminal event in halothane hepatitis is hepatic metabolism, yet the enzyme responsible for oxidative halothane metabolism and trifluoroacetylated neoantigen formation remains unidentified. This investigation tested the hypothesis that cytochrome P450 2E1 (CYP2E1) is responsible for human halothane metabolism in vivo. Methods 20 elective surgical patients received either disulfiram (500 mg orally, n=10) or nothing (controls, n=10) the night before surgery. Disulfiram, converted in vivo to an effective inhibitor of P450 2E1, was used as a metabolic probe for P450 2E1. All patients received standard halothane anaesthesia (1.0% end-tidal, 3 h). Blood halothane and plasma and urine trifluoroacetic acid, bromide, and fluoride concentrations were measured for up to 96 h postoperatively. Findings Total halothane dose, measured by cumulative end-tidal (3.8 SE 0.1 minimum alveolar concentration hours) and blood halothane concentrations, was similar in the two groups. Plasma concentrations and urinary excretion of trifluoroacetic acid and bromide, indicative of oxidative and total (oxidative and reductive) halothane metabolism, respectively, were significantly diminished in disulfiram-treated patients. In control and disulfiram-treated patients cumulative 96 h postoperative trifluoroacetic acid excretion was 12 900 (SE 1700) and 2010 (440) mu mol, respectively (p<0.001) while that of bromide was 1720 (290) and 160 (70) mu mol (p<0.001). Interpretation The substantial attenuation of trifluoroacetic acid production by disulfiram after halothane anaesthesia suggests that P450 2E1 is a predominant enzyme responsible for human oxidative halothane metabolism. Inhibition of P450 2E1 by a single preoperative oral disulfiram dose greatly diminished production of the halothane metabolite responsible for the neoantigen formation that initiates halothane hepatitis. Single-dose disulfiram may provide effective prophylaxis against halothane hepatitis.	UNIV WASHINGTON,DEPT MED CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACEUT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kharasch, ED (corresponding author), UNIV WASHINGTON,DEPT ANESTHESIOL,BOX 356540,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349, R01GM048712] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29 GMY8349, R01 GM48712] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER MT, 1993, ANESTH ANALG, V76, P817; BROWN RM, 1995, ANESTH ANALG, V80, pS60; COUSINS MJ, 1979, ANAESTH INTENS CARE, V7, P9, DOI 10.1177/0310057X7900700102; COUSINS MJ, 1989, AUST NZ J SURG, V59, P5, DOI 10.1111/j.1445-2197.1989.tb01457.x; ECKES L, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1447; EMERY MG, 1995, INT SOC STUDY XENOBI, V8, P168; GRUENKE LD, 1988, J PHARMACOL EXP THER, V246, P454; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; ILYIN GP, 1994, BIOCHEM PHARMACOL, V48, P561, DOI 10.1016/0006-2952(94)90286-0; KAWAGUCHI R, 1989, Hiroshima Journal of Medical Sciences, V38, P27; KENNA JG, 1990, DRUG METAB DISPOS, V18, P788; KHARASCH ED, 1993, ANESTHESIOLOGY, V79, P795, DOI 10.1097/00000542-199310000-00023; KHARASCH ED, 1995, ANESTHESIOLOGY, V82, P1379, DOI 10.1097/00000542-199506000-00009; KHARASCH ED, 1994, CLIN PHARMACOL THER, V55, P434, DOI 10.1038/clpt.1994.53; KHARASCH ED, 1993, CLIN PHARMACOL THER, V53, P643, DOI 10.1038/clpt.1993.85; KNIGHTS KM, 1987, BIOCHEM PHARMACOL, V36, P897, DOI 10.1016/0006-2952(87)90182-1; KOOP DR, 1990, BIOESSAYS, V12, P429, DOI 10.1002/bies.950120906; LOESCH J, 1987, PHARMACOL RES, V19, P395, DOI 10.1016/0031-6989(87)90079-8; NEWTON DJ, 1995, DRUG METAB DISPOS, V23, P154; OSHEA D, 1994, CLIN PHARMACOL THER, V56, P359, DOI 10.1038/clpt.1994.150; POHL LR, 1989, DRUG METAB REV, V20, P203, DOI 10.3109/03602538909103537; RAY DC, 1989, BRIT J ANAESTH, V63, P531, DOI 10.1093/bja/63.5.531; RAY DC, 1991, BRIT J ANAESTH, V67, P84, DOI 10.1093/bja/67.1.84; RICE SA, 1987, TOXICOL APPL PHARM, V87, P411, DOI 10.1016/0041-008X(87)90246-8; SAKAGUCHI Y, 1994, CAN J ANAESTH, V41, P398, DOI 10.1007/BF03009862; THUMMEL KE, 1993, DRUG METAB DISPOS, V21, P350; URBAN G, 1994, CHEM RES TOXICOL, V7, P170, DOI 10.1021/tx00038a009; WOOD M, 1986, ANESTH ANALG, V65, P481; YAMAZAKI H, 1992, CARCINOGENESIS, V13, P1789, DOI 10.1093/carcin/13.10.1789; YOUNG SR, 1975, ANESTHESIOLOGY, V42, P451, DOI 10.1097/00000542-197504000-00015	30	79	82	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1367	1371		10.1016/S0140-6736(96)91011-9	http://dx.doi.org/10.1016/S0140-6736(96)91011-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637342				2022-12-28	WOS:A1996UL90400010
J	Naylor, CD; McLellan, BA				Naylor, CD; McLellan, BA			Air ambulances: Missions of mercy or flights of futility?	LANCET			English	Editorial Material							IMPACT; TRAUMA		UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,REG TRAUMA PROGRAM,TORONTO,ON,CANADA; UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT SURG,TORONTO,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Naylor, CD (corresponding author), UNIV TORONTO,INST CLIN EVALUAT SCI,TORONTO,ON,CANADA.							BAXT WG, 1983, JAMA-J AM MED ASSOC, V249, P3047, DOI 10.1001/jama.249.22.3047; BAXT WG, 1987, JAMA-J AM MED ASSOC, V257, P3246, DOI 10.1001/jama.257.23.3246; NICHOLL JP, 1995, BRIT MED J, V311, P217, DOI 10.1136/bmj.311.6999.217; NICHOLL JP, 1995, INJURY, V25, P145; RHEE KJ, 1990, AVIAT SPACE ENVIR MD, V61, P750	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1348	1349						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637337				2022-12-28	WOS:A1996UL90400005
J	Wonderling, D; McDermott, C; Buxton, M; Kinmonth, AL; Pyke, S; Thompson, S; Wood, D				Wonderling, D; McDermott, C; Buxton, M; Kinmonth, AL; Pyke, S; Thompson, S; Wood, D			Costs and cost effectiveness of cardiovascular screening and intervention: The British family heart study	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure costs and cost effectiveness of the British family heart study cardiovascular screening and intervention programme. Design-Cost effectiveness analysis of randomised controlled trial. Clinical and resource use data taken from trial and unit cost data from external estimates. Setting-13 general practices across Britain. Subjects-4185 men aged 40-59 and their 2827 partners. Intervention-Nurse led programme using a family centred approach, with follow up according to degree of risk. Main outcome measures-Cost of the programme itself; overall short term cost to NHS; cost per 1% reduction in coronary risk at one year. Results-Estimated cost of putting the programme into practice for one year was pound 63 per person (95% confidence interval pound 60 to pound 65). The overall short term cost to the health service was pound 77 per man (pound 29 to pound 124) but only pound 13 per woman (-pound 48 to pound 74), owing to differences in utilisation of other health service resources. The cost per 1% reduction in risk was pound 5.08 per man (pound 5.92 including broader health service costs) and pound 5.78 per woman (pound 1.28 taking into account wider health service savings). Conclusions-The direct cost of the programme to a four partner practice of 7500 patients would be approximately pound 58 000. Annually, pound 8300 would currently be paid to a practice of this size working to the ma target on the health promotion bands, plus any additional reimbursement of practice staff salaries for which the practice qualified. The broader short term costs to the NHS may augment these costs for men but offset them considerably for women.	BRUNEL UNIV,HLTH ECON RES GRP,UXBRIDGE UB8 3PH,MIDDX,ENGLAND; UNIV SOUTHAMPTON,FAC MED,SOUTHALL SO16 5ST,MIDDX,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,MED STAT UNIT,LONDON WC1E 7HT,ENGLAND; NATL HEART & LUNG INST,DEPT CLIN EPIDEMIOL,LONDON SW3 6LY,ENGLAND	Brunel University; University of Southampton; University of London; London School of Hygiene & Tropical Medicine; Imperial College London				Wonderling, David/0000-0003-0315-6273				[Anonymous], 1995, COMP HLTH STAT; BRYAN S, 1995, J EPIDEMIOL COMMUN H, V49, P70, DOI 10.1136/jech.49.1.70; *CHAR I PUBL FIN A, 1994, HLTH DATABASE 994, V1; *DEP EMPL, 1994, 1994 DEP EMPL A; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Langham S, 1996, BRIT MED J, V312, P1265, DOI 10.1136/bmj.312.7041.1265; NETTEN A, 1994, UNIT COSTS COMMUNITY; *OFF POP CENS SURV, 1994, OPCS MON 1994; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; Wonderling D, 1996, BRIT MED J, V312, P1274, DOI 10.1136/bmj.312.7041.1274; 1994, BRIT MED J, V308, P313; 1995, BRIT MED J, V310, P1099; 1994, BR J GEN PRACT, V44, P62	13	40	40	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1269	1273		10.1136/bmj.312.7041.1269	http://dx.doi.org/10.1136/bmj.312.7041.1269			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634617	Green Published, Green Submitted			2022-12-28	WOS:A1996UM40400023
J	Wonderling, D; Langham, S; Buxton, M; Normand, C; McDermott, C				Wonderling, D; Langham, S; Buxton, M; Normand, C; McDermott, C			What can be concluded from the Oxcheck and British family heart studies: Commentary on cost effectiveness analyses	BRITISH MEDICAL JOURNAL			English	Article							INTERVENTIONS; DISEASE	Objectives-To provide a commentary on the economic evaluations of the Oxcheck and British family heart studies: direct comparison of their relative effectiveness and cost effectiveness; comparisons with other interventions; and consideration of problems encountered. Design-Modelling from cost and effectiveness data to estimates of cost per life year gained. Subjects-Middle aged men and women. Interventions-Screening for cardiovascular risk factors followed by appropriate lifestyle advice and drug intervention in general practice, and other primary coronary risk management strategies. Main outcome measures-Life years gained; cost per life year gained. Results-Depending on the assumed duration of risk reduction, the programme cost per discounted life year gained ranged from pound 34 800 for a 1 year duration to pound 1500 for 20 years for the British family heart study and from pound 29 300 to pound 900 for Oxcheck. These figures exclude broader net clinical and cost effects and longer term clinical and cost effects other than coronary mortality. Conclusions-Despite differences in underlying methods, the estimates in the two economic analyses of the studies can be directly compared. Neither study was large enough to provide precise estimates of the overall net cost. Modelling to cost per life year gained provides more readily interpretable measures. These estimates emphasise the importance of the relatively weak evidence on duration of effect. Only if the effect lasts at least five years is the Oxcheck programme likely to be cost effective. The effect must last for about 10 years to justify the extra cost associated with the British family heart study.	BRUNEL UNIV,HLTH ECON RES GRP,UXBRIDGE UB8 3PH,MIDDX,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND	Brunel University; University of London; London School of Hygiene & Tropical Medicine				Wonderling, David/0000-0003-0315-6273; Normand, Charles/0000-0002-0885-5754				Akehurst R, 1994, BR J MED EC, V7, P115; ASSMAN G, 1990, SOCIAL EC CONTEXTS C, P37; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; *DEP HLTH, 1994, ASS OPT CHD STROK TA; *DEP HLTH, 1995, POL APPR HLTH; *DEP HLTH EC OP RS, 1994, REG COST EFF STUD; DRUMMOND MF, 1993, MED DECIS MAKING, V13, P184, DOI 10.1177/0272989X9301300303; FIELD K, 1995, BRIT MED J, V310, P1109, DOI 10.1136/bmj.310.6987.1109; KRISTIANSEN IS, 1991, BRIT MED J, V302, P1119, DOI 10.1136/bmj.302.6785.1119; Langham S, 1996, BRIT MED J, V312, P1265, DOI 10.1136/bmj.312.7041.1265; MASON J, 1993, BRIT MED J, V306, P570, DOI 10.1136/bmj.306.6877.570; MAYNARD A, 1991, ECON J, V101, P1277, DOI 10.2307/2234443; NISSINEN A, 1986, MED CARE, V24, P767, DOI 10.1097/00005650-198608000-00012; *OFF HLTH EC, 1995, HLTH EC EV DAT COMP; *OFF POP CENS SURV, 1991, 1991 OFF POP CEN DH2; *ORG EC COOP DEV, 1995, OECD HLTH DAT EC OCD; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; RECKLESS JPD, 1990, SOCIAL EC CONTEXTS C, P94; STOTT N, 1994, BRIT MED J, V308, P285, DOI 10.1136/bmj.308.6924.285; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; Wonderling D, 1996, BRIT MED J, V312, P1269, DOI 10.1136/bmj.312.7041.1269; 1994, BRIT MED J, V308, P313; 1995, BRIT MED J, V310, P1099; 1994, BRIT MED J, V308, P308	25	53	53	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 18	1996	312	7041					1274	1278		10.1136/bmj.312.7041.1274	http://dx.doi.org/10.1136/bmj.312.7041.1274			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM404	8634618	Green Published			2022-12-28	WOS:A1996UM40400024
J	Rosano, GMC; Leonardo, F; Sarrel, PM; Beale, CM; DeLuca, F; Collins, P				Rosano, GMC; Leonardo, F; Sarrel, PM; Beale, CM; DeLuca, F; Collins, P			Cyclical variation in paroxysmal supraventricular tachycardia in women	LANCET			English	Article							MENSTRUAL-CYCLE; NOREPINEPHRINE; ESTRADIOL; ESTROGEN	Background Paroxysmal supraventricular tachycardia (SVT) in premenopausal women is often judged to be related to anxiety, and may be associated with the menstrual cycle. The aim of this study was to determine whether a cyclical variation of episodes of SVT exists and to correlate such variation with cyclical variation in plasma ovarian hormones. Methods 26 women (mean age 36 [SD 8]) years; with paroxysmal SVT were screened; those with regular menses who experienced at least three episodes of paroxysmal SVT in two consecutive 48-hour ambulatory ECG recordings were included. 13 patients (aged 32 [6] years) met these criteria. Patients underwent 48-hour ambulatory ECG monitoring and determination of plasma concentrations of oestradiol-17 beta and progesterone on day 7, 14, 21, and 28 of their menstrual cycle. Findings An increase in the number and duration of episodes of paroxysmal SVT was observed on day 28 as compared to day 7 of the menstrual cycle. A significant positive correlation was found between plasma progesterone and number of episodes and duration of SVT (5.6 [2.2] ng/mL; r=0.83, p=0.0004; and r=0.82, p=0.0005), while a significant inverse correlation was found between plasma oestradiol-17 beta and number of episodes and duration of SVT (155 [22] pg/mL; r=-0.89, p<0.0001; acid r=-0.81, p=0.0007). Interpretation Women with paroxysmal SVT and normal menses exhibit a cyclical Variation in the occurrence of the arrhythmia with their menstrual cycle. There is a close correlation between the episodes of paroxysmal SVT and the plasma concentrations of ovarian hormones. These data suggest that changes in plasma levels of ovarian hormones (and their interaction) may be of importance in determining episodes of arrhythmia in such patients. The mechanisms of these effects are unknown.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,NATL HEART & LUNG INST,DIV CARDIAC MED,LONDON SW3 6LY,ENGLAND; IST H SAN RAFFAELE,ROME,ITALY; UNIV REGGIO CALABRIA,I-89100 REGGIO CALABRIA,ITALY; YALE UNIV,SCH MED,NEW HAVEN,CT	Imperial College London; Universita Mediterranea di Reggio Calabria; Yale University			Rosano, Giuseppe M. C./K-8718-2018	Rosano, Giuseppe M. C./0000-0003-4023-2263; Webb, Carolyn/0000-0002-2538-6953				ASSO D, 1982, BIOL PSYCHOL, V15, P95, DOI 10.1016/0301-0511(82)90034-5; BADANO AR, 1978, AM J OBSTET GYNECOL, V131, P299, DOI 10.1016/0002-9378(78)90605-1; BALL P, 1972, J CLIN ENDOCR METAB, V34, P736, DOI 10.1210/jcem-34-4-736; CARR BR, 1991, HARRISONS PRINCIPLES, P1776; COLLINS A, 1985, PSYCHOSOM MED, V47, P512, DOI 10.1097/00006842-198511000-00002; COLLINS P, 1993, LANCET, V341, P1264, DOI 10.1016/0140-6736(93)91158-I; DAVIDSON L, 1985, CLIN EXP PHARMACOL P, V12, P489, DOI 10.1111/j.1440-1681.1985.tb00899.x; DU XJ, 1995, CARDIOVASC RES, V30, P161, DOI 10.1016/S0008-6363(95)00030-5; HAMLET MA, 1980, AM J PHYSIOL, V239, pH450, DOI 10.1152/ajpheart.1980.239.4.H450; HAN SZ, 1995, CIRCULATION, V91, P2619, DOI 10.1161/01.CIR.91.10.2619; HARDER DR, 1979, J CELL PHYSIOL, V100, P375, DOI 10.1002/jcp.1041000218; JIANG C, 1992, BRIT J PHARMACOL, V106, P739, DOI 10.1111/j.1476-5381.1992.tb14403.x; KENSHALO DR, 1966, J APPL PHYSIOL, V21, P1031, DOI 10.1152/jappl.1966.21.3.1031; KRONENBERG F, 1984, MATURITAS, V6, P31, DOI 10.1016/0378-5122(84)90063-X; LOWN B, 1971, CIRCULATION, V44, P130, DOI 10.1161/01.CIR.44.1.130; MANFREDINI R, 1995, CHRONOBIOL INT, V12, P55, DOI 10.3109/07420529509064500; Reid R L, 1983, Clin Obstet Gynecol, V26, P710, DOI 10.1097/00003081-198309000-00019; SARREL PM, 1990, MATURITAS, V12, P287, DOI 10.1016/0378-5122(90)90008-T; WEINER JS, 1962, FED PROC, V21, P184	19	103	107	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					786	788		10.1016/S0140-6736(96)90867-3	http://dx.doi.org/10.1016/S0140-6736(96)90867-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622333	hybrid			2022-12-28	WOS:A1996UB15300008
J	Ikeda, SR				Ikeda, SR			Voltage-dependent modulation of N-type calcium channels by G-protein beta gamma subunits	NATURE			English	Article							RAT SYMPATHETIC NEURONS; CA2+ CHANNELS; BINDING; INHIBITION; MUTATIONS; CURRENTS	THE most commonly used signal transduction pathway for receptor-mediated N-type Ca2+-channel modulation involves activation of a heterotrimeric G protein to produce voltage-dependent inhibition(1). Although it is widely assumed that G alpha mediates this effect, experiments to address this hypothesis directly are lacking. Here I show that transient overexpression of G beta gamma in sympathetic neurons mimics and occludes the voltage-dependent Ca2+ channel modulation produced by noradrenaline (NA). Conversely, overexpression of G alpha produces minimal effects on basal Ca2+ channel behaviour but attenuates NA-mediated inhibition in a manner consistent with the buffering of G beta gamma. These observations indicate that it is G beta gamma, and not G alpha, that mediates voltage-dependent inhibition of N-type Ca2+ channels. The identification of G beta gamma as the mediator of this pathway has broad implications as G-protein-coupled receptors, many of which are implicated in disease or are targets of therapeutic agents, couple to N-type Ca2+ channels(2) and may modulate synaptic transmission by this mechanism(3,4).			Ikeda, SR (corresponding author), MED COLL GEORGIA, DEPT PHARMACOL & TOXICOL, AUGUSTA, GA 30912 USA.			Ikeda, Stephen/0000-0002-4088-9508				ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; Bourinet E., 1995, Society for Neuroscience Abstracts, V21, P515; CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; HELM R, 1995, NATURE, V373, P663; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; IKEDA SR, 1995, NEURON, V14, P1029, DOI 10.1016/0896-6273(95)90341-0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MULLER S, 1995, BIOCHEM SOC T, V23, P141; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; ROCHE JP, 1995, FEBS LETT, V371, P43, DOI 10.1016/0014-5793(95)00860-C; SCHOFIELD GG, 1990, EUR J PHARMACOL, V180, P37, DOI 10.1016/0014-2999(90)90590-3; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; ZHU Y, 1994, NEURON, V13, P657, DOI 10.1016/0896-6273(94)90033-7	30	652	663	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 21	1996	380	6571					255	258		10.1038/380255a0	http://dx.doi.org/10.1038/380255a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637575				2022-12-28	WOS:A1996UB11700054
J	Amon, A				Amon, A			Mother and daughter are doing fine: Asymmetric cell division in yeast	CELL			English	Review							CYCLE				Amon, A (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE CTR 9,CAMBRIDGE,MA 02144, USA.			Amon, Angelika/0000-0001-9837-0314				CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HERSKOWITZ I, 1992, TRANSCRIPTIONAL REGU, P949; KENYON C, 1995, CELL, V82, P297; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LEHMANN R, 1995, CELL, V83, P353, DOI 10.1016/0092-8674(95)90111-6; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; SHAPIRO L, 1993, CELL, V73, P841, DOI 10.1016/0092-8674(93)90266-S; STJOHNSTON D, 1995, CELL, V81, P567; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517	17	25	25	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 8	1996	84	5					651	654		10.1016/S0092-8674(00)81041-7	http://dx.doi.org/10.1016/S0092-8674(00)81041-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TZ990	8625401	Bronze			2022-12-28	WOS:A1996TZ99000001
J	Denollet, J; Sys, SU; Stroobant, N; Rombouts, H; Gillebert, TC; Brutsaert, DL				Denollet, J; Sys, SU; Stroobant, N; Rombouts, H; Gillebert, TC; Brutsaert, DL			Personality as independent predictor of long-term mortality in patients with coronary heart disease	LANCET			English	Article							MYOCARDIAL-INFARCTION; ARTERY DISEASE; MENTAL STRESS; A BEHAVIOR; SURVIVAL; SUPPORT	Background Emotional distress has been related to mortality in patients with coronary heart disease (CHD), but little is known about the role of personality in long-term prognosis. We postulated that type-D personality (the tendency to suppress emotional distress) was a predictor of long-term mortality in CHD, independently of established biomedical risk factors. Methods We studied 268 men and 35 women with angiographically documented CHD, aged 31-79 years, who were taking part in an outpatient rehabilitation programme. All patients completed personality questionnaires at entry to the programme. We contacted them 6-10 years later (mean 7.9) to find out survival status. The main endpoint was death from all causes. Findings At follow-up, 38 patients had died; there were 24 cardiac deaths. The rate of death was higher for type-D patients than for those without type-D (23 [27%]/85 vs 15 [7%]/218; p<0.00001). The association between type-D personality and mortality was still evident more than 5 years after the coronary event and was found in both men and women. Mortality was also associated with impaired left ventricular function, three-vessel disease, low exercise tolerance, and the lack of thrombolytic therapy after myocardial When we for these biomedical in multiple regression analysis, the impact of type-D remained significant (odds ratio 4.1 [95% CI 1.9-8.8]; p=0.0004). In this group of CHD patients, type-D was an independent predictor of both cardiac and non-cardiac mortality. Social alienation and depression were also related to mortality, but did not add to the predictive power of type-D. Interpretation We found that type-D personality was a significant predictor of long-term mortality in patients with established CHD, independently of biomedical risk factors. Personality traits should be taken into account in the association between emotional distress and mortality in CHD.	UNIV ANTWERP,DEPT PHYSIOL & MED,B-2020 ANTWERP,BELGIUM; STATE UNIV GHENT,DEPT PSYCHOL,B-9000 GHENT,BELGIUM; UNIV HOSP,ANTWERP,BELGIUM	University of Antwerp; Ghent University			Gillebert, Thierry C/F-5551-2014	Gillebert, Thierry C/0000-0002-3832-919X				Asendorpf JB, 1993, EMOTION INHIBITION H, P80; BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003; BLUMENTHAL JA, 1987, PSYCHOSOM MED, V49, P331, DOI 10.1097/00006842-198707000-00002; BOUCHARD TJ, 1994, SCIENCE, V264, P1700, DOI 10.1126/science.8209250; CARNEY RM, 1988, J PSYCHOSOM RES, V32, P159, DOI 10.1016/0022-3999(88)90050-5; DEFEYTER PJ, 1982, CIRCULATION, V66, P527, DOI 10.1161/01.CIR.66.3.527; DENOLLET J, 1995, PSYCHOSOM MED, V57, P582, DOI 10.1097/00006842-199511000-00011; DENOLLET J, 1992, PSYCHOL MED, V22, P667, DOI 10.1017/S0033291700038113; DENOLLET J, 1991, PSYCHOSOM MED, V53, P538, DOI 10.1097/00006842-199109000-00005; DENOLLET J, 1995, EUR HEART J, V16, P1070, DOI 10.1093/oxfordjournals.eurheartj.a061049; DIMSDALE JE, 1988, NEW ENGL J MED, V318, P110, DOI 10.1056/NEJM198801143180209; EMOND M, 1994, CIRCULATION, V90, P2645, DOI 10.1161/01.CIR.90.6.2645; ERDMAN RAM, 1986, J CARDIOPULM REHABIL, V6, P206, DOI DOI 10.1097/00008483-198606000-00001; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; FRIEDMAN HS, 1995, AM PSYCHOL, V50, P69, DOI 10.1037/0003-066X.50.2.69; GOTTDIENER JS, 1994, J AM COLL CARDIOL, V24, P1645, DOI 10.1016/0735-1097(94)90169-4; GOTTLIEB S, 1994, AM J CARDIOL, V74, P727, DOI 10.1016/0002-9149(94)90319-0; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; KATSUYA T, 1995, LANCET, V345, P1600, DOI 10.1016/S0140-6736(95)90115-9; KOP WJ, 1994, PSYCHOSOM MED, V56, P281, DOI 10.1097/00006842-199407000-00001; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MALKOFF SB, 1993, PSYCHOSOM MED, V55, P477, DOI 10.1097/00006842-199311000-00001; MILLON T, 1982, MILLON BEHAVIORAL HL; Pennebaker J.W., 1993, EMOTION INHIBITION H, P146; PHILLIPS DP, 1993, LANCET, V342, P1142, DOI 10.1016/0140-6736(93)92124-C; POWELL LH, 1993, PSYCHOSOM MED, V55, P426, DOI 10.1097/00006842-199309000-00005; ROTER DL, 1992, HEALTH PSYCHOL, V11, P163, DOI 10.1037/0278-6133.11.3.163; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; VANDERPLOEG HM, 1980, ZBV EEN NEDERLANDSTA; YEUNG AC, 1991, NEW ENGL J MED, V325, P1551, DOI 10.1056/NEJM199111283252205	30	483	509	2	63	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					417	421		10.1016/S0140-6736(96)90007-0	http://dx.doi.org/10.1016/S0140-6736(96)90007-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV722	8618481				2022-12-28	WOS:A1996TV72200007
J	Jeffcoate, W				Jeffcoate, W			Making sense	LANCET			English	Editorial Material											Jeffcoate, W (corresponding author), NOTTINGHAM CITY HOSP NHS TRUST,DEPT ENDOCRINOL & DIABET,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.							ASHER R, 1959, LANCET, V2, P359; ASHER R, 1972, TALKING SENSE, P20	2	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					451	452		10.1016/S0140-6736(96)90018-5	http://dx.doi.org/10.1016/S0140-6736(96)90018-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618491				2022-12-28	WOS:A1996TV72200017
J	Iglehart, JK				Iglehart, JK			The quandary over graduates of foreign medical schools in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*COUNC GRAD MED ED, 1994, 4 REP REC IMPR ACC H; *CTR HLTH PROF U C, 1995, 3 REP PEW HLTH PROF; FEIN EB, 1996, NY TIMES        0502, pB4; Fein Esther B, 1996, N Y Times Web, pB5; Glanz J, 1996, SCIENCE, V272, P190, DOI 10.1126/science.272.5259.190; Iglehart JK, 1996, NEW ENGL J MED, V334, P1071, DOI 10.1056/NEJM199604183341621; IGLEHART JK, 1985, NEW ENGL J MED, V313, P831, DOI 10.1056/NEJM198509263131325; LEE PR, 1996, PAL ALT MED FDN ANN; Levine FJ, 1996, SCIENCE, V271, P1649, DOI 10.1126/science.271.5256.1649; LOHR KN, 1996, NATIONS PHYSICIAN WO; MITKA M, 1996, AM MED NEWS     0306, P6; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; Mullan F, 1996, HEALTH AFFAIR, V15, P250, DOI 10.1377/hlthaff.15.2.250; *PHYS PAYM REV COM, 1994, ANN REP C 1994; Schroeder SA, 1996, NEW ENGL J MED, V334, P1130, DOI 10.1056/NEJM199604253341713; SHINE KI, 1995, JAMA-J AM MED ASSOC, V273, P1057, DOI 10.1001/jama.273.13.1057; WHITCOMB ME, 1995, JAMA-J AM MED ASSOC, V274, P696, DOI 10.1001/jama.274.9.696	17	28	28	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1996	334	25					1679	1683		10.1056/NEJM199606203342521	http://dx.doi.org/10.1056/NEJM199606203342521			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ706	8628378				2022-12-28	WOS:A1996UQ70600027
J	Landesman, SH; Kalish, LA; Burns, DN; Minkoff, H; Fox, HE; Zorrilla, C; Garcia, P; Fowler, MG; Mofenson, L; Tuomala, R				Landesman, SH; Kalish, LA; Burns, DN; Minkoff, H; Fox, HE; Zorrilla, C; Garcia, P; Fowler, MG; Mofenson, L; Tuomala, R			Obstetrical factors and the transmission of human immunodeficiency virus type I from mother to child	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TO-INFANT TRANSMISSION; MONONUCLEAR CELL COCULTURES; HIV-INFECTION; VERTICAL TRANSMISSION; SEROPOSITIVE WOMEN; CD4 PERCENTAGE; REPLICATION; RISK; SECRETIONS; COCAINE	Background, A substantial proportion of perinatally acquired infections with the human immunodeficiency virus type 1 (HIV-1) occur at or near delivery, which suggests that obstetrical factors may have an important influence on transmission, We evaluated the relation of such factors and other variables to the perinatal transmission of HIV-1. Methods. The Women and Infants Transmission Study is a prospective, observational study of HIV-1-infected women who were enrolled during pregnancy and followed with their infants for three years after delivery, We studied obstetrical, clinical, immunologic, and virologic data on 525 women who delivered live singleton infants whose HIV-1-infection status was known as of August 31, 1994. Results. Among mothers with membranes that ruptured more than four hours before delivery, the rate of transmission of HIV-1 to the infants was 25 percent, as compared with 14 percent among mothers with membranes that ruptured four hours or less before delivery, In a multivariate analysis, the presence of ruptured membranes for more than four hours nearly doubled the risk of transmission (odds ratio, 1.82; 95 percent confidence interval, 1.10 to 3.00; P = 0.02), regardless of the mode of delivery, The other maternal factors independently associated with transmission were illicit-drug use during pregnancy (odds ratio, 1.90; 95 percent confidence interval, 1.14 to 3.16; P = 0.01), low antenatal CD4+ lymphocyte count (<29 percent of total lymphocytes) (odds ratio, 2.82; 1.67 to 4.76; P<0.001), and birth weight <2500 g (odds ratio, 1.86; 1.03 to 3.34; P = 0.04), Conclusions. The risk of transmission of HIV-1 from mother to infant increases when the fetal membranes rupture more than four hours before delivery.	SUNY HLTH SCI CTR,DEPT OBSTET & GYNECOL,DIV MATERNAL FETAL MED,BROOKLYN,NY 11203; NEW ENGLAND RES INST,WATERTOWN,MA 02172; NICHHD,PEDIAT ADOLESCENT & MATERNAL AIDS BRANCH,BETHESDA,MD 20892; GEORGE WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,WASHINGTON,DC; UNIV PUERTO RICO,DEPT OBSTET & GYNECOL,SAN JUAN,PR 00936; NORTHWESTERN UNIV,SCH MED,DEPT OBSTET & GYNECOL,CHICAGO,IL 60611; NIAID,VACCINE TRIALS & EPIDEMIOL BRANCH,BETHESDA,MD 20892; BRIGHAM & WOMENS HOSP,DEPT OBSTET & GYNECOL,BOSTON,MA 02115	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; HealthCore, Inc; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); George Washington University; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Brigham & Women's Hospital	Landesman, SH (corresponding author), SUNY HLTH SCI CTR,DEPT MED,DIV INFECT DIS,450 CLARKSON AVE,BOX 122,BROOKLYN,NY 11203, USA.		Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808	NIAID NIH HHS [AI-82505, AI-82506, AI-82507] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI082507, N01AI082505, N01AI082506] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS EJ, 1995, PEDIATRICS, V96, P451; Agresti A., 1990, CATEGORICAL DATA ANA, pXV; BAGASRA O, 1993, J INFECT DIS, V168, P1157, DOI 10.1093/infdis/168.5.1157; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; BURGARD M, 1992, NEW ENGL J MED, V327, P1192, DOI 10.1056/NEJM199210223271702; BURNS DN, 1994, J ACQ IMMUN DEF SYND, V7, P718; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; DEVASH Y, 1991, P NATL ACAD SCI USA, V88, P1084, DOI 10.1073/pnas.88.3.1084a; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; DULIEGE AM, 1995, J PEDIATR-US, V126, P625, DOI 10.1016/S0022-3476(95)70365-9; DUNN DT, 1994, J ACQ IMMUN DEF SYND, V7, P1064; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; GABIANO C, 1992, PEDIATRICS, V90, P362; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, LANCET, V2, P1351; HALSEY NA, 1992, J ACQ IMMUN DEF SYND, V5, P153; HENIN Y, 1993, J ACQ IMMUN DEF SYND, V6, P72; HOLLINGER FB, 1992, J CLIN MICROBIOL, V30, P1787, DOI 10.1128/JCM.30.7.1787-1794.1992; HOLLINGER FB, 1992, 8 INT C AIDS 3 STD W, V1, P23; HOSMER DW, 1989, APPL LOGISTIC REGRES; KIDD PG, 1993, AIDS, V7, P933, DOI 10.1097/00002030-199307000-00005; KRIVINE A, 1992, LANCET, V339, P1187, DOI 10.1016/0140-6736(92)91131-Q; KUHN L, 1994, AM J PUBLIC HEALTH, V84, P1110, DOI 10.2105/AJPH.84.7.1110; LALLEMANT M, 1994, LANCET, V343, P1001, DOI 10.1016/S0140-6736(94)90126-0; LEPAGE P, 1993, AM J EPIDEMIOL, V137, P589, DOI 10.1093/oxfordjournals.aje.a116716; LEPAGE P, 1992, AIDS, V6, P882, DOI 10.1097/00002030-199208000-00021; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; MAYAUX MJ, 1995, J ACQ IMMUN DEF SYND, V8, P188; MCINTOSH K, 1994, J INFECT DIS, V170, P996, DOI 10.1093/infdis/170.4.996; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MINKOFF H, 1994, AM J OBSTET GYNECOL, V171, P1167, DOI 10.1016/0002-9378(94)90127-9; MINKOFF II, 1995, AM J OBSTET GYNECOL, V173, P585; MOFENSON LM, 1995, PEDIATR INFECT DIS J, V14, P169, DOI 10.1097/00006454-199503000-00001; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; NAIR P, 1993, J ACQ IMMUN DEF SYND, V6, P298; NESHEIM SR, 1994, AIDS, V8, P1293, DOI 10.1097/00002030-199409000-00012; PETERSON PK, 1991, J IMMUNOL, V146, P81; PETERSON PK, 1990, AIDS, V4, P869, DOI 10.1097/00002030-199009000-00006; Rodriguez EM, 1996, AIDS, V10, P273, DOI 10.1097/00002030-199603000-00006; RODRIGUEZ EM, 1991, PEDIATR AIDS HIV INF, V3, P107; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROGERS MF, 1991, PEDIATR INFECT DIS J, V10, P523, DOI 10.1097/00006454-199107000-00009; ROSSI P, 1990, LANCET, V335, P359, DOI 10.1016/0140-6736(90)90651-K; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SACHS BP, 1983, JAMA-J AM MED ASSOC, V250, P2157, DOI 10.1001/jama.250.16.2157; SCHAFER DF, 1982, NEW ENGL J MED, V307, P1582; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; TALLON DF, 1984, J IMMUNOL, V132, P1784; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; VILLARI P, 1993, ONLINE J CURR C 0708; 1994, BRIT J OBSTET GYNAEC, V101, P136; 1994, MMWR-MORBID MORTAL W, V43, P1; 1992, LANCET, V339, P1007; 1994, LANCET, V343, P1464	59	297	316	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1996	334	25					1617	1623		10.1056/NEJM199606203342501	http://dx.doi.org/10.1056/NEJM199606203342501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ706	8628356				2022-12-28	WOS:A1996UQ70600001
J	Rosen, SD; Paulesu, E; Nihoyannopoulos, P; Tousoulis, D; Frackowiak, RSJ; Frith, CD; Jones, T; Camici, PG				Rosen, SD; Paulesu, E; Nihoyannopoulos, P; Tousoulis, D; Frackowiak, RSJ; Frith, CD; Jones, T; Camici, PG			Silent ischemia as a central problem: Regional brain activation compared in silent and painful myocardial ischemia	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial ischemia; coronary disease; angina pectoris; central nervous system; ischemia, silent	CORONARY-ARTERY DISEASE; EXERCISE-INDUCED ANGINA; STABLE ANGINA; CORTEX; SYMPTOMS; RAT; LOCALIZATION; INFARCTION; MECHANISMS; PECTORIS	Objective: To test whether the silence of painless myocardial ischemia is caused by abnormal handling by the central nervous system of afferent messages from the heart. Design: Nonrandomized study. Setting: A tertiary referral center (postgraduate medical school). Patients: 2 matched groups of nondiabetic patients with coronary artery disease. Group A consisted of nine patients with reproducible stress-induced angina; group B consisted of nine patients with reproducible stress-induced myocardial ischemia but no angina. Interventions: Intravenous placebo infusion and low-dose (5 and 10 mu g/kg per minute) and high-dose (20 to 35 mu g/kg per minute) dobutamine infusions. Measurements: Positron emission tomography was used to measure regional cerebral blood flow changes as an index of neuronal activation during painful arid silent myocardial ischemia induced by intravenous dobutamine. Results: Regional cerebral blood flow changes during myocardial ischemia were compared with those during baseline conditions and during placebo infusion. During myocardial ischemia, regional cerebral blood flow increased bilaterally in the thalami and prefrontal, basal frontal, and ventral cingulate cortices in patients in group A. Both thalami were activated in group B, but cortical activation was limited to the right frontal region. A formal comparison of groups A and B showed significant differences (P < 0.01) in activation of the basal frontal cortex, ventral cingulate cortex, and left temporal pole. In both groups, thalamic regional cerebral blood flow remained increased after the symptoms and signs of ischemia had ceased. Conclusions: Bilateral activation of the thalamus can be shown in both angina and silent ischemia; thus, peripheral nerve dysfunction cannot completely explain silent ischemia. Frontal cortical activation appears to be necessary for the sensation of pain. Abnormal central processing of afferent pain messages from the heart may play a determining role in silent myocardial ischemia.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, LONDON W12 0NN, ENGLAND; UNIV MILAN, INB CNR, IST SCI H SAN RAFFAELE, MILAN, ITALY; HAMMERSMITH HOSP, DIV MED, LONDON W12 0NN, ENGLAND; NEUROL INST, WELLCOME DEPT COGNITI NEUROL, LONDON WC1N 3BG, ENGLAND	Imperial College London; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Imperial College London; University of London; University College London	Rosen, SD (corresponding author), HAMMERSMITH HOSP, MRC, CTR CLIN SCI, CYCLOTRON UNIT, DU CANE RD, LONDON W12 0NN, ENGLAND.		Camici, Paolo/AAN-1959-2020; Rosen, Stuart/AAE-4649-2020; Frith, Chris D/A-2171-2009; Frackowiak, Richard/H-4383-2011; Frackowiak, Richard S/I-1809-2013; PAULESU, ERALDO/C-2737-2017	Camici, Paolo/0000-0001-5584-0750; Frith, Chris D/0000-0002-8665-0690; Frackowiak, Richard/0000-0002-3151-822X; PAULESU, ERALDO/0000-0002-9224-754X				AHN J, 1994, CIRCULATION, V90, P57; [Anonymous], 1993, NEUROBIOLOGY CINGULA; Babey AM, 1939, NEW ENGL J MED, V220, P410, DOI 10.1056/NEJM193903092201002; BARSKY AJ, 1990, JAMA-J AM MED ASSOC, V264, P1132, DOI 10.1001/jama.264.9.1132; CAMICI P, 1986, CIRCULATION, V74, P81, DOI 10.1161/01.CIR.74.1.81; CHANNER KS, 1994, LANCET, V344, P964, DOI 10.1016/S0140-6736(94)92326-4; CHIERCHIA S, 1983, J AM COLL CARDIOL, V1, P924, DOI 10.1016/S0735-1097(83)80211-3; CRONIN CC, 1994, LANCET, V344, P965; DEANFIELD JE, 1983, LANCET, V2, P753; DROSTE C, 1990, ADV CARDIOL, V37, P142; ELLESTAD MH, 1984, AM J CARDIOL, V54, P982, DOI 10.1016/S0002-9149(84)80129-0; EPSTEIN SE, 1988, NEW ENGL J MED, V318, P1038, DOI 10.1056/NEJM198804213181606; FALCONE C, 1988, J AM COLL CARDIOL, V11, P719, DOI 10.1016/0735-1097(88)90202-1; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; FRISTON KJ, 1991, BRAIN WORK MENTAL AC, P267; GLAZIER JJ, 1986, AM J CARDIOL, V58, P667, DOI 10.1016/0002-9149(86)90335-8; GOTTLIEB SO, 1988, JAMA-J AM MED ASSOC, V259, P1030, DOI 10.1001/jama.259.7.1030; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; Heberden W., 1772, MED T COLL PHYSICIAN, V2, P59; HELLER GV, 1987, AM J CARDIOL, V59, P735, DOI 10.1016/0002-9149(87)91083-6; HONG RA, 1987, JAMA-J AM MED ASSOC, V257, P1937, DOI 10.1001/jama.257.14.1937; HURLEY KM, 1991, J COMP NEUROL, V308, P249, DOI 10.1002/cne.903080210; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KLEIN J, 1994, CIRCULATION, V89, P1958; LANGER A, 1991, AM J CARDIOL, V67, P1073, DOI 10.1016/0002-9149(91)90868-L; MALLIANI A, 1989, TXB PAIN, P128; MALLIANI A, 1987, SILENT ISCHEMIA CURR, P19; MATA M, 1980, J NEUROCHEM, V34, P213, DOI 10.1111/j.1471-4159.1980.tb04643.x; MELLER ST, 1992, NEUROSCIENCE, V48, P501, DOI 10.1016/0306-4522(92)90398-L; OPIE LH, 1991, DRUGS HEART, P143; QUYYUMI AA, 1985, BRIT HEART J, V53, P186; RAICHLE ME, 1987, NERVOUS SYSTEM HIGHE, P643; ROSEN SD, 1994, LANCET, V344, P147, DOI 10.1016/S0140-6736(94)92755-3; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; SHAKESPEARE CF, 1994, BRIT HEART J, V71, P22; SHEPS DS, 1990, AM HEART J, V119, P983, DOI 10.1016/S0002-8703(05)80351-5; SPINKS TJ, 1992, PHYS MED BIOL, V37, P1637, DOI 10.1088/0031-9155/37/8/002; TAKAO Y, 1992, EUR J PHARMACOL, V215, P245, DOI 10.1016/0014-2999(92)90034-2; Talairach J., 1988, COPLANAR STEREOTAXIC; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; TERREBERRY RR, 1983, BRAIN RES, V278, P245, DOI 10.1016/0006-8993(83)90246-9; TZIVONI D, 1988, AM J CARDIOL, V62, P661, DOI 10.1016/0002-9149(88)91198-8; Van Hoesen G. W. M., 1993, NEUROBIOLOGY CINGULA, P249, DOI DOI 10.1007/978-1-4899-6704-6_9; VANRIJN T, 1986, LIFE SCI, V38, P609, DOI 10.1016/0024-3205(86)90054-8; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208; WALL PD, 1978, BRAIN, V101, P1, DOI 10.1093/brain/101.1.1; WARNES CA, 1984, AM J CARDIOL, V54, P65, DOI 10.1016/0002-9149(84)90305-9; Warren J., 1812, N ENGL J MED SURG, V1, P1; WHITE JC, 1957, CIRCULATION, V16, P644, DOI 10.1161/01.CIR.16.4.644; WOOLF CJ, 1983, NATURE, V306, P739, DOI 10.1038/306739a0	54	145	151	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1996	124	11					939	+		10.7326/0003-4819-124-11-199606010-00001	http://dx.doi.org/10.7326/0003-4819-124-11-199606010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL905	8624061				2022-12-28	WOS:A1996UL90500001
J	Ravindranath, Y; Yeager, AM; Chang, MN; Steuber, CP; Krischer, J; GrahamPole, J; Carroll, A; Inoue, S; Camitta, B; Weinstein, HJ				Ravindranath, Y; Yeager, AM; Chang, MN; Steuber, CP; Krischer, J; GrahamPole, J; Carroll, A; Inoue, S; Camitta, B; Weinstein, HJ			Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; PEDIATRIC-ONCOLOGY-GROUP; ACUTE NONLYMPHOBLASTIC LEUKEMIA; HIGH-DOSE CYTARABINE; 1ST REMISSION; MAINTENANCE THERAPY; PROGNOSTIC FACTORS; CHILDREN; INTENSIFICATION	Background. The value of autologous bone marrow transplantation in the treatment of children with acute myeloid leukemia (AML) is unknown. We compared autologous bone marrow transplantation with intensive consolidation chemotherapy as treatments for children with AML in first remission. Methods. We induced remission with one course of daunorubicin, cytarabine, and thioguanine, followed by one course of high-dose cytarabine (3 g per square meter of body-surface area for six doses), Patients in remission after the second course of induction therapy were eligible for randomization, Between June 1988 and March 1993, 552 of 649 enrolled patients who could be evaluated (85 percent) entered remission, A total of 209 patients were not eligible for randomization; of the remaining 343 patients, 232 were randomly assigned to receive six courses of intensive chemotherapy (117 patients) or autologous transplantation (115 patients), Of the original 649 patients, 189, including 21 with Down's syndrome, were nonrandomly assigned to receive intensive chemotherapy. Results, The mean (+/-SE) rates of event-free survival and overall survival for the entire group at three years were 34+/-2.5 percent and 42+/-2.6 percent, respectively, For patients who were randomly assigned to one of the two treatment groups, the rates of event-free survival three years after randomization were not significantly different in the two groups when examined by intention-to-treat analysis: 36+/-5.8 percent for the intensive-chemotherapy group as compared with 38+/-6.4 percent for the autologous-transplantation group; and the relative risk of treatment failure for the chemotherapy group as compared with the autologous-transplantation group was 0.81 (P=0.20 by the log-rank test; 95 percent confidence interval, 0.58 to 1.12), Overall survival at three years followed a similar pattern. There was a lower relapse rate (31 percent vs, 58 percent, P<0.001) but a higher rate of treatment-related mortality (15 percent vs, 2.7 percent, P=0.005) in the group treated with autologous transplantation than in the intensive-chemotherapy group. The event-free survival at three years for the nonrandomized intensive-chemotherapy group was 39+/-5.1 percent, and for a contemporaneous group of patients each of whom received a histocompatible bone marrow transplant from a sibling, it was 52+/-8.0 percent. Conclusions. Treatment of children with AML in first remission with either autologous bone marrow transplantation or intensive chemotherapy prolongs event-free survival equally. (C) 1996, Massachusetts Medical Society.	CHILDRENS HOSP MICHIGAN, BARBARA ANN KARMANOS CANC INST, DETROIT, MI 48201 USA; WAYNE STATE UNIV, DETROIT, MI USA; EMORY UNIV, ATLANTA, GA 30322 USA; PEDIAT ONCOL GRP, STAT OFF, GAINESVILLE, FL USA; UNIV FLORIDA, DEPT STAT, GAINESVILLE, FL 32611 USA; TEXAS CHILDRENS HOSP, BAYLOR COLL MED, HOUSTON, TX 77030 USA; H LEE MOFFIT CANC CTR & RES INST, TAMPA, FL USA; UNIV FLORIDA, SHANDS TEACHING HOSP, GAINESVILLE, FL USA; UNIV ALABAMA, BIRMINGHAM, AL USA; HURLEY MED CTR, FLINT, MI USA; MED COLL WISCONSIN, MIDWEST CHILDRENS CANC CTR, MILWAUKEE, WI 53226 USA; CHILDRENS HOSP WISCONSIN, MILWAUKEE, WI 53201 USA; DANA FARBER CANC INST, BOSTON, MA 02115 USA; CHILDRENS HOSP, BOSTON, MA 02115 USA	Barbara Ann Karmanos Cancer Institute; Children's Hospital of Michigan; Wayne State University; Emory University; State University System of Florida; University of Florida; Baylor College of Medicine; State University System of Florida; University of Florida; University of Alabama System; University of Alabama Birmingham; Medical College of Wisconsin; Children's Hospital of Wisconsin; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital			Krischer, Jeffrey P/I-5004-2012; Raimondi, Susana C/N-8166-2018; Warrier, Rajasekharan P/D-4512-2011		NATIONAL CANCER INSTITUTE [U10CA020549, U10CA029691, U10CA003161] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29691, CA-03161, CA-20549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMADORI S, 1993, J CLIN ONCOL, V11, P1046, DOI 10.1200/JCO.1993.11.6.1046; APPELBAUM FR, 1988, BLOOD, V72, P179; APPELBAUM FR, 1983, BLOOD, V61, P949; BOSTROM B, 1985, BLOOD, V65, P1191; BURNETT AK, 1984, LANCET, V2, P1068; CASSILETH PA, 1993, J CLIN ONCOL, V11, P314, DOI 10.1200/JCO.1993.11.2.314; COX DR, 1972, J R STAT SOC B, V34, P187; CREUTZIG U, 1995, BLOOD, V86, P3097; CREUTZIG U, 1985, BLOOD, V65, P298; GORIN NC, 1990, BLOOD, V75, P1606; GRAHAMPOLE J, 1989, LANCET, V2, P1517; GRIER HE, 1987, J CLIN ONCOL, V5, P1026, DOI 10.1200/JCO.1987.5.7.1026; HAKAMI N, 1987, J CLIN ONCOL, V5, P1022, DOI 10.1200/JCO.1987.5.7.1022; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWENBERG B, 1990, J CLIN ONCOL, V8, P287; MCMILLAN AK, 1990, BLOOD, V76, P480; NESBIT ME, 1994, J CLIN ONCOL, V12, P127, DOI 10.1200/JCO.1994.12.1.127; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RAVINDRANATH Y, 1991, J CLIN ONCOL, V9, P572, DOI 10.1200/JCO.1991.9.4.572; RAVINDRANATH Y, 1992, BLOOD, V80, P2210; REIFFERS J, 1989, BRIT J HAEMATOL, V72, P57, DOI 10.1111/j.1365-2141.1989.tb07652.x; SANDERS JE, 1985, BLOOD, V66, P460; SCHILLER GJ, 1992, J CLIN ONCOL, V10, P41, DOI 10.1200/JCO.1992.10.1.41; STEUBER CP, 1991, J CLIN ONCOL, V9, P247, DOI 10.1200/JCO.1991.9.2.247; STEVENS RF, 1994, MED PEDIATR ONCOL, V23, P172; WEINSTEIN HJ, 1983, BLOOD, V62, P315; WOODS WG, 1993, J CLIN ONCOL, V11, P1448, DOI 10.1200/JCO.1993.11.8.1448; WOODS WG, 1990, CANCER, V66, P1106, DOI 10.1002/1097-0142(19900915)66:6<1106::AID-CNCR2820660605>3.0.CO;2-Y; WOODS WG, 1994, BLOOD S1, V83, pA232; YEAGER AM, 1986, NEW ENGL J MED, V315, P141, DOI 10.1056/NEJM198607173150301; ZITTOUN RA, 1995, NEW ENGL J MED, V332, P217, DOI 10.1056/NEJM199501263320403	31	203	208	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1996	334	22					1428	1434		10.1056/NEJM199605303342203	http://dx.doi.org/10.1056/NEJM199605303342203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM493	8618581	Bronze			2022-12-28	WOS:A1996UM49300003
J	Oliveria, SA; Osborne, MP				Oliveria, SA; Osborne, MP			Diet, breast cancer, and case-control studies	LANCET			English	Editorial Material									CORNELL UNIV,MED CTR,NEW YORK,NY 10021	Cornell University	Oliveria, SA (corresponding author), STRANG CANC PREVENT CTR,NEW YORK,NY, USA.							Rothman K, 1986, MODERN EPIDEMIOLOGY; Walker AM, 1991, OBSERVATION INFERENC; Willett W., 1990, NUTR EPIDEMIOLOGY	3	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 18	1996	347	9012					1346	1346		10.1016/S0140-6736(96)91003-X	http://dx.doi.org/10.1016/S0140-6736(96)91003-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL904	8637334				2022-12-28	WOS:A1996UL90400002
J	Miles, MM; Shaw, RJ				Miles, MM; Shaw, RJ			Effect of inadvertent intradermal administration of high close percutaneous BCG vaccine (vol 312, pg 1014, 1996)	BRITISH MEDICAL JOURNAL			English	Correction, Addition									ST MARYS HOSP,CHEST & ALLERY CLIN,LONDON W2 1NY,ENGLAND	Imperial College London	Miles, MM (corresponding author), PARKSIDE HLTH COMMUNITY TRUST,LONDON W9 3XZ,ENGLAND.							*DEP HLTH, 1992, IMM INF DIS, P76; HALL C, 1994, INDEPENDENT     1125, P4; Miles MM, 1996, BRIT MED J, V312, P1014; 1990, BRIT MED J, V300, P995	4	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1205	1205						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634566				2022-12-28	WOS:A1996UL05800023
J	Steinman, L				Steinman, L			Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system	CELL			English	Review							BASIC-PROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; DISEASE; INTERFERON; PEPTIDE; IMMUNE; GENE		STANFORD UNIV,SCH MED,BECKMAN CTR MOL & GENET MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305	Stanford University	Steinman, L (corresponding author), WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL.			Steinman, Lawrence/0000-0002-2437-2250				ALTMANN DM, 1991, IMMUNOL TODAY, V12, P267, DOI 10.1016/0167-5699(91)90124-C; Bauer J, 1995, CURR OPIN IMMUNOL, V7, P839, DOI 10.1016/0952-7915(95)80057-3; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; Brocke Stefan, 1994, Trends in Microbiology, V2, P250, DOI 10.1016/0966-842X(94)90630-0; COPPEL RL, 1995, IMMUNOL REV, V144, P17, DOI 10.1111/j.1600-065X.1995.tb00064.x; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; GAUTAM AM, 1992, J EXP MED, V176, P605, DOI 10.1084/jem.176.2.605; GIJBELS K, 1992, J NEUROIMMUNOL, V41, P29, DOI 10.1016/0165-5728(92)90192-N; GIJBELS K, 1994, J CLIN INVEST, V94, P2177, DOI 10.1172/JCI117578; KARIN N, 1994, J EXP MED, V180, P2227, DOI 10.1084/jem.180.6.2227; KURTZKE JF, 1983, MULT SCLER, P49; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MATHISEN PM, 1993, P NATL ACAD SCI USA, V90, P10125, DOI 10.1073/pnas.90.21.10125; OKSENBERG JR, 1993, JAMA-J AM MED ASSOC, V270, P2362, DOI 10.1001/jama.270.19.2362; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; PRIBYL TM, 1993, P NATL ACAD SCI USA, V90, P10695, DOI 10.1073/pnas.90.22.10695; RAINE CS, 1990, CLIN IMMUNOL IMMUNOP, V57, P173, DOI 10.1016/0090-1229(90)90032-L; SELMAJ K, 1991, ANN NEUROL, V30, P694, DOI 10.1002/ana.410300510; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; STEINMAN L, 1995, MOL MED TODAY, V1, P79, DOI 10.1016/S1357-4310(95)92366-7; STEINMAN L, 1995, NATURE, V375, P739, DOI 10.1038/375739b0; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061; WUCHERPFENNIG KW, 1994, J IMMUNOL, V152, P5581; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	31	756	788	1	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 3	1996	85	3					299	302		10.1016/S0092-8674(00)81107-1	http://dx.doi.org/10.1016/S0092-8674(00)81107-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616884	Bronze			2022-12-28	WOS:A1996UK14000002
J	vanderHeide, A; Jacobs, JWG; Bijlsma, JWJ; Heurkens, AHM; vanBoomaFrankfort, C; vanderVeen, MJ; Haanen, HCM; Hofman, DM				vanderHeide, A; Jacobs, JWG; Bijlsma, JWJ; Heurkens, AHM; vanBoomaFrankfort, C; vanderVeen, MJ; Haanen, HCM; Hofman, DM			The effectiveness of early treatment with ''second-line'' antirheumatic drugs - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						arthritis, rheumatoid; antirheumatic agents; anti-inflammatory agents, non-steroidal; quality of life	EARLY RHEUMATOID-ARTHRITIS; DISEASE; THERAPY; CLASSIFICATION; PROGRESSION; CRITERIA; PATIENT; DAMAGE; HANDS	Objective: To compare two therapeutic strategies for patients with recent-onset rheumatoid arthritis. Design: Open, randomized clinical trial. Setting: Outpatient clinics of six clinical centers. Patients: 238 consecutive patients with recently diagnosed rheumatoid arthritis. Interventions: Delayed or immediate introduction of treatment with slow-acting antirheumatic drugs (SAARDs). Measurements: Primary end points were functional disability, pain, joint score, and erythrocyte sedimentation rate at 6 and 12 months and progression of radiologic abnormalities at 12 months. Results: Statistically significant advantages at 12 months for patients receiving the SAARD strategy (immediate treatment with SAARDs) with regard to all primary end points that may be clinically important are indicated by the differences in improvements from baseline and their 95% CIs. These differences were 0.3 (95% CI, 0.2 to 0.6) for disability (range, 0 to 3), 10 mm (CI, 1 to 19 mm) for pain (range, 0 to 100 mm), 39 (CI, 4 to 74) for joint score (range, 0 to 534), and 11 mm/h (CI, 3 to 19 mm/h) for erythrocyte sedimentation rate (range, 1 to 140 mm/h), all in favor of SAARD treatment. The SAARD strategy also appears to be advantageous at 6 months. Radiologic abnormalities progressed at an equal rate in the SAARD and the non-SAARD groups; the difference in progression (range, 0 to 448) was 1 (CI, -3 to 5). Analyses were based on the intention-to-treat principle and thus included 29% of patients in the non-SAARD group who discontinued the non-SAARD treatment strategy; treatment was usually discontinued because of insufficient effectiveness. The SAARD strategy including two alternative SAARDs could not be continued by 8% of patients, usually because of adverse reactions. Conclusions: Early introduction of SAARDs may be more beneficial than delayed introduction for patients with recently diagnosed rheumatoid arthritis.	ERASMUS UNIV ROTTERDAM, FAC MED, DEPT PUBL HLTH, 3000 DR ROTTERDAM, NETHERLANDS; EEMLAND HOSP, DEPT RHEUMATOL, 3816 CP AMERSFOORT, NETHERLANDS; DIAKONESSEN HOSP, DEPT RHEUMATOL, 3582 KE UTRECHT, NETHERLANDS; ST JANSDAL HOSP, DEPT RHEUMATOL, 3840 AC HARDERWIJK, NETHERLANDS; ST ANTONIUS HOSP, DEPT RHEUMATOL, 3435 CM NIEUWEGEIN, NETHERLANDS; HOSP HILVERSUM, DEPT RHEUMATOL, 1201 DA HILVERSUM, NETHERLANDS; JAN VAN BREEMAN INST, DEPT RHEUMATOL, 1056 AB AMSTERDAM, NETHERLANDS	Erasmus University Rotterdam; Diakonessenhuis; St. Antonius Hospital Utrecht	vanderHeide, A (corresponding author), UNIV UTRECHT HOSP, DEPT RHEUMATOL F02 223, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							ALARCON GS, 1992, J RHEUMATOL, V19, P1868; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BENSEN WG, 1990, J RHEUMATOL, V17, P987; BIJLSMA JWJ, 1990, J REHABIL SCI, V3, P71; BROOK A, 1977, ANN RHEUM DIS, V36, P71, DOI 10.1136/ard.36.1.71; CAPELL HA, 1992, ANN RHEUM DIS, V51, P424, DOI 10.1136/ard.51.3.424; EBERHARDT KB, 1990, RHEUMATOL INT, V10, P135, DOI 10.1007/BF02274837; EDMONDS JP, 1993, ARTHRITIS RHEUM, V36, P336, DOI 10.1002/art.1780360308; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; FRIES JF, 1990, J RHEUMATOL, V17, P14; FRIES JF, 1990, J RHEUMATOL, V17, P12; FUCHS HA, 1989, J RHEUMATOL, V16, P585; GOLDSMITH CH, 1993, J RHEUMATOL, V20, P561; HESS EV, 1989, J RHEUMATOL, V16, P1175; IANNUZZI L, 1983, NEW ENGL J MED, V309, P1023, DOI 10.1056/NEJM198310273091704; JAFFE IA, 1990, J RHEUMATOL, V17, P24; KANTOR TG, 1990, J RHEUMATOL, V17, P1580; KUSHNER I, 1989, J RHEUMATOL, V16, P1; Luukkainen R, 1980, Scand J Rheumatol Suppl, V34, P1; MOTTONEN TT, 1988, ANN RHEUM DIS, V47, P648, DOI 10.1136/ard.47.8.648; NORUSIS MJ, 1988, SPSS PC PLUS TM BASE; PAULUS HE, 1992, ARTHRITIS RHEUM, V35, P364, DOI 10.1002/art.1780350317; PINCUS T, 1990, J RHEUMATOL, V17, P1582; Rasker J J, 1989, Scand J Rheumatol Suppl, V79, P45; ROTH SH, 1989, J RHEUMATOL, V16, P1408; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SCOTT DL, 1987, LANCET, V1, P1108; SCOTT DL, 1989, ANN RHEUM DIS, V48, P256, DOI 10.1136/ard.48.3.256; SHARP JT, 1985, ARTHRITIS RHEUM, V28, P1326, DOI 10.1002/art.1780281203; SIGLER JW, 1974, ANN INTERN MED, V80, P21, DOI 10.7326/0003-4819-80-1-21; THOMPSON PW, 1987, ARTHRITIS RHEUM, V30, P618, DOI 10.1002/art.1780300603; VANDENBRINK HR, 1993, J RHEUMATOL, V20, P28; VANDERHEIDE A, 1993, ANN RHEUM DIS, V52, P497, DOI 10.1136/ard.52.7.497; VANDERHEIDE A, 1992, SEMIN ARTHRITIS RHEU, V21, P287, DOI 10.1016/0049-0172(92)90022-6; VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140-6736(89)92442-2; VANDERHEIJDE DMFM, 1992, ARTHRITIS RHEUM-US, V35, P26; VANLEEUWEN MA, 1994, J RHEUMATOL, V21, P425; WIJNANDS MJH, 1992, BRIT J RHEUMATOL, V31, P253, DOI 10.1093/rheumatology/31.4.253; WILLIAMS HJ, 1988, ARTHRITIS RHEUM, V31, P702, DOI 10.1002/art.1780310602; WILSKE KR, 1989, J RHEUMATOL, V16, P565; WILSKE KR, 1990, J RHEUMATOL, V17, P4; WOLFE F, 1990, J RHEUMATOL, V17, P994; WOLFE F, 1990, J RHEUMATOL, V17, P24; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408	44	398	409	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1996	124	8					699	+		10.7326/0003-4819-124-8-199604150-00001	http://dx.doi.org/10.7326/0003-4819-124-8-199604150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD936	8633829				2022-12-28	WOS:A1996UD93600001
J	Polito, JMII; Rees, RC; Childs, B; Mendeloff, AI; Harris, ML; Bayless, TM				Polito, JMII; Rees, RC; Childs, B; Mendeloff, AI; Harris, ML; Bayless, TM			Preliminary evidence for genetic anticipation in Crohn's disease	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; HUNTINGTONS-DISEASE; PREVALENCE	Background The term genetic anticipation is used to describe earlier onset of disease, increased severity, or both, in succeeding generations of families affected by a particular disease. This process has been linked with expanded genomic trinucleotide repeat regions in some neurological disorders. Crohn's disease, an inflammatory bowel disorder, has genetic influences, which remain undefined. We studied pairs of two-generation first-degree relatives with Crohn's disease to seek evidence for genetic participation in this disorder. Methods Through retrospective review of the records of 552 patients treated for Crohn's disease at Johns Hopkins Hospital, we identified 27 pairs of two-generation first-degree relatives. We also studied 32 such pairs identified through a multicentre survey. After exploratory analyses by t tests, a generalised estimating equations approach was used to fit a marginal regression model. Findings The age at diagnosis was earlier in the younger member of the pair both in the Johns Hopkins Hospital dataset (18.9 [SE 6.9] vs 31.4 [12.0] years) and in the multicentre survey dataset (16.9 [7.4] vs 33.1 [11.9] years). The regression model confirmed the findings:the best-fitting model for the Johns Hopkins Hospital data showed an average 10.8 (SE 4.2) year difference in age at diagnosis between parent and child; that for the multicentre data showed an average difference of 15.1 (1.5) years. There was evidence of a further difference between the second and third generations. Disease was more extensive in the offspring than in the parent for 15 of the 27 pairs at Johns Hopkins Hospital; in 13 of these pairs the affected parent was the father. Interpretation The evidence of a lower age at diagnosis and a greater extent of disease in the younger member of two-generation pairs affected by Crohn's disease, as well as the association with paternal transmission, suggest that genetic anticipation does occur in Crohn's disease. A search for triplet repeat regions is warranted.	JOHNS HOPKINS UNIV,SCH MED,DIV GASTROENTEROL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT MED PEDIATR,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOSTAT,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV HOSP,MEYERHOFF CTR DIGEST DIS INFLAMMATORY BOWEL DIS,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine								ADAMS P, 1988, AM J HUM GENET, V43, P695; BARCLAY SK, 1994, GASTROENTEROLOGY, V106, pA658; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; LASHNER BA, 1986, GASTROENTEROLOGY, V91, P1396, DOI 10.1016/0016-5085(86)90193-9; MACDONALD ME, 1993, J MED GENET, V30, P982, DOI 10.1136/jmg.30.12.982; MADDOX J, 1994, NATURE, V368, P685, DOI 10.1038/368685a0; MONSEN U, 1991, SCAND J GASTROENTERO, V26, P302, DOI 10.3109/00365529109025046; PENROSE LS, 1948, ANN EUGENIC, V14, P125; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	10	95	97	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 23	1996	347	9004					798	800		10.1016/S0140-6736(96)90870-3	http://dx.doi.org/10.1016/S0140-6736(96)90870-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622336	hybrid			2022-12-28	WOS:A1996UB15300011
J	Beversdorf, D; Moses, P; Reeves, A; Dunn, J				Beversdorf, D; Moses, P; Reeves, A; Dunn, J			A man with weight loss, ataxia, and confusion for 3 months	LANCET			English	Article							ADULT CELIAC-DISEASE; VITAMIN-E-DEFICIENCY		DARTMOUTH HITCHCOCK MED CTR,DEPT PATHOL,LEBANON,NH 03756; UNIV VERMONT,COLL MED,DIV GASTROENTEROL,BURLINGTON,VT 05405	Dartmouth College; University of Vermont	Beversdorf, D (corresponding author), DARTMOUTH HITCHCOCK MED CTR,DEPT MED,NEUROL SECT,1 MED CTR DR,LEBANON,NH 03756, USA.		Beversdorf, David Q./M-2786-2016	Beversdorf, David Q./0000-0002-0298-0634				COLLIN P, 1991, NEUROLOGY, V41, P372, DOI 10.1212/WNL.41.3.372; KINNEY HC, 1982, J NEUROL SCI, V53, P9, DOI 10.1016/0022-510X(82)90076-4; MAURO A, 1991, ACTA NEUROL SCAND, V84, P167, DOI 10.1111/j.1600-0404.1991.tb04927.x; RADER DJ, 1993, JAMA-J AM MED ASSOC, V270, P865, DOI 10.1001/jama.270.7.865; TISON F, 1989, J NEUROL, V236, P307, DOI 10.1007/BF00314464; TRABERT W, 1992, NEUROLOGY, V42, P1641, DOI 10.1212/WNL.42.8.1641-b	6	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 17	1996	347	8999					446	446		10.1016/S0140-6736(96)90014-8	http://dx.doi.org/10.1016/S0140-6736(96)90014-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV722	8618488	Bronze			2022-12-28	WOS:A1996TV72200014
J	Gurley, RJ; Lum, N; Sande, M; Lo, B; Katz, MH				Gurley, RJ; Lum, N; Sande, M; Lo, B; Katz, MH			Persons found in their homes helpless or dead	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPPORT	Background. Healthcare providers and providers of emergency services are sometimes Galled to help with people who are found alone in their homes either helpless or dead. It is not known who is at risk for being found helpless or dead, what the mortality rates are among those found alive, or how frequently this situation occurs. Methods. We conducted a population-based study of patients who were found in their homes either helpless or dead. Over 12 weeks, paramedics employed by the city of San Francisco identified 387 such events involving 367 persons. We obtained information on these patients from the emergency-medical-services department or the hospitals to which they were taken and determined their outcomes. Results. The median age of the persons found helpless or dead was 73 years; 51 percent were women. The frequency of such incidents increased sharply with age, from a rate of 3 per 1000 per year among those 60 to 64 years of age to 27 per 1000 per year among those 85 years of age or older. The highest rate was among men 85 years and older who were living alone (123 per 1000 per year). In 23 percent of the cases, the person was found dead, an additional 5 percent died in the hospital. Thus, total mortality was 28 percent, Of the patients found alive, 62 percent were admitted to the hospital. The average hospital stay was eight days, and 52 percent of those admitted required intensive care. Of the survivors, 62 percent were unable to return to living independently. The total mortality was 67 percent for patients who were estimated to have been helpless for more than 72 hours, as compared with 12 percent for those who had been helpless for less than 1 hour. Conclusions. For elderly people who live alone, becoming incapacitated and unable to Set help is a common event, which usually marks the end of their ability to live independently. (C) 1996, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA; SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110; CITY & CTY SAN FRANCISCO,DEPT PUBL HLTH,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO & BERKELEY,JOINT MED SCH PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; San Francisco Department of Public Health; University of California System; University of California San Francisco								Cantor M., 1985, HDB AGING SOCIAL SCI, P745; CRIMMINS EM, 1990, RES AGING, V12, P3, DOI 10.1177/0164027590121001; CUMMINGS SR, 1994, NEW ENGL J MED, V331, P872, DOI 10.1056/NEJM199409293311310; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; Hennon C. B., 1983, FAM RELAT, P149; JACOBSEN SJ, 1990, AM J PUBLIC HEALTH, V80, P871, DOI 10.2105/AJPH.80.7.871; STEINBACH U, 1992, J GERONTOL, V47, pS183, DOI 10.1093/geronj/47.4.S183; TREAS J, 1977, GERONTOLOGIST, V17, P486, DOI 10.1093/geront/17.6.486; TREAS J, 1981, GERONTOLOGIST, V21, P98; 1993, STAT B METROP INSUR, V74, P2	10	142	143	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	1996	334	26					1710	1716		10.1056/NEJM199606273342606	http://dx.doi.org/10.1056/NEJM199606273342606			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UT400	8637517				2022-12-28	WOS:A1996UT40000006
J	Taha, AS; Hudson, N; Hawkey, CJ; Swannell, AJ; Trye, PN; Cottrell, J; Mann, SG; Simon, TJ; Sturrock, RD; Russell, RI				Taha, AS; Hudson, N; Hawkey, CJ; Swannell, AJ; Trye, PN; Cottrell, J; Mann, SG; Simon, TJ; Sturrock, RD; Russell, RI			Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-INFLAMMATORY DRUGS; GASTRODUODENAL MUCOSAL DAMAGE; CONTROLLED TRIAL; DOUBLE-BLIND; MISOPROSTOL; RANITIDINE; ULCERATION; PROTECTION; ARTHRITIS; PLACEBO	Background. Acid suppression with famotidine, a histamine H-2-receptor antagonist, provides protection against gastric injury in normal subjects receiving short courses of aspirin or naproxen. The efficacy of famotidine in preventing peptic ulcers in patients receiving long-term therapy with nonsteroidal antiinflammatory drugs (NSAIDs) is not known. Methods. We studied the efficacy of two doses of famotidine (20 mg and 40 mg, each given orally twice daily), as compared with placebo, in preventing peptic ulcers in 285 patients without peptic ulcers who were receiving long-term NSAID therapy for rheumatoid arthritis (82 percent) or osteoarthritis (18 percent), The patients were evaluated clinically and by endoscopy at base line and after 4, 12, and 24 weeks of treatment, The evaluators were unaware of the treatment assignment, The primary end point was the cumulative incidence of gastric or duodenal ulceration at 24 weeks. Results. The cumulative incidence of gastric ulcers was 20 percent in the placebo group, 13 percent in the group of patients receiving 20 mg of famotidine twice daily (P = 0.24 for the comparison with placebo), and 8 percent in the group receiving 40 mg of famotidine twice daily (P = 0.03 for the comparison with placebo). The proportion of patients in whom duodenal ulcers developed was significantly lower with both doses of famotidine than with placebo (13 percent in the placebo group, 4 percent in the low-dose famotidine group [P=0.04], and 2 percent in the high-dose famotidine group [P=0.01]), Both doses of famotidine were well tolerated. Conclusions Treatment with high-dose famotidine significantly reduces the cumulative incidence of both gastric and duodenal ulcers in patients with arthritis receiving long-term NSAID therapy. (C) 1996, Massachusetts Medical Society.	GLASGOW ROYAL INFIRM,DEPT GASTROENTEROL,GLASGOW G4 0SF,LANARK,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT RHEUMATOL,GLASGOW G4 0SF,LANARK,SCOTLAND; UNIV NOTTINGHAM HOSP,NOTTINGHAM,ENGLAND; MERCK SHARP & DOHME LTD,HODDESDON,HERTS,ENGLAND; MERCK RES LABS,BLUE BELL,PA	University of Glasgow; University of Glasgow; University of Nottingham; Merck & Company; Merck & Company			Taha, Ali/AAF-4644-2020	Taha, Ali S/0000-0003-0873-1302				AABAKKEN L, 1990, ALIMENT PHARM THERAP, V4, P295; BARDHAN KD, 1993, BRIT J RHEUMATOL, V32, P990; BARRIER CH, 1989, ARTHRITIS RHEUM, V32, P926; DANESHMEND TK, 1989, GASTROENTEROLOGY, V97, P944, DOI 10.1016/0016-5085(89)91502-3; DANESHMEND TK, 1990, GUT, V31, P514, DOI 10.1136/gut.31.5.514; EHSANULLAH RSB, 1988, BRIT MED J, V297, P1017, DOI 10.1136/bmj.297.6655.1017; FRENCH PC, 1994, EUR J GASTROEN HEPAT, V6, P1141, DOI 10.1097/00042737-199412000-00013; GRAHAM DY, 1988, LANCET, V2, P1277; GRAHAM DY, 1993, ANN INTERN MED, V119, P257, DOI 10.7326/0003-4819-119-4-199308150-00001; HAWKEY C, 1990, BRIT MED J, V300, P764; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; HUDSON N, 1992, GUT               S1, V33, pS42; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; ROBINSON MG, 1989, DIGEST DIS SCI, V34, P424, DOI 10.1007/BF01536266; ROHNER HG, 1986, AM J MED, V81, P13, DOI 10.1016/0002-9343(86)90595-4; ROWE PH, 1987, GASTROENTEROLOGY, V93, P863, DOI 10.1016/0016-5085(87)90451-3; SAVARINO V, 1987, DIGESTION, V37, P103, DOI 10.1159/000199475; SHERRER YS, 1986, ARTHRITIS RHEUM, V29, P494, DOI 10.1002/art.1780290406; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Simon TJ, 1994, AM J GASTROENTEROL, V89, P1644; SKANDER MP, 1988, BRIT MED J, V297, P833, DOI 10.1136/bmj.297.6652.833; WALLACE JL, 1990, AM J PHYSIOL, V259, pG462, DOI 10.1152/ajpgi.1990.259.3.G462; WALT RP, 1992, NEW ENGL J MED, V327, P1575	23	347	363	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1996	334	22					1435	1439		10.1056/NEJM199605303342204	http://dx.doi.org/10.1056/NEJM199605303342204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM493	8618582	Bronze			2022-12-28	WOS:A1996UM49300004
J	Mrzljak, L; Bergson, C; Pappy, M; Huff, R; Levenson, R; GoldmanRakic, PS				Mrzljak, L; Bergson, C; Pappy, M; Huff, R; Levenson, R; GoldmanRakic, PS			Localization of dopamine D4 receptors in GABAergic neurons of the primate brain	NATURE			English	Article							HIPPOCAMPAL-NEURONS; ARACHIDONIC-ACID; SOMATOSTATIN; SLEEP; METABOLITES; INHIBITION; CA1	DOPAMINE receptors are the principal targets of drugs used in the treatment of schizophrenia(1). Among the five mammalian dopamine-receptor subtypes, the D4 subtype is of particular interest because of its high affinity for the atypical neuroleptic clozapine(1-3). Interest in clozapine stems from its effectiveness in reducing positive and negative symptoms in acutely psychotic and treatment-resistant schizophrenic patients,without eliciting extrapyramidal side effects(4). We have produced a subtype-specific antibody against the D4 receptor and localized it within specific cellular elements and synaptic circuits of the central nervous system. The D4-receptor antibody labelled GABAergic neurons in the cerebral cortex, hippocampus, thalamic reticular nucleus, globus pallidus and the substantia nigra (pars reticulata). Labelling was also observed in a subset of cortical pyramidal cells. Our findings suggest that clozapine's beneficial effects in schizophrenia may be achieved, in part, through D4-mediated GABA modulation, possibly implicating disinhibition of excitatory transmission in intrinsic cortical, thalamocortical and extrapyramidal pathways.	YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510; PENN STATE UNIV,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033; UPJOHN PHARMACIA CELL BIOL,KALAMAZOO,MI 49001	Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				Levenson, Robert/0000-0002-0936-8421				ANDERSEN P, 1971, EXP BRAIN RES, V13, P208; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P607; BORBELY AA, 1989, PHYSIOL REV, V69, P605, DOI 10.1152/physrev.1989.69.2.605; DANGUIR J, 1986, BRAIN RES, V367, P26, DOI 10.1016/0006-8993(86)91574-X; DELECEA L, 1994, MOL BRAIN RES, V25, P286, DOI 10.1016/0169-328X(94)90164-3; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GLUSCHANKOF P, 1984, P NATL ACAD SCI-BIOL, V81, P6662, DOI 10.1073/pnas.81.21.6662; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P243, DOI 10.1152/jn.1961.24.3.243; MAURER R, 1982, P NATL ACAD SCI-BIOL, V79, P4815, DOI 10.1073/pnas.79.15.4815; MOORE SD, 1988, SCIENCE, V239, P278, DOI 10.1126/science.2892268; PROSPEROGARCIA O, 1994, PHARMACOL BIOCHEM BE, V49, P413, DOI 10.1016/0091-3057(94)90442-1; SCHARFMAN HE, 1989, BRAIN RES, V493, P205, DOI 10.1016/0006-8993(89)91155-4; SCHONBRUNN AH, 1978, J BIOL CHEM, V235, P6473; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SHIROMANI PJ, 1987, ANNU REV PHARMACOL, V27, P137; STEFFENSEN SC, 1991, BRAIN RES, V538, P46, DOI 10.1016/0006-8993(91)90374-5; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; VEBER DF, 1979, NATURE, V280, P512, DOI 10.1038/280512a0	21	389	403	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 16	1996	381	6579					245	248		10.1038/381245a0	http://dx.doi.org/10.1038/381245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UL249	8622768				2022-12-28	WOS:A1996UL24900057
J	Lieberman, JM; Chiu, SS; Wong, VK; Partridge, S; Chang, SJ; Chiu, CY; Gheesling, LL; Carlone, GM; Ward, JI				Lieberman, JM; Chiu, SS; Wong, VK; Partridge, S; Chang, SJ; Chiu, CY; Gheesling, LL; Carlone, GM; Ward, JI			Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLUENZAE TYPE-B; CAPSULAR POLYSACCHARIDE VACCINE; GROUP-A; MENINGOCOCCAL DISEASE; BACTERICIDAL ACTIVITY; ANTIBODY; INFANTS; IMMUNIZATION; AGE	Objective.-To assess the safety and immumogenicity of a bivalent serogroups A/C meningococcal oligosaccharide-protein conjugate vaccine compared with the licensed meningococcal polysaccharide vaccine. Design.-Randomized controlled trial. Study population.-Ninety healthy 18- to 24-month-old children who were seen at a southern California Kaiser Permanente clinic. Interventions.-Vaccination with either the meningococcal conjugate vaccine (at 1 of 2 dosages) or the polysaccharide vaccine, with 2 doses given 2 months apart. Main Outcome Measures.-Immune response to each vaccine dose as determined by measurement of serogroup-specific total antibodies by enzyme-linked immunosorbent assay (ELISA) and by assessment of serum bactericidal activity. Results.-Both vaccines appeared to be safe, and nearly all children responded with greater than 4-fold increases in antibody levels. The 2 dosages of the conjugate vaccine induced similar antibody responses; therefore, the data for the 2 conjugate vaccine groups were combined, Following 2 doses, ELISA antibody levels against group C meningococcus were significantly higher in conjugate vaccine recipients than in polysaccharide vaccine recipients (16.66 mu g/mL vs 8.31 mu g/mL; P<.001), but antibody levels against group A were not significantly different (22.75 mu g/mL vs 21.24 mu g/mL; P=.70). The serum bactericidal assays showed striking differences between the conjugate and polysaccharide vaccine groups. Geometric mean serum bactericidal titers were significantly higher in conjugate vaccine recipients (755.6 vs 37.6 for group A, P<.001;3197.9 vs 11.4 for group C, P<.001). Conclusions.-The immune response induced by this meningococcal oligosaccharide-protein conjugate vaccine was qualitatively different from that induced by the polysaccharide vaccine, and the antibodies it elicited provided greater functional activity.	KAISER PERMANENTE,SO CALIF REG,BELLFLOWER,GA; CTR DIS CONTROL & PREVENT,DIV BACTERIAL & MYCOT DIS,CHILDHOOD & RESP DIS BRANCH,ATLANTA,GA	Kaiser Permanente; Centers for Disease Control & Prevention - USA	Lieberman, JM (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,CTR VACCINE RES,1124 W CARSON ST,E-6,TORRANCE,CA 90502, USA.		Chiu, Susan Shui Seng/C-4247-2009	Chiu, Susan Shui Seng/0000-0002-3908-1974	NIAID NIH HHS [N0-AI-15124] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIR J, 1990, J INFECT DIS, V162, P163, DOI 10.1093/infdis/162.1.163; ANDERSON EL, 1994, INFECT IMMUN, V62, P3391, DOI 10.1128/IAI.62.8.3391-3395.1994; ARTENSTEIN MS, 1970, NEW ENGL J MED, V282, P417, DOI 10.1056/NEJM197002192820803; CARLONE GM, 1992, J CLIN MICROBIOL, V30, P154, DOI 10.1128/JCM.30.1.154-159.1992; CEESAY SJ, 1993, J INFECT DIS, V167, P1212, DOI 10.1093/infdis/167.5.1212; CONSTANTINO P, 1992, VACCINE, V10, P691; FINNE J, 1983, LANCET, V2, P355; GHEESLING LL, 1994, J CLIN MICROBIOL, V32, P1475, DOI 10.1128/JCM.32.6.1475-1482.1994; GOLD R, 1979, J INFECT DIS, V140, P690, DOI 10.1093/infdis/140.5.690; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; GOLDSCHNEIDER I, 1973, J INFECT DIS, V128, P769, DOI 10.1093/infdis/128.6.769; GOLDSCHNEIDER I, 1972, J INFECT DIS, V125, P509, DOI 10.1093/infdis/125.5.509; GRAHAM DR, 1995, 35 INT C ANT AG CHEM; HETHERINGTON SV, 1992, J INFECT DIS, V165, P753, DOI 10.1093/infdis/165.4.753; HOLDER PK, 1995, CLIN DIAGN LAB IMMUN, V2, P132, DOI 10.1128/CDLI.2.2.132-137.1995; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; KAYHTY H, 1980, J INFECT DIS, V142, P861, DOI 10.1093/infdis/142.6.861; MACDONALD K, 1995, 35 INT C ANT AG CHEM; MILAGRES LG, 1994, INFECT IMMUN, V62, P4419, DOI 10.1128/IAI.62.10.4419-4424.1994; MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2; PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302; PINNER RW, 1991, J INFECT DIS, V164, P368, DOI 10.1093/infdis/164.2.368; REINGOLD AL, 1985, LANCET, V2, P114; ROMERO JD, 1994, CLIN MICROBIOL REV, V7, P559, DOI 10.1128/CMR.7.4.559-575.1994; SCHLESINGER Y, 1992, JAMA-J AM MED ASSOC, V267, P1489, DOI 10.1001/jama.267.11.1489; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; STEIN KE, 1992, J INFECT DIS, V165, pS49, DOI 10.1093/infdis/165-Supplement_1-S49; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; TAUNAY ADE, 1974, PEDIATR RES, V8, P429; TWUMASI PA, 1995, J INFECT DIS, V171, P632, DOI 10.1093/infdis/171.3.632; WAHDAN MH, 1973, B WORLD HEALTH ORGAN, V48, P667; WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390	33	122	149	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1499	1503		10.1001/jama.275.19.1499	http://dx.doi.org/10.1001/jama.275.19.1499			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622225				2022-12-28	WOS:A1996UJ93700034
J	James, AA				James, AA			Dengue hemorrhagic fever	SCIENCE			English	Editorial Material											James, AA (corresponding author), UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717, USA.			James, Anthony/0000-0001-5577-3308				GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; Olson KE, 1996, SCIENCE, V272, P884, DOI 10.1126/science.272.5263.884	2	4	4	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					829	829		10.1126/science.272.5263.829	http://dx.doi.org/10.1126/science.272.5263.829			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629013				2022-12-28	WOS:A1996UK75700042
J	Niemann, HB; Atreya, SK; Carignan, GR; Donahue, TM; Haberman, JA; Harpold, DN; Hartle, RE; Hunten, DM; Kasprzak, WT; Mahaffy, PR; Owen, TC; Spencer, NW; Way, SH				Niemann, HB; Atreya, SK; Carignan, GR; Donahue, TM; Haberman, JA; Harpold, DN; Hartle, RE; Hunten, DM; Kasprzak, WT; Mahaffy, PR; Owen, TC; Spencer, NW; Way, SH			The Galileo probe mass spectrometer: Composition of Jupiter's atmosphere	SCIENCE			English	Article							GIANT PLANETS; ABUNDANCES; SATURN; SOLAR; RATIO	The composition of the jovian atmosphere from 0.5 to 21 bars along the descent trajectory was determined by a quadrupole mass spectrometer on the Galileo probe. The mixing ratio of He (helium) to H-2 (hydrogen), 0.156, is close to the solar ratio. The abundances of methane, water, argon, neon, and hydrogen sulfide were measured; krypton and xenon were detected. As measured in the jovian atmosphere, the amount of carbon is 2.9 times the solar abundance relative to H-2, the amount of sulfur is greater than the solar abundance, and the amount of oxygen is much less than the solar abundance. The neon abundance compared with that of hydrogen is about an order of magnitude less than the solar abundance. Isotopic ratios of carbon and the noble gases are consistent with solar values. The measured ratio of deuterium to hydrogen (D/H) of (5 +/- 2) x 10(-5) indicates that this ratio is greater in solar-system hydrogen than in local interstellar hydrogen, and the He-3/He-4 ratio of (1.1 +/- 0.2) x 10(-4) provides a new value for protosolar (solar nebula) helium isotopes. Together, the D/H and He-3/He-4 ratios are consistent with conversion in the sun of protosolar deuterium to present-day He-3.	UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721; UNIV HAWAII,INST ASTRON,HONOLULU,HI 96822	University of Michigan System; University of Michigan; University of Arizona; University of Hawaii System	Niemann, HB (corresponding author), NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771, USA.		Mahaffy, Paul/E-4609-2012; Harpold, Dan/I-3345-2013	Mahaffy, Paul/0000-0003-1896-1726; 				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; CARLSON BE, 1993, J GEOPHYS RES-PLANET, V98, P5251, DOI 10.1029/92JE02737; CONRATH BJ, 1984, ASTROPHYS J, V282, P807, DOI 10.1086/162267; DEPATER I, 1985, ICARUS, V62, P143, DOI 10.1016/0019-1035(85)90177-0; GAUTIER D, 1989, ORIGIN EVOLUTION PLA, P504; Geiss J., 1993, ORIGIN EVOLUTION ELE, V89; Hubbard WB, 1989, ORIGIN EVOLUTION PLA, P539; INGERSOLL AP, 1995, NATURE, V374, P706, DOI 10.1038/374706a0; LINSKY JL, 1993, ASTROPHYS J, V402, P694, DOI 10.1086/172170; LINSKY JL, 1995, LIGHT ELEMENT ABUNDA, P215; LUNINE JI, 1985, ASTROPHYS J SUPPL S, V58, P493, DOI 10.1086/191050; MARTEN A, 1980, ICARUS, V41, P410, DOI 10.1016/0019-1035(80)90225-0; Mason B., 1962, METEORITES; NIEMANN HB, 1992, SPACE SCI REV, V60, P111, DOI 10.1007/BF00216852; NOLL KS, 1991, ICARUS, V89, P168, DOI 10.1016/0019-1035(91)90096-C; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; POLLACK JB, 1989, ORIGIN EVOLUTION PLA, P564; RAGENT B, 1996, SCIENCE, V272, P855; SMITH WH, 1989, ASTROPHYS J, V336, P967, DOI 10.1086/167067; SMOLUCHO.R, 1967, NATURE, V215, P691, DOI 10.1038/215691a0; SPRAGUE AL, IN PRESS ICARUS; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P221, DOI 10.1086/190478; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P239, DOI 10.1086/190479; STEVENSON DJ, 1982, ANNU REV EARTH PL SC, V10, P257, DOI 10.1146/annurev.ea.10.050182.001353; vonZahn U, 1996, SCIENCE, V272, P849, DOI 10.1126/science.272.5263.849; WIIK HB, 1956, GEOCHIM COSMOCHIM AC, V9, P279, DOI 10.1016/0016-7037(56)90028-X; [No title captured]	29	207	211	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					846	849		10.1126/science.272.5263.846	http://dx.doi.org/10.1126/science.272.5263.846			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629016				2022-12-28	WOS:A1996UK75700049
J	Muller, JE; Mittleman, MA; Maclure, M; Sherwood, JB; Tofler, GH				Muller, JE; Mittleman, MA; Maclure, M; Sherwood, JB; Tofler, GH			Triggering myocardial infarction by sexual activity - Low absolute risk and prevention by regular physical exertion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine the relative risks of nonfatal myocardial infarction (MI) triggered by sexual activity among the general population and in patients with prior coronary heart disease. Design.-Relative risks and effect modification were calculated by the case-crossover method, a new epidemiologic technique designed to quantify the transient change in risk following exposure to a potential disease trigger. Setting/Participants.-A total of 1774 patients with MI were interviewed in 45 hospitals throughout the United States. Data were gathered on potential triggers of MI occurring immediately prior to the event and during the previous year. Results are presented for the 858 patients who were sexually active in the year prior to the MI, with attention to the 273 patients who had coronary artery disease prior to their index MI, and the effect of regular exertion on risk. Main Outcome Measure.-The relative risk of nonfatal MI following sexual activity. Results.-Of the 858 patients, 79 (9%) reported sexual activity in the 24 hours preceding MI, and 27 (3%) reported sexual activity in the 2 hours preceding onset of symptoms of MI. The relative risk of MI occurring in the 2 hours after sexual activity was 2.5 (95% confidence interval [CI], 1.7-3.7). The relative risk of triggering onset of MI among patients with a history of prior angina (2.1 [95% CI, 0.8-5.8]) or prior MI (2.9 [95% CI, 1.3-6.5) was not greater than that observed in those without prior cardiac disease. Sexual activity was a likely contributor to the onset of MI in only 0.9% of cases and regular exertion was associated with decreasing risk. Conclusions.-Sexual activity can trigger the onset of MI, However, the relative risk is low, and since the absolute hourly risk of MI is extremely low, the absolute risk increase caused by sexual activity also is extremely low (1 chance in a million for a healthy individual). Moreover, the relative risk is not increased in patients with a prior history of cardiac disease and regular exercise appears to prevent triggering, These findings should be useful for counseling patients and decreasing the fear of sexual activity that often prevents complete rehabilitation from cardiovascular disease.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Muller, JE (corresponding author), DEACONESS HOSP,DIV CARDIOVASC,INST PREVENT CARDIOVASC DIS,DEPT MED,1 AUTUMN ST,5TH FLOOR,BOSTON,MA 02215, USA.			Mittleman, Murray/0000-0001-9788-7274	NHLBI NIH HHS [HL41016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM HEART ASS, 1995, 1995 STAT SUPPL HEAR; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; ANDERSON KM, 1993, AM HEART J, V121, P293; ESLER M, 1995, J CLIN ENDOCR METAB, V80, P435, DOI 10.1210/jc.80.2.435; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HELLERSTEIN HK, 1970, ARCH INTERN MED, V125, P987, DOI 10.1001/archinte.125.6.987; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; MITTLEMAN MA, 1995, CIRCULATION, V92, P1720, DOI 10.1161/01.CIR.92.7.1720; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; MULLER JE, 1994, J AM COLL CARDIOL, V23, P809, DOI 10.1016/0735-1097(94)90772-2; NALBANTGIL I, 1976, AM HEART J, V91, P405, DOI 10.1016/S0002-8703(76)80235-9; PAPADOPOULOS C, 1980, ARCH INTERN MED, V140, P38, DOI 10.1001/archinte.140.1.38; PAPADOPOULOS C, 1986, CHEST, V90, P681, DOI 10.1378/chest.90.5.681; Rothman K, 1986, MODERN EPIDEMIOLOGY; ROTHMAN KJ, 1981, AM J EPIDEMIOL, V114, P253, DOI 10.1093/oxfordjournals.aje.a113189; STEIN RA, 1977, CIRCULATION, V55, P738, DOI 10.1161/01.CIR.55.5.738; TARDIF GS, 1989, ARCH PHYS MED REHAB, V70, P763; TRIMBLE GX, 1970, MED ASPECTS HUM SEX, V5, P64; UENO M, 1963, JPN J LEGAL MED, V17, P330; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396	23	281	293	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	1996	275	18					1405	1409		10.1001/jama.275.18.1405	http://dx.doi.org/10.1001/jama.275.18.1405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ303	8618365				2022-12-28	WOS:A1996UJ30300025
J	Weil, DS; Knox, RC				Weil, DS; Knox, RC			Effects of limiting handgun purchases on interstate transfer of firearms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOMICIDE; SUICIDE; REGULATIONS; RATES	Objective.-To determine the effect of limiting handgun purchases to 1 per month on the illegal movement of firearms across state lines. Design.-Data from the Bureau of Alcohol, Tobacco, and Firearms firearms trace database were obtained for traces requested for firearms recovered in connection with criminal investigations. The analysis incorporates data on date and location of purchase for 14 606 firearms purchased prior to (September 1989 through June 1993) and after (July 1993 through March 1995) enactment of a Virginia law limiting handgun purchases to 1 per month. Main Outcome Measures.-Odds of tracing a firearm acquired prior to implementation of the law to Virginia vs another state in the Southeast compared with the odds for firearms acquired after the law took effect. Results.-For firearms recovered anywhere in the United States, 3201 (27%) of 11 876 acquired prior to the implementation of the law and 519 (19%) of 2730 purchased after the law was enacted were traced to Virginia (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.58-0.71). For traces initiated in the northeast corridor (New York, New Jersey, Connecticut, Rhode Island, and Massachusetts), 1103 (34.8%) of 3169 of the firearms acquired before the 1-gun-a-month law took effect and 142 (15.5%) of 919 firearms purchased after implementation were traced to Virginia (OR, 0.34; CI, 0.28-0.41). Conclusion.-Gun control policies involving licensing, registration, and restricting the number of purchases represent efforts to limit the supply of guns available in the illegal market. This study provides evidence that restricting handgun purchases to 1 per month is an effective means of disrupting the illegal interstate transfer of firearms.			Weil, DS (corresponding author), CTR PREVENT HANDGUN VIOLENCE,1225 I ST NW,SUITE 1100,WASHINGTON,DC 20005, USA.							BECK A, 1993, SURVEY STATE PRISON, P19; *BUR ALC TOB FIR, 1995, SOURC CRIM GUNS SO C, P21; *BUR ALC TOB FIR, 1994, 1994 BALT TRAC STUD; *BUR JUST STAT, 1992, PROS STAFF COURTS 19, P1; CENTERWALL BS, 1991, AM J EPIDEMIOL, V134, P1245, DOI 10.1093/oxfordjournals.aje.a116027; EDDS M, 1993, VIRGINIA PILOT  0103, pA9; FREEDMAN A, 1992, WALL STREET J   0218, pA1; FREEDMAN A, 1992, WALL STREET J   0228, pA6; HOUSER HB, 1991, AM J EPIDEMIOL, V134, P1261, DOI 10.1093/oxfordjournals.aje.a116028; KILLIAS M, 1993, CAN MED ASSOC J, V148, P1721; LARSON E, 1994, LETHAL PASSAGE TRAVE, P104; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; McDowall D, 1995, J CRIM LAW CRIM, V86, P193, DOI 10.2307/1144006; MONTGOMERY B, 1993, ATLANTA CONSTIT 1011, pA1; MONTGOMERY B, 1993, ATLANTA CONSTIT 1011, pA4; SHELEY JF, 1993, GUN ACQUISITION POSS, P6; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; SLOAN JH, 1990, NEW ENGL J MED, V322, P369, DOI 10.1056/NEJM199002083220605; ZAWITZ M, 1995, FIREARMS CRIME CRIMI, P1	19	38	38	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	1996	275	22					1759	1761		10.1001/jama.275.22.1759	http://dx.doi.org/10.1001/jama.275.22.1759			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UP307	8637175				2022-12-28	WOS:A1996UP30700031
J	Arnold, SF; Klotz, DM; Collins, BM; Vonier, PM; Guillette, LJ; McLachlan, JA				Arnold, SF; Klotz, DM; Collins, BM; Vonier, PM; Guillette, LJ; McLachlan, JA			Synergistic activation of estrogen receptor with combinations of environmental chemicals	SCIENCE			English	Article							BREAST-CANCER; BINDING-SITES; RESIDUES	Certain chemicals in the environment are estrogenic. The low potencies of these compounds, when studied singly, suggest that they may have little effect on biological systems. The estrogenic potencies of combinations of such chemicals were screened in a simple yeast estrogen system (YES) containing human estrogen receptor (hER). Combinations of two weak environmental estrogens, such as dieldrin, endosulfan, or toxaphene, were 1000 times as potent in hER-mediated transactivation as any chemical alone. Hydroxylated polychlorinated biphenyls shown previously to synergistically alter sexual development in turtles also synergized in the YES. The synergistic interaction of chemical mixtures with the estrogen receptor may have profound environmental implications. These results may represent a previously uncharacterized level of regulation of estrogen-associated responses.	TULANE XAVIER CTR BIOENVIRONM RES,NEW ORLEANS,LA 70112; TULANE UNIV,SCH PUBL HLTH & TROP MED,DEPT ENVIRONM HLTH SCI,NEW ORLEANS,LA 70112; TULANE UNIV,MED CTR,PROGRAM MOLEC & CELLULAR BIOL,NEW ORLEANS,LA 70112; UNIV FLORIDA,DEPT ZOOL,GAINESVILLE,FL 32611; TULANE UNIV,MED CTR,DEPT PHARMACOL,NEW ORLEANS,LA 70112	Tulane University; Xavier University of Louisiana; Tulane University; Tulane University; State University System of Florida; University of Florida; Tulane University								ARNOLD S, UNPUB; ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; Arnold SF, 1996, ENVIRON HEALTH PERSP, V104, P544, DOI 10.2307/3432996; AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; BERGERON JM, 1994, ENVIRON HEALTH PERSP, V102, P780, DOI 10.2307/3432139; BERN H, 1992, CHEM INDUCED ALTERAT, V21, P9; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143; FARGIN A, 1988, CHEM-BIOL INTERACT, V66, P101, DOI 10.1016/0009-2797(88)90044-0; FRY DM, 1995, ENVIRON HEALTH PERSP, V103, P165, DOI 10.2307/3432528; GUILLETTE LJ, 1995, ENVIRON HEALTH PERSP, V103, P31, DOI 10.2307/3432409; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; JOBLING S, 1995, ENVIRON HEALTH PERSP, V103, P582, DOI 10.2307/3432434; JOBLING S, 1993, AQUAT TOXICOL, V27, P361, DOI 10.1016/0166-445X(93)90064-8; KLOTZ DM, UNPUB; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; MARTIN PM, 1988, P NATL ACAD SCI USA, V85, P2533, DOI 10.1073/pnas.85.8.2533; MCLACHLAN JA, 1993, ENVIRON HEALTH PERSP, V101, P386, DOI 10.2307/3431891; MCLACHLAN JA, 1992, CHEM INDUCED ALTERAT, V21, P107; NEWBOLD RR, 1990, CANCER RES, V50, P7677; RUH TS, 1977, ENDOCRINOLOGY, V100, P420, DOI 10.1210/endo-100-2-420; Safe S.H., 1995, HUM ECOL RISK ASSESS, V1, P17; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHERINS RJ, 1995, NEW ENGL J MED, V332, P327, DOI 10.1056/NEJM199502023320510; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; SUMPTER JP, 1995, ENVIRON HEALTH PERSP, V103, P173, DOI 10.2307/3432529; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648	30	411	432	1	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1996	272	5267					1489	1492		10.1126/science.272.5267.1489	http://dx.doi.org/10.1126/science.272.5267.1489			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UP899	8633243				2022-12-28	WOS:A1996UP89900050
J	Schwaber, MJ				Schwaber, MJ			Outpatient clinic	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Schwaber, MJ (corresponding author), HADASSAH UNIV HOSP MT SCOPUS, DEPT MED, POB 24035, IL-91240 JERUSALEM, ISRAEL.		Schwaber, Mitchell/AAI-2486-2019						0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1996	124	11					1012	1013		10.7326/0003-4819-124-11-199606010-00011	http://dx.doi.org/10.7326/0003-4819-124-11-199606010-00011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL905	8624052				2022-12-28	WOS:A1996UL90500011
J	Lohse, PA; Szostak, JW				Lohse, PA; Szostak, JW			Ribozyme-catalysed amino-acid transfer reactions	NATURE			English	Article							RNA	THE 'RNA world' hypothesis proposes an early stage in the evolution of life in which both genomic and catalytic functions were fulfilled by RNA(1). The evolution of RNA-catalysed protein synthesis would have been a necessary step in the transition from such an RNA world to modern protein-dominated biology, For this to have been possible, RNA must be capable of catalysing amide-bond formation using acylated carrier RNA substrates as amino-acid donors. We have used in vitro selection and evolution to isolate ribozymes with acyl transferase activity from a pool of random RNA sequences. One of these acyl transferases with a 5'-amino group transfers an amino acid to itself in a reaction that we propose to be analogous to peptidyl transfer on the ribosome.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHUNAG NM, 1971, BIOCHIM BIOPHYS ACTA, V228, P536, DOI 10.1016/0005-2787(71)90059-1; FAHNESTOCK S, 1970, BIOCHEMISTRY-US, V9, P2477, DOI 10.1021/bi00814a013; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; SYNETOS D, 1987, BIOCHIM BIOPHYS ACTA, V923, P275, DOI 10.1016/0304-4165(87)90014-6; ULANOVSKY L, 1990, NATURE, V343, P190, DOI 10.1038/343190a0; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0	10	175	211	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 30	1996	381	6581					442	444		10.1038/381442a0	http://dx.doi.org/10.1038/381442a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UN479	8632803				2022-12-28	WOS:A1996UN47900056
J	Thadhani, R; Pascual, M; Bonventre, JV				Thadhani, R; Pascual, M; Bonventre, JV			Medical progress - Acute renal failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE TUBULAR-NECROSIS; CRITICALLY-ILL PATIENTS; PROXIMAL TUBULE; INTERSTITIAL NEPHRITIS; COMPLEMENT ACTIVATION; ADENINE-NUCLEOTIDES; DIALYSIS MEMBRANES; ARTERY STENOSIS; RISK-FACTORS; KIDNEY		MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,TRANSPLANTAT UNIT,BOSTON,MA 02114; HARVARD MIT DIV HLTH SCI & TECHNOL,BOSTON,MA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University				Pascual, Manuel A./0000-0001-7747-1693	NIDDK NIH HHS [DK-38452, DK-39773] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039773, R37DK039773, P01DK038452] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBATE M, 1994, AM J PHYSIOL-RENAL, V267, pF971, DOI 10.1152/ajprenal.1994.267.6.F971; ABUELO JG, 1995, ANN INTERN MED, V123, P601, DOI 10.7326/0003-4819-123-8-199510150-00007; ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ARNAOUT MA, 1985, NEW ENGL J MED, V312, P457, DOI 10.1056/NEJM198502213120801; BADR KF, 1994, SEMIN NEPHROL, V14, P3; BALDWIN L, 1994, ANN INTERN MED, V120, P744, DOI 10.7326/0003-4819-120-9-199405010-00004; BALDWIN WM, 1995, TRANSPLANTATION, V59, P797, DOI 10.1097/00007890-199503270-00001; BEERI R, 1995, KIDNEY INT, V47, P1806, DOI 10.1038/ki.1995.249; BELLOMO R, 1993, CRIT CARE MED, V21, P522, DOI 10.1097/00003246-199304000-00011; BELLOMO R, 1993, AM J KIDNEY DIS, V21, P400, DOI 10.1016/S0272-6386(12)80268-X; BETTER OS, 1990, NEW ENGL J MED, V322, P825; BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163; BONVENTRE JV, 1992, ANNU REV MED, V43, P523, DOI 10.1146/annurev.me.43.020192.002515; BREZIS M, 1991, J CLIN INVEST, V88, P390, DOI 10.1172/JCI115316; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; BRIDOUX F, 1992, NEPHROL DIAL TRANSPL, V7, P100, DOI 10.1093/oxfordjournals.ndt.a092076; CAMERON JS, 1988, Q J MED, V66, P97; CAMERON JS, 1986, Q J MED, V59, P337; CARBONE LG, 1988, AM J KIDNEY DIS, V12, P72, DOI 10.1016/S0272-6386(88)80076-3; CHAN L, 1994, AM J PHYSIOL, V266, pF135, DOI 10.1152/ajprenal.1994.266.1.F135; CHERTOW GM, 1995, ARCH INTERN MED, V155, P1505, DOI 10.1001/archinte.155.14.1505; CHEUNG AK, 1990, J AM SOC NEPHROL, V1, P150; CHUGH KS, 1994, RENAL FAILURE, V16, P37, DOI 10.3109/08860229409044846; COMBE C, 1994, AM J KIDNEY DIS, V24, P437, DOI 10.1016/S0272-6386(12)80900-0; CONGER JD, 1991, KIDNEY INT, V39, P1087, DOI 10.1038/ki.1991.138; CONGER JD, 1995, AM J KIDNEY DIS, V26, P565, DOI 10.1016/0272-6386(95)90590-1; COOPER K, 1987, ARCH INTERN MED, V147, P1213, DOI 10.1001/archinte.147.7.1213; CORWIN HL, 1987, AM J NEPHROL, V7, P8, DOI 10.1159/000167421; CORWIN HL, 1989, SEMIN DIALYSIS, V2, P220; DAVIDMAN M, 1991, ARCH INTERN MED, V151, P1809, DOI 10.1001/archinte.151.9.1809; DIXON BS, 1985, AM J KIDNEY DIS, V6, P71, DOI 10.1016/S0272-6386(85)80144-X; Eason JD, 1996, TRANSPLANTATION, V61, P224, DOI 10.1097/00007890-199601270-00011; ESNAULT V, 1988, NEPHROLOGIE, V9, P277; FEEST TG, 1993, BMJ-BRIT MED J, V306, P481, DOI 10.1136/bmj.306.6876.481; FINN WF, 1990, MED CLIN N AM, V74, P873, DOI 10.1016/S0025-7125(16)30523-5; FISH EM, 1994, NEW ENGL J MED, V330, P1580; FLANCBAUM L, 1994, CRIT CARE MED, V22, P61, DOI 10.1097/00003246-199401000-00014; FRANKLIN S, 1995, J AM SOC NEPHROL, V6, P387; GALPIN JE, 1978, AM J MED, V65, P756, DOI 10.1016/0002-9343(78)90793-3; GILLUM DM, 1986, CLIN NEPHROL, V25, P249; GOES N, 1995, TRANSPLANTATION, V59, P565; GOLIGORSKY MS, 1993, P NATL ACAD SCI USA, V90, P5700, DOI 10.1073/pnas.90.12.5700; GRANGER DN, 1995, ANNU REV PHYSIOL, V57, P311, DOI 10.1146/annurev.ph.57.030195.001523; GRINO JM, 1994, ANN INTERN MED, V121, P345, DOI 10.7326/0003-4819-121-5-199409010-00006; HAKIM RM, 1984, NEW ENGL J MED, V311, P878, DOI 10.1056/NEJM198410043111403; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; HAKIM RM, 1993, KIDNEY INT, V44, P484, DOI 10.1038/ki.1993.272; HAKIM RM, 1994, J AM SOC NEPHROL, V5, P394; HALLORAN PF, 1988, TRANSPLANTATION, V46, P223, DOI 10.1097/00007890-198808000-00007; HAMMERMAN MR, 1994, J AM SOC NEPHROL, V5, P1; HARRIS KPG, 1991, EUR J HAEMATOL, V47, P119; HAUG CE, 1993, TRANSPLANTATION, V55, P766, DOI 10.1097/00007890-199304000-00016; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; HOWDIESHELL TR, 1992, AM SURGEON, V58, P378; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; INSCHO EW, 1995, AM J PHYSIOL-RENAL, V268, pF876, DOI 10.1152/ajprenal.1995.268.5.F876; JENNETTE JC, 1990, MED CLIN N AM, V74, P893; Johnson K J, 1993, Curr Opin Nephrol Hypertens, V2, P625, DOI 10.1097/00041552-199307000-00014; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAUFMAN J, 1991, AM J KIDNEY DIS, V17, P191, DOI 10.1016/S0272-6386(12)81128-0; KELLERMAN PS, 1990, AM J PHYSIOL, V259, pF279, DOI 10.1152/ajprenal.1990.259.2.F279; KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; KILGORE KS, 1995, J IMMUNOL, V155, P1434; KLAUSNER JM, 1989, AM J PHYSIOL, V256, pF794, DOI 10.1152/ajprenal.1989.256.5.F794; KON V, 1989, J CLIN INVEST, V83, P1762, DOI 10.1172/JCI114079; KRIBBEN A, 1994, J CLIN INVEST, V93, P1922, DOI 10.1172/JCI117183; KYLE RA, 1994, ANNU REV MED, V45, P71; LEVIN ER, 1995, NEW ENGL J MED, V333, P356, DOI 10.1056/NEJM199508103330607; LIANO F, 1989, NEPHRON, V51, P307, DOI 10.1159/000185314; LIEBERTHAL W, 1990, SEMIN NEPHROL, V10, P571; LINDNER A, 1979, KIDNEY INT, V16, P158, DOI 10.1038/ki.1979.117; MAHER ER, 1989, Q J MED, V72, P857; MAILLET PJ, 1986, RADIOLOGY, V160, P659, DOI 10.1148/radiology.160.3.3526405; MALIS CD, 1991, CIRCULATION, V84, P1393, DOI 10.1161/01.CIR.84.3.1393; MALIS CD, 1983, AM J PHYSIOL, V245, pF735, DOI 10.1152/ajprenal.1983.245.6.F735; MARKS RM, 1989, NATURE, V339, P314, DOI 10.1038/339314a0; MASON J, 1989, MINER ELECTROL METAB, V15, P114; MASON PD, 1995, BRIT MED J, V310, P116; MASON PD, 1994, BRIT MED J, V309, P1557, DOI 10.1136/bmj.309.6968.1557; MCDONALD RH, 1964, J CLIN INVEST, V43, P1116, DOI 10.1172/JCI104996; MEHTA RL, 1994, SEMIN NEPHROL, V14, P64; MEYER KB, 1994, MINER ELECTROL METAB, V20, P201; MILLER TR, 1978, ANN INTERN MED, V89, P47, DOI 10.7326/0003-4819-89-1-47; MOHAUPT M, 1989, Renal Failure, V11, P177, DOI 10.3109/08860228909054929; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; MOLITORIS BA, 1992, AM J PHYSIOL, V263, pF488, DOI 10.1152/ajprenal.1992.263.3.F488; MOORE RD, 1984, ANN INTERN MED, V100, P352, DOI 10.7326/0003-4819-100-3-352; MORRISSEY JJ, 1994, KIDNEY INT, V45, P998, DOI 10.1038/ki.1994.135; MYERS BD, 1986, NEW ENGL J MED, V314, P97; NEUMAYER HH, 1989, NEPHROL DIAL TRANSPL, V4, P1030; NEUMAYER HH, 1992, KIDNEY INT, V41, pS87; NOIRI E, 1994, KIDNEY INT, V46, P1050, DOI 10.1038/ki.1994.366; NORMAN RW, 1982, CAN MED ASSOC J, V127, P601; NOVIS BK, 1994, ANESTH ANALG, V78, P143; OLSEN S, 1989, MEDICINE, V68, P173, DOI 10.1097/00005792-198905000-00005; PARRISH AE, 1992, CLIN NEPHROL, V38, P135; PASCUAL J, 1990, J AM GERIATR SOC, V38, P25, DOI 10.1111/j.1532-5415.1990.tb01592.x; PASCUAL J, 1995, J AM SOC NEPHROL, V6, P144; PASCUAL M, 1993, KIDNEY INT, V43, P903, DOI 10.1038/ki.1993.127; Pascual M, 1996, KIDNEY INT, V49, P309, DOI 10.1038/ki.1996.47; PAUL AB, 1994, BR J UROL, V7, P642; PITMAN SW, 1977, CANCER TREAT REP, V61, P695; RACUSEN LC, 1991, LAB INVEST, V64, P546; RAHMAN SN, 1994, KIDNEY INT, V45, P1731, DOI 10.1038/ki.1994.225; RAHMAN SN, 1995, J AM SOC NEPHROL, V6, P474; RAO TKS, 1995, AM J KIDNEY DIS, V25, P390; RICHARDS NT, 1994, NEPHROL DIAL TRANSPL, V9, P1255; Richet G, 1969, Ann Med Interne (Paris), V120, P657; ROGERS SA, 1995, AM J PHYSIOL-RENAL, V268, pF128, DOI 10.1152/ajprenal.1995.268.1.F128; ROSEN S, 1991, VIRCHOWS ARCH B, V61, P169; RUDNICK MR, 1995, KIDNEY INT, V47, P254, DOI 10.1038/ki.1995.32; RUFFING KA, 1994, CLIN NEPHROL, V41, P163; RUGGENENTI P, 1993, KIDNEY INT, V43, P706, DOI 10.1038/ki.1993.101; Safirstein Robert L., 1995, P839; SANDS JM, 1991, J AM SOC NEPHROL, V1, P1081; SAWYER MH, 1988, AM J MED, V84, P1067, DOI 10.1016/0002-9343(88)90313-0; SCHENA FP, 1994, NEPHROL DIAL TRANSPL, V9, P1541; SCHEPENS MAAM, 1994, J THORAC CARDIOV SUR, V107, P134; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; SCHMIDSCHONBEIN GW, 1987, FASEB J, V46, P2397; SCHULMAN G, 1991, KIDNEY INT, V40, P1069, DOI 10.1038/ki.1991.316; SCHUMER M, 1992, AM J PATHOL, V140, P831; SEVANIAN A, 1985, Journal of Free Radicals in Biology and Medicine, V1, P263, DOI 10.1016/0748-5514(85)90130-8; SHANKEL SW, 1992, ARCH INTERN MED, V152, P986, DOI 10.1001/archinte.152.5.986; SHAPIRO SR, 1976, J UROLOGY, V115, P136, DOI 10.1016/S0022-5347(17)59101-6; SHAW SG, 1987, J CLIN INVEST, V80, P1232, DOI 10.1172/JCI113197; SHILLIDAY I, 1994, RENAL FAILURE, V16, P3, DOI 10.3109/08860229409044843; SHUSTERMAN N, 1987, AM J MED, V83, P65, DOI 10.1016/0002-9343(87)90498-0; SIEGEL NJ, 1980, KIDNEY INT, V17, P338, DOI 10.1038/ki.1980.39; SNOWDOWNE KW, 1985, J BIOL CHEM, V260, P4998; SOLEZ K, 1979, MEDICINE, V58, P362, DOI 10.1097/00005792-197909000-00003; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; SPENCER AJ, 1991, J AM SOC NEPHROL, V1, P1321; SPONSEL H, 1995, AM J KIDNEY DIS, V25, P96, DOI 10.1016/0272-6386(95)90634-7; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPURNEY RF, 1991, CRIT CARE MED, V19, P8, DOI 10.1097/00003246-199101000-00007; SZERLIP HM, 1991, ANN INTERN MED, V115, P153, DOI 10.7326/0003-4819-115-2-153; TEXTOR SC, 1993, TRANSPLANTATION, V55, P1332, DOI 10.1097/00007890-199306000-00023; THADHANI RI, 1995, MEDICINE, V74, P350, DOI 10.1097/00005792-199511000-00005; THOMPSON BT, 1994, LANCET, V344, P7, DOI 10.1016/S0140-6736(94)91044-8; TROPPMANN C, 1995, TRANSPLANTATION, V59, P962, DOI 10.1097/00007890-199504150-00007; TURNEY JH, 1990, Q J MED, V74, P83; TURNEY JH, 1990, LANCET, V335, P971, DOI 10.1016/0140-6736(90)91033-7; VAKEVA A, 1995, KIDNEY INT, V47, P918, DOI 10.1038/ki.1995.137; VETTERLEIN F, 1986, AM J PHYSIOL, V251, pH510, DOI 10.1152/ajpheart.1986.251.3.H510; WEINSTEIN JM, 1992, NEPHRON, V62, P413, DOI 10.1159/000187090; WEISBERG LS, 1994, KIDNEY INT, V45, P259, DOI 10.1038/ki.1994.32; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WILSON DM, 1976, BMJ-BRIT MED J, V2, P459, DOI 10.1136/bmj.2.6033.459; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; WOODROW G, 1992, NEPHROL DIAL TRANSPL, V7, P230, DOI 10.1093/oxfordjournals.ndt.a092111; ZANARDO G, 1994, J THORAC CARDIOV SUR, V107, P1489, DOI 10.1016/S0022-5223(94)70429-5	154	1261	1336	0	46	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1996	334	22					1448	1460		10.1056/NEJM199605303342207	http://dx.doi.org/10.1056/NEJM199605303342207			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UM493	8618585				2022-12-28	WOS:A1996UM49300007
J	Weinberger, M; Oddone, EZ; Henderson, WG				Weinberger, M; Oddone, EZ; Henderson, WG			Does increased access to primary care reduce hospital readmissions?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH SURVEY SF-36; MEDICARE POPULATION; RISK-FACTORS; COST	Background. For chronically ill patients, readmission to the hospital can be frequent and costly, We studied the effect of an intervention designed to increase access to primary care after discharge from the hospital, with the goals of reducing readmissions and emergency department visits and increasing patients' quality of life and satisfaction with care. Methods. In a multicenter randomized, controlled trial at nine Veterans Affairs Medical Centers, we randomly assigned 1396 veterans hospitalized with diabetes, chronic obstructive pulmonary disease, or congestive heart failure to receive either usual care or an intensive primary care intervention, The intervention involved close follow-up by a nurse and a primary care physician, beginning before discharge and continuing for the next six months. Results. The patients were severely ill, Half of those with congestive heart failure (504 patients) had disease in New York Heart Association class III or IV; 30 percent of those with diabetes (751 patients) had end-organ damage; and a quarter of those with chronic obstructive pulmonary disease (583 patients) required home oxygen treatment or oral corticosteroids, The patients had extremely poor quality-of-life scores, Although they received more intensive primary care than the controls, the patients in the intervention group had significantly higher rates of readmission (0.19 vs, 0.14 per month, P=0.005) and more days of rehospitalization (10.2 vs, 8.8, P=0.041), The patients in the intervention group were more satisfied with their care (P<0.001), but there was no difference between the study groups in quality-of-life scores, which remained very low (P=0.53). Conclusions. For veterans discharged from Veterans Affairs hospitals, the primary care intervention we studied increased rather than decreased the rate of rehospitalization, although patients in the intervention group were more satisfied with their care. (C) 1996, Massachusetts Medical Society.	VAMC, CTR HLTH SERV RES PRIMARY CARE, DURHAM, NC USA; VAMC, CTR COOPERAT STUDIES HLTH SERV, HINES, IL USA		Weinberger, M (corresponding author), RICHARD L ROUDEBUSH VET ADM MED CTR, 1481 W 10TH ST, INDIANAPOLIS, IN 46202 USA.							ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; ANDERSON GF, 1985, INQUIRY-J HEALTH CAR, V22, P251; ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; DAVIES AR, 1988, HEALTH AFFAIR, V7, P33, DOI 10.1377/hlthaff.7.1.33; EVANS RL, 1993, MED CARE, V31, P358, DOI 10.1097/00005650-199304000-00007; FITZGERALD JF, 1994, ARCH INTERN MED, V154, P1721, DOI 10.1001/archinte.154.15.1721; HOLLOWAY JJ, 1990, HEALTH SERV RES, V25, P213; KAHN RL, 1960, AM J PSYCHIAT, V117, P326, DOI 10.1176/ajp.117.4.326; KAZIS LE, 1993, 11 ANN HSR D SERV M, P57; LUDKE RL, 1990, HEALTH SERV RES, V25, P501; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; ODDONE EZ, 1993, CLIN RES, V41, pA819; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; SAFRAN C, 1989, MED CARE, V27, P204, DOI 10.1097/00005650-198902000-00010; SMITH DM, 1985, J CHRON DIS, V38, P213, DOI 10.1016/0021-9681(85)90064-5; SMITH DM, 1987, J GEN INTERN MED, V2, P168, DOI 10.1007/BF02596146; SMITH DM, 1988, MED CARE, V26, P699, DOI 10.1097/00005650-198807000-00005; Starfield B., 1992, PRIMARY CARE CONCEPT; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; WAITE K, 1994, J CLIN EPIDEMIOL, V47, P1229, DOI 10.1016/0895-4356(94)90127-9; Ware J E Jr, 1983, Eval Program Plann, V6, P291, DOI 10.1016/0149-7189(83)90009-5; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 1993, SF36 HLTH SURVEY MAN; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227; Weinberger M, 1989, QRB Qual Rev Bull, V15, P255; Weinberger M, 1996, J CLIN EPIDEMIOL, V49, P135, DOI 10.1016/0895-4356(95)00556-0; WEINBERGER M, 1988, MED CARE, V26, P1092, DOI 10.1097/00005650-198811000-00007; ZOOK CJ, 1980, MILBANK FUND Q, V58, P454, DOI 10.2307/3349734; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804; 1995, HLTH CARE FINANC R S, V16, P159; [No title captured]	35	559	562	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	1996	334	22					1441	1447		10.1056/NEJM199605303342206	http://dx.doi.org/10.1056/NEJM199605303342206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UM493	8618584				2022-12-28	WOS:A1996UM49300006
J	Ames, R				Ames, R			Angioplasty for renal artery stenosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ATHEROSCLEROTIC RENOVASCULAR DISEASE; PULMONARY-EDEMA; HYPERTENSION; INSUFFICIENCY; CAPTOPRIL; FAILURE				Ames, R (corresponding author), ST LUKES ROOSEVELT HOSP, DEPT MED, NEW YORK, NY 10025 USA.							DEAN RH, 1981, ARCH SURG-CHICAGO, V116, P1408; DIAMOND JR, 1993, AM J KIDNEY DIS, V21, P328, DOI 10.1016/S0272-6386(12)80756-6; GRIM CE, 1981, ANN INTERN MED, V95, P439, DOI 10.7326/0003-4819-95-4-439; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; MAILLOUX LU, 1988, AM J MED, V84, P855, DOI 10.1016/0002-9343(88)90063-0; MISSOURIS CG, 1993, LANCET, V341, P1521, DOI 10.1016/0140-6736(93)90645-W; MIYAMORI I, 1988, AM J HYPERTENS, V1, P359, DOI 10.1093/ajh/1.4.359; *NIH NAT I DIAB DI, 1991, US REN DAT SYST 1991, P13; PEDERSEN TR, 1994, LANCET, V344, P1383; PICKERING TG, 1987, CIRCULATION, V76, P274; Pickering Thomas G., 1995, P2039; PLOUIN PF, 1993, HYPERTENSION, V21, P89, DOI 10.1161/01.HYP.21.1.89; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; RIBSTEIN J, 1988, AM J HYPERTENS, V1, P239, DOI 10.1093/ajh/1.3.239; RIMMER JM, 1993, ANN INTERN MED, V118, P712, DOI 10.7326/0003-4819-118-9-199305010-00010; SCOBLE JE, 1989, CLIN NEPHROL, V31, P119; SOS TA, 1983, NEW ENGL J MED, V309, P274, DOI 10.1056/NEJM198308043090504; TOLLEFSON DFJ, 1991, J VASC SURG, V14, P327; TOTO RD, 1991, ANN INTERN MED, V115, P513, DOI 10.7326/0003-4819-115-7-513	19	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1476	1476		10.1001/jama.275.19.1476	http://dx.doi.org/10.1001/jama.275.19.1476			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622210				2022-12-28	WOS:A1996UJ93700016
J	Davis, GL				Davis, GL			Hepatitis C virus infection among health care workers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							RISK-FACTORS; PERSONNEL				Davis, GL (corresponding author), UNIV FLORIDA,COLL MED,SECT HEPATOBILIARY DIS,GAINESVILLE,FL 32611, USA.							ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; COOPER BW, 1992, INFECT CONT HOSP EP, V13, P82, DOI 10.1086/646477; DAVIS GL, 1994, GASTROENTEROL CLIN N, V23, P603; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; HOFMANN H, 1990, INFECTION, V18, P286, DOI 10.1007/BF01647006; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KLEIN RS, 1991, LANCET, V338, P1539, DOI 10.1016/0140-6736(91)92369-D; MANIAN FA, 1992, ANN INTERN MED, V116, P345; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; SCHIFF ER, 1992, HEPATOLOGY, V16, P1300	11	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1474	1474		10.1001/jama.275.19.1474	http://dx.doi.org/10.1001/jama.275.19.1474			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622209				2022-12-28	WOS:A1996UJ93700015
J	Wilkie, T				Wilkie, T			Sources in science: Who can we trust?	LANCET			English	Editorial Material								Journalists' sources of medical and scientific news seem limitless-journals, press releases, press conferences, newsletters, scientific meetings, and ''tipoffs''. But whether any one piece of information satisfies two important criteria-journalistic interest and scientific credibility-is another matter. Peer-reviewed journals, in particular, are perceived to be trustworthy sources. Yet, there are increasing concerns in scientific publishing about commercial pressures from pharmaceutical companies, honorary authorship, scientific error, and outright fraud, which journalists cannot be expected to detect. That is down to the scientific community, which must recognise the importance of maintaining impartial sources of public information.			Wilkie, T (corresponding author), INDEPENDENT,1 CANADA SQ,CANARY WHARF,LONDON E14 5DL,ENGLAND.							ALTMAN DG, 1994, JAMA-J AM MED ASSOC, V272, P166, DOI 10.1001/jama.272.2.166; Bailey AS, 1996, LANCET, V347, P189, DOI 10.1016/S0140-6736(96)90371-2; CONNOR S, 1995, INDEPENDENT     0324; CORBITT G, 1990, LANCET, V336, P51, DOI 10.1016/0140-6736(90)91561-N; EDWARDS G, 1995, ADDICTION, V90, P3, DOI 10.1111/j.1360-0443.1995.tb00997.x; Fletcher R., 1991, SCI IDEOLOGY MEDIA C; GRAYSON L, 1995, SCI DECEPTION; Gregory J., 1991, COMMUNICATING SCI HD; HUMPHREY GF, 1992, MED SCI LAW      JUL, P199; LOCK S, 1988, BRIT MED J, V297, P1531, DOI 10.1136/bmj.297.6662.1531; MADDOX J, 1995, NATURE, V378, P521, DOI 10.1038/378521a0; Merton Robert K., 1942, J LEGAL POLITICAL SO, V1, P115; ROBERTS IS, 1976, NEW SCI, V72, P466; SHASHOK K, 1995, EUR SCI EDITING, P11; STEWART W, 1995, ROYAL SOC BERN LECT; The Royal Society, 1995, PEER REV ASS REC DEV; *U SUSS SCI POL RE, 1995, CHANG FAC BRIT SCI; WILKIE T, 1991, INT J SCI EDUC, V13, P575, DOI 10.1080/0950069910130509; YANKAUER A, 1995, ADDICTION, V90, P1309, DOI 10.1111/j.1360-0443.1995.tb03540.x; ZHU TF, 1995, NATURE, V374, P503, DOI 10.1038/374503a0; ZIMAN J, 1995, ROYAL SOC MED LECT 2; ZIMAN J, 1995, ONE MIND COLLECTIVIZ; 1987, P CIB FDN C LOND; 1995, SCIENCE, V270, P1912	24	48	49	1	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 11	1996	347	9011					1308	1311		10.1016/S0140-6736(96)90947-2	http://dx.doi.org/10.1016/S0140-6736(96)90947-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UK758	8622510				2022-12-28	WOS:A1996UK75800015
J	Lifson, AR				Lifson, AR			Mosquitoes, models, and dengue	LANCET			English	Editorial Material											Lifson, AR (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455, USA.							Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; FOCKS DA, 1995, AM J TROP MED HYG, V53, P489, DOI 10.4269/ajtmh.1995.53.489; GUBLER DJ, 1994, AM J TROP MED HYG, V50, P50, DOI 10.4269/ajtmh.1994.50.50; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; GUBLER DJ, 1994, INFECT AGENT DIS, V2, P383; Horton R, 1996, LANCET, V347, P134, DOI 10.1016/S0140-6736(96)90333-5; LANCIOTTI RS, 1994, J GEN VIROL, V75, P65, DOI 10.1099/0022-1317-75-1-65; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; LLOYD LS, 1994, AM J TROP MED HYG, V50, P401, DOI 10.4269/ajtmh.1994.50.401; Organizacion Mundial de la Salud (OMS), 1995, DENGUE DENGUE HEMORR, V548; Patz JA, 1996, JAMA-J AM MED ASSOC, V275, P217, DOI 10.1001/jama.275.3.217; 1994, WKLY EPIDEMIOL REV, V69, P177	12	51	56	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1201	1202		10.1016/S0140-6736(96)90730-8	http://dx.doi.org/10.1016/S0140-6736(96)90730-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622446				2022-12-28	WOS:A1996UJ59700005
J	vanEs, LA; Hofman, A				vanEs, LA; Hofman, A			The dichotomy of medicine	LANCET			English	Article											vanEs, LA (corresponding author), NWO,COUNCIL MED SCI,THE HAGUE,NETHERLANDS.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 4	1996	347	9010					1233	1234		10.1016/S0140-6736(96)90742-4	http://dx.doi.org/10.1016/S0140-6736(96)90742-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ597	8622456				2022-12-28	WOS:A1996UJ59700016
J	Kotzin, BL				Kotzin, BL			Systemic lupus erythematosus	CELL			English	Review							MICE; ANTIBODIES; MODELS; LPR		NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT IMMUNOL, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kotzin, BL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, 1400 JACKSON ST, DENVER, CO 80206 USA.							BERNSTEIN KA, 1995, J IMMUNOL, V154, P2424; BOCKENSTEDT LK, 1995, J IMMUNOL, V154, P3516; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DRAKE CG, 1995, IMMUNOL REV, V144, P51, DOI 10.1111/j.1600-065X.1995.tb00065.x; EISENBERG RA, 1987, J CLIN INVEST, V80, P691, DOI 10.1172/JCI113123; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; HERRON LR, 1993, J IMMUNOL, V151, P3450; IZUI S, 1981, J EXP MED, V154, P517, DOI 10.1084/jem.154.2.517; JAMES JA, 1995, J EXP MED, V181, P453, DOI 10.1084/jem.181.2.453; KONO DH, 1994, P NATL ACAD SCI USA, V91, P10168, DOI 10.1073/pnas.91.21.10168; KOTZIN BL, 1995, SAMTERS IMMUNOLOGIC, P667; MOHAN C, 1995, J IMMUNOL, V154, P1470; MOHAN C, 1993, J EXP MED, V177, P1367, DOI 10.1084/jem.177.5.1367; MOREL L, 1994, IMMUNITY, V1, P219, DOI 10.1016/1074-7613(94)90100-7; RADIC MZ, 1993, J IMMUNOL, V150, P4966; RATHMELL JC, 1994, J IMMUNOL, V153, P2831; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; SATOH M, 1995, P NATL ACAD SCI USA, V92, P10934, DOI 10.1073/pnas.92.24.10934; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SINGH RR, 1995, J EXP MED, V181, P2017, DOI 10.1084/jem.181.6.2017; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; TOPFER F, 1995, P NATL ACAD SCI USA, V92, P875, DOI 10.1073/pnas.92.3.875; Van Houten N, 1994, Semin Immunol, V6, P1, DOI 10.1006/smim.1994.1001	29	573	624	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					303	306		10.1016/S0092-8674(00)81108-3	http://dx.doi.org/10.1016/S0092-8674(00)81108-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616885	Bronze			2022-12-28	WOS:A1996UK14000003
J	Shah, NM; Groves, AK; Anderson, DJ				Shah, NM; Groves, AK; Anderson, DJ			Alternative neural crest cell fates are instructively promoted by TGF beta superfamily members	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; ACHAETE-SCUTE HOMOLOG-1; SMOOTH-MUSCLE CELL; CLONAL ANALYSIS; GROWTH-FACTORS; NEURONAL DIFFERENTIATION; NERVOUS-SYSTEM; MOUSE EMBRYO; LINEAGE; COMMITMENT	How growth factors influence the fate of multipotent progenitor cells is not well understood. Most hematopoietic growth factors act selectively as survival factors, rather than instructively as lineage determination signals. In the neural crest, neuregulin instructively promotes gliogenesis, but how alternative fates are determined is unclear. We demonstrate that bone morphogenic protein 2 (BMP2) induces the basic-helix-loop-helix protein MASH1 and neurogenesis in neural crest stem cells. In vivo, MASH1(+) cells are located near sites of BMPS mRNA expression. Some smooth muscle differentiation is also observed in BMP2. A related factor, transforming growth factor beta 1 (TGF beta 1), exclusively promotes smooth muscle differentiation. Like neuregulin, BMP2 and TGF beta 1 act instructively rather than selectively. The neural crest and hematopoietic systems may therefore utilize growth factors in different ways to generate cellular diversity.	CALTECH, HOWARD HUGHES MED INST, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute				Groves, Andrew/0000-0002-0784-7998	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023476] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23476] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKHURST RJ, 1990, DEVELOPMENT, V108, P645; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DJ, 1991, J NEUROSCI, V11, P3507; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; BRONNERFRASER M, 1993, CURR OPIN GENET DEV, V3, P641, DOI 10.1016/0959-437X(93)90101-T; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; DAVIS CB, 1994, CURR OPIN IMMUNOL, V6, P266, DOI 10.1016/0952-7915(94)90100-7; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DICKSON MC, 1993, DEVELOPMENT, V117, P625; DUPIN E, 1995, DEV BIOL, V168, P529, DOI 10.1006/dbio.1995.1100; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GROVES AK, 1995, DEVELOPMENT, V121, P887; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Horstadius S., 1950, NEURAL CREST; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; ITO K, 1993, DEV BIOL, V156, P191, DOI 10.1006/dbio.1993.1069; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; KELLY OG, 1995, TRENDS GENET, V11, P273, DOI 10.1016/S0168-9525(00)89074-5; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KIRBY ML, 1987, PEDIATR RES, V21, P219, DOI 10.1203/00006450-198703000-00001; KIRBY ML, 1990, CIRCULATION, V82, P332, DOI 10.1161/01.CIR.82.2.332; KRANTZ SB, 1991, BLOOD, V77, P419; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN N, 1991, GLIA, V4, P175; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; METCALF D, 1982, J CELL PHYSIOL, V111, P275, DOI 10.1002/jcp.1041110308; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MILLAN FA, 1991, DEVELOPMENT, V111, P131; NAKAMURA H, 1982, J EMBRYOL EXP MORPH, V70, P1; OGAWA M, 1993, BLOOD, V81, P2844; OWENS GK, 1995, PHYSIOL REV, V75, P487; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Sieber-Blum M., 1990, Comments on Developmental Neurobiology, V1, P225; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; SIEBERBLUM M, 1991, NEURON, V6, P949, DOI 10.1016/0896-6273(91)90235-R; SIMPSON P, 1995, NEURON, V15, P739, DOI 10.1016/0896-6273(95)90163-9; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; Sommer L, 1995, NEURON, V15, P1245, DOI 10.1016/0896-6273(95)90005-5; STEMPLE DL, 1993, DEV BIOL, V159, P12, DOI 10.1006/dbio.1993.1218; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STERN CD, 1991, DEVELOPMENT, V113, P207; SUDA T, 1984, P NATL ACAD SCI-BIOL, V81, P2520, DOI 10.1073/pnas.81.8.2520; VARLEY JE, 1995, DEV DYNAM, V203, P434, DOI 10.1002/aja.1002030406; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	74	675	707	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 3	1996	85	3					331	343		10.1016/S0092-8674(00)81112-5	http://dx.doi.org/10.1016/S0092-8674(00)81112-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UK140	8616889	Bronze			2022-12-28	WOS:A1996UK14000007
J	Rimm, EB; Ascherio, A; Giovannucci, E; Spiegelman, D; Stampfer, MJ; Willett, WC				Rimm, EB; Ascherio, A; Giovannucci, E; Spiegelman, D; Stampfer, MJ; Willett, WC			Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TOTAL DIETARY FIBER; FOOD FREQUENCY QUESTIONNAIRE; BLOOD-LIPIDS; PRODUCTS; FAT; MORTALITY; REPRODUCIBILITY; CHOLESTEROL; VALIDITY; CANCER	Objective.-To examine prospectively the relationship between dietary fiber and risk of coronary heart disease. Design.-Cohort study. Setting.-In 1986, a total of 43 757 US male health professionals 40 to 75 years of age and free from diagnosed cardiovascular disease and diabetes completed a detailed 131-item dietary questionnaire used to measure usual intake of total dietary fiber and specific food sources of fiber. Main Outcome Measure.-Fatal and nonfatal myocardial infarction (MI). Results.-During 6 years of follow-up, we documented 734 cases of MI (229 were fatal coronary heart disease). The age-adjusted relative risk (RR) for total MI was 0.59 (95% confidence interval [CI], 0.46 to 0.76) among men in the highest quintile of total dietary fiber intake (median, 28.9 g/d) compared with men in the lowest quartile (median, 12.4 g/d). The inverse association was strongest for fatal coronary disease (RR, 0.45; 95% CI, 0.28 to 0.72). After controlling for smoking, physical activity and other known nondietary cardiovascular risk factors, dietary saturated fat, vitamin E, total energy intake, and alcohol intake, the RRs were only modestly attenuated. A 10-g increase in total dietary fiber corresponded to an RR for total MI of 0.81 (95% CI, 0.70 to 0.93). Within the three main food contributors to total fiber intake (vegetable, fruit, and cereal), cereal fiber was most strongly associated with a reduced risk of total MI (RR, 0.71; 95% CI, 0.55 to 0.91 for each 10-g increase in cereal fiber per day). Conclusions.-Our results suggest an inverse association between fiber intake and MI. These results support current national dietary guidelines to increase dietary fiber intake and suggest that fiber, independent of fat intake, is an important dietary component for the prevention of coronary disease.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Rimm, EB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON JW, 1986, AM J GASTROENTEROL, V81, P907; ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; ASCHERIO A, 1995, AM J EPIDEMIOL, V141, pS65; BURR ML, 1989, LANCET, V2, P757; CARA L, 1992, AM J CLIN NUTR, V55, P81, DOI 10.1093/ajcn/55.1.81; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FESKENS EJM, 1994, AM J EPIDEMIOL, V140, P350, DOI 10.1093/oxfordjournals.aje.a117257; GABH Rose, 1982, WHO MONOGRAPH SERIES; HALLFRISCH J, 1995, AM J CLIN NUTR, V61, P379, DOI 10.1093/ajcn/61.2.379; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HOLLAND GWA, 1991, MCCANCE WIDDOWSONS C; HUMBLE CG, 1993, AM J PREV MED, V9, P197, DOI 10.1016/S0749-3797(18)30715-3; HUNNINGHAKE DB, 1994, AM J CLIN NUTR, V59, P1050, DOI 10.1093/ajcn/59.5.1050; JENKINS DJA, 1993, NEW ENGL J MED, V329, P21, DOI 10.1056/NEJM199307013290104; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KROMHOUT D, 1982, LANCET, V2, P518; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARCKMANN P, 1990, ATHEROSCLEROSIS, V80, P227, DOI 10.1016/0021-9150(90)90030-M; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; PAUL AA, 1978, MCCANCE WIDDOWSONS C, P37; PROSKY L, 1985, J ASSOC OFF ANA CHEM, V68, P677; PROSKY L, 1984, J ASSOC OFF ANA CHEM, V67, P1044; PROSKY L, 1988, J ASSOC OFF ANA CHEM, V71, P1017; RABEN A, 1994, AM J CLIN NUTR, V59, P1386, DOI 10.1093/ajcn/59.6.1386; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; ROTHMANN K, 1986, MODERN EPIDEMIOLOGY; SMITH U, 1994, AM J CLIN NUTR, V59, p686S, DOI 10.1093/ajcn/59.3.686S; SUNDELL IB, 1993, HAEMOSTASIS, V23, P45; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; Trowell HC, 1981, W DIS THEIR EMERGENC; VAHOUNY GV, 1980, LIPIDS, V15, P1012, DOI 10.1007/BF02534316; Vollendorf Nicholas W., 1993, Journal of Food Composition and Analysis, V6, P203, DOI 10.1006/jfca.1993.1023; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037; 1990, NIH903046 US DEP HLT; 1989, RECOMMENDED DIETARY; 1992, USDA HOME GARDEN B, V252	46	623	661	0	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 14	1996	275	6					447	451		10.1001/jama.275.6.447	http://dx.doi.org/10.1001/jama.275.6.447			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU638	8627965				2022-12-28	WOS:A1996TU63800032
J	DAquila, RT; Hughes, MD; Johnson, VA; Fischl, MA; Sommadossi, JP; Liou, SH; Timpone, J; Myers, M; Basgoz, N; Niu, M; Hirsch, MS; Costanzo, L; Ruben, S; Berzins, B; Martinez, A; Fishman, I; Kazial, K; Cort, SN; Robinson, P; Hall, D; Macy, H; McLaren, C; Rooney, J; Warwick, J; CavailleColl, M; Valentine, F; Booth, D; Soeiro, R; Stein, D; Zingman, B; Schliosberg, J; Polsky, B; Sepkowitz, K; Sharpe, V; Giordano, M; Wanke, C; Gulick, R; Craven, D; Grodman, C; Fife, K; Black, J; Todd, K; Nixon, H; Sperber, K; Gerits, P; Mildvan, D; Nicholas, P; Murphy, RL; Kessler, H; Pulvirenti, J; Squires, K; Saag, M; Weingarten, J; Gnann, J; Havlir, D; Fegan, C; Spector, S; Richman, D; Jacobson, M; Dybeck, K; Joseph, P; Clanon, K; McKenzie, S; Daniel, P; Dayton, D; Leonard, J; Schooley, R; Kuritzkes, D; Ray, G; Putnam, B; Jayaweera, D; PatroneReese, J; Tanner, T; Moebus, J; Reed, N; StJacque, R; Henry, K; Swindells, S; Eron, J; Ragan, D; Horton, J; Lane, T; Frank, I; Norris, A; Pomerantz, R; Hauptman, S; Geiseler, J; Leedom, J; Canchola, F; Olson, C; Deyton, L; Pettinelli, C				DAquila, RT; Hughes, MD; Johnson, VA; Fischl, MA; Sommadossi, JP; Liou, SH; Timpone, J; Myers, M; Basgoz, N; Niu, M; Hirsch, MS; Costanzo, L; Ruben, S; Berzins, B; Martinez, A; Fishman, I; Kazial, K; Cort, SN; Robinson, P; Hall, D; Macy, H; McLaren, C; Rooney, J; Warwick, J; CavailleColl, M; Valentine, F; Booth, D; Soeiro, R; Stein, D; Zingman, B; Schliosberg, J; Polsky, B; Sepkowitz, K; Sharpe, V; Giordano, M; Wanke, C; Gulick, R; Craven, D; Grodman, C; Fife, K; Black, J; Todd, K; Nixon, H; Sperber, K; Gerits, P; Mildvan, D; Nicholas, P; Murphy, RL; Kessler, H; Pulvirenti, J; Squires, K; Saag, M; Weingarten, J; Gnann, J; Havlir, D; Fegan, C; Spector, S; Richman, D; Jacobson, M; Dybeck, K; Joseph, P; Clanon, K; McKenzie, S; Daniel, P; Dayton, D; Leonard, J; Schooley, R; Kuritzkes, D; Ray, G; Putnam, B; Jayaweera, D; PatroneReese, J; Tanner, T; Moebus, J; Reed, N; StJacque, R; Henry, K; Swindells, S; Eron, J; Ragan, D; Horton, J; Lane, T; Frank, I; Norris, A; Pomerantz, R; Hauptman, S; Geiseler, J; Leedom, J; Canchola, F; Olson, C; Deyton, L; Pettinelli, C			Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; COMBINATION THERAPY; MULTIDRUG-RESISTANCE; REPLICATION; INHIBITION; INTERFERON	Objective: To study the addition of a third human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, nevirapine, to the combination of zidovudine and didanosine. Design: A 48-week, randomized, double-blind, placebo-controlled trial at 16 AIDS (acquired immunodeficiency syndrome) Clinical Trials Units. Patients: 398 adults who had HIV-1 infection, had 350 or fewer CD4(+) T lymphocytes/mm(3), and had had more than 6 months of previous nucleoside therapy. Intervention: 1) Either nevirapine or placebo (200 mg/d for 2 weeks, then 400 mg/d thereafter) and 2) open-label zidovudine (600 mg/d) and didanosine (400 mg/d for patients weighing greater than or equal to 60 kg). Measurements: CD4(+) T lymphocyte counts, time to first HIV-1 disease progression event or death, adverse events, and nevirapine levels in plasma samples taken at random were measured in all patients. Plasma levels of HIV-1 RNA; HIV-1 infectivity titer in peripheral blood mononuclear cells; serum p24 antigen levels; and plasma levels of zidovudine and didanosine were measured in patients enrolled at half the study sites. Results: After 48 weeks of study treatment, the patients assigned to the triple-combination regimen (nevirapine, zidovudine, and didanosine) had an 18% higher mean absolute CD4 cell count (95% CI, 7% to 29%; P = 0.001), a 0.32 log(10) lower mean infectious HIV-1 titer in peripheral blood mononuclear cells (CI, 0.05 to 0.59 log(10) infectious units per million cells; P = 0.023), and a 0.25 log(10) lower mean plasma HIV-1 RNA level (CI, 0.03 to 0.48 log(10) RNA copies/mL; P = 0.028) than did patients assigned to the double-combination regimen (zidovudine and didanosine). Severe rashes were more common among patients assigned to receive the triple combination (9% compared with 2%; P = 0.002). Risk for disease progression did not differ between the two groups (relative hazard of the triple-combination group, 1.24 [CI, 0.75 to 2.06]; P > 0.2), although the study had only moderate power to detect a major difference. Conclusions: Adding nevirapine to zidovudine and didanosine improved the long-term immunologic and virologic effects of therapy and was associated with severe rash among the patients studied, who had had extensive previous therapy. These results support 1) the continuing development of combinations of more than two antiretroviral drugs to increase and prolong HIV-1 suppression and 2) the potential utility of nevirapine in combination regimens.	AIDS CLIN TRIALS GRP OPERAT OFF, ROCKVILLE, MD USA; NORTHWESTERN UNIV, CHICAGO, IL 60611 USA; NIAID, PHARMACEUT & REGULATORY AFFAIRS BRANCH, BETHESDA, MD 20892 USA; FRONTIER SCI & TECHNOL RES FDN INC, STAT & DATA MANAGEMENT CTR, AMHERST, MA USA; BOEHRINGER INGELHEIM PHARMACEUT INC, RIDGEFIELD, CT 06877 USA; BRISTOL MYERS SQUIBB CO, WALLINGFORD, CT 06492 USA; GLAXO WELLCOME CO, RES TRIANGLE PK, NC USA; US FDA, BETHESDA, MD 20014 USA; NYU, MED CTR, NEW YORK, NY USA; CLIN SITE MONITORING GRP, DURHAM, NC USA; ALBERT EINSTEIN COLL MED, NEW YORK, NY USA; CORNELL UNIV, NEW YORK, NY USA; BOSTON CITY HOSP, BOSTON, MA 02118 USA; INDIANA UNIV, INDIANAPOLIS, IN 46204 USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA; UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; UNIV CINCINNATI, CINCINNATI, OH USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO USA; UNIV MIAMI, MIAMI, FL 33152 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; UNIV PENN, PHILADELPHIA, PA 19104 USA; UNIV SO CALIF, LOS ANGELES, CA USA; NIAID, DIV AIDS, BETHESDA, MD 20892 USA; MASSACHUSETTS GEN HOSP, INFECT DIS UNIT, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, AIDS CLIN TRIALS GRP STAT DATA & ANAL CTR, BOSTON, MA 02115 USA; UNIV ALABAMA, SCH MED, DEPT MED, DIV INFECT DIS, BIRMINGHAM, AL 35294 USA; VET AFFAIRS MED CTR, BIRMINGHAM, AL 35294 USA; UNIV MIAMI, SCH MED, DEPT MED, MIAMI, FL 33101 USA; UNIV ALABAMA, DEPT PHARMACOL, DIV CLIN PHARMACOL, SCH MED, BIRMINGHAM, AL 35294 USA; GENENTECH INC, DEPT BIOSTAT, S SAN FRANCISCO, CA 94080 USA; GEORGETOWN UNIV, MED CTR, DEPT MED, DIV INFECT DIS, WASHINGTON, DC 20007 USA; BOEHRINGER INGELHEIM PHARMACEUT INC, RIDGEFIELD, CT 06877 USA; US FDA, DIV BIOSTAT & EPIDEMIOL, ROCKVILLE, MD 20852 USA	Northwestern University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Frontier Science Foundation; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; US Food & Drug Administration (FDA); New York University; Yeshiva University; Cornell University; Boston Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Icahn School of Medicine at Mount Sinai; University of California System; University of California San Diego; University of California System; University of California San Francisco; University System of Ohio; University of Cincinnati; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Miami; University of Minnesota System; University of Minnesota Twin Cities; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; University of Alabama System; University of Alabama Birmingham; Roche Holding; Genentech; Georgetown University; Boehringer Ingelheim; US Food & Drug Administration (FDA)				Murphy, Robert/0000-0003-3936-2052				*BIOEQ TASK FORC, 1988, REP BIOEQ TASK FORC; CALVELLI T, 1993, CYTOMETRY, V14, P702, DOI 10.1002/cyto.990140703; CAMERON B, 1996, 3 C HUM RETR OPP INF; CHEESEMAN SH, 1995, J ACQ IMMUN DEF SYND, V8, P141; CHEESEMAN SH, 1993, ANTIMICROB AGENTS CH, V37, P178, DOI 10.1128/AAC.37.2.178; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; COLLIER AC, 1993, ANN INTERN MED, V119, P786, DOI 10.7326/0003-4819-119-8-199310150-00003; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DORNSIFE RE, 1991, ANTIMICROB AGENTS CH, V35, P322, DOI 10.1128/AAC.35.2.322; Draper N.R., 1981, APPL REGRESSION ANAL, Vsecond, DOI DOI 10.1002/9781118625590; EMINI EA, 1993, NATURE, V364, P679, DOI 10.1038/364679b0; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GELMAN R, 1993, CLIN IMMUNOL IMMUNOP, V66, P150, DOI 10.1006/clin.1993.1019; GULICK R, 1996, 3 C HUM RETR OPP INF; HAMMER S, 1995, 35 INT C ANT AG CHEM; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; JAPOUR AJ, 1994, J CLIN MICROBIOL, V32, P2291, DOI 10.1128/JCM.32.9.2291-2294.1994; Jayaraj Andrew, 1992, Pharmaceutical Research (New York), V9, pS334; JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANG HJK, 1994, BIOCHEM PHARMACOL, V48, P2109; KOJIMA E, 1995, J INFECT DIS, V171, P1152, DOI 10.1093/infdis/171.5.1152; KOUP RA, 1993, AIDS, V7, P1181, DOI 10.1097/00002030-199309000-00005; LARDER BA, 1993, NATURE, V365, P451, DOI 10.1038/365451a0; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; MAZZULI T, 1994, ANTIMICROB AGENTS CH, V38, P656, DOI 10.1128/AAC.38.4.656; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RUSCONI S, 1994, J INFECT DIS, V170, P1361, DOI 10.1093/infdis/170.6.1361; SAAG M, 1994, 34 INT C ANT AG CHEM; SCHOOLEY RT, 1996, 3 C RETR OPP INF WAS, P202; TADEPALLI SM, 1990, CLIN CHEM, V36, P897; WILSON CC, 1995, J INFECT DIS, V172, P88, DOI 10.1093/infdis/172.1.88; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9; YENI P, 1995, 5 EUR C CLIN ASP TRE; 1992, MMWR MORB MORTAL WIK, V41, P1	46	239	243	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1019	1030		10.7326/0003-4819-124-12-199606150-00001	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00001			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633815				2022-12-28	WOS:A1996UQ65800001
J	Singh, N; Carrigan, DR				Singh, N; Carrigan, DR			Human herpesvirus-6 in transplantation: An emerging pathogen	ANNALS OF INTERNAL MEDICINE			English	Review							BONE-MARROW TRANSPLANTATION; RENAL-TRANSPLANTATION; ANTIVIRALS INVITRO; EXANTHEM-SUBITUM; PERIPHERAL-BLOOD; INFECTION; RECIPIENTS; SUSCEPTIBILITY; VIRUS; PNEUMONITIS	Background: Human herpesvirus-6 can be an opportunistic pathogen in transplant recipients. Purpose: To summarize the epidemiologic and clinical aspects of human herpesvirus-6 infection, the immunologic basis of the pathogenicity of human herpesvirus-6, and the management of human herpesvirus-6 infection in transplant recipients. Data Sources: English-language articles identified through a MEDLINE search from 1986 (when human herpesvirus-6 was discovered) to the present, bibliographies of identified articles, and recognized texts. Study Selection: Reports on human herpesvirus-6 infections in bone marrow transplant recipients and in solid organ transplant recipients. Data Extraction: Data on the virology, detection, epidemiology, clinical features, and treatment of human herpesvirus-6 infection were manually abstracted from the indicated sources and summarized. Data quality and validity were independently assessed by both authors. Data Synthesis: Human herpesvirus-6 infection occurred in 38% to 60% of bone marrow transplant recipients and 31% to 55% of solid organ transplant recipients, usually 2 to 4 weeks after transplantation. Human herpesvirus-6 has two variants, designated variant A and variant B; transplant recipients were infected almost exclusively with variant B. Bone marrow suppression, interstitial pneumonitis, and encephalitis were the most commonly reported types of clinical disease caused by human herpesvirus-6. The marrow-suppressive effect of human herpesvirus-6 ranged from transient or self-limited bone marrow suppression to chronic or fatal aplastic anemia; bone marrow suppression was thought to be partially cytokine-mediated. Because it can depress cell-mediated immunity, human herpesvirus-6 may facilitate superinfection by other pathogens. Human herpesvirus-6 resembles cytomegalovirus in its antiviral susceptibilities: It is resistant to acyclovir but susceptible to ganciclovir and foscarnet. Prophylaxis of human herpesvirus-6 infection is feasible in transplant recipients, but this issue must be studied further. Conclusion: Human herpesvirus-6 can be a pathogen in transplant recipients. Prompt recognition of disease associated with human herpesvirus-6 is important because this virus is susceptible to currently available antiviral agents. Future research should focus on delineating the complete clinical spectrum, immunologic sequelae, and efficacy of prophylactic strategies for human herpesvirus-6 infection in transplant recipients.	MED COLL WISCONSIN, DEPT PATHOL, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin	Singh, N (corresponding author), VET ADM MED CTR, INFECT DIS SECT, UNIV DR C, PITTSBURGH, PA 15240 USA.							Ablashi D V, 1994, In Vivo, V8, P581; ABLASHI DV, 1987, NATURE, V329, P207, DOI 10.1038/329207a0; AGUT H, 1991, J INFECT DIS, V163, P1382, DOI 10.1093/infdis/163.6.1382; AGUT H, 1993, NEW ENGL J MED, V329, P203, DOI 10.1056/NEJM199307153290311; AKESSONJOHANSSON A, 1990, ANTIMICROB AGENTS CH, V34, P2417, DOI 10.1128/AAC.34.12.2417; ASANO Y, 1992, ARCH DIS CHILD, V67, P1484, DOI 10.1136/adc.67.12.1484; BURD EM, 1993, BLOOD, V81, P1645; BURNS WH, 1990, J INFECT DIS, V162, P634, DOI 10.1093/infdis/162.3.634; CARRIGAN DR, 1994, BLOOD, V84, P3307; CARRIGAN DR, 1995, BLOOD, V85, P294, DOI 10.1182/blood.V85.1.294.bloodjournal851294; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CARRIGAN DR, 1995, BLOOD, V86, P835, DOI 10.1182/blood.V86.2.835.bloodjournal862835; CARRIGAN DR, 1992, HUMAN HERPESVIRUS 6, V4, P281; CARRIGAN DR, 1996, 96 GEN M AM SOC MICR; CHOU SW, 1990, J CLIN MICROBIOL, V28, P851, DOI 10.1128/JCM.28.5.851-854.1990; CONE RW, 1994, LEUKEMIA LYMPHOMA, V15, P235, DOI 10.3109/10428199409049719; CONE RW, 1993, NEW ENGL J MED, V329, P156, DOI 10.1056/NEJM199307153290302; DROBYSKI WR, 1993, J CLIN MICROBIOL, V31, P1515, DOI 10.1128/JCM.31.6.1515-1520.1993; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; DROBYSKI WR, 1994, NEW ENGL J MED, V330, P1356, DOI 10.1056/NEJM199405123301905; FLAMAND L, 1993, J VIROL, V67, P6768, DOI 10.1128/JVI.67.11.6768-6777.1993; FLAMAND L, 1995, BLOOD, V85, P1263, DOI 10.1182/blood.V85.5.1263.bloodjournal8551263; FRENKEL N, 1994, BONE MARROW TRANSPL, V14, P839; Herbein G, 1996, CLIN INFECT DIS, V22, P171, DOI 10.1093/clinids/22.1.171; HORVAT RT, 1993, J INFECT DIS, V167, P1274, DOI 10.1093/infdis/167.6.1274; JACOBS U, 1994, TRANSPLANT P, V26, P3121; JARRETT RF, 1990, J MED VIROL, V32, P73, DOI 10.1002/jmv.1890320113; KNOX KK, 1994, LANCET, V343, P1647, DOI 10.1016/S0140-6736(94)93105-4; Knox KK, 1996, J ACQ IMMUN DEF SYND, V11, P370, DOI 10.1097/00042560-199604010-00007; Knox KK, 1996, CLIN INFECT DIS, V22, P174, DOI 10.1093/clinids/22.1.174; KNOX KK, 1995, CLIN INFECT DIS, V20, P406, DOI 10.1093/clinids/20.2.406; KNOX KK, 1994, LANCET, V343, P577, DOI 10.1016/S0140-6736(94)91524-5; KNOX KK, 1995, J ACQ IMMUN DEF SYND, V9, P69; KNOX KK, 1992, J INFECT DIS, V165, P925, DOI 10.1093/infdis/165.5.925; Krueger G R, 1994, In Vivo, V8, P457; LAWRENCE GL, 1990, J VIROL, V64, P287, DOI 10.1128/JVI.64.1.287-299.1990; LUSSO P, 1995, IMMUNOL TODAY, V16, P67, DOI 10.1016/0167-5699(95)80090-5; LUSSO P, 1991, J IMMUNOL, V147, P685; MCCULLERS JA, 1995, CLIN INFECT DIS, V21, P571, DOI 10.1093/clinids/21.3.571; MORRIS DJ, 1989, NEW ENGL J MED, V320, P1560; OKUNO T, 1989, J CLIN MICROBIOL, V27, P651, DOI 10.1128/JCM.27.4.651-653.1989; OKUNO T, 1990, TRANSPLANTATION, V49, P519, DOI 10.1097/00007890-199003000-00009; PITALIA AK, 1993, J MED VIROL, V41, P103, DOI 10.1002/jmv.1890410204; PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201; ROSENFELD CS, 1995, EXP HEMATOL, V23, P626; RUSSLER SK, 1989, LANCET, V2, P382; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SCHONNEBECK M, 1991, In Vivo (Attiki), V5, P255; SECCHIERO P, 1995, J INFECT DIS, V171, P273, DOI 10.1093/infdis/171.2.273; SHIRAKI K, 1989, ANTIVIR RES, V12, P311, DOI 10.1016/0166-3542(89)90058-2; Singh N, 1995, TRANSPLANTATION, V60, P1355; STREICHER HZ, 1988, J VIROL METHODS, V21, P301, DOI 10.1016/0166-0934(88)90075-4; WARD KN, 1989, J MED VIROL, V28, P69, DOI 10.1002/jmv.1890280203; WILBORN F, 1994, BLOOD, V83, P3052, DOI 10.1182/blood.V83.10.3052.3052; YAMANISHI K, 1988, LANCET, V1, P1065; YOSHIKAWA T, 1991, BLOOD, V78, P1381; YOSHIKAWA T, 1992, PEDIATRICS, V89, P888; YOSHIKAWA T, 1992, TRANSPLANTATION, V54, P879, DOI 10.1097/00007890-199211000-00022	58	160	162	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1996	124	12					1065	1071		10.7326/0003-4819-124-12-199606150-00007	http://dx.doi.org/10.7326/0003-4819-124-12-199606150-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ658	8633821				2022-12-28	WOS:A1996UQ65800007
J	Fihn, SD; Callahan, CM; Martin, DC; McDonell, MB; Henikoff, JG; White, RH				Fihn, SD; Callahan, CM; Martin, DC; McDonell, MB; Henikoff, JG; White, RH			The risk for and severity of bleeding complications in elderly patients treated with warfarin	ANNALS OF INTERNAL MEDICINE			English	Article						warfarin; hemorrhage; age factors; prothrombin time; atrial fibrillation	ORAL ANTICOAGULANT-THERAPY; ATRIAL-FIBRILLATION; THROMBOEMBOLIC COMPLICATIONS; FOLLOW-UP; OUTPATIENTS; PREVENTION; STROKE; HEMORRHAGE	Objective: To determine whether increasing age is associated with an increased risk for bleeding during warfarin treatment. Design: Combined retrospective and prospective cohort studies. Setting: 6 anticoagulation clinics. Patients: 2376 patients receiving warfarin for various indications. Measurements: Bleeding events categorized as minor (resulting in no costs or consequences), serious (requiring testing or treatment), life-threatening, or fatal. Results: 812 first bleeding events (4 fatal, 33 life-threatening, 222 serious, and 553 minor) occurred during 3702 patient-years. Age was inversely related to the mean warfarin dose and dose-adjusted prothrombin time ratio. The unadjusted incidence of minor bleeding complications did not vary according to age group: 18.0 per 100 patient-years for patients younger than 50 years of age, 21.5 for patients 50 to 59 years of age, 24.0 for patients 60 to 69 years of age; 23.5 for patients 70 to 79 years of age, and 16.3 for patients 80 years of age and older. The unadjusted incidence of serious bleeding complications also did not vary according to age group: 9.3 per 100 patient-years for patients younger than 50 years of age, 7.1 for patients 50 to 59 years of age, 6.6 for patients 60 to 69 years of age, 5.1 for patients 70 to 79 years of age, and 4.4 for patients 80 years of age and older. The unadjusted incidence of life-threatening or fatal complications combined was significantly higher among the oldest patients: 0.75 per 100 patient-years for patients younger than 50 years of age, 0.97 for patients 50 to 59 years of age, 1.10 for patients 60 to 69 years of age, 0.68 for patients 70 to 79 years of age, and 3.38 for patients 80 years of age and older. Patients 80 years of age and older had a relative risk of 4.5 (95% CI, 1.3 to 15.6) compared with patients younger than 50 years of age. After adjustment for the intensity of anticoagulation therapy and the deviation in the prothrombin time ratio using Cox and Poisson regression, age was not generally associated with the occurrence of bleeding; relative risk estimates ranged from 0.99 to 1.03 per year of age (lower-bound 95% CI, 0.97 to 1.01; upper-bound 95% CI, 1.00 to 1.09). The single exception was life-threatening and fatal complications in patients 80 years of age or older (relative risk, 4.6 [CI, 1.2 to 18.1]). Conclusions: Age did not appear to be an important determinant of risk for bleeding in patients receiving warfarin, with the possible exception of age 80 years or older. The intensity of anticoagulation therapy and the deviation in the prothrombin time ratio were much stronger predictors of risk for bleeding.	PRIMARY CARE CTR, DIV GEN INTERNAL MED, SACRAMENTO, CA 95817 USA		Fihn, SD (corresponding author), VET AFFAIRS PUGET SOUND HEALTHCARE SYST, NW VET AFFAIRS HLTH SERV RES & DEV FIELD PROGRAM, SEATTLE, WA 98108 USA.		Fihn, Stephan/ABA-1040-2020					ANTANI MR, 1993, CLIN RES A, V41; BECKER DM, 1994, J GEN INTERN MED, V9, P525, DOI 10.1007/BF02599227; BEYTH RJ, 1995, MAYO CLIN PROC, V70, P806, DOI 10.4065/70.8.806; BEYTH RJ, 1995, DRUG AGING, V6, P45, DOI 10.2165/00002512-199506010-00004; BEYTH RJ, 1992, CLIN RES, V40, pA552; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; CHANG HJ, 1990, ARCH INTERN MED, V150, P83, DOI 10.1001/archinte.150.1.83; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COON WW, 1974, ARCH INTERN MED, V133, P386, DOI 10.1001/archinte.133.3.386; DAVIS FB, 1977, ARCH INTERN MED, V137, P197, DOI 10.1001/archinte.137.2.197; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FIHN SD, 1994, J GEN INTERN MED, V9, P131, DOI 10.1007/BF02600026; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; FORFAR JC, 1979, BRIT HEART J, V42, P128; GITTER MJ, 1995, MAYO CLIN PROC, V70, P725, DOI 10.4065/70.8.725; GUESS HA, 1987, AM J EPIDEMIOL, V125, P340, DOI 10.1093/oxfordjournals.aje.a114535; GURWITZ JH, 1992, ANN INTERN MED, V116, P901, DOI 10.7326/0003-4819-116-11-901; GURWITZ JH, 1988, ARCH INTERN MED, V148, P1733, DOI 10.1001/archinte.148.8.1733; HIRSH J, 1986, CHEST, V89, pS11, DOI 10.1378/chest.89.2_Supplement.11S; HIRSH J, 1989, CHEST, V95, pS5, DOI 10.1378/chest.95.2.5S; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; JAMES AH, 1992, J CLIN PATHOL, V45, P704, DOI 10.1136/jcp.45.8.704; KENT DL, 1992, MED DECIS MAKING, V12, P132, DOI 10.1177/0272989X9201200206; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; LANDEFELD CS, 1989, AM J MED, V87, P144; LAUNBJERG J, 1991, J INTERN MED, V229, P351, DOI 10.1111/j.1365-2796.1991.tb00358.x; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LAWLESS JF, 1982, STATISTICAL MODELS M; LUNDSTROM T, 1989, J INTERN MED, V225, P137, DOI 10.1111/j.1365-2796.1989.tb00053.x; MCBRIDE R, 1994, LANCET, V343, P687; MCCRORY DC, 1995, ARCH INTERN MED, V155, P277, DOI 10.1001/archinte.155.3.277; MCCULLAGH P, 1989, GENERALIZED LINEAR M, P194; MCINNES GT, 1987, J ROY COLL PHYS LOND, V21, P42; OMALLEY K, 1977, BRIT J CLIN PHARMACO, V4, P309, DOI 10.1111/j.1365-2125.1977.tb00718.x; PETERSEN P, 1989, LANCET, V1, P175; PETITTI DB, 1986, AM J MED, V81, P255, DOI 10.1016/0002-9343(86)90260-3; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PETTY GW, 1988, ANN NEUROL, V23, P570, DOI 10.1002/ana.410230607; SCHNEIDER D, 1979, 791352 DHEW PHS PUBL; SCHOR S, 1968, FUNDAMENTALS BIOSTAT, P105; SHEPHERD AMM, 1977, BRIT J CLIN PHARMACO, V4, P315, DOI 10.1111/j.1365-2125.1977.tb00719.x; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; 1996, ARCH INTERN MED, V156, P401; 1996, NEW ENGL J MED, V333, P5; 1990, NEW ENGL J MED, V322, P863	49	465	486	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1996	124	11					970	+		10.7326/0003-4819-124-11-199606010-00004	http://dx.doi.org/10.7326/0003-4819-124-11-199606010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL905	8624064				2022-12-28	WOS:A1996UL90500004
J	Fiscus, SA; Adimora, AA; Schoenbach, VJ; Lim, W; McKinney, R; Rupar, D; Kenny, J; Woods, C; Wilfert, C				Fiscus, SA; Adimora, AA; Schoenbach, VJ; Lim, W; McKinney, R; Rupar, D; Kenny, J; Woods, C; Wilfert, C			Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CHILDBEARING WOMEN; NORTH-CAROLINA; UNITED-STATES; POPULATION	Objectives.-To assess health care providers' identification of human immunodeficiency virus (HIV)-exposed infants, to ascertain the prevalence of transplacental or oral zidovudine treatment among infants exposed to HIV, and to estimate the impact of zidovudine use on perinatal transmission in rural and urban North Carolina. Design.-Survey of North Carolina newborns tested for HIV infection in 1993 and 1994 compared with the number of anonymous HIV-positive childbearing women. Setting.-North Carolina hospitals, public health clinics, and private physicians' offices. Main Outcome Measures.-Rates of identification of HIV-exposed infants and of perinatal HIV-1 transmission, determined by HIV culture and polymerase chain reaction testing in the infants. Results:-The proportion of HIV-exposed children in North Carolina who were identified and tested increased from 60% in 1993 to 82% for all of 1994, and to more than 90% for the last quarter of 1994. The HIV-exposed infants born in rural counties were more likely to be recognized than those born in urban counties (P<.001). In 1994, most infants were evaluated relatively early in life: 39% by 1 week of age, 63% by 6 weeks, and 76% by 3 months. Among infants with recognized HIV exposure, transmission decreased significantly between 1993 and 1994, from 21% to 8.5%, respectively (P=.009). After the announcement of the results of AIDS Clinical Trials Group Protocol 076, zidovudine was given to 75% of HIV-positive women who delivered infants in North Carolina, Only 5.7% of infants who received any zidovudine became infected, compared with 18.9% of infants who received no zidovudine (P=.007). Conclusions.-Health care providers in North Carolina are identifying most of the stale's HIV-seropositive pregnant women, treating them with zidovudine, and testing their infants soon after birth for HIV infection. The use of zidovudine in pregnant women and their infants has reduced perinatal HIV transmission in the state.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT EPIDEMIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710; CAROLINAS MED CTR,DEPT PEDIAT,CHARLOTTE,NC 28203; E CAROLINA UNIV,SCH MED,DEPT PEDIAT,GREENVILLE,NC; BOWMAN GRAY SCH MED,DEPT PEDIAT,WINSTON SALEM,NC	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; Carolinas Medical Center; University of North Carolina; East Carolina University; Wake Forest University; Wake Forest Baptist Medical Center	Fiscus, SA (corresponding author), UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CB 7140,CHAPEL HILL,NC 27599, USA.				NIAID NIH HHS [U01-AI27555] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COPLAN J, 1995, PEDIATRICS, V96, P1083; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; FISCUS SA, 1995, J CLIN MICROBIOL, V33, P246, DOI 10.1128/JCM.33.1.246-247.1995; GRANT C, 1992, PEDIATRICS, V90, P174; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HAMMER S, 1993, J CLIN MICROBIOL, V31, P2557, DOI 10.1128/JCM.31.10.2557-2564.1993; HELMS CM, 1993, J GEN INTERN MED, V8, P210, DOI 10.1007/BF02599269; HOLLINGER FB, 1994, ACTG VIROLOGY MANUAL; HSU HW, 1992, PEDIATR INFECT DIS J, V11, P941, DOI 10.1097/00006454-199211110-00007; MALDONADO YA, 1995, J INFECT DIS, V171, P689, DOI 10.1093/infdis/171.3.689; MCINTOSH K, 1994, J INFECT DIS, V170, P996, DOI 10.1093/infdis/170.4.996; RUMLEY RL, 1991, AIDS, V5, P1373, DOI 10.1097/00002030-199111000-00015; SIMONDS RJ, 1995, NEW ENGL J MED, V332, P786, DOI 10.1056/NEJM199503233321206; SISON AV, 1992, CLIN MICROBIOL REV, V5, P238, DOI 10.1128/CMR.5.3.238-247.1992; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2851; WASSER SC, 1993, J ACQ IMMUN DEF SYND, V6, P1035; 1995, MMWR-MORBID MORTAL W, V44, P1; 1992, J ACQ IMMUN DEF SYND, V5, P1169; 1995, MMWR-MORBID MORTAL W, V44, P81; 1992, MMWR-MORBID MORTAL W, V41, P463; 1994, MMWR-MORBID MORTAL W, V43, P285	22	125	129	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1483	1488						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622222				2022-12-28	WOS:A1996UJ93700031
J	Schmieder, RE; Martus, P; Klingbeil, A				Schmieder, RE; Martus, P; Klingbeil, A			Reversal of left ventricular hypertrophy in essential hypertension - A meta-analysis of randomized double-blind studies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SLOW-RELEASE NIFEDIPINE; SYSTEMIC HYPERTENSION; BLOOD-PRESSURE; ANTIHYPERTENSIVE THERAPY; MODERATE HYPERTENSION; SYSTOLIC FUNCTION; MASS REGRESSION; SUDDEN-DEATH; HYDROCHLOROTHIAZIDE; HEART	Objective.-To determine the ability of various antihypertensive agents to reduce left ventricular hypertrophy, a strong, blood pressure-independent cardiovascular risk factor, in persons with essential hypertension. Data Sources.-MEDLINE, DIMDI, RINGDOC, ADES, EMBASE, and review articles through July 1995 (English-language and full articles only). Study Selection.-Meta-analysis of all published articles including only double-blind, randomized, controlled clinical studies with parallel-group design. Data Extraction.-Intensive literature search and data extraction according to a prefixed scheme performed independently by 2 investigators. Reduction of left ventricular mass index after antihypertensive therapy with placebos, diuretics, beta-blockers, calcium channel blockers, or angiotensin-converting enzyme (ACE) inhibitors was the principal parameter. Data Synthesis.-Of 471 identified references describing the effects of antihypertensive drugs on left ventricular hypertrophy, only 39 clinical trials fulfilled the inclusion criteria of our study. We found that the decrease in left ventricular mass index was more marked the greater was the decline in blood pressure (systolic r=0.46, P<.001; diastolic r=0.21, P=.08) and the longer was the duration of therapy (r=0.38, P<.01). After adjustment for different durations of treatment (mean duration of treatment, 25 weeks), left ventricular mass decreased 13% with ACE inhibitors, 9% with calcium channel blockers, 6% with beta-blockers, and 7% with diuretics. There was a significant difference between drug classes (P<.01): ACE inhibitors reduced left ventricular mass more than beta-blockers (significant, P<.05) and diuretics (tendency, P=.08). Similar differences between drug classes were found with regard to effect on left ventricular wall thickness (P<.05). Conclusions.-The database of articles published through July 1995 is small and incomplete, and most of the articles are of poor scientific quality. in this first meta-analysis including only double-blind, randomized, controlled clinical studies, decline in blood pressure, duration of drug treatment, and drug class determined the reductions in left ventricular mass index. The ACE inhibitors seemed to be more potent than beta-blockers and diuretics in the reduction of left ventricular mass index; calcium channel blockers were somewhat in the intermediate range. The ACE inhibitors and, to a lesser extent, calcium channel blockers emerged as first-line candidates to reduce the risk associated with left ventricular hypertrophy.			Schmieder, RE (corresponding author), UNIV ERLANGEN NURNBERG, DEPT INTERNAL MED 4, MED KLIN 4, BRESLAUER STR 201, D-90471 NURNBERG, GERMANY.							AgabitiRosei E, 1995, J HYPERTENS, V13, P1325, DOI 10.1097/00004872-199511000-00015; AGABITROSEI E, 1992, AM J MED, V92, pS79, DOI 10.1016/0002-9343(92)90153-3; ALPERT MA, 1985, AM J CARDIOL, V55, P783, DOI 10.1016/0002-9149(85)90156-0; BOHLEN L, 1994, J HYPERTENS       S3, V12, pS140; CARR AA, 1990, AM J HYPERTENS, V3, P8, DOI 10.1093/ajh/3.1.8; CHAN TYK, 1992, INT J CARDIOL, V35, P387, DOI 10.1016/0167-5273(92)90238-X; CHRISTENSEN R, 1987, PLANE ANSWERS COMPLE, P22; CRUICKSHANK JM, 1992, J HUM HYPERTENS, V6, P85; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DAHLOF B, 1992, J HYPERTENS, V10, P1513, DOI 10.1097/00004872-199210120-00012; DENOLLE T, 1993, AM J HYPERTENS, V6, P907; DESIMONE G, 1994, J AM COLL CARDIOL, V23, P1444, DOI 10.1016/0735-1097(94)90390-5; DESIMONE G, 1984, CURR THER RES CLIN E, V36, P537; DESIMONE G, 1989, AM J HYPERTENS, V2, P139, DOI 10.1093/ajh/2.3.139; DEVEREUX RB, 1987, HYPERTENSION, V9, P19; DEVEREUX RB, 1991, AM J HYPERTENS, V4, pS603, DOI 10.1093/ajh/4.11S.603S; DEVEREUX RB, 1991, CURRENT ADV ACE INHI, V2, P43; DICKERSIN K, 1985, CONTROL CLIN TRIALS, V6, P306, DOI 10.1016/0197-2456(85)90106-0; DITTRICH HC, 1992, AM J CARDIOL, V69, P1559, DOI 10.1016/0002-9149(92)90703-2; EAGLE KA, 1993, J HUM HYPERTENS, V7, P341; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; FERNANDEZ PG, 1984, CURR MED RES OPIN, V9, P170, DOI 10.1185/03007998409109577; FERRARA LA, 1985, CLIN PHARMACOL THER, V38, P434, DOI 10.1038/clpt.1985.200; FERRARA LA, 1984, EUR J CLIN PHARMACOL, V27, P525, DOI 10.1007/BF00556886; FRISHMAN WH, 1989, AM J CARDIOL, V63, pI69, DOI 10.1016/0002-9149(89)90133-1; GENOVESIEBERT A, 1992, EUR HEART J, V13, P45, DOI 10.1093/eurheartj/13.suppl_A.45; GHALI JK, 1979, AM J CARDIOL, V44, P999; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GILES TD, 1987, AM J CARDIOL, V60, P103, DOI 10.1016/0002-9149(87)90994-5; GLASSER SP, 1989, J CLIN PHARMACOL, V29, P791, DOI 10.1002/j.1552-4604.1989.tb03421.x; GONZALEZFERNAND.RA, 1993, CARDIOL ELDER, V1, P185; GONZALEZFERNANDEZ RA, 1993, AM J HYPERTENS, V6, P308, DOI 10.1093/ajh/6.4.308; GOSSE P, 1992, ARCH MAL COEUR VAISS, V85, P1249; GRAETTINGER WF, 1989, CHEST, V96, P74, DOI 10.1378/chest.96.1.74; GRANDI AM, 1991, AM J HYPERTENS, V4, P516, DOI 10.1093/ajh/4.6.516; GRANGER CB, 1985, J AM COLL CARDIOL, V5, P862, DOI 10.1016/S0735-1097(85)80424-1; GRODZICKI T, 1992, CIRCULATION, V86, P64; HIMELMAN RB, 1988, J AM COLL CARDIOL, V12, P915, DOI 10.1016/0735-1097(88)90454-8; HUTING J, 1991, CLIN CARDIOL, V14, P134; IKEDA U, 1991, AM J PHYSIOL, V260, pH953, DOI 10.1152/ajpheart.1991.260.3.H953; JENNINGS G, 1991, J CARDIOVASC PHARM, V17, pS70, DOI 10.1097/00005344-199117002-00015; JULA AM, 1994, CIRCULATION, V89, P1023, DOI 10.1161/01.CIR.89.3.1023; Kaplan NM, 1990, CLIN HYPERTENSION, P182; KELEMEN MH, 1990, JAMA-J AM MED ASSOC, V263, P2766, DOI 10.1001/jama.263.20.2766; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LEEHEY DJ, 1988, AM J CARDIOL, V62, P1218, DOI 10.1016/0002-9149(88)90263-9; LEONETTI G, 1993, J HYPERTENS, V11, pS356; LEONETTI G, 1991, J HYPERTENS       S3, V9, P529; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LICATA G, 1989, CURR THER RES CLIN E, V46, P103; LIEBSON P, 1992, CIRCULATION, V86, P599; LIEVRE M, 1995, HYPERTENSION, V25, P92, DOI 10.1161/01.HYP.25.1.92; LOPEZ NC, 1991, J CARDIOVASC PHARM, V18, pS101; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MCMAHON FG, 1985, LOW DOSE ORAL TRANSD, P81; MENSAH GA, 1993, J HYPERTENS, V11, P1429, DOI 10.1097/00004872-199312000-00016; MESSERLI FH, 1990, CIRCULATION, V81, P1128, DOI 10.1161/01.CIR.81.3.1128; MESSERLI FH, 1987, ARCH INTERN MED, V147, P1725, DOI 10.1001/archinte.147.10.1725; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; Norusis M J, 1993, SPSS WINDOWS ADV STA; OTTERSTAD JE, 1992, J INTERN MED, V231, P493, DOI 10.1111/j.1365-2796.1992.tb00965.x; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; Schmieder R E, 1988, Am J Med, V84, P136, DOI 10.1016/0002-9343(88)90220-3; SCHMIEDER RE, 1989, AM J MED, V87, P22; SCHMIEDER RE, 1988, CIRCULATION, V78, P951, DOI 10.1161/01.CIR.78.4.951; SCHNEEWEISS A, 1990, J HUM HYPERTENS, V4, P535; SCHOBEL HP, IN PRESS AM HEART J; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904; SCHULTE KL, 1992, AM J CARDIOL, V70, P468, DOI 10.1016/0002-9149(92)91192-7; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SENIOR R, 1993, J CARDIOVASC PHARM, V22, pS106; SHIGEMATSU S, 1990, CARDIOLOGY, V77, P280, DOI 10.1159/000174609; SILBERBERG JS, 1989, KIDNEY INT, V36, P286, DOI 10.1038/ki.1989.192; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; STEENSGAARDHANSEN F, 1988, DRUGS, V36, P70, DOI 10.2165/00003495-198800367-00013; STRAUER BE, 1979, AM J CARDIOL, V44, P999, DOI 10.1016/0002-9149(79)90235-2; SZLACHCIC J, 1990, CARDIOVASC DRUG THER, V4, P427, DOI 10.1007/BF01857749; SZLACHCIC J, 1989, AM J CARDIOL, V63, P198, DOI 10.1016/0002-9149(89)90285-3; TUBAU JF, 1989, HYPERTENSION, V14, P1; Van Leeuwen J. T. M., 1992, Journal of Drug Development, V5, P119; VYSSOULIS GP, 1995, INT J CARDIOL, V49, P45, DOI 10.1016/0167-5273(95)02283-3; WEINSTEIN M, 1984, ARCH INTERN MED, V144, P1629, DOI 10.1001/archinte.144.8.1629; WEISS RJ, 1987, J CLIN HYPERTENS, V3, P135; WETZCHEWALD D, 1992, J INTERN MED, V231, P303, DOI 10.1111/j.1365-2796.1992.tb00539.x; YURENEV AP, 1992, AM J HYPERTENS, V5, pS182, DOI 10.1093/ajh/5.6.182S	87	525	550	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	1996	275	19					1507	1513		10.1001/jama.275.19.1507	http://dx.doi.org/10.1001/jama.275.19.1507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ937	8622227				2022-12-28	WOS:A1996UJ93700036
J	Brough, RJ; OFlynn, K				Brough, RJ; OFlynn, K			Lesson of the week - Recurrent pelvic endometriosis and bilateral ureteric obstruction associated with hormone replacement therapy	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; UROPATHY				Brough, RJ (corresponding author), MANCHESTER ROYAL INFIRM,DEPT UROL,MANCHESTER M13 9WL,LANCS,ENGLAND.							BALL TL, 1963, AM J OBSTET GYNECOL, V84, P1516; BARBIERI RL, 1990, AM J OBSTET GYNECOL, V162, P565, DOI 10.1016/0002-9378(90)90430-F; Dick A L, 1973, Br J Urol, V45, P153, DOI 10.1111/j.1464-410X.1973.tb12132.x; KANE C, 1985, AM J OBSTET GYNECOL, V151, P207, DOI 10.1016/0002-9378(85)90013-4; LAM AM, 1992, AUST NZ J OBSTET GYN, V32, P83, DOI 10.1111/j.1479-828X.1992.tb01910.x; LANGMADE CF, 1975, AM J OBSTET GYNECOL, V122, P463, DOI 10.1016/S0002-9378(16)33538-4; MANYONDA IT, 1989, EUR J OBSTET GYN R B, V31, P195, DOI 10.1016/0028-2243(89)90182-2; MOORE JG, 1979, AM J OBSTET GYNECOL, V134, P162, DOI 10.1016/0002-9378(79)90881-0; RIVLIN ME, 1985, FERTIL STERIL, V44, P274; WHEELER JM, 1983, AM J OBSTET GYNECOL, V146, P247, DOI 10.1016/0002-9378(83)90744-5	10	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1221	1222						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634571				2022-12-28	WOS:A1996UL05800028
J	Dockerty, JD; Cox, B; Borman, B; Sharples, K				Dockerty, JD; Cox, B; Borman, B; Sharples, K			Population mixing and the incidence of childhood leukaemias: Retrospective comparison in rural areas of New Zealand	BRITISH MEDICAL JOURNAL			English	Article									CENT REG HLTH AUTHOR,WELLINGTON,NEW ZEALAND		Dockerty, JD (corresponding author), UNIV OTAGO,SCH MED,DEPT PREVENT & SOCIAL MED,POB 913,DUNEDIN,NEW ZEALAND.			Dockerty, John/0000-0002-5644-9398				ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839; BRESLOW NE, 1984, INT J EPIDEMIOL, V13, P112, DOI 10.1093/ije/13.1.112; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; MUIR KR, 1990, BRIT MED J, V300, P676, DOI 10.1136/bmj.300.6725.676-b	5	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 11	1996	312	7040					1203	1204						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL058	8634564				2022-12-28	WOS:A1996UL05800020
J	Coats, S; Flanagan, WM; Nourse, J; Roberts, JM				Coats, S; Flanagan, WM; Nourse, J; Roberts, JM			Requirement of p27(Kip1) for restriction point control of the fibroblast cell cycle	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; MAMMALIAN FIBROBLASTS; ACTIVATING KINASE; DEPENDENT KINASE; GROWTH-FACTOR; 3T3 CELLS; PHOSPHORYLATION; G1; OLIGONUCLEOTIDES; INHIBITION	Cells deprived of serum mitogens will either undergo immediate cell cycle arrest or complete mitosis and arrest in the next cell cycle. The transition from mitogen dependence to mitogen independence occurs in the mid- to late G(1) phase of the cell cycle and is called the restriction point. Murine Balb/c-3T3 fibroblasts deprived of serum mitogens accumulated the cyclin-dependent kinase (CDK) inhibitor p27(Kip1). This was correlated with inactivation of essential G(1) cyclin-CDK complexes and with cell cycle arrest in G(1). The ability of specific mitogens to allow transit through the restriction point paralleled their ability to down-regulate p27, and antisense inhibition of p27 expression prevented cell cycle arrest in response to mitogen depletion. Therefore, p27 is an essential component of the pathway that connects mitogenic signals to the cell cycle at the restriction point.	GILEAD SCI,FOSTER CITY,CA 94404; STANFORD UNIV,SCH MED,PROGRAM CANC BIOL,STANFORD,CA 94305	Gilead Sciences; Stanford University	Coats, S (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; ELDEIRY W, 1993, CELL, V75, P89; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; FROEHLER BC, 1992, TETRAHEDRON LETT, V33, P5307, DOI 10.1016/S0040-4039(00)79079-4; FROEHLER BC, 1993, TETRAHEDRON LETT, V34, P1003, DOI 10.1016/S0040-4039(00)77476-4; FROEHLER BC, 1993, PROTOCOLS OLIGONUCLE; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARVEY JC, 1992, SCIENCE, V258, P1481; HERRERA R, UNPUB; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LARSSON O, 1989, J CELL PHYSIOL, V139, P477, DOI 10.1002/jcp.1041390305; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEOF EB, 1983, EXP CELL RES, V147, P202, DOI 10.1016/0014-4827(83)90285-9; LEWIS J, 1996, P NATL ACAD SCI USA, V93, P2400; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOULDS C, 1995, BIOCHEMISTRY-US, V34, P5044, DOI 10.1021/bi00015a015; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, NATURE, V78, P67; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAVIPRAKASH K, 1995, J VIROL, V69, P69, DOI 10.1128/JVI.69.1.69-74.1995; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TEMIN HM, 1971, J CELL PHYSIOL, V78, P161, DOI 10.1002/jcp.1040780202; TOYASHIMA H, 1994, CELL, V78, P67; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	48	635	669	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					877	880		10.1126/science.272.5263.877	http://dx.doi.org/10.1126/science.272.5263.877			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629023				2022-12-28	WOS:A1996UK75700060
J	vonZahn, U; Hunten, DM				vonZahn, U; Hunten, DM			The helium mass fraction in Jupiter's atmosphere	SCIENCE			English	Article							VOYAGER MEASUREMENTS; ABUNDANCE; SOLAR; SATURN	On 7 December 1995, the NASA Galileo probe provided in situ measurements of the helium abundance in the atmosphere of Jupiter. A Jamin interferometer measured the refractive index of the jovian atmosphere in the pressure region from 2 to 14 bars. These measurements indicate that the atmospheric helium mole fraction is 0.136 +/- 0.004. The corresponding helium mass fraction is slightly below the presolar value, which suggests that separation of helium from hydrogen in Jupiter's interior is only in its early stages.	UNIV ARIZONA, DEPT PLANETARY SCI, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA	University of Arizona	vonZahn, U (corresponding author), UNIV ROSTOCK, INST ATMOSPHARENPHYS, SCHLOSS STR 4-6, KUHLUNGSBORN, GERMANY.							ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BAHCALL JN, 1992, REV MOD PHYS, V64, P885, DOI 10.1103/RevModPhys.64.885; BASU S, 1995, ESA SPECIAL PUBLICAT, V376, P35; CHABRIER G, 1992, ASTROPHYS J, V391, P817, DOI 10.1086/171390; CONRATH B, 1987, J GEOPHYS RES, V92, P15003, DOI 10.1029/JA092iA13p15003; CONRATH BJ, 1984, ASTROPHYS J, V282, P807, DOI 10.1086/162267; GUILLOT T, 1994, ICARUS, V112, P354, DOI 10.1006/icar.1994.1189; Hubbard WB, 1989, ORIGIN EVOLUTION PLA, P539; Jenkins FA, 1976, FUNDAMENTALS OPTICS; KOSOVICHEV AG, 1992, MON NOT R ASTRON SOC, V259, P536, DOI 10.1093/mnras/259.3.536; LEWIS JS, 1974, SCI AM, V230, P51, DOI 10.1038/scientificamerican0374-50; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; OLIVE KA, 1995, ASTROPHYS J SUPPL S, V97, P49, DOI 10.1086/192134; Perez Hernandez F., 1994, Monthly Notices of the Royal Astronomical Society, V269, P475; PODOLAK M, 1975, ICARUS, V25, P627, DOI 10.1016/0019-1035(75)90044-5; PROFFITT CR, 1994, ASTROPHYS J, V425, P849, DOI 10.1086/174030; SALPETER EE, 1973, ASTROPHYS J LETT, V181, pL183; SMOLUCHO.R, 1967, NATURE, V215, P691, DOI 10.1038/215691a0; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P221, DOI 10.1086/190478; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P239, DOI 10.1086/190479; Stix M., 1989, SUN; VONZAHN U, 1992, SPACE SCI REV, V60, P263, DOI 10.1007/BF00216857	23	57	57	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 10	1996	272	5263					849	851		10.1126/science.272.5263.849	http://dx.doi.org/10.1126/science.272.5263.849			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK757	8629017				2022-12-28	WOS:A1996UK75700050
J	Yfanti, G; Andreadis, E; Spiliadou, C; Diamantopoulos, EJ				Yfanti, G; Andreadis, E; Spiliadou, C; Diamantopoulos, EJ			A woman with fever and a jejunal stricture	LANCET			English	Article							CAPILLARIA-HEPATICA INFESTATION		EVANGELISMOS MED CTR, DEPT INTERNAL MED 4, ATHENS, GREECE; EVANGELISMOS MED CTR, DEPT PATHOL, ATHENS, GREECE	Evangelismos Hospital; Evangelismos Hospital								CHOE GY, 1993, AM J TROP MED HYG, V48, P610, DOI 10.4269/ajtmh.1993.48.610; el-Nassery S F, 1991, J Egypt Soc Parasitol, V21, P467; KOKAI GK, 1990, HISTOPATHOLOGY, V17, P275, DOI 10.1111/j.1365-2559.1990.tb00723.x; PANNENBECKER J, 1990, MONATSSCHR KINDERH, V138, P767; SINGLETON GR, 1991, INT J PARASITOL, V21, P945, DOI 10.1016/0020-7519(91)90171-3	5	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	1996	347	9004					802	802		10.1016/S0140-6736(96)90872-7	http://dx.doi.org/10.1016/S0140-6736(96)90872-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB153	8622338				2022-12-28	WOS:A1996UB15300013
J	Cook, DJ; Schlemmer, S; Balucani, N; Wagner, DR; Steiner, B; Saykally, RJ				Cook, DJ; Schlemmer, S; Balucani, N; Wagner, DR; Steiner, B; Saykally, RJ			Infrared emission spectra of candidate interstellar aromatic molecules	NATURE			English	Article							MICRON EMISSION; IRAS SOURCES; FEATURES; SPECTROSCOPY; HYDROCARBONS; CATIONS; BANDS; STATE	INTERSTELLAR dust is responsible, through surface reactions, for the creation of molecular hydrogen, the main component of the interstellar clouds in which new stars form, Intermediate between small, gas-phase molecules and dust are the polycyclic aromatic hydrocarbons (PAHs). Such molecules could account for 2-30% of the carbon in the Galaxy(1), and may provide nucleation sites for the formation of carbonaceous dust(2,3). Although PAHs have been proposed(4,5) as the sources of the unidentified infrared emission bands that are observed in the spectra of a variety of interstellar sources(6-11), the emission characteristics of such molecules are sources still poorly understood. Here we report laboratory emission spectra of several representative PAHs, obtained in conditions approximating those of the interstellar medium, and measured over the entire spectral region spanned by the unidentified infrared bands. We find that neutral PAHs of small and moderate size can at best make only a minor contribution to these emission bands, Cations of these molecules, as well as much larger PAHs and their cations, remain viable candidates for the sources of these bands.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Balucani, Nadia/GPX-7659-2022; Schlemmer, Stephan/E-2903-2015; Balucani, Nadia/B-8211-2011	Balucani, Nadia/0000-0001-5121-5683; Schlemmer, Stephan/0000-0002-1421-7281; Balucani, Nadia/0000-0001-5121-5683; SAYKALLY, RICHARD/0000-0001-8942-3656				ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; Allamandola LJ, 1995, ASTR SOC P, V73, P23; ALLAMANDOLA LJ, 1985, ASTROPHYS J, V290, pL25, DOI 10.1086/184435; ALLAMANDOLA LJ, 1989, ASTROPHYS J, V345, pL59, DOI 10.1086/185552; BRENNER JD, 1992, ASTROPHYS J, V388, pL39, DOI 10.1086/186325; CADWELL BJ, 1994, ASTROPHYS J, V429, P285, DOI 10.1086/174318; CHERCHNEFF I, 1989, ASTROPHYS J, V341, pL21, DOI 10.1086/185448; COHEN M, 1989, ASTROPHYS J, V341, P246, DOI 10.1086/167489; DEMUIZON MJ, 1990, ASTRON ASTROPHYS, V235, P367; FLICKINGER GC, 1991, ASTROPHYS J, V380, pL43, DOI 10.1086/186169; GEBALLE TR, 1985, ASTROPHYS J, V292, P500, DOI 10.1086/163182; HUDGINS DM, 1995, J PHYS CHEM-US, V99, P3033, DOI 10.1021/j100010a011; JOBLIN C, 1994, ASTRON ASTROPHYS, V281, P923; JOBLIN C, 1995, ASTRON ASTROPHYS, V299, P835; LANGHOFF SR, IN PRESS J PHYS CHEM; LEGER A, 1989, ANN PHYS-PARIS, V14, P181, DOI 10.1051/anphys:01989001402018100; LEGER A, 1984, ASTRON ASTROPHYS, V137, pL5; OMONT A, 1986, ASTRON ASTROPHYS, V164, P159; PETROFF MD, 1987, APPL PHYS LETT, V51, P406, DOI 10.1063/1.98404; SCHLEMMER S, 1994, SCIENCE, V265, P1686, DOI 10.1126/science.11539830; SCHUTTE WA, 1990, ASTROPHYS J, V360, P577, DOI 10.1086/169146; SHAN J, 1991, ASTROPHYS J, V383, P459, DOI 10.1086/170803; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; SZCZEPANSKI J, 1993, ASTROPHYS J, V414, P646, DOI 10.1086/173110; SZCZEPANSKI J, 1993, CHEM PHYS LETT, V205, P434, DOI 10.1016/0009-2614(93)87147-U; TIELENS AGGM, 1990, NASA CONF P, V3061, P59; VALA M, 1994, J PHYS CHEM-US, V98, P9187, DOI 10.1021/j100088a017; WILLIAMS RM, 1995, ASTROPHYS J, V443, P675, DOI 10.1086/175559; WITTEBORN FC, 1989, ASTROPHYS J, V341, P270, DOI 10.1086/167490	29	100	101	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 21	1996	380	6571					227	229		10.1038/380227a0	http://dx.doi.org/10.1038/380227a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UB117	8637570				2022-12-28	WOS:A1996UB11700044
